<SEC-DOCUMENT>0001213900-23-030316.txt : 20230417
<SEC-HEADER>0001213900-23-030316.hdr.sgml : 20230417
<ACCEPTANCE-DATETIME>20230417171538
ACCESSION NUMBER:		0001213900-23-030316
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230417
DATE AS OF CHANGE:		20230417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aditxt, Inc.
		CENTRAL INDEX KEY:			0001726711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823204328
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39336
		FILM NUMBER:		23824742

	BUSINESS ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219
		BUSINESS PHONE:		909-488-0844

	MAIL ADDRESS:	
		STREET 1:		737 N. FIFTH STREET, SUITE 200
		CITY:			RICHMOND
		STATE:			VA
		ZIP:			23219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aditx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADiTx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20171229
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_aditxtinc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:23 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:adtx="http://www.aditxt.com./20221231" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap-sup="http://fasb.org/us-gaap-sup/2022q3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>



</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport"><b>&#9746;</b></ix:nonNumeric>&#160;<b>ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For fiscal year ended:&#160;<b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport"><b>&#9744;</b></ix:nonNumeric>&#160;<b>TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _______________
to _______________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number:&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-39336</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>Aditxt, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 50%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>82-3204328</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<br/>
incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">737 N. Fifth Street</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></b></span></td> <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 49%; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Richmond</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">VA</ix:nonNumeric></b></span></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23219</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code:&#160;<b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(650)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">870-1200</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of Each Class</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Each Exchange on Which&#160;Registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADTX</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Stock Market LLC</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section&#160;12(g)&#160;of
the Act:&#160;<b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes &#9744;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>&#160;&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 of Regulation S-T (&#167;
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post
such files).&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="white-space: nowrap; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td colspan="2" style="white-space: nowrap; text-align: justify">&#160;</td> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="white-space: nowrap; text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in this filing reflect the correction
of an error to previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;&#160;&#160;No&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant on June 30, 2022, based on a closing price of $7.16 was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd">7,923,275</ix:nonFraction>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 14, 2023, the registrant had <span style="background-color: white">4,834,731</span>
and&#160;<span style="background-color: white"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">4,832,714</ix:nonFraction></span>&#160;shares of common stock, $0.001 par value per share, issued and outstanding,
respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Portions of the Registrant&#8217;s definitive
proxy statement relating to its 2022 annual meeting of stockholders (the &#8220;2022 Proxy Statement&#8221;) are incorporated by reference
into Part III of this Annual Report on Form 10-K where indicated. The 2022 Proxy Statement will be filed with the Securities and Exchange
Commission (the &#8220;SEC&#8221;) within 120 days after the end of the fiscal year to which this report relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ANNUAL REPORT ON FORM 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE YEAR ENDED DECEMBER 31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 10%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 80%; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I</a></b></span></td>
    <td style="vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_008">PART II</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">[Reserved]</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_018">PART III</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_024">PART IV</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16</span></td>
    <td style="vertical-align: top; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    10-K Summary</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">SIGNATURES</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions,
estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond
our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements
that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as &#8220;may,&#8221;
&#8220;can,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;should,&#8221; &#8220;indicate,&#8221; &#8220;would,&#8221;
&#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;expect,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;plan,&#8221; &#8220;point to,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221;
&#8220;potential&#8221; and other similar words and expressions of the future. The matters discussed in these forward-looking statements
are subject to risks, uncertainties and other factors that could cause our actual results to differ materially from those projected, anticipated
or implied in the forward-looking statements. As a result, you should not place undue reliance on any forward-looking statements. Except
to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTOR SUMMARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
numerous risks and uncertainties, including those highlighted in Section 1A titled &#8220;Risk Factors,&#8221; that represent challenges
that we face in connection with the successful implementation of our strategy. The occurrence of one or more of the events or circumstances
described in the section titled &#8220;Risk Factors,&#8221; alone or in combination with other events or circumstances, may have an adverse
effect on our business, cash flows, financial condition and results of operations. Such risks include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
have generated no significant revenue from commercial sales to date and our future profitability is uncertain;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and
you will likely lose your entire investment;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
financial situation creates doubt whether we will continue as a going concern;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may need to raise additional funding, which may not be available on acceptable terms, or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
if we can raise additional funding, we may be required to do so on terms that are dilutive to you.;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization
of our future product candidates, if any;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate
adequate safety and efficacy to the satisfaction of applicable regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
our future pre-clinical development and future clinical Phase I/II studies are unsuccessful, we may be unable to obtain regulatory approval
of, or commercialize, our product candidates on a timely basis or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and
the revenue that we generate from their sales, if any, may be limited;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
events involving our products may lead the FDA or applicable foreign regulatory agency to delay or deny clearance for our products or
result in product recalls that could harm our reputation, business and financial results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
technology is subject to licenses from LLU and Stanford (as defined below), each of which are revocable in certain circumstances, including
in the event we do not achieve certain payments and milestone deadlines. Without these licenses, we may not be able to continue to develop
our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
we were to lose our CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we
would no longer be able to offer our assays (including our AditxtScore&#8482; platform), which would limit our revenues and harm our
business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be
able to test specimens from those states;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
results of operations will be affected by the level of royalty and milestone payments that we are required to pay to third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
technologies and products under development, and our business, may fail if we are not able to successfully commercialize them and ultimately
generate significant revenues as a result;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customers
may not adopt our products quickly, or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19
may impact our business and operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
failure to obtain or maintain patents, licensing agreements and other intellectual property could materially impact our ability to compete
effectively;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">some
of our intellectual property may be subject to &#8220;march-in&#8221; rights by the U.S. federal government;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
do not expect to pay dividends in the foreseeable future;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
have issued a significant number of restricted stock awards, restricted stock units, options and warrants and may continue to do so in
the future. The vesting and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder
may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future sales or issuances of substantial amounts of our common stock, including, potentially as a result of future acquisitions or strategic transactions, including the transaction with Cellvera Global, could result in significant dilution;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">while
we have entered into a Share Exchange Agreement with Cellvera Global, we cannot assure you that the transaction contemplated by the Share
Exchange Agreement will be consummated or, that if such transaction is consummated, that it will be accretive to stockholder value;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
have provided loans to Cellvera Global in the principal amount of $14.5 million, if we are unable to complete the transactions contemplated
by the Share Exchange Agreement, we cannot provide any assurance that we will be able to timely collect such amounts from Cellvera Global,
if at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may engage in future acquisitions or strategic transactions, including the transaction with Cellvera Global, which may require us to
seek additional financing or financial commitments, increase our expenses and/or present significant distractions to our management;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
received the determination from Nasdaq that we regained compliance with the Nasdaq continued listing requirements, however, we remain
subject to a panel monitor of our ongoing compliance until March 28, 2023 and if we fail to comply with such requirements during the
panel monitor, it could result in the delisting of our securities by Nasdaq; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusive
forum provisions in our amended and restated certificate of incorporation and amended and restated bylaws.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.</b>&#160;<b>Business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an innovation company with a mission of
Making Promising Innovations Possible, Together. We develop, build, and grow innovations with a focus on monitoring and modulating the
immune system. We take a socialized approach to innovation by engaging stakeholders into all aspects of the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our innovation portfolio includes
the following programs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">-</td><td style="text-align: justify">Adimune&#8482; - Immune modulation technologies which are
currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and allergies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">-</td><td style="text-align: justify">AditxtScore&#8482; - Immune monitoring technologies designed
to provide a personalized comprehensive profile of the immune system.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ADI<sup>TM</sup> (Immune Modulation Program)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discovery of immunosuppressive
(anti-rejection and monoclonal) drugs over 40 years ago has made possible life-saving organ transplantation procedures and blocking of
unwanted immune responses in autoimmune diseases. However, immune suppression leads to significant undesirable side effects, such as increased
susceptibility to life-threatening infections and cancers, because it indiscriminately and broadly suppresses immune function throughout
the body. While the use of these drugs has been justifiable because they prevent or delay organ rejection, their use for treatment of
autoimmune diseases and allergies may not be acceptable because of the aforementioned side effects. Furthermore, transplanted organs often
ultimately fail despite the use of immune suppression, and about 40% of transplanted organs survive no more than 5 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New, focused therapeutic approaches
are needed that modulate only the immune cells involved in rejection of the transplanted organ, as this approach can be safer for patients
than indiscriminate immune suppression. Such approaches are referred to as immune tolerance, and when therapeutically induced, may be
safer for patients and potentially allow long-termer survival of transplanted tissues and organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the late 1990s, academic
research on these approaches was conducted at the Transplant Center in Loma Linda University (&#8220;LLU&#8221;) in connection with a
project that secured initial grant funding from the U.S. Department of Defense. The focus of that project was induction of tolerance for
skin allografting for burn victims. Twenty years of research at LLU and an affiliated incubator led to a series of discoveries that have
been translated into a large patent portfolio of therapeutic approaches that may be applied to the modulation of the immune system to
induce tolerance to self and transplanted organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an exclusive worldwide
license for commercializing Apoptotic DNA Immunotherapy&#8482; (ADI&#8482;) nucleic acid-based technology (which is currently at the pre-clinical
stage) from LLU, ADI&#8482; which utilizes a novel approach that mimics the way the body naturally induces tolerance to our own tissues
(&#8220;therapeutically induced immune tolerance&#8221;). While immune suppression requires continuous administration to prevent rejection
of a transplanted organ, induction of tolerance has the potential to retrain the immune system to accept the organ for longer periods
of time. Thus, ADI&#8482; may allow patients to live with transplanted organs with significantly reduced immune suppression. ADI&#8482;
is a technology platform which we believe can be engineered to address a wide variety of indications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing ADI&#8482;
products for organ transplantation including skin allografting, autoimmune diseases, and allergies, with the initial focus on psoriasis,
type 1 diabetes and skin allografting, indications for which we have compelling preclinical data. To submit a Biologics License Application
(&#8220;BLA&#8221;) for a biopharmaceutical product, clinical safety and efficacy must be demonstrated in clinical studies conducted with
human subjects. For products in our class of drugs, the first-in-human trials will be a combination of Phase I (safety/tolerability) and
Phase II (efficacy) in affected subjects. To obtain approval to initiate the Phase I/IIa studies, an Investigational New Drug or Clinical
Trial Application will be submitted that will include a compilation of non-clinical efficacy data as well as manufacturing and pre-clinical
safety/toxicology data. To date, we have conducted non-clinical studies in a stringent model of skin transplantation using genetically
mismatched donor and recipient animals demonstrating a 3-fold increase in the survival of the skin allograft in animals that were tolerized
with ADI&#8482; compared to animals that receive immune suppression alone. Prolongation of graft life was observed despite discontinuation
of immune suppression after the first 5 weeks. In a non-obese diabetic mouse model of type 1 diabetes, we showed reversal of hyperglycemia
with 80% of the animals showing durable glycemic control for the 40-week study period. Additionally, in an induced non-clinical model
for psoriasis, ADI&#8482; treatment resulted in a 69% reduction in skin thickness and a 38% decrease in skin flaking (two clinical parameters
for assessment of psoriasis skin lesions). The Phase I/IIa studies in psoriasis will evaluate the safety/tolerability of ADI&#8482; in
patients diagnosed with psoriasis. Since the drug will be administered in subjects diagnosed with psoriasis, effectiveness of the drug
to improve psoriatic lesions will also be evaluated. In the type 1 diabetes clinical studies, newly diagnosed subjects will receive ADI&#8482;
treatment to evaluate safety and efficacy. In another Phase I/IIa study, patients requiring skin allografts will receive weekly intra-dermal
injections of ADI&#8482; in combination with standard immune suppression to assess safety/tolerability and possibility of reducing levels
of immunosuppressive drugs as well as prolongation of graft life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advantages</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADI&#8482; is a nucleic acid-based
technology (<i>e.g.</i>, DNA-based), which we believe selectively suppresses only those immune cells involved in attacking or rejecting
self and transplanted tissues and organs. It does so by tapping into the body&#8217;s natural process of cell turnover (apoptosis) to
retrain the immune system to stop unwanted attacks on self or transplanted tissues. Apoptosis is a natural process used by the body to
clear dying cells and to allow recognition and tolerance to self-tissues. ADI&#8482; triggers this process by enabling the cells of the
immune system to recognize the targeted tissues as &#8220;self&#8221;. Conceptually, it is designed to retrain the immune system to accept
the tissues, similar to how natural apoptosis reminds our immune system to be tolerant to our own &#8220;self&#8221; tissues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While efforts have been made
by various groups to promote tolerance through cell therapies and&#160;<i>ex vivo</i>&#160;manipulation of patient cells (takes place
outside the body), to our knowledge, we will be unique in our approach of using in-body induction of apoptosis to promote tolerance to
specific tissues.&#160;In addition, ADI&#8482; treatment itself will not require additional hospitalization, only an injection of minute
amounts of the therapeutic drug into the skin.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Reduce Chronic Rejection</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While immunosuppressants control
acute rejection during the early time-period after receiving an organ, chronic rejection of the organ that occurs one or more years after
the transplant procedure continues to pose a major challenge for organ recipients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Chronic rejection has been
likened to autoimmunity (a misdirected immune response that occurs when the immune system goes awry), where specific tissues in the transplanted
organ become targets of immune attack.&#160;In other words, chronic rejection may not be caused just by differences between the donor
and the recipient, but rather by an immune response by the recipient to specific tissues in the organ.&#160;Our pre-clinical studies suggest
that ADI&#8482; has the ability to tolerize to specific tissues in a transplanted organ, and conceivably, reduce incidences of chronic
rejection.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, preclinical studies
have demonstrated that ADI&#8482; treatment significantly and substantially prolongs graft survival, in addition to successfully &#8220;reversing&#8221;
other established immune-mediated inflammatory processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Reduce immune suppression</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies in animal models have
shown that conditioning/desensitizing the animals to receive the transplant, prolongs the survival of the transplanted tissue or organ.&#160;These
studies have used repeated exposure to low doses of protein components in specific organs to reduce immunologic recognition and attack
on the transplanted organ.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on some of our data,
we believe that with ADI&#8482; treatment, recipients can be conditioned/desensitized, thereby retraining the immune system to more readily
accept the organ and also reduce the levels of immunosuppressive drugs needed post-transplantation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Preformed Antibodies</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies have shown that presence
of preformed antibodies prior to transplantation procedures increases the rate of organ rejection. Preformed antibodies can develop in
previously transplanted patients, patients who have given birth, and patients who have previously received blood transfusions. With more
than 113,000 patients on transplant waiting lists in the U.S. alone, patients with pre-existing antibodies have much lower chances of
qualifying to receive organs due to their increased risk of rejection &#8211; even with immune suppression.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sadly, transplanted patients
have a probability of needing re-transplantation at some point due to eventual chronic rejection of their transplanted organ, with the
possible exception of some newborn recipients. With increased incidence of preformed antibodies, these patients may never have the opportunity
to receive another organ. Based on experimental data, we believe that ADI&#8482; may have the potential to address this issue providing
these individuals better opportunities for receiving an organ.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Technology Platform</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADI&#8482; utilizes a novel
approach that mimics the way our bodies naturally induce tolerance to our own tissues.&#160;It is a technology platform, which we believe
can be engineered to address a wide variety of indications. ADI&#8482; includes two DNA molecules which are designed to deliver signals
to induce tolerance.&#160;The first DNA molecule encodes a pro-apoptotic protein, which induces &#8216;programmed&#8217; cell death (apoptosis).&#160;This
is a core component of the technology because it is intended to greatly increase the recruitment of dendritic cells, which are implicated
in regulating the immune system.&#160;The second DNA molecule encodes the protein of interest (guiding antigen), which is modified to
promote a path of tolerance.&#160;The guiding antigen is intended to result in tolerance induction specific to the tissue where the protein
is found.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADI&#8482; has shown efficacy
in several preclinical models (skin allografting, psoriasis, type 1 diabetes, alopecia areata and others) and its efficacy can be attributed
to multiple factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
does not rely on a single mechanistic approach.&#160;It has multiple components (interchangeable target antigen, apoptosis, methylated
plasmid DNA) that affect different arms of the immune system, which may collectively play a role in rejecting self or transplanted tissues.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
activates key immune cells known to maintain tolerance in test animals and humans.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
has been successfully applied to several autoimmune models and a stringent transplantation model.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
lends itself to repeat dosing, which may be required to achieve its full potential therapeutic effect.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proof of Concept: Skin Grafting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Results shown are 5 weeks
post-transplantation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proof-of-concept experiment
performed in transplantation was a skin allograft transplantation procedure in which the donor skin was obtained from white BALB/c mice
and transplanted to black C57BL/6 mice. The experiment was designed to address a more challenging scenario where the donor tissue was
obtained from a donor which is genetically mismatched with the recipient. This is unlike clinical scenarios where the donor and recipient
are genetically matched as much as possible. While these experiments were repeated in several separate experiments, the results shown
here were obtained from a study conducted with 14 mice in the ADI&#8482; treatment group and 7 mice in the control group. Prior to submission
of an Investigational New Drug or Clinical Trial Application, additional non-clinical studies will be conducted to establish the precise
protocol (e.g. timing of vaccine administration, dosing, and appropriate immunosuppressive agents that will be used in combination with
ADI&#8482;) that will be used in the clinical trials. Pre-clinical safety/toxicology studies have already been conducted by a GLP lab
to ensure product safety for clinical testing. These studies have shown no signs of toxicity to ADI&#8482; treatment in mice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;<img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proof of Concept: Psoriasis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psoriasis
causes increased skin thickness and scaling in an established 10-day psoriasis model</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
treatment resulted in a 69% reduction in skin thickening and 38% reduction in scaling over the 10-day study period</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proof of Concept: Type 1 Diabetes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Typically, 90% of female NOD
mice develop spontaneous autoimmune diabetes if left untreated. Disease progression may be different for individual animals much like
the clinical scenario in human patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADI&#8482; was administered
once a week for 8 weeks after each animal developed hyperglycemia. All animals responded with 80% showing durable response for the entire
40-week study period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
1 or autoimmune diabetes is a condition where the body&#8217;s immune system mistakenly attacks cells in the pancreas resulting in diminished
production of insulin, a hormone that is required for regulation of glucose</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADI&#8482;
incorporates an antigen (GAD) expressed in the pancreas</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
of ADI&#8482; using GAD as the guiding antigen over an 8-week period in animals with T1D restores insulin production and reverses hyperglycemia</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>License Agreement with Loma Linda University</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2018, we entered
into an Assignment Agreement (the &#8220;Assignment Agreement&#8221;) with Sekris Biomedical, Inc. (&#8220;Sekris&#8221;). Sekris was
a party to a license agreement with LLU, entered and made effective on May 25, 2011, and amended on June 24, 2011, July 16, 2012 and December
27, 2012 (the &#8220;Original Agreement,&#8221; and together with the Assignment Agreement, the &#8220;Sekris Agreements&#8221;). Pursuant
to the Assignment Agreement, Sekris transferred and assigned all of its rights, obligations and liabilities under the Original Agreement,
of whatever kind or nature, to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 10,000 shares of our
common stock (the &#8220;Sekris Warrant&#8221;). The warrant was immediately exercisable and has an exercise price of $200.00 per share.
The expiration date of the warrant is March 8, 2023. On March 15, 2018, as amended on July 1, 2020, we entered into a LLU License Agreement
directly with Loma Linda University, which amends and restates the Sekris Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LLU License
Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical
information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled
by LLU and/or any of its affiliates (the &#8220;LLU Patent and Technology Rights&#8221;) and related to therapy for immune-mediated inflammatory
diseases (the ADI&#8482; technology). In consideration for the LLU License Agreement, we issued 500 shares of common stock to LLU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LLU License
Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July 2020 for outstanding milestone payments
and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically,
we are required to make the following milestone payments to LLU: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March
31, 2026; and $500,000 on March 31, 2027. In lieu of the $175,000 milestone payment due on March 31, 2022, the Company paid LLU an extension
fee of $100,000. Upon payment of this extension fee, an additional year will be added for the March 31, 2022 milestone. Additionally,
as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made the
following payments to LLU: $70,000 at the end of December 2018, and a final payment of $60,000 at the end of March 2019. We are required
to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe royalty payments
of (i) 1.5% of Net Product Sales (as such terms are defined under the LLU License Agreement) and Net Service Sales on any Licensed Products
(defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or
supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services (as such terms are defined
under the LLU License Agreement) not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond
the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development
and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and
Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LLU License Agreement
shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application
licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU.
LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance
fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision
that requires us to meet certain deadlines for milestone events (each, a &#8220;Milestone Deadline&#8221;)) not cured within 90 days after
delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by
us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application
to initiate first-in-human clinical trials on or before March 31, 2022, which has been extended to March 31, 2023 due to payment of a
$100,000 extension fee paid in March 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Pre-clinical and Clinical Plans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The resources and efforts
used for the IND-enabling work summarized below supports both the psoriasis and TID clinical programs</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-level objectives for
psoriasis clinical program:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of IND-enabling work. Aditxt has completed GMP manufacturing of clinical grade drug substances (DNA plasmids) and initiated GMP formulation of clinical grade the drug product (ADI-100) that will be used for the first-in-human studies in subjects with psoriatic lesions.&#160;&#160;Included in the manufacturing program is stability studies; the regulatory agency requires one month of stability data for the GMP material for submission of the clinical trial application (CTA).&#160;&#160;Stability data will continue to be gathered while the clinical trials are ongoing and up to 24 months.&#160;&#160;Aditxt has also completed the in-life portion of the toxicology studies.&#160;&#160;Safety data have been recorded and Aditxt is now awaiting immunotoxicology data, which are forthcoming.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon completion of GMP manufacturing and toxicology studies, a CTA will be submitted in Q2 2023 to initiate the Phase I/II FIH clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FIH clinical studies will
combine Phase I (designed to test clinical safety) and Phase IIa (designed to obtain proof of effectiveness in human subjects), in subjects
with psoriatic skin lesions. We have selected this indication for several reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing preclinical data have shown promising results in reducing scaling and skin thickness in the mouse model;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
relative ease of visualization of healing of psoriatic lesions; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
need for therapies that suitable and justifiable in individuals with mild to moderate psoriasis (current biologic therapies are primarily
used in moderate to severe cases).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have identified a contract
research organization with capabilities to conduct a multi-center study and ability to recruit the needed number of subjects to complete
the clinical trials. Upon approval by the regulatory agency clinical trials will be initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-level objectives for
type 1 diabetes (T1D) clinical program:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of IND-enabling work.&#160;&#160;Aditxt has completed GMP manufacturing of clinical grade drug substances (DNA plasmids) and initiated formulation of the drug product (ADI-100) that will be used for the first-in-human studies in subjects with T1D.&#160;&#160;Included in the manufacturing program is stability studies; the regulatory agency requires one month of stability data for the GMP material for submission of the clinical trial application (CTA).&#160;&#160;Stability data will continue to be gathered while the clinical trials are ongoing and up to 24 months.&#160;&#160;Aditxt has also completed the in-life portion of the toxicology studies.&#160;&#160;Safety data have been recorded and Aditxt is now awaiting immunotoxicology data, which are forthcoming.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Phase I/II Study to demonstrate safety and clinical proof-of-concept in T1D</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical studies will
combine Phase I (designed to test clinical safety) and Phase II (designed to obtain proof of effectiveness in human subjects), in T1D
patients. We have selected this indication for several reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing preclinical data have shown promising results using ADI&#8482; to reverse hyperglycemia in the mouse model; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is currently no treatment for T1D and the only option for patients suffering from T1D is life-long insulin replacement therapy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be identifying clinical
trial centers with adequate patients. Upon approval by the regulatory agency clinical trials will be initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">High-level objectives for
skin allograft clinical program:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical studies to identify the appropriate protocol for dosing and combination of ADI&#8482; with immune suppression protocols.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of IND-enabling work including GMP manufacturing and toxicology studies.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Phase I/II Study to demonstrate safety and clinical proof-of-concept in patients requiring skin allografts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical studies will
combine Phase I (designed to test clinical safety) and Phase II (designed to obtain proof of effectiveness in human subjects), in patients
requiring skin allografts. We have selected this indication for several reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our existing preclinical data have shown promising results using ADI&#8482; to prolong skin allograft survival in mismatched mouse model; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relative ease of visualization of graft quality without the need for biopsies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be identifying clinical
trial centers with adequate patients. Upon approval by the regulatory agency clinical trials will be initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing our immune
monitoring platforms with the objective of utilizing them as clinical assays in pre-clinical and clinical studies. The multiplex technologies
could potentially allow evaluation of more analytes with less tissue samples.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Drug Approval Process</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, FDA
approval is required before any new drugs can be introduced to the market.&#160;We currently have a product candidate for our first-in-human
studies, but as of the date of report, we have not submitted an application to the regulatory agencies for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are working with a contract
manufacturer who has the knowledge, product ingredients including plasmid DNA molecules, and our patented methylating bacterial strain.&#160;The
contract manufacturer has completed GMP manufacturing of the plasmid DNA molecules also known as the drug substances. The drug substances
are planned to be shipped to another GMP facility for formulation and fill/finish process in vials that will be used in the clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The product candidate selected
for clinical trials must be subjected to pre-clinical safety/toxicology studies by an independent GLP (Good Laboratory Practice) laboratory
to demonstrate its suitability for clinical testing in human patients.&#160;Upon completion of manufacturing and safety/toxicology testing,
an Investigational New Drug (IND) or Clinical Trial Application will be prepared for submission to the regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of clearance
to initiate clinical testing, the ADI&#8482; product can be tested in human patients.&#160;Our product will be tested in clinical trials
in patients with psoriasis, T1D and one in patients who require skin allografting. Therefore, our first-in-human studies will be combined
Phase I/Phase II studies in which safety and efficacy data will be obtained.&#160;We plan to start with psoriasis and T1D.&#160;In parallel,
we will preparing for clinical trials in skin allografting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing our immune monitoring platforms
with the objective of utilizing them as clinical assays in pre-clinical and clinical studies. The multiplex technologies could potentially
allow evaluation of more analytes with less tissue samples.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Target Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis affects close to
100 million people worldwide and presents a large market estimated at over $20 billion annually. Topical and systemic therapeutics including
vitamin D analogs, steroids, retinoids, immunosuppressants and biologics (i.e. monoclonal antibodies). While in more recent years, several
classes of biologics have entered the market, most are primarily used for patients suffering from moderate to severe psoriasis because
of their impairment of systemic immune responsiveness to infections and cancers. Pre-clinical safety studies by Aditxt have shown that
ADI&#8482; does not impair resistance to a systemic infection using a bacterial species known as <i>Listeria monocytogenes</i> or the
ability to suppress the growth of an implanted melanoma tumor. The absence of immune impairment is important for application of ADI&#8482;
in patients suffering from mild to moderate psoriasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">T1D is one of the most common
chronic disorders in children and affects nearly 2 million Americans with the incidence and prevalence increasing at alarming rates in
industrialized countries. Current treatment consists of daily administration of insulin as replacement therapy, which can induce life-threatening
hypoglycemia and does not completely prevent morbidity and mortality associated with the disease. Aditxt is leveraging the ADI&#8482;
technology to develop a new class of immunotherapy designed to arrest the autoimmune destruction of the insulin producing beta cells of
the pancreas. This will be the first therapy to achieve this elusive goal, which can increase the span and quality of life for up to 40,000
of US citizens and about 300,000 people around the world who develop T1D each year, with a 3-5% increase in yearly incidence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S. alone, there are
over 36,000 patients who receive organ transplantations each year, with more than 113,000 on transplant waiting lists.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The field of organ transplantation
has been made possible and continues to rely on broad-acting immunosuppressive drugs, high levels of which can result in a compromised
immune system that renders organ recipients susceptible to cancer and potentially life-threatening infections including re-activation
of latent viruses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, immunosuppressants
control acute rejection during the early time-period after receiving an organ but chronic rejection of the organ remains an unmet challenge
for surgeons and transplant recipients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While efforts have been made
by various groups to promote tolerance through cell therapies and&#160;<i>ex vivo</i>&#160;manipulation of patient cells, these procedures
take place outside the body and may require hospitalization.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, transplanted patients
will need re-transplantation at some point, with the possible exception of some newborn recipients. With increased incidence of preformed
antibodies, these patients may never have the opportunity to receive another organ. Preformed antibodies can develop in previously transplanted
patients, patients who have given birth, and patients who have previously received blood transfusions.&#160;These patients have much lower
chances of qualifying to receive organs due to their increased risk of rejection &#8211; even with immune suppression.&#160;The potential
to reduce formation of preformed antibodies in these patients will provide better opportunities for them to receive another transplanted
organ.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are gaps between current
approaches and what the market needs.&#160;We believe that ADI&#8482; addresses these gaps.&#160;ADI&#8482; is simple to administer (does
not require&#160;<i>ex-vivo&#160;</i>treatment of patient cells), it does not appear to suppress the immune system, it may allow patients
to live with transplanted organs with significantly reduced immune suppression, it may provide for longer-term survival of transplanted
tissues and organs, may be more effective because it does not rely on a single immune pathway/mechanism, and potentially provides patients
with pre-existing antibodies a chance to qualify to receive organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While these advantages present
opportunities for unmet medical needs in the field of organ transplantation, the industry in which we operate is highly competitive. A
small company such as us will meet significant challenges including regulatory requirements for approval of a new class of therapeutic
agents, challenges in large scale manufacturing and marketing, cost of developing a novel therapeutic agent, which may require co-development
partners who may or may not be willing to work with us, and the willingness of transplant surgeons to adopt our therapeutic vaccines in
their existing immune suppression protocols. These challenges pose risks that we may not be able to overcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>AditxtScore<sup>TM</sup> (Immune Monitoring
Program)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that understanding
the status of an individual&#8217;s immune system is key to understanding health by the numbers and for developing therapeutics that result
in better outcomes for more individuals. We have secured an exclusive worldwide license for commercializing a technology platform named
AditxtScore&#8482;, which provides a personalized comprehensive profile of the immune system. AditxtScore&#8482; is intended to be informative
for individual immune responses to viruses, bacteria, peptides, drugs, supplements, bone marrow and solid organ transplants and cancer.
It has broad applicability to many other agents of clinical interest impacting the immune system, including those not yet identified such
as emerging infectious agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AditxtScore&#8482; is being
designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their
immune system. We believe AditxtScore&#8482; can also assist the medical community in anticipating possible immune responses and reactions
to viruses, bacteria, allergens and foreign tissues such as transplanted organs. This capability may be possible by having the ability
to determine the body&#8217;s potential response and for developing a plan to deal with an undesirable reaction by the immune system.
Its advantages include the ability to provide a simple, rapid, accurate, high throughput assays that can be multiplexed to determine the
immune status with respect to several factors simultaneously, in 3-16 hours. In addition, it can determine and differentiate between various
types of cellular and humoral immune responses (T and B cells and other cell types). It also provides for simultaneous monitoring of cell
activation and levels of cytokine release (i.e., cytokine storms).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to utilize AditxtScore&#8482;
in our upcoming pre-clinical and clinical studies to monitor subjects&#8217; immune response before, during and after ADI&#8482; drug
administration. We are also evaluating plans to obtain regulatory approval for AditxtScore&#8482;&#8217;s use as a clinical assay and
seeking to secure manufacturing, marketing and distribution partnerships for application in the various markets. To obtain regulatory
approval to use AditxtScore&#8482; as a clinical assay, we have conducted validation studies to evaluate its performance in detection
of antibodies and plan to continue conducting additional validation studies for new applications in autoimmune diseases and transplantation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(1)&#160;<span style="text-decoration:underline">Organ Rejection</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Typically, by the time a transplanted
or a native organ shows signs of failure, the damage is already done, and reversal of the tissue injury becomes challenging. Access to
early warning signs of damage would be invaluable to reverse or even prevent the damage. There are currently no practical, efficient assays
available to measure cellular immune responses and available tools do not provide timely information for patients. AditxtScore&#8482;
can be used to provide a sensitive and rapid tool for pre-transplant monitoring and to determine T and B cell response and to differentiate
between various types of cellular immune responses. It can be multiplexed providing information about the number of cells responding as
well as quantifying the amounts of various cytokines released by the cells in the same assay. Determination of cellular response has valuable
applications for prediction, monitoring, early detection, and treatment of disease, including organ failure/rejection, as well as treatment
efficacy. It can also reveal dysfunction of the immune system that can potentially contribute to more severe disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">(2) Autoimmunity</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our immune system develops
to differentiate self from non-self. In autoimmunity, the body&#8217;s ability to distinguish this difference is impaired. Detection of
early signs of immune misrecognition may allow earlier intervention to reduce tissue destruction and to potential reverse the process
more effectively. Better tools are needed to recognize immune responses to our own tissues earlier, and with more sensitivity and accuracy.
AditxtScore&#8482; harnesses the promise to develop such tools that can be used for early diagnosis, evaluation of treatment effectiveness
and determination of the need for maintenance therapies when needed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(3)&#160;<span style="text-decoration:underline">Allergies</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our immune system protects
us by acting as a barrier against foreign substances and by eliminating them when they penetrate our bodies. Once the initial exposure
has occurred, memory cells develop to prepare the body against a future exposure. This process is called immunity. In certain situations,
however, instead of immunity, the immune system develops memory cells that result in a more severe reaction during a future exposure to
the same substance. This type of response is called a hypersensitivity response, commonly known as an allergic response. AditxtScore&#8482;
can be used to develop multiplex panels each designed to test and monitor immune response to allergens. Based on the ability of this technology
to run multiple tests in a single assay, 100 or more substances can potentially be tested simultaneously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(4)&#160;<span style="text-decoration:underline">Drug/Vaccine Response</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no effective
assays to predict and easily assess responses to drugs or vaccines. To determine whether an individual has responded to a particular vaccine,
antibody titers are measured. This process may take several days or even weeks. Furthermore, for vaccines that require a series of injections,
titers are not measured between injections and may not be known for months. AditxtScore&#8482; can be used to determine whether a patient
is a responder or non-responder (e.g. individuals with a suppressed immune response may be non-responders). It can provide an effective
and rapid tool for potentially determining beneficial responses to a vaccine and can be used to monitor levels of immune responsiveness
post vaccination. It can allow evaluation of multiple vaccines in a single test (for memory B cell detection). This application can be
useful for vaccines, cancer therapeutics anti-rejection drugs, anti-viral drugs, among others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(5)&#160;<span style="text-decoration:underline">Disease Susceptibility</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disease susceptibility can
vary from one individual to another, and it can be a function of various factors, including genetic variability and differences in human
leukocyte antigens (HLA) encoded by major histocompatibility complex (MHC) and responsible for regulation of the immune system in humans.
People with certain HLA types may have higher or lower susceptibility to diseases. AditxtScore&#8482; can be used to develop assays to
evaluate differences in HLA types in individuals to help elucidate the relationship between certain HLA types and susceptibility to various
diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(6)&#160;<span style="text-decoration:underline">Infectious Diseases</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Infectious diseases can cause
a major predicament for scientific and medical professionals, epidemiologists, and infectious disease specialists, who need to determine
how to treat patients in real-time while efficacious therapies are still being developed. Proper decision making requires understanding
why some affected individuals show minor or no symptoms, some recover, and others die. This is fundamental to creating effective targeted
therapeutics which may differ depending on the underlying profile of the individual at risk for, or with, disease. The immune system plays
a major role in how any given individual responds to the infectious agent. This response can be inadequate or too robust or appropriately
effective. Regardless, the kinetics of the response by the cellular and humoral (antibody) immune systems to the infectious agent are
often unknown. A basic critical question, then, is what do the dynamics of the immune response look like from exposure to and through
the disease period and during convalescence for those who survive and those who don&#8217;t; and how might vaccines and therapies alter
these profiles such that predictions of vaccine/drug efficacy could be inferred prior to vaccination/treatment and/or disease severity
or progression be prognosticated. AditxtScore&#8482; can be used to help address these questions with multiplex assays each designed to
test and monitor the immune response to infectious agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreement with Leland Stanford Junior
University (&#8220;Stanford&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 3, 2020, we entered
into an exclusive license agreement (the &#8220;February 2020 License Agreement&#8221;) with Stanford regarding a patent concerning a
method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an exclusive
worldwide license to Stanford&#8217;s patent regarding use, import, offer, and sale of Licensed Products (as defined in the agreement).
The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement,
and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive
license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those
terms are defined in the February 2020 License Agreement&#8221;). However, Stanford agreed to not grant further licenses under the Licensed
Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the February 2020
License Agreement which extended our exclusive right to license the technology deployed in AditxtScore<sup>TM</sup>&#160;and securing
worldwide exclusivity in all fields of use of the licensed technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were obligated to pay and
paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 375 shares of the Company&#8217;s common stock to
Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement in the
amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of the patent. The
Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone fees of $50,000 on
the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in
vitro diagnostic product developed and a potential licensed product. The Company paid a milestone fee for a clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product of $25,000 in March of 2022. We are also required
to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which
has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and
operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation
studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which
has been completed), (iv) submit a 510(k) application to the FDA, Emergency Use Authorization (&#8220;EUA&#8221;), or a Laboratory Developed
Test (&#8220;LDT&#8221;) by March 31, 2021 (which has been completed), (vi) develop a prototype assay for human profiling by December
31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity, or
infectious disease purposes by March 31, 2022 (which has been completed) and (viii) provided further development and commercialization
milestones for specific fields of use in writing prior to December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated upon our election on at least 30 days advance
notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and commercializing
Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020 License Agreement;
or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30) day cure period
to remedy such violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Plan of Operations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial application of
the platform was AditxtScore&#8482; for COVID-19 which was designed to provide a more complete assessment of an individual&#8217;s infection
and immunity status with respect to the SARS-CoV-2 virus. Infection status is determined by evaluating the presence or absence of the
virus, and immunity status by measuring levels of antibodies against viral antigens and their ability to neutralize the virus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In early 2021, we established
our AditxtScore&#8482; Immune Monitoring Center in Richmond, Virginia (the &#8220;Center&#8221;). The Center operates as a Clinical Laboratory
Improvement Amendments (CLIA) certified facility for the processing of our AditxtScore&#8482; for COVID-19 Lab Developed Test (LDT) for
our prospective channel partners, including labs and hospitals.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, we filed for
an Emergency Use Authorization (EUA) with the FDA with the ultimate objective of filing a 510(K) application. On January 14, 2022, we
submitted requests to obtain two EUAs for our antibody and neutralizing tests following an announcement on November 15, 2021 by the Department
of Health and Human Services that COVID-19 related tests will require FDA review and FDA&#8217;s position that COVID-19 tests that have
been in use prior to the announcement must submit applications for EUAs but can continue to operate unless informed otherwise. In the
meantime, we are providing AditxtScore&#8482; as a service as a Laboratory Developed Test (LDT) to assess immunity status to COVID-19.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The public health emergency
is planned to be ending in May 2023. Thus, COVID-related assays are no longer considered as priority for review by FDA and will not be
considered for EUAs. In May, FDA may provide more guidance regarding whether COVID-related assays will revert back to pre-pandemic review
process or whether they will require full regulatory review (e.g. 510k). Assays that are not developed for evaluation of infection or
immunity status to SARS-CoV-2 will continue to be offered as LDTs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Intellectual Property (IP)</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We strive to protect and
enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking,
maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect
our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the
United States, to protect our proprietary technology, inventions, improvements and product candidates that are important to the development
and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates,
continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-therapy.
We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available. Our commercial success will
depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements;
to preserve the confidentiality of our trade secrets; to obtain and maintain licenses to use intellectual property owned by third parties;
to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing
on the valid and enforceable patents and other proprietary rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our innovation portfolio
includes: (1) ADI&#8482; immune modulation technologies, which are currently at the pre-clinical stage and are designed to retrain the
immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies;
and (2) AditxtScore&#8482; immune monitoring technologies designed to provide a personalized comprehensive profile of the immune system.
Both categories are protected by multiple families of patents and patent applications, including several issued U.S. and non-U.S. patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The projected expiration
dates for the ADI&#8482; patents and patents issuing from pending applications extend until 2043 for some patents. As of the date of
this report, our patent portfolio for ADI&#8482; includes both patents and patent applications licensed from LLU or Stanford and patent
applications owned solely by Aditxt, including 120 granted patents, 2 allowed patent applications and 30 pending patient applications
in U.S. and other regions. These patents and patent applications cover three different technical aspects of ADI&#8482;, treatment of
autoimmune diseases and type 1 diabetes, treatment of organ transplantation, and development of a new class of immunotherapeutics for
various indications. The patents and patent applications cover both methods of treatment for these indications as well as compositions
of matter including plasmids that are able to induce tolerance to antigens or prevention of immune attack on antigens, depending on the
indication, along with methods of producing such plasmids.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AditxtScore&#8482; technology
is also protected by multiple families of patents and patent applications, including several issued U.S. and non-U.S. patents. The projected
expiration dates for these AditxtScore&#8482; patents and patents issuing from pending applications ranges from 2037 to 2043. As of the
date of this report, our patent portfolio for AditxtScore&#8482; includes both patents and patent applications licensed from Stanford
and patent applications owned solely by Aditxt, including granted patents and 12 applications. These patents and patent applications
encompass methods, systems and kits for detection and measurement of specific immune responses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also possess and/or in-license
substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related
manufacturing processes and technology. We plan to continue expanding and strengthening our IP portfolio with additional patent applications
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, Aditxt signed
an agreement with a regulatory consultant based in&#160;Munich, Germany, which will play a central role in navigating the first ADI&#8482;&#160;therapeutic
program through the clinical trial and regulatory process. The firm has been working with the Aditxt&#8217;s ADI&#8482;&#160;team to
submit a clinical trial application to the regulatory agency in Germany. Psoriasis is the first indication being targeted for clinical
trial in the ADI&#8482;&#160;therapeutics pipeline. Other candidates that are advancing toward clinical trials include ADI&#8482; for
type 1 diabetes and skin allografting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have sixty-one (61) full
time employees as of December 31, 2022. We consider the relations with our employees to be good.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider the risks described
below, as well as general economic and business risks and the other information in this Annual Report on Form&#160;10-K. The occurrence
of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results
of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties
not presently known to us or that we currently deem immaterial may also harm our business.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Financial Position and
Need for Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have generated no significant revenue
from commercial sales to date and our future profitability is uncertain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in September
2017 and have a limited operating history and our business is subject to all of the risks inherent in the establishment of a new business
enterprise. Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays frequently
encountered in connection with development and expansion of a new business enterprise. Since inception, we have incurred losses and expect
to continue to operate at a net loss for at least the next several years as we commence our research and development efforts, conduct
clinical trials and develop manufacturing, sales, marketing and distribution capabilities. Our net loss for the years ended December
31, 2022 and 2021 was $27,549,876 and $46,371,364, respectively, and our accumulated deficit as of December 31, 2022 was $95,040,362.
There can be no assurance that the products under development by us will be approved for sale in the U.S. or elsewhere. Furthermore,
there can be no assurance that if such products are approved, they will be successfully commercialized, and the extent of our future
losses and the timing of our profitability are highly uncertain. If we are unable to achieve profitability, we may be unable to continue
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain the capital necessary
to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to continue
to seek capital from time to time to continue development of our lead drug candidate beyond our initial combined Phase I/IIa clinical
trial and to acquire and develop other product candidates. Once approved for commercialization, we cannot provide any assurances that
any revenues it may generate in the future will be sufficient to fund our ongoing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhance products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
treatment modalities. In addition, we may need to accelerate the growth of our sales capabilities and distribution beyond what is currently
envisioned, and this would require additional capital. However, we may not be able to secure funding when we need it or on favorable
terms. We may not be able to raise sufficient funds to commercialize the product candidates we intend to develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. This could result in sharing revenues which we might otherwise retain
for ourselves. Any of these actions may harm our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of capital we
may need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing
and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost
necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our financial situation creates doubt whether
we will continue as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company was incorporated
on September 28, 2017 and through the date of this report has generated no significant revenues. For the years ended December 31, 2022
and 2021, the Company had a net loss of $27,649,876 and $46,371,364, respectively. There can be no assurances that we will be able to
achieve a level of revenues adequate to generate sufficient cash flow from operations or additional financing through private placements,
public offerings and/or bank financing necessary to support our working capital requirements. To the extent that funds generated from
any private placements, public offerings and/or bank financing are insufficient, we will have to raise additional working capital. No
assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise
substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to
discontinue operations, which would cause investors to lose their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need to raise additional funding,
which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay,
limit or terminate our product development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect that our
current cash position will be sufficient to fund our current operations for the next 12 months. Our operating plan may change as a result
of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity
or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic
alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain
regulatory approval for, and to commercialize, our product candidates. Raising funds in the current economic environment may present
additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares
to decline. The sale of additional equity or convertible securities may dilute our existing stockholders. The incurrence of indebtedness
would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations
on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through
arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to
relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have
a material adverse effect on our business, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business
opportunities, as desired, which could materially affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we can raise additional funding,
we may be required to do so on terms that are dilutive to you.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The capital markets have
been unpredictable in the past for unprofitable companies such as ours. In addition, it is generally difficult for development stage
companies to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often
depends on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at
all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate
funds are not available on acceptable terms, or at all, our business, including our results of operations, financial condition and our
continued viability will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Unstable
market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have
serious adverse consequences on our business, financial condition, and stock price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">The
global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressure, and interest rate changes,
increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely
affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism, or
other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one
in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected
countries or others could exacerbate market and economic instability. More recently, the closures of Silicon Valley Bank (&#8220;SVB&#8221;)
and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation (FDIC) created bank-specific
and broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the
FDIC jointly released a statement that depositors at SVB and Signature Bank would have access to their funds, even those in excess of
the standard FDIC insurance limits, under a systemic risk exception, future adverse developments with respect to specific financial institutions
or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term
working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial
market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely
affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market
conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may
cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure
to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy,
financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk
that one or more of our current service providers, financial institutions, manufacturers and other partners may be adversely affected
by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget. The Company
does not hold any deposits or securities or maintain any accounts at SVB or Signature Bank.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Product Development, Regulatory
Approval, Manufacturing and Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The regulatory approval process is expensive,
time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our future product candidates,
if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not be permitted
to market our product candidates in the United States until we receive approval from the FDA, or in any foreign countries until we receive
the requisite approval from corresponding agencies in such countries. The testing, manufacturing, labeling, approval, selling, marketing
and distribution of health and life science-related products are subject to extensive regulation, which regulations differ from country
to country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Successfully completing our
clinical program and obtaining approval of a Biologics License Application (&#8220;BLA&#8221;) is a complex, lengthy, expensive and uncertain
process, and the FDA or other applicable foreign regulator may delay, limit or deny approval of our product candidates for many reasons,
including, among others, because:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction of the
    FDA or foreign regulator;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or foreign regulator
    for marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may require that we conduct additional clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may not approve the formulation, labeling or specifications of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    contract research organizations (CROs) and other contractors that we may retain to conduct our clinical trials may take actions outside
    of our control that materially adversely impact our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may find the data from preclinical studies and clinical trials insufficient to demonstrate that our product
    candidate(s) are safe and effective for their proposed indications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may disagree with our interpretation of data from our preclinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may not accept data generated at our clinical trial sites or may disagree with us over whether to accept
    efficacy results from clinical trial sites outside the United States or outside the EU, as applicable, where the standard of care
    is potentially different from that in the United States or in the EU, as applicable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    and when our BLAs or foreign equivalents are submitted to the applicable regulatory authorities, such agencies may have difficulties
    scheduling the necessary review meetings in a timely manner, may recommend against approval of our application or may recommend or
    require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution
    and use restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may require development of a Risk Evaluation and Mitigation Strategy (REMS), which would use risk minimization
    strategies to ensure that the benefits of certain prescription drugs outweigh their risks, as a condition of approval or post-approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other applicable foreign regulatory agencies may not approve the manufacturing processes or facilities of third-party manufacturers
    with which we contract; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or the other applicable foreign regulatory agencies may change their approval policies or adopt new regulations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in
completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy
to the satisfaction of applicable regulatory authorities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is difficult to predict
if or when any of our product candidates, will prove safe or effective in humans or&#160;will&#160;receive regulatory approval. Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies
to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain
as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure
of one or more clinical studies can occur at any stage of testing. Events that may prevent successful or timely completion of clinical
development include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching, or failing to reach, a consensus with regulatory agencies on study design;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching, or failing to reach, agreement on acceptable terms with a sufficient number of prospective contract research organizations
    (&#8220;CROs&#8221;) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly
    among different CROs and trial sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board (&#8220;IRB&#8221;) or Ethics Committee (&#8220;EC&#8221;) approval at each clinical
    study site;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in recruiting a sufficient number of suitable patients to participate in our clinical studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory agencies, after an inspection of our clinical study operations or study sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our&#160;CROs, other third parties or us to adhere to the clinical study, regulatory or legal requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s good clinical practices (&#8220;GCP&#8221;) or applicable regulatory guidelines in
    other countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in the
    testing, validation, manufacturing and delivery of sufficient quantities of our product candidates to the clinical sites;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in having patients&#8217;
    complete participation in a study or return for post-treatment follow-up;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical study sites or
    patients dropping out of a study;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay or failure to address
    any patient safety concerns that arise during the course of a trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated costs or
    increases in costs of clinical trials of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence of serious adverse
    events associated with the product candidates that are viewed to outweigh their potential benefits; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements
    and guidance that require amending or submitting new clinical protocols.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could also encounter delays
if a clinical trial is suspended or terminated by us, by the IRBs or ECs of the institutions in which such trials are being conducted,
by an independent Safety Review Board (&#8220;SRB&#8221;) for such trial or by the FDA, European Medicines Agency (&#8220;EMA&#8221;),
or other regulatory authorities. Such authorities&#160;may&#160;suspend or terminate a clinical trial due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen
safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any inability to successfully
complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from
product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes
to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical study delays could
also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors
to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates.&#160;In
addition, any delays in completing our clinical trials will increase our costs, slow down&#160;our&#160;product candidate development
and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly
harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outcome of preclinical
studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial
do not necessarily predict final results. Further, preclinical and clinical data are often susceptible to various interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have, nonetheless, failed to obtain marketing approval.&#160;If the results of our clinical studies are inconclusive or if there
are safety concerns or adverse events associated with our other product candidates, we may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be delayed
    in obtaining marketing approval for our product candidates, if approved at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval
    for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval with labeling
    that includes significant use or distribution restrictions or safety warnings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be required
    to change the way the product is administered;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be required to perform
    additional clinical studies to support approval or be subject to additional post-marketing testing requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have regulatory authorities
    withdraw their approval of a product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation
    strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be sued; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience damage to our
    reputation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our product
candidates could potentially cause other adverse events that have not yet been predicted. The inclusion of ill patients in our clinical
studies may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using. As
described above, any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and impair
our ability to commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our future pre-clinical development
and future clinical Phase I/II studies are unsuccessful, we may be unable to obtain regulatory approval of, or commercialize, our product
candidates on a timely basis or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The successful completion
of pre-clinical development and multiple clinical trials is critical to the success of our future products. If the pre-clinical development
and clinical trials are unsuccessful or produce inconsistent results or unanticipated adverse side effects, or if we are unable to collect
reliable data, regulatory approval of our products could be delayed or not given and as a result we may be unable to commercialize our
products. Generally, we expect to engage third parties such as consultants, universities or other collaboration partners to conduct clinical
trials on our behalf. Incompatible practices or misapplication of our products by these third parties could impair the success of our
clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval
for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that we generate from
their sales, if any, may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved for marketing,
the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical community, including
physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will depend on a number
of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative convenience, dosing
    burden and ease of administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity
    of any adverse effects;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of physicians
    to prescribe our product candidates, and the target patient population to try new therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy of
    our product candidates compared to competing products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the introduction of any
    new products that may in the future become available targeting indications for which our product candidates may be approved;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new procedures or therapies
    that may reduce the incidences of any of the indications in which our product candidates may show utility;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing and
    cost-effectiveness;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inclusion or omission
    of our product candidates in applicable therapeutic and vaccine guidelines;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our
    own or any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in approved labeling from regulatory authorities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid,
    private health insurers and other third-party payors or to receive the necessary pricing approvals from government bodies regulating
    the pricing and usage of therapeutics; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of patients
    to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our product candidates
are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate
sufficient revenues and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party
payors on the benefits of our product candidates may require significant resources and may never be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if we obtain
regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product candidates
successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability
to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render our product candidates not commercially viable. For example, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the
performance of costly post-marketing clinical trials, or may approve any of our product candidates with a label that does not include
the labeling claims necessary or desirable for the successful commercialization for that indication. Further, the FDA or comparable foreign
regulatory authorities may place conditions on approvals or require risk management plans or a Risk Evaluation and Mitigation Strategy
(&#8220;REMS&#8221;) to assure the safe use of the drug. If the FDA or applicable foreign regulatory agency concludes a REMS is needed,
the sponsor of the BLA must submit a proposed REMS; the regulatory agencies will not approve the BLA without an approved REMS, if required.
A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
methods, patient registries and other risk minimization tools. The regulatory agencies may also require a REMS for an approved product
when new safety information emerges. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescription or dispensing of our product candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory
standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the
commercial success of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adverse events involving our products may
lead the FDA or applicable foreign regulatory agency to delay or deny clearance for our products or result in product recalls that could
harm our reputation, business and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a product receives regulatory
clearance or approval, the agency has the authority to require the recall of commercialized products in the event of adverse side effects,
material deficiencies or defects in design or manufacture. The authority to require a recall must be based on a regulatory finding that
there is a reasonable probability that the product would cause serious injury or death. Manufacturers may, under their own initiative,
recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us or one of our distributors
could occur as a result of adverse side effects, impurities or other product contamination, manufacturing errors, design or labeling
defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an
adverse effect on our financial condition and results of operations. The regulatory agencies require that certain classifications of
recalls be reported to them within ten (10) working days after the recall is initiated. Companies are required to maintain certain records
of recalls, even if they are not reportable to the regulatory agency. We may initiate voluntary recalls involving our products in the
future that we determine do not require notification of the regulatory agencies. If the regulatory agency disagrees with our determinations,
they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively
affect our sales. In addition, the regulatory agency could take enforcement action for failing to report the recalls when they were conducted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The in-licensing of technologies and the
successful testing and early development of technologies in the laboratory may not be indicative of future results and may not result
in commercially viable technologies or products. Further, our future products may have to be modified from their originally conceived
versions in order to reach or be successful in the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Positive results from laboratory
testing and early developmental successes, may not be predictive of future successful development, commercialization and sales results
and should not be relied upon as evidence that products developed from our technologies will become commercially viable and successful.
Further, the products we plan to develop in the future may have to be significantly modified from their originally conceived versions
in order for us to control costs, compete with similar products, receive market acceptance, meet specific development and commercialization
timeframes, avoid potential infringement of the proprietary rights of others, or otherwise succeed in developing our business and earning
ongoing revenues. This can be a costly and resource draining activity. What appear to be promising technologies when we license them
may not lead to viable technologies or products, or to commercial success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Complying with numerous regulations pertaining
to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the Clinical
Laboratory Improvement Amendment of 1988, or CLIA, which is a federal law regulating clinical laboratories that perform testing on specimens
derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory
is located in Richmond, Virginia and must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended
to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel
qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance
and inspections. We currently hold a CLIA certificate to perform high-complexity testing. Laboratories performing high complexity testing
are required to meet more stringent requirements than laboratories performing less complex tests. CLIA regulations require clinical laboratories
like ours to comply with various operational, personnel, facilities administration, quality, and proficiency testing requirements intended
to ensure that testing services are accurate, reliable and timely. CLIA certification is a prerequisite for reimbursement eligibility
for services provided to state and federal health care program beneficiaries. CLIA is user-fee funded. Therefore, all costs of administering
the program must be covered by the regulated facilities, including certification and survey costs. To renew this certificate, we are
subject to survey and inspection every two years. Moreover, CLIA inspectors may make periodic inspections of our clinical laboratory
outside of the renewal process. The failure to comply with CLIA requirements can result in enforcement actions, including the revocation,
suspension, or limitation of our CLIA certificate of compliance, as well as a directed plan of correction, state on-site monitoring,
civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible
to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected
to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance,
we could incur significant expenses and potentially lose revenue in doing so.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, certain states
require laboratory licenses in order to test specimens from patients in those states or received from ordering physicians in those states.
We may also be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays outside the
United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we were to lose our CLIA
certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able
to offer our assays (including our AditxtScore&#8482; platform), which would limit our revenues and harm our business. If we were to
lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens
from those states.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the Company and our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our technology is subject to licenses from
LLU and Stanford, each of which are revocable in certain circumstances, including in the event we do not achieve certain payments and
milestone deadlines. Without these licenses, we may not be able to continue to develop our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LLU License Agreement
may be terminated by LLU in the event of a breach by us of any non-payment provision (including the provision that requires us to meet
certain deadlines for milestone events (each, a &#8220;Milestone Deadline&#8221;)) not cured within 90 days after delivery of written
notice by LLU. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application to initiate
first-in-human clinical trials on or before March 31, 2022 (which has been extended to March 31, 2023 due to payment of a $100,000 extension
fee in March 2022), (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii) the completion of Phase
III clinical trials by March 31, 2026 and (iv) biologic licensing approval (BLA) by the FDA by March 31, 2027. If the LLU License Agreement
were to be terminated by LLU, we would lose our most significant asset and may no longer be able to develop our product candidates, which
would have a material adverse effect on our operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The February 2020 License
Agreement with Stanford may be terminated by Stanford if we (i) are delinquent on any report or payments; (ii) are not diligently developing
and commercializing Licensed Product (as defined in the February 2020 License Agreement); (iii) miss a milestone described in the agreement;
(iv) are in breach of any other provision of the agreement; or (v) if we provide a false report to Stanford. The Termination discussed
above will take effect only upon 30 days written notice by Stanford unless we remedy the breach within a 30-day cure period. If the February
2020 License Agreement were to be terminated by Stanford, we would lose a significant asset and may no longer be able to develop our
product candidates, which would have a material adverse effect on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our results of operations will be affected
by the level of royalty and milestone payments that we are required to pay to third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LLU License Agreement
and February 2020 License Agreement with Stanford each require us to remit royalty payments and meet certain performance milestones related
to in-licensed intellectual property. Any failure on our part to pay royalties owed or meet milestones could lead to us losing rights
under our licenses and could thereby adversely affect our business. As our product sales increase, we may, from time-to-time, disagree
with our third-party collaborators as to the appropriate royalties owed and the resolution of such disputes may be costly and may consume
management&#8217;s time. Furthermore, we may enter into additional license agreements in the future, which may also include royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face substantial competition, which
may result in others discovering, developing or commercializing products before or more successfully than we do.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development and commercialization
of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized biotechnology companies,
as well as products and processes being developed at universities and other research institutions. Our competitors have developed, are
developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments
include those that have already been approved and accepted by the medical community and any new treatments that may enter the market.
We believe that a significant number of products are currently available, under development, and may become commercially available in
the future, for the treatment of indications for which we may try to develop product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More established companies
may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of
our competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors
may have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before we are
able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that
are safer, more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and
marketing their products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mergers and acquisitions
in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific,
management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our technologies and products under development,
and our business, may fail if we are not able to successfully commercialize them and ultimately generate significant revenues as a result.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Successful development of
technologies and our product candidates will require significant additional investment, including costs associated with additional development,
completing trials and obtaining regulatory approval, as well as the ability to manufacture or have others manufacture our products in
sufficient quantities at acceptable costs while also preserving product quality. Difficulties often encountered in scaling up production
include problems involving production yields, quality control and assurance, shortage of qualified personnel, production costs and process
controls. In addition, we are subject to inherent risks associated with new technologies and products. These risks include the possibility
that any of our technologies or future products may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be found unsafe;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be ineffective
    or less effective than anticipated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail to receive
    necessary regulatory approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be difficult
    to competitively price relative to alternative solutions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be harmful
    to consumers or the environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be difficult
    to manufacture on an economically viable scale;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject
    to supply chain constraints for raw materials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail to be
    developed and accepted by the market prior to the successful marketing of alternative products by competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be difficult
    to market because of infringement on the proprietary rights of third parties; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be too expensive
    for commercial use.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we may be faced
with lengthy market partner or distributor evaluation and approval processes. Consequently, we may incur substantial expenses and devote
significant management effort in order to customize products for market partner or distributor acceptance, though there can be no assurance
of such acceptance. As a result, we cannot accurately predict the volume or timing of any future sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customers may not adopt our products quickly,
or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers in the sector in
which we operate can be generally cautious in their adoption of new products and technologies. In addition, given the relative novelty
of our future planned products (including our AditxtScore&#8482; platform), customers of those products may require education regarding
their utility and use, which may delay their adoption. There can be no assurance that customers will adopt our products quickly, or at
all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The significant level of competition in
the markets for our products developed in the future may result in pricing pressure, reduced margins or the inability of our future products
to achieve market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The markets for our future
products are intensely competitive and rapidly changing. We may be unable to compete successfully, which may result in price reductions,
reduced margins and the inability to achieve market acceptance for our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may have
longer operating histories, significantly greater resources, greater brand recognition and large customer bases than we do. As a result,
they may be able to devote greater resources to the manufacture, promotion or sale of their products, receive greater resources and support
from market partners and independent distributors, initiate or withstand substantial price competition or more readily take advantage
of acquisition or other opportunities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties for the distribution
of our current and future products, including our AditxtScore&#8482; platform.&#160;If these parties do not distribute our products in
a satisfactory or timely manner, in sufficient quantities or at an acceptable cost, our sales and development efforts could be delayed
or otherwise negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third parties
for the distribution of our current and future products, including our AditxtScore&#8482; platform. Our reliance on third parties to
distribute products may present significant risks to us, including the risk that should any of these third parties fail to adequately
distribute our products and services to end consumers and other market participants, our business may be materially harmed. Additionally,
if we need to enter into agreements for the distribution of our future products with other third parties, there can be no assurance we
will be able to do so on favorable terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may rely on third parties for the production
of our future products.&#160;If these parties do not produce our products at a satisfactory quality, in a timely manner, in sufficient
quantities or at an acceptable cost, our sales and development efforts could be delayed or otherwise negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely on third parties
for the manufacture of our future products. Our reliance on third parties to manufacture our future products may present significant
risks to us, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control
    over delivery schedules, yields and product reliability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    deviations from internal and regulatory specifications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure
    of a key manufacturer to perform as we require for technical, market or other reasons;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in establishing additional manufacturer relationships if we are presented with the need to transfer our manufacturing process technologies
    to them;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation
    of our intellectual property; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks
    in potentially meeting our product development schedule or satisfying the requirements of our market partners, distributors, direct
    customers and end users.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we need to enter into
agreements for the manufacturing of our future products, there can be no assurance we will be able to do so on favorable terms, if at
all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to establish successful
relations with third-party market partners or distributors, or these market partners or distributors do not focus adequate resources
on selling our products or are otherwise unsuccessful in selling them, sales of our products may not develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate relying on
independent market partners and distributors to distribute and assist us with the marketing and sale of our products. Our future revenue
generation and growth will depend in large part on our success in establishing and maintaining this sales and distribution channel. If
our market partners and distributors are unable to sell our products, or receive negative feedback from end users, they may not continue
to purchase or market our products. In addition, there can be no assurance that our market partners and distributors will focus adequate
resources on selling our products to end users or will be successful in selling them. Many of our potential market partners and distributors
are in the business of distributing and sometimes manufacturing other, possibly competing, products.&#160;As a result, these market partners
and distributors may perceive our products as a threat to various product lines currently being distributed or manufactured by them.
In addition, these market partners and distributors may earn higher margins by selling competing products or combinations of competing
products. If we are unable to establish successful relationships with independent market partners and distributors, we will need to further
develop our own sales and distribution capabilities, which would be expensive and time-consuming and might not be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to attract and retain
highly skilled employees and contractors, we may not be able to implement our business model successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will rely upon employees
and third-party consultant/contractors to effectively establish, manage and grow our business. Consequently, we believe that our future
viability will depend largely on our ability to attract and retain highly skilled personnel.&#160;In order to do so, we may need to pay
higher compensation, fees, and/or other incentives to our employees or consultants than we currently expect, and such higher compensation
payments would have a negative effect on our operating results. Competition for experienced, high-quality employees, consultants and
contractors is intense and we cannot assure that we will be able to recruit and retain such personnel. We may not be able to hire or
retain the necessary personnel to implement our business strategy. Our failure to hire and retain such personnel could impair our ability
to develop new products and manage our business effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The loss of our management team or other
key personnel would have an adverse impact on our future development and impair our ability to succeed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the early stages of development,
our business will be significantly dependent on the Company&#8217;s management team and other key personnel. Our success will be particularly
dependent upon our Chief Executive Officer, Mr. Amro Albanna and our Chief Innovation Officer, Dr. Shahrokh Shabahang. The loss of any
one of these individuals or any other future key personnel could have a material adverse effect on the Company and our ability to further
execute our intended business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of our products may be limited
by regulations, and we may be exposed to product liability and remediation claims.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of our planned products
may be regulated by various local, state, federal and foreign regulators.&#160;Even if we are able to comply with all such regulations
and obtain all necessary registrations, we cannot provide assurance that our future products will not cause injury to the environment,
people, or animals and/or otherwise have unintended adverse consequences, under all circumstances. For example, our products may be improperly
combined with other chemicals or, even when properly combined, our products may be blamed for damage caused by those other chemicals.
The costs of remediation or products liability could materially adversely affect our results, financial condition and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be held liable for, or incur costs
to settle, liability and remediation claims if any products we develop, or any products that use or incorporate any of our technologies,
cause injury or are found unsuitable during product testing, manufacturing, marketing, sale or use. These risks exist even with respect
to products that have received, or may in the future receive, regulatory approval, registration or clearance for commercial use. We cannot
guarantee that we will be able to avoid product liability exposure.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the stage customary to
do so, we expect to maintain product liability insurance at levels we believe are sufficient and consistent with industry standards for
like companies and products. However, we cannot guarantee that our product liability insurance will be sufficient to help us avoid product
liability-related losses. In the future, it is possible that meaningful insurance coverage may not be available on commercially reasonable
terms or at all. In addition, a product liability claim could result in liability to us greater than our assets or insurance coverage.
Moreover, even if we have adequate insurance coverage, product liability claims or recalls could result in negative publicity or force
us to devote significant time and attention to these matters, which could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There may be limitations on the effectiveness
of our internal controls, and a failure of our control systems to prevent error or fraud may materially harm our Company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect that internal
control over financial accounting and disclosure, even if timely and well established, will prevent all error and all fraud. A control
system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s
objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits
of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control
systems to prevent error or fraud could materially adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>COVID-19 may impact our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 30, 2020, the
World Health Organization declared the COVID-19 coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221;
and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include
restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The
COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies
and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long
these conditions will last and what the complete financial effect will be to the Company, capital raise efforts and additional development
of our technologies may be negatively affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Intellectual Property
Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The failure to obtain or maintain patents,
licensing agreements and other intellectual property could materially impact our ability to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order for our business
to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on, a proprietary position with respect
to our technologies and intellectual property. However, there are significant risks associated with our actual or proposed intellectual
property. The risks and uncertainties that we face with respect to our rights principally include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending patent
    applications we have filed or will file may not result in issued patents or may take longer than we expect to result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to interference proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to reexamination proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to post grant review proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to&#160;<i>inter partes&#160;</i>review proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to derivation proceedings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject
    to opposition proceedings in the U.S. or in foreign countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patents
    that are issued to us may not provide meaningful protection;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not
    be able to develop additional proprietary technologies that are patentable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may challenge patents licensed or issued to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may have independently developed and patented (or may in the future independently develop and patent) similar or alternative technologies,
    or duplicate our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may design around technologies we have licensed or developed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    of patents is complex, uncertain and very expensive and we may not be able to secure,&#160;enforce and defend our patents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the event
    that we were to ever seek to enforce our patents in ligation, there is some risk that they could be deemed invalid, not infringed,
    or unenforceable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
any patents will be issued as a result of any pending or future applications, or that any patents, once issued, will provide us with
adequate protection from competing products. For example, issued patents may be circumvented or challenged, declared invalid or unenforceable,
or narrowed in scope. In addition, since publication of discoveries in scientific or patent literature often lags behind actual discoveries,
we cannot be certain that we or our licensors were the first to invent or to file patent applications covering them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that
others may have or may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses
requiring the payment of significant fees or royalties in order to enable us to conduct our business. There is no guarantee that such
licenses will be available based on commercially reasonable terms. As to those patents that we have licensed, our rights depend on maintaining
our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
patent protection for our products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop
and commercialize products similar or identical to ours, and our ability to successfully commercialize our products could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent prosecution process
is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable
cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our development
output before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position of life
science companies generally is highly uncertain, involves complex legal and factual questions and has in past years been the subject
of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United
States and we may fail to seek or obtain patent protection in all major markets. For example, unlike the U.S., European patent law restricts
the patentability of methods of treatment of the human body. Our pending and future patent applications may not result in patents being
issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive
technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries
may diminish the value of our patents or narrow the scope of our patent protection, even post-grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent patent reform legislation
has increased the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued
patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act
includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications
are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office, or USPTO, recently developed new regulations
and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the
Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents, all of which could have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we may be subject
to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, reexamination,&#160;<i>inter
partes&#160;</i>review, post-grant review or interference proceedings challenging our patent rights (whether licensed or otherwise held)
or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of,
or invalidate, our patent rights (whether licensed or otherwise held), allow third parties to commercialize our technology or products
and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications (whether
licensed or otherwise held) is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our patent applications
(whether licensed or otherwise held) result in the issuance of patents, they may not issue in a form that will provide us with any meaningful
protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be
able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of a patent
is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed or owned patents may be challenged in the
courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or
in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical products, or limit the duration of the patent protection of our products. Given the
amount of time required for the development, testing and regulatory review of new life science product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property rights
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our intellectual property rights, which could be expensive, time-consuming and ultimately unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe
our intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be
expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against
us alleging that we infringe their intellectual property or that our intellectual property is invalid or unenforceable. In addition,
in a patent infringement proceeding, a court may decide that a licensed or owned patent of ours is invalid or unenforceable, in whole
or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover that technology. Moreover, lawsuits to protect or enforce our intellectual property rights could be expensive,
time-consuming and ultimately unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may initiate legal proceedings
alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
upon our ability to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties.
There is considerable intellectual property litigation in the life sciences industry. We cannot guarantee that our product candidates
will not infringe third-party patents or other proprietary rights. We may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to our products and technology, including&#160;<i>inter partes&#160;</i>review,
interference, or derivation proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement
claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are found to infringe
a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing
and marketing our products. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even
if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed
to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could
be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed
a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets
of third parties could have a similar negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining and maintaining
our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed
by governmental patent agencies, and our own patent protection could be reduced or eliminated for noncompliance with these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees
and annuities on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of
the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure
to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal
documents. In such an event, our competitors might be able to enter our markets, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims by third parties
asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain employees and contractors
were previously employed at universities or other companies, including potential competitors. Although we try to ensure that our employees
and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these
employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s
former employer. Litigation may be necessary to defend against these claims, and any such litigation could have an unfavorable outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while it is
our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements
assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and
we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what
we regard as our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail in prosecuting
or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.
Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and adverse results,
and be a distraction to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Some intellectual property which we own
or have licensed may have been discovered through government funded programs such as, for example, the government funded programs referenced
in intellectual property licensed under the LLU License Agreement, and thus may be subject to federal regulations such as &#8220;march-in&#8221;
rights, certain reporting requirements, and a preference for United States industry. Compliance with such regulations may limit our exclusive
rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S.
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the intellectual
property rights we own or have licensed have been generated through the use of United States government funding and may therefore be
subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied
in our current or future products and product candidates pursuant to the Bayh-Dole Act of 1980. These United States government rights
in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license
to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive,
partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps
have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or
(iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in
rights&#8221;). The United States government also has the right to take title to these inventions if we fail to disclose the invention
to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the
United States government may acquire title to these inventions in any country in which a patent application is not filed within specified
time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance
with which may require us to expend substantial resources. In addition, the United States government requires that any products embodying
the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing
preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have
been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States
or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may
limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by
the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property litigation could
cause us to spend substantial resources and distract our personnel from their normal responsibilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have an adverse effect on the price of our common stock. Such litigation or proceedings could increase our operating
losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may
not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to
compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may spend considerable resources developing
and maintaining patents, licensing agreements and other intellectual property that may later be abandoned or may otherwise never result
in products brought to market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not all technologies and
candidate products that initially show potential as the basis for future products ultimately meet the rigors of our development process
and as a result may be abandoned and/or never otherwise result in products brought to market.&#160;In some cases, prior to abandonment
we may be required to incur significant costs developing and maintaining intellectual property and/or maintaining license agreements
and our business could be harmed by such costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on information technology, and
if we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations
could be disrupted, and our business could be negatively affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on information technology
networks and systems to process, transmit and store electronic and financial information; to coordinate our business; and to communicate
within our Company and with customers, suppliers, partners and other third-parties. These information technology systems may be susceptible
to damage, disruptions or shutdowns, hardware or software failures, power outages, computer viruses, cyber-attacks, telecommunication
failures, user errors or catastrophic events. If our information technology systems suffer severe damage, disruption or shutdown, and
our business continuity plans do not effectively resolve the issues in a timely manner, our operations could be disrupted, and our business
could be negatively affected. In addition, cyber-attacks could lead to potential unauthorized access and disclosure of confidential information,
and data loss and corruption. There is no assurance that we will not experience these service interruptions or cyber-attacks in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We received a written notice from Nasdaq
that we have failed to comply with certain listing requirements of the Nasdaq Stock Market, which could result in our Common Stock being
delisted from the Nasdaq Stock Market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 18, 2022, the
Company received a notification from the Listing Qualifications Staff The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) related to our
failure to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days leading
up to January 18, 2022, the Company no longer met this requirement. The Nasdaq Listing Rules provided a compliance period of 180 calendar
days in which to regain compliance. Accordingly, if at any time from the date of this notice until July 18, 2022, the closing bid price
our common stock is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide us with written confirmation of compliance
and the matter will be closed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 19, 2022, the Company
received a letter from the Nasdaq of notifying the Company that it has not regained compliance with the minimum bid price rule in Nasdaq
Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Rule&#8221;) by July 18, 2022 and is not eligible for a second 180 day extension
as the Company does not comply with the stockholders&#8217; equity initial listing requirement for The Nasdaq Capital market. The letter also
stated that, unless the Company requests an appeal, the Company&#8217;s securities would be delisted from The Nasdaq Capital Market and would
be suspended at the opening of business on July 28, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company submitted an
appeal to Nasdaq, which stayed the delisting and suspension of the Company&#8217;s securities pending the decision of the Nasdaq Hearings Panel.
At the hearing in September 2022, the Company presented its views and its plans to regain compliance with the Minimum Bid Price Rule
to the Panel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 28, 2022, the
Company received the determination from Nasdaq that the Company had regained compliance with the requirements to remain listed in the
Nasdaq Capital Market subject to a Panel Monitor of the Company&#8217;s compliance with such requirements as set forth in Listing Rule
5815(d)(4)(A) until March 28, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, within that monitoring
period, the Listing Qualifications staff (&#8220;Staff&#8221;) finds the Company out of compliance with one or more listing standards
during that period notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with
respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect
to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff
will issue a Staff Delist Determination and the Company will have an opportunity to request a new hearing with the initial Hearings Panel
or a newly convened Hearings Panel if the initial Hearings Panel is unavailable. The Company will have the opportunity to respond/present
to the Hearings Panel as provided by Listing Rule 5815(d)(4)(A). If the hearing is unsuccessful, the Company&#8217;s securities may be
at that time delisted from Nasdaq. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the monitoring period,
the Company failed to maintain compliance with the minimum bid price of $1.00 per share for 9 consecutive trading days between March 16,
2023 and March 28, 2023. Since the end of the monitoring period, the Company has failed to maintain compliance with the minimum bid price
of $1.00 per share for 12 consecutive trading days between March 29, 2023 and April 14, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are delisted from Nasdaq,
our common stock may be eligible for trading on an over-the-counter market. If we are not able to obtain a listing on another stock exchange
or quotation service for our common stock, it may be extremely difficult or impossible for stockholders to sell their shares. We intend
to monitor the closing bid price of our common stock and may be required to seek approval from our stockholders to affect a reverse stock
split of the issued and outstanding shares of our common stock. However, there can be no assurance that the reverse stock split would
be approved by our stockholders. Further, there can be no assurance that the market price per new share of our common stock after the
reverse stock split will remain unchanged or increase in proportion to the reduction in the number of old shares of our common stock
outstanding before the reverse stock split. Even if the reverse stock split is approved by our stockholders, there can be no assurance
that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq
listing rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are delisted from Nasdaq,
but obtain a substitute listing for our common stock, it will likely be on a market with less liquidity, and therefore experience potentially
more price volatility than experienced on Nasdaq. Stockholders may not be able to sell their shares of common stock on any such substitute
market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result
of these factors, if our common stock is delisted from Nasdaq, the value and liquidity of our common stock, warrants and pre-funded warrants
would likely be significantly adversely affected. A delisting of our common stock from Nasdaq could also adversely affect our ability
to obtain financing for our operations and/or result in a loss of confidence by investors, employees and/or business partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not expect to pay dividends in the
foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to declare
dividends for the foreseeable future, as we anticipate that we will reinvest any and all future earnings in the development and growth
of our business. Therefore, investors will not receive any funds unless they sell their securities, and holders may be unable to sell
their securities on favorable terms or at all. We cannot assure you of a positive return on your investment or that you will not lose
the entire amount of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales or issuances of substantial
amounts of our common stock, including, potentially, as a result of the future acquisitions or strategic transactions, including the transaction
with Cellvera Global, could result in significant dilution.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 28, 2021, we entered
into a Share Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued
and outstanding equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a
cash payment of $250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the
remaining 90.5% of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our
common stock and a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.&#160;Additionally,
we may elect to raise additional capital due to market conditions or strategic considerations. If additional shares are issued in connection
with the proposed acquisition transaction or additional capital is raised through the sale of equity or convertible debt securities, the
issuance of those securities could result in further dilution to our stockholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>While we have entered into a Share Exchange
Agreement with&#160;Cellvera Global, we cannot assure you that the transactions contemplated by the Share Exchange Agreement will be
consummated or, that if such transactions are consummated, they will be accretive to stockholder value.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The initial closing under
the Share Exchange Agreement was expected to occur on or before January 31, 2022. We can provide no assurance that the conditions to
the initial closing will be satisfied.&#160;Further, even if we are able to complete the initial closing following the satisfaction of
such conditions, there is no guarantee that the conditions to the secondary closing, including but not limited to, the approval of the
transaction by our stockholders, will be completed in the time frame or in the manner currently anticipated, or that we will recognize
the anticipated benefits of the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In connection with the contemplated acquisition
of Cellvera Global, we have provided secured loans to Cellvera Global in the aggregate principal amount of $14.5 million, which amounts
came due on January 31, 2022. Although, we have agreed to forbear from exercising our rights and remedies against Cellvera Global while
we continue to work towards an initial closing under the Share Exchange Agreement, if we are unable to complete the transactions contemplated
by the Share Exchange Agreement, we cannot provide any assurance that we will be able to timely collect such amounts from Cellvera Global,
if at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the contemplated
acquisition of Cellvera Global, we entered into a Secured Credit Agreement with Cellvera Global, pursuant to which we have provided secured
loans to Cellvera Global in the aggregate principal amount of $14.5 million, which amounts became due on January 31, 2022. On February
14, 2022, we entered into a Forbearance Agreement with Cellvera Global, pursuant to which we agreed to forbear from exercising our rights
and remedies against Cellvera Global until the earlier of June 30, 2022 or the date of any default under the Forbearance Agreement.&#160;Under
the Forbearance Agreement, the Company and the Borrower also agreed to certain amendments to the Credit Agreement, including, but not
limited to: (i) the delivery by Cellvera&#160;Global&#160;of certain financial statements and forecasts, and (ii) certain regularly scheduled
payments to be made by Cellvera&#160;Global&#160;to the Company during the forbearance period.&#160;If Cellvera Global defaults upon its
obligations under the Forbearance Agreement or if we are otherwise unable to complete the contemplated acquisition of Cellvera Global
under the Share Exchange Agreement, we cannot provide any assurance that we will be able to time collect the amounts due under the Secured
Credit Agreement, if at all. The note receivable to Cellvera Global was deemed impaired and written down to zero as of December 31, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may engage in future acquisitions or
strategic transactions, including the transaction with Cellvera Global, which may require us to seek additional financing or financial
commitments, increase our expenses and/or present significant distractions to our management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described herein, we entered
into a Share Exchange Agreement with Cellvera Global in December 2021. We have also entered into other non-binding letters of intent.
We may need to acquire additional financing to fund our obligations under the Share Exchange Agreement, the letter of intent or to fund
other potential acquisitions or strategic transactions (particularly, if the acquired entity is not cash flow positive or does not have
significant cash on hand). Obtaining financing through the issuance or sale of additional equity and/or debt securities, if possible,
may not be at favorable terms and may result in additional dilution to our current stockholders. Additionally, any such transaction may
require us to incur non-recurring or other charges, may increase our near and long-term expenditures and may pose significant integration
challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, an acquisition
or strategic transaction may entail numerous operational and financial risks, including the risks outlined above and additionally:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
to unknown liabilities;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
of our business and diversion of our management&#8217;s time and attention in order to develop acquired products or technologies;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
than expected acquisition and integration costs;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">write-downs
of assets or goodwill or impairment charges;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
amortization expenses;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
to retain key employees of any acquired businesses.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, although there
can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transactions
that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Upon dissolution of our Company, you may
not recoup all or any portion of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a liquidation,
dissolution or winding-up of our Company, whether voluntary or involuntary, our assets would be used to pay all of our debts and liabilities,
and only thereafter would any remaining assets be distributed to our stockholders, subject to rights of the holders of the Preferred
Stock, if any, on a&#160;<i>pro rata&#160;</i>basis. There can be no assurance that we will have assets available from which to pay any
amounts to our stockholders upon such a liquidation, dissolution or winding-up. In such an event, you would lose all of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitation of Liability and Indemnification
of Management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Delaware General Corporation
Law and the Company&#8217;s Amended and Restated Certificate of Incorporation provide for the limitation of the liability of directors
for monetary damages. Such provisions may discourage shareholders from bringing a lawsuit against directors for breaches of fiduciary
duty and may also have the effect of reducing the likelihood of derivative litigation against directors and officers even though such
action, if successful, might otherwise be a benefit to the Company&#8217;s shareholders.&#160;In addition, a shareholder&#8217;s investment
in the Company may be adversely affected to the extent that costs of settlement and damage awards against the Company&#8217;s officers
or directors are paid by the Company pursuant to such provisions. Additionally, in accordance with Delaware law and the Company&#8217;s
Amended and Restated Certificate of Incorporation, the Company shall indemnify, hold harmless and provide advancement of expenses, to
the fullest extent permitted by applicable law, directors, officers, employees, and agents that are made a party or threatened to be
made a party to legal proceedings by reason of the fact that such parties were working at the request of the Company.&#160;We direct
you to the Company&#8217;s Amended and Restated Certificate of Incorporation for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions under Delaware
law could discourage, delay or prevent a change in control of our Company and could affect the trading price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Delaware corporation
and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting
us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested
stockholder, even if a change in control would be beneficial to our existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management team is required to devote
substantial time to public company compliance initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a publicly reporting company,
we incur significant legal, accounting and other expenses. Our management and other personnel devote a substantial amount of time to
comply with our reporting obligations. Moreover, these reporting obligations increase our legal and financial compliance costs and make
some activities more time-consuming and costly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to develop our internal controls
over financial reporting as we grow could have an adverse impact on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our Company matures, we
will need to develop our current internal control systems and procedures to manage our growth. We are required to establish and maintain
appropriate internal controls over financial reporting. Failure to establish appropriate controls, or any failure of those controls once
established, could adversely impact our public disclosures regarding our business, financial condition or results of operations. In addition,
management&#8217;s assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed
in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses
and conditions that need to be addressed in our internal control over financial reporting, disclosure of management&#8217;s assessment
of our internal controls over financial reporting or disclosure of our public accounting firm&#8217;s attestation to or report on management&#8217;s
assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could issue &#8220;blank check&#8221;&#160;preferred
stock&#160;without stockholder approval with the effect of diluting interests of then-current stockholders and impairing their voting
rights, and provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Certificate of Incorporation provides for the authorization to issue up to 3,000,000 shares of &#8220;blank check&#8221;&#160;preferred
stock&#160;with designations, rights and preferences as may be determined from time to time by our board of directors. Our board of directors
is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting
or other rights which could dilute the interest of, or impair the voting power of, our common stockholders. The issuance of a series
of preferred stock could be used as a method of discouraging, delaying or preventing a change in control. For example, it would be possible
for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt
to change control of our company. In addition, advanced notice is required prior to stockholder proposals, which might further delay
a change of control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Amended and Restated Certificate of
Incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum&#160;for substantially
all disputes between the Company and its stockholders, which could limit stockholders&#8217; ability to obtain a favorable judicial forum
for disputes with the Company or its directors, officers or employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Certificate of Incorporation provides that unless the Company consents in writing to the selection of an alternative forum, the State
of Delaware is the&#160;sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of the Company, (ii)
any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company
or the Company&#8217;s stockholders, (iii) any action asserting a claim against the Company, its directors, officers or employees arising
pursuant to any provision of the&#160;Delaware General Corporation Law&#160;(the &#8220;DGCL&#8221;) or our Amended and Restated Certificate
of Incorporation or the Company&#8217;s Amended and Restated Bylaws, or (iv) any action asserting a claim against the Company, its directors,
officers, employees or agents governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim
as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery
(and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination),
which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery
does not have subject matter jurisdiction. This exclusive forum provision would not apply to suits brought to enforce any liability or
duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To
the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction
over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 22 of the Securities
Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the
Securities Act or the rules and regulations thereunder. However, our Amended and Restated Bylaws contain a federal forum provision which
provides that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United
States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation are deemed to
have notice of and consented to this provision. The Supreme Court of Delaware has held that this type of exclusive federal forum provision
is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce such a provision, if applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These choice of forum provisions
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or
its directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.
Alternatively, if a court were to find our choice of forum provisions contained in either our Amended and Restated Certificate of Incorporation
or Amended and Restated Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an &#8220;emerging growth company&#8221;
and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our
common stock less attractive to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we intend to take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging
growth companies&#8221; including not being required to comply with the auditor attestation requirements of Section&#160;404(b) of the
Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden
parachute payments not previously approved. In addition, pursuant to Section&#160;107 of the JOBS Act, as an &#8220;emerging growth company&#8221;
we intend to take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act, for complying
with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements may not
be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage
of these reporting exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an &#8220;emerging growth
company&#8221; until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion
or more; (ii)&#160;the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public
offering; (iii)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible debt during the previous three years;
or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1B. Unresolved Staff Comments.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Properties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease property consisting
of office and laboratory space located at 2569 Wyandotte, St., Suite 101 Mountain View, CA 94043. The lease expires on August 31, 2024,
subject to extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease property consisting
of office space located at 532 Broadhollow Road, Suite 118, Melville, NY 11747. The lease expires on December 31, 2024, subject to extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We lease property consisting
of office and laboratory space located at 737 N. 5<sup>th</sup> Street Richmond, Virginia 23219. The lease expires on August 31, 2026,
subject to extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Legal Proceedings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject
to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Mine Safety Disclosures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Market for Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2020, our common
stock began trading on the Nasdaq Capital Market under the symbol &#8220;ADTX.&#8221; Prior to that time, there was no public market
for our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 29, 2022, there
were approximately 164&#160;record holders of our common stock and no holders of our preferred stock. The actual number of holders of
our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares
are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose
shares may be held in trust by other entities.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid or declared
any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.
We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination
to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results
of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors
that our board of directors deems relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 31, 2022, the
Company issued a consultant 60 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2022, the
Company issued a consultant 60 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2022, the Company
issued a consultant 60 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 27, 2022, the Company
issued a consultant 16,296 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 7, 2022, the Company issued
a consultant 131,151 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On December 27, 2022, the Company issued
a consultant 9,837 shares of common stock for services rendered.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The issuances above were made pursuant
to Section 4(a)(2) of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by Item&#160;5 of Form&#160;10-K regarding equity compensation plans is incorporated herein by reference to Item&#160;12 of Part&#160;III
of this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Issuer Purchases of Equity Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not purchase any of
our registered equity securities during the period covered by this Annual Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Proceeds from Initial Public Offering</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 2, 2020, we completed
our initial public offering (&#8220;IPO&#8221;). In connection therewith, we issued 24,534 Units (the &#8220;IPO Units&#8221;), excluding
the underwriters&#8217; option to cover overallotments, at an offering price of $450.00 per IPO Unit, resulting in gross proceeds of
approximately $11.0 million. The IPO Units issued in the IPO consisted of one share of common stock, one Series A warrant, and one Series
B warrant. The Series A warrants originally had an exercise price of $450.00 and a term of 5 years. In addition, we issued a Unit Purchase
Option at an exercise price of $562.50 per unit to the underwriters to purchase up to 1,350 units, with each unit consisting of (i) one
share of common stock and (ii) one Series A Warrant. On August 19, 2020 we modified the exercise price of the Series A Warrants from
$450.00 per share to $225.00 per share. The term of the Series A Warrants was not modified. The Series B warrants have an exercise price
of $562.50 per share, a term of 5 years and contain a cashless exercise option upon certain criteria being met. As of December 31, 2020,
substantially all of the Series B warrants issued in the IPO have been exercised pursuant to a cashless provision therein.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We received net proceeds
of $8.5 million in the IPO, after deducting underwriting discounts and commissions and issuance expenses borne by us. No payments were
made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates,
other than payments in the ordinary course of business to officers for salaries and to non-employee directors pursuant to our director
compensation policy. Dawson James Securities, Inc. acted as lead book-running manager of the offering and as representative of the underwriters&#160;for
the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been no material
change in the planned use of proceeds from our IPO from that described in the final prospectus related to the offering, dated June 29,
2020, as filed with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. [Reserved]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7. Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read together with our financial statements and the related
notes and other financial information included elsewhere in this report. Some of the information contained in this discussion and analysis
or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking
statements that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an innovation company with a mission of
Making Promising Innovations Possible, Together. We develop, build, and grow innovations with a focus on monitoring and modulating the
immune system. We take a socialized approach to innovation by engaging stakeholders into all aspects of the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our innovation portfolio includes
the following programs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">-</td><td style="text-align: justify">Adimune&#8482; - Immune modulation technologies which are
currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and allergies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">-</td><td style="text-align: justify">AditxtScore&#8482; - Immune monitoring technologies designed
to provide a personalized comprehensive profile of the immune system.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>ADI&#8482; (Immune
Modulation Program)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Background</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discovery of immunosuppressive
(anti-rejection and monoclonal) drugs over 40 years ago has made possible life-saving organ transplantation procedures and blocking of
unwanted immune responses in autoimmune diseases. However, immune suppression leads to significant undesirable side effects, such as
increased susceptibility to life-threatening infections and cancers, because it indiscriminately and broadly suppresses immune function
throughout the body. While the use of these drugs has been justifiable because they prevent or delay organ rejection, their use for treatment
of autoimmune diseases and allergies may not be acceptable because of the aforementioned side effects. Furthermore, transplanted organs
often ultimately fail despite the use of immune suppression, and about 40% of transplanted organs survive no more than 5 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New, focused therapeutic
approaches are needed that modulate only the immune cells involved in rejection of the transplanted organ, as this approach can be safer
for patients than indiscriminate immune suppression. Such approaches are referred to as immune tolerance, and when therapeutically induced,
may be safer for patients and potentially allow longer-term survival of transplanted tissues and organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the late 1990s, academic
research on these approaches was conducted at the Transplant Center in Loma Linda University (&#8220;LLU&#8221;) in connection with a
project that secured initial grant funding from the U.S. Department of Defense. The focus of that project was induction of tolerance
for skin allografting for burn victims. Twenty years of research at LLU and an affiliated incubator led to a series of discoveries that
have been translated into a large patent portfolio of therapeutic approaches that may be applied to the modulation of the immune system
to induce tolerance to self and transplanted organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an exclusive worldwide
license for commercializing Apoptotic DNA Immunotherapy&#8482; (ADI&#8482;), a nucleic acid-based technology (which is currently at the
pre-clinical stage), from LLU. ADI&#8482; utilizes a novel approach that mimics the way the body naturally induces tolerance to our own
tissues (&#8220;therapeutically induced immune tolerance&#8221;). While immune suppression requires continuous administration to prevent
rejection of a transplanted organ, induction of tolerance has the potential to retrain the immune system to accept the organ for longer
periods of time. Thus, ADI&#8482; may allow patients to live with transplanted organs with significantly reduced immune suppression.
ADI&#8482; is a technology platform which we believe can be engineered to address a wide variety of indications.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing ADI&#8482;
products for organ transplantation including skin allografting, autoimmune diseases, and allergies, with the initial focus on psoriasis,
type 1 diabetes and skin allografting, indications for which we have compelling preclinical data. To submit a Biologics License Application
(&#8220;BLA&#8221;) for a biopharmaceutical product, clinical safety and efficacy must be demonstrated in clinical studies conducted
with human subjects. For products in our class of drugs, the first-in-human trials will be a combination of Phase I (safety/tolerability)
and Phase II (efficacy) in affected subjects. To obtain approval to initiate the Phase I/IIa studies, an Investigational New Drug or
Clinical Trial Application will be submitted that will include a compilation of non-clinical efficacy data as well as manufacturing and
pre-clinical safety/toxicology data. To date, we have conducted non-clinical studies in a stringent model of skin transplantation using
genetically mismatched donor and recipient animals demonstrating a 3-fold increase in the survival of the skin allograft in animals that
were tolerized with ADI&#8482; compared to animals that receive immune suppression alone. Prolongation of graft life was observed despite
discontinuation of immune suppression after the first 5 weeks. In a non-obese diabetic mouse model of type 1 diabetes, we showed reversal
of hyperglycemia with 80% of the animals showing durable glycemic control for the 40-week study period. Additionally, in an induced non-clinical
model for psoriasis, ADI&#8482; treatment resulted in a 69% reduction in skin thickness and a 38% decrease in skin flaking (two clinical
parameters for assessment of psoriasis skin lesions). The Phase I/IIa studies in psoriasis will evaluate the safety/tolerability of ADI&#8482;
in patients diagnosed with psoriasis. Since the drug will be administered in subjects diagnosed with psoriasis, effectiveness of the
drug to improve psoriatic lesions will also be evaluated. In the type 1 diabetes clinical studies, newly diagnosed subjects will receive
ADI&#8482; treatment to evaluate safety and efficacy. In another Phase I/IIa study, patients requiring skin allografts will receive weekly
intra-dermal injections of ADI&#8482; in combination with standard immune suppression to assess safety/tolerability and possibility of
reducing levels of immunosuppressive drugs as well as prolongation of graft life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>AditxtScore&#8482;
(Immune Monitoring Program)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that understanding
the status of an individual&#8217;s immune system is key to understanding health by the numbers and for developing therapeutics that
result in better outcomes for more individuals. We have secured an exclusive worldwide license for commercializing a technology platform
named AditxtScore&#8482;, which provides a personalized comprehensive profile of the immune system. AditxtScore&#8482; is intended to
be informative for individual immune responses to viruses, bacteria, peptides, drugs, supplements, bone marrow and solid organ transplants
and cancer. It has broad applicability to many other agents of clinical interest impacting the immune system, including those not yet
identified such as emerging infectious agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AditxtScore&#8482; is being
designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by
their immune system. We believe AditxtScore&#8482; can also assist the medical community in anticipating possible immune responses and
reactions to viruses, bacteria, allergens and foreign tissues such as transplanted organs. This capability may be possible by having
the ability to determine the body&#8217;s potential response and for developing a plan to deal with an undesirable reaction by the immune
system. Its advantages include the ability to provide a simple, rapid, accurate, high throughput assays that can be multiplexed to determine
the immune status with respect to several factors simultaneously, in 3-16 hours. In addition, it can determine and differentiate between
various types of cellular and humoral immune responses (T and B cells and other cell types). It also provides for simultaneous monitoring
of cell activation and levels of cytokine release (i.e., cytokine storms).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to utilize AditxtScore&#8482;
in our upcoming pre-clinical and clinical studies to monitor subjects&#8217; immune response before, during and after ADI&#8482; drug
administration. We are also evaluating plans to obtain regulatory approval for AditxtScore&#8482;&#8217;s use as a clinical assay and
seeking to secure manufacturing, marketing and distribution partnerships for application in the various markets. To obtain regulatory
approval to use AditxtScore&#8482; as a clinical assay, we have conducted validation studies to evaluate its performance in detection
of antibodies and plan to continue conducting additional validation studies for new applications in autoimmune diseases and transplantation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License Agreement
with Loma Linda University</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2018, we entered
into an Assignment Agreement (the &#8220;Assignment Agreement&#8221;) with Sekris Biomedical, Inc. (&#8220;Sekris&#8221;). Sekris was
a party to a license agreement with LLU, entered and made effective on May 25, 2011, and amended on June 24, 2011, July 16, 2012 and
December 27, 2012 (the &#8220;Original Agreement,&#8221; and together with the Assignment Agreement, the &#8220;Sekris Agreements&#8221;).
Pursuant to the Assignment Agreement, Sekris transferred and assigned all of its rights, obligations and liabilities under the Original
Agreement, of whatever kind or nature, to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 10,000 shares
of our common stock (the &#8220;Sekris Warrant&#8221;). The warrant was immediately exercisable and has an exercise price of $200.00
per share. The expiration date of the warrant is March 8, 2023. On March 15, 2018, as amended on July 1, 2020, we entered into a LLU
License Agreement directly with Loma Linda University, which amends and restates the Sekris Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LLU License
Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical
information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled
by LLU and/or any of its affiliates (the &#8220;LLU Patent and Technology Rights&#8221;) and related to therapy for immune-mediated inflammatory
diseases (the ADI&#8482; technology). In consideration for the LLU License Agreement, we issued 500 shares of common stock to LLU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LLU License
Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July 2020 for outstanding milestone payments
and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically,
we are required to make the following milestone payments to LLU: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on
March 31, 2026; and $500,000 on March 31, 2027. In lieu of the $175,000 milestone payment due on March 31, 2022, the Company paid LLU
an extension fee of $100,000. Upon payment of this extension fee, an additional year will be added for the March 31, 2022 milestone.
Additionally, as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights,
we made the following payments to LLU: $70,000 at the end of December 2018, and a final payment of $60,000 at the end of March 2019.
We are required to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe
royalty payments of (i) 1.5% of Net Product Sales (as such terms are defined under the LLU License Agreement) and Net Service Sales on
any Licensed Products (defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development,
manufacture or supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services (as such
terms are defined under the LLU License Agreement) not covered by a valid patent claim for technology rights and know-how for a three
(3) year period beyond the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing
our development and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and
to LLU Patent and Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LLU License Agreement
shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application
licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to
LLU. LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license
maintenance fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including
the provision that requires us to meet certain deadlines for milestone events (each, a &#8220;Milestone Deadline&#8221;)) not cured within
90 days after delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License
Agreement by us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an
IND application to initiate first-in-human clinical trials on or before March 31, 2022, which has been extended to March 31, 2023 due
to payment of a $100,000 extension fee paid in March 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March
31, 2024, (iii) the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March
31, 2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License Agreement
with Leland Stanford Junior University (&#8220;Stanford&#8221;)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 3, 2020, we entered
into an exclusive license agreement (the &#8220;February 2020 License Agreement&#8221;) with Stanford regarding a patent concerning a
method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an
exclusive worldwide license to Stanford&#8217;s patent regarding use, import, offer, and sale of Licensed Products (as defined in the
agreement). The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of
the agreement, and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted
a non-exclusive license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory
(as those terms are defined in the February 2020 License Agreement&#8221;). However, Stanford agreed to not grant further licenses under
the Licensed Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the
February 2020 License Agreement which extended our exclusive right to license the technology deployed in AditxtScore<sup>TM</sup>&#160;and
securing worldwide exclusivity in all fields of use of the licensed technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were obligated to pay
and paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 375 shares of the Company&#8217;s common stock
to Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement in
the amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of the patent.
The Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone fees of $50,000
on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an
in vitro diagnostic product developed and a potential licensed product. The Company paid a milestone fee for a clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product of $25,000 in March of 2022. We are also required
to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which
has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing
and operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct
validation studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30,
2020 (which has been completed), (iv) submit a 510(k) application to the FDA, Emergency Use Authorization (&#8220;EUA&#8221;), or a Laboratory
Developed Test (&#8220;LDT&#8221;) by March 31, 2021 (which has been completed), (vi) develop a prototype assay for human profiling by
December 31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity,
or infectious disease purposes by March 31, 2022 (which has been completed) and (viii) provided further development and commercialization
milestones for specific fields of use in writing prior to December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated upon our election on at least 30 days
advance notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and
commercializing Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020
License Agreement; or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30)
day cure period to remedy such violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Our Team</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have assembled a team of experts from a variety of scientific fields and commercial backgrounds, with many years of collective experience
that ranges from founding startup biotech companies, to developing and marketing biopharmaceutical products, to designing clinical trials,
and to management of private and public companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
were incorporated on September 28, 2017 and have not generated significant revenues to date. During the year ended December 31, 2022,
we had a net loss of $27,649,876 and cash of $2,768,640 as of December 31, 2022. The Company will require significant additional capital
to operate in the normal course of business and fund clinical studies in the long-term. As a result of the May 2022 purchase and sale
of future receipts (a &#8220;Future Receipts Agreement&#8221;), the August 2022 Senior Secured Convertible Note, the August 2022 Future
Receipts Agreement and the September 2022 public offering we received net proceeds of approximately $21,000,000 during the last twelve
months. We believe that the remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates
substantial doubt about our ability to continue as a going concern beyond one year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Financial Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation of our
performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered
by companies in their early stages of operations. Our financial statements as of December 31, 2022, show a net loss of $27,649,876. We
expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The
amount of future losses and when, if ever, we will achieve profitability are uncertain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Results
of operations for the years ended December 31, 2022 and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
generated revenue of $933,715 and $105,034 for the years ended December 31, 2022 and 2021, respectively. Cost of sales for the years
ended December 31, 2022 and 2021 was $766,779 and $77,979, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the years ended December 31, 2022, we incurred a loss from operations of $25,480,098. This is due to general and administrative expenses
of $15,985,552, which includes $1,516,805 in stock-based compensation, research and development of $7,268,084, which includes $591,518
in stock-based compensation, sales and marketing expenses of $1,849,460, which includes $1,023,045 in stock-based compensation and impairment
on note receivable of $534,938. The $7,268,084 in research and development is mainly comprised of $2,145,382 in consulting expenses,
and $3,375,757 in compensation offset by a one-time adjustment to research and development purchases. During the year, the Company transitioned
from purchasing certain inventory items to internally manufacturing these items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the year ended December 31, 2021, we incurred a loss from operations of $41,934,928. This is due to general and administrative expenses
of $22,084,389, which includes $3,927,551 in stock-based compensation, research and development of $5,042,617, which includes $713,130
in stock-based compensation, sales and marketing expenses of $334,977, and impairment on note receivable of $14,500,000. The $5,042,617
in research and development is comprised of $76,455 in licensing fees, $1,960,196 in product development, $2,039,533 in compensation,
and $966,433 in other research and development expense.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
decrease in expenses during the year ended December 31, 2022 compared to the year ended December 31, 2021 was due to the impairment on
note receivable during the year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Liquidity and Capital
Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable
future and may never become profitable. As of December 31, 2022, we had an accumulated deficit of $95,040,362 We had working capital
of $1,099,839 as of December 31, 2022. During year ended December 31, 2022, we purchased $367,079 in fixed assets. These fixed assets
were purchased to continue the buildout of our operations. Approximately $300,000 of purchased fixed assets were lab equipment, $62,000
were computers, and $5,000 were office furniture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financial statements have been prepared assuming that we will continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have funded our operations from proceeds from the sale of equity and debt securities. On July 2, 2020, we completed our IPO and raised
approximately $9.5 million in net proceeds. At the time of the IPO, we believed that these funds would be sufficient to fund our operations
for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 10, 2020, we completed a follow-on public offering. In connection therewith, we issued 48,000 units, or Follow-On Units, excluding
the underwriters&#8217; option to cover overallotments, at an offering price of $200.00 per Follow-On Unit, resulting in gross proceeds
of approximately $9.6 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 25, 2021, we entered into a securities purchase agreement with an institutional accredited investor (the &#8220;Investor&#8221;)
for the sale of a $6,000,000 senior secured convertible note (the &#8220;Convertible Note&#8221;). The Convertible Note had a term of
24 months, was originally convertible at a price of $200.00 per share and was issued at an original issuance discount of $1,000,000.
On August 30, 2021, the Company entered into a defeasance and waiver agreement with the Investor, pursuant to which the Investor has
agreed in exchange for (a) a cash payment by the Company to the Investor of $1.2 million (the Cash Payment&#8221;), (b) a waiver, in
part of the conversion price adjustment provision such that the January 2021 Note shall be convertible into 96,050 shares of common stock
(without giving effect to the conversion notice received by the Company from the Investor prior to the date hereof totaling (20,115 shares),
and (c) a voluntary and permanent reduction by the Company of the exercise price of the warrant to purchase 16,000 shares of the common
stock of the Company (the &#8220;January 2021 Warrant&#8221;) to $126.50 per share. As of December 31, 2022, the outstanding principle
of the convertible note had been converted to 96,050 shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 30, 2021, we completed a registered direct; offering and raised approximately $10.1 million in net proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 20, 2021, we completed an offering for net proceeds of $3.8 million. As part of this offering, we issued 56,667 shares of the
Company&#8217;s common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 6, 2021, we completed an offering for net proceeds of $16.0 million. As part of this offering, we issued 164,929 units consisting
of shares of the Company&#8217;s common stock and warrant to purchase shares of the Company&#8217;s common stock and 166,572 prefunded
warrants. The warrant issued as part of the units had an exercise price of $57.50 and the prefunded warrants had an exercise price of
$0.001.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 20, 2022, we completed a public offering for net proceeds of $17.2&#160;million (the &#8220;September 2022 Offering&#8221;).
As part of the September 2022 Offering, we issued&#160;1,224,333 of shares of the Company&#8217;s common stock, pre-funded warrants to
purchase 2,109,000 shares of the Company&#8217;s common stock and&#160;warrants to purchase 3,333,333 shares of the Company&#8217;s common
stock. The warrants had an exercise price of $6.00&#160;and the pre-funded warrants had an exercise price of $0.001.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may need to raise significant additional capital to continue to fund our operations and the clinical trials for our product candidates.
We may seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form of third-party
funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants.
The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have
rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities,
or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party
funding arrangement could require us to relinquish valuable rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
source, timing, and availability of any future financing will depend principally upon market conditions, and, more specifically, on the
progress of our clinical development program. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of
necessary funds may require us to, among other things, delay, scale back or eliminate expenses including some or all our planned development,
including our clinical trials. While we may need to raise funds in the future, we believe the current cash reserves should be sufficient
to fund our operation for the foreseeable future. Because of these factors, we believe that this creates doubt about our ability to continue
as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Contractual Obligations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table shows our contractual obligations as of December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment&#160;Due&#160;by&#160;Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,269,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,129,853</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,004,982</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">710,546</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">423,930</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financed asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409,983</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total contractual obligations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,679,294</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,539,836</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,004,982</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">710,546</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">423,930</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Critical Accounting
Polices and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of
our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount
of assets, liabilities, revenue, costs and expenses, and related disclosures. We believe that our critical accounting policies described
under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Plan of Operations&#8212;Critical Accounting
Policies&#8221; in our Prospectus, dated September 1, 2020, filed with the SEC pursuant to Rule 424(b), are critical to fully understanding
and evaluating our financial condition and results of operations. The following involve the most judgment and complexity:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Accordingly,
we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results of operations.
If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our
reported financial condition and results of operations could be materially affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Off-Balance Sheet
Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time the Company enters short term research and development contracts. These contracts have payment provisions which require payment
once regulatory and completion milestones are met. As of December 31, 2022, the Company has approximately $1.6 million outstanding, subject
to these milestones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>JOBS Act</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April&#160;5, 2012, the JOBS Act was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221;
can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act, for complying with new
or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting
standards until those standards would otherwise apply to private companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">When
favorable, we have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS
Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided
under the JOBS Act.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS&#160;Act.&#160;Subject
to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company,&#8221; we intend to rely on certain of these exemptions,
including without limitation, (i)&#160;providing an auditor&#8217;s attestation report on our system of internal controls&#160;over financial
reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act and (ii)&#160;complying with any requirement that may be adopted
by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) regarding mandatory audit firm rotation or a supplement to the
auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion
and analysis. We will remain an &#8220;emerging growth company&#8221; until the earliest of (i)&#160;the last day of the fiscal year
in which we have total annual gross revenues of $1.07&#160;billion or more; (ii)&#160;the last day of our fiscal year following the fifth
anniversary of the date of the completion of our IPO (December 31, 2025); (iii)&#160;the date on which we have issued more than $1&#160;billion
in nonconvertible debt during the previous three years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer
under the rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Recently Issued and
Adopted Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">See
Note 3 - Summary of Significant Accounting Policies to the accompanying financial statements for a description of other accounting policies
and recently issued accounting pronouncements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">See
Note 12 &#8211; Subsequent Event to the accompanying financial statements for a description of material recent developments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7A. Quantitative and Qualitative Disclosures
About Market Risk.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not required to provide
the information required by this Item as it is a &#8220;smaller reporting company,&#8221; as defined in Rule 229.10(f)(1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. Financial Statements and Supplementary
Data.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See pages F-1 through F-29
following the Exhibit Index of this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9. Changes in and Disagreements with
Accountants on Accounting and Financial Disclosure.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9A. Controls and Procedures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Assessment of the Effectiveness of Internal
Controls over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure Controls and Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Rules
13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), we, under the supervision
and with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange
Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, our Chief Executive Officer and
Chief Financial Officer concluded that our disclosure controls and procedures were (a) designed to ensure that the information we are
required to disclose in our reports under the Exchange Act is recorded, processed, and reported in an accurate manner and on a timely
basis and the information that we are required to disclose in our Exchange Act reports is accumulated and communicated to management
to permit timely decisions with respect to required disclosure and (b) operating in an effective manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Change in Internal Control Over Financial
Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No change occurred in our
internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) during the year ended December
31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9B. Other Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2023, the Company
formed a wholly-owned subsidiary, Pearsanta, Inc. in order to accelerate the growth of the Company&#8217;s AditxtScore program through
future strategic revenue and growth oriented transactions. In connection with the formation of Pearsanta and Corinne Pankovcin&#8217;s
anticipated role in driving such strategic revenue and growth oriented transactions, Ms. Pankovcin&#8217; s title was changed from President
to Chief Commercialization Officer, effective April 12, 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">N/A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;10. Directors, Executive Officers
and Corporate Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our definitive proxy statement related
to the 2023 Annual Meeting of Stockholders, or the Proxy Statement, which we intend to file with the SEC within 120 days of the end of
our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;11. Executive Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to
file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to
file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;13. Certain Relationships and Related
Transactions, and Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to
file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#160;14. Principal Accounting Fees and
Services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our Proxy Statement, which we intend to
file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. Exhibits, Financial Statement Schedules.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this report:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statements:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Balance Sheets</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Statements of Operations</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Statements of Changes in Stockholders&#8217; Equity</a> </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Statements of Cash Flows</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes to Financial Statements</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statement Schedules:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All financial statement schedules
have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the
notes thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>EXHIBIT INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 9%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 90%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022081157/ea170511ex1-1_aditxtinc.htm">At The Market Offering Agreement dated December 20, 2022 between Aditxt, Inc. and H.C. Wainwright &amp; Co., LLC (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on December 20, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021067652/ea153046ex2-1_aditxtinc.htm">Share Exchange Agreement, dated as of December 28, 2021 by and between AiPharma Group Ltd. and Aditxt, Inc. (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on December 28, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-7_aditxtinc.htm">Amendment to Share Exchange Agreement by and between AiPharma Group Ltd. and Aditxt, Inc. (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022033320/ea161694ex10-1_aditxt.htm">Second Amendment to Share Exchange Agreement by and between AiPharma Group Ltd. and Aditxt, Inc. (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex3-1_aditxtherape.htm">Amended and Restated Certificate of Incorporation (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020021942/f10q0620ex3-2_aditxtherape.htm">Certificate of Amendment, dated June 29, 2020 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 13, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex3-3_aditxtherape.htm">Amended and Restated Bylaws (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020024322/ea126150ex3-4_aditxther.htm">Certificate of Designation Series A Preferred Stock (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248491)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021029051/ea141620ex3-1_aditxtherap.htm">Certificate of Amendment, filed with the Secretary of State of the State of Delaware on May 24, 2021 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 25, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021036167/ea143935ex3-1_aditxt.htm">Certificate of Amendment, dated July 6, 2021 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on July 8, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022038247/ea162633ex3-1_aditxtinc.htm">Amendment No. 1 to Amended and Restated Bylaws of Aditxt, Inc. (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on July 8, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022040493/ea162995ex3-1_aditxtinc.htm">Certificate of Designation of Series B Preferred Stock, dated July 19, 2022 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390022055772/ea165724ex3-1_aditxt.htm">Certificate of Amendment to Certificate of Incorporation of Aditxt, Inc. (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021017776/f10k2020ex4-1_aditx.htm">Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 25, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex4-1_aditxtherape.htm">Form the Company&#8217;s common stock certificate (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020024322/ea126150ex4-2_aditxther.htm">Form of Series A-1 Warrant Agent Agreement (including the terms of the Series A-1 Warrant) (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248491)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020024322/ea126150ex4-3_aditxther.htm">Form of Series B-1 Warrant Agent Agreement (including the terms of the Series B-1 Warrant) (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-248491)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021045481/ea146635ex4-1_aditxtinc.htm">Form of Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 30, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-1_aditxtherape.htm">Form of Promissory Note issued to Sekris Biomedical, Inc. (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-2_aditxtherape.htm">Warrant, dated March 8, 2018, issued to Sekris Biomedical, Inc. (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-3_aditxtherape.htm">Form of Private Placement Subscription Agreement (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-4_aditxtherape.htm">Patent Licensing Agreement, dated February 3, 2020 (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-5_aditxtherape.htm">Patent and Technology License Agreement, dated March 15, 2018 between Loma Linda University and Aditx Therapeutics, Inc. (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020021942/f10q0620ex10-1_aditxtherape.htm">Amendment Agreement to the Patent and Technology License Agreement, dated July 1, 2020 by and between Loma Linda University and Aditx Therapeutics, Inc. (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 13, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-6_aditxtherape.htm">2017 Equity Incentive Plan and forms of award agreements thereunder (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-7_aditxtherape.htm">Consulting Agreement, dated March 1, 2018 between Aditx Therapeutics, Inc. and Canyon Ridge Development LLC d/b/a Mission Critical Solutions International (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-8_aditxtherape.htm">Form of July 2018 Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-9_aditxtherape.htm">Form of July 2018 Note (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-10_aditxtherape.htm">Form of April 2018 Promissory Note (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-11_aditxtherape.htm">Form of March 2019 Promissory Note (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-12_aditxtherape.htm">Form of October 2019 Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-13_aditxtherape.htm">Form of October 2019 Note (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)&#160;</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-14_aditxtherape.htm">Form of January 2020 Note Purchase Agreement (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex10-15_aditxtherape.htm">Form of January 2020 Private Placement Promissory Note (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-235933)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390020038611/ea130308ex10-1_aditxtherap.htm">Consulting Agreement by and between the Company and Salveo Diagnostics, Inc., dated November 18, 2020 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on November 23, 2020)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021004257/ea133934ex4-1_aditxtherap.htm">Form of Senior Secured Convertible Promissory Note (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on January 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021004257/ea133934ex4-2_aditxtherap.htm">Form of Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on January 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021004257/ea133934ex10-1_aditxtherap.htm">Form of Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on January 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021004257/ea133934ex10-2_aditxtherap.htm">Form of Registration Rights Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on January 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021012193/ea136652ex10-1_aditxtherap.htm">Employment Agreement, dated as of February 24, 2021, by and between the Company and Amro Albanna (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on February 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021012193/ea136652ex10-2_aditxtherap.htm">2021 Omnibus Equity Incentive Plan (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on February 26, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021025416/ea140542ex10-1_aditxtherap.htm">Lease Agreement, dated as of May 4, 2021, by and between LS Biotech Eight, LLC as Landlord, and Aditxt Therapeutics, Inc., as Tenant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 10, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021045481/ea146635ex10-1_aditxtinc.htm">Form of Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 30, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021045481/ea146635ex10-2_aditxtinc.htm">Placement Agency Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 30, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021045481/ea146635ex10-3_aditxtinc.htm">Form of Placement Agent Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 30, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021045481/ea146635ex10-4_aditxtinc.htm">Waiver and Defeasance Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 30, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-5_aditxtinc.htm">Secured Credit Agreement, dated as of August 27, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-6_aditxtinc.htm">Security Agreement, dated as of August 27, 2021 by and between AiPharma Asia Limited and the Company (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-7_aditxtinc.htm">Security Agreement, dated as of August 27, 2021 by and between AiPharma Limited and the Company (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a>&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-8_aditxtinc.htm">Security Agreement &#8211; AiPharma Limited and Aditxt (BVI Law) (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a>&#160;&#160;</span></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-9_aditxtinc.htm">Floating Charge (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-10_aditxtinc.htm">Transaction Agreement, dated as of October 4, 2021, by and between the Company and AiPharma Global Holdings LLC (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-11_aditxtinc.htm">First Amendment to Secured Credit Agreement with AiPharma Global Holdings LLC dated October 18, 2021 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-36_aditxtinc.htm">Second Amendment to Secured Credit Agreement with AiPharma Global Holdings LLC dated October 27, 2021(incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-12_aditxtinc.htm">Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Amro Albanna, Chief Executive Officer (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-13_aditxtinc.htm">Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Corinne Pankovcin, President and Secretary (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-14_aditxtinc.htm">Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Thomas Farley, Chief Financial Officer (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-15_aditxtinc.htm">Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Shahrokh Shabahang, Chief Innovation Officer (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390021059330/f10q0921ex10-16_aditxtinc.htm">Employment Agreement, dated as of November 14, 2021 between Aditxt, Inc. and Rowena Albanna, Chief Operating Officer (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 15, 2021)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-42_aditxtinc.htm">Form of Warrant Reduction and Release Agreement dated as of November 24, 2021 (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-43_aditxtinc.htm">First Amendment to Transaction Agreement dated November 30, 2021, by and between the Company and AiPharma Global Holdings LLC (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-44_aditxtinc.htm">Third Amendment to Secured Credit Agreement dated November 30, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-45_aditxtinc.htm">Second Amendment to Transaction Agreement dated December 7, 2021, by and between the Company and AiPharma Global Holdings LLC (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-46_aditxtinc.htm">Secured Credit Agreement, dated as of December 8, 2021, by and among the Company and the Target Company (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-47_aditxtinc.htm">Third Amendment to Transaction Agreement dated December 17, 2021, by and between the Company and AiPharma Global Holdings LLC (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-48_aditxtinc.htm">Fifth Amendment to Secured Credit Agreement dated December 22, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-49_aditxtinc.htm">Sixth Amendment to Secured Credit Agreement dated December 28, 2021, by and among AiPharma, AiPharma Holdings Limited, AiPharma Asia Limited and the Company (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-50_aditxtinc.htm">Employment Agreement between Aditxt, Inc. and Matthew Shatzkes, Chief Legal Officer and General Counsel (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-51_aditxtinc.htm">Forbearance Agreement and Seventh Amendment to Secured Credit Agreement dated as of February 14, 2022 by and among the Company, Cellvera Global Holdings LLC, Cellvera Holdings Ltd., Cellvera Asia Limited (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022016723/f10k2021ex10-52_aditxtinc.htm">Fourth Amendment to Transaction Agreement dated December 22,2021, by and between the Company and AiPharma Global Holdings LLC (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K filed on March 31, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022020113/f10k2021a1ex10-53_aditxtinc.htm">Series C Warrant Agent Agreement (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on April 15, 2022)</a></span></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022020113/f10k2021a1ex10-54_aditxtinc.htm">Form of Placement Agent Warrant dated January 25, 2021 (incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on April 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-1_aditxtinc.htm">Forbearance Agreement and Eighth Amendment to Secured Credit Agreement dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-2_aditxtinc.htm">Security Agreement between Cellvera Holdings and Aditxt, Inc. dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-3_aditxtinc.htm">Security Agreement between Cellvera Development LLC and Aditxt, Inc. dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-4_aditxtinc.htm">Security Agreement between Cellvera Global Holdings and Aditxt, Inc. dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-5_aditxtinc.htm">Amended and Restated Security Agreement between Cellvera Asia Limited and Aditxt, Inc. dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
</table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022027113/f10q0322ex10-6_aditxtinc.htm">Revenue Sharing Agreement by and among Aditxt, Inc., Cellvera Global Holdings LLC and Cellvera Asia Limited dated as of March 31, 2022 (incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on May 16, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022031169/ea161091ex10-1_aditxt.htm">Form of Agreement for the Purchase and Sale of Future Receipts (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 3, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022032926/ea161620ex10-1_aditxt.htm">Amendment No. 1 to Series C Warrant Agent Agreement dated June 15, 2022 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022032926/ea161620ex10-2_aditxt.htm">Inducement Offer to Exercise Series C Common Stock Purchase Warrants (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.64</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022032926/ea161620ex10-3_aditxt.htm">Form of New Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.65</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022032926/ea161620ex10-4_aditxt.htm">Form of Placement Agent Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on June 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.66</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022040493/ea162995ex10-1_aditxtinc.htm">Subscription and Investment Representation Agreement, dated July 19, 2022 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on July 20, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.67</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022041776/ea163372ex10-1_aditxt.htm">Unsecured Promissory Note dated July 21, 2022 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on July 26, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.68</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022046348/ea164147ex10-1_aditxt.htm">Form of Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.69</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022046348/ea164147ex10-2_aditxt.htm">Form of August 2022 Note (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.70</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022046348/ea164147ex10-3_aditxt.htm">Form of August 2022 Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.71</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022046348/ea164147ex10-4_aditxt.htm">Form of Registration Rights Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022046348/ea164147ex10-5_aditxt.htm">Form of Security Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on August 10, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.73</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022054568/ea165454ex10-1_aditxtinc.htm">Form of First Amendment and Waiver effective as of August 31, 2022 (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on September 7, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.74</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022054568/ea165454ex10-3_aditxtinc.htm">Form of Warrant (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on September 7, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.75</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022056026/ea165784ex1-1_aditxtinc.htm">Form of Securities Purchase Agreement (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 filed on September 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.76</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022056026/ea165784ex4-6_aditxtinc.htm">Form of Warrant (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 filed on September 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.77</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022056026/ea165784ex4-7_aditxtinc.htm">Form of Placement Agent&#8217;s Warrant (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 filed on September 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.78</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022056026/ea165784ex4-8_aditxtinc.htm">Form of Pre-Funded Warrant (incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 filed on September 15, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.79</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022082618/ea170702ex10-1_aditxt.htm">Amendment No. 2 to Series C Warrant Agent Agreement (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on December 23, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1726711/000121390022082618/ea170702ex10-2_aditxt.htm">Form of Amended and Restated Unit Purchase Option (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on December 23, 2022)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center">10.81</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390023021769/ea175528ex10-1_aditxt.htm">Form of Consulting Agreement (incorporated by reference to the Registrant's Current Report on Form 8-K filed on March 21, 2023)</a></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center">10.82</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1726711/000121390023028342/ea176710ex10-1_aditxt.htm">Form of Business Loan and Security Agreement dated April 4, 2023(incorporated by reference to the Registrant's Current Report on Form 8-K filed on April 7, 2023)</a></p></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex23-1_aditxtinc.htm">Consent of dbb<i>mckennon</i>, independent registered public accounting firm</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-1_aditxtinc.htm">Certification of Principal Executive Officer Pursuant to Rules&#160;13a-14(a)&#160;and
15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-2_aditxtinc.htm">Certification of Principal Financial and Accounting Officer Pursuant
to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of
the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex32-1_aditxtinc.htm">Certification of the Principal Executive, Financial, and Accounting
Officers under Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
    XBRL and contained in Exhibit 101).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized on this&#160;17<sup>th</sup>&#160;day of April 2023.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aditxt, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amro Albanna</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POWER OF ATTORNEY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL BY THESE PRESENTS,
that each person whose signature appears below constitutes and appoints Amro Albanna and Thomas J. Farley, and each of them, as his or
her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place,
or stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with exhibits thereto and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that
said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amro Albanna</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</span></td>
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal Executive Officer)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas J. Farley</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas J. Farley</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal Financial and Accounting Officer)</i></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian Brady</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Brady</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Namvar Kiaie</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namvar Kiaie</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey W. Runge, M.D.</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Runge, M.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shahrokh Shabahang</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Innovation Officer and Director</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shahrokh Shabahang</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE YEARS ENDED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DECEMBER 31, 2022 AND 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 90%; text-align: justify">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB ID#&#160;<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">3501</ix:nonNumeric>)</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_002">Balance Sheets</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_003">Statements of Operations</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_004">Statements of Stockholders&#8217; Equity</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_005">Statements of Cash Flows</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#f_006">Notes to Financial Statements</a></span></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aditxt, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
balance sheets of Aditxt, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations, stockholders&#8217;
equity, and cash flows, for the years ended December 31, 2022 and 2021, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting
principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements,
the Company&#8217;s net losses, negative cash flow from operations, and ability to access capital raise substantial doubt about its ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">dbb<i>mckennon</i></ix:nonNumeric>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">San Diego, California</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 17, 2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">2,768,640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">7,872,061</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">527,961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">89,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PublicUtilitiesInventory" scale="0" unitRef="usd">950,093</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PublicUtilitiesInventory" scale="0" unitRef="usd">494,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">496,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd">460,102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Note receivable, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="0" unitRef="usd">500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">4,743,563</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,416,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:FixedAsset" scale="0" unitRef="usd">2,318,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:FixedAsset" scale="0" unitRef="usd">2,267,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="0" unitRef="usd">214,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd">355,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd">379,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Right of use asset - long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssetLongTerm" scale="0" unitRef="usd">3,160,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssetLongTerm" scale="0" unitRef="usd">4,097,117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">289,539</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">10,735,249</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">16,663,907</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,958,502</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,575,543</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Financing on fixed assets &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:FinancingOnFixedAssets" scale="0" unitRef="usd">409,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:FinancingOnFixedAssets" scale="0" unitRef="usd">700,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred rent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditCurrent" scale="0" unitRef="usd">188,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditCurrent" scale="0" unitRef="usd">186,058</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Lease liability - current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilityShortTermCurrent" scale="0" unitRef="usd">1,086,658</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilityShortTermCurrent" scale="0" unitRef="usd">1,145,126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,643,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,607,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Financing on fixed assets - long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:FinancingOfFixedAssetLongTerm" scale="0" unitRef="usd">110,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Lease liability - long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilityLongTermNoncurrent" scale="0" unitRef="usd">1,885,218</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilityLongTermNoncurrent" scale="0" unitRef="usd">2,765,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">5,528,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">6,483,134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction>&#160;par value,&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">3,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized,&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction>&#160;par value,&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized,&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">4,307,487</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">890,614</ix:nonFraction>&#160;shares issued and&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">4,305,470</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">888,579</ix:nonFraction>&#160;shares outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">4,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Treasury stock,&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" unitRef="shares">2,017</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" unitRef="shares">2,017</ix:nonFraction>&#160;shares, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">201,605</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">201,605</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">100,443,967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">77,734,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">95,040,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">67,352,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">5,206,307</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,180,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">10,735,249</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">16,663,907</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year<br/> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">REVENUE</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 9pt">Sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">933,715</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">105,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">766,779</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">77,979</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">166,936</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">27,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">General and administrative expenses, includes $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,516,805</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">3,927,551</ix:nonFraction>&#160;in stock-based compensation, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">15,985,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd">22,084,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Research and development, includes $<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">591,518</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">713,130</ix:nonFraction>&#160;in stock-based compensation, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,268,084</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,042,617</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sales and marketing, includes $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">1,023,045</ix:nonFraction>, and $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">0</ix:nonFraction>&#160;in stock-based compensation, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,849,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">334,977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Impairment on notes receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="0" unitRef="usd">543,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringSettlementAndImpairmentProvisions" scale="0" unitRef="usd">14,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">25,647,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">41,961,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">25,480,098</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">41,934,928</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">OTHER EXPENSE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">753,038</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">93,209</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">57,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd">3,101</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">58,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">2,500,970</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Amortization of debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">1,533,048</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd">1,845,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">2,169,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="0" unitRef="usd">4,436,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">27,649,876</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">46,371,364</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Income tax provision</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">27,649,876</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">46,371,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Implied Dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStock" scale="0" unitRef="usd">37,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStock" scale="0" unitRef="usd">102,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">27,612,199</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">46,269,097</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10">Net loss per share - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">14.89</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">121.18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12">Weighted average number of shares outstanding during the year - basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">1,854,724</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">381,811</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YEARS ENDED DECEMBER 31, 2022 AND 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Preferred<br/>
                                            Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Preferred<br/>
    Shares<br/> Par</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Preferred
                                            B<br/> Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Preferred&#160;B<br/> Shares<br/> Par</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Common<br/>
                                            Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Outstanding</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Common<br/>
                                            Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><b>Par</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Treasury<br/>
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Additional<br/>
    Paid-in<br/> Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated<br/>
    Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total<br/>
    Stockholders&#8217;<br/> Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance December 31, 2021</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-15; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">888,597</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">899</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">201,605</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">77,734,288</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">67,352,809</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,180,773</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock option and warrant compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="0" unitRef="usd">1,413,904</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="0" unitRef="usd">1,413,904</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of restricted stock
    units for compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">18,469</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfRestrictedStockUnitsForCompensation" scale="0" unitRef="usd">19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfRestrictedStockUnitsForCompensation" scale="0" unitRef="usd">1,209,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfRestrictedStockUnitsForCompensation" scale="0" unitRef="usd">1,209,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of shares for services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForServicesinShares" scale="0" unitRef="shares">148,227</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">150</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">507,408</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">507,558</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Exercise of warrants, modification
    of warrants, and issuance of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" scale="0" unitRef="shares">179,419</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">180</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">1,203,589</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd">1,203,769</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Sale of Series B Preferred
    shares to related party</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="adtx:SaleOfSeriesBPreferredSharesToRelatedParty1" scale="0" unitRef="shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:SaleOfSeriesBPreferredSharesToRelatedParty" scale="0" unitRef="usd">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:SaleOfSeriesBPreferredSharesToRelatedParty" scale="0" unitRef="usd">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Redemption of Series B Preferred
    shares to related party</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="adtx:RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" scale="0" sign="-" unitRef="shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" sign="-" unitRef="usd">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" sign="-" unitRef="usd">20,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares issued as inducement
    on loans, net of issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" scale="0" unitRef="shares">47,779</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" scale="0" unitRef="usd">48</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" scale="0" unitRef="usd">146,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" scale="0" unitRef="usd">146,522</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Warrants issued with loans</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">878,622</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd">878,622</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Reset provision on warrants&#160;&#160;&#160;and
    modification of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:ResetProvisionOnWarrantsAndModificationOfWarrants" scale="0" unitRef="usd">37,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="adtx:ResetProvisionOnWarrantsAndModificationOfWarrants" scale="0" sign="-" unitRef="usd">37,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of shares for debt
    issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">10,477</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">96,019</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">96,030</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">1,766,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrants" scale="0" unitRef="usd">1,767</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrants" scale="0" sign="-" unitRef="usd">1,767</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of shares and warrants
    for offering, net of issuance costs</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">1,224,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">1,224</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">17,232,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">17,233,307</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance costs related to exercise
    of warrants, modification of warrants, and issuance of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" scale="0" sign="-" unitRef="usd">94,195</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" scale="0" sign="-" unitRef="usd">94,195</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of shares for settlement of AP</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">9,237</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">79,991</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">80,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Rounding from reverse stock
    split</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="adtx:RoundingAdjustmentFromStockSplitShares" scale="0" unitRef="shares">12,015</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="adtx:RoundingAdjustmentFromStockSplit" scale="0" sign="-" unitRef="usd">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:RoundingAdjustmentFromStockSplit" scale="0" sign="-" unitRef="usd">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">27,649,876</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">27,649,876</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance December 31, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 9pt">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">4,305,470</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">4,307</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">201,605</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">100,443,967</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">95,040,362</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">5,206,</span><span style="font-family: Times New Roman, Times, Serif">307</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>YEARS ENDED DECEMBER 31, 2022 AND 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Preferred<br/> Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred<br/> Shares<br/> Par</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common<br/> Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Outstanding</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common<br/> Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Par</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Treasury<br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Additional<br/> Paid-in<br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> Stockholders&#8217;<br/> Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 36%">Balance December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c31" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">259,474</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">262</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">201,605</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">32,092,003</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">20,879,178</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">11,011,482</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock option and warrant compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="0" unitRef="usd">1,016,962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="0" unitRef="usd">1,016,962</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">189,844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrants" scale="0" unitRef="usd">191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrants" scale="0" unitRef="usd">3,727,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExerciseOfWarrants" scale="0" unitRef="usd">3,727,285</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Restricted stock unit compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd">1,843,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" unitRef="usd">1,843,902</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Issuance of shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForServicesinShares" scale="0" unitRef="shares">4,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">366,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" unitRef="usd">336,117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for employee compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">9,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="0" unitRef="usd">191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="0" unitRef="usd">1,443,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="0" unitRef="usd">1,443,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for vested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForVestedRestrictedStockUnits" scale="0" unitRef="shares">16,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" scale="0" unitRef="usd">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" scale="0" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for the conversion of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares">96,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForTheSettlementOfDebt" scale="0" unitRef="usd">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForTheSettlementOfDebt" scale="0" unitRef="usd">5,749,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForTheSettlementOfDebt" scale="0" unitRef="usd">5,749,922</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fair value of warrants issued with convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,322,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,322,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and warrants for offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">256,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">26,123,354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd">26,123,611</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for offerings, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="INF" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" scale="0" unitRef="shares">56,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts" scale="0" unitRef="usd">57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts" scale="0" unitRef="usd">3,744,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts" scale="0" unitRef="usd">3,745,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrant consideration for convertible debt offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd">231,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd">231,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Reduction in exercise price of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd">102,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" sign="-" unitRef="usd">102,267</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">46,371,364</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">46,371,364</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Balance December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">888,597</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">899</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">201,605</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">77,734,288</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd">67,352,809</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">10,180,773</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;See accompanying notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><b>&#160;</b></span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year<br/> Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year<br/> Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">27,649,876</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">46,371,364</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">3,131,368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,640,681</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">428,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">369,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd">1,533,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd">1,845,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" sign="-" unitRef="usd">2,500,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Impairment on notes receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd">543,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd">14,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:DisposalOfFixedAssets1" scale="0" unitRef="usd">6,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">36,767</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">312,460</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd">23,884</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" unitRef="usd">306,954</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDepositsOutstanding" scale="0" unitRef="usd">438,117</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDepositsOutstanding" scale="0" unitRef="usd">89,844</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 27pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">455,396</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">494,697</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">412,959</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">1,333,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">22,392,006</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">22,278,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchase of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromProductiveAssets" scale="0" unitRef="usd">367,079</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromProductiveAssets" scale="0" unitRef="usd">1,015,752</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Tenant improvement allowance receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:TIAllowanceReceivable" scale="0" sign="-" unitRef="usd">125,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:TIAllowanceReceivable" scale="0" unitRef="usd">287,018</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Notes receivable and accrued interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:NoteReceivablesAndAccruedInterest" scale="0" unitRef="usd">15,002,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">241,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">16,305,291</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from note payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSecuredNotesPayable" scale="0" unitRef="usd">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repayments of note payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd">80,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from notes and convertible notes payable, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:DiscountOnConvertibleNotePayableFromOfferingCosts" scale="0" unitRef="usd">2,795,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:DiscountOnConvertibleNotePayableFromOfferingCosts" scale="0" unitRef="usd">4,473,540</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Repayments of notes and convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" scale="0" sign="-" unitRef="usd">3,206,887</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" scale="0" sign="-" unitRef="usd">315,790</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sale of Series B Preferred shares to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:SaleOfPreferredSharesToRelatedParty" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Redemption of Series B Preferred shares to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" sign="-" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common stock and warrants issued for cash, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">17,233,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">29,868,611</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercise of warrants, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">1,109,574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">3,727,285</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Payments on financing on fixed asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" unitRef="usd">400,491</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="0" unitRef="usd">598,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash paid on extinguishment of note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd">1,200,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">17,530,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">35,954,670</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET DECREASE IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">5,103,421</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">2,628,765</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">CASH AT BEGINNING OF YEAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">7,872,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">10,500,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">CASH AT END OF YEAR</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">2,768,640</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">7,872,061</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash paid for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash paid for interest expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOtherLongTermDebt" scale="0" unitRef="usd">753,038</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOtherLongTermDebt" scale="0" unitRef="usd">15,789</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NON-CASH INVESTING AND FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Issuance of shares for the settlement of notes payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:OriginalOfferingDiscountOnConvertibleNotePayable" scale="0" unitRef="usd">5,749,922</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Lease liability recognized from right of use asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd">3,131,388</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Issuance of shares for the settlement of accounts payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">80,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Original offering discount on convertible note payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:OriginalIssuanceDiscountOnNotesPayable" scale="0" unitRef="usd">1,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Debt discount from warrants issued with convertible note payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" scale="0" unitRef="usd">878,622</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" scale="0" unitRef="usd">1,322,840</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Debt discount from warrant consideration for convertible debt offering costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" scale="0" unitRef="usd">231,316</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Debt discount from shares issued as inducement for convertible note payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd">146,522</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Liability recognized for financed assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:LiabilityRecognizedForFinancedAssets" scale="0" unitRef="usd">821,862</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Reduction in exercise price of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:ReductionInExercisePriceOfWarrants" scale="0" unitRef="usd">102,267</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Shares issued for debt offering costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssuedForIntangibleAssets" scale="0" unitRef="usd">96,030</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Warrant modification</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="0" unitRef="usd">37,677</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Deferred issuance costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="0" unitRef="usd">50,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADITXT, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; ORGANIZATION AND NATURE OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Company Background</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotech innovation company with a mission
of prolonging life and enhancing its quality by improving the health of the immune system. We are an innovation company developing and
commercializing technologies with a focus on monitoring and modulating the immune system. Our immune reprogramming technologies are currently
at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection
of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technologies are designed to provide a personalized
comprehensive profile of the immune system and we plan to utilize them in our upcoming reprogramming clinical trials to monitor subjects&#8217;
immune response before, during and after drug administration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Stock Split</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 13, 2022, the Company effectuated
a 1 for 50 reverse stock split (the &#8220;Reverse Split&#8221;). The Company&#8217;s stock began trading on a split-adjusted basis effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#8217;s common
stock. All shares amounts referenced in this report are adjusted to reflect the Reverse Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Offerings</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021, the Company completed a registered
direct offering (&#8220;August 2021 Offering&#8221;). In connection therewith, the Company issued&#160;<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares">91,667</ix:nonFraction>&#160;shares of common stock,
at a purchase price of $<ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" scale="0" unitRef="usdPershares">120.00</ix:nonFraction>&#160;per share, resulting in gross proceeds of approximately $<ix:nonFraction contextRef="c42" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" scale="6" unitRef="usd">11.0</ix:nonFraction>&#160;million. In a concurrent private
placement, the Company issued warrants to purchase up to&#160;<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares">91,667</ix:nonFraction>&#160;shares.&#160;<ix:nonNumeric contextRef="c42" name="adtx:DebtInstrumentTermDescription">The warrants have an exercise price of $126.50&#160;per
share and are exercisable for a&#160;five-year&#160;period commencing six months from the date of issuance.</ix:nonNumeric>&#160;The warrants exercise
price was subsequently repriced to $<ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="adtx:WarrantsExercisePrice" scale="0" unitRef="usdPershares">75.00</ix:nonFraction>. In addition, the Company issued a warrant to the placement agent to purchase up to&#160;<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="adtx:PurchaseOfCommonStock" scale="0" unitRef="shares">4,584</ix:nonFraction>&#160;shares
of common stock at an exercise price of $<ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">150.00</ix:nonFraction>&#160;per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2021, the Company entered into
an underwriting agreement with Revere Securities LLC, relating to the public offering (the &#8220;October 2021 Offering&#8221;) of&#160;<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares">56,667</ix:nonFraction>&#160;shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) by the Company. The Shares were offered, issued, and sold at a price to
the public of $<ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShares" scale="0" unitRef="usdPershares">75.00</ix:nonFraction>&#160;per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective
shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13,
2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $<ix:nonFraction contextRef="c46" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" scale="6" unitRef="usd">4.25</ix:nonFraction>&#160;million. The Company utilized a portion of
the proceeds, net of underwriting discounts of approximately $<ix:nonFraction contextRef="c46" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:OtherUnderwritingExpense" scale="6" unitRef="usd">3.91</ix:nonFraction>&#160;million from the October 2021 Offering to fund certain obligations
under the Credit Agreement. (See Note 4)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 6, 2021, the Company completed a public
offering for net proceeds of $<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">16.0</ix:nonFraction>&#160;million (the &#8220;December 2021 Offering&#8221;). As part of the December 2021 Offering, we
issued&#160;<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitIssued" scale="0" unitRef="shares">164,929</ix:nonFraction>&#160;units consisting of shares of the Company&#8217;s common stock and warrant to purchase shares of the Company&#8217;s
common stock and&#160;<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="adtx:PrefundedWarrantsShares" scale="0" unitRef="shares">166,572</ix:nonFraction>&#160;prefunded warrants. The warrant issued as part of the units had an exercise price of $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShares" scale="0" unitRef="usdPershares">57.50</ix:nonFraction>&#160;and
the prefunded warrants had an exercise price of $<ix:nonFraction contextRef="c49" decimals="3" format="ixt:num-dot-decimal" name="adtx:PrefundedWarrantsShares" scale="0" unitRef="shares">0.001</ix:nonFraction>. On June 15, 2022, the Company entered an agreement with a holder of certain warrants
in the December 2021 Offering. (See Note 11)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2022, the Company completed a
public offering for net proceeds of $<ix:nonFraction contextRef="c50" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd">17.2</ix:nonFraction>&#160;million (the &#8220;September 2022 Offering&#8221;). As part of the September 2022 Offering,
we issued&#160;<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShares" scale="0" unitRef="usdPershares">1,224,333</ix:nonFraction> of shares of the Company&#8217;s common stock, pre-funded warrants to purchase <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="adtx:PurchaseOfEquityShares" scale="0" unitRef="shares">2,109,000</ix:nonFraction> shares of common stock,
and warrants to purchase <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares">3,333,333</ix:nonFraction> shares of the Company&#8217;s common stock. The warrants had an exercise price of $<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">6.00</ix:nonFraction>&#160;and the
pre-funded warrants had an exercise price of $<ix:nonFraction contextRef="c52" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a limited operating history and
is in the very early stages of generating revenue from intended operations. The Company&#8217;s business and operations are sensitive
to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions.
A host of factors beyond the Company&#8217;s control could cause fluctuations in these conditions. Adverse conditions may include: changes
in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for
clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These
adverse conditions could affect the Company&#8217;s financial condition and the results of its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &#8220;Public Health Emergency of
International Concern&#8221; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the
spread of the coronavirus included restrictions on travel, and quarantines in certain areas, and forced closures for certain types of
public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had an adverse impact on the economies and
financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these
conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts
and additional development of our technologies may be negatively affected.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="adtx_GoingConcernsDisclosureTextBlock-c0_cont_1" escape="true" name="adtx:GoingConcernsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; GOING CONCERN ANALYSIS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="adtx_GoingConcernsDisclosureTextBlock-c0_cont_2" id="adtx_GoingConcernsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management Plans</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="adtx_GoingConcernsDisclosureTextBlock-c0_cont_3" id="adtx_GoingConcernsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated on September 28,
2017 and has not generated significant revenues to date. During the year ended December 31, 2022, the Company had a net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetLossCashFlowFromOperatingActivities" scale="0" unitRef="usd">27,649,876</ix:nonFraction>&#160;and
negative cash flow from operating activities of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaid" scale="0" unitRef="usd">22,049,040</ix:nonFraction>. As of December 31, 2022, the Company&#8217;s cash balance was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">2,768,640</ix:nonFraction>.
As of December 31, 2022, the Company had $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CustomerFunds" scale="6" unitRef="usd">51.5</ix:nonFraction>&#160;million of&#160;remaining availability, subject to regulatory requirements, to raise
future funds pursuant to an effective shelf registration statement filed with the SEC on Form S-3 declared effective on July 13, 2021.
However, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely
affect the Company&#8217;s ability to raise capital in an efficient manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="adtx_GoingConcernsDisclosureTextBlock-c0_cont_4" id="adtx_GoingConcernsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the shelf registration, the Company
has the ability to raise capital from equity of debt through private placements or public offerings pursuant to a registration statement
on Form S-1. We may also secure loans from related parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="adtx_GoingConcernsDisclosureTextBlock-c0_cont_5" id="adtx_GoingConcernsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of these factors, the Company believes
that this creates substantial doubt with the Company&#8217;s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="adtx_GoingConcernsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements included in this report
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the matters discussed herein. The Company&#8217;s ability to continue as a going
concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to
control operating expenses. In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances,
and other initiatives to strengthen the Company.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and
the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the
reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include
the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair
value of stock options and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements and Fair Value of
Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not identify any assets or liabilities
that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the short-term nature of all financial
assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash accounts at financial
institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally
insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all the Company&#8217;s accounts
receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk
is mitigated due to the Company&#8217;s number of customers. In addition, for receivables due from U.S government agencies, the Company
does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and
payment is primarily dependent upon submitting the appropriate documentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include short-term,
liquid investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of laboratory materials and
supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable
value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="adtx_FixedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="adtx:FixedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedAt="adtx_FixedAssetsPolicyTextBlock-c0_cont_2" id="adtx_FixedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets are stated at cost less accumulated
depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs
are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are
removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the
straight-line method over the estimated useful lives or lease life of the related assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="adtx_FixedAssetsPolicyTextBlock-c0_cont_3" id="adtx_FixedAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Useful lives assigned to fixed assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"><ix:continuation id="adtx_FixedAssetsPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="width: 50%; text-align: justify"><ix:nonNumeric contextRef="c54" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three years to five years</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab Equipment</span></td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c55" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven to ten years</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Furniture</span></td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c56" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other fixed assets</span></td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c57" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></ix:nonNumeric></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="text-align: justify"><ix:nonNumeric contextRef="c58" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of estimated useful life or remaining lease term</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are stated at cost less accumulated
amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated
useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable and Allowance for Doubtful
Accounts</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are stated at the amount management
expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company
determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management.
As of December 31, 2022 and 2021, there was an allowance for doubtful accounts of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" unitRef="usd">18,634</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:fixed-zero" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" unitRef="usd">zero</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="adtx_OfferingCostsPolicyTextBlock-c0_cont_1" escape="true" name="adtx:OfferingCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation id="adtx_OfferingCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offering costs incurred in connection with equity are recorded as a
reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606 (Revenue From Contracts
with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects
the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle,
the Company applies the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the contract with a customer</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determine the transaction price</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocate the transaction price to performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize revenue when or as the Company satisfies a performance obligation</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues reported from services relating to the
AditxtScore&#8482; are recognized when the AditxtScore<sup>TM </sup>report is delivered to the customer. The services performed include
the analysis of specimens received in the Company&#8217;s CLIA laboratory and the generation of results which are then delivered upon
completion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in the following
manner for the following types of customers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client Payers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client payers include physicians or other entities
for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for
client payers based on historical collection experience and the period of time the receivable has been outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_12" id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Pay:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_13" id="_RevenueRecognitionPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Customers are billed based on established patient
fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the
ability of the patients to pay.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_14" id="_RevenueRecognitionPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insurance:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursements from healthcare insurers are based
on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between
amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of
the Company&#8217;s contractual arrangements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Topic 842 (Leases), operating lease expense
is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space,
and lab equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases with an initial term of twelve months or
less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right
of use (&#8220;ROU&#8221;) assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
costs under the provisions of ASC 718, Compensation&#8212;Stock Compensation, which requires the measurement and recognition of compensation
expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense
recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant
date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled
during the periods reported. Stock-based compensation is recognized as expense over the employee&#8217;s requisite vesting period and
over the nonemployee&#8217;s period of providing goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="adtx_PatentsPolicyTextBlock-c0_cont_1" escape="true" name="adtx:PatentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation id="adtx_PatentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurs fees from patent licenses,
which is reflected in research and development expenses, and are expensed as incurred. During the years ended December 31, 2022 and 2021,
the Company incurred patent licensing fees for the patents of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:LicensingFeeForPatents" scale="0" unitRef="usd">263,273</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:LicensingFeeForPatents" scale="0" unitRef="usd">76,455</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incur research and development costs during
the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs
qualify for capitalization under applicable guidance. During the years ended December 31, 2022 and 2021, the Company incurred research
and development costs of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">7,268,084</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">5,042,617</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Net Loss per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per common share is computed by dividing the net loss by
the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the
net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect
of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock
equivalents because their inclusion would be anti-dilutive. As of December 31, 2022,&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantsOfStockOptions" scale="0" unitRef="shares">44,710</ix:nonFraction>&#160;stock options,&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="0" unitRef="shares">7,197</ix:nonFraction>&#160;unvested&#160;restricted
stock units, and&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:DilutiveEarningShares" scale="0" unitRef="shares">5,090,024</ix:nonFraction>&#160;warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of
December 31, 2021,&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantsOfStockOptions" scale="0" unitRef="shares">44,710</ix:nonFraction>&#160;stock options, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" scale="0" unitRef="shares">15,565</ix:nonFraction> unvested restricted stock units and&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantsExercisedShares" scale="0" unitRef="shares">601,399</ix:nonFraction>&#160;warrants were excluded
from dilutive earnings per share as their effects were anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and 2021,
the Company recognized an implied dividend from the modification of warrants of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockAwardForfeituresDividends" scale="0" unitRef="usd">37,667</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockAwardForfeituresDividends" scale="0" unitRef="usd">102,267</ix:nonFraction>, respectively. Theses implied dividends
resulted in an increase in the net loss attributable to common stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB issues ASUs to amend the authoritative
literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes
that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or
(iv) are not expected to have a significant impact on our financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; NOTE RECEIVABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cellvera Global Note Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2021, the Company entered into a
letter of intent (&#8220;the LOI&#8221;) to acquire AiPharma Global Holdings LLC, a Delaware limited liability company, which subsequently
changed its name to Cellvera Global Holdings LLC (&#8220;Cellvera Global&#8221;) which is commercializing COVID-19 antiviral oral therapy.
Key terms of the proposed transaction as stated in the Letter of Intent included: the completion of a proposed $<ix:nonFraction contextRef="c59" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLoansPayable" scale="6" unitRef="usd">6.5</ix:nonFraction>&#160;million secured
loan from the Company to Cellvera Global by August 31, 2021, as well as the issuance of such number of shares of the Company&#8217;s common
stock that yields&#160;<ix:nonFraction contextRef="c60" decimals="2" format="ixt:num-dot-decimal" name="adtx:CommonStockYieldsPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% of the number of the Company&#8217;s outstanding shares post-closing of the transaction. The acquisition is
subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive
agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed
to be issued in the transaction. The Company and Cellvera Global agreed to an exclusivity period until September 30, 2021 (the &#8220;Exclusivity
Period&#8221;), with a view to settling the definitive agreement. On September 30, 2021, the parties entered into a letter agreement pursuant
to which they agreed to extend the Exclusivity Period until October 4, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c61" name="adtx:DescriptionOfShareExchangeAgreement">On December 28, 2021, we entered into a Share
Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued and outstanding
equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of
$250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5%
of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and
a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.</ix:nonNumeric>&#160;Additionally,
we may elect to raise additional capital due to market conditions or strategic considerations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the contemplated acquisition
with Cellvera Global,&#160;the Company entered into a secured credit agreement dated August 27, 2021 (the &#8220;Credit Agreement&#8221;)
with Cellvera Global and certain affiliated entities (collectively, the &#8220;Borrower&#8221;), pursuant to which the Company made a
secured loan to Cellvera Global in the principal amount of $<ix:nonFraction contextRef="c62" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansSecuritized" scale="6" unitRef="usd">6.5</ix:nonFraction>&#160;million (the &#8220;Loan&#8221;). The Loan was funded on August 31,
2021, following the closing of the Company&#8217;s August 2021 Offering. The Loan bears interest at a rate of&#160;<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum and matured
on November 30, 2021. The Loan is secured by certain accounts receivable and other assets of Cellvera Global and certain of its affiliates.
The Credit Agreement also contains certain covenants that prohibit Cellvera Global from incurring additional indebtedness, incurring liens
or making any dispositions of its property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2021,&#160;<ix:nonNumeric contextRef="c64" name="adtx:CreditAgreementAmendmentDescription">the Company entered
into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the &#8220;Credit Agreement Amendment&#8221;),
pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by
$8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment.
The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the
Company from the exercise of existing warrants or any other capital raises, including the October Offering.</ix:nonNumeric>&#160;As of December 31, 2021,
an additional $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="adtx:AdvancedCreditAgreement" scale="6" unitRef="usd">8.0</ix:nonFraction>&#160;million was advanced under the Credit Agreement for a total of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="adtx:CreditAgreement" scale="6" unitRef="usd">14.5</ix:nonFraction>&#160;million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement was amended on multiple occasions,
for which the final amendment was signed on December 31, 2021, extending the Loan&#8217;s maturity date to January 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_8" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that Cellvera Global may
not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableWithVariableRatesOfInterest1" scale="6" unitRef="usd">14.5</ix:nonFraction>&#160;million as of December
31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_9" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forbearance Agreement:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_10" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2022, the Company&#8217;s $<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" scale="6" unitRef="usd">14.5</ix:nonFraction>&#160;million
loan to Cellvera Global became fully due and payable under the Credit Agreement. On February 14, 2022, the Company entered into a Forbearance
Agreement and Seventh Amendment to Credit Agreement (the &#8220;Forbearance Agreement&#8221;) with Cellvera Global.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_11" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Forbearance Agreement, the Company
agreed to forbear from exercising its rights and remedies against Cellvera Global and certain affiliated guarantor parties until the earlier
of (i) June 30, 2022 or (ii) the date of occurrence of any event of default under the Forbearance Agreement (the &#8220;Forbearance Period&#8221;).
Given that the parties continue to conduct due diligence in connection with the Share Exchange Agreement, the Company and Cellvera Global
also agreed that should the initial closing occur under the Share Exchange Agreement, the existing event of default will be waived. Under
the Forbearance Agreement, the Company and Cellvera Global also agreed to certain amendments to the Credit Agreement, including, but not
limited to: (i) the delivery by the Borrower of certain financial statements and forecasts, and (ii) certain regularly scheduled payments
to be made by Cellvera Global to the Company during the Forbearance Period. As of the date of filing of this Quarterly Report, the regularly
scheduled payments under the Forbearance Agreement have not been made, and the note receivable remains fully impaired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_12" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2022, the Company and Cellvera Global
entered into a Forbearance Agreement and Eighth Amendment to the Credit Agreement (the &#8220;April Forbearance Agreement&#8221;) pursuant
to which among other things (i) the Company agreed to extend the forbearance period until the earlier of March 31, 2023 or the date of
occurrence of any event of default under the April Forbearance Agreement, (ii) Cellvera Global shall be permitted to factor certain receivables,
and (iii) certain conforming changes were made relating to the Revenue Sharing Agreement (as defined below). In connection with the Forbearance
Agreement, the Company entered into a series of security agreements with Cellvera Global (the &#8220;Security Agreements&#8221;) and certain
affiliated entities pursuant to which Cellvera Global enhanced the Company&#8217;s security interest in connection with the Credit Agreement.
In addition, and as a condition to entering into the April Forbearance Agreement, the Company required that Cellvera Global enter into
a Revenue Sharing Agreement (the &#8220;Revenue Sharing Agreement&#8221;), pursuant to which, among other things, Cellvera Global agreed
to pay the Company a certain portion of its revenues up to the aggregate amount of $<ix:nonFraction contextRef="c66" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="6" unitRef="usd">30</ix:nonFraction>&#160;million. As of the date of filing of this
Annual Report, the Company has not received any payments from Cellvera Global pursuant to the Revenue Sharing Agreement. Upon termination
of the April Forbearance agreement, the amounts under the Secured Credit agreement (as amended) shall become immediately due and payable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_13" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the April Forbearance
Agreement and the Revenue Sharing Agreement, the Company and AiPharma Group, Ltd. entered into an Amendment to the Share Exchange Agreement
(the &#8220;Share Exchange Amendment&#8221;) which amended the Share Exchange Agreement to, among other things: (i) modify the financial
statements required to be delivered by AiPharma Group, Ltd. at the initial closing to include the unaudited financial statements for the
three months ended March 31, 2022 and 2021, (ii) permit the Company to amend its Certificate of Incorporation without the consent of AiPharma
Group, Ltd. in order to effect a reverse stock split of the Company&#8217;s common stock, if necessary, in order to maintain its listing
on the Nasdaq Capital Market, and (iii) make certain other conforming changes related to the March Forbearance Agreement and Revenue Sharing
Agreement.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_14" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Target Company Note Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_15" id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2021, the Company entered into
a secured credit agreement dated December 10, 2021 (the &#8220;Target Company Credit Agreement&#8221;) and signed on December 10, 2021
with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd">500,000</ix:nonFraction> (the
&#8220;Target Company Loan&#8221;) and agreed to make additional secured loans, as requested by the Target Company and approved by the
Company, in an amount not to exceed $<ix:nonFraction contextRef="c68" decimals="-5" format="ixt:num-dot-decimal" name="adtx:DebtLoanAmount" scale="6" unitRef="usd">4.5</ix:nonFraction> million. The Target Company Loan bears interest at a rate of <ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableWithFixedRatesOfInterest1" scale="0" unitRef="usd">8</ix:nonFraction>% per annum and mature on December
8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of
the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit
the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject
to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the
Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security
interest in all of the Target Company&#8217;s assets as security for the Target Company Loan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that the Target Company
may not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of the principal and accrued
interest of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" unitRef="usd">0.5</ix:nonFraction>&#160;million as of December 31, 2022.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; FIXED ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s fixed assets include the following
on December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">376,429</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">197,907</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">178,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,572,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">579,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,993,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">56,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">8,200</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">48,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">8,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">1,224</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">7,381</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold Improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">120,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">29,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">90,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">3,134,850</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">815,987</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">2,318,863</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s fixed assets include the following
on December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">312,489</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">75,053</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">237,436</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,240,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">306,688</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">1,933,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">90,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">4,857</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">85,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Fixed Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">10,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">412</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">10,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,654,307</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">387,010</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">2,267,297</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_6" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">428,977</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">369,236</ix:nonFraction>,
for the years ended December 31, 2022 and 2021, respectively. None of the Company&#8217;s fixed assets serve as collateral against any
loans as of December 31, 2022 and December 31, 2021, other than those subject to the financed asset liability. As of December 31, 2022
and 2021, the fixed assets that serve as collateral subject to the financed asset liability have a carrying value of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TimeDepositsAtCarryingValue" scale="0" unitRef="usd">1,359,091</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TimeDepositsAtCarryingValue" scale="0" unitRef="usd">1,690,420</ix:nonFraction>,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_7" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financed Assets:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_8" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, the Company purchased two pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" scale="0" unitRef="usd">19,487</ix:nonFraction>, with an interest rate of <ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_9" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January of 2021, the Company purchased one
piece of lab equipment and financed it for a period of twenty-four months with a monthly payment of $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" scale="0" unitRef="usd">9,733</ix:nonFraction>, with an interest rate of <ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_10" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March of 2021, the Company purchased five pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" scale="0" unitRef="usd">37,171</ix:nonFraction>, with an interest rate of <ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">8</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_11" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maturities as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" scale="0" unitRef="usd">111,512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">111,512</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; INTANGIBLE ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets include
the following on December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">321,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">214,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">321,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">214,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets include
the following on December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_IntangibleAssetsDisclosureTextBlock-c0_cont_4"><ix:continuation id="_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">321,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">214,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd">321,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd">107,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd">214,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IntangibleAssetsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:AmortizationOfIntangibleAsset" scale="0" unitRef="usd">107,000</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:AmortizationOfIntangibleAsset" scale="0" unitRef="usd">107,000</ix:nonFraction>&#160;for
the years ended December 31, 2022 and 2021, respectively. None of the Company&#8217;s intangible assets serve as collateral against any
loans as of December 31, 2022 and 2021. The Company&#8217;s proprietary technology is being amortized over its estimated useful life of
<ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="adtx:EstimatedUsefulLife">three years</ix:nonNumeric>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company granted&#160;<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">9,600</ix:nonFraction>&#160;restricted
stock units to an officer of the Company pursuant to the Company&#8217;s 2021 Equity Incentive Plan. The Company recognized $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="usd">146,613</ix:nonFraction>&#160;in
stock-based compensation for the issuance of these vested and unvested restricted stock units during the year ended December 31, 2022.
(Note 11)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#8220;Purchaser&#8221;), pursuant to which the Company
agreed to issue and sell one (1) share of the Company&#8217;s Series B Preferred Stock (the &#8220;Preferred Stock&#8221;), par value
$<ix:nonFraction contextRef="c90" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>&#160;per share, to the Purchaser for $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd">20,000</ix:nonFraction>&#160;in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company filed a certificate
of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="adtx:PreferredStockVotes" scale="0" unitRef="shares">250,000,000</ix:nonFraction>&#160;votes and will vote together with the outstanding shares of the Company&#8217;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#8217;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#8217;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStockCash" scale="0" unitRef="usd">20,000</ix:nonFraction>&#160;in cash. On September 13, 2022, the
share was redeemed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2022, the Chief Executive Officer
loaned $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent" scale="0" unitRef="usd">80,000</ix:nonFraction> to the Company.&#160;The loan was evidenced by an unsecured promissory note (the &#8220;Promissory Note&#8221;). Pursuant
to the terms of the Promissory Note, it will accrue interest at a rate of four and three-quarters percent (<ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">4.75</ix:nonFraction>%) per annum, the Prime
rate on the date of signing, and is due on the earlier of January 22, 2023, or an event of default. On October 7, 2022, the Company fully
repaid the $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="adtx:PromissoryNotes" scale="0" unitRef="usd">80,000</ix:nonFraction> Promissory Note and $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">812</ix:nonFraction> of accrued interest to its Chief Executive Officer. The Chief Executive Officer and the Company
entered the Promissory Note on July 21, 2022.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2022, the Company entered into an agreement
for the purchase and sale of future receipts (the &#8220;Future Receipts Agreement&#8221;) with a commercial funding source pursuant to
which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="adtx:AggregateAmount" scale="0" unitRef="usd">792,000</ix:nonFraction>&#160;(the &#8220;Future
Receipts Purchased Amount&#8221; for gross proceeds to the Company of $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="adtx:GrossProceeds" scale="0" unitRef="usd">550,000</ix:nonFraction>, less origination fees of $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd">16,500</ix:nonFraction>&#160;and professional
service fees of $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">13,500</ix:nonFraction>. Pursuant to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#8217;s
present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be
repaid by the Company in 28 weekly installments of approximately $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="0" unitRef="usd">28,000</ix:nonFraction> with the final payment due on December 7, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022, the principal balance and
accrued interest was paid off in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2022, the Company entered into an
Agreement for the Purchase and Sale of Future Receipts (the &#8220;Agreement&#8221;) with a commercial funding source pursuant to which
the Company agreed to sell to the funder certain future trade receipts in the aggregate amount $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="adtx:AggregateAmount" scale="0" unitRef="usd">288,000</ix:nonFraction> (the &#8220;Purchased Amount&#8221;)
for gross proceeds to the Company of $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfNotesPayable" scale="0" unitRef="usd">200,000</ix:nonFraction>, less origination fees of $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd">20,000</ix:nonFraction>. Pursuant to the Agreement, the Company granted the funder
a security interest in all of the Company&#8217;s present and future accounts receivable in an amount not to exceed the Purchased Amount.
The Purchased Amount shall be repaid by the Company in 20 weekly installments of approximately $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="0" unitRef="usd">14,400</ix:nonFraction> with the final payment due on January
18, 2023. In connection with the Agreement, the Company also issued a warrant to purchase <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantToPurchaseCommonShares" scale="0" unitRef="shares">26,667</ix:nonFraction> shares of the Company&#8217;s common
stock with an exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="adtx:ExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction> and an expiration of five years from the issuance date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022, the principal balance and
accrued interest was paid off in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Note Financing:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 4, 2022, the Company entered into a
Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors to purchase $<ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd">1,277,778</ix:nonFraction>&#160;in principal amount&#160;<ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="adtx:PrincipalAmountPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>%
Senior Secured Promissory Notes (the &#8220;August 2022 Notes&#8221;), resulting in gross proceeds to the Company of $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd">1,150,000</ix:nonFraction>, exclusive
of placement agent commission and fees and other offering expenses. In connection therewith, the Company issued,&#160;<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">25,556</ix:nonFraction>&#160;shares
of common stock as commitment fees and warrants (the &#8220;August 2022 Warrants&#8221;) to purchase up to&#160;<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">108,517</ix:nonFraction>&#160;shares of
the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2022, the Company entered into a
SPA with certain accredited investors to purchase $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="adtx:InvestorPurchaseAmount" scale="0" unitRef="usd">555,556</ix:nonFraction> in principal amount of August 2022 Notes, resulting in gross proceeds to the
Company of $<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="adtx:GrossProceeds" scale="0" unitRef="usd">500,000</ix:nonFraction>. In connection therewith, the Company issued <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">11,112</ix:nonFraction> shares of common stock as commitment fees and August 2022 Warrants
to purchase up to <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">47,182</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Notes have a maturity date of
twelve (12) months from the date of issuance and are convertible at the option of the Investor at any time prior to maturity in shares
of Common Stock (the &#8220;Conversion Shares&#8221;) at an initial conversion price of $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">11.78</ix:nonFraction> per share, subject to adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Warrants are exercisable for a period of five (5) years
from the period commencing on the commencement date (as defined in the August 2022 Warrant) and ending on 5:00 p.m. eastern standard time
on the date that is five (5) years after the date of issuance, at an initial exercise price of $11.78, subject to adjustment provided
therein (including cashless exercise). These warrants were valued using a Black-Scholes Model and the resulting relative fair value was
recorded as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2022, the Company entered into a
First Amendment and Waiver with the holders of the August 2022 Warrants, pursuant to which the exercise price of the August 2022 Warrants
was reduced to $<ix:nonFraction contextRef="c59" decimals="2" format="ixt:num-dot-decimal" name="adtx:WarrantExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction> per share and the August 2022 Warrants were modified such that they are not exercisable unless and until the Company
obtains stockholder approval of the issuance of any shares of common stock upon exercise of the August 2022 Warrants. On September 16,
2022, the exercise price of the August 2022 Warrants was further adjusted to $<ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">6.00</ix:nonFraction> per share. These warrants were valued using a Black-Scholes
Model and the resulting valuation was recorded as an implied dividend.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Note Financing Follow On:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_13" id="_DebtDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2022, the Company entered into
a SPA with a certain accredited investor to purchase $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="adtx:PrincipalAmount" scale="0" unitRef="usd">555,555</ix:nonFraction> in principal amount of August 2022 Notes, resulting in gross proceeds to
the Company of $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="adtx:GrossProceeds" scale="0" unitRef="usd">500,000</ix:nonFraction>. In connection therewith, the Company issued <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">11,112</ix:nonFraction> shares of common stock as commitment fees and warrants (the
&#8220;August 2022 Follow On Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">74,074</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_14" id="_DebtDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Follow On Warrants are exercisable for a period of
five (5) years from the period commencing on the commencement date (as defined in the August 2022 Follow On Warrant) and ending on 5:00
p.m. eastern standard time on the date that is five (5) years after the date of issuance, at an initial exercise price of $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="adtx:ExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction>, subject
to adjustments. These warrants were valued using a Black-Scholes Model and the resulting relative fair value was recorded as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_15" id="_DebtDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2022, the exercise price of the
August 2022 Follow On Warrants was adjusted to $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">6.00</ix:nonFraction> per share. These warrants were valued using a Black-Scholes Model and the resulting
valuation was recorded as an implied dividend.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the principal balance
of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedBalancePrincipalAmount" scale="0" unitRef="usd">2,388,888</ix:nonFraction>, a prepayment penalty of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaymentFeesOnAdvancesNet" scale="0" unitRef="usd">238,889</ix:nonFraction> and all accrued interest of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">119,444</ix:nonFraction> relating to the August 2022 Notes was paid off in
full.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; LEASES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lease agreements generally do not provide
an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement
date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on December 31, 2022 and
December 31, 2021 for all leases that commenced prior to that date. In determining this rate, which is used to determine the present value
of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease
and in a similar economic environment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters is located in Richmond,
Virginia, where we lease approximately <ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetLeases" scale="0" unitRef="sqm">25,000</ix:nonFraction> square feet. The lease expires in <ix:nonNumeric contextRef="c113" name="adtx:LeasesExpire">August 2026</ix:nonNumeric>, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also lease approximately <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetLeases" scale="0" unitRef="sqft">5,810</ix:nonFraction> square feet
of laboratory and office space in Mountain View, California. The lease expires in <ix:nonNumeric contextRef="c114" name="adtx:LeasesExpire">August 2024</ix:nonNumeric>, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we lease approximately <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetLeases" scale="0" unitRef="sqm">3,150</ix:nonFraction> square
feet of office space in Melville, New York. The lease expires in <ix:nonNumeric contextRef="c115" name="adtx:LeasesExpire">December 2024</ix:nonNumeric>, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December 31, 2022 the Company is
in arrears on certain lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Costs</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of total lease costs:</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expense</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">1,396,875</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="0" unitRef="usd">819,587</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease costs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd">1,396,875</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd">819,587</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Positions as of December 31, 2022 and
December 31, 2021</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_10" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROU lease assets and lease liabilities for our
operating leases are recorded on the balance sheet as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_11" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Right of use asset &#8211; long term</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssetShortTerm" scale="0" unitRef="usd">3,160,457</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssetShortTerm" scale="0" unitRef="usd">4,097,117</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total right of use asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalRightOfUseAsset" scale="0" unitRef="usd">3,160,457</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalRightOfUseAsset" scale="0" unitRef="usd">4,097,117</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities &#8211; short term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilitiesShortTerm" scale="0" unitRef="usd">1,086,658</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilitiesShortTerm" scale="0" unitRef="usd">1,145,126</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilitiesLongTerm" scale="0" unitRef="usd">1,885,218</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeaseLiabilitiesLongTerm" scale="0" unitRef="usd">2,765,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalLeaseLiability" scale="0" unitRef="usd">2,971,876</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalLeaseLiability" scale="0" unitRef="usd">3,911,059</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_12" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Terms and Discount Rate as of December
31, 2022</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_13" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years) &#8211; operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.70</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">8.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_14" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Maturities of leases are as follows:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LeasesOfLesseeDisclosureTextBlock-c0_cont_15" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Year Ended December 31, 2022</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd">1,129,853</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd">1,004,982</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd">710,546</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd">423,930</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd">3,269,311</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd">297,436</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:OperatingLeasesLiabilityCurrent" scale="0" unitRef="usd">1,086,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total maturities, due beyond one year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" unitRef="usd">1,885,218</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; COMMITMENTS &amp; CONTIGENCIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License Agreement with Loma Linda University</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2018, as amended
on July 1, 2020, we entered into a LLU License Agreement directly with Loma Linda University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LLU License
Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical
information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled
by LLU and/or any of its affiliates (the &#8220;LLU Patent and Technology Rights&#8221;) and related to therapy for immune-mediated inflammatory
diseases (the ADI&#8482; technology). In consideration for the LLU License Agreement, we issued <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">500</ix:nonFraction> shares of common stock to LLU.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LLU License
Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesAndLicenses" scale="0" unitRef="usd">455,000</ix:nonFraction> in July 2020 for outstanding milestone payments
and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically,
we are required to make the following milestone payments to LLU: $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DirectTaxesAndLicensesCosts" scale="0" unitRef="usd">175,000</ix:nonFraction> on March 31, 2022; $<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DirectTaxesAndLicensesCosts" scale="0" unitRef="usd">100,000</ix:nonFraction> on March 31, 2024; $<ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DirectTaxesAndLicensesCosts" scale="0" unitRef="usd">500,000</ix:nonFraction> on March
31, 2026; and $<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DirectTaxesAndLicensesCosts" scale="0" unitRef="usd">500,000</ix:nonFraction> on March 31, 2027. In lieu of the $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" unitRef="usd">175,000</ix:nonFraction> milestone payment due on March 31, 2022, the Company paid LLU an extension
fee of $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="srt:ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" scale="0" unitRef="usd">100,000</ix:nonFraction>. Upon payment of this extension fee, an additional year will be added for the March 31, 2022 milestone. Additionally,
as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made the
following payments to LLU: $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InformationTechnologyAndDataProcessing" scale="0" unitRef="usd">70,000</ix:nonFraction> at the end of December 2018, and a final payment of $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" unitRef="usd">60,000</ix:nonFraction> at the end of March 2019. We are required
to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe royalty payments
of (i) <ix:nonFraction contextRef="c122" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage" scale="-2" unitRef="pure">1.5</ix:nonFraction>% of Net Product Sales (as such terms are defined under the LLU License Agreement) and Net Service Sales on any Licensed Products
(defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or
supply), and (ii) <ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage" scale="-2" unitRef="pure">0.75</ix:nonFraction>% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services (as such terms are defined
under the LLU License Agreement) not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond
the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development
and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and
Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The LLU License Agreement
shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application
licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU.
LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance
fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision
that requires us to meet certain deadlines for milestone events (each, a &#8220;Milestone Deadline&#8221;)) not cured within 90 days after
delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by
us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application
to initiate first-in-human clinical trials on or before March 31, 2022, which has been extended to March 31, 2023 due to payment of a
$<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyFeePaidIndirectly" scale="0" unitRef="usd">100,000</ix:nonFraction> extension fee paid in March 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></ix:continuation></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreement with Leland Stanford Junior
University</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2020, we entered
into an exclusive license agreement (the &#8220;February 2020 License Agreement&#8221;) with Stanford regarding a patent concerning a
method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an exclusive
worldwide license to Stanford&#8217;s patent regarding use, import, offer, and sale of Licensed Products (as defined in the agreement).
The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement,
and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive
license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those
terms are defined in the February 2020 License Agreement&#8221;). However, Stanford agreed to not grant further licenses under the Licensed
Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the February 2020
License Agreement which extended our exclusive right to license the technology deployed in AditxtScore<sup>TM</sup>&#160;and securing
worldwide exclusivity in all fields of use of the licensed technology.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were obligated to pay and
paid a fee of $<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyFeePaidIndirectly" scale="0" unitRef="usd">25,000</ix:nonFraction> to Stanford within 60 days of February 3, 2020. We also issued <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">375</ix:nonFraction> shares of the Company&#8217;s common stock to
Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement in the
amount of $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" unitRef="usd">40,000</ix:nonFraction> for 2021 through 2024 and $<ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="0" unitRef="usd">60,000</ix:nonFraction> starting in 2025 until the license expires upon the expiration of the patent. The
Company is required to pay and has paid $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionOtherPaymentsRequired" scale="0" unitRef="usd">25,000</ix:nonFraction> for the issuances of certain patents. The Company will pay milestone fees of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:PaymentOfMilestoneFees" scale="0" unitRef="usd">50,000</ix:nonFraction> on
the first commercial sales of a licensed product and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClearanceFees" scale="0" unitRef="usd">25,000</ix:nonFraction> at the beginning of any clinical study for regulatory clearance of an in
vitro diagnostic product developed and a potential licensed product. The Company paid a milestone fee for a clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product of $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration" scale="0" unitRef="usd">25,000</ix:nonFraction> in March of 2022. We are also required
to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which
has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and
operations, and financial forecasts until at least $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" scale="0" unitRef="usd">10,000,000</ix:nonFraction> in revenue by June 30, 2020 (which has been completed), (iii) conduct validation
studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which
has been completed), (iv) submit a 510(k) application to the FDA, Emergency Use Authorization (&#8220;EUA&#8221;), or a Laboratory Developed
Test (&#8220;LDT&#8221;) by March 31, 2021 (which has been completed), (vi) develop a prototype assay for human profiling by December
31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity, or
infectious disease purposes by March 31, 2022 (which has been completed) and (viii) provided further development and commercialization
milestones for specific fields of use in writing prior to December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="us-gaap:BroadcastersLicenseAgreementCommitmentsDescription">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to <ix:nonNumeric contextRef="c0" name="us-gaap:LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual">$5</ix:nonNumeric> million annually or 6% when
Net Sales are above $5 million annually.</ix:nonNumeric> The February 2020 License Agreement may be terminated upon our election on at least 30 days advance
notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and commercializing
Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020 License Agreement;
or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30) day cure period
to remedy such violation.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2021, the Company increased the number
of authorized shares of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c128" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>&#160;per share, from&#160;<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">27,000,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction>&#160;(the
&#8220;Authorized Shares Increase&#8221;) by filing a Certificate of Amendment (the &#8220;Certificate of Amendment&#8221;) to its Amended
and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation
Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the
Company at the Company&#8217;s Annual Meeting of Stockholders on May 19, 2021.&#160;On September 13, 2022, the Company effectuated a 1
for 50 reverse stock split (the &#8220;Reverse Split&#8221;). The Company&#8217;s stock began trading at the Reverse Split price effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#8217;s common
stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" unitRef="shares">148,227</ix:nonFraction>&#160;shares of common stock and recognized expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">507,558</ix:nonFraction>&#160;in stock-based compensation for consulting services,
consisting of capital markets and investor relations. The stock-based compensation for consulting services is calculated by the number
shares multiplied by the closing price on the effective date of the contract. The Company also granted&#160;<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">11,644</ix:nonFraction>&#160;Restricted Stock
Units and,&#160;<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">18,469</ix:nonFraction>&#160;Restricted Stock Units&#160;vested which resulted in the issuance of shares. As a result, the Company recognized
expense of $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="adtx:RecognizedExpense" scale="0" unitRef="usd">1,209,906</ix:nonFraction>&#160;in stock-based compensation. The stock-based compensation for shares issued or RSU&#8217;s granted during the
period were valued based on the fair market value on the date of grant. The Company issued <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssued1" scale="0" unitRef="shares">58,256</ix:nonFraction> shares in relation to the issuance of
notes (See Note 8). The Company issued <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">1,224,333</ix:nonFraction> shares of common stock as part of the September 2022 Offering (See Note 1). The Company
also issued <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">1,766,917</ix:nonFraction> shares of common stock as a result of the exercise of prefunded warrants from the September 2022 Offering (See Note
1). The Company issued <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">179,419</ix:nonFraction> shares of common stock from the exercise of warrant, modification of warrant, and the issuance of warrant.
The Company issued <ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesIssued1" scale="0" unitRef="shares">9,237</ix:nonFraction> shares of common stock for the settlement of accounts payable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company
issued <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" unitRef="shares">2,031</ix:nonFraction> shares of common stock and recognized expense of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" unitRef="usd">254,242</ix:nonFraction> in stock-based compensation for consulting services. The Company
also issued <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesOfCommonStock" scale="0" unitRef="shares">1,602</ix:nonFraction> shares of common stock to Stanford University and two employees and recognized expense of $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="adtx:RecognizedExpense" scale="0" unitRef="usd">64,875</ix:nonFraction> relating to the agreement
with Stanford University. The Company also issued <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">189,843</ix:nonFraction> shares of common stock upon the exercise of warrants and received $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">3,727,285</ix:nonFraction>
in cash proceeds. The Company granted <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="adtx:SettlementOfAccountsPayableShares" scale="0" unitRef="shares">9,300</ix:nonFraction> Restricted Stock Awards, as a result the Company recognized expense of $<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="adtx:RecognizedExpense" scale="0" unitRef="usd">1,443,700</ix:nonFraction> in stock-based
compensation. The Company granted <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:SettlementOfAccountsPayableShares" scale="0" unitRef="shares">500</ix:nonFraction> Restricted Stock Awards of which <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="0" unitRef="shares">500</ix:nonFraction> vested, as a result, the Company recognized expense of $<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="adtx:RecognizedExpense" scale="0" unitRef="usd">17,000</ix:nonFraction>
in stock-based compensation for consulting services. The Company also granted <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">36,456</ix:nonFraction> Restricted Stock Units, of which <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">16,519</ix:nonFraction> vested and
resulted in the issuance of shares, as a result, the Company recognized expense of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:RecognizedExpense" scale="0" unitRef="usd">1,843,902</ix:nonFraction> in stock-based compensation. (See Note 7)
The Company issued <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesOfCommonStock" scale="0" unitRef="shares">96,050</ix:nonFraction> shares of common stock for the conversion of a convertible note. (See Note 9) The Company issued <ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="adtx:sharesIssued1" scale="0" unitRef="shares">91,667</ix:nonFraction> shares
of common stock as part of the August 2021 Offering. The Company issued <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesOfCommonStock" scale="0" unitRef="shares">56,667</ix:nonFraction> shares of common stock as part of the October 2021 Offering.
The Company issued <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="adtx:SharesOfCommonStock" scale="0" unitRef="shares">164,929</ix:nonFraction> shares of common stock as part of the December 2021 Offering. The stock-based compensation for shares issued
or RSU&#8217;s granted during the period, were valued based on the fair market value on the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue&#160;<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">3,000,000</ix:nonFraction>&#160;shares
of preferred stock, par value $<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>&#160;per share. There were no shares of preferred stock outstanding as of December 31, 2022 and December
31, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuance of Series B Preferred Stock:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#8220;Purchaser&#8221;), pursuant to which the Company
agreed to issue and sell <ix:nonFraction contextRef="c144" decimals="0" format="ixt-sec:numwordsen" name="adtx:SharesOfCommonStock" scale="0" unitRef="shares">one</ix:nonFraction> (1) share of the Company&#8217;s Series B Preferred Stock (the &#8220;Preferred Stock&#8221;), par value
$<ix:nonFraction contextRef="c145" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>&#160;per share, to the Purchaser for $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" scale="0" unitRef="usd">20,000</ix:nonFraction>&#160;in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company filed a certificate
of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">250,000,000</ix:nonFraction>&#160;votes and will vote together with the outstanding shares of the Company&#8217;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#8217;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#8217;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RedemptionPremium" scale="0" unitRef="usd">20,000</ix:nonFraction>&#160;in cash. On September 13, 2022, the
share was redeemed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redemption of Series B Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2022, the Company paid $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyFeePaidIndirectly" scale="0" unitRef="usd">20,000</ix:nonFraction> in
consideration for the <ix:nonFraction contextRef="c94" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendsShares" scale="0" unitRef="shares">one</ix:nonFraction> share of Preferred Stock which was redeemed on September 13, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;).&#160;The 2017 Plan provides for the grant of equity
awards to directors, employees, and consultants.&#160;The Company is authorized to issue up to&#160;<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares">2,500,000</ix:nonFraction>&#160;shares of our common
stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after
adoption, unless terminated earlier by the Board of Directors.&#160;All shares of our common stock pursuant to awards under the 2017 Plan
have been awarded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2021, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for grants of nonqualified
stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based
awards (collectively, the &#8220;Awards&#8221;). Eligible recipients of Awards include employees, directors or independent contractors
of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) will
administer the 2021 Plan. A total of&#160;<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares">60,000</ix:nonFraction>&#160;shares of common stock, par value $<ix:nonFraction contextRef="c149" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction>&#160;per share, of the Company may be issued
pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a
stock option will be no less than one hundred percent (<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="adtx:FairMarketValue" scale="-2" unitRef="pure">100</ix:nonFraction>%) of the Fair Market Value (as defined in the 2021 Plan) of a share of Common
Stock on the date of grant. The 2021 Plan was submitted and approved by the Company&#8217;s stockholders at the 2021 annual meeting of
stockholders, held on May 19, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
granted no new options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company
granted <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:CompanyGranted" scale="0" unitRef="shares">1,850</ix:nonFraction> stock option grants, with a weighted average grant date fair value $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="adtx:weightedAverageGrant" scale="0" unitRef="usd">8.39</ix:nonFraction>. The fair value of each option granted was estimated
using the assumption and/or factors in the Black-Scholes Model.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is an analysis of the stock option
grant activity under the Plan:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock-c0_cont_1" escape="true" name="adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">44,710</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">170.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">6.74</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">44,710</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">170.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance">5.74</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" scale="0" unitRef="shares">9,063</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">108.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c174" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">7,038</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="adtx:WeightedAverageExercisesPriceVested" scale="0" unitRef="usdPershares">112.41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,025</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">96.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 there were <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">42,685</ix:nonFraction> exercisable
options, these options had a weighted average exercise price $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares">173.50</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to options granted and vesting expense of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="adtx:StockOptionsShares" scale="0" unitRef="shares">791,187</ix:nonFraction>&#160;during the year ended December 31, 2022, of which $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShare" scale="0" unitRef="usdPershares">555,772</ix:nonFraction>&#160;is
included in general and administrative expenses and $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShare" scale="0" unitRef="usdPershares">235,415</ix:nonFraction>&#160;is included in research and development expenses in the accompanying
statements of operations. The remaining value to be expensed is $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="adtx:ShareBasedPaymentRemnainingExpenses" scale="0" unitRef="usd">179,892</ix:nonFraction>&#160;with a weighted average vesting term of&#160;<ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">0.75</ix:nonNumeric>&#160;years
as of December 31, 2022. The Company recognized stock-based compensation expense related to options issued and vesting of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="0" unitRef="usd">826,795</ix:nonFraction> during
the year ended December 31, 2021, of which $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd">587,209</ix:nonFraction> is included in general and administrative expenses and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">239,586</ix:nonFraction> is included in research
and development expenses in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes warrant forfeitures
as they occur as there is insufficient historical data to accurately determine future forfeitures rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="adtx:warrantIssued" scale="0" unitRef="shares">6,497,530</ix:nonFraction>&#160;warrants.&#160;During the year ended December 31, 2021, the Company issued&#160;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="adtx:warrantIssued" scale="0" unitRef="shares">678,242</ix:nonFraction>&#160;warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, the fair
value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$<ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction>-<ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">20.00</ix:nonFraction></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure">2.55</ix:nonFraction>%-<ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure">3.47</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c177" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric>-<ix:nonNumeric contextRef="c178" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.50</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">147</ix:nonFraction>%-<ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">165</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the fair
value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">200.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c137" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure">0.17</ix:nonFraction>%-<ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure">0.42</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.00</ix:nonNumeric>-<ix:nonNumeric contextRef="c179" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">154</ix:nonFraction>%-<ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">159</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate assumption for warrants
granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term
of warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined the expected volatility
assumption for warrants granted using the historical volatility of comparable public companies&#8217; common stock. The Company will continue
to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that
the Company&#8217;s common stock has enough market history to use historical volatility.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The dividend yield assumption for warrants granted
is based on the Company&#8217;s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends
on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes warrant forfeitures as
they occur as there is insufficient historical data to accurately determine future forfeitures rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant issuances are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36"><ix:continuation continuedAt="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock-c0_cont_2" id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">601,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">83.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.38</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">6,497,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">4.71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="adtx:WeightedAverageRemainingLifeGranted">4.66</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="adtx:StockIssuedDuringPeriodShareStockOptionsExercised" scale="0" sign="-" unitRef="shares">1,946,419</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expired or forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">62,512</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">45.62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Rounding for Reverse Split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">5,090,024</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.83</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance">4.54</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37"><ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c175" decimals="INF" format="ixt:num-dot-decimal" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" scale="0" unitRef="shares">92,567</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">75.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" scale="0" unitRef="shares">6,497,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="adtx:WeightedAverageExercisePriceGranted" scale="0" unitRef="usdPershares">4.71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">6,435,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="adtx:WeightedAverageExercisesPriceVested" scale="0" unitRef="usdPershares">5.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c176" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">55,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="adtx:WeightedAverageExercisePriceExpiredOrForfeited" scale="0" unitRef="usdPershares">20.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c175" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">100,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.50</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to warrants granted and vesting expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantsIssuedAndVesting" scale="0" unitRef="usd">609,748</ix:nonFraction> during the year ended December 31, 2022, of which $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd">105,049</ix:nonFraction>&#160;is
included in general and administrative and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">504,699</ix:nonFraction> is included in sales and marketing in the accompanying Statements of Operations. The
Company recognized stock-based compensation expense related to warrants granted and vesting expense of $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="adtx:WarrantsIssuedAndVesting" scale="0" unitRef="usd">189,899</ix:nonFraction>&#160;during the year ended
December 31, 2021, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to
be expensed is <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd">zero</ix:nonFraction> as of December 31, 2022. The weighted average vesting term is <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">0.22</ix:nonNumeric> years as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, the Company entered an agreement
with a holder of certain of the Series C Warrants (the &#8220;Holder&#8221;).&#160;Pursuant to the agreement, the Holder has agreed to
exercise in cash <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd">179,419</ix:nonFraction> of its Series C Warrants at a reduced exercise price of $<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">7.50</ix:nonFraction> per Share (reduced from $<ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">57.50</ix:nonFraction> per share), for
gross proceeds to the Company of approximately $<ix:nonFraction contextRef="c156" decimals="-4" format="ixt:num-dot-decimal" name="adtx:GrossProceeds" scale="6" unitRef="usd">1.35</ix:nonFraction> million. As an inducement to such exercise, the Company has agreed to reduce the
exercise price of the Holder&#8217;s remaining Series C Warrants to purchase up to <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares">49,153</ix:nonFraction> Shares from $<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShare" scale="0" unitRef="usdPershares">57.50</ix:nonFraction> to $<ix:nonFraction contextRef="c158" decimals="3" format="ixt:num-dot-decimal" name="adtx:ExercisePricePerShare" scale="0" unitRef="usdPershares">12.395</ix:nonFraction> per share, which
will be non-exercisable for a period of six months following the closing date. The modification of this exercise price resulted in an
increase of $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="0" unitRef="usd">344,158</ix:nonFraction> to the fair value of the Series C Warrants. This modification was an inducement on the transaction and as such was
recorded to equity resulting in no net change to additional paid in capital. In addition, the Company issued to the Holder a new warrant
to purchase up to <ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">407,991</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">12.395</ix:nonFraction> per share, which will be non-exercisable
for a period of six months following issuance date and have a term of five and one-half years.&#160;This inducement resulted in a total
increase of $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">3,759,044</ix:nonFraction>&#160;to the fair value of the warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2022, the Company and the Warrant
Agent entered into Amendment No. 2 to the Series C Warrant Agent Agreement, pursuant to which the exercise price of the Series C Warrants
was reduced from $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">57.50</ix:nonFraction> per share to $<ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">12.395</ix:nonFraction> per share. In addition, on December 21, 2022, the Company issued an Amended and Restated
Unit Purchase Option to the agent in the Offering reflecting a reduced exercise price of $<ix:nonFraction contextRef="c162" decimals="3" format="ixt:num-dot-decimal" name="adtx:OfferingReflectingReducedExercisePricePerShare" scale="0" unitRef="usdPershares">12.395</ix:nonFraction> per Unit. This modification of these
warrants resulted in a $<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd">29,058</ix:nonFraction> increase to the fair value of the warrants (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_42" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_43" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_42"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of Restricted Stock Units (&#8220;RSUs&#8221;)
issuances are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_44" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_43"><ix:continuation id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested RSUs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">15,565</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">96.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">11,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">22.74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">18,506</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">70.65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares">1,506</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">77.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">7,197</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">46.72</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_45" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_44"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to RSUs granted and vesting expense of $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="adtx:VestingExpense" scale="0" unitRef="usd">1,222,875</ix:nonFraction>&#160;and&#160;$<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="adtx:VestingExpense" scale="0" unitRef="usd">1,843,902</ix:nonFraction> during the years ended December 31, 2022 and
December 31, 2021, respectively, of which, $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd">848,597</ix:nonFraction>&#160;is included in general and administrative, $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">356,105</ix:nonFraction>&#160;is included in research
and development, and $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="0" unitRef="usd">18,346</ix:nonFraction> is included in sales and marketing in the accompanying Statements of Operations. The remaining value to be
expensed is $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="adtx:ShareBasedPaymentRemnainingExpenses" scale="0" unitRef="usd">321,603</ix:nonFraction>&#160;with a weighted average vesting term of&#160;<ix:nonNumeric contextRef="c131" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">0.40</ix:nonNumeric>&#160;years as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_45"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
granted a total of&#160;<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="adtx:GrantTotal" scale="0" unitRef="shares">11,644</ix:nonFraction>&#160;RSUs. As of December 31, 2022,&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares">18,506</ix:nonFraction> RSUs vested and the Company issued&#160;<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">18,469</ix:nonFraction>&#160;shares
of common stock for the&#160;<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="adtx:CommonStockIssuedVested" scale="0" unitRef="shares">18,469</ix:nonFraction> vested RSUs.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8211; INCOME TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December&#160;31, 2022 and
2021, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by
the Company. The Company&#8217;s losses before income taxes consist solely of losses from domestic operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of income tax expense (benefit)
computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Income taxes at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" unitRef="pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" unitRef="pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">1.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">6.9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure">1.0</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure">0.1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Permanent Differences/Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="adtx:PermanentDifferencesOthers" scale="-2" sign="-" unitRef="pure">10.5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="adtx:PermanentDifferencesOthers" scale="-2" sign="-" unitRef="pure">5.0</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="adtx:ChangeInValuationAllowanceinDollars" scale="-2" sign="-" unitRef="pure">13.1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="adtx:ChangeInValuationAllowanceinDollars" scale="-2" sign="-" unitRef="pure">23.0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="adtx:TotalProvisionForIncomeTaxesinDollars" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="adtx:TotalProvisionForIncomeTaxesinDollars" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred taxes are recognized for temporary differences
between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s
deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are comprised of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 13.7pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" unitRef="usd">13,499,811</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" unitRef="usd">10,896,410</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="0" unitRef="usd">430,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="0" unitRef="usd">161,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd">1,511,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd">1,541,936</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd">722,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd">1,169,887</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Section 174 Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:Section174Capitalization" scale="0" unitRef="usd">1,547,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Loss on impairment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" unitRef="usd">3,288,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" unitRef="usd">4,140,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 13.7pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd">114,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd">23,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 27.35pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">21,114,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd">17,934,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:ValuationAllowance" scale="0" sign="-" unitRef="usd">20,217,401</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:ValuationAllowance" scale="0" sign="-" unitRef="usd">16,670,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetDeferredTaxAssets" scale="0" unitRef="usd">897,533</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:NetDeferredTaxAssets" scale="0" unitRef="usd">1,263,837</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssets" scale="0" sign="-" unitRef="usd">722,127</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:RightOfUseAssets" scale="0" sign="-" unitRef="usd">1,169,887</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:FixedAssets" scale="0" sign="-" unitRef="usd">175,406</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:FixedAssets" scale="0" sign="-" unitRef="usd">93,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalDeferredTaxLiabilities" scale="0" sign="-" unitRef="usd">897,533</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="adtx:TotalDeferredTaxLiabilities" scale="0" sign="-" unitRef="usd">1,263,837</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&#8217;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&#160;31, 2022 and 2021, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&#8217;s valuation allowance increased during 2022 by approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" unitRef="usd">3.5</ix:nonFraction>&#160;million primarily
due to the generation of net operating loss and tax credit carryforwards and the capitalization of research and experimental expenditures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022 and 2021, the Company
had U.S. federal net operating loss carryforwards of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd">56.6</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" unitRef="usd">38.0</ix:nonFraction>&#160;million, respectively, which may be available to
offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8221; TCJA&#8221;) will generally allow losses incurred after
2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss
carryover or&#160;<ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="adtx:NetOperatingLossCarryover" scale="-2" unitRef="pure">80</ix:nonFraction>% of a corporation&#8217;s taxable income (subject to Section&#160;382 of the Internal Revenue Code of 1986, as amended).
Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent
of the lesser of a corporation&#8217;s net operating loss carryover or&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="adtx:NetOperatingLossCarryover" scale="-2" unitRef="pure">100</ix:nonFraction>% of a corporation&#8217;s taxable income and be available
for&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="adtx:incomeLossOfGenerated">twenty years</ix:nonNumeric>&#160;from the period the loss was generated. The Company has federal net operating losses generated following 2017
of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="adtx:NetOperatingLosse" scale="6" unitRef="usd">56.5</ix:nonFraction>&#160;million, which do not expire. The federal net operating losses generated prior to 2018 of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="adtx:NetOperatingLossesGeneratedPrior" scale="6" unitRef="usd">0.1</ix:nonFraction>&#160;million will expire
at various dates through 2037.&#160;<ix:nonNumeric contextRef="c5" name="us-gaap:LessorOperatingLeaseDescription">The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019
and 2020 to the five prior tax years.</ix:nonNumeric>&#160;In addition, net operating losses generated in these years could fully offset prior year taxable
income without the&#160;<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="adtx:PercentageOfIncomeTaxable" scale="-2" unitRef="pure">80</ix:nonFraction>% of the taxable income limitation under the TCJA which was enacted on December 22, 2017. The Company has been
generating losses since its inception, as such the net operating loss carryback provision under the CARES Act is not applicable to the
Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022 and 2021, the Company
also had U.S. state net operating loss carryforwards (post-apportioned) of $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">26.2</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">44.8</ix:nonFraction>&#160;million, respectively, which
may be available to offset future income tax liabilities and expire at various dates through 2042.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, the Company had
$<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" unitRef="usd">0.1</ix:nonFraction> million federal tax credit carryforwards available to reduce future tax liabilities which expire at various dates through 2042. As
of December&#160;31, 2021, the Company had no federal tax credit carryforwards. As of December&#160;31, 2022 and 2021, the Company had
state research and development tax credit carryforwards of approximately $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="6" unitRef="usd">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" scale="6" unitRef="usd">0.2</ix:nonFraction>&#160;million, respectively, which
may be available to reduce future tax liabilities and can be carried over indefinitely.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the U.S. federal and state net
operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section&#160;382
and Section&#160;383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes
that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and
research and development credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively.
The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership
changes since its formation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research
and development tax credit carryforwards before utilization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not, as of yet, conducted a study
of research and development tax credit carryforwards. Such a study, once undertaken by the Company, may result in an adjustment to the
research and development tax credit carryforwards; however, a full valuation allowance has been provided against the Company&#8217;s research
and development tax credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance.
Thus, there would be no impact to the balance sheet or statement of operations if an adjustment is required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files tax returns in the United States,
California, Virginia, and New York. The Company is subject to U.S. federal and state tax examinations by tax authorities for the tax years
ended December 31, 2019 through present. As of December&#160;31, 2022 and 2021, the Company has recorded no liability for unrecognized
tax benefits, interest, or penalties related to federal and state income tax matters and there currently no pending tax examinations.
The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_2" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2022, the Company entered into
an At The Market Offering Agreement (the &#8220;ATM&#8221;) with H.C. Wainwright &amp; Co., LLC as agent (the &#8220;Agent&#8221;), pursuant
to which the Company may offer and sell, from time to time through the Agent, shares of the Company&#8217;s common stock having an aggregate
offering price of up to $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="adtx:AggregateOfferingPriceaAmount" scale="0" unitRef="usd">50,000,000</ix:nonFraction> (the &#8220;Shares&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_3" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The offer and sale of
the Shares was made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-257645) filed by the
Company with the SEC on July 2, 2021, amended on July 6, 2021 and declared effective by the SEC on July 13, 2021, under the Securities
Act of 1933, as amended.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_4" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No sales of Shares were
made during the year ended December 31, 2022 under the ATM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_5" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the period beginning
January 1, 2023 through the date of this report, the Company sold <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">338,513</ix:nonFraction> Shares at an average price of $<ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap-sup:InvestmentCompanyIssuanceOfSharesPerShare" scale="0" unitRef="usdPershares">1.55</ix:nonFraction> per share under the ATM.
The sale of Shares generated net proceeds of approximately $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForCommissions" scale="0" unitRef="usd">507,000</ix:nonFraction> after paying commissions and related fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_6" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Adimune,
Inc. a Delaware, wholly owned subsidiary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_7" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Pearsanta,
Inc. a Delaware, wholly owned subsidiary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_8" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2023, the Company entered into
an agreement for the purchase and sale of future receipts (the &#8220;Future Receipts Agreement&#8221;) with a commercial funding source
pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement" scale="0" unitRef="usd">2,160,000</ix:nonFraction>&#160;(the
&#8220;Future Receipts Purchased Amount&#8221; for gross proceeds to the Company of $<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="adtx:GrossProceed" scale="0" unitRef="usd">1,500,000</ix:nonFraction>, less origination fees of $<ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OriginationOfNotesReceivableFromRelatedParties" scale="0" unitRef="usd">75,000</ix:nonFraction>. Pursuant
to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#8217;s present and future
accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be repaid by the Company
in 28 weekly installments of approximately $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="0" unitRef="usd">77,000</ix:nonFraction> with the final payment due on September 5, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_9" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2023, the Company entered into a consulting
agreement (the "Independent Consulting Agreement") with an independent consultant for a term of thirty days. Pursuant to the
Independent Consulting Agreement, the independent consultant agreed to provide the Company with business advisory services, guidance on
growth strategies and networking with its clients on a non-exclusive basis for general business purposes (the "Independent Consulting
Services&#8221;). In consideration for the Independent Consulting Services, the Company issued to the independent consultant <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">187,000</ix:nonFraction> shares
of the Company's common stock (the "Independent Consulting Shares"). The issuance of the Independent Consulting Shares will
not be registered under the Securities Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ScheduleOfSubsequentEventsTextBlock-c0_cont_10" id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4, 2023, the Company entered into a Business
Loan and Security Agreement (the "April Loan Agreement") with a commercial funding source (the "April Lender"), pursuant
to which the Company obtained a loan from the April Lender in the principal amount of $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BadDebtReserveForTaxPurposesOfQualifiedLender" scale="0" unitRef="usd">1,060,000</ix:nonFraction>, which includes origination fees of $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDeferredLoanOriginationFeesNet" scale="0" unitRef="usd">60,000</ix:nonFraction>
(the "April Loan"). Pursuant to the April Loan Agreement, the Company granted the April Lender a continuing secondary security
interest in certain collateral (as defined in the April Loan Agreement). The total amount of interest and fees payable by the Company
to the April Lender under the April Loan (the "April Repayment Amount") will be (i) $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" unitRef="usd">1,000,000</ix:nonFraction> if paid prior to April 6, 2023,
(ii) $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" unitRef="usd">1,219,000</ix:nonFraction> if paid prior to April 10, 2023, or (iii) $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" unitRef="usd">1,590,000</ix:nonFraction> if paid after April 10, 2023 and will be repaid in 20 weekly installments
of $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PriorPeriodReclassificationAdjustment" scale="0" unitRef="usd">79,500</ix:nonFraction> commencing on April 10, 2023 and ending on August 21, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ScheduleOfSubsequentEventsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 13, 2023, the Company formed Adivir, Inc.
a Delaware, wholly owned subsidiary.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-29</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>









































































































































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:NotesAndLoansReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:DeferredCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="adtx:FinancingOfFixedAssetLongTerm" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-10" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">121.18</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">14.89</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-12" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">1854724</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-13" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">381811</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-16" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-19" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-25" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-26" name="adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-29" name="adtx:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-32" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-33" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-34" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-35" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="0" id="hidden-fact-36" name="us-gaap:StockholdersEquity" unitRef="usd">5206307</ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-37" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-38" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-41" name="adtx:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-45" name="adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-46" name="adtx:IssuanceOfSharesForTheSettlementOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-49" name="adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-50" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-51" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-53" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-55" name="adtx:DisposalOfFixedAssets1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="adtx:NoteReceivablesAndAccruedInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="us-gaap:ProceedsFromSecuredNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-58" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-59" name="adtx:SaleOfPreferredSharesToRelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-62" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-63" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-64" name="adtx:OriginalOfferingDiscountOnConvertibleNotePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-66" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="adtx:OriginalIssuanceDiscountOnNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-68" name="adtx:DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-69" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-70" name="adtx:LiabilityRecognizedForFinancedAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="adtx:ReductionInExercisePriceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-72" name="adtx:SharesIssuedForIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-73" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-74" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-75" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-76" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-77" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-79" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-80" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c165" id="hidden-fact-83" name="adtx:WeightedAverageRemainingLifeGranted" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c165" id="hidden-fact-84" name="adtx:StockIssuedDuringPeriodShareStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c165" id="hidden-fact-86" name="adtx:WeightedAverageRemainingLifeExercised" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c165" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c165" id="hidden-fact-89" name="adtx:WeightedAverageRemainingLifeExpiredOrForfeited" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c168" id="hidden-fact-90" name="adtx:WeightedAverageRemainingLifeExercised" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c168" id="hidden-fact-91" name="adtx:WeightedAverageRemainingLifeExpiredOrForfeited" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c168" id="hidden-fact-92" name="adtx:WeightedAverageExercisePriceRoundingForReverseSplit" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c168" id="hidden-fact-93" name="adtx:WeightedAverageRemainingLifeRoundingForReverseSplit" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c174" id="hidden-fact-94" name="adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-95" name="adtx:WeightedAverageExercisePriceGranted" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-97" name="adtx:WeightedAverageExercisePriceExpiredOrForfeited" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-98" name="adtx:Section174Capitalization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-99" name="adtx:NetDeferredTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-100" name="adtx:NetDeferredTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001726711</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="adtx-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-18</xbrli:startDate>
    <xbrli:endDate>2021-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-20</xbrli:startDate>
    <xbrli:endDate>2021-10-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-06</xbrli:startDate>
    <xbrli:endDate>2021-12-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-20</xbrli:startDate>
    <xbrli:endDate>2022-09-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sic:Z2520</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-02</xbrli:startDate>
    <xbrli:endDate>2021-12-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:ProprietaryTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:TotalIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:ProprietaryTechnologyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:TotalIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-10</xbrli:startDate>
    <xbrli:endDate>2022-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCes/mD+nH2NlNQ5ZxwdyOknm] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2022-10-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adtx:FutureReceiptsAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-27</xbrli:startDate>
    <xbrli:endDate>2022-05-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-27</xbrli:startDate>
    <xbrli:endDate>2022-05-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adtx:FutureReceiptsAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-04</xbrli:startDate>
    <xbrli:endDate>2022-08-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:August2022WarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-11</xbrli:startDate>
    <xbrli:endDate>2022-08-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-16</xbrli:startDate>
    <xbrli:endDate>2022-09-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:August2022FollowOnWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-02</xbrli:startDate>
    <xbrli:endDate>2022-09-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:VA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:CA</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:NY</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-03-01</xbrli:startDate>
    <xbrli:endDate>2026-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2027-03-01</xbrli:startDate>
    <xbrli:endDate>2027-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-03</xbrli:startDate>
    <xbrli:endDate>2020-02-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adtx:StanfordUniversityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">adtx:RestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">adtx:RestrictedStockUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adtx:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-01</xbrli:startDate>
    <xbrli:endDate>2017-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:OneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:OneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adtx:SeriesCWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-01</xbrli:startDate>
    <xbrli:endDate>2022-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adtx:SeriesCWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-01</xbrli:startDate>
    <xbrli:endDate>2017-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-02</xbrli:startDate>
    <xbrli:endDate>2022-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-01</xbrli:startDate>
    <xbrli:endDate>2023-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-09-01</xbrli:startDate>
    <xbrli:endDate>2023-09-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-21</xbrli:startDate>
    <xbrli:endDate>2023-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-21</xbrli:startDate>
    <xbrli:endDate>2023-04-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-21</xbrli:startDate>
    <xbrli:endDate>2023-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-21</xbrli:startDate>
    <xbrli:endDate>2023-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001726711</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-01</xbrli:startDate>
    <xbrli:endDate>2023-08-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>f10k2022ex23-1_aditxtinc.htm
<DESCRIPTION>CONSENT OF DBBMCKENNON, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We consent to the incorporation by reference in the
Registration Statement on Form S-8 (File No. 333-246324), Registration Statement on Form S-3 (File No. 333-257645) and Registration Statement
on Form S-1 (File No. 333-266183) of our report dated April 17, 2023, relating to the financial statements of Aditxt, Inc. for the years
ended December 31, 2022 and 2021, which includes an explanatory paragraph regarding substantial doubt about its ability to continue as
a going concern, and appear in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">/s/ dbb<I>mckennon</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Newport Beach, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">April 17, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10k2022ex31-1_aditxtinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Amro Albanna, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Aditxt, Inc;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,&nbsp;is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 17, 2023</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Amro Albanna</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<BR>
(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>f10k2022ex31-2_aditxtinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Thomas J. Farley, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Aditxt, Inc;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 17, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Thomas J. Farley</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas J. Farley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>f10k2022ex32-1_aditxtinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ENACTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of Aditxt,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ending December 31, 2022, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), each of Amro Albanna, Chief Executive Officer of the Company and Thomas J. Farley, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Amro Albanna</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 17, 2023</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Thomas J. Farley</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas J. Farley</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X F(# 2(  A$! Q$!_\0
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M0O\ X5ZY:(SV[1SJ/?FN6O="U/2P1=V,JC^]MS7TP,]C^=-EA@G4K-&D@]&
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M>1FS\OO4OB+Q#H6O:GI%W+'<7"2)LNXEB(9>.OYU/IUKJUXFJ:)H&ER)HUV
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M=4J<F)R2%HH W?=#'Z"GB"X?[L#X^E:+#S?0S=6*ZC**F%I<D9\AZ3[-<#K
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MU3<N*3.E;6M/2?R6N4$G3';-/EU2R@F$,TZ+*?X!U->;7]U(_AT72?9X5\X
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M7P5=8CP?M.>/7-=YI^3IUOGKY8I5LX!'Y0B3RCR5QWJ=0 @ & !TII$-W%H
MHI1UIDB$[>>HI"<#D@<?E2GD_2N7\=Z]_P (_P"%KJZ#;99?W49]">,T M3E
MO&'C.._U"3PY8EH[+&R]OQ'N2,'M]:E^%\^GV,FHZ#8RQSB!]\<XZNI]:YS2
M=?C\(VD&EW,EOJUO<_O&<*,DMS@^M;?@^>SO_B5=7&G6)LHTM LT>S:"V>M!
M7+I<]44#CTI],'0'L*?02 I:04M #3C-<-\5(!-X39^\<@(KN2,URWC^RGO_
M  G<PVZ[I."!4RE97!*^AYY\(G'_  D=PH.08LU[5FO&OA;9S:?K\K7.U=\>
M!GJ37LH.14QJ*0W'EW%'6G4+THK004444 )3';"]_K3ZSM:U6WT73)KZZ8".
M->G=CV H XGXH6'GQZ1=/<M;11W*AYE./+!_BK ;4M>UV:7PU:+#J]HP _M-
MTP(1Z^YK*UO59/%=I>2>*4O=.A89L[?80F!R&8UZ?X GM+SP=8S6<$<493:P
M0=2.,T 7?"OARR\+Z*FG6@SMY>0]7;N:W5&"3[=!2(NU<,02*@GNH;9L.<MZ
M"@"=>G(HY-0_;K=85E+C:W0TY9XI=VUAE1DC- $F>V*/T]J@2]MYFV*XS3#?
M6YE*A\=L]OI0!9]^GM2=^?PJ":]MX&*E@9 ,X]*AM;]'LEN)3@;B!CO0!<Y_
MQH..W-1)<P21,X; 'WEI%N8&<*&^8]*&,F[=,4W/..2*CGNH+=@DI^8]!ZU'
M]NMA"TOF@*O!/I63E8+%C^/VI,C<",YJM]OMEBWF7KT]ZEAN8KA"T3 X[=Z<
M9W"Q)C( ZC.:CN23:W!'/[ML<=\5("<;AVZT*,$A?NGDUH(\/\/IH=G%<7.N
M7L]T_P!J81:?'D@'/=:T[*^OM%\36VMPZ4=-T&[(AEA<XRQX#;>U%Q;7WAGQ
MY?6&EV%JTVIL9X+NXQB,]P*K>,+!!I4DVN>)!<Z@'4QVL384,#P!0![(?4'Y
M2,BE[\U1TB2270[*27.\P+G-73TH0F5+Z+S(F&.&&#7F-Y#Y-Y)&?4UZQ)@Q
M^M><>)81%JG3&X5X>9PNKGKX"=G8QSVI:!R,T5\F]SZ)"=,FM[P@=FK$#NM8
M1^[6UX5.-;'^[7H8%_O$<.,7[MGHOI61JH_XF%O[FM>LC5O^/VV/H:^UA\)\
MO(V5?Y1]**C7[H^E%429_B ?NP?0U?@(:WB;_9%5=?7-J3[U-9-NLH3[4P*?
MB-/,\-7ZGDF(G]*^<%KZ;O(O.L;F/J'B(_2OFJY3RKZ:+!^61EH)9&:*#13$
M ..:]%^%NH>6UQ8NV%'SJ/6O.O6M3PYJ!TS7K>XW8C+!7'M2$CZ*A?='3ZHV
M-PLD:8QEQN7Z5>[\=.U!H.[4(0#SR>Q]*!2#Y&...>?>@#Q0K-X@UO7(H-&-
MU>R3^6+EB56';T.>U;VC^([[P9J5GX>\1Z@E^+GB.=#\T1]&]O>J6HIK6C>,
M-1TBSO(;2QO5-PDK\%CU*BL71M*UW78M3M1;1EY01]KF'W<="#0:1BFKL]TR
M"  1@C*L.].'3CIWKE/A_JCZCX6CAFD62>R<P2,#G)7BNK&#EAD*>U!G;4*6
MDI: "@=:*4=:  TM(:7'% !0.M%*.M !^-+24M  >E(.M*>E)N^7/0 \YH 7
M^(>E>=_%6:2*WT4I;FY7[:N8 ,F0>F*ZK7O$^F>';4W%]-CC*QKRS_05Y?XI
M\5ZGXJT6'4]%LTALK:Y#1SRMB0,#Z4AHLWZ>$+C3IK@*=)U2$[Q!*OS!^P"G
MMFNI^'6DWUOI,NK:MAM0OCN(VXVIT J/1_ =M=7]OKVNS_VC?>6ICWJ J<>@
MZUW4>-@Q@8X % -]!RC 'I3Z:!P!3J8@%+2"EH 2J&K#_B6W ']PU?JEJ:[[
M&8#^X:YZWPLJ&Z/+-)<P:Q;L3_'BO6D;<J_2O'D)CO$/\22?UKUVT;?:QOZJ
M*\["5+MH[,5&R18!IU-IU>PMCA"CM113 05YQ\37-]?:1HJWL=IYLGFEY.AV
M]J]''!KS#XG)IUMK>CZEK-LT]@FZ,JN<ACTZ4 322>*X[5DNK/2M7M%4\AAN
M"X["KOPJ<MX5=O*$<?GOA.R\\BN$UJY\*FP:+2'U.UU&<^7;QAF&]C['M7K'
MA+1SH/ABSL7R71 7SU+'K0!MD9'3GVK$EW+JTKR3K&FW'S"MP %<9R#4<D$4
MI = P'J* ,,0HL5LB2>8IFSDBK%VLGVBZ$7&8QT'6M811A1E% 7IQ2[0"#QS
M[4 9/F6WV:&-1^_\OY2H_G4),/\ 9 0D>?NXXYW9K72W1-Q5%#MWQ2?9HBQD
M\L FE<#,M@L4UP+G!D9!C(Y/%54#%;5RPCCW' (X!K?>&-V5F4,PXS0UO&T8
MC9%V?W:+,#&:W@9II&N&=FZE1P*1)G@GMX]RSHS8^4<K6RL$4:E0B^61C '6
MF1VD,>?+0(<YI-7!&9J)1=<M#)RNT@BLZZ3+7953Y!D4!0.];TUBEQ?).QX0
M8V^M3&"+:RA %/45C*FS1,QYPL.HV1E4?9_+ X'\5+:F5M2NFL@I4GKVK7D@
MCE0+(@*@<"EBBC@0I$@441A8'(2$2^6/M 4/_L&GXP<4 D=*#70C,P?%GA:U
M\5:;]EF=X;A,M!/&<,C?6O)VL;:/6[#P?J%G'!?^8))[UVW"10<K@]B:]OO+
MJ.QLI[R7[L$9?\A7CMCI_B/Q#97UU)HL,CZA(7M[F9L-&O\ "0>U 'LZHL:)
M&H^5% 4>U X Y_"N1\!:MJ$NGRZ1K17^T]/.UR#G>O8UUV. 6H6P=1&&:X?Q
MC$%N8),=*[JN-\:+^ZB/H:\O'K]VSOPC]\Y+-)1UHKXU[L^GCL X!K=\*C=J
M^[T6L+J"/6NA\'H3J,I/117?E\?WB.+&/W#O1T%8^J'=?P)6RO(4>M8U[E]9
M0#^$"OM(;'S$MS:1?D7Z45*(S@451)4U>/S+,U6T>3=I_/9L5I7B[[9AZBL;
M1VVB:$]0<TP-91DE>Q&*^=?%-L]EXIOHMN%\PD5]%*<8/I7C7Q8T_P"S>((;
ML#Y9TY/TH$S@^V.]%'8>]%,D*0C(SG%+1G'- 'L'@37O[0TB-'.9X/E/TKOH
MGW(#V[5\]^&-9;1-9C<_ZF4XD^E>Y6%VDBHZ-F%QN0^U(JYKYXIK8. >_% ;
M=VXI:!G/^+?"EGXHTK[-<G9.G,,P."I],^E<#J.H^(K".VT'4;-[#34&V:^M
M@3YBCL*]=QFE(60;9%5AZ,,T!>QY-\//$'AS19=4L8KX16QF!B:8')/O7J=M
M?6M\H-K<PSC'S&-P?TKR/5;,IXXU;0;;28I;C4MKQS,N%B0#DTV^\-0Z#J%A
MI7AC4GL]37YYYVD^1O4$&@<8MGLV<<4M</X,\<)K=Q+I6H)Y>H6Q*[QPDY'=
M3WKM\GOC/M0)Z"THZTVE% "GK3ATIIZTX=*!V$I1UI*!UH$+2]J,U&6YYX![
M]J!$@[XYK"\3Z['X>T2>^*^;-C;%".=[]A5\ZC9J2)+N!2IY^<#^M>;^-YKC
M7O%-E::7?VZM8(;G:7&V1NP- TSF/[66TFC\57LAN]6;*SV,H^6 'IP:O:Q!
MI^N66FWFDRM8W=_<*LUDGW7YY..U+KNJ:%KNGQ:U %CUV)@DUBHR)V'\)_QK
MJ/!7A6XEU8^)M8LX[6[DC"PVB](5]?K07I8]!MHO)M88N,H@7GV%2K[TX4&@
M@7M12"EH !2TE+VH :>M07 #1,/4&K&*CD&4(]:RJ1NF.+LT>/Z@ABU*<#^%
ML_K7I?A^?[1HUNQZ[<5P?B6W\C6G&/O\UTO@BY\S3VA)^:,UXN&:C6:/3Q$>
M:FI'7(:=31CI3J]U'EA111]*H!*Y_P 86.GW_AN[347$<*+O$IY*,.A%=!UZ
MUYQ\2?M.J7NE^'K6Y6V^T.97=VPI"]C0!C> @VN>($G\01*EW8IML(W0#S(_
M[_UKUT'OGGTKQCQ#IM[IXAUR;Q-:/<Z9AHX(B/F4?PUZMH>K0ZUHUKJ$6"L\
M88X[&@#3&!U^\:;3AP.?PH/2@!I]SP*I2:I;))L8GKC('%6I#A&95R<'CUKE
M+F1Y;:8%VC??Q$!]ZL9RL4M3HI=1MXF6-GRQ&>*;_:-N8//!RN<5CVLBIJD.
M]"?W('(J'R)%?[0 ?LYFR<UCSLJR-R#5+>9';.W:.<T)JEJ[@*Q(89S69=,M
MU</+ N8UB.>PJ(,LNEVT$*CS-V3@4<\@LC3M=8BN;N:#85\KDL:>=7MC(/E)
M&<;^U9V&2XOHMI$D@^48Z\5%%+''I<MJP(G8\+BCG861IMK$0U-;4(2"N0V*
ME6^B2.2623<%.!BLV+_1;VV,W'[K'2JQ5E"3;2\2S9/MSUIJ;V"QOVMY#=DB
M/((]:FJK:W$-Q</Y"8..9,8JW73!:$R"D-+2&F2CFO'[NG@?46CSD+SMZ@=Z
MX+2)](_LFR23QE>H@C'[M5.$]NE>IZS8#5-%O++.#+$P_''%>6:%X@U&TT29
M)O#5M/!IK&*60@!OE[\^M,#2\#?9D^(&IK8ZI+J$<ENI>1QC;7IY&.*X+X<6
M[7LE]XFELULS?86*+&"$%=[_ .@]J%J E<EXU/[B+ZUUU<9XV8%X$KS<>[4V
MCLPFM1')&BD'I2U\9+=GU4=$ ^\!ZUUO@R(".67OG%<D2 ,_A7>>%+8Q::N>
MK'->KED;S/.QTK1L=&OW@*QH<2ZRY]*UW;8AD/\ "*RM%0R7DDO8M7UQ\V]S
MH<"B@CFBJ$(ZY7;7.Q?Z-K+(>DE=-7/:Q'Y5S',.QH U6QG/05P_Q2TMKWPX
MMTBY>W;)/M7:H1)!&P[C-17]HM[IMQ:2*&62,@CWH$SYF_A'/OBBI;RW:UO[
MBVD7:\3E<'T[5%3)84=:** $8%E(SUKT?P%XD#QKIEU)B5?]4Q/4>E><TZ*2
M2&=)83ME0Y!H ^DK.ZW91NJ]15[K7#>%]=CUK38Y/,'VF$8=>Y-==:7(<88T
MBDRYT[T8S3>"<BG"@9R7C/P[>:E''JFC2B#6;93Y3]I%[J:\M@LX=6\5V=O=
M74\&HODWB3';@CK@^E>^@ ;CG ["LO5O#&DZX,WMJAE(XF088?C06IVT/./$
MR1W=_;V7AF2WM_["7SGG##YCW3/?(KLK;XA>'AHMO>W-]&A=/G5?F*MWSBJ=
MO\+/#]KO,;W 65LO^\/S_6N%O].LO#MQJ/A5;!5NM1G!L6*\%,\\T$[GHD7Q
M.\*R[2+YE#'"EHV /TK?T_7-.U10;&ZBF8]5#C<!]*\R\5/I>@ZSHEM<P0?8
M;*/+C;G+$=ZH+IMGJD&N>*=*9[%H5!MFC.U20/2@ODTN>V;ANV]Q2AN_KZ5P
M7@WQL+G1 GB%OLE_%&&<S#;YBXZCUK(U#QMK'B?57TGPJAA2.,NT\JXW+[$T
M$)7/5.^!S2YP<$<>M>!*FNW=E83/X@NEO;BY,4L:2XP >XK<AU/QIH/B:;3!
M-]MM8(A,ZN0SE/44!*%F>G:YKMEX?TY[V^D"IT1<\NQZ 5Y-K_B+7-8:\2_N
MY-#@*;[6!3\\H[9JOJ>L67Q O+NXN;DVR6$>ZV@F.PF0<Y [U>\1IIVN^']&
M\1W-PI>/8D_S8QZ\4%PMU*A\-Z;=^';#Q-:>?-]F.+Z$R$[P/O&M#P=X,T+Q
M1=W^M+#-'9RN%ML,1P.M48(K^]U^XTCPD'?0+Q5\Z<#Y5/\ %R?6O8-'TNVT
M?3(+"UC5(84Q@>M!#2*&E>"=!T>43VFGQ_:/^>C#)K>"D8R<GUI<CUI=ZCO0
M(44IJ,RJ.K"FM<1C^(4!8E'6G56^U1C/S"HWOE'1J +G/I3JS&U#Y>#47V]R
M>M &M37/RGBJ]K*S\GI5D\CBE)70UN<#XTML20W 'L:I^$KO[-JXB9ODD'ZU
MU?B:U%SIT@"Y(&17G5G(;>\AES@J^#7SU5.%>YZM/WJ-CV)3G!J2JMG,L]M'
M(IR"HYJSFO=IR4HW/+EHQ:***U)$'WCFO+?BE;62:UHU_JHE_L]2T;>4#NW'
MITKU*N?\8:(-=T">W3BX3YX&[AQR* //HH--N(7BT?P7-<X!_?7)P#[G-=/\
M+'F'A(PSIL,<SJ%[+STKAX=?\5:WI]W;W-VNG-8(4FC.$=^.H]:]"^&]C)I_
M@NT6?<99"7);J<GK0!UZG)/M0:13^M*: &E22#GI41MXRP8QH3ZD<U/3&ZU$
MHQ I_8D^V?:NI QMJP54IM*J5[K5&75%6>6-$)*=>*)-5@1(@!EY>% '>LWR
MHNS+36\30O$J *XP0*9;VD5M"D2*#M[XYJK+JFQ_+C0F91E\#H*JWVM2I]E%
MO'GS6VM@5-XAJ;11/,WE%W XW8IAMX0^\QIN'\1%5)]1$+B*)"S@;F'I4?\
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M.])5[5=(OM#O&MKZ$HRG E(X(JCUZ4R&%%%% !1110 4444 %%%% !FBBB@
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M?S@31MYVF$$@C'2N6TK5;"+P7K>FW%X@D64M"B\LQ] *[=OA?X;-U]H"7:S
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MO,=<^'&LZ-N>U7[7;]<KR:"+'(44LL<EN^R:*2-AQAABD[^M 6"BDS1C\!0
MM%)D>O-'XT +1249H 6BBB@ HH^M&.,B@ X')H&>WZTW<!U_(<UJZ5X<U?6Y
M56TLY-A/WR, 4!8S,A>N/J:T]&\/:GK\_E:?;,5SAI'& !ZUZ/X>^$L$+K/K
M$@E<<B-3P*]&M+*VL+=8;:%8D XVC&:!V.*T'X9Z9IEJPO#]JN9$(9CT4UQF
MC> IY?',ME<Q,+&V?S%8CAN>E>W[<C!'RTGEA6W!1O/4X[4BK!&BQHJ(,*H
M4>F*FIB@C '0=*?F@!#2BCK2T#"BBB@ HHHH 3%%+28-*P#2.>M07-L)5)]J
MGQ2]J+!L<Y<V@8-&ZY4^M<GJ6@/$6FM?F7NM>DS0I*"I%94]IY3':,@UPXC#
M1FMCKHXJ4'8\OQAN0R2@].E;>F^)+W3RH=O,AZ$$Y-;%_HUM=DG:$E_O5S=Y
MI5W8')0NG]]:\:=*I0=XGI*=.LO>/0-.\1V-ZB@2!'/\+&M=&#C.01V(->-
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M/]5:Q)]%% <I\]67@WQ!J+?N=.9 ?XGXKJM-^$5_<;3J5T(EZD1]:]CS@?*
M/I1UY/6@JQR&E?#C0=*"LT/VB0?Q25U4,$-O$$@C2-1P @J:@4!8!G'/-!Z4
MIQ2=30,<O2DQ1G%')H =28I0.*6@  HHHH **** "BBB@ HHHH 3%&.*6B@"
M+)SC%(ZAN"M2$4F326HF9UQ89.4K/E@*@K(NX'^''6NA^M1M$CYXJ)0A+1HN
M,Y+5'$WF@6MSEE_<OUP*PKK0;VV)*@.GMS7HD^G @E>M46@D3BO/K8&#UB=U
M+&..C/.)$:-L2(0?<4)))&2T<I7T"GFN^FM8)1B>%6_"LZ;P]9399&,9KSI8
M*I'8[(XFG/<P;?6M2MN5F)'H:T(?&%]'P\8?WIDGAB7<3%.&';-5GT#4$Z*K
M>XJ%]8@7:A(UX_'$F#NM^:1_'$_\%M^M81TB^7_E@:C.F7P/_'NU)U\0+V%#
M<V9/&=](/EB53[U4E\3:G.O^LV#VJF-*O7_Y8-4BZ/?L,"+@^M1S8AE*%")6
MFOKJ;B6X=Z@(&<XY]36Q%X=NW^\RJ*M1>&DW RSD^PH^KUJFY;JT8K0YWD>_
ML*F@M+B=@(8FYZDBNKBTBRA(Q'N/J:NI#M 5$"K["MZ672O[QC/&QM9'.VOA
MUF(-S)M]A6W:6-O;C9!%\P_B(K1BL'<C /UJ\MK%"NYV7C\Z]6E@H0Z'GU,5
M.6A1CM'F<9S@5>5(;5?F(R.<>M()F<[+=" >K$5+!I^7W7#;SVS7>HQBM#C;
M;>I7)GOGV*I6+UK0MK..V&<9/K5A$"C 7 ]*?3$(>U+1BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "D[TM% #2*.2.*=10!4EL8ICNV[7]1
M5?R+BW;Y'WCT-:=)Q0!FBZ(;$R%??%3I*K#Y6!%6)$1QAP#54V*$Y0XH EQQ
MZT=>V*@-M/'RKY%.WSKP\><=Z )N1TQ0.O>H?M !PT9%.$Z'UH DX]Z4 >],
M\Q"?O?I2B5/[] #N/0TM-\U/4TGF >] $F1Z&EJ,.3T6EPYH ?THW"DVN1S3
M@A'6@!IR>@XIP!]*7%.H :!2XI:* "BBB@ HHHH **** "BBB@ HHHH ****
M "FXIU% #"N:3!':I** (\K3&1&!! J7:*:8\T 5)+%&%5FT[@[<9^E:>UE'
M%-+$=5HL.YC/9R+V_*H3!*.,-BM[>#U6FDQGKQ4\D1\S,/9(.N?RII23T/Y5
MND0X_P#K4PB'U_2H]E#L5[61B^7(1WH$4GH:V?W"]1DTF^,?=CS^%/V4.PN=
MF4MK*1TZT]+!RW(YK2\TMPL/-+MN&&,!?>J48H7,RJM@JX+$4\_9X>!\S^E3
MK9,_,LA/TJ9+6*,\+^)JB2H&GE.(X]@/>GIIP9M\S$FKX]L8IU #$C5!A0 *
M7'-.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *,444 &!Z4F!BEHH 3%&*6B@!"JD8(!IOE)_=%/HH C\E/[HH
M\I/[@J2B@!GEH.U."KV I:* $P!VI:** "BBB@ HHHH **** "BBB@ HHHH
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MP!GBG^&YXHI[RPC;*1OF//'%:-KI:P2QRNWFM&@49I7TQ#JT-^AVL%VE1WH
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MB*YO/[+74&E)/.4QVS0YV&D=$3D 8SS3B<L?85@FZN[C5EMXY-L/E!R>]/\
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MQD="34NE9CYBE#IDBZ3+:%OF9B1^/-59-.OY[2*V^1!&P/ ZUT Q_%UH)&X
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M50O   I:** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (V'KTIAC!.YE4X]J**A@(8U==K -]1TI1$,8( 'I113Y4(4*I.
M<=*4KD],CN***.5 -$8&Y54 =00*:8U)'[M23U)%%%+E0QSJIZJ#CM1L"G(4
M8] ***%% A!$HZJO7/ IVT#YL#=VHHIM#'BG'D444T(!TI:**8!1110 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S G # 2(  A$! Q$!_\0
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MT\;KXU\-BXFVIJ%L1%=(O3=V8>QKMJNY M%%% PHHHH **** "BBB@ HHHH
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M,TZ[6&X,;\ G !H$6VMUOHF'1AUK%D>?3KJ.XC)2:!P\3C^$^M:IG-M?[?\
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MDA+'L3U%1<23ECG;GK5N8J("T;=>E(I%>5R$&!S5,3+$78\L:?-)F/@GZUF
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MBMHF,A:***HD**** "BBB@ HHHH **** "N*^*AQX#N_]]/YUVM</\6)/*\
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M#<&.5-#,V?87AM]_AO36];9#^E:M9/AG'_",Z9CI]F3^5:U60%%%% !1110
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MB;M5/5;<-"P/6@AGUMX9X\,:7C_GV3^0K6K(\,C;X8TL=Q;)_(5KU9F%%%%
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MFU3^0K7JR HHHH **** "L7Q8<>$M7_Z])/_ $&MKM6+XJY\)ZM_UZ2?^@T
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M#!_XJ"#G_IB:5AW/('?;<@CH3TJW,^Z$J. W:O4YOV?[^15 U^ $=_)-2_\
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MO#=G+$X62&X4Y0C:>WTH Z3Q1XH'AZ.SV6WVN6XE5=H;&U"<%J=_PDFWQ>=
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MBM_PS?>'H[J.&PO;N2ZEB VS!\<#W'% '9CD_2EI!2T %%%% !1110 4444
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MY0_GM'&9>HC'0#VKIQ0 M%%% !1110 4444 -*\^U-" =%''3CI]*DHH C*
MC:5!'H12[1SQU]J?10 S:,_=''3CI1M&=VT;O7'-/HH 9MYS@>Y[T8YZ8S3Z
M* (P@&<*!GK@8S2E5)#%06'0XY%/HH 8RAAAE!'H12%01@J"/2I** &]?QH
MP,8_*G44 ,VX/'?K@4AC0C!12!ZBI** (U14!VH%!Z@#&: @48"@#T Q4E%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI-;%% &5<:':74MY+)OS=QA).>@'3%5X_"]F@.Z29V:6.4L[9)*?=K=P*7%
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MH+7..< YS4MMHGD:E%>-<$F)/+"HNW=]?6@#;%%(*6@ HHHH **** "BBB@
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M(_.#@TRY\+F]OOM%S>O("P<J1TP,$#T%2+X>E.G7&GO?LUI(I$2;>4YSU]J
M':IK<UK8Z?=10R#SY55XRGSX(Z >M//B>S-@+Q(;J2/>4<+%S&1UW#M4LVD2
M7%MIZ37)9[202%P/OXJA<>%/.1D6]=$:5Y63'!W>OO0!(_B:WMY[B>:8M9JD
M914C);YJ-9UV>VTJVGM+>=);F0(N^+)09[BFGPHAC"BZ; \K!Q_<.:U=3T[^
MT1 /,,9AE$H([D=J *(\360G%NQFSGR_M!CQ&9,?=SZUEIXAU#R TCI'_H\L
MC-LW896P.*T#X85KHC[4_P!A,YN#;X_Y:?7TIG_"*C[,8OM3 F%XLXZ;CG-
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M@L;Z'4;2.YMG#1.,@U:JI86OV.SCM\J=HQE5VBK0Z"@!:*** "BBB@ HHHH
M**** "F-V^M%% "^E(>U%% "]S1W_&BB@!:3L:**  ]11WHHH =WI#THHH 0
M]*#WHHH /7Z4H[444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %-/:BB@!:3M110 >M(.@HHH 4\*:#]VBB@ [BBBB@!/3ZTZBB@!%ZFC%%%
M"^E-/0T44 .[?A2=Q110 #M2?PFBB@!1UI!SG\:** %/44'THHH #U_&D_B%
K%% #NN:0=2*** #L**** !:4@8HHH 0?>HHHH /6@]J**  'FG444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '' G # 2(  A$! Q$!_\0
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MFS1FN<TW6K_^U?[+U6VCAN&0O%)&V5<"F:KXDDT[7H].%N9?,BW(%ZLWI]*
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M\Q@1]V@#+O\ _D?M-'/_ ![M75#I67<:/%/KEOJAD820H4"8X.:U* "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGED'L3T- #VTJ)UE!=OWL@D/U%-DTF-G>19&25I/,##L:235X4D,8C=F\TQ
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M-*N)4>22.*225][)G!0]MIK2&I6_E[BS)A@N"O//2EEU&VB9E=SN5@I&WN:
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MD\H$,,B2LK&1CR,>U7QJEL)BA8[3\H?'RD^@-*^HVX@259!M<$J2#SB@"\
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M4 8<.E3Q0W,893YD2JK'U'6LXGR+F9I8R=K+B#)&XXQD"NMQ3/*7.=HW>I%
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M #(9 Q*8(*8!R.O%3TF*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%
M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%)SF@GB@!,TQY%3&Y@.<<FF7%Q';0O-*X5$&22>E>">
M./'=SKNJ+#I\SP6=L_R,IP78=_I2E)1W.S"8.IBI<L$?0 8$<4O2N#^'_C=/
M$5F+2Z94OXA@@_\ +3'<5W0.>G-"::NC&O1G1J.$UJB2BD% IF(M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBM?$FE1WENW)&'0]5/H:W/:NO?8^!G"5.3A):H?11102%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6B@#$\57,UGX9U"X@
M?9(D)*MZ5\MR3M,?,9B[$DESU8GO7T]XU'_%':I_UP:OEN%2T2@>E<U=ZH^M
MX=2M)]21%+FK2J$7CK3(T"+ZGN:?7*V?<4J5E=[D4L>1N%09^:KG7@]*@FBV
MG(IIDU:=M4=Y\);Z>+QB+=)"(I8B7CSP2.]?0"]*^=/A/_R/\7_7!J^BQUKN
MI/W3\TSI)8IV'4445H>.%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %!Z444 <]XT_Y$W5/^N#?RKYCMH]D*D]2*^G/&G_ "*&
MI_\ 7$U\SQ_ZE?I7+7W/MN%XIQF_,=BBE-)7*?<!2XR*2E[4"M='6?"N,I\0
M8?3R&KZ(KY[^%_\ R/$/_7)J^A1TKNH_"?F&?QY<8Q:***V/!"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_&G_ "*&
MI_\ 7$U\S1_ZI?I7TSXT_P"1/U/_ *XFOF:/_5+7+B.A]QPM\,_4>:2E-)7*
M?;!1110!V/PN_P"1YA'_ $R:OH4=*^>OA=_R/4/_ %Q:OH4=*[Z/PGYCQ!_O
MC%HHHK4^?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(V)S'[K74 @GBLZ5:%57BRITY0=I#J***W("BBB@#G_&G_(GZG_UQ-?,T?\
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MJ*#Z@4_%  #FEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD
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ME+YMK9PQ2=-ZH :T@***+$\\I.[8ZBBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #: G # 2(  A$! Q$!_\0
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M]%-WJ8RX(9<9RISGZ4Q9T9$?<JA\8#D T#):*JWM_!I\2R7+[59@B@#+.QZ
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M*!A1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8O\
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M,?[-NN?]H4?\+1T__H&W7_?0KS*BES,+GIW_  M'3_\ H&77_?0I/^%HZ?\
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ML:G1O]XTZFIT;_>-.H$@HHHI#"H+NUBO;=H)P3&Q!(!]#D5/10!G7NB66HW
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M)[5J^&.?$EG]3_*M\/F&(G5C%RZF=;!4(TY22U2/3%^^_P!13Z8OWG^M/K[
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MQQ57_A#-(_YYR_\ ?=?-8O+*U6M*<6K,]K#8^E3I*$KW1YW17HG_  AFC_\
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MD/ BD'_3SUQ]RC_A U_Y_P!O^^*7]EXG^4/[1H=SC:*[+_A O^G]O^^*3_A
ME_Z"#?\ ?%']EXC^4/[1H=R]X(_Y ;_]=FKI:S=$TD:-8FV$QFRY?<1CK6E7
MUF&ING1C&6Z/GZ\U.I*2V8R/[I^II],C^Z?J:?728H****0PH/6B@]:8#4Z-
M_O&G4Q.C?[QI] D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %(
M:6B@!B_ZQ_PI]-7_ %C_ (4Z@04444#"BBB@!H^\_P!:=VIH!W/]:=0(****
M!A0:**!#%_UDGX4^F@?O']\4Z@ HHHH&%%%% #5^\_UIU-7[S'WIU D%%%%
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M7TR]GGGFCE\Z81Y=7P4,?W2OH149\*66X2BZOA<$LSS^>2S[A@@CIC\*WJ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****!!1110 4444#"BBB@ HHHH ****!!
:1110,**** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  :D# 2(  A$! Q$!_\0
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M &N2V[,DR6K,K X(]ZQO"][._P '+>[DF>6X-F6WYY)Q0!WJ,,9#*5Z#;S2
M9))&/;WKRCP+XT@\/?#*WU37)I9!)=-$&SDDDUV-OX]T2ZU^'1C)+'<W,8DM
M]Z$"4>U '4(<]P?6GUY=HWQ'OK_XCZGHDUCLL;1,1[1\P/J?:N@TOXBZ1K%]
M+:6232202&.8[?ECQW)H [&D)P,UQ3_$WP\MP?WTALUF^SO>!#Y:R9QMS_6M
M;6/%6GZ1):PL);B>Z4O#'"A;<HZG(Z"@#;/KGG^\:>HQGICM7$7'Q$TVX\&Z
MOK.C!KB3301+$PP4?WJIX,^(27_@+_A(/$!6U\O/FR@85N>-HH ]$J,L=O4
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MEL+DW @C$QX\S:,_G5F@ HHHH ***0]* %HI,T4M0%HIM.HN 444E,!:***
M"BBB@ I"P! />EIKXQ\WYT (9% !.>:7>-H;G%8'BW7%\-^'I]1,8E*%4CC8
MX#,3@9/UKG[;Q9K5EI.J7^KVUO(+>W$L0MWW OC[AH [\R*.IQ]:"X%><V7C
MO4;*2-=>M(P+K3VU"%8N2BJ,E33M$\:ZO-KFD1ZG9QK9:Q"TMNZ'F+'0'ZT
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M.X<<= !0!+1110 4444 %%%% !1110 4444 %%%%+J E!Z4=,GM32>/:DVD
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M_P 9K"*.9'DM]*E$J@\H2P//I7= X=0!\I'45P]Y;P1_&;3I$AC5I-+E\QE
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MRIU$<CYX++UZT >GQ86)!N+_ "C!_"AB6P&QQR2.U)$0T2.%V J,+[8XJ8*
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M-))>S?J.\/ZD^JZ1%>21^6[D@K]#BM2J]G:QV=N((EPB^O<^M6#5'*+1110
M4444 0R,RH3N P"0W8?6O%M2U6QN]5:YU&>RE0W8B)^QL0S \<_UKV>:(31N
MG574J2/0C%>>-X2UQ]/?P^%MO[/,P>*\VC<L8;.W'K[T >A1JWEK\PZ<GM^%
M2QR(Z91PX'&0<UEZMIL=[HSZ>UU);1$!?.23:WTS7E$-S=Z'-XRLH;NZMO*M
M$6"*=R=N1@R*: /:_,20'8P;!P<'I42R+(K@,I<'#!3S^->.FYO/"UQ9QV&I
M2R_;-!ENI?.?=^]5>'%6-!6?3=;\)7D>H3R?;[1I+N-Y,B5CSN'TH UK.^U*
M^^+MJ=2THZ<8M-F2$&42&5=_WACI7I*#YO\ /->:VVO6FM?&&T:VAND^RZ;-
M&_GPE,D/U7/45Z4N,CL,<9H DHHHH **** "BBB@ HHHH **** $/2HW8*"Q
MZ $FI#TJEJ$GE64K'J1M'XUE4=HL:(=*4O!+*PYDD.#ZCM6D,CC' JM8Q&*S
MB0\$*,_6K7;TJ*"M32!G$:\/[7\=:+HY.ZVMPU[*?1U/R@UVVX 9[5Q'@YQJ
MNMZYKQ!\B:80PY[;.#C\:[,@<#MUK?9"8RYF5+=R3CY37'Z&C7_B17D ,=K%
MNSZ2$_X5M^(9=E@R!MI8<'Z<U0\%P[K"XU$J0]]*90#Z#C'Z5@Y7J:=#C<N>
MMR]CHYYX;:%KB:18XD&2['  K$UGQ;I.EZ0]\][&P:,F,1'>S>^!7.?$ W.I
M26FG:6'NY8',MU:H<*Z>A-8]EH!T'0KW6+VTCBDO&6&W@D^9H%8X.#V^E=#5
MHW.^E%2MZE3PWIVI>)-2V/(VFVT9-R6B;]ZXD[JW;->A#P+X>$,,3:;&YC;?
MYK<NQ[[CWS5/P-:K'!<2[<&-O(''4+TKL,_+[FLX:*YOBI7J<O8P/%MZ=)\*
M7UQ;X21(2D 7CYNPK(^&^FB+0_M^W N@&5<?</\ %^M4?BA.UTNCZ!;R&.ZO
M+E9%QW"GG-=YI]HEE80VR* (U ('KWKH^&'J<2^(L*& K(U4^;>6EJ/F!DW.
M/]FMDG K%MA]IUZ>7^&!?*_'K4QUU-X;MLVE7 P*=BD7O3JEF8E)W]Z=36.,
M'&: ,WQ!?#3?#]_>@X\F%FS^%9W@6Q_L_P (6<8'^L!F_P"^SN_K57XBW.SP
MR;3!_P!-N$M>.^ZNDL;?[)I]M; 8$42I^0Q0!9Z8-*#FD)P,4@/%)L!V:,TW
M=2T!9B]:K7+^5&TN"VP%@HZGVJS3&*YQCDT68)GS=J7CCQQ%XEGL([F9)I+C
M]S!Y9SL)X_ "O:Y[N[N?#5E/&LJ3L565?NECCGZ<U:NK;0V\36EU<M -62,K
M$"PW;3UK5N9(4MI9+DKY*<MN["A*QI.2=K(H>&KJXN]%AFNXVBE)8%'.2 #@
M<UL@@\UE#6=/CF@MXW8^8,KL3('U/:M(GN1TZ4S,DHHHH **** (G)*%4.TD
M<$]J\KUCQ1XSTG4[BU"R3R),HA2.TW+,A/)W=L"O5<=,#/.3FO._$DOC5/$+
M?V=*RQ;U^SHL09-N?FW'MQ0!V.IZ5#KNDFRN]Z)*H9GC;:RM6-9> -+BCO3>
MR37LU[#]GEEE?)\L= /2NJ7F-2<;\<XZ9[U)@]/7VH Y'2O 6E:9*[R![H>3
M]FB\UMVR+&"HHT;P!I>CZM'J"R33R6R-':J[96%6Z@"NMYQSG(]*7!^GTH X
M*YNX+CXRZ?#'.CR0:5*)54\H2PZ^E=T "X;N..:X>[A@C^,NF,D$:RRZ5*7D
M48+?-W]:[A5^;/./?M0!+1110 444F1ZTK@+1113 **** "BDS2T -/0UEZH
M?/\ LUM_ST<'\N:U3R*RR/-UL9Z0)D?C7/6=DD-&@25..<'I@5D>*M1?3?#-
M_=1,/.6(B(>KGH*T;R>.VMIIY"0L:%VP>PKP7Q3\9K'6/LUK]C*6D%XLLA#?
M,X0],>]:1T5D(]D\)Z>-,\,V,&S#L@ED7T9N3^M;3!L;0..N:HV>KV-U96UR
MD\:)/&KHI89 (SS3-4UBVL[&:<3Q,47. XIR?+[S)E/D7,^AS_C2Y9E@L8G_
M -(E(\M1_$V>1^56;S4I+2.WT'18PU^T8#,.5@'<GWKBY=8N];\26D-KY7GY
MW0/G_5FO2-(TB'1K-@'5KAOFFG<\N??VK&A-5$YV.+"S564JEMQ=$T6'2+38
MKF2X?F6X;K(?\*Y_X@7 ;[!IQ',Y>0?5!D5S7Q;^(U]X:AL%\/ZA:F5Y"LZ
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M>K Z5AZKK5OH&@_VG?[BL:J&5%RS,>B@?6LG3/B#87:W8U"SNM*EM8?/:*[
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MW)85Y]\6=9U+3?#*7.BWL(<2A9%W@DK5/7K_ $;39&LK*6ZU;4"0-JR91?\
M>;IBO-/%^CW:PQ2SO&L\K;GBB?<H^AZ5M1H0FU[5VB=4*5:H[1B=!\._B)?0
MFZ_MO4XQ:CY8EVD_-ZUW ^*.F(V6O+<(.F0<UY+X$TL2ZM-%<6,]_NCRL$#
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M7! (I BKT%.7%&,T>8[NV@H'%&*7I12>H(3%.'2DI13 **** "BBB@ HHHH
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M=!FO/D72XOC1:6^G1VT<J:9+]J2! I#%@1NQWKT-<;L#\?:@!^!Z4;1Z4M%
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M;[/)1]C^)/;5_#__ (#R4 =O17$?8OB3_P!!;P__ . \E'V+XD_]!;P__P"
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M@O\ O)9AE8T[G'>M^L'Q);:S/81MHLL(N8I SQRK\LR=T]L^M '"V_CW7/\
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %2 ;$# 2(  A$! Q$!_\0
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MKZ.YU:>!K>W:)<) A&.!ZUW)/&TGD] *0#&6&,]R* /,;/P1XN@\+-X:.JV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 5$\D=/3-=G"C1P(LDF]E&"YXS0!-1110 4444 %%%% !1110 4444 %%%%
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MD9"'(S7?5P7@NUAM/&WC.&VB2&(7,#!$&!DIDG\:[V@ HHHH **** "BBB@
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MZ;!;/.?WA&3N_.FZ9X7T31[Z:\T_388+B8DO(N223]>GX5N&F;ANVD'<U '
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MC?#9&I^.M>U<=( +#\5.:0CM10>E,R?2DSNZ$>AI <YXCQ>:MI6FYY:3S_\
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M'C+2_#'AV./28/#;W,^HH0\D;G>!Z\FLWPZ?"TUM-IVH:3-I5WIENLBW>_\
M>N"< @#J:WY5>YY+C-RNGIV/7[G3K*Z1DN+6)U/4E ,?C7SOX^MD/C">WTJ-
MH8;= RE6++N[D'IFNXAT7QUJ=I*=-UFX@TUFRB:AS-,GMCH"*XOQ;JVN^'[^
M*QGT>&QM5 >U1AN\R0=P?KVI3BK'9A:CA)L[70O$7CZWT:W9O#PN4V 1ESAV
M'8FGV.M^)[S4)I[!=)M;Q4(ELI=R[F[>V:T?#WC;5SH5N;W0KV]O"N9&B 4#
M/08-&K:IJ.MVDD4W@"\5L$K++(HQ[\<U7PK0RJM2EJM3CM,O=9O-?9[63/B-
M'S<3F3$31]U':N]'Q"GL)/)UC0KF$KPUQ&RM&?<=Z\4BTO59=;:PBTVZ2YR2
M8ER/E^M=M'#XOT_8+?P,D@B&-\\F[=^%#G<Q4)['HB_$3PN]NTJZM%\H)VMD
M'/I63X)\0VOB36K[59YHH9T3R8X2V/W8/#<UYWXLO=5?1-VK>';+39%?(>%<
M9%<SX7GM[C6HEGLVU!5&5MH'PV*GGZ%+#U&[]#ZG-W;8_P"/F'_OX*R=<\4Z
M9H%D)[B=)'8X2*-P6;Z5YTNGV#Q[U\!ZO]?/X_G7GWCNS@CNK.XCT6ZT[DJZ
M2R$[O3%$YV1O1P[J3L?2FDZO9ZU8I>64RR1MU /*GT-7Z\U^#6DPZ=X/\]9O
M-FN969CG(&.U>EU47=&,X\LG$6D/0TM%,DY/5?"0O[XSQR>6".>3UK:TW3X]
M/MUAB' ZY.<FM "EJG4D]&:.K*4;,P+OPTEU<)(M_<0J)S.\:8PY/8^U;J+M
M0*3G QGUIW:@=*DR0M%%% R%GV*23PN2QSC%>'IJVA-XBU&[M;M,3:@#,ID!
M._./E]17N#Q+(NR3Y@P(8=B*\/72$TCQ?J-OI?ANU<QWPGS-;%OW;$ ;&Z#'
M6@#W/)P#[4X=.E(#\H!ZXI<@8'2@!<48I-PQFC<* .(\(_\ (^^-?^OB#_T7
M7<5P7@R>*X\;>-98)4EC-S -R-D9$?(S7>T %&*** $Q3>=IXY!I]-P> * /
M*OBUH:0:,=7@'$;@21#WZD5YKX1O;F3Q#"VEH;F=>51B<$5[I\0[9+KP7>QN
MDKG VK$,DGM7AW@7POK#^(5 6[LF"$J_EE>?3-=M'#T:M)SG*TEL=E+,G0A[
M)QNF>QS>,]6TZ)?MWAB\3U=&##\A7G/Q$\16VN7^GW$4#PO'&0/.0J5YZ5VW
M]E^([,[?+U"X0<[S=#->>?$ZVO;A;.[E,P904\MU_K65/!1KODE+0SH8K#TY
M<U6%P\(75QI<5UJMK>0Q -AT>0 GW.>HKUOP]XEM]6FCDBP)SA9T5@1_O5Y9
M\./"-KK>GW-S*+=[U6PD,XW KZXJ;5O"D&DWWFP3WVE28P523Y%.>N?3VK@Q
M6$^KSM"6B+K1IUI<]!678Q/'WB_7],\9ZU;P^(+^V2.0F"%)!M ]O05Z)X*\
M8Z?I?A:TFOK2]-S<KYD]UY1D,S'JV17D7BGPE-+KEM,ETMP;IAYKLV3G_:->
ME0WGB+2](M]/TW6;9PL6Q(HK?<8Q_GO64<3%)*^K,I7;4'&QO:_\1=/OM$N%
MT:260[2LLC1,/+]L'O7F<GBC4+BTBMU91R!N YP.Q]:WKVSU_3_#D_\ :>J6
M5KY@+E54,\G^]CIFO/;'5X8[Z!Y28D1PQE R!^'>H^H5L3+GC&]CV<'B<'0I
M2C4UD=996^JBY34=4LY9)XSFR@92($']YAZUM^,]9UK5-&MH-0L/(4X8/"W!
M/X5?_M7Q#K.EEM.C@D@<862YF50??:>:Y77HY]"MH[Z;4"UQNP\ ;='GV'I6
MRPE:JG3A'4\Z.90C5YU3V'>$+^\TO5S/'>06A:/:9+E24 ]/K7H0\2:Q.5\C
M7]'D/M"QS7G_ (1US2M;U&7^WA']E\O:+=%QS_?%=?<>#_"U]&)-.U1[2%!G
M:C[&_,THX&MAX\M2).(QOMZGM90LO(XOQM>3W.M![VXAEEV 'RAM _ UK^"M
M/U;4]/=--:>&/S"#<(_R@^XI$\-6>G:[+/YJWR&(*!*_F8]\U/HEC=:7#>_9
M=2NH()IS*(;92>OIZ5Q0E"57E9I+B.C.G]7A"S1U<?P^2!_M^IRM?RA,21@D
M*?>N1U#PIH\H>XM%NHP),NA;C9WQ6VWAO5M6MG:*^UT+CC==;0WL16+?W\NC
MR+HN/,NV C +9*GW-3BZ<X-.FKG$\XKT)>ZWJ=#_ &3I%S>06FE:C'8VUO$L
MDP:4 2.1\N0?UJCJ%[KGAO4%ETM[65YV"/Y+9MS[E>N?>M&W\&Z3-;PK#8?:
M;S:#,90<!N_-6[_PT38&U2.+3,?ZMU3<0?4GTK:52I[.]K.QA4G7DF^K.>U;
MQ-K"VQ>Y@MFLY) ;Z.VCQ(ZCWJA'XS\3M;3R>%?#\UM9 ?<N5/ Z97TK?TOP
MW<3ZO;R7.N6[16S NBQ[?.^N:[62TMU+-%?/M(QY88%,?2LL+7<H<TG<RPD\
M133C65T>,ZAH?CMI(O$DHF?8OS_:9!*(U]5 ZBM#0O 6MZS>'Q7J=UY3Q@+:
M+;J5+J/XB#V]JW/$6NWWA(+:1W FLYSO55&#'[#VK1\#^-7U5[FWDMY2(1OW
M_>(KJAC%*5K'I_5JRC[51]WN7[?4O%UA'YA@M=:A' CMOW<BCWSWKB-;\1ZI
MXLUC:NCVL8TN4/&ETNYT?ZUZ=+>6<LWGVKRV]P._ED*WLU>?:UHD3ZW/?17\
ML,ER?WT2G(!]<UO4KTUNSAG5C!7N=-X5^(VGZCHBSZM-%;WJS-%(D:\94UIZ
MCX^T.UTRZN8;U7EBC+*A!Y-97AO2O#6A:'%9F(7KM(SF1H]Q9CUS4^L6-DVE
M79_L&&.%HB#+@ X^E6ZD'#F-:7[UI1ZG'GXC>)8+(:Y+86'V7@LR1_.4^M=D
MGQ"CO(XFTO1[Z^+J"<(4P2.G/6O,$\1:?)9#2WLW6 ,$W%N!SUKUJWNF%I (
MM9M$4(H4-C(&*Y*6*Y[JQWXG 5<.DY]3A?B+J6L:QI5DNJ^%YK*P6X#2,SB4
MX]PM<]HT<">,-(E\*Z:JW*%O,#1%5QCN37HOBC73I6E-,^H17@S_ *N-ADFN
M8T3QJD]\L2Q20%^ 8QDD_A45,6X32L:4<#7J474C\*.T.O>,+=6$GAI;ALY'
ME2@#'XUY;X\U.\U7Q$DFIZ=+9".(8LI7#_\  LBO0'@\3W\WDK<O:;C\HW;B
MP]?:J6M?#*:XD2[:_DN9\8<N<DT8BK*</=1>"C1I5DZTM/(C^#$S^1J-N)&,
M",&2,GA,^E>LCFN0\"^$E\,VDYW$R7#9;VKKQ75AT^17./&RIRKR=+X1U%%%
M=!R!BC%%% !1110 4444 1%@/X@!C/T%>4ZMXK\8+XDDBL;B!; 70CCC2U\U
MFBS]\L.@->I7, FM;B(-@RHR9';(Q7G/AWP#XF\.WRW,/B*.;]RMN8WA!P@;
M/Y^] '?ZEJ$6F:?)>7"RF&,;CY8W,?8"N*T/XD_VMX;US7)K%XH].D94@/WV
MQTSZ9KT *" K $#!R?6O,-)\(ZO_ &+XQLY$6*>_NY9;5ST;/W<T :%A\0;R
M&94URP$'VBQ;4+?8V<1J,D'WI=#\>7]YK&EP:A8"&UU>)I;20'E .@(]ZRK?
MPOX@\0W$#:C EB++27T\<Y\R1EP6^E3:#H7B&77/#T5]:)!::);M#+*3DRMT
M4K[4 :?@BT@L?&?C."V@2"(7,+!$&!DH23^-=_7GO@*RBT[QAXSMH7E=!=0M
MNE?<V2A)Y]*]"H **** "BBB@!C#)'3Z&FXX)QFGE03FEVC-&HGJ1J1@<\>]
M<_XC\(V/B=HC?/,!%T5&^4UT90$8HV@>M";6H2BI*S.#C^&FFZ?:NVFW=S;W
MP.Z.=7Z'T([CVJ(:K>&&33?$FGI=%,JTT:<M[A?ZUZ#M%9NHZ<MZRR(WE7$7
M,<HZ@^A]15<W-I(27)9QZ'S;JJ+;:M=PVQ8Q*Y* GHOI7:>&_!8UZT@NK:?4
M;2?_ ):7BRE J_W0/XA7(^-&6/Q1?130^1*')E\LY#>X]*]D\,6][JWAC3H
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MQ \<ZR!C_A ];_\ '/\ &E_X3G6?^A$UO_QS_&@#MLT9KB?^$YUG_H1-;_\
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MB7Q(GAVQBF-E<7<\\GEPV\ RSM]>U<\?&V@:KH1UF^T^076F7(5;27F2*?H
M#TS6]XJUQ="TU)YK.XGMI'\N::V&6@4C[^.I_"O+;#3[T^&[V[M+6>?3+?4Q
M=12S(1-<1]RPZY% 'J/AOQ5'XA-S;O9S6%[;$"6VF(+*#T/%='7GW@R5M8\6
M:KKUO!*EA)&L,3RH49R.IP?RKT 'IQUH =1110 5R/BCQJGANZ2VBTN\U&8Q
M-/(L' BC7JQ)X_"NNKS_ .(6L6EO:R:-J$&HV]M=PDK>V:[LM_SS.!D9H 76
M/&&C6<&D>(H-.-]?7R_9[3:X1PK<D$GC&:ZG1=2N-5T];FXL);!R?]7(X;/X
MBO+62P7P[X<?QEX=G\B.)U!MU)2'GY=RCG<1@UU_PRMM0M/#+_;-ZV[2LUG'
M)G<D6>!S0!W(Z44#I10 4ULYZX'>G4UAGB@#F/%OC*Q\'VMK+>K)-+<S"**&
M,\MD]?PK+N_%FE^%YFT_3-'FG2)3=WHMS@6P;DNV>N>O%<1\38O$%PUU-<^'
M+FY5;N'['/'(&5%!YPHY!/K5_4KFXT;5M:N[_3YU_MS38XK1%0N3(JXV-CI0
M!ZUI][!J5C#>VKAX)T#HP[@U;K \'6,VF^$]/M;E-DRQ NG]TGM6_0 4444
M%%%% !1110 4444 %%%% "-G'%,P=W(X[YJ2C% $70'<.O.*<,[NF!ZT^B@
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MGC>WMXL-N*'(WMW!J?3- UF?[3+/H.GZ8R63P@PL&:60C'!_A%>D_4T'T]:
M/-_"?@_4?"LULUI'$L%]$1J$1Y D ^5A5"S\):^WBBRNXM-BTOR+DO<2P7&8
MYH\]/+Z9->K_ )>U(<YZ\8Y% '*:?']O\>7VH(A5+2(6Q8_QD\\5UM0P016X
M(B0+DY..]34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 !Z4T=*** &)]T?4U(O2BB@ [FD_@HHH 6D7I110 B_=/UI5^Y110 HZ"
MHY/O_P# 3110 O\ RV7_ ':DHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>adtx-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:22 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.aditxt.com./20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:adtx="http://www.aditxt.com./20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet" id="adtx_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals" id="adtx_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement" id="adtx_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals" id="adtx_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3" id="adtx_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow" id="adtx_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness" id="adtx_r_OrganizationandNatureofBusiness">
        <link:definition>007 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/GoingConcernAnalysis" id="adtx_r_GoingConcernAnalysis">
        <link:definition>008 - Disclosure - Going Concern Analysis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies" id="adtx_r_SummaryofSignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NoteReceivable" id="adtx_r_NoteReceivable">
        <link:definition>010 - Disclosure - Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/FixedAssets" id="adtx_r_FixedAssets">
        <link:definition>011 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IntangibleAssets" id="adtx_r_IntangibleAssets">
        <link:definition>012 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/RelatedPartyTransactions" id="adtx_r_RelatedPartyTransactions">
        <link:definition>013 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NotesPayable" id="adtx_r_NotesPayable">
        <link:definition>014 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/Leases" id="adtx_r_Leases">
        <link:definition>015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/CommitmentsContingencies" id="adtx_r_CommitmentsContingencies">
        <link:definition>016 - Disclosure - Commitments &amp; Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquity" id="adtx_r_StockholdersEquity">
        <link:definition>017 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxes" id="adtx_r_IncomeTaxes">
        <link:definition>018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SubsequentEvents" id="adtx_r_SubsequentEvents">
        <link:definition>019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy" id="adtx_r_AccountingPoliciesByPolicy">
        <link:definition>020 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables" id="adtx_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/FixedAssetsTables" id="adtx_r_FixedAssetsTables">
        <link:definition>022 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IntangibleAssetsTables" id="adtx_r_IntangibleAssetsTables">
        <link:definition>023 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/LeasesTables" id="adtx_r_LeasesTables">
        <link:definition>024 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquityTables" id="adtx_r_StockholdersEquityTables">
        <link:definition>025 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxesTables" id="adtx_r_IncomeTaxesTables">
        <link:definition>026 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails" id="adtx_r_OrganizationandNatureofBusinessDetails">
        <link:definition>027 - Disclosure - Organization and Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails" id="adtx_r_GoingConcernAnalysisDetails">
        <link:definition>028 - Disclosure - Going Concern Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails" id="adtx_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable" id="adtx_r_ScheduleofusefullivesassignedtofixedassetsTable">
        <link:definition>030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NoteReceivableDetails" id="adtx_r_NoteReceivableDetails">
        <link:definition>031 - Disclosure - Note Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/FixedAssetsDetails" id="adtx_r_FixedAssetsDetails">
        <link:definition>032 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleoffixedassetsTable" id="adtx_r_ScheduleoffixedassetsTable">
        <link:definition>033 - Disclosure - Fixed Assets (Details) - Schedule of fixed assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesTable" id="adtx_r_ScheduleofmaturitiesTable">
        <link:definition>034 - Disclosure - Fixed Assets (Details) - Schedule of maturities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IntangibleAssetsDetails" id="adtx_r_IntangibleAssetsDetails">
        <link:definition>035 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofintangibleassetsTable" id="adtx_r_ScheduleofintangibleassetsTable">
        <link:definition>036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails" id="adtx_r_RelatedPartyTransactionsDetails">
        <link:definition>037 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NotesPayableDetails" id="adtx_r_NotesPayableDetails">
        <link:definition>038 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/LeasesDetails" id="adtx_r_LeasesDetails">
        <link:definition>039 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable" id="adtx_r_ScheduleofleasecostsTable">
        <link:definition>040 - Disclosure - Leases (Details) - Schedule of lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable" id="adtx_r_ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable">
        <link:definition>041 - Disclosure - Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable" id="adtx_r_ScheduleofleasetermsanddiscountrateTable">
        <link:definition>042 - Disclosure - Leases (Details) - Schedule of lease terms and discount rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable" id="adtx_r_ScheduleofmaturitiesofleasesTable">
        <link:definition>043 - Disclosure - Leases (Details) - Schedule of maturities of leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/CommitmentsContingenciesDetails" id="adtx_r_CommitmentsContingenciesDetails">
        <link:definition>044 - Disclosure - Commitments &amp; Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquityDetails" id="adtx_r_StockholdersEquityDetails">
        <link:definition>045 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" id="adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
        <link:definition>046 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCes9u8F3rnBIokFmzaKONQnG] CSR-->
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable" id="adtx_r_ScheduleofwarrantyissuanceTable">
        <link:definition>047 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of warranty issuance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" id="adtx_r_ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable">
        <link:definition>048 - Disclosure - Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxesDetails" id="adtx_r_IncomeTaxesDetails">
        <link:definition>049 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable" id="adtx_r_ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable">
        <link:definition>050 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>051 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SubsequentEventsDetails" id="adtx_r_SubsequentEventsDetails">
        <link:definition>052 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="GoingConcernsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_GoingConcernsDisclosureAbstract"/>
  <xs:element name="ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract"/>
  <xs:element name="ScheduleOfFixedAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfFixedAssetsAbstract"/>
  <xs:element name="ScheduleOfMaturitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfMaturitiesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfLeaseTermsAndDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfMaturitiesOfLeasesAbstract"/>
  <xs:element name="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
  <xs:element name="ScheduleOfWarrantyIssuanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfWarrantyIssuanceAbstract"/>
  <xs:element name="ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract"/>
  <xs:element name="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract4"/>
  <xs:element name="RevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RevenueAbstract"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract7"/>
  <xs:element name="OtherExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OtherExpenseAbstract"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract39"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract41"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract42"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract51"/>
  <xs:element name="ComponentsOfTotalLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ComponentsOfTotalLeaseCostsAbstract"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_UnlabeledAbstract52"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DeferredTaxAssetsAbstract"/>
  <xs:element name="FixedAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FixedAsset"/>
  <xs:element name="RightOfUseAssetLongTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RightOfUseAssetLongTerm"/>
  <xs:element name="FinancingOnFixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FinancingOnFixedAssets"/>
  <xs:element name="OperatingLeaseLiabilityShortTermCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OperatingLeaseLiabilityShortTermCurrent"/>
  <xs:element name="FinancingOfFixedAssetLongTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FinancingOfFixedAssetLongTerm"/>
  <xs:element name="OperatingLeaseLiabilityLongTermNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OperatingLeaseLiabilityLongTermNoncurrent"/>
  <xs:element name="IssuanceOfRestrictedStockUnitsForCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfRestrictedStockUnitsForCompensation"/>
  <xs:element name="IssuanceOfSharesForServicesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForServicesinShares"/>
  <xs:element name="ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares"/>
  <xs:element name="SaleOfSeriesBPreferredSharesToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SaleOfSeriesBPreferredSharesToRelatedParty"/>
  <xs:element name="SaleOfSeriesBPreferredSharesToRelatedParty1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1"/>
  <xs:element name="RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares"/>
  <xs:element name="SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts"/>
  <xs:element name="SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares"/>
  <xs:element name="ResetProvisionOnWarrantsAndModificationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExerciseOfWarrants"/>
  <xs:element name="IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants"/>
  <xs:element name="RoundingAdjustmentFromStockSplit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RoundingAdjustmentFromStockSplit"/>
  <xs:element name="RoundingAdjustmentFromStockSplitShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RoundingAdjustmentFromStockSplitShares"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits"/>
  <xs:element name="IssuanceOfSharesForVestedRestrictedStockUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForVestedRestrictedStockUnits"/>
  <xs:element name="IssuanceOfSharesForTheSettlementOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
  <xs:element name="IssuanceOfSharesForOfferingsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts"/>
  <xs:element name="IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares"/>
  <xs:element name="DisposalOfFixedAssets1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DisposalOfFixedAssets1"/>
  <xs:element name="TIAllowanceReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_TIAllowanceReceivable"/>
  <xs:element name="NoteReceivablesAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NoteReceivablesAndAccruedInterest"/>
  <xs:element name="DiscountOnConvertibleNotePayableFromOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts"/>
  <xs:element name="SaleOfPreferredSharesToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SaleOfPreferredSharesToRelatedParty"/>
  <xs:element name="OriginalOfferingDiscountOnConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OriginalOfferingDiscountOnConvertibleNotePayable"/>
  <xs:element name="OriginalIssuanceDiscountOnNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OriginalIssuanceDiscountOnNotesPayable"/>
  <xs:element name="DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable"/>
  <xs:element name="DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts"/>
  <xs:element name="LiabilityRecognizedForFinancedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LiabilityRecognizedForFinancedAssets"/>
  <xs:element name="ReductionInExercisePriceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ReductionInExercisePriceOfWarrants"/>
  <xs:element name="SharesIssuedForIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesIssuedForIntangibleAssets"/>
  <xs:element name="GoingConcernsDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_GoingConcernsDisclosureTextBlock"/>
  <xs:element name="LeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_LeasesTable"/>
  <xs:element name="LeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_LeasesLineItems"/>
  <xs:element name="FixedAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_FixedAssetsPolicyTextBlock"/>
  <xs:element name="OfferingCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OfferingCostsPolicyTextBlock"/>
  <xs:element name="PatentsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PatentsPolicyTextBlock"/>
  <xs:element name="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
  <xs:element name="RightOfUseAssetShortTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RightOfUseAssetShortTerm"/>
  <xs:element name="TotalRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalRightOfUseAsset"/>
  <xs:element name="OperatingLeaseLiabilitiesShortTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OperatingLeaseLiabilitiesShortTerm"/>
  <xs:element name="OperatingLeaseLiabilitiesLongTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OperatingLeaseLiabilitiesLongTerm"/>
  <xs:element name="TotalLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalLeaseLiability"/>
  <xs:element name="OperatingLeasesLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OperatingLeasesLiabilityCurrent"/>
  <xs:element name="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <xs:element name="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
  <xs:element name="WeightedAverageRemainingLifeGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageRemainingLifeGranted"/>
  <xs:element name="StockIssuedDuringPeriodShareStockOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodShareStockOptionsExercised"/>
  <xs:element name="WeightedAverageRemainingLifeExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageRemainingLifeExercised"/>
  <xs:element name="WeightedAverageRemainingLifeExpiredOrForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageRemainingLifeExpiredOrForfeited"/>
  <xs:element name="WeightedsAverageRemainingLifeOutstandingEndingBalance" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance"/>
  <xs:element name="WeightedAverageExercisePriceRoundingForReverseSplit" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceRoundingForReverseSplit"/>
  <xs:element name="WeightedAverageRemainingLifeRoundingForReverseSplit" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit"/>
  <xs:element name="StockholdersEquityDetailsScheduleofwarrantyissuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable"/>
  <xs:element name="StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
  <xs:element name="WeightedAverageExercisePriceGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceGranted"/>
  <xs:element name="WeightedAverageExercisesPriceVested" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisesPriceVested"/>
  <xs:element name="WeightedAverageExercisePriceExpiredOrForfeited" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceExpiredOrForfeited"/>
  <xs:element name="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
  <xs:element name="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems"/>
  <xs:element name="PermanentDifferencesOthers" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PermanentDifferencesOthers"/>
  <xs:element name="ChangeInValuationAllowanceinDollars" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ChangeInValuationAllowanceinDollars"/>
  <xs:element name="TotalProvisionForIncomeTaxesinDollars" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalProvisionForIncomeTaxesinDollars"/>
  <xs:element name="Section174Capitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_Section174Capitalization"/>
  <xs:element name="ValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ValuationAllowance"/>
  <xs:element name="NetDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetDeferredTaxAssets"/>
  <xs:element name="RightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RightOfUseAssets"/>
  <xs:element name="FixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FixedAssets"/>
  <xs:element name="TotalDeferredTaxLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalDeferredTaxLiabilities"/>
  <xs:element name="NetDeferredTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetDeferredTaxes"/>
  <xs:element name="OrganizationandNatureofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_OrganizationandNatureofBusinessDetailsTable"/>
  <xs:element name="OrganizationandNatureofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
  <xs:element name="DebtInstrumentTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DebtInstrumentTermDescription"/>
  <xs:element name="WarrantsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsExercisePrice"/>
  <xs:element name="PurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_PurchaseOfCommonStock"/>
  <xs:element name="ExercisePricePerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExercisePricePerShares"/>
  <xs:element name="PrefundedWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_PrefundedWarrantsShares"/>
  <xs:element name="PurchaseOfEquityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_PurchaseOfEquityShares"/>
  <xs:element name="NetLossCashFlowFromOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetLossCashFlowFromOperatingActivities"/>
  <xs:element name="LicensingFeeForPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LicensingFeeForPatents"/>
  <xs:element name="WarrantsOfStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsOfStockOptions"/>
  <xs:element name="DilutiveEarningShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DilutiveEarningShares"/>
  <xs:element name="WarrantsExercisedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsExercisedShares"/>
  <xs:element name="CommonStockYieldsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonStockYieldsPercentage"/>
  <xs:element name="DescriptionOfShareExchangeAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DescriptionOfShareExchangeAgreement"/>
  <xs:element name="CreditAgreementAmendmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CreditAgreementAmendmentDescription"/>
  <xs:element name="AdvancedCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AdvancedCreditAgreement"/>
  <xs:element name="CreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_CreditAgreement"/>
  <xs:element name="DebtLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DebtLoanAmount"/>
  <xs:element name="AmortizationOfIntangibleAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AmortizationOfIntangibleAsset"/>
  <xs:element name="EstimatedUsefulLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_EstimatedUsefulLife"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="PreferredStockVotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PreferredStockVotes"/>
  <xs:element name="PromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_PromissoryNotes"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_NotesPayableDetailsTable"/>
  <xs:element name="NotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NotesPayableDetailsLineItems"/>
  <xs:element name="AggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AggregateAmount"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_GrossProceeds"/>
  <xs:element name="WarrantToPurchaseCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantToPurchaseCommonShares"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExercisePrice"/>
  <xs:element name="PrincipalAmountPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PrincipalAmountPercentage"/>
  <xs:element name="InvestorPurchaseAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_InvestorPurchaseAmount"/>
  <xs:element name="WarrantExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantExercisePrice"/>
  <xs:element name="PrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_PrincipalAmount"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_LeasesDetailsLineItems"/>
  <xs:element name="NetLeases" type="dtr:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetLeases"/>
  <xs:element name="LeasesExpire" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_LeasesExpire"/>
  <xs:element name="CommitmentsContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_CommitmentsContingenciesDetailsTable"/>
  <xs:element name="CommitmentsContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommitmentsContingenciesDetailsLineItems"/>
  <xs:element name="PaymentOfMilestoneFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_PaymentOfMilestoneFees"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDetailsLineItems"/>
  <xs:element name="RecognizedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RecognizedExpense"/>
  <xs:element name="SharesIssued1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesIssued1"/>
  <xs:element name="SharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesOfCommonStock"/>
  <xs:element name="SettlementOfAccountsPayableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SettlementOfAccountsPayableShares"/>
  <xs:element name="sharesIssued1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_sharesIssued1"/>
  <xs:element name="FairMarketValue" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_FairMarketValue"/>
  <xs:element name="CompanyGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CompanyGranted"/>
  <xs:element name="weightedAverageGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_weightedAverageGrant"/>
  <xs:element name="StockOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockOptionsShares"/>
  <xs:element name="ExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExercisePricePerShare"/>
  <xs:element name="ShareBasedPaymentRemnainingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedPaymentRemnainingExpenses"/>
  <xs:element name="warrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_warrantIssued"/>
  <xs:element name="WarrantsIssuedAndVesting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsIssuedAndVesting"/>
  <xs:element name="OfferingReflectingReducedExercisePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_OfferingReflectingReducedExercisePricePerShare"/>
  <xs:element name="VestingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_VestingExpense"/>
  <xs:element name="GrantTotal" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_GrantTotal"/>
  <xs:element name="CommonStockIssuedVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonStockIssuedVested"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IncomeTaxesDetailsLineItems"/>
  <xs:element name="NetOperatingLossCarryover" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetOperatingLossCarryover"/>
  <xs:element name="incomeLossOfGenerated" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_incomeLossOfGenerated"/>
  <xs:element name="NetOperatingLosse" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetOperatingLosse"/>
  <xs:element name="NetOperatingLossesGeneratedPrior" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetOperatingLossesGeneratedPrior"/>
  <xs:element name="PercentageOfIncomeTaxable" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PercentageOfIncomeTaxable"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SubsequentEventsDetailsLineItems"/>
  <xs:element name="AggregateOfferingPriceaAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AggregateOfferingPriceaAmount"/>
  <xs:element name="GrossProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_GrossProceed"/>
  <xs:element name="August2022FollowOnWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_August2022FollowOnWarrantsMember"/>
  <xs:element name="August2022WarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_August2022WarrantsMember"/>
  <xs:element name="FutureReceiptsAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_FutureReceiptsAgreementMember"/>
  <xs:element name="LabEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_LabEquipmentMember"/>
  <xs:element name="NonvestedRSUsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NonvestedRSUsMember"/>
  <xs:element name="NonvestedStockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NonvestedStockOptionsMember"/>
  <xs:element name="NonvestedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NonvestedWarrantsMember"/>
  <xs:element name="OneYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OneYearMember"/>
  <xs:element name="OtherFixedAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OtherFixedAssetsMember"/>
  <xs:element name="ProprietaryTechnologyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ProprietaryTechnologyMember"/>
  <xs:element name="RestrictedStockAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RestrictedStockAwardsMember"/>
  <xs:element name="RestrictedStockUnitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RestrictedStockUnitsMember"/>
  <xs:element name="SeriesCWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SeriesCWarrantsMember"/>
  <xs:element name="StanfordUniversityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StanfordUniversityMember"/>
  <xs:element name="TotalIntangibleAssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalIntangibleAssetsMember"/>
  <xs:element name="TwoZeroOneSevenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
  <xs:element name="VestedAndNonvestedStockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_VestedAndNonvestedStockOptionsMember"/>
  <xs:element name="VestedAndNonvestedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_VestedAndNonvestedWarrantsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>adtx-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:22 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesofleasesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventory"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PublicUtilitiesInventory" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAsset" xlink:href="adtx-20221231.xsd#adtx_FixedAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="adtx_FixedAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="adtx_RightOfUseAssetLongTerm" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20221231.xsd#adtx_FinancingOnFixedAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="adtx_FinancingOnFixedAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityShortTermCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="adtx_OperatingLeaseLiabilityShortTermCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOfFixedAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_FinancingOfFixedAssetLongTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="adtx_FinancingOfFixedAssetLongTerm" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityLongTermNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="adtx_OperatingLeaseLiabilityLongTermNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringSettlementAndImpairmentProvisions" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_InterestExpenseOther" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherIncome" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherExpenses" order="2" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCevTrMfuxeTeBZHC4SL35V/2y5hnT26+u6Q=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_DisposalOfFixedAssets1" xlink:href="adtx-20221231.xsd#adtx_DisposalOfFixedAssets1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adtx_DisposalOfFixedAssets1" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="adtx_TIAllowanceReceivable" xlink:href="adtx-20221231.xsd#adtx_TIAllowanceReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="adtx_TIAllowanceReceivable" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="adtx_NoteReceivablesAndAccruedInterest" xlink:href="adtx-20221231.xsd#adtx_NoteReceivablesAndAccruedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="adtx_NoteReceivablesAndAccruedInterest" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DiscountOnConvertibleNotePayableFromOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfPreferredSharesToRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adtx_SaleOfPreferredSharesToRelatedParty" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>adtx-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:22 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ShareholdersEquityType2or3" roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_OrganizationandNatureofBusiness" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_GoingConcernAnalysis" roleURI="http://www.aditxt.com./role/GoingConcernAnalysis"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NoteReceivable" roleURI="http://www.aditxt.com./role/NoteReceivable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssets" roleURI="http://www.aditxt.com./role/FixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssets" roleURI="http://www.aditxt.com./role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_RelatedPartyTransactions" roleURI="http://www.aditxt.com./role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NotesPayable" roleURI="http://www.aditxt.com./role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_Leases" roleURI="http://www.aditxt.com./role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_CommitmentsContingencies" roleURI="http://www.aditxt.com./role/CommitmentsContingencies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquity" roleURI="http://www.aditxt.com./role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxes" roleURI="http://www.aditxt.com./role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SubsequentEvents" roleURI="http://www.aditxt.com./role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_AccountingPoliciesByPolicy" roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssetsTables" roleURI="http://www.aditxt.com./role/FixedAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssetsTables" roleURI="http://www.aditxt.com./role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_LeasesTables" roleURI="http://www.aditxt.com./role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquityTables" roleURI="http://www.aditxt.com./role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxesTables" roleURI="http://www.aditxt.com./role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofusefullivesassignedtofixedassetsTable" roleURI="http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleoffixedassetsTable" roleURI="http://www.aditxt.com./role/ScheduleoffixedassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofintangibleassetsTable" roleURI="http://www.aditxt.com./role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofleasecostsTable" roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable" roleURI="http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofleasetermsanddiscountrateTable" roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesofleasesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofwarrantyissuanceTable" roleURI="http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" roleURI="http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable" roleURI="http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_OrganizationandNatureofBusinessDetails" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_GoingConcernAnalysisDetails" roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NoteReceivableDetails" roleURI="http://www.aditxt.com./role/NoteReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssetsDetails" roleURI="http://www.aditxt.com./role/FixedAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssetsDetails" roleURI="http://www.aditxt.com./role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_RelatedPartyTransactionsDetails" roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NotesPayableDetails" roleURI="http://www.aditxt.com./role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_LeasesDetails" roleURI="http://www.aditxt.com./role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_CommitmentsContingenciesDetails" roleURI="http://www.aditxt.com./role/CommitmentsContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquityDetails" roleURI="http://www.aditxt.com./role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxesDetails" roleURI="http://www.aditxt.com./role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SubsequentEventsDetails" roleURI="http://www.aditxt.com./role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PublicUtilitiesInventory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAsset" xlink:href="adtx-20221231.xsd#adtx_FixedAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adtx_FixedAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adtx_RightOfUseAssetLongTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20221231.xsd#adtx_FinancingOnFixedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="adtx_FinancingOnFixedAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityShortTermCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="adtx_OperatingLeaseLiabilityShortTermCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOfFixedAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_FinancingOfFixedAssetLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adtx_FinancingOfFixedAssetLongTerm" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityLongTermNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="adtx_OperatingLeaseLiabilityLongTermNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_RevenueAbstract" xlink:href="adtx-20221231.xsd#adtx_RevenueAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="adtx_RevenueAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RevenueAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RevenueAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringSettlementAndImpairmentProvisions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OtherExpenseAbstract" xlink:href="adtx-20221231.xsd#adtx_OtherExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="adtx_OtherExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_OtherExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OtherExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DividendsPreferredStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfRestrictedStockUnitsForCompensation" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfRestrictedStockUnitsForCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfRestrictedStockUnitsForCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForServicesinShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForServicesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForServicesinShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForVestedRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:href="adtx-20221231.xsd#adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ResetProvisionOnWarrantsAndModificationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ExerciseOfWarrants" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RoundingAdjustmentFromStockSplit" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_RoundingAdjustmentFromStockSplit" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RoundingAdjustmentFromStockSplitShares" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplitShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_RoundingAdjustmentFromStockSplitShares" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="41" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DisposalOfFixedAssets1" xlink:href="adtx-20221231.xsd#adtx_DisposalOfFixedAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adtx_DisposalOfFixedAssets1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TIAllowanceReceivable" xlink:href="adtx-20221231.xsd#adtx_TIAllowanceReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="adtx_TIAllowanceReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NoteReceivablesAndAccruedInterest" xlink:href="adtx-20221231.xsd#adtx_NoteReceivablesAndAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="adtx_NoteReceivablesAndAccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NoteReceivablesAndAccruedInterest" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DiscountOnConvertibleNotePayableFromOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfPreferredSharesToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="adtx_SaleOfPreferredSharesToRelatedParty" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalOfferingDiscountOnConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_OriginalOfferingDiscountOnConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_OriginalOfferingDiscountOnConvertibleNotePayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20221231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20221231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_LiabilityRecognizedForFinancedAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ReductionInExercisePriceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ReductionInExercisePriceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_ReductionInExercisePriceOfWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedForIntangibleAssets" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_SharesIssuedForIntangibleAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysis">
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernsDisclosureAbstract" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernsDisclosureTextBlock" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="adtx_GoingConcernsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NoteReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/Leases">
    <loc xlink:type="locator" xlink:label="adtx_LeasesLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesTable" xlink:href="adtx-20221231.xsd#adtx_LeasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_LeasesLineItems" xlink:to="adtx_LeasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_LeasesLineItems" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/CommitmentsContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssetsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_FixedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_FixedAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingCostsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_OfferingCostsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PatentsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_PatentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_PatentsPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LabEquipmentMember" xlink:href="adtx-20221231.xsd#adtx_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adtx_LabEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="sic_Z2520" xlink:href="https://xbrl.sec.gov/sic/2022/sic-2022.xsd#sic_Z2520"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sic_Z2520" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OtherFixedAssetsMember" xlink:href="adtx-20221231.xsd#adtx_OtherFixedAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adtx_OtherFixedAssetsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleoffixedassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LabEquipmentMember" xlink:href="adtx-20221231.xsd#adtx_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adtx_LabEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OtherFixedAssetsMember" xlink:href="adtx-20221231.xsd#adtx_OtherFixedAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adtx_OtherFixedAssetsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfMaturitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ProprietaryTechnologyMember" xlink:href="adtx-20221231.xsd#adtx_ProprietaryTechnologyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="adtx_ProprietaryTechnologyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalIntangibleAssetsMember" xlink:href="adtx-20221231.xsd#adtx_TotalIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="adtx_TotalIntangibleAssetsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasecostsTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_LeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetShortTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="adtx_RightOfUseAssetShortTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalRightOfUseAsset" xlink:href="adtx-20221231.xsd#adtx_TotalRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="adtx_TotalRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilitiesShortTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesShortTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="adtx_OperatingLeaseLiabilitiesShortTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilitiesLongTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="adtx_OperatingLeaseLiabilitiesLongTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalLeaseLiability" xlink:href="adtx-20221231.xsd#adtx_TotalLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="adtx_TotalLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesOfLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeasesLiabilityCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeasesLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="adtx_OperatingLeasesLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_VestedAndNonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedStockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_VestedAndNonvestedStockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_VestedAndNonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_VestedAndNonvestedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedRSUsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedRSUsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_NonvestedRSUsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageRemainingLifeGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodShareStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeExercised" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageRemainingLifeExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExpiredOrForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceRoundingForReverseSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeRoundingForReverseSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:href="adtx-20221231.xsd#adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCeuB01O1Ow81SGE6YrxYwKOz] CSR-->
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedStockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_NonvestedStockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_NonvestedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_WeightedAverageExercisePriceGranted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisesPriceVested" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisesPriceVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_WeightedAverageExercisesPriceVested" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceExpiredOrForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_WeightedAverageExercisePriceExpiredOrForfeited" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PermanentDifferencesOthers" xlink:href="adtx-20221231.xsd#adtx_PermanentDifferencesOthers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="adtx_PermanentDifferencesOthers" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ChangeInValuationAllowanceinDollars" xlink:href="adtx-20221231.xsd#adtx_ChangeInValuationAllowanceinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="adtx_ChangeInValuationAllowanceinDollars" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalProvisionForIncomeTaxesinDollars" xlink:href="adtx-20221231.xsd#adtx_TotalProvisionForIncomeTaxesinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ChangeInValuationAllowanceinDollars" xlink:to="adtx_TotalProvisionForIncomeTaxesinDollars" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_Section174Capitalization" xlink:href="adtx-20221231.xsd#adtx_Section174Capitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_Section174Capitalization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ValuationAllowance" xlink:href="adtx-20221231.xsd#adtx_ValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="adtx_ValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetDeferredTaxAssets" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ValuationAllowance" xlink:to="adtx_NetDeferredTaxAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssets" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="adtx_RightOfUseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssets" xlink:href="adtx-20221231.xsd#adtx_FixedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="adtx_FixedAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalDeferredTaxLiabilities" xlink:href="adtx-20221231.xsd#adtx_TotalDeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_FixedAssets" xlink:to="adtx_TotalDeferredTaxLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetDeferredTaxes" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_FixedAssets" xlink:to="adtx_NetDeferredTaxes" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails">
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_OrganizationandNatureofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtInstrumentTermDescription" xlink:href="adtx-20221231.xsd#adtx_DebtInstrumentTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_DebtInstrumentTermDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_WarrantsExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_PurchaseOfCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePricePerShares" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_ExercisePricePerShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PrefundedWarrantsShares" xlink:href="adtx-20221231.xsd#adtx_PrefundedWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_PrefundedWarrantsShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfEquityShares" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfEquityShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_PurchaseOfEquityShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysisDetails">
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernsDisclosureAbstract" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_NetLossCashFlowFromOperatingActivities" xlink:href="adtx-20221231.xsd#adtx_NetLossCashFlowFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="adtx_NetLossCashFlowFromOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="us-gaap_InterestPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="us-gaap_Cash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="us-gaap_CustomerFunds" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LicensingFeeForPatents" xlink:href="adtx-20221231.xsd#adtx_LicensingFeeForPatents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_LicensingFeeForPatents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsOfStockOptions" xlink:href="adtx-20221231.xsd#adtx_WarrantsOfStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_WarrantsOfStockOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DilutiveEarningShares" xlink:href="adtx-20221231.xsd#adtx_DilutiveEarningShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_DilutiveEarningShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisedShares" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_WarrantsExercisedShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockAwardForfeituresDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockAwardForfeituresDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedStockAwardForfeituresDividends" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NoteReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherLoansPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockYieldsPercentage" xlink:href="adtx-20221231.xsd#adtx_CommonStockYieldsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_CommonStockYieldsPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DescriptionOfShareExchangeAgreement" xlink:href="adtx-20221231.xsd#adtx_DescriptionOfShareExchangeAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_DescriptionOfShareExchangeAgreement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CreditAgreementAmendmentDescription" xlink:href="adtx-20221231.xsd#adtx_CreditAgreementAmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_CreditAgreementAmendmentDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_AdvancedCreditAgreement" xlink:href="adtx-20221231.xsd#adtx_AdvancedCreditAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_AdvancedCreditAgreement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CreditAgreement" xlink:href="adtx-20221231.xsd#adtx_CreditAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_CreditAgreement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithVariableRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithVariableRatesOfInterest1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansReceivableWithVariableRatesOfInterest1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtLoanAmount" xlink:href="adtx-20221231.xsd#adtx_DebtLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="adtx_DebtLoanAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_TimeDepositsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_AmortizationOfIntangibleAsset" xlink:href="adtx-20221231.xsd#adtx_AmortizationOfIntangibleAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="adtx_AmortizationOfIntangibleAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_EstimatedUsefulLife" xlink:href="adtx-20221231.xsd#adtx_EstimatedUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="adtx_EstimatedUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PreferredStockVotes" xlink:href="adtx-20221231.xsd#adtx_PreferredStockVotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_PreferredStockVotes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PromissoryNotes" xlink:href="adtx-20221231.xsd#adtx_PromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_PromissoryNotes" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsTable" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_August2022WarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022WarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="adtx_August2022WarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_August2022FollowOnWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022FollowOnWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="adtx_August2022FollowOnWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FutureReceiptsAgreementMember" xlink:href="adtx-20221231.xsd#adtx_FutureReceiptsAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="adtx_FutureReceiptsAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_AggregateAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_AggregateAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_GrossProceeds" xlink:href="adtx-20221231.xsd#adtx_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_GrossProceeds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_LegalFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantToPurchaseCommonShares" xlink:href="adtx-20221231.xsd#adtx_WarrantToPurchaseCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_WarrantToPurchaseCommonShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_ExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PrincipalAmountPercentage" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmountPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_PrincipalAmountPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestorPurchaseAmount" xlink:href="adtx-20221231.xsd#adtx_InvestorPurchaseAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_InvestorPurchaseAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_WarrantExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PrincipalAmount" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_PrincipalAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="adtx_LeasesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_LeasesDetailsLineItems" xlink:to="adtx_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_LeasesDetailsTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="stpr_VA" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="stpr_CA" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="stpr_NY" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetLeases" xlink:href="adtx-20221231.xsd#adtx_NetLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_LeasesDetailsLineItems" xlink:to="adtx_NetLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesExpire" xlink:href="adtx-20221231.xsd#adtx_LeasesExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_LeasesDetailsLineItems" xlink:to="adtx_LeasesExpire" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/CommitmentsContingenciesDetails">
    <loc xlink:type="locator" xlink:label="adtx_CommitmentsContingenciesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_CommitmentsContingenciesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="adtx_CommitmentsContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_CommitmentsContingenciesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_CommitmentsContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_CommitmentsContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_DirectTaxesAndLicensesCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InformationTechnologyAndDataProcessing" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationTechnologyAndDataProcessing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_InformationTechnologyAndDataProcessing" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_CostMaintenance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionOtherPaymentsRequired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PaymentOfMilestoneFees" xlink:href="adtx-20221231.xsd#adtx_PaymentOfMilestoneFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="adtx_PaymentOfMilestoneFees" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClearanceFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClearanceFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_ClearanceFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20221231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesCWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_SeriesCWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adtx_SeriesCWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OneYearMember" xlink:href="adtx-20221231.xsd#adtx_OneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="adtx_OneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RestrictedStockAwardsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="adtx_RestrictedStockAwardsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RestrictedStockUnitsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="adtx_RestrictedStockUnitsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StanfordUniversityMember" xlink:href="adtx-20221231.xsd#adtx_StanfordUniversityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="adtx_StanfordUniversityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RecognizedExpense" xlink:href="adtx-20221231.xsd#adtx_RecognizedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_RecognizedExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssued1" xlink:href="adtx-20221231.xsd#adtx_SharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_SharesIssued1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_SharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_SharesOfCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SettlementOfAccountsPayableShares" xlink:href="adtx-20221231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_SettlementOfAccountsPayableShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_sharesIssued1" xlink:href="adtx-20221231.xsd#adtx_sharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_sharesIssued1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedemptionPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_RedemptionPremium" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FairMarketValue" xlink:href="adtx-20221231.xsd#adtx_FairMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_FairMarketValue" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CompanyGranted" xlink:href="adtx-20221231.xsd#adtx_CompanyGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_CompanyGranted" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_weightedAverageGrant" xlink:href="adtx-20221231.xsd#adtx_weightedAverageGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_weightedAverageGrant" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionsShares" xlink:href="adtx-20221231.xsd#adtx_StockOptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_StockOptionsShares" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_ExercisePricePerShare" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20221231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_warrantIssued" xlink:href="adtx-20221231.xsd#adtx_warrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_warrantIssued" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsIssuedAndVesting" xlink:href="adtx-20221231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_WarrantsIssuedAndVesting" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_GrossProceeds" xlink:href="adtx-20221231.xsd#adtx_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_GrossProceeds" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingReflectingReducedExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_OfferingReflectingReducedExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_OfferingReflectingReducedExercisePricePerShare" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_VestingExpense" xlink:href="adtx-20221231.xsd#adtx_VestingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_VestingExpense" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_GrantTotal" xlink:href="adtx-20221231.xsd#adtx_GrantTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_GrantTotal" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockIssuedVested" xlink:href="adtx-20221231.xsd#adtx_CommonStockIssuedVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_CommonStockIssuedVested" order="56" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestIncomeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossCarryover" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossCarryover"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_NetOperatingLossCarryover" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_incomeLossOfGenerated" xlink:href="adtx-20221231.xsd#adtx_incomeLossOfGenerated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_incomeLossOfGenerated" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLosse" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLosse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_NetOperatingLosse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossesGeneratedPrior" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossesGeneratedPrior"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_NetOperatingLossesGeneratedPrior" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LessorOperatingLeaseDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PercentageOfIncomeTaxable" xlink:href="adtx-20221231.xsd#adtx_PercentageOfIncomeTaxable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_PercentageOfIncomeTaxable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="srt_RestatementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_AggregateOfferingPriceaAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateOfferingPriceaAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_AggregateOfferingPriceaAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_InvestmentCompanyIssuanceOfSharesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_GrossProceed" xlink:href="adtx-20221231.xsd#adtx_GrossProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_GrossProceed" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OriginationOfNotesReceivableFromRelatedParties" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredLoanOriginationFeesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>adtx-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:22 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">NET LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Total other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AT BEGINNING OF YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AT END OF YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernsDisclosureAbstract" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GoingConcernsDisclosureAbstract_lbl" xml:lang="en-US">Going Concern Analysis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernsDisclosureAbstract" xlink:to="adtx_GoingConcernsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total maturities, due beyond one year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Number, Nonvested at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted- Average Exercise Price, Nonvested at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PublicUtilitiesInventory_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventory" xlink:to="us-gaap_PublicUtilitiesInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Note receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract" xlink:to="adtx_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAsset" xlink:href="adtx-20221231.xsd#adtx_FixedAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FixedAsset_lbl" xml:lang="en-US">Fixed assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAsset" xlink:to="adtx_FixedAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RightOfUseAssetLongTerm_lbl" xml:lang="en-US">Right of use asset - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract0" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract0" xlink:to="adtx_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20221231.xsd#adtx_FinancingOnFixedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FinancingOnFixedAssets_lbl" xml:lang="en-US">Financing on fixed assets &#8211; current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityShortTermCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl" xml:lang="en-US">Lease liability - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:to="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract1" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract1" xlink:to="adtx_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOfFixedAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_FinancingOfFixedAssetLongTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FinancingOfFixedAssetLongTerm_lbl" xml:lang="en-US">Financing on fixed assets - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOfFixedAssetLongTerm" xlink:to="adtx_FinancingOfFixedAssetLongTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityLongTermNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl" xml:lang="en-US">Lease liability - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:to="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract2" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract2" xlink:to="adtx_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract3" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract3" xlink:to="adtx_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 100,000,000 shares authorized, 4,307,487 and 890,614 shares issued and 4,305,470 and 888,579 shares outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract4" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract4" xlink:to="adtx_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RevenueAbstract" xlink:href="adtx-20221231.xsd#adtx_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RevenueAbstract_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RevenueAbstract" xlink:to="adtx_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract5" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract5" xlink:to="adtx_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses, includes $1,516,805 and $3,927,551 in stock-based compensation, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, includes $591,518 and $713,130 in stock-based compensation, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales and marketing, includes $1,023,045, and $0 in stock-based compensation, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions_lbl" xml:lang="en-US">Impairment on notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="us-gaap_RestructuringSettlementAndImpairmentProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract6" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract6" xlink:to="adtx_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract7" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract7" xlink:to="adtx_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OtherExpenseAbstract" xlink:href="adtx-20221231.xsd#adtx_OtherExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OtherExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OtherExpenseAbstract" xlink:to="adtx_OtherExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract8" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract8" xlink:to="adtx_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract9" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract9" xlink:to="adtx_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract10" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract10" xlink:to="adtx_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract11" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract11" xlink:to="adtx_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract12" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract12" xlink:to="adtx_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract13" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract13" xlink:to="adtx_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the year - basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the year - basic and diluted (in Shares) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract14" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract14" xlink:to="adtx_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock option and warrant compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract15" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract15" xlink:to="adtx_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfRestrictedStockUnitsForCompensation" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfRestrictedStockUnitsForCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl" xml:lang="en-US">Issuance of restricted stock units for compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfRestrictedStockUnitsForCompensation" xlink:to="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock units for compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Restricted stock of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract16" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract16" xlink:to="adtx_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of shares for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForServicesinShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForServicesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForServicesinShares_lbl" xml:lang="en-US">Issuance of shares for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForServicesinShares" xlink:to="adtx_IssuanceOfSharesForServicesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract17" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract17" xlink:to="adtx_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Exercise of warrants, modification of warrants, and issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl" xml:lang="en-US">Exercise of warrants, modification of warrants, and issuance of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:to="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract18" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract18" xlink:to="adtx_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl" xml:lang="en-US">Sale of Series B Preferred shares to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl" xml:lang="en-US">Sale of Series B Preferred shares to related party (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract19" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract19" xlink:to="adtx_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Redemption of Series B Preferred shares to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:href="adtx-20221231.xsd#adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl" xml:lang="en-US">Redemption of Series B Preferred shares to related party (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:to="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract20" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract20" xlink:to="adtx_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl" xml:lang="en-US">Shares issued as inducement on loans, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl" xml:lang="en-US">Shares issued as inducement on loans, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract21" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract21" xlink:to="adtx_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Warrants issued with loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract22" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract22" xlink:to="adtx_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ResetProvisionOnWarrantsAndModificationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl" xml:lang="en-US">Reset provision on warrants and modification of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:to="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract23" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract23" xlink:to="adtx_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of shares for debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of shares for debt issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract24" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract24" xlink:to="adtx_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract25" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract25" xlink:to="adtx_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of shares and warrants for offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of shares and warrants for offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract26" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract26" xlink:to="adtx_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:to="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract27" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract27" xlink:to="adtx_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for settlement of AP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for settlement of AP (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract28" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract28" xlink:to="adtx_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RoundingAdjustmentFromStockSplit" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RoundingAdjustmentFromStockSplit_lbl" xml:lang="en-US">Rounding from reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplit" xlink:to="adtx_RoundingAdjustmentFromStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RoundingAdjustmentFromStockSplitShares" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplitShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RoundingAdjustmentFromStockSplitShares_lbl" xml:lang="en-US">Rounding from reverse stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplitShares" xlink:to="adtx_RoundingAdjustmentFromStockSplitShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract29" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract29" xlink:to="adtx_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract30" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract30" xlink:to="adtx_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract31" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract31" xlink:to="adtx_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract32" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract32" xlink:to="adtx_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract33" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract33" xlink:to="adtx_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock unit compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract34" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract34" xlink:to="adtx_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract35" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract35" xlink:to="adtx_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Issuance of shares for employee compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of shares for employee compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Recognized expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract36" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract36" xlink:to="adtx_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of shares for vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForVestedRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of shares for vested restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract37" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract37" xlink:to="adtx_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl" xml:lang="en-US">Issuance of shares for the conversion of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of shares for the conversion of debt (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract38" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract38" xlink:to="adtx_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Fair value of warrants issued with convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract39" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract39" xlink:to="adtx_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract40" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract40" xlink:to="adtx_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of shares for offerings, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of shares for offerings, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract41" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract41" xlink:to="adtx_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant consideration for convertible debt offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract42" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract42" xlink:to="adtx_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Reduction in exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract43" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract43" xlink:to="adtx_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract44" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract44" xlink:to="adtx_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DisposalOfFixedAssets1" xlink:href="adtx-20221231.xsd#adtx_DisposalOfFixedAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DisposalOfFixedAssets1_lbl" xml:lang="en-US">Disposal of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DisposalOfFixedAssets1" xlink:to="adtx_DisposalOfFixedAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract45" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract45" xlink:to="adtx_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract46" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract46" xlink:to="adtx_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DiscountOnConvertibleNotePayableFromOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl" xml:lang="en-US">Proceeds from notes and convertible notes payable, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:to="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of notes and convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfPreferredSharesToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty_lbl" xml:lang="en-US">Sale of Series B Preferred shares to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfPreferredSharesToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Redemption of Series B Preferred shares to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Common stock and warrants issued for cash, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Exercise of warrants and received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract47" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract47" xlink:to="adtx_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract48" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract48" xlink:to="adtx_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract49" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract49" xlink:to="adtx_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract50" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract50" xlink:to="adtx_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherLongTermDebt" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract51" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract51" xlink:to="adtx_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalOfferingDiscountOnConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_OriginalOfferingDiscountOnConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OriginalOfferingDiscountOnConvertibleNotePayable_lbl" xml:lang="en-US">Issuance of shares for the settlement of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalOfferingDiscountOnConvertibleNotePayable" xlink:to="adtx_OriginalOfferingDiscountOnConvertibleNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability recognized from right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of shares for the settlement of accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20221231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl" xml:lang="en-US">Original offering discount on convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable_lbl" xml:lang="en-US">Debt discount from warrants issued with convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" xlink:to="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts_lbl" xml:lang="en-US">Debt discount from warrant consideration for convertible debt offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" xlink:to="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Debt discount from shares issued as inducement for convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20221231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LiabilityRecognizedForFinancedAssets_lbl" xml:lang="en-US">Liability recognized for financed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilityRecognizedForFinancedAssets" xlink:to="adtx_LiabilityRecognizedForFinancedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ReductionInExercisePriceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ReductionInExercisePriceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ReductionInExercisePriceOfWarrants_lbl" xml:lang="en-US">Reduction in exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ReductionInExercisePriceOfWarrants" xlink:to="adtx_ReductionInExercisePriceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedForIntangibleAssets" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesIssuedForIntangibleAssets_lbl" xml:lang="en-US">Shares issued for debt offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedForIntangibleAssets" xlink:to="adtx_SharesIssuedForIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_lbl" xml:lang="en-US">Warrant modification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 2,017 and 2,017 shares, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Implied Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Impairment on notes receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xml:lang="en-US">Purchase of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TIAllowanceReceivable" xlink:href="adtx-20221231.xsd#adtx_TIAllowanceReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adtx_TIAllowanceReceivable_lbl" xml:lang="en-US">Tenant improvement allowance receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TIAllowanceReceivable" xlink:to="adtx_TIAllowanceReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NoteReceivablesAndAccruedInterest" xlink:href="adtx-20221231.xsd#adtx_NoteReceivablesAndAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adtx_NoteReceivablesAndAccruedInterest_lbl" xml:lang="en-US">Notes receivable and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NoteReceivablesAndAccruedInterest" xlink:to="adtx_NoteReceivablesAndAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payments on financing on fixed asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Cash paid on extinguishment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Sales and marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">B Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US">Preferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND NATURE OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernsDisclosureTextBlock" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_GoingConcernsDisclosureTextBlock_lbl" xml:lang="en-US">GOING CONCERN ANALYSIS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernsDisclosureTextBlock" xlink:to="adtx_GoingConcernsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of useful lives assigned to fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xml:lang="en-US">Useful lives assigned to fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">NOTE RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Cost Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ComponentsOfTotalLeaseCostsAbstract" xlink:href="adtx-20221231.xsd#adtx_ComponentsOfTotalLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ComponentsOfTotalLeaseCostsAbstract_lbl" xml:lang="en-US">Components of total lease costs:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ComponentsOfTotalLeaseCostsAbstract" xlink:to="adtx_ComponentsOfTotalLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetShortTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RightOfUseAssetShortTerm_lbl" xml:lang="en-US">Right of use asset &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalRightOfUseAsset" xlink:href="adtx-20221231.xsd#adtx_TotalRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalRightOfUseAsset_lbl" xml:lang="en-US">Total right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalRightOfUseAsset" xlink:to="adtx_TotalRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_UnlabeledAbstract52" xlink:href="adtx-20221231.xsd#adtx_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract52" xlink:to="adtx_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilitiesShortTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesShortTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OperatingLeaseLiabilitiesShortTerm_lbl" xml:lang="en-US">Operating lease liabilities &#8211; short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesShortTerm" xlink:to="adtx_OperatingLeaseLiabilitiesShortTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeaseLiabilitiesLongTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesLongTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OperatingLeaseLiabilitiesLongTerm_lbl" xml:lang="en-US">Operating lease liabilities &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesLongTerm" xlink:to="adtx_OperatingLeaseLiabilitiesLongTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalLeaseLiability" xlink:href="adtx-20221231.xsd#adtx_TotalLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalLeaseLiability_lbl" xml:lang="en-US">Total lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalLeaseLiability" xlink:to="adtx_TotalLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of lease terms and discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years) &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate &#8211; operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS &amp; CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl" xml:lang="en-US">Schedule of analysis of the stock option grant activity under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of shares, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageRemainingLifeGranted_lbl" xml:lang="en-US">Weighted Average Remaining Life, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeGranted" xlink:to="adtx_WeightedAverageRemainingLifeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodShareStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xml:lang="en-US">Number, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeExercised" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageRemainingLifeExercised_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExercised" xlink:to="adtx_WeightedAverageRemainingLifeExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExpiredOrForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl" xml:lang="en-US">Weighted Average Remaining Life, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:href="adtx-20221231.xsd#adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:to="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Number, Rounding for Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceRoundingForReverseSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl" xml:lang="en-US">Weighted Average Exercise Price, Rounding for Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" xlink:to="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeRoundingForReverseSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl" xml:lang="en-US">Weighted Average Remaining Life, Rounding for Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:to="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of warranty issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl" xml:lang="en-US">Number, Nonvested at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Nonvested at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl" xml:lang="en-US">Number, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceGranted" xlink:to="adtx_WeightedAverageExercisePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisesPriceVested" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisesPriceVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisesPriceVested_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisesPriceVested" xlink:to="adtx_WeightedAverageExercisesPriceVested_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceExpiredOrForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceExpiredOrForfeited" xlink:to="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life in years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Income taxes at U.S. statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax Credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PermanentDifferencesOthers" xlink:href="adtx-20221231.xsd#adtx_PermanentDifferencesOthers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PermanentDifferencesOthers_lbl" xml:lang="en-US">Permanent Differences/Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PermanentDifferencesOthers" xlink:to="adtx_PermanentDifferencesOthers_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ChangeInValuationAllowanceinDollars" xlink:href="adtx-20221231.xsd#adtx_ChangeInValuationAllowanceinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ChangeInValuationAllowanceinDollars_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ChangeInValuationAllowanceinDollars" xlink:to="adtx_ChangeInValuationAllowanceinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalProvisionForIncomeTaxesinDollars" xlink:href="adtx-20221231.xsd#adtx_TotalProvisionForIncomeTaxesinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalProvisionForIncomeTaxesinDollars_lbl" xml:lang="en-US">Total provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalProvisionForIncomeTaxesinDollars" xlink:to="adtx_TotalProvisionForIncomeTaxesinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US">Tax credits carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_Section174Capitalization" xlink:href="adtx-20221231.xsd#adtx_Section174Capitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_Section174Capitalization_lbl" xml:lang="en-US">Section 174 Capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_Section174Capitalization" xlink:to="adtx_Section174Capitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Loss on impairment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ValuationAllowance" xlink:href="adtx-20221231.xsd#adtx_ValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ValuationAllowance" xlink:to="adtx_ValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetDeferredTaxAssets" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetDeferredTaxAssets_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxAssets" xlink:to="adtx_NetDeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssets" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RightOfUseAssets_lbl" xml:lang="en-US">Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssets" xlink:to="adtx_RightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssets" xlink:href="adtx-20221231.xsd#adtx_FixedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FixedAssets_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssets" xlink:to="adtx_FixedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalDeferredTaxLiabilities" xlink:href="adtx-20221231.xsd#adtx_TotalDeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalDeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalDeferredTaxLiabilities" xlink:to="adtx_TotalDeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetDeferredTaxes" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetDeferredTaxes_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxes" xlink:to="adtx_NetDeferredTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OperatingLeasesLiabilityCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeasesLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adtx_OperatingLeasesLiabilityCurrent_lbl" xml:lang="en-US">Less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeasesLiabilityCurrent" xlink:to="adtx_OperatingLeasesLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Number of shares, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Vested, share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LabEquipmentMember" xlink:href="adtx-20221231.xsd#adtx_LabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LabEquipmentMember" xlink:to="adtx_LabEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="sic_Z2520" xlink:href="https://xbrl.sec.gov/sic/2022/sic-2022.xsd#sic_Z2520"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="sic_Z2520_lbl" xml:lang="en-US">Office Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sic_Z2520" xlink:to="sic_Z2520_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OtherFixedAssetsMember" xlink:href="adtx-20221231.xsd#adtx_OtherFixedAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OtherFixedAssetsMember_lbl" xml:lang="en-US">Other Fixed Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OtherFixedAssetsMember" xlink:to="adtx_OtherFixedAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Office Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ProprietaryTechnologyMember" xlink:href="adtx-20221231.xsd#adtx_ProprietaryTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ProprietaryTechnologyMember_lbl" xml:lang="en-US">Proprietary Technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ProprietaryTechnologyMember" xlink:to="adtx_ProprietaryTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalIntangibleAssetsMember" xlink:href="adtx-20221231.xsd#adtx_TotalIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalIntangibleAssetsMember_lbl" xml:lang="en-US">Total Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalIntangibleAssetsMember" xlink:to="adtx_TotalIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_VestedAndNonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedStockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_VestedAndNonvestedStockOptionsMember_lbl" xml:lang="en-US">Vested and Nonvested Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestedAndNonvestedStockOptionsMember" xlink:to="adtx_VestedAndNonvestedStockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_VestedAndNonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_VestedAndNonvestedWarrantsMember_lbl" xml:lang="en-US">Vested and Nonvested Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestedAndNonvestedWarrantsMember" xlink:to="adtx_VestedAndNonvestedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedRSUsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedRSUsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NonvestedRSUsMember_lbl" xml:lang="en-US">Nonvested RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedRSUsMember" xlink:to="adtx_NonvestedRSUsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedStockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NonvestedStockOptionsMember_lbl" xml:lang="en-US">Nonvested Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedStockOptionsMember" xlink:to="adtx_NonvestedStockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NonvestedWarrantsMember_lbl" xml:lang="en-US">Nonvested Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedWarrantsMember" xlink:to="adtx_NonvestedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnderlyingAssetClassAxis_lbl" xml:lang="en-US">Underlying Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="us-gaap_UnderlyingAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Company issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:to="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Issued warrants to purchase of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtInstrumentTermDescription" xlink:href="adtx-20221231.xsd#adtx_DebtInstrumentTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DebtInstrumentTermDescription_lbl" xml:lang="en-US">Debt instrument term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtInstrumentTermDescription" xlink:to="adtx_DebtInstrumentTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisePrice" xlink:to="adtx_WarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePricePerShares" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExercisePricePerShares_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShares" xlink:to="adtx_ExercisePricePerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Net of underwriting discounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PrefundedWarrantsShares" xlink:href="adtx-20221231.xsd#adtx_PrefundedWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PrefundedWarrantsShares_lbl" xml:lang="en-US">Prefunded warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrefundedWarrantsShares" xlink:to="adtx_PrefundedWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfEquityShares" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfEquityShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PurchaseOfEquityShares_lbl" xml:lang="en-US">Purchase of equity shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Share purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price term (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetLossCashFlowFromOperatingActivities" xlink:href="adtx-20221231.xsd#adtx_NetLossCashFlowFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetLossCashFlowFromOperatingActivities_lbl" xml:lang="en-US">Net loss cash flow from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetLossCashFlowFromOperatingActivities" xlink:to="adtx_NetLossCashFlowFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerFunds_lbl" xml:lang="en-US">Future funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerFunds" xlink:to="us-gaap_CustomerFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl" xml:lang="en-US">Allowance for doubtful accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LicensingFeeForPatents" xlink:href="adtx-20221231.xsd#adtx_LicensingFeeForPatents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LicensingFeeForPatents_lbl" xml:lang="en-US">Licensing fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsOfStockOptions" xlink:href="adtx-20221231.xsd#adtx_WarrantsOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsOfStockOptions_lbl" xml:lang="en-US">Stock options issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsOfStockOptions" xlink:to="adtx_WarrantsOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl" xml:lang="en-US">Restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DilutiveEarningShares" xlink:href="adtx-20221231.xsd#adtx_DilutiveEarningShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DilutiveEarningShares_lbl" xml:lang="en-US">Dilutive earning shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DilutiveEarningShares" xlink:to="adtx_DilutiveEarningShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisedShares" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsExercisedShares_lbl" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedShares" xlink:to="adtx_WarrantsExercisedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockAwardForfeituresDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockAwardForfeituresDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockAwardForfeituresDividends_lbl" xml:lang="en-US">Recognized an implied dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockAwardForfeituresDividends" xlink:to="us-gaap_RestrictedStockAwardForfeituresDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLoansPayable_lbl" xml:lang="en-US">Completion of a proposed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayable" xlink:to="us-gaap_OtherLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockYieldsPercentage" xlink:href="adtx-20221231.xsd#adtx_CommonStockYieldsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonStockYieldsPercentage_lbl" xml:lang="en-US">Common stock yields percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockYieldsPercentage" xlink:to="adtx_CommonStockYieldsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DescriptionOfShareExchangeAgreement" xlink:href="adtx-20221231.xsd#adtx_DescriptionOfShareExchangeAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DescriptionOfShareExchangeAgreement_lbl" xml:lang="en-US">Share exchange agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DescriptionOfShareExchangeAgreement" xlink:to="adtx_DescriptionOfShareExchangeAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest rate per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_CreditAgreementAmendmentDescription" xlink:href="adtx-20221231.xsd#adtx_CreditAgreementAmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CreditAgreementAmendmentDescription_lbl" xml:lang="en-US">Credit agreement amendment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreementAmendmentDescription" xlink:to="adtx_CreditAgreementAmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AdvancedCreditAgreement" xlink:href="adtx-20221231.xsd#adtx_AdvancedCreditAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AdvancedCreditAgreement_lbl" xml:lang="en-US">Advanced credit agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AdvancedCreditAgreement" xlink:to="adtx_AdvancedCreditAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CreditAgreement" xlink:href="adtx-20221231.xsd#adtx_CreditAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CreditAgreement_lbl" xml:lang="en-US">Credit agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreement" xlink:to="adtx_CreditAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithVariableRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithVariableRatesOfInterest1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableWithVariableRatesOfInterest1_lbl" xml:lang="en-US">Note receivable amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithVariableRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithVariableRatesOfInterest1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss_lbl" xml:lang="en-US">Credit agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DebtLoanAmount" xlink:href="adtx-20221231.xsd#adtx_DebtLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DebtLoanAmount_lbl" xml:lang="en-US">Debt loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtLoanAmount" xlink:to="adtx_DebtLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl" xml:lang="en-US">Loan interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xml:lang="en-US">Carrying value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="us-gaap_TimeDepositsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl" xml:lang="en-US">Monthly payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AmortizationOfIntangibleAsset" xlink:href="adtx-20221231.xsd#adtx_AmortizationOfIntangibleAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AmortizationOfIntangibleAsset_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AmortizationOfIntangibleAsset" xlink:to="adtx_AmortizationOfIntangibleAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_EstimatedUsefulLife" xlink:href="adtx-20221231.xsd#adtx_EstimatedUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_EstimatedUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_EstimatedUsefulLife" xlink:to="adtx_EstimatedUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PreferredStockVotes" xlink:href="adtx-20221231.xsd#adtx_PreferredStockVotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PreferredStockVotes_lbl" xml:lang="en-US">Preferred stock votes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockVotes" xlink:to="adtx_PreferredStockVotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US">Cash received on consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Accrue interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PromissoryNotes" xlink:href="adtx-20221231.xsd#adtx_PromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PromissoryNotes_lbl" xml:lang="en-US">Promissory note amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PromissoryNotes" xlink:to="adtx_PromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AggregateAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AggregateAmount_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AggregateAmount" xlink:to="adtx_AggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GrossProceeds" xlink:href="adtx-20221231.xsd#adtx_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceeds" xlink:to="adtx_GrossProceeds_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adtx_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceeds" xlink:to="adtx_GrossProceeds_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Origination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional service fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xml:lang="en-US">Repaid purchase amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantToPurchaseCommonShares" xlink:href="adtx-20221231.xsd#adtx_WarrantToPurchaseCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantToPurchaseCommonShares_lbl" xml:lang="en-US">Warrant to purchase common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantToPurchaseCommonShares" xlink:to="adtx_WarrantToPurchaseCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePrice" xlink:to="adtx_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Sale of net issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PrincipalAmountPercentage" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmountPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PrincipalAmountPercentage_lbl" xml:lang="en-US">Principal amount percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrincipalAmountPercentage" xlink:to="adtx_PrincipalAmountPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant to purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestorPurchaseAmount" xlink:href="adtx-20221231.xsd#adtx_InvestorPurchaseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_InvestorPurchaseAmount_lbl" xml:lang="en-US">Purchase amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestorPurchaseAmount" xlink:to="adtx_InvestorPurchaseAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantExercisePrice_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantExercisePrice" xlink:to="adtx_WarrantExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PrincipalAmount" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PrincipalAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrincipalAmount" xlink:to="adtx_PrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl" xml:lang="en-US">Principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetLeases" xlink:href="adtx-20221231.xsd#adtx_NetLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetLeases_lbl" xml:lang="en-US">Net lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetLeases" xlink:to="adtx_NetLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesExpire" xlink:href="adtx-20221231.xsd#adtx_LeasesExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LeasesExpire_lbl" xml:lang="en-US">Lease expires</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesExpire" xlink:to="adtx_LeasesExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesAndLicenses_lbl" xml:lang="en-US">License fee paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectTaxesAndLicensesCosts_lbl" xml:lang="en-US">License milestone payment due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectTaxesAndLicensesCosts" xlink:to="us-gaap_DirectTaxesAndLicensesCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xml:lang="en-US">Payment due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts_lbl" xml:lang="en-US">Extension fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" xlink:to="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InformationTechnologyAndDataProcessing" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationTechnologyAndDataProcessing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InformationTechnologyAndDataProcessing_lbl" xml:lang="en-US">Technology rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationTechnologyAndDataProcessing" xlink:to="us-gaap_InformationTechnologyAndDataProcessing_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Final payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl" xml:lang="en-US">Net Product percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl" xml:lang="en-US">Fee paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl0" xml:lang="en-US">Company paid (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionOtherPaymentsRequired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired_lbl" xml:lang="en-US">Required to pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" xlink:to="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PaymentOfMilestoneFees" xlink:href="adtx-20221231.xsd#adtx_PaymentOfMilestoneFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PaymentOfMilestoneFees_lbl" xml:lang="en-US">Payment of milestone fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PaymentOfMilestoneFees" xlink:to="adtx_PaymentOfMilestoneFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClearanceFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClearanceFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClearanceFees_lbl" xml:lang="en-US">Regulatory clearance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClearanceFees" xlink:to="us-gaap_ClearanceFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl" xml:lang="en-US">Potential</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount_lbl" xml:lang="en-US">Financial revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual_lbl" xml:lang="en-US">Loss Contingency Accrual, Product Liability, Net, Explanation of Material Change in Accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" xlink:to="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl" xml:lang="en-US">License maintenance fees description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Company issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Issuance of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RecognizedExpense" xlink:href="adtx-20221231.xsd#adtx_RecognizedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RecognizedExpense_lbl" xml:lang="en-US">Recognized expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RecognizedExpense" xlink:to="adtx_RecognizedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssued1" xlink:href="adtx-20221231.xsd#adtx_SharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesIssued1_lbl" xml:lang="en-US">Company issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssued1" xlink:to="adtx_SharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Issue of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrant issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_SharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesOfCommonStock_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesOfCommonStock" xlink:to="adtx_SharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SettlementOfAccountsPayableShares" xlink:href="adtx-20221231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl" xml:lang="en-US">Settlement of accounts payable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_sharesIssued1" xlink:href="adtx-20221231.xsd#adtx_sharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_sharesIssued1_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_sharesIssued1" xlink:to="adtx_sharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare_lbl" xml:lang="en-US">Preferred stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability_lbl" xml:lang="en-US">Purchaser (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedemptionPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedemptionPremium_lbl" xml:lang="en-US">Redemption preferred stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US">Preferred stock share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Granted stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FairMarketValue" xlink:href="adtx-20221231.xsd#adtx_FairMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FairMarketValue_lbl" xml:lang="en-US">Fair market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FairMarketValue" xlink:to="adtx_FairMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CompanyGranted" xlink:href="adtx-20221231.xsd#adtx_CompanyGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CompanyGranted_lbl" xml:lang="en-US">Company granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CompanyGranted" xlink:to="adtx_CompanyGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_weightedAverageGrant" xlink:href="adtx-20221231.xsd#adtx_weightedAverageGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_weightedAverageGrant_lbl" xml:lang="en-US">Weighted average grant (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_weightedAverageGrant" xlink:to="adtx_weightedAverageGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Stock Option, Exercise Price, Decrease (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionsShares" xlink:href="adtx-20221231.xsd#adtx_StockOptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockOptionsShares_lbl" xml:lang="en-US">Stock options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionsShares" xlink:to="adtx_StockOptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExercisePricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShare" xlink:to="adtx_ExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20221231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl" xml:lang="en-US">Share based payment remaining expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Weighted average vesting term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_warrantIssued" xlink:href="adtx-20221231.xsd#adtx_warrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_warrantIssued_lbl" xml:lang="en-US">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_warrantIssued" xlink:to="adtx_warrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsIssuedAndVesting" xlink:href="adtx-20221231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsIssuedAndVesting_lbl" xml:lang="en-US">Warrants issued and vesting (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsIssuedAndVesting" xlink:to="adtx_WarrantsIssuedAndVesting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Remaining expensed (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Weighted average vesting term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant exercise price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US">Exercise price increase (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrant (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingReflectingReducedExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_OfferingReflectingReducedExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OfferingReflectingReducedExercisePricePerShare_lbl" xml:lang="en-US">Offering Reflecting Reduced Exercise Price, Per Share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingReflectingReducedExercisePricePerShare" xlink:to="adtx_OfferingReflectingReducedExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_VestingExpense" xlink:href="adtx-20221231.xsd#adtx_VestingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_VestingExpense_lbl" xml:lang="en-US">Vesting expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestingExpense" xlink:to="adtx_VestingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GrantTotal" xlink:href="adtx-20221231.xsd#adtx_GrantTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_GrantTotal_lbl" xml:lang="en-US">Grant total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrantTotal" xlink:to="adtx_GrantTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockIssuedVested" xlink:href="adtx-20221231.xsd#adtx_CommonStockIssuedVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonStockIssuedVested_lbl" xml:lang="en-US">Common stock issued, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedVested" xlink:to="adtx_CommonStockIssuedVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossCarryover" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossCarryover"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetOperatingLossCarryover_lbl" xml:lang="en-US">Percentage of net operating loss carryover</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossCarryover" xlink:to="adtx_NetOperatingLossCarryover_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_incomeLossOfGenerated" xlink:href="adtx-20221231.xsd#adtx_incomeLossOfGenerated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_incomeLossOfGenerated_lbl" xml:lang="en-US">Income loss of generated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_incomeLossOfGenerated" xlink:to="adtx_incomeLossOfGenerated_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLosse" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLosse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetOperatingLosse_lbl" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLosse" xlink:to="adtx_NetOperatingLosse_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossesGeneratedPrior" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossesGeneratedPrior"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetOperatingLossesGeneratedPrior_lbl" xml:lang="en-US">Net operating losses generated prior</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossesGeneratedPrior" xlink:to="adtx_NetOperatingLossesGeneratedPrior_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xml:lang="en-US">Net operating losses, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PercentageOfIncomeTaxable" xlink:href="adtx-20221231.xsd#adtx_PercentageOfIncomeTaxable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PercentageOfIncomeTaxable_lbl" xml:lang="en-US">Income taxable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PercentageOfIncomeTaxable" xlink:to="adtx_PercentageOfIncomeTaxable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AggregateOfferingPriceaAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateOfferingPriceaAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AggregateOfferingPriceaAmount_lbl" xml:lang="en-US">Aggregate offering pricea amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AggregateOfferingPriceaAmount" xlink:to="adtx_AggregateOfferingPriceaAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_InvestmentCompanyIssuanceOfSharesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare_lbl" xml:lang="en-US">Average price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" xlink:to="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US">Paying commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GrossProceed" xlink:href="adtx-20221231.xsd#adtx_GrossProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_GrossProceed_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceed" xlink:to="adtx_GrossProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OriginationOfNotesReceivableFromRelatedParties_lbl" xml:lang="en-US">Origination fees</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCety4YpXhpPRBzb7NM8qMGOKhcqO3tFy2l8=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_OriginationOfNotesReceivableFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Final payment due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Issued shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" xlink:to="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredLoanOriginationFeesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet_lbl" xml:lang="en-US">Origination fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" xlink:to="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xml:lang="en-US">Repayment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssetsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_FixedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FixedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssetsPolicyTextBlock" xlink:to="adtx_FixedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingCostsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PatentsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_PatentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PatentsPolicyTextBlock_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FutureReceiptsAgreementMember" xlink:href="adtx-20221231.xsd#adtx_FutureReceiptsAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FutureReceiptsAgreementMember_lbl" xml:lang="en-US">Future Receipts Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FutureReceiptsAgreementMember" xlink:to="adtx_FutureReceiptsAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adtx_FutureReceiptsAgreementMember_lbl0" xml:lang="en-US">Future Receipts Agreement[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FutureReceiptsAgreementMember" xlink:to="adtx_FutureReceiptsAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_August2022WarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022WarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_August2022WarrantsMember_lbl" xml:lang="en-US">August 2022 Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_August2022WarrantsMember" xlink:to="adtx_August2022WarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_August2022FollowOnWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022FollowOnWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_August2022FollowOnWarrantsMember_lbl" xml:lang="en-US">August 2022 Follow On Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_August2022FollowOnWarrantsMember" xlink:to="adtx_August2022FollowOnWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_VA_lbl" xml:lang="en-US">Virginia [Membe]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_VA" xlink:to="stpr_VA_lbl"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_CA_lbl" xml:lang="en-US">California [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <loc xlink:type="locator" xlink:label="stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_NY_lbl" xml:lang="en-US">New York [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StanfordUniversityMember" xlink:href="adtx-20221231.xsd#adtx_StanfordUniversityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StanfordUniversityMember_lbl" xml:lang="en-US">Stanford University [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StanfordUniversityMember" xlink:to="adtx_StanfordUniversityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RestrictedStockAwardsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RestrictedStockAwardsMember" xlink:to="adtx_RestrictedStockAwardsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RestrictedStockUnitsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RestrictedStockUnitsMember" xlink:to="adtx_RestrictedStockUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20221231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OneYearMember" xlink:href="adtx-20221231.xsd#adtx_OneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OneYearMember_lbl" xml:lang="en-US">One Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OneYearMember" xlink:to="adtx_OneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesCWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_SeriesCWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesCWarrantsMember" xlink:to="adtx_SeriesCWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeMember_lbl" xml:lang="en-US">Interest Income [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeMember" xlink:to="us-gaap_InterestIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesTable" xlink:href="adtx-20221231.xsd#adtx_LeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LeasesTable_lbl" xml:lang="en-US">Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesTable" xlink:to="adtx_LeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LeasesLineItems_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesLineItems" xlink:to="adtx_LeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of warranty issuance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:to="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of warranty issuance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:to="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Nature of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="adtx_OrganizationandNatureofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Nature of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_OrganizationandNatureofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RelatedPartyTransactionsDetailsTable" xlink:to="adtx_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsTable" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="adtx_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NotesPayableDetailsLineItems_lbl" xml:lang="en-US">Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_NotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnderlyingAssetClassDomain_lbl" xml:lang="en-US">Underlying Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnderlyingAssetClassDomain" xlink:to="us-gaap_UnderlyingAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesDetailsTable" xlink:to="adtx_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LeasesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesDetailsLineItems" xlink:to="adtx_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US">Other Commitments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommitmentsContingenciesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommitmentsContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments &amp; Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommitmentsContingenciesDetailsTable" xlink:to="adtx_CommitmentsContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommitmentsContingenciesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommitmentsContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments &amp; Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommitmentsContingenciesDetailsLineItems" xlink:to="adtx_CommitmentsContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsTable" xlink:to="adtx_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDetailsLineItems" xlink:to="adtx_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncomeTaxesDetailsTable" xlink:to="adtx_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="adtx_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AdvancedCreditAgreement_lbl0" xml:lang="en-US">Advanced credit agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AdvancedCreditAgreement" xlink:to="adtx_AdvancedCreditAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AggregateOfferingPriceaAmount_lbl0" xml:lang="en-US">Aggregate offering pricea amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AggregateOfferingPriceaAmount" xlink:to="adtx_AggregateOfferingPriceaAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AmortizationOfIntangibleAsset_lbl0" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AmortizationOfIntangibleAsset" xlink:to="adtx_AmortizationOfIntangibleAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ChangeInValuationAllowanceinDollars_lbl0" xml:lang="en-US">Change in valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ChangeInValuationAllowanceinDollars" xlink:to="adtx_ChangeInValuationAllowanceinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CommonStockIssuedVested_lbl0" xml:lang="en-US">Number of common stock issued, vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedVested" xlink:to="adtx_CommonStockIssuedVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CommonStockYieldsPercentage_lbl0" xml:lang="en-US">Common stock yields percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockYieldsPercentage" xlink:to="adtx_CommonStockYieldsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CreditAgreement_lbl0" xml:lang="en-US">Credit agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreement" xlink:to="adtx_CreditAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CreditAgreementAmendmentDescription_lbl0" xml:lang="en-US">Credit agreement amendment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreementAmendmentDescription" xlink:to="adtx_CreditAgreementAmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DebtInstrumentTermDescription_lbl0" xml:lang="en-US">Debt instrument term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtInstrumentTermDescription" xlink:to="adtx_DebtInstrumentTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DebtLoanAmount_lbl0" xml:lang="en-US">The amount of debt loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtLoanAmount" xlink:to="adtx_DebtLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DescriptionOfShareExchangeAgreement_lbl0" xml:lang="en-US">Description of share exchange agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DescriptionOfShareExchangeAgreement" xlink:to="adtx_DescriptionOfShareExchangeAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DilutiveEarningShares_lbl0" xml:lang="en-US">Dilutive Earning Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DilutiveEarningShares" xlink:to="adtx_DilutiveEarningShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl0" xml:lang="en-US">The amount of discount on convertible note payable from offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:to="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DisposalOfFixedAssets1_lbl0" xml:lang="en-US">Disposal of fixed assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DisposalOfFixedAssets1" xlink:to="adtx_DisposalOfFixedAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl0" xml:lang="en-US">Number of share exercise of warrants, modification of warrants, and issuance of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:to="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExercisePrice_lbl0" xml:lang="en-US">Every stock option has an exercise price, also called the strike price, which is the price at which a share can be bought.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePrice" xlink:to="adtx_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExercisePricePerShare_lbl0" xml:lang="en-US">Exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShare" xlink:to="adtx_ExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExercisePricePerShares_lbl0" xml:lang="en-US">Exercise price per shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShares" xlink:to="adtx_ExercisePricePerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FairMarketValue_lbl0" xml:lang="en-US">Fair market value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FairMarketValue" xlink:to="adtx_FairMarketValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FinancingOfFixedAssetLongTerm_lbl0" xml:lang="en-US">Financing of fixed asset - long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOfFixedAssetLongTerm" xlink:to="adtx_FinancingOfFixedAssetLongTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FinancingOnFixedAssets_lbl0" xml:lang="en-US">Financing on fixed assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FixedAsset_lbl0" xml:lang="en-US">Fixed Assets Value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAsset" xlink:to="adtx_FixedAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FixedAssets_lbl0" xml:lang="en-US">Fixed Assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssets" xlink:to="adtx_FixedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FixedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Fixed Assets Policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssetsPolicyTextBlock" xlink:to="adtx_FixedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_GoingConcernsDisclosureTextBlock_lbl0" xml:lang="en-US">Going concern disclosure text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernsDisclosureTextBlock" xlink:to="adtx_GoingConcernsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_GrantTotal_lbl0" xml:lang="en-US">Number of shares grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrantTotal" xlink:to="adtx_GrantTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_GrossProceed_lbl0" xml:lang="en-US">The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceed" xlink:to="adtx_GrossProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_GrossProceeds_lbl1" xml:lang="en-US">The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceeds" xlink:to="adtx_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl0" xml:lang="en-US">The amount of issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:to="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl0" xml:lang="en-US">The amount of issuance of restricted stock units for compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfRestrictedStockUnitsForCompensation" xlink:to="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl0" xml:lang="en-US">Issuance of shares for offerings, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForServicesinShares_lbl0" xml:lang="en-US">Number of share issuance of shares for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForServicesinShares" xlink:to="adtx_IssuanceOfSharesForServicesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl0" xml:lang="en-US">Issuance of shares for the settlement of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl0" xml:lang="en-US">Issuance of shares for vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_LeasesExpire_lbl0" xml:lang="en-US">Lease expiration date means the last day of the lease term, subject to any other date on which the lease is terminated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesExpire" xlink:to="adtx_LeasesExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_LicensingFeeForPatents_lbl0" xml:lang="en-US">Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetDeferredTaxAssets_lbl0" xml:lang="en-US">Net deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxAssets" xlink:to="adtx_NetDeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetDeferredTaxes_lbl0" xml:lang="en-US">Net deferred taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxes" xlink:to="adtx_NetDeferredTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetLossCashFlowFromOperatingActivities_lbl0" xml:lang="en-US">Net loss cash flow from operating activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetLossCashFlowFromOperatingActivities" xlink:to="adtx_NetLossCashFlowFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetOperatingLossCarryover_lbl0" xml:lang="en-US">Net operating loss carryover.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossCarryover" xlink:to="adtx_NetOperatingLossCarryover_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetOperatingLosse_lbl0" xml:lang="en-US">Net operating losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLosse" xlink:to="adtx_NetOperatingLosse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetOperatingLossesGeneratedPrior_lbl0" xml:lang="en-US">Net operating losses generated prior.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossesGeneratedPrior" xlink:to="adtx_NetOperatingLossesGeneratedPrior_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NoteReceivablesAndAccruedInterest_lbl0" xml:lang="en-US">Note receivable and accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NoteReceivablesAndAccruedInterest" xlink:to="adtx_NoteReceivablesAndAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Offering Costs Policy Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OfferingReflectingReducedExercisePricePerShare_lbl0" xml:lang="en-US">Per share of offering reflecting reduced exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingReflectingReducedExercisePricePerShare" xlink:to="adtx_OfferingReflectingReducedExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OperatingLeaseLiabilitiesLongTerm_lbl0" xml:lang="en-US">Operating lease liabilities long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesLongTerm" xlink:to="adtx_OperatingLeaseLiabilitiesLongTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OperatingLeaseLiabilitiesShortTerm_lbl0" xml:lang="en-US">Operating lease liabilities short term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesShortTerm" xlink:to="adtx_OperatingLeaseLiabilitiesShortTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl0" xml:lang="en-US">Operating Lease Liability Long Term Noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:to="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl0" xml:lang="en-US">Operating Lease Liability Short Term Current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:to="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OperatingLeasesLiabilityCurrent_lbl0" xml:lang="en-US">Present value of lessee&apos;s discounted obligation for lease payments from operating lease, classified as current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeasesLiabilityCurrent" xlink:to="adtx_OperatingLeasesLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl0" xml:lang="en-US">Original issuance discount on notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PatentsPolicyTextBlock_lbl0" xml:lang="en-US">Patents Policy Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PaymentOfMilestoneFees_lbl0" xml:lang="en-US">The amount of milestone fees payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PaymentOfMilestoneFees" xlink:to="adtx_PaymentOfMilestoneFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PermanentDifferencesOthers_lbl0" xml:lang="en-US">Permanent Differences/Others.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PermanentDifferencesOthers" xlink:to="adtx_PermanentDifferencesOthers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PreferredStockVotes_lbl0" xml:lang="en-US">Number of preferred stock votes in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockVotes" xlink:to="adtx_PreferredStockVotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PrefundedWarrantsShares_lbl0" xml:lang="en-US">Prefunded warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrefundedWarrantsShares" xlink:to="adtx_PrefundedWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PrincipalAmountPercentage_lbl0" xml:lang="en-US">Precentage of principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrincipalAmountPercentage" xlink:to="adtx_PrincipalAmountPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PromissoryNotes_lbl0" xml:lang="en-US">Amount of promissory notes may also be referred to as an IOU, a loan agreement, or just a note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PromissoryNotes" xlink:to="adtx_PromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PurchaseOfCommonStock_lbl0" xml:lang="en-US">Purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PurchaseOfEquityShares_lbl0" xml:lang="en-US">Purchase of equity shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RecognizedExpense_lbl0" xml:lang="en-US">The amount of recognized expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RecognizedExpense" xlink:to="adtx_RecognizedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl0" xml:lang="en-US">Number of shares redemption of series B preferred shares to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:to="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ReductionInExercisePriceOfWarrants_lbl0" xml:lang="en-US">The amount of reduction in exercise price of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ReductionInExercisePriceOfWarrants" xlink:to="adtx_ReductionInExercisePriceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl0" xml:lang="en-US">The amount of reset provision on warrants and modification of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:to="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RightOfUseAssetLongTerm_lbl0" xml:lang="en-US">Right of use asset &#8211; long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RightOfUseAssetShortTerm_lbl0" xml:lang="en-US">Right of use asset &#8211; short term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RightOfUseAssets_lbl0" xml:lang="en-US">Right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssets" xlink:to="adtx_RightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RoundingAdjustmentFromStockSplit_lbl0" xml:lang="en-US">Rounding adjustment from stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplit" xlink:to="adtx_RoundingAdjustmentFromStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RoundingAdjustmentFromStockSplitShares_lbl0" xml:lang="en-US">Rounding adjustment from stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplitShares" xlink:to="adtx_RoundingAdjustmentFromStockSplitShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty_lbl0" xml:lang="en-US">Sale of preference shares are company stock with dividends that are paid to shareholders before common stock dividends are paid out.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfPreferredSharesToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl0" xml:lang="en-US">The amount of sale of series B preferred shares to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl0" xml:lang="en-US">Number of shares sale of series B preferred shares to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_Section174Capitalization_lbl0" xml:lang="en-US">The Tax Cuts and Jobs Act of 2017 (TCJA) made a significant change to Section 174 that went into effect for taxable years beginning after December 31, 2021. The change completely eliminated the ability to currently deduct R&amp;E expenses. Instead, taxpayers must now capitalize and amortize these costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_Section174Capitalization" xlink:to="adtx_Section174Capitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl0" xml:lang="en-US">Settlement of accounts payable shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl0" xml:lang="en-US">Share based payment remnaining expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharesIssued1_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssued1" xlink:to="adtx_SharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl0" xml:lang="en-US">The amount of shares issued as inducement on loans, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl0" xml:lang="en-US">Number of shares shares issued as inducement on loans, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharesIssuedForIntangibleAssets_lbl0" xml:lang="en-US">Shares issued for intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedForIntangibleAssets" xlink:to="adtx_SharesIssuedForIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharesOfCommonStock_lbl0" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesOfCommonStock" xlink:to="adtx_SharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl0" xml:lang="en-US">Issuance of shares for vested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockOptionsShares_lbl0" xml:lang="en-US">Stock option exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionsShares" xlink:to="adtx_StockOptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_TotalDeferredTaxLiabilities_lbl0" xml:lang="en-US">Total deferred tax liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalDeferredTaxLiabilities" xlink:to="adtx_TotalDeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_TotalLeaseLiability_lbl0" xml:lang="en-US">Total lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalLeaseLiability" xlink:to="adtx_TotalLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_TotalProvisionForIncomeTaxesinDollars_lbl0" xml:lang="en-US">Total provision for income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalProvisionForIncomeTaxesinDollars" xlink:to="adtx_TotalProvisionForIncomeTaxesinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_TotalRightOfUseAsset_lbl0" xml:lang="en-US">Total right of use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalRightOfUseAsset" xlink:to="adtx_TotalRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ValuationAllowance" xlink:to="adtx_ValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_VestingExpense_lbl0" xml:lang="en-US">Vesting expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestingExpense" xlink:to="adtx_VestingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantExercisePrice_lbl0" xml:lang="en-US">Warrant exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantExercisePrice" xlink:to="adtx_WarrantExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantToPurchaseCommonShares_lbl0" xml:lang="en-US">Warrant To Purchase Common Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantToPurchaseCommonShares" xlink:to="adtx_WarrantToPurchaseCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantsExercisePrice_lbl0" xml:lang="en-US">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisePrice" xlink:to="adtx_WarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantsExercisedShares_lbl0" xml:lang="en-US">Warrants Exercised Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedShares" xlink:to="adtx_WarrantsExercisedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantsOfStockOptions_lbl0" xml:lang="en-US">Warrants Of Stock Options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsOfStockOptions" xlink:to="adtx_WarrantsOfStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl0" xml:lang="en-US">Weighted- Average Exercise Price, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceExpiredOrForfeited" xlink:to="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisePriceGranted_lbl0" xml:lang="en-US">Weighted- Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceGranted" xlink:to="adtx_WeightedAverageExercisePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl0" xml:lang="en-US">Price per share of weighted average exercise price rounding for reverse split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" xlink:to="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisesPriceVested_lbl0" xml:lang="en-US">Weighted- Average Exercise Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisesPriceVested" xlink:to="adtx_WeightedAverageExercisesPriceVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageRemainingLifeExercised_lbl0" xml:lang="en-US">Weighted Average Remaining Life Exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExercised" xlink:to="adtx_WeightedAverageRemainingLifeExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl0" xml:lang="en-US">Weighted Average Remaining Life, Expired or forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl0" xml:lang="en-US">Weighted average remaining Life, rounding for reverse split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:to="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl0" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:to="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_incomeLossOfGenerated_lbl0" xml:lang="en-US">Income loss  of Generated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_incomeLossOfGenerated" xlink:to="adtx_incomeLossOfGenerated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_sharesIssued1_lbl0" xml:lang="en-US">Number of shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_sharesIssued1" xlink:to="adtx_sharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_warrantIssued_lbl0" xml:lang="en-US">Number of share warrant issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_warrantIssued" xlink:to="adtx_warrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExercisePricePerShares_lbl1" xml:lang="en-US">Exercise Price Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShares" xlink:to="adtx_ExercisePricePerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SaleOfPreferredSharesToRelatedParty_lbl1" xml:lang="en-US">Sale Of Preferred Shares To Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfPreferredSharesToRelatedParty_lbl1"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesOfLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfMaturitiesOfLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="adtx_ScheduleOfMaturitiesOfLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl1" xml:lang="en-US">Reset Provision On Warrants And Modification Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:to="adtx_ResetProvisionOnWarrantsAndModificationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedemptionPremium_lbl0" xml:lang="en-US">Redemption Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SeriesCWarrantsMember_lbl0" xml:lang="en-US">Series CWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesCWarrantsMember" xlink:to="adtx_SeriesCWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RecognizedExpense_lbl1" xml:lang="en-US">Recognized Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RecognizedExpense" xlink:to="adtx_RecognizedExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OperatingLeaseLiabilitiesShortTerm_lbl1" xml:lang="en-US">Operating Lease Liabilities Short Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesShortTerm" xlink:to="adtx_OperatingLeaseLiabilitiesShortTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventory_lbl0" xml:lang="en-US">Public Utilities, Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventory" xlink:to="us-gaap_PublicUtilitiesInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsShares_lbl0" xml:lang="en-US">Preferred Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl1" xml:lang="en-US">Operating Lease Liability Short Term Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityShortTermCurrent" xlink:to="adtx_OperatingLeaseLiabilityShortTermCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl0" xml:lang="en-US">Other Payments to Acquire Businesses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalRightOfUseAsset_lbl1" xml:lang="en-US">Total Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalRightOfUseAsset" xlink:to="adtx_TotalRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl1" xml:lang="en-US">Discount On Convertible Note Payable From Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:to="adtx_DiscountOnConvertibleNotePayableFromOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0" xml:lang="en-US">Broadcasters License Agreement Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet_lbl0" xml:lang="en-US">Amortization of Deferred Loan Origination Fees, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" xlink:to="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectTaxesAndLicensesCosts_lbl0" xml:lang="en-US">Cost, Direct Tax and License</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectTaxesAndLicensesCosts" xlink:to="us-gaap_DirectTaxesAndLicensesCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract38" xlink:to="adtx_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract39" xlink:to="adtx_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl1" xml:lang="en-US">Original Issuance Discount On Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeMember_lbl0" xml:lang="en-US">Interest Income [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeMember" xlink:to="us-gaap_InterestIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExerciseOfWarrants_lbl1" xml:lang="en-US">Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract40" xlink:to="adtx_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GoingConcernsDisclosureTextBlock_lbl1" xml:lang="en-US">Going Concerns Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernsDisclosureTextBlock" xlink:to="adtx_GoingConcernsDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DebtInstrumentTermDescription_lbl1" xml:lang="en-US">Debt Instrument Term Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtInstrumentTermDescription" xlink:to="adtx_DebtInstrumentTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract43" xlink:to="adtx_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract44" xlink:to="adtx_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract41" xlink:to="adtx_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract42" xlink:to="adtx_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract47" xlink:to="adtx_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract48" xlink:to="adtx_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract45" xlink:to="adtx_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PrincipalAmount_lbl0" xml:lang="en-US">Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrincipalAmount" xlink:to="adtx_PrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract46" xlink:to="adtx_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableWithVariableRatesOfInterest1_lbl0" xml:lang="en-US">Loans Receivable with Variable Rates of Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithVariableRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithVariableRatesOfInterest1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RevenueAbstract_lbl0" xml:lang="en-US">Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RevenueAbstract" xlink:to="adtx_RevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LabEquipmentMember_lbl0" xml:lang="en-US">Lab Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LabEquipmentMember" xlink:to="adtx_LabEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract49" xlink:to="adtx_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_Section174Capitalization_lbl1" xml:lang="en-US">Section174 Capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_Section174Capitalization" xlink:to="adtx_Section174Capitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract50" xlink:to="adtx_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract51" xlink:to="adtx_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl1" xml:lang="en-US">Weighted Average Remaining Life Rounding For Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:to="adtx_WeightedAverageRemainingLifeRoundingForReverseSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract52" xlink:to="adtx_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl1" xml:lang="en-US">Weighted Average Exercise Price Rounding For Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceRoundingForReverseSplit" xlink:to="adtx_WeightedAverageExercisePriceRoundingForReverseSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0" xml:lang="en-US">Prepayment Fees on Advances, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_NY_lbl0" xml:lang="en-US">NEW YORK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NY" xlink:to="stpr_NY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NonvestedWarrantsMember_lbl0" xml:lang="en-US">Nonvested Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedWarrantsMember" xlink:to="adtx_NonvestedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract18" xlink:to="adtx_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract19" xlink:to="adtx_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract16" xlink:to="adtx_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl1" xml:lang="en-US">Weighteds Average Remaining Life Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:to="adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PatentsPolicyTextBlock_lbl1" xml:lang="en-US">Patents Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract17" xlink:to="adtx_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLoansPayable_lbl0" xml:lang="en-US">Other Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLoansPayable" xlink:to="us-gaap_OtherLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl0" xml:lang="en-US">Increase (Decrease) in Deposits Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DebtLoanAmount_lbl1" xml:lang="en-US">Debt Loan Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtLoanAmount" xlink:to="adtx_DebtLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract21" xlink:to="adtx_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract22" xlink:to="adtx_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract20" xlink:to="adtx_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract25" xlink:to="adtx_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract26" xlink:to="adtx_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract23" xlink:to="adtx_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract24" xlink:to="adtx_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract29" xlink:to="adtx_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfFixedAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfFixedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfFixedAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Fixed Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfFixedAssetsAbstract" xlink:to="adtx_ScheduleOfFixedAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract27" xlink:to="adtx_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract28" xlink:to="adtx_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExercisePricePerShare_lbl1" xml:lang="en-US">Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePricePerShare" xlink:to="adtx_ExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AdvancedCreditAgreement_lbl1" xml:lang="en-US">Advanced Credit Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AdvancedCreditAgreement" xlink:to="adtx_AdvancedCreditAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl0" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract32" xlink:to="adtx_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract33" xlink:to="adtx_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract30" xlink:to="adtx_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract31" xlink:to="adtx_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract36" xlink:to="adtx_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract37" xlink:to="adtx_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract34" xlink:to="adtx_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract35" xlink:to="adtx_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PaymentOfMilestoneFees_lbl1" xml:lang="en-US">Payment Of Milestone Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PaymentOfMilestoneFees" xlink:to="adtx_PaymentOfMilestoneFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PreferredStockVotes_lbl1" xml:lang="en-US">Preferred Stock Votes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockVotes" xlink:to="adtx_PreferredStockVotes_lbl1"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract_lbl" xml:lang="en-US">Schedule Of Analysis Of The Stock Option Grant Activity Under The Plan Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl1" xml:lang="en-US">Issuance Of Shares For Offerings Net Of Issuance Costs Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalDeferredTaxLiabilities_lbl1" xml:lang="en-US">Total Deferred Tax Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalDeferredTaxLiabilities" xlink:to="adtx_TotalDeferredTaxLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RestrictedStockAwardsMember_lbl0" xml:lang="en-US">Restricted Stock Awards Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RestrictedStockAwardsMember" xlink:to="adtx_RestrictedStockAwardsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl0" xml:lang="en-US">Prior Period Reclassification Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceGranted_lbl1" xml:lang="en-US">Weighted Average Exercise Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceGranted" xlink:to="adtx_WeightedAverageExercisePriceGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl0" xml:lang="en-US">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability_lbl0" xml:lang="en-US">Assets Sold under Agreements to Repurchase, Repurchase Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl2" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl1" xml:lang="en-US">Weighted Average Exercise Price Expired Or Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceExpiredOrForfeited" xlink:to="adtx_WeightedAverageExercisePriceExpiredOrForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract10" xlink:to="adtx_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract11" xlink:to="adtx_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract14" xlink:to="adtx_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract15" xlink:to="adtx_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract12" xlink:to="adtx_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract13" xlink:to="adtx_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl1" xml:lang="en-US">Issuance Of Shares For The Settlement Of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesIssuedForIntangibleAssets_lbl1" xml:lang="en-US">Shares Issued For Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedForIntangibleAssets" xlink:to="adtx_SharesIssuedForIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract2" xlink:to="adtx_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract1" xlink:to="adtx_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract4" xlink:to="adtx_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract3" xlink:to="adtx_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl0" xml:lang="en-US">Deferred Income Taxes and Tax Credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetLeases_lbl0" xml:lang="en-US">Net Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetLeases" xlink:to="adtx_NetLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract0" xlink:to="adtx_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract9" xlink:to="adtx_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss_lbl0" xml:lang="en-US">Securities Purchased under Agreements to Resell, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract6" xlink:to="adtx_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract5" xlink:to="adtx_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract8" xlink:to="adtx_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract7" xlink:to="adtx_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl1" xml:lang="en-US">Exercise Of Warrants Modification Of Warrants And Issuance Of Warrantsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:to="adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable_lbl0" xml:lang="en-US">Proceeds from Secured Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSecuredNotesPayable" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageRemainingLifeExercised_lbl1" xml:lang="en-US">Weighted Average Remaining Life Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExercised" xlink:to="adtx_WeightedAverageRemainingLifeExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl1" xml:lang="en-US">Sale Of Series BPreferred Shares To Related Party1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty1_lbl1"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfMaturitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfMaturitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfMaturitiesAbstract" xlink:to="adtx_ScheduleOfMaturitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl1" xml:lang="en-US">Offering Costs Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl0" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_VestingExpense_lbl1" xml:lang="en-US">Vesting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestingExpense" xlink:to="adtx_VestingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LeasesExpire_lbl1" xml:lang="en-US">Leases Expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LeasesExpire" xlink:to="adtx_LeasesExpire_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl0" xml:lang="en-US">Temporary Equity, Aggregate Amount of Redemption Requirement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_UnlabeledAbstract" xlink:to="adtx_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts_lbl0" xml:lang="en-US">Debt Discount From Warrant Consideration For Convertible Debt Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" xlink:to="adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessor, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl1" xml:lang="en-US">Shares Issued As Inducement On Loans Net Of Issuance Costsin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl0" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetOperatingLosse_lbl1" xml:lang="en-US">Net Operating Losse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLosse" xlink:to="adtx_NetOperatingLosse_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RightOfUseAssetLongTerm_lbl1" xml:lang="en-US">Right Of Use Asset Long Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AggregateOfferingPriceaAmount_lbl1" xml:lang="en-US">Aggregate Offering Pricea Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AggregateOfferingPriceaAmount" xlink:to="adtx_AggregateOfferingPriceaAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl0" xml:lang="en-US">Registration Payment Arrangement, Maximum Potential Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_VestedAndNonvestedStockOptionsMember_lbl0" xml:lang="en-US">Vested And Nonvested Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestedAndNonvestedStockOptionsMember" xlink:to="adtx_VestedAndNonvestedStockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_August2022WarrantsMember_lbl0" xml:lang="en-US">August2022 Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_August2022WarrantsMember" xlink:to="adtx_August2022WarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract_lbl" xml:lang="en-US">Schedule Of Lease Terms And Discount Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:to="adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl1" xml:lang="en-US">Shares Issued As Inducement On Loans Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:to="adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired_lbl0" xml:lang="en-US">Sale Leaseback Transaction, Other Payments Required</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" xlink:to="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockCash_lbl0" xml:lang="en-US">Dividends, Preferred Stock, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Recognition and Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual_lbl0" xml:lang="en-US">Loss Contingency Accrual, Product Liability, Net, Explanation of Material Change in Accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" xlink:to="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FixedAssetsPolicyTextBlock_lbl1" xml:lang="en-US">Fixed Assets Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssetsPolicyTextBlock" xlink:to="adtx_FixedAssetsPolicyTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GrossProceeds_lbl2" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceeds" xlink:to="adtx_GrossProceeds_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PercentageOfIncomeTaxable_lbl0" xml:lang="en-US">Percentage Of Income Taxable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PercentageOfIncomeTaxable" xlink:to="adtx_PercentageOfIncomeTaxable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsOfStockOptions_lbl1" xml:lang="en-US">Warrants Of Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsOfStockOptions" xlink:to="adtx_WarrantsOfStockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Analysis Of The Stock Option Grant Activity Under The Plan Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantToPurchaseCommonShares_lbl1" xml:lang="en-US">Warrant To Purchase Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantToPurchaseCommonShares" xlink:to="adtx_WarrantToPurchaseCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PrincipalAmountPercentage_lbl1" xml:lang="en-US">Principal Amount Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrincipalAmountPercentage" xlink:to="adtx_PrincipalAmountPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl1" xml:lang="en-US">Proceeds from (Repayments of) Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsExercisedShares_lbl1" xml:lang="en-US">Warrants Exercised Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedShares" xlink:to="adtx_WarrantsExercisedShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of Each Warrant Issued Was Estimated Using The Assumption Ranges And Or Factors In The Black Scholes Model Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract" xlink:to="adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl0" xml:lang="en-US">Time Deposits, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="us-gaap_TimeDepositsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_VestedAndNonvestedWarrantsMember_lbl0" xml:lang="en-US">Vested And Nonvested Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_VestedAndNonvestedWarrantsMember" xlink:to="adtx_VestedAndNonvestedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare_lbl0" xml:lang="en-US">InvestmentCompanyIssuanceOfSharesPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" xlink:to="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl0" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl1" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl1" xml:lang="en-US">Issuance Of Shares For Vested Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_IssuanceOfSharesForVestedRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LiabilityRecognizedForFinancedAssets_lbl0" xml:lang="en-US">Liability Recognized For Financed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilityRecognizedForFinancedAssets" xlink:to="adtx_LiabilityRecognizedForFinancedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl0" xml:lang="en-US">Product Liability Contingency, Third-Party Recovery, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FutureReceiptsAgreementMember_lbl1" xml:lang="en-US">Future Receipts Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FutureReceiptsAgreementMember" xlink:to="adtx_FutureReceiptsAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PermanentDifferencesOthers_lbl1" xml:lang="en-US">Permanent Differences Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PermanentDifferencesOthers" xlink:to="adtx_PermanentDifferencesOthers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OriginationOfNotesReceivableFromRelatedParties_lbl0" xml:lang="en-US">Origination of Notes Receivable from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_OriginationOfNotesReceivableFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl1" xml:lang="en-US">Redemption Of Series BPreferred Shares To Related Partyin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:to="adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl0" xml:lang="en-US">License Agreement Terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalIntangibleAssetsMember_lbl0" xml:lang="en-US">Total Intangible Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalIntangibleAssetsMember" xlink:to="adtx_TotalIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OperatingLeaseLiabilitiesLongTerm_lbl1" xml:lang="en-US">Operating Lease Liabilities Long Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilitiesLongTerm" xlink:to="adtx_OperatingLeaseLiabilitiesLongTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts_lbl0" xml:lang="en-US">Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" xlink:to="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PromissoryNotes_lbl1" xml:lang="en-US">Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PromissoryNotes" xlink:to="adtx_PromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender_lbl0" xml:lang="en-US">Bad Debt Reserve, Tax Purpose of Qualified Lender</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" xlink:to="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DescriptionOfShareExchangeAgreement_lbl1" xml:lang="en-US">Description Of Share Exchange Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DescriptionOfShareExchangeAgreement" xlink:to="adtx_DescriptionOfShareExchangeAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl1" xml:lang="en-US">Issuance Costs Related To Exercise Of Warrants Modification Of Warrants And Issuance Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:to="adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl0" xml:lang="en-US">CALIFORNIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ProprietaryTechnologyMember_lbl0" xml:lang="en-US">Proprietary Technology Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ProprietaryTechnologyMember" xlink:to="adtx_ProprietaryTechnologyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClearanceFees_lbl0" xml:lang="en-US">Clearance Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClearanceFees" xlink:to="us-gaap_ClearanceFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfIntangibleAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfIntangibleAssetsAbstract" xlink:to="adtx_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Zero One Seven Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_August2022FollowOnWarrantsMember_lbl0" xml:lang="en-US">August2022 Follow On Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_August2022FollowOnWarrantsMember" xlink:to="adtx_August2022FollowOnWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CreditAgreementAmendmentDescription_lbl1" xml:lang="en-US">Credit Agreement Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreementAmendmentDescription" xlink:to="adtx_CreditAgreementAmendmentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_sharesIssued1_lbl1" xml:lang="en-US">shares Issued1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_sharesIssued1" xlink:to="adtx_sharesIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetOperatingLossesGeneratedPrior_lbl1" xml:lang="en-US">Net Operating Losses Generated Prior</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossesGeneratedPrior" xlink:to="adtx_NetOperatingLossesGeneratedPrior_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerFunds_lbl0" xml:lang="en-US">Customer Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerFunds" xlink:to="us-gaap_CustomerFunds_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ComponentsOfTotalLeaseCostsAbstract_lbl0" xml:lang="en-US">Components Of Total Lease Costs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ComponentsOfTotalLeaseCostsAbstract" xlink:to="adtx_ComponentsOfTotalLeaseCostsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl1" xml:lang="en-US">Settlement Of Accounts Payable Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockOptionsShares_lbl1" xml:lang="en-US">Stock Options Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionsShares" xlink:to="adtx_StockOptionsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_incomeLossOfGenerated_lbl1" xml:lang="en-US">income Loss Of Generated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_incomeLossOfGenerated" xlink:to="adtx_incomeLossOfGenerated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl1" xml:lang="en-US">Stock Issued During Period Share Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="adtx_StockIssuedDuringPeriodShareStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl0" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance Of Shares For Offerings Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts" xlink:to="adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl0" xml:lang="en-US">Weighted Average Number of Shares, Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesAndLicenses_lbl0" xml:lang="en-US">Taxes and Licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesAndLicenses" xlink:to="us-gaap_TaxesAndLicenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetLossCashFlowFromOperatingActivities_lbl1" xml:lang="en-US">Net Loss Cash Flow From Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetLossCashFlowFromOperatingActivities" xlink:to="adtx_NetLossCashFlowFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0" xml:lang="en-US">Schedule of Subsequent Events [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisesPriceVested_lbl1" xml:lang="en-US">Weighted Average Exercises Price Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisesPriceVested" xlink:to="adtx_WeightedAverageExercisesPriceVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesIssued1_lbl1" xml:lang="en-US">Shares Issued1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssued1" xlink:to="adtx_SharesIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl1" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable_lbl0" xml:lang="en-US">Debt Discount From Warrants Issued With Convertible Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" xlink:to="adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PrefundedWarrantsShares_lbl1" xml:lang="en-US">Prefunded Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PrefundedWarrantsShares" xlink:to="adtx_PrefundedWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl0" xml:lang="en-US">Preferred Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OtherFixedAssetsMember_lbl0" xml:lang="en-US">Other Fixed Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OtherFixedAssetsMember" xlink:to="adtx_OtherFixedAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RoundingAdjustmentFromStockSplit_lbl1" xml:lang="en-US">Rounding Adjustment From Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplit" xlink:to="adtx_RoundingAdjustmentFromStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_InvestorPurchaseAmount_lbl0" xml:lang="en-US">Investor Purchase Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestorPurchaseAmount" xlink:to="adtx_InvestorPurchaseAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AggregateAmount_lbl0" xml:lang="en-US">Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AggregateAmount" xlink:to="adtx_AggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="sic_Z2520_lbl0" xml:lang="en-US">2520 Office Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sic_Z2520" xlink:to="sic_Z2520_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LicensingFeeForPatents_lbl1" xml:lang="en-US">Licensing Fee For Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantExercisePrice_lbl1" xml:lang="en-US">Warrant Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantExercisePrice" xlink:to="adtx_WarrantExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl0" xml:lang="en-US">Treasury Stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalLeaseLiability_lbl1" xml:lang="en-US">Total Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalLeaseLiability" xlink:to="adtx_TotalLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonStockYieldsPercentage_lbl1" xml:lang="en-US">Common Stock Yields Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockYieldsPercentage" xlink:to="adtx_CommonStockYieldsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageRemainingLifeGranted_lbl0" xml:lang="en-US">Weighted Average Remaining Life Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeGranted" xlink:to="adtx_WeightedAverageRemainingLifeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CompanyGranted_lbl0" xml:lang="en-US">Company Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CompanyGranted" xlink:to="adtx_CompanyGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockAwardForfeituresDividends_lbl0" xml:lang="en-US">Restricted Stock Award, Forfeitures, Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockAwardForfeituresDividends" xlink:to="us-gaap_RestrictedStockAwardForfeituresDividends_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Useful Lives Assigned To Fixed Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract" xlink:to="adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfWarrantyIssuanceAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfWarrantyIssuanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfWarrantyIssuanceAbstract_lbl" xml:lang="en-US">Schedule Of Warranty Issuance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfWarrantyIssuanceAbstract" xlink:to="adtx_ScheduleOfWarrantyIssuanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_weightedAverageGrant_lbl0" xml:lang="en-US">weighted Average Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_weightedAverageGrant" xlink:to="adtx_weightedAverageGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl1" xml:lang="en-US">Weighted Average Remaining Life Expired Or Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_WeightedAverageRemainingLifeExpiredOrForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule Of Lease Costs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfLeaseCostsAbstract" xlink:to="adtx_ScheduleOfLeaseCostsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl0" xml:lang="en-US">Other Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_lbl0" xml:lang="en-US">Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:to="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl1" xml:lang="en-US">Investment Company, Fee Paid Indirectly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0" xml:lang="en-US">Investment Owned, Balance, Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OtherExpenseAbstract_lbl0" xml:lang="en-US">Other Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OtherExpenseAbstract" xlink:to="adtx_OtherExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Public Utility Property, Plant, and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FixedAsset_lbl1" xml:lang="en-US">Fixed Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAsset" xlink:to="adtx_FixedAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ChangeInValuationAllowanceinDollars_lbl1" xml:lang="en-US">Change In Valuation Allowancein Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ChangeInValuationAllowanceinDollars" xlink:to="adtx_ChangeInValuationAllowanceinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RightOfUseAssets_lbl1" xml:lang="en-US">Right Of Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssets" xlink:to="adtx_RightOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FinancingOnFixedAssets_lbl1" xml:lang="en-US">Financing On Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsExercisePrice_lbl1" xml:lang="en-US">Warrants Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisePrice" xlink:to="adtx_WarrantsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FairMarketValue_lbl1" xml:lang="en-US">Fair Market Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FairMarketValue" xlink:to="adtx_FairMarketValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InformationTechnologyAndDataProcessing_lbl0" xml:lang="en-US">Information Technology and Data Processing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationTechnologyAndDataProcessing" xlink:to="us-gaap_InformationTechnologyAndDataProcessing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetDeferredTaxes_lbl1" xml:lang="en-US">Net Deferred Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxes" xlink:to="adtx_NetDeferredTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GrantTotal_lbl1" xml:lang="en-US">Grant Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrantTotal" xlink:to="adtx_GrantTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_VA_lbl0" xml:lang="en-US">VIRGINIA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_VA" xlink:to="stpr_VA_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl0" xml:lang="en-US">Sale Leaseback Transaction, Monthly Rental Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TIAllowanceReceivable_lbl0" xml:lang="en-US">TIAllowance Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TIAllowanceReceivable" xlink:to="adtx_TIAllowanceReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl0" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StanfordUniversityMember_lbl0" xml:lang="en-US">Stanford University Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StanfordUniversityMember" xlink:to="adtx_StanfordUniversityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl1" xml:lang="en-US">Sale Of Series BPreferred Shares To Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfSeriesBPreferredSharesToRelatedParty" xlink:to="adtx_SaleOfSeriesBPreferredSharesToRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesOfCommonStock_lbl1" xml:lang="en-US">Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesOfCommonStock" xlink:to="adtx_SharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to Officers or Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AmortizationOfIntangibleAsset_lbl1" xml:lang="en-US">Amortization Of Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AmortizationOfIntangibleAsset" xlink:to="adtx_AmortizationOfIntangibleAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DisposalOfFixedAssets1_lbl1" xml:lang="en-US">Disposal Of Fixed Assets1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DisposalOfFixedAssets1" xlink:to="adtx_DisposalOfFixedAssets1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NonvestedRSUsMember_lbl0" xml:lang="en-US">Nonvested RSUs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedRSUsMember" xlink:to="adtx_NonvestedRSUsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OfferingReflectingReducedExercisePricePerShare_lbl1" xml:lang="en-US">Offering Reflecting Reduced Exercise Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingReflectingReducedExercisePricePerShare" xlink:to="adtx_OfferingReflectingReducedExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare_lbl0" xml:lang="en-US">Auction Market Preferred Securities, Stock Series, Par Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl1" xml:lang="en-US">Operating Lease Liability Long Term Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeaseLiabilityLongTermNoncurrent" xlink:to="adtx_OperatingLeaseLiabilityLongTermNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalProvisionForIncomeTaxesinDollars_lbl1" xml:lang="en-US">Total Provision For Income Taxesin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalProvisionForIncomeTaxesinDollars" xlink:to="adtx_TotalProvisionForIncomeTaxesinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PurchaseOfEquityShares_lbl1" xml:lang="en-US">Purchase Of Equity Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsIssuedAndVesting_lbl0" xml:lang="en-US">Warrants Issued And Vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsIssuedAndVesting" xlink:to="adtx_WarrantsIssuedAndVesting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonStockIssuedVested_lbl1" xml:lang="en-US">Common Stock Issued Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedVested" xlink:to="adtx_CommonStockIssuedVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt_lbl0" xml:lang="en-US">Interest Expense, Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOtherLongTermDebt" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RestrictedStockUnitsMember_lbl0" xml:lang="en-US">Restricted Stock Units Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RestrictedStockUnitsMember" xlink:to="adtx_RestrictedStockUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Shares For Vested Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:to="adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions_lbl0" xml:lang="en-US">Restructuring, Settlement and Impairment Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:to="us-gaap_RestructuringSettlementAndImpairmentProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OriginalOfferingDiscountOnConvertibleNotePayable_lbl0" xml:lang="en-US">Original Offering Discount On Convertible Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalOfferingDiscountOnConvertibleNotePayable" xlink:to="adtx_OriginalOfferingDiscountOnConvertibleNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl0" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ValuationAllowance_lbl1" xml:lang="en-US">Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ValuationAllowance" xlink:to="adtx_ValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl1" xml:lang="en-US">Share Based Payment Remnaining Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl0" xml:lang="en-US">Dividends, Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DilutiveEarningShares_lbl1" xml:lang="en-US">Dilutive Earning Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DilutiveEarningShares" xlink:to="adtx_DilutiveEarningShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RightOfUseAssetShortTerm_lbl1" xml:lang="en-US">Right Of Use Asset Short Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GrossProceed_lbl1" xml:lang="en-US">Gross Proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GrossProceed" xlink:to="adtx_GrossProceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RoundingAdjustmentFromStockSplitShares_lbl1" xml:lang="en-US">Rounding Adjustment From Stock Split Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RoundingAdjustmentFromStockSplitShares" xlink:to="adtx_RoundingAdjustmentFromStockSplitShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FinancingOfFixedAssetLongTerm_lbl1" xml:lang="en-US">Financing Of Fixed Asset Long Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOfFixedAssetLongTerm" xlink:to="adtx_FinancingOfFixedAssetLongTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_warrantIssued_lbl1" xml:lang="en-US">warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_warrantIssued" xlink:to="adtx_warrantIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl0" xml:lang="en-US">Loans Receivable with Fixed Rates of Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ReductionInExercisePriceOfWarrants_lbl1" xml:lang="en-US">Reduction In Exercise Price Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ReductionInExercisePriceOfWarrants" xlink:to="adtx_ReductionInExercisePriceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PurchaseOfCommonStock_lbl1" xml:lang="en-US">Purchase Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OneYearMember_lbl0" xml:lang="en-US">One Year Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OneYearMember" xlink:to="adtx_OneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount_lbl0" xml:lang="en-US">Financial Guarantee Insurance Contracts, Accelerated Premium Revenue, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NonvestedStockOptionsMember_lbl0" xml:lang="en-US">Nonvested Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedStockOptionsMember" xlink:to="adtx_NonvestedStockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForServicesinShares_lbl1" xml:lang="en-US">Issuance Of Shares For Servicesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForServicesinShares" xlink:to="adtx_IssuanceOfSharesForServicesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl0" xml:lang="en-US">Principal Amount Outstanding on Loans Securitized or Asset-Backed Financing Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NoteReceivablesAndAccruedInterest_lbl1" xml:lang="en-US">Note Receivables And Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NoteReceivablesAndAccruedInterest" xlink:to="adtx_NoteReceivablesAndAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetDeferredTaxAssets_lbl1" xml:lang="en-US">Net Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetDeferredTaxAssets" xlink:to="adtx_NetDeferredTaxAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetOperatingLossCarryover_lbl1" xml:lang="en-US">Net Operating Loss Carryover</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossCarryover" xlink:to="adtx_NetOperatingLossCarryover_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl1" xml:lang="en-US">Issuance Of Restricted Stock Units For Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfRestrictedStockUnitsForCompensation" xlink:to="adtx_IssuanceOfRestrictedStockUnitsForCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of AReconciliation Of Income Tax Expense Benefit Computed At The Statutory Federal Income Tax Rate To Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FixedAssets_lbl1" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssets" xlink:to="adtx_FixedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl0" xml:lang="en-US">Payments for Commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CreditAgreement_lbl1" xml:lang="en-US">Credit Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CreditAgreement" xlink:to="adtx_CreditAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OperatingLeasesLiabilityCurrent_lbl1" xml:lang="en-US">Operating Leases Liability Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OperatingLeasesLiabilityCurrent" xlink:to="adtx_OperatingLeasesLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExercisePrice" xlink:to="adtx_ExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Rou Lease Assets And Lease Liabilities For Our Operating Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:to="adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_EstimatedUsefulLife_lbl0" xml:lang="en-US">Estimated Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_EstimatedUsefulLife" xlink:to="adtx_EstimatedUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>adtx-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 17 17:14:22 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ShareholdersEquityType2or3" roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_OrganizationandNatureofBusiness" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_GoingConcernAnalysis" roleURI="http://www.aditxt.com./role/GoingConcernAnalysis"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NoteReceivable" roleURI="http://www.aditxt.com./role/NoteReceivable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssets" roleURI="http://www.aditxt.com./role/FixedAssets"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssets" roleURI="http://www.aditxt.com./role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_RelatedPartyTransactions" roleURI="http://www.aditxt.com./role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NotesPayable" roleURI="http://www.aditxt.com./role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_Leases" roleURI="http://www.aditxt.com./role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_CommitmentsContingencies" roleURI="http://www.aditxt.com./role/CommitmentsContingencies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquity" roleURI="http://www.aditxt.com./role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxes" roleURI="http://www.aditxt.com./role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SubsequentEvents" roleURI="http://www.aditxt.com./role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_AccountingPoliciesByPolicy" roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssetsTables" roleURI="http://www.aditxt.com./role/FixedAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssetsTables" roleURI="http://www.aditxt.com./role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_LeasesTables" roleURI="http://www.aditxt.com./role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquityTables" roleURI="http://www.aditxt.com./role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxesTables" roleURI="http://www.aditxt.com./role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofusefullivesassignedtofixedassetsTable" roleURI="http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleoffixedassetsTable" roleURI="http://www.aditxt.com./role/ScheduleoffixedassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofintangibleassetsTable" roleURI="http://www.aditxt.com./role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofleasecostsTable" roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable" roleURI="http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofleasetermsanddiscountrateTable" roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofmaturitiesofleasesTable" roleURI="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofwarrantyissuanceTable" roleURI="http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" roleURI="http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable" roleURI="http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_OrganizationandNatureofBusinessDetails" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_GoingConcernAnalysisDetails" roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NoteReceivableDetails" roleURI="http://www.aditxt.com./role/NoteReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_FixedAssetsDetails" roleURI="http://www.aditxt.com./role/FixedAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IntangibleAssetsDetails" roleURI="http://www.aditxt.com./role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_RelatedPartyTransactionsDetails" roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_NotesPayableDetails" roleURI="http://www.aditxt.com./role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_LeasesDetails" roleURI="http://www.aditxt.com./role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_CommitmentsContingenciesDetails" roleURI="http://www.aditxt.com./role/CommitmentsContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_StockholdersEquityDetails" roleURI="http://www.aditxt.com./role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_IncomeTaxesDetails" roleURI="http://www.aditxt.com./role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#adtx_r_SubsequentEventsDetails" roleURI="http://www.aditxt.com./role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PublicUtilitiesInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAsset" xlink:href="adtx-20221231.xsd#adtx_FixedAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="FixedAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="RightOfUseAssetLongTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingOnFixedAssets" xlink:href="adtx-20221231.xsd#adtx_FinancingOnFixedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="FinancingOnFixedAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilityShortTermCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityShortTermCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityShortTermCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingOfFixedAssetLongTerm" xlink:href="adtx-20221231.xsd#adtx_FinancingOfFixedAssetLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="FinancingOfFixedAssetLongTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilityLongTermNoncurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilityLongTermNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="OperatingLeaseLiabilityLongTermNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueAbstract" xlink:href="adtx-20221231.xsd#adtx_RevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="RevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringSettlementAndImpairmentProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringSettlementAndImpairmentProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringSettlementAndImpairmentProvisions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpenseAbstract" xlink:href="adtx-20221231.xsd#adtx_OtherExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_OtherExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DividendsPreferredStock" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredClassBMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfRestrictedStockUnitsForCompensation" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfRestrictedStockUnitsForCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfRestrictedStockUnitsForCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForServicesinShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForServicesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForServicesinShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForVestedRestrictedStockUnits" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForVestedRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForVestedRestrictedStockUnits" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForTheSettlementOfDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfSeriesBPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SaleOfSeriesBPreferredSharesToRelatedParty" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfSeriesBPreferredSharesToRelatedParty1" xlink:href="adtx-20221231.xsd#adtx_SaleOfSeriesBPreferredSharesToRelatedParty1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SaleOfSeriesBPreferredSharesToRelatedParty1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" xlink:href="adtx-20221231.xsd#adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SharesIssuedAsInducementOnLoansNetOfIssuanceCosts" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResetProvisionOnWarrantsAndModificationOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ResetProvisionOnWarrantsAndModificationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ResetProvisionOnWarrantsAndModificationOfWarrants" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrants" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForOfferingsNetOfIssuanceCosts" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForOfferingsNetOfIssuanceCosts" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" xlink:href="adtx-20221231.xsd#adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoundingAdjustmentFromStockSplit" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RoundingAdjustmentFromStockSplit" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoundingAdjustmentFromStockSplitShares" xlink:href="adtx-20221231.xsd#adtx_RoundingAdjustmentFromStockSplitShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RoundingAdjustmentFromStockSplitShares" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalOfFixedAssets1" xlink:href="adtx-20221231.xsd#adtx_DisposalOfFixedAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DisposalOfFixedAssets1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="TIAllowanceReceivable" xlink:href="adtx-20221231.xsd#adtx_TIAllowanceReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="TIAllowanceReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NoteReceivablesAndAccruedInterest" xlink:href="adtx-20221231.xsd#adtx_NoteReceivablesAndAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NoteReceivablesAndAccruedInterest" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoteReceivablesAndAccruedInterest" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSecuredNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSecuredNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DiscountOnConvertibleNotePayableFromOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DiscountOnConvertibleNotePayableFromOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="DiscountOnConvertibleNotePayableFromOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfPreferredSharesToRelatedParty" xlink:href="adtx-20221231.xsd#adtx_SaleOfPreferredSharesToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SaleOfPreferredSharesToRelatedParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestExpenseOtherLongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalOfferingDiscountOnConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_OriginalOfferingDiscountOnConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="OriginalOfferingDiscountOnConvertibleNotePayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20221231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="OriginalIssuanceDiscountOnNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" xlink:href="adtx-20221231.xsd#adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20221231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="LiabilityRecognizedForFinancedAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReductionInExercisePriceOfWarrants" xlink:href="adtx-20221231.xsd#adtx_ReductionInExercisePriceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReductionInExercisePriceOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedForIntangibleAssets" xlink:href="adtx-20221231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SharesIssuedForIntangibleAssets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysis">
    <loc xlink:type="locator" xlink:label="GoingConcernsDisclosureAbstract" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GoingConcernsDisclosureTextBlock" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernsDisclosureAbstract" xlink:to="GoingConcernsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NoteReceivable">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesTable" xlink:href="adtx-20221231.xsd#adtx_LeasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesTable" xlink:to="LeasesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesLineItems" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/CommitmentsContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_ScheduleOfSubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssetsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_FixedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FixedAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OfferingCostsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsPolicyTextBlock" xlink:href="adtx-20221231.xsd#adtx_PatentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentsPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="adtx-20221231.xsd#adtx_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="sic_Z2520" xlink:href="https://xbrl.sec.gov/sic/2022/sic-2022.xsd#sic_Z2520"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="sic_Z2520" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherFixedAssetsMember" xlink:href="adtx-20221231.xsd#adtx_OtherFixedAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OtherFixedAssetsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleoffixedassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFixedAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfFixedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFixedAssetsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="adtx-20221231.xsd#adtx_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherFixedAssetsMember" xlink:href="adtx-20221231.xsd#adtx_OtherFixedAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OtherFixedAssetsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ProprietaryTechnologyMember" xlink:href="adtx-20221231.xsd#adtx_ProprietaryTechnologyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="ProprietaryTechnologyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalIntangibleAssetsMember" xlink:href="adtx-20221231.xsd#adtx_TotalIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="TotalIntangibleAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_LeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetShortTerm" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="RightOfUseAssetShortTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalRightOfUseAsset" xlink:href="adtx-20221231.xsd#adtx_TotalRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="TotalRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesShortTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesShortTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilitiesShortTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesLongTerm" xlink:href="adtx-20221231.xsd#adtx_OperatingLeaseLiabilitiesLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilitiesLongTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalLeaseLiability" xlink:href="adtx-20221231.xsd#adtx_TotalLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="TotalLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeasesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfMaturitiesOfLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesLiabilityCurrent" xlink:href="adtx-20221231.xsd#adtx_OperatingLeasesLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="OperatingLeasesLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:to="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="VestedAndNonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedStockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="VestedAndNonvestedStockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestedAndNonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_VestedAndNonvestedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="VestedAndNonvestedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonvestedRSUsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedRSUsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="NonvestedRSUsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLifeGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageRemainingLifeGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareStockOptionsExercised" xlink:href="adtx-20221231.xsd#adtx_StockIssuedDuringPeriodShareStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="StockIssuedDuringPeriodShareStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLifeExercised" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageRemainingLifeExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeExpiredOrForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageRemainingLifeExpiredOrForfeited" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHebsHyb1cEGeki8grP59tBne+FV85lwOdiuDZFiCaxzJLZvDOtie65v4Xr8ywkd3mvkdjAAnq0LwwVlEgRofe8cZOerCrPGvVHdk1JCBfs/kYLW+L9tQTy7JsReDC2UxO0CbthSlzm/SPwxPiOvEgx4KsPy3NCesRa3v3CE5aiK2vTfmav/7M] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceRoundingForReverseSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageExercisePriceRoundingForReverseSplit" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLifeRoundingForReverseSplit" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageRemainingLifeRoundingForReverseSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageRemainingLifeRoundingForReverseSplit" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedsAverageRemainingLifeOutstandingEndingBalance" xlink:href="adtx-20221231.xsd#adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedsAverageRemainingLifeOutstandingEndingBalance" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantyIssuanceAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfWarrantyIssuanceAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantyIssuanceAbstract" xlink:to="StockholdersEquityDetailsScheduleofwarrantyissuanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonvestedStockOptionsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedStockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="NonvestedStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonvestedWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_NonvestedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="NonvestedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofwarrantyissuanceTable" xlink:to="StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" xlink:href="adtx-20221231.xsd#adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceGranted" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="WeightedAverageExercisePriceGranted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisesPriceVested" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisesPriceVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="WeightedAverageExercisesPriceVested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExpiredOrForfeited" xlink:href="adtx-20221231.xsd#adtx_WeightedAverageExercisePriceExpiredOrForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="WeightedAverageExercisePriceExpiredOrForfeited" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract" xlink:to="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable" xlink:to="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PermanentDifferencesOthers" xlink:href="adtx-20221231.xsd#adtx_PermanentDifferencesOthers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="PermanentDifferencesOthers" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInValuationAllowanceinDollars" xlink:href="adtx-20221231.xsd#adtx_ChangeInValuationAllowanceinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract" xlink:to="ChangeInValuationAllowanceinDollars" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalProvisionForIncomeTaxesinDollars" xlink:href="adtx-20221231.xsd#adtx_TotalProvisionForIncomeTaxesinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInValuationAllowanceinDollars" xlink:to="TotalProvisionForIncomeTaxesinDollars" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20221231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="adtx-20221231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Section174Capitalization" xlink:href="adtx-20221231.xsd#adtx_Section174Capitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="Section174Capitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowance" xlink:href="adtx-20221231.xsd#adtx_ValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetDeferredTaxAssets" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAllowance" xlink:to="NetDeferredTaxAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssets" xlink:href="adtx-20221231.xsd#adtx_RightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="RightOfUseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssets" xlink:href="adtx-20221231.xsd#adtx_FixedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="FixedAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalDeferredTaxLiabilities" xlink:href="adtx-20221231.xsd#adtx_TotalDeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FixedAssets" xlink:to="TotalDeferredTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetDeferredTaxes" xlink:href="adtx-20221231.xsd#adtx_NetDeferredTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FixedAssets" xlink:to="NetDeferredTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandNatureofBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="OrganizationandNatureofBusinessDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentTermDescription" xlink:href="adtx-20221231.xsd#adtx_DebtInstrumentTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="DebtInstrumentTermDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="WarrantsExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="PurchaseOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShares" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="ExercisePricePerShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsShares" xlink:href="adtx-20221231.xsd#adtx_PrefundedWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="PrefundedWarrantsShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfEquityShares" xlink:href="adtx-20221231.xsd#adtx_PurchaseOfEquityShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="PurchaseOfEquityShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysisDetails">
    <loc xlink:type="locator" xlink:label="GoingConcernsDisclosureAbstract" xlink:href="adtx-20221231.xsd#adtx_GoingConcernsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossCashFlowFromOperatingActivities" xlink:href="adtx-20221231.xsd#adtx_NetLossCashFlowFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernsDisclosureAbstract" xlink:to="NetLossCashFlowFromOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernsDisclosureAbstract" xlink:to="us-gaap_InterestPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernsDisclosureAbstract" xlink:to="us-gaap_Cash" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerFunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernsDisclosureAbstract" xlink:to="us-gaap_CustomerFunds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingFeeForPatents" xlink:href="adtx-20221231.xsd#adtx_LicensingFeeForPatents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicensingFeeForPatents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOfStockOptions" xlink:href="adtx-20221231.xsd#adtx_WarrantsOfStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WarrantsOfStockOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DilutiveEarningShares" xlink:href="adtx-20221231.xsd#adtx_DilutiveEarningShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DilutiveEarningShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedShares" xlink:href="adtx-20221231.xsd#adtx_WarrantsExercisedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WarrantsExercisedShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockAwardForfeituresDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockAwardForfeituresDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedStockAwardForfeituresDividends" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NoteReceivableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_OtherLoansPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockYieldsPercentage" xlink:href="adtx-20221231.xsd#adtx_CommonStockYieldsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="CommonStockYieldsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfShareExchangeAgreement" xlink:href="adtx-20221231.xsd#adtx_DescriptionOfShareExchangeAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="DescriptionOfShareExchangeAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOnLoansSecuritized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansSecuritized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditAgreementAmendmentDescription" xlink:href="adtx-20221231.xsd#adtx_CreditAgreementAmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="CreditAgreementAmendmentDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancedCreditAgreement" xlink:href="adtx-20221231.xsd#adtx_AdvancedCreditAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="AdvancedCreditAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditAgreement" xlink:href="adtx-20221231.xsd#adtx_CreditAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="CreditAgreement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithVariableRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithVariableRatesOfInterest1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansReceivableWithVariableRatesOfInterest1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_IncomeTaxHolidayAggregateDollarAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtLoanAmount" xlink:href="adtx-20221231.xsd#adtx_DebtLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="DebtLoanAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/FixedAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TimeDepositsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimeDepositsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_TimeDepositsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IntangibleAssetsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfIntangibleAsset" xlink:href="adtx-20221231.xsd#adtx_AmortizationOfIntangibleAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="AmortizationOfIntangibleAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedUsefulLife" xlink:href="adtx-20221231.xsd#adtx_EstimatedUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="EstimatedUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockVotes" xlink:href="adtx-20221231.xsd#adtx_PreferredStockVotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PreferredStockVotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotes" xlink:href="adtx-20221231.xsd#adtx_PromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PromissoryNotes" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FutureReceiptsAgreementMember" xlink:href="adtx-20221231.xsd#adtx_FutureReceiptsAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FutureReceiptsAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="August2022WarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022WarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2022WarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2022FollowOnWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_August2022FollowOnWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2022FollowOnWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="NotesPayableDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="AggregateAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="adtx-20221231.xsd#adtx_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="GrossProceeds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_LegalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantToPurchaseCommonShares" xlink:href="adtx-20221231.xsd#adtx_WarrantToPurchaseCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="WarrantToPurchaseCommonShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="adtx-20221231.xsd#adtx_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="ExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmountPercentage" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmountPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="PrincipalAmountPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestorPurchaseAmount" xlink:href="adtx-20221231.xsd#adtx_InvestorPurchaseAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="InvestorPurchaseAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantExercisePrice" xlink:href="adtx-20221231.xsd#adtx_WarrantExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="WarrantExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmount" xlink:href="adtx-20221231.xsd#adtx_PrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="PrincipalAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedBalancePrincipalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalancePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedBalancePrincipalAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaymentFeesOnAdvancesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaymentFeesOnAdvancesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_PrepaymentFeesOnAdvancesNet" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnderlyingAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_UnderlyingAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="stpr_VA" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="stpr_CA" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis" xlink:to="stpr_NY" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NetLeases" xlink:href="adtx-20221231.xsd#adtx_NetLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="NetLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeasesExpire" xlink:href="adtx-20221231.xsd#adtx_LeasesExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="LeasesExpire" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/CommitmentsContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsContingenciesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsContingenciesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_CommitmentsContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsTable" xlink:to="CommitmentsContingenciesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesAndLicenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesAndLicenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_TaxesAndLicenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectTaxesAndLicensesCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DirectTaxesAndLicensesCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_DirectTaxesAndLicensesCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InformationTechnologyAndDataProcessing" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationTechnologyAndDataProcessing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_InformationTechnologyAndDataProcessing" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_CostMaintenance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleLeasebackTransactionOtherPaymentsRequired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_SaleLeasebackTransactionOtherPaymentsRequired" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfMilestoneFees" xlink:href="adtx-20221231.xsd#adtx_PaymentOfMilestoneFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="PaymentOfMilestoneFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClearanceFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClearanceFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_ClearanceFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsContingenciesDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StanfordUniversityMember" xlink:href="adtx-20221231.xsd#adtx_StanfordUniversityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="StanfordUniversityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCWarrantsMember" xlink:href="adtx-20221231.xsd#adtx_SeriesCWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockAwardsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockAwardsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="RestrictedStockAwardsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitsMember" xlink:href="adtx-20221231.xsd#adtx_RestrictedStockUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="RestrictedStockUnitsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OneYearMember" xlink:href="adtx-20221231.xsd#adtx_OneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20221231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoZeroOneSevenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedExpense" xlink:href="adtx-20221231.xsd#adtx_RecognizedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="RecognizedExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssued1" xlink:href="adtx-20221231.xsd#adtx_SharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SharesIssued1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfCommonStock" xlink:href="adtx-20221231.xsd#adtx_SharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SharesOfCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfAccountsPayableShares" xlink:href="adtx-20221231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="SettlementOfAccountsPayableShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="sharesIssued1" xlink:href="adtx-20221231.xsd#adtx_sharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="sharesIssued1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedemptionPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_RedemptionPremium" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyFeePaidIndirectly" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyFeePaidIndirectly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyFeePaidIndirectly" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendsShares" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValue" xlink:href="adtx-20221231.xsd#adtx_FairMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="FairMarketValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyGranted" xlink:href="adtx-20221231.xsd#adtx_CompanyGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CompanyGranted" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="weightedAverageGrant" xlink:href="adtx-20221231.xsd#adtx_weightedAverageGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="weightedAverageGrant" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsShares" xlink:href="adtx-20221231.xsd#adtx_StockOptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="StockOptionsShares" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_ExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ExercisePricePerShare" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20221231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="ShareBasedPaymentRemnainingExpenses" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="warrantIssued" xlink:href="adtx-20221231.xsd#adtx_warrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="warrantIssued" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedAndVesting" xlink:href="adtx-20221231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="WarrantsIssuedAndVesting" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="adtx-20221231.xsd#adtx_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="GrossProceeds" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingReflectingReducedExercisePricePerShare" xlink:href="adtx-20221231.xsd#adtx_OfferingReflectingReducedExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="OfferingReflectingReducedExercisePricePerShare" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingExpense" xlink:href="adtx-20221231.xsd#adtx_VestingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="VestingExpense" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantTotal" xlink:href="adtx-20221231.xsd#adtx_GrantTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="GrantTotal" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedVested" xlink:href="adtx-20221231.xsd#adtx_CommonStockIssuedVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockIssuedVested" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_InterestIncomeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossCarryover" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossCarryover"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="NetOperatingLossCarryover" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="incomeLossOfGenerated" xlink:href="adtx-20221231.xsd#adtx_incomeLossOfGenerated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="incomeLossOfGenerated" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLosse" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLosse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="NetOperatingLosse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossesGeneratedPrior" xlink:href="adtx-20221231.xsd#adtx_NetOperatingLossesGeneratedPrior"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="NetOperatingLossesGeneratedPrior" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LessorOperatingLeaseDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIncomeTaxable" xlink:href="adtx-20221231.xsd#adtx_PercentageOfIncomeTaxable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="PercentageOfIncomeTaxable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="adtx-20221231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RestatementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateOfferingPriceaAmount" xlink:href="adtx-20221231.xsd#adtx_AggregateOfferingPriceaAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregateOfferingPriceaAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd#us-gaap_InvestmentCompanyIssuanceOfSharesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyIssuanceOfSharesPerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceed" xlink:href="adtx-20221231.xsd#adtx_GrossProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="GrossProceed" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OriginationOfNotesReceivableFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OriginationOfNotesReceivableFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OriginationOfNotesReceivableFromRelatedParties" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredLoanOriginationFeesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_AmortizationOfDeferredLoanOriginationFeesNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="adtx-20221231.xsd#adtx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921925216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aditxt, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,832,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,923,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001726711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3204328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">737 N. Fifth Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">23219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">870-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">dbbmckennon<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921702624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 2,768,640<span></span>
</td>
<td class="nump">$ 7,872,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">527,961<span></span>
</td>
<td class="nump">89,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventory', window );">Inventory</a></td>
<td class="nump">950,093<span></span>
</td>
<td class="nump">494,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">496,869<span></span>
</td>
<td class="nump">460,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Note receivable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">4,743,563<span></span>
</td>
<td class="nump">9,416,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FixedAsset', window );">Fixed assets, net</a></td>
<td class="nump">2,318,863<span></span>
</td>
<td class="nump">2,267,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">107,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">355,366<span></span>
</td>
<td class="nump">379,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RightOfUseAssetLongTerm', window );">Right of use asset - long term</a></td>
<td class="nump">3,160,457<span></span>
</td>
<td class="nump">4,097,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred issuance costs</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">10,735,249<span></span>
</td>
<td class="nump">16,663,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,958,502<span></span>
</td>
<td class="nump">1,575,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FinancingOnFixedAssets', window );">Financing on fixed assets &#8211; current</a></td>
<td class="nump">409,983<span></span>
</td>
<td class="nump">700,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">188,581<span></span>
</td>
<td class="nump">186,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OperatingLeaseLiabilityShortTermCurrent', window );">Lease liability - current</a></td>
<td class="nump">1,086,658<span></span>
</td>
<td class="nump">1,145,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">3,643,724<span></span>
</td>
<td class="nump">3,607,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FinancingOfFixedAssetLongTerm', window );">Financing on fixed assets - long term</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">110,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OperatingLeaseLiabilityLongTermNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">1,885,218<span></span>
</td>
<td class="nump">2,765,933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">5,528,942<span></span>
</td>
<td class="nump">6,483,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 shares authorized, 4,307,487 and 890,614 shares issued and 4,305,470 and 888,579 shares outstanding, respectively</a></td>
<td class="nump">4,307<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 2,017 and 2,017 shares, respectively</a></td>
<td class="num">(201,605)<span></span>
</td>
<td class="num">(201,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">100,443,967<span></span>
</td>
<td class="nump">77,734,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(95,040,362)<span></span>
</td>
<td class="num">(67,352,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">5,206,307<span></span>
</td>
<td class="nump">10,180,773<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 10,735,249<span></span>
</td>
<td class="nump">$ 16,663,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FinancingOfFixedAssetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing of fixed asset - long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FinancingOfFixedAssetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FinancingOnFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing on fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FinancingOnFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FixedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Assets Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FixedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OperatingLeaseLiabilityLongTermNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Long Term Noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OperatingLeaseLiabilityLongTermNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OperatingLeaseLiabilityShortTermCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Short Term Current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OperatingLeaseLiabilityShortTermCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset &#8211; long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period end amount for a type of inventory held by the utility in a schedule of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921880256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,307,487<span></span>
</td>
<td class="nump">890,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,305,470<span></span>
</td>
<td class="nump">888,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595923198352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 933,715<span></span>
</td>
<td class="nump">$ 105,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">766,779<span></span>
</td>
<td class="nump">77,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">166,936<span></span>
</td>
<td class="nump">27,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, includes $1,516,805 and $3,927,551 in stock-based compensation, respectively</a></td>
<td class="nump">15,985,552<span></span>
</td>
<td class="nump">22,084,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, includes $591,518 and $713,130 in stock-based compensation, respectively</a></td>
<td class="nump">7,268,084<span></span>
</td>
<td class="nump">5,042,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales and marketing, includes $1,023,045, and $0 in stock-based compensation, respectively</a></td>
<td class="nump">1,849,460<span></span>
</td>
<td class="nump">334,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringSettlementAndImpairmentProvisions', window );">Impairment on notes receivable</a></td>
<td class="nump">543,938<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,647,034<span></span>
</td>
<td class="nump">41,961,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET LOSS FROM OPERATIONS</a></td>
<td class="num">(25,480,098)<span></span>
</td>
<td class="num">(41,934,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OtherExpenseAbstract', window );"><strong>OTHER EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="num">(753,038)<span></span>
</td>
<td class="num">(93,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">57,348<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">58,960<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,500,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="num">(1,533,048)<span></span>
</td>
<td class="num">(1,845,358)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total other expense</a></td>
<td class="num">(2,169,778)<span></span>
</td>
<td class="num">(4,436,436)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(27,649,876)<span></span>
</td>
<td class="num">(46,371,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(27,649,876)<span></span>
</td>
<td class="num">(46,371,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Implied Dividends</a></td>
<td class="num">(37,667)<span></span>
</td>
<td class="num">(102,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (27,612,199)<span></span>
</td>
<td class="num">$ (46,269,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (14.89)<span></span>
</td>
<td class="num">$ (121.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding during the year - basic and diluted (in Shares)</a></td>
<td class="nump">1,854,724<span></span>
</td>
<td class="nump">381,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OtherExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OtherExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringSettlementAndImpairmentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restructuring charges, remediation cost, and asset impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringSettlementAndImpairmentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921201392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,131,368<span></span>
</td>
<td class="nump">$ 4,640,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (14.89)<span></span>
</td>
<td class="num">$ (121.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding during the year - basic and diluted (in Shares) (in Shares)</a></td>
<td class="nump">1,854,724<span></span>
</td>
<td class="nump">381,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,516,805<span></span>
</td>
<td class="nump">$ 3,927,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">591,518<span></span>
</td>
<td class="nump">713,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,023,045<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917928672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred </div>
<div>Preferred Shares</div>
</th>
<th class="th"><div>Preferred Shares</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="num">$ (201,605)<span></span>
</td>
<td class="nump">$ 32,092,003<span></span>
</td>
<td class="num">$ (20,879,178)<span></span>
</td>
<td class="nump">$ 11,011,482<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">259,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock option and warrant compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,016,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForServicesinShares', window );">Issuance of shares for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of shares for employee compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of shares for employee compensation (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits', window );">Issuance of shares for vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForVestedRestrictedStockUnits', window );">Issuance of shares for vested restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForTheSettlementOfDebt', window );">Issuance of shares for the conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,749,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,749,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares for the conversion of debt (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Fair value of warrants issued with convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares for debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,727,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,727,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,843,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,843,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of shares and warrants for offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,123,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,123,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares and warrants for offering, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts', window );">Issuance of shares for offerings, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,744,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,745,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares', window );">Issuance of shares for offerings, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant consideration for convertible debt offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Reduction in exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,267<span></span>
</td>
<td class="num">(102,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,371,364)<span></span>
</td>
<td class="num">(46,371,364)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 899<span></span>
</td>
<td class="num">(201,605)<span></span>
</td>
<td class="nump">77,734,288<span></span>
</td>
<td class="num">(67,352,809)<span></span>
</td>
<td class="nump">10,180,773<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">888,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock option and warrant compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfRestrictedStockUnitsForCompensation', window );">Issuance of restricted stock units for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units for compensation (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507,408<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceOfSharesForServicesinShares', window );">Issuance of shares for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Exercise of warrants, modification of warrants, and issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,203,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,203,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares', window );">Exercise of warrants, modification of warrants, and issuance of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SaleOfSeriesBPreferredSharesToRelatedParty', window );">Sale of Series B Preferred shares to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SaleOfSeriesBPreferredSharesToRelatedParty1', window );">Sale of Series B Preferred shares to related party (in Shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Redemption of Series B Preferred shares to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares', window );">Redemption of Series B Preferred shares to related party (in Shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts', window );">Shares issued as inducement on loans, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares', window );">Shares issued as inducement on loans, net of issuance costs (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">47,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ResetProvisionOnWarrantsAndModificationOfWarrants', window );">Reset provision on warrants and modification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,677<span></span>
</td>
<td class="num">(37,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of shares for debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of shares for debt issuance costs (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of shares and warrants for offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,232,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,233,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares and warrants for offering, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants', window );">Issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for settlement of AP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for settlement of AP (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RoundingAdjustmentFromStockSplit', window );">Rounding from reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RoundingAdjustmentFromStockSplitShares', window );">Rounding from reverse stock split (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,649,876)<span></span>
</td>
<td class="num">(27,649,876)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,307<span></span>
</td>
<td class="num">$ (201,605)<span></span>
</td>
<td class="nump">$ 100,443,967<span></span>
</td>
<td class="num">$ (95,040,362)<span></span>
</td>
<td class="nump">$ 5,206,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,305,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share exercise of warrants, modification of warrants, and issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfRestrictedStockUnitsForCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of restricted stock units for compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfRestrictedStockUnitsForCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for offerings, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForServicesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share issuance of shares for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForServicesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForTheSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for the settlement of debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForTheSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for vested restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares redemption of series B preferred shares to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ResetProvisionOnWarrantsAndModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reset provision on warrants and modification of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ResetProvisionOnWarrantsAndModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RoundingAdjustmentFromStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rounding adjustment from stock split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RoundingAdjustmentFromStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RoundingAdjustmentFromStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rounding adjustment from stock split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RoundingAdjustmentFromStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SaleOfSeriesBPreferredSharesToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of series B preferred shares to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SaleOfSeriesBPreferredSharesToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SaleOfSeriesBPreferredSharesToRelatedParty1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares sale of series B preferred shares to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SaleOfSeriesBPreferredSharesToRelatedParty1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued as inducement on loans, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares shares issued as inducement on loans, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for vested restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921567328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (27,649,876)<span></span>
</td>
<td class="num">$ (46,371,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,131,368<span></span>
</td>
<td class="nump">4,640,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">428,977<span></span>
</td>
<td class="nump">369,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">107,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount</a></td>
<td class="nump">1,533,048<span></span>
</td>
<td class="nump">1,845,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Impairment on notes receivable</a></td>
<td class="nump">543,938<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DisposalOfFixedAssets1', window );">Disposal of fixed assets</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(36,767)<span></span>
</td>
<td class="num">(312,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">23,884<span></span>
</td>
<td class="num">(306,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositsOutstanding', window );">Deposits</a></td>
<td class="num">(438,117)<span></span>
</td>
<td class="num">(89,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(455,396)<span></span>
</td>
<td class="num">(494,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">412,959<span></span>
</td>
<td class="nump">1,333,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,392,006)<span></span>
</td>
<td class="num">(22,278,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Purchase of fixed assets</a></td>
<td class="num">(367,079)<span></span>
</td>
<td class="num">(1,015,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_TIAllowanceReceivable', window );">Tenant improvement allowance receivable</a></td>
<td class="nump">125,161<span></span>
</td>
<td class="num">(287,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NoteReceivablesAndAccruedInterest', window );">Notes receivable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(15,002,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(241,918)<span></span>
</td>
<td class="num">(16,305,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredNotesPayable', window );">Proceeds from note payable - related party</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of note payable - related party</a></td>
<td class="num">(80,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DiscountOnConvertibleNotePayableFromOfferingCosts', window );">Proceeds from notes and convertible notes payable, net of offering costs</a></td>
<td class="nump">2,795,000<span></span>
</td>
<td class="nump">4,473,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Repayments of notes and convertible notes payable</a></td>
<td class="num">(3,206,887)<span></span>
</td>
<td class="num">(315,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SaleOfPreferredSharesToRelatedParty', window );">Sale of Series B Preferred shares to related party</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Redemption of Series B Preferred shares to related party</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock and warrants issued for cash, net of issuance costs</a></td>
<td class="nump">17,233,307<span></span>
</td>
<td class="nump">29,868,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants, net of offering costs</a></td>
<td class="nump">1,109,574<span></span>
</td>
<td class="nump">3,727,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments on financing on fixed asset</a></td>
<td class="num">(400,491)<span></span>
</td>
<td class="num">(598,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Cash paid on extinguishment of note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,530,503<span></span>
</td>
<td class="nump">35,954,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH</a></td>
<td class="num">(5,103,421)<span></span>
</td>
<td class="num">(2,628,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT BEGINNING OF YEAR</a></td>
<td class="nump">7,872,061<span></span>
</td>
<td class="nump">10,500,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT END OF YEAR</a></td>
<td class="nump">2,768,640<span></span>
</td>
<td class="nump">7,872,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherLongTermDebt', window );">Cash paid for interest expense</a></td>
<td class="nump">753,038<span></span>
</td>
<td class="nump">15,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OriginalOfferingDiscountOnConvertibleNotePayable', window );">Issuance of shares for the settlement of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,749,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liability recognized from right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,131,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares for the settlement of accounts payable</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OriginalIssuanceDiscountOnNotesPayable', window );">Original offering discount on convertible note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable', window );">Debt discount from warrants issued with convertible note payable</a></td>
<td class="nump">878,622<span></span>
</td>
<td class="nump">1,322,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts', window );">Debt discount from warrant consideration for convertible debt offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">231,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Debt discount from shares issued as inducement for convertible note payable</a></td>
<td class="nump">146,522<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LiabilityRecognizedForFinancedAssets', window );">Liability recognized for financed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">821,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ReductionInExercisePriceOfWarrants', window );">Reduction in exercise price of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">102,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesIssuedForIntangibleAssets', window );">Shares issued for debt offering costs</a></td>
<td class="nump">96,030<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Warrant modification</a></td>
<td class="nump">37,677<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred issuance costs</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DiscountOnConvertibleNotePayableFromOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of discount on convertible note payable from offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DiscountOnConvertibleNotePayableFromOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DisposalOfFixedAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal of fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DisposalOfFixedAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LiabilityRecognizedForFinancedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LiabilityRecognizedForFinancedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NoteReceivablesAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note receivable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NoteReceivablesAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OriginalIssuanceDiscountOnNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original issuance discount on notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OriginalIssuanceDiscountOnNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OriginalOfferingDiscountOnConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OriginalOfferingDiscountOnConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ReductionInExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reduction in exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ReductionInExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SaleOfPreferredSharesToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of preference shares are company stock with dividends that are paid to shareholders before common stock dividends are paid out.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SaleOfPreferredSharesToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesIssuedForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesIssuedForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TIAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TIAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595925011616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND NATURE OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; ORGANIZATION AND NATURE OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Company Background</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotech innovation company with a mission
of prolonging life and enhancing its quality by improving the health of the immune system. We are an innovation company developing and
commercializing technologies with a focus on monitoring and modulating the immune system. Our immune reprogramming technologies are currently
at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection
of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technologies are designed to provide a personalized
comprehensive profile of the immune system and we plan to utilize them in our upcoming reprogramming clinical trials to monitor subjects&#8217;
immune response before, during and after drug administration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reverse Stock Split</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 13, 2022, the Company effectuated
a 1 for 50 reverse stock split (the &#8220;Reverse Split&#8221;). The Company&#8217;s stock began trading on a split-adjusted basis effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#8217;s common
stock. All shares amounts referenced in this report are adjusted to reflect the Reverse Split.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Offerings</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2021, the Company completed a registered
direct offering (&#8220;August 2021 Offering&#8221;). In connection therewith, the Company issued&#160;91,667&#160;shares of common stock,
at a purchase price of $120.00&#160;per share, resulting in gross proceeds of approximately $11.0&#160;million. In a concurrent private
placement, the Company issued warrants to purchase up to&#160;91,667&#160;shares.&#160;The warrants have an exercise price of $126.50&#160;per
share and are exercisable for a&#160;five-year&#160;period commencing six months from the date of issuance.&#160;The warrants exercise
price was subsequently repriced to $75.00. In addition, the Company issued a warrant to the placement agent to purchase up to&#160;4,584&#160;shares
of common stock at an exercise price of $150.00&#160;per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2021, the Company entered into
an underwriting agreement with Revere Securities LLC, relating to the public offering (the &#8220;October 2021 Offering&#8221;) of&#160;56,667&#160;shares
of the Company&#8217;s common stock (the &#8220;Shares&#8221;) by the Company. The Shares were offered, issued, and sold at a price to
the public of $75.00&#160;per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective
shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13,
2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25&#160;million. The Company utilized a portion of
the proceeds, net of underwriting discounts of approximately $3.91&#160;million from the October 2021 Offering to fund certain obligations
under the Credit Agreement. (See Note 4)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 6, 2021, the Company completed a public
offering for net proceeds of $16.0&#160;million (the &#8220;December 2021 Offering&#8221;). As part of the December 2021 Offering, we
issued&#160;164,929&#160;units consisting of shares of the Company&#8217;s common stock and warrant to purchase shares of the Company&#8217;s
common stock and&#160;166,572&#160;prefunded warrants. The warrant issued as part of the units had an exercise price of $57.50&#160;and
the prefunded warrants had an exercise price of $0.001. On June 15, 2022, the Company entered an agreement with a holder of certain warrants
in the December 2021 Offering. (See Note 11)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2022, the Company completed a
public offering for net proceeds of $17.2&#160;million (the &#8220;September 2022 Offering&#8221;). As part of the September 2022 Offering,
we issued&#160;1,224,333 of shares of the Company&#8217;s common stock, pre-funded warrants to purchase 2,109,000 shares of common stock,
and warrants to purchase 3,333,333 shares of the Company&#8217;s common stock. The warrants had an exercise price of $6.00&#160;and the
pre-funded warrants had an exercise price of $0.001.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a limited operating history and
is in the very early stages of generating revenue from intended operations. The Company&#8217;s business and operations are sensitive
to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions.
A host of factors beyond the Company&#8217;s control could cause fluctuations in these conditions. Adverse conditions may include: changes
in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for
clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These
adverse conditions could affect the Company&#8217;s financial condition and the results of its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &#8220;Public Health Emergency of
International Concern&#8221; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the
spread of the coronavirus included restrictions on travel, and quarantines in certain areas, and forced closures for certain types of
public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had an adverse impact on the economies and
financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these
conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts
and additional development of our technologies may be negatively affected.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595924791632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern Analysis<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GoingConcernsDisclosureAbstract', window );"><strong>Going Concern Analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GoingConcernsDisclosureTextBlock', window );">GOING CONCERN ANALYSIS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; GOING CONCERN ANALYSIS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management Plans</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated on September 28,
2017 and has not generated significant revenues to date. During the year ended December 31, 2022, the Company had a net loss of $27,649,876&#160;and
negative cash flow from operating activities of $22,049,040. As of December 31, 2022, the Company&#8217;s cash balance was $2,768,640.
As of December 31, 2022, the Company had $51.5&#160;million of&#160;remaining availability, subject to regulatory requirements, to raise
future funds pursuant to an effective shelf registration statement filed with the SEC on Form S-3 declared effective on July 13, 2021.
However, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely
affect the Company&#8217;s ability to raise capital in an efficient manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the shelf registration, the Company
has the ability to raise capital from equity of debt through private placements or public offerings pursuant to a registration statement
on Form S-1. We may also secure loans from related parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of these factors, the Company believes
that this creates substantial doubt with the Company&#8217;s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements included in this report
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the matters discussed herein. The Company&#8217;s ability to continue as a going
concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to
control operating expenses. In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances,
and other initiatives to strengthen the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140596007421536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and
the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the
reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include
the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair
value of stock options and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements and Fair Value of
Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not identify any assets or liabilities
that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the short-term nature of all financial
assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash accounts at financial
institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally
insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all the Company&#8217;s accounts
receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk
is mitigated due to the Company&#8217;s number of customers. In addition, for receivables due from U.S government agencies, the Company
does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and
payment is primarily dependent upon submitting the appropriate documentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include short-term,
liquid investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of laboratory materials and
supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable
value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets are stated at cost less accumulated
depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs
are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are
removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the
straight-line method over the estimated useful lives or lease life of the related assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Useful lives assigned to fixed assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three years to five years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab Equipment</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Furniture</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other fixed assets</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of estimated useful life or remaining lease term</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are stated at cost less accumulated
amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated
useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable and Allowance for Doubtful
Accounts</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are stated at the amount management
expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company
determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management.
As of December 31, 2022 and 2021, there was an allowance for doubtful accounts of $18,634&#160;and&#160;zero, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offering costs incurred in connection with equity are recorded as a
reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606 (Revenue From Contracts
with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects
the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle,
the Company applies the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the contract with a customer</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determine the transaction price</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocate the transaction price to performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize revenue when or as the Company satisfies a performance obligation</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues reported from services relating to the
AditxtScore&#8482; are recognized when the AditxtScore<sup>TM </sup>report is delivered to the customer. The services performed include
the analysis of specimens received in the Company&#8217;s CLIA laboratory and the generation of results which are then delivered upon
completion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in the following
manner for the following types of customers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client Payers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client payers include physicians or other entities
for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for
client payers based on historical collection experience and the period of time the receivable has been outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Pay:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Customers are billed based on established patient
fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the
ability of the patients to pay.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insurance:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursements from healthcare insurers are based
on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between
amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of
the Company&#8217;s contractual arrangements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Topic 842 (Leases), operating lease expense
is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space,
and lab equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases with an initial term of twelve months or
less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right
of use (&#8220;ROU&#8221;) assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
costs under the provisions of ASC 718, Compensation&#8212;Stock Compensation, which requires the measurement and recognition of compensation
expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense
recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant
date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled
during the periods reported. Stock-based compensation is recognized as expense over the employee&#8217;s requisite vesting period and
over the nonemployee&#8217;s period of providing goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurs fees from patent licenses,
which is reflected in research and development expenses, and are expensed as incurred. During the years ended December 31, 2022 and 2021,
the Company incurred patent licensing fees for the patents of $263,273&#160;and $76,455, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incur research and development costs during
the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs
qualify for capitalization under applicable guidance. During the years ended December 31, 2022 and 2021, the Company incurred research
and development costs of $7,268,084 and $5,042,617, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Net Loss per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per common share is computed by dividing the net loss by
the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the
net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect
of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock
equivalents because their inclusion would be anti-dilutive. As of December 31, 2022,&#160;44,710&#160;stock options,&#160;7,197&#160;unvested&#160;restricted
stock units, and&#160;5,090,024&#160;warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of
December 31, 2021,&#160;44,710&#160;stock options, 15,565 unvested restricted stock units and&#160;601,399&#160;warrants were excluded
from dilutive earnings per share as their effects were anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and 2021,
the Company recognized an implied dividend from the modification of warrants of $37,667 and $102,267, respectively. Theses implied dividends
resulted in an increase in the net loss attributable to common stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB issues ASUs to amend the authoritative
literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes
that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or
(iv) are not expected to have a significant impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140596007336512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">NOTE RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; NOTE RECEIVABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cellvera Global Note Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2021, the Company entered into a
letter of intent (&#8220;the LOI&#8221;) to acquire AiPharma Global Holdings LLC, a Delaware limited liability company, which subsequently
changed its name to Cellvera Global Holdings LLC (&#8220;Cellvera Global&#8221;) which is commercializing COVID-19 antiviral oral therapy.
Key terms of the proposed transaction as stated in the Letter of Intent included: the completion of a proposed $6.5&#160;million secured
loan from the Company to Cellvera Global by August 31, 2021, as well as the issuance of such number of shares of the Company&#8217;s common
stock that yields&#160;50% of the number of the Company&#8217;s outstanding shares post-closing of the transaction. The acquisition is
subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive
agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed
to be issued in the transaction. The Company and Cellvera Global agreed to an exclusivity period until September 30, 2021 (the &#8220;Exclusivity
Period&#8221;), with a view to settling the definitive agreement. On September 30, 2021, the parties entered into a letter agreement pursuant
to which they agreed to extend the Exclusivity Period until October 4, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2021, we entered into a Share
Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued and outstanding
equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of
$250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5%
of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and
a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.&#160;Additionally,
we may elect to raise additional capital due to market conditions or strategic considerations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the contemplated acquisition
with Cellvera Global,&#160;the Company entered into a secured credit agreement dated August 27, 2021 (the &#8220;Credit Agreement&#8221;)
with Cellvera Global and certain affiliated entities (collectively, the &#8220;Borrower&#8221;), pursuant to which the Company made a
secured loan to Cellvera Global in the principal amount of $6.5&#160;million (the &#8220;Loan&#8221;). The Loan was funded on August 31,
2021, following the closing of the Company&#8217;s August 2021 Offering. The Loan bears interest at a rate of&#160;8% per annum and matured
on November 30, 2021. The Loan is secured by certain accounts receivable and other assets of Cellvera Global and certain of its affiliates.
The Credit Agreement also contains certain covenants that prohibit Cellvera Global from incurring additional indebtedness, incurring liens
or making any dispositions of its property.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2021,&#160;the Company entered
into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the &#8220;Credit Agreement Amendment&#8221;),
pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by
$8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment.
The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the
Company from the exercise of existing warrants or any other capital raises, including the October Offering.&#160;As of December 31, 2021,
an additional $8.0&#160;million was advanced under the Credit Agreement for a total of $14.5&#160;million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Credit Agreement was amended on multiple occasions,
for which the final amendment was signed on December 31, 2021, extending the Loan&#8217;s maturity date to January 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that Cellvera Global may
not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of $14.5&#160;million as of December
31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forbearance Agreement:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2022, the Company&#8217;s $14.5&#160;million
loan to Cellvera Global became fully due and payable under the Credit Agreement. On February 14, 2022, the Company entered into a Forbearance
Agreement and Seventh Amendment to Credit Agreement (the &#8220;Forbearance Agreement&#8221;) with Cellvera Global.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Forbearance Agreement, the Company
agreed to forbear from exercising its rights and remedies against Cellvera Global and certain affiliated guarantor parties until the earlier
of (i) June 30, 2022 or (ii) the date of occurrence of any event of default under the Forbearance Agreement (the &#8220;Forbearance Period&#8221;).
Given that the parties continue to conduct due diligence in connection with the Share Exchange Agreement, the Company and Cellvera Global
also agreed that should the initial closing occur under the Share Exchange Agreement, the existing event of default will be waived. Under
the Forbearance Agreement, the Company and Cellvera Global also agreed to certain amendments to the Credit Agreement, including, but not
limited to: (i) the delivery by the Borrower of certain financial statements and forecasts, and (ii) certain regularly scheduled payments
to be made by Cellvera Global to the Company during the Forbearance Period. As of the date of filing of this Quarterly Report, the regularly
scheduled payments under the Forbearance Agreement have not been made, and the note receivable remains fully impaired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2022, the Company and Cellvera Global
entered into a Forbearance Agreement and Eighth Amendment to the Credit Agreement (the &#8220;April Forbearance Agreement&#8221;) pursuant
to which among other things (i) the Company agreed to extend the forbearance period until the earlier of March 31, 2023 or the date of
occurrence of any event of default under the April Forbearance Agreement, (ii) Cellvera Global shall be permitted to factor certain receivables,
and (iii) certain conforming changes were made relating to the Revenue Sharing Agreement (as defined below). In connection with the Forbearance
Agreement, the Company entered into a series of security agreements with Cellvera Global (the &#8220;Security Agreements&#8221;) and certain
affiliated entities pursuant to which Cellvera Global enhanced the Company&#8217;s security interest in connection with the Credit Agreement.
In addition, and as a condition to entering into the April Forbearance Agreement, the Company required that Cellvera Global enter into
a Revenue Sharing Agreement (the &#8220;Revenue Sharing Agreement&#8221;), pursuant to which, among other things, Cellvera Global agreed
to pay the Company a certain portion of its revenues up to the aggregate amount of $30&#160;million. As of the date of filing of this
Annual Report, the Company has not received any payments from Cellvera Global pursuant to the Revenue Sharing Agreement. Upon termination
of the April Forbearance agreement, the amounts under the Secured Credit agreement (as amended) shall become immediately due and payable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the April Forbearance
Agreement and the Revenue Sharing Agreement, the Company and AiPharma Group, Ltd. entered into an Amendment to the Share Exchange Agreement
(the &#8220;Share Exchange Amendment&#8221;) which amended the Share Exchange Agreement to, among other things: (i) modify the financial
statements required to be delivered by AiPharma Group, Ltd. at the initial closing to include the unaudited financial statements for the
three months ended March 31, 2022 and 2021, (ii) permit the Company to amend its Certificate of Incorporation without the consent of AiPharma
Group, Ltd. in order to effect a reverse stock split of the Company&#8217;s common stock, if necessary, in order to maintain its listing
on the Nasdaq Capital Market, and (iii) make certain other conforming changes related to the March Forbearance Agreement and Revenue Sharing
Agreement.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Target Company Note Receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2021, the Company entered into
a secured credit agreement dated December 10, 2021 (the &#8220;Target Company Credit Agreement&#8221;) and signed on December 10, 2021
with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the
&#8220;Target Company Loan&#8221;) and agreed to make additional secured loans, as requested by the Target Company and approved by the
Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December
8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of
the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit
the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject
to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the
Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security
interest in all of the Target Company&#8217;s assets as security for the Target Company Loan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that the Target Company
may not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of the principal and accrued
interest of $0.5&#160;million as of December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140596007361776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; FIXED ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s fixed assets include the following
on December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">376,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(197,907</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178,522</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,572,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(579,015</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,993,705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,224</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,381</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold Improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,134,850</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(815,987</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,318,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s fixed assets include the following
on December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">312,489</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(75,053</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">237,436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,240,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306,688</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,933,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,857</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Fixed Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,809</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,654,307</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(387,010</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,267,297</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $428,977&#160;and $369,236,
for the years ended December 31, 2022 and 2021, respectively. None of the Company&#8217;s fixed assets serve as collateral against any
loans as of December 31, 2022 and December 31, 2021, other than those subject to the financed asset liability. As of December 31, 2022
and 2021, the fixed assets that serve as collateral subject to the financed asset liability have a carrying value of $1,359,091 and $1,690,420,
respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financed Assets:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2020, the Company purchased two pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $19,487, with an interest rate of 8%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January of 2021, the Company purchased one
piece of lab equipment and financed it for a period of twenty-four months with a monthly payment of $9,733, with an interest rate of 8%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March of 2021, the Company purchased five pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $37,171, with an interest rate of 8%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maturities as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,512</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140596007340032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; INTANGIBLE ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets include
the following on December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">321,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(214,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">107,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">321,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(214,000</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">107,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets include
the following on December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">321,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(107,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">214,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">321,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(107,000</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">214,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense was $107,000&#160;and $107,000&#160;for
the years ended December 31, 2022 and 2021, respectively. None of the Company&#8217;s intangible assets serve as collateral against any
loans as of December 31, 2022 and 2021. The Company&#8217;s proprietary technology is being amortized over its estimated useful life of
three years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595923730256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2022, the Company granted&#160;9,600&#160;restricted
stock units to an officer of the Company pursuant to the Company&#8217;s 2021 Equity Incentive Plan. The Company recognized $146,613&#160;in
stock-based compensation for the issuance of these vested and unvested restricted stock units during the year ended December 31, 2022.
(Note 11)</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#8220;Purchaser&#8221;), pursuant to which the Company
agreed to issue and sell one (1) share of the Company&#8217;s Series B Preferred Stock (the &#8220;Preferred Stock&#8221;), par value
$0.001&#160;per share, to the Purchaser for $20,000&#160;in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company filed a certificate
of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;250,000,000&#160;votes and will vote together with the outstanding shares of the Company&#8217;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#8217;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#8217;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000&#160;in cash. On September 13, 2022, the
share was redeemed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2022, the Chief Executive Officer
loaned $80,000 to the Company.&#160;The loan was evidenced by an unsecured promissory note (the &#8220;Promissory Note&#8221;). Pursuant
to the terms of the Promissory Note, it will accrue interest at a rate of four and three-quarters percent (4.75%) per annum, the Prime
rate on the date of signing, and is due on the earlier of January 22, 2023, or an event of default. On October 7, 2022, the Company fully
repaid the $80,000 Promissory Note and $812 of accrued interest to its Chief Executive Officer. The Chief Executive Officer and the Company
entered the Promissory Note on July 21, 2022.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140596007376000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 27, 2022, the Company entered into an agreement
for the purchase and sale of future receipts (the &#8220;Future Receipts Agreement&#8221;) with a commercial funding source pursuant to
which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $792,000&#160;(the &#8220;Future
Receipts Purchased Amount&#8221; for gross proceeds to the Company of $550,000, less origination fees of $16,500&#160;and professional
service fees of $13,500. Pursuant to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#8217;s
present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be
repaid by the Company in 28 weekly installments of approximately $28,000 with the final payment due on December 7, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022, the principal balance and
accrued interest was paid off in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2022, the Company entered into an
Agreement for the Purchase and Sale of Future Receipts (the &#8220;Agreement&#8221;) with a commercial funding source pursuant to which
the Company agreed to sell to the funder certain future trade receipts in the aggregate amount $288,000 (the &#8220;Purchased Amount&#8221;)
for gross proceeds to the Company of $200,000, less origination fees of $20,000. Pursuant to the Agreement, the Company granted the funder
a security interest in all of the Company&#8217;s present and future accounts receivable in an amount not to exceed the Purchased Amount.
The Purchased Amount shall be repaid by the Company in 20 weekly installments of approximately $14,400 with the final payment due on January
18, 2023. In connection with the Agreement, the Company also issued a warrant to purchase 26,667 shares of the Company&#8217;s common
stock with an exercise price of $7.50 and an expiration of five years from the issuance date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022, the principal balance and
accrued interest was paid off in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Note Financing:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 4, 2022, the Company entered into a
Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors to purchase $1,277,778&#160;in principal amount&#160;10%
Senior Secured Promissory Notes (the &#8220;August 2022 Notes&#8221;), resulting in gross proceeds to the Company of $1,150,000, exclusive
of placement agent commission and fees and other offering expenses. In connection therewith, the Company issued,&#160;25,556&#160;shares
of common stock as commitment fees and warrants (the &#8220;August 2022 Warrants&#8221;) to purchase up to&#160;108,517&#160;shares of
the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 11, 2022, the Company entered into a
SPA with certain accredited investors to purchase $555,556 in principal amount of August 2022 Notes, resulting in gross proceeds to the
Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and August 2022 Warrants
to purchase up to 47,182 shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Notes have a maturity date of
twelve (12) months from the date of issuance and are convertible at the option of the Investor at any time prior to maturity in shares
of Common Stock (the &#8220;Conversion Shares&#8221;) at an initial conversion price of $11.78 per share, subject to adjustments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Warrants are exercisable for a period of five (5) years
from the period commencing on the commencement date (as defined in the August 2022 Warrant) and ending on 5:00 p.m. eastern standard time
on the date that is five (5) years after the date of issuance, at an initial exercise price of $11.78, subject to adjustment provided
therein (including cashless exercise). These warrants were valued using a Black-Scholes Model and the resulting relative fair value was
recorded as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2022, the Company entered into a
First Amendment and Waiver with the holders of the August 2022 Warrants, pursuant to which the exercise price of the August 2022 Warrants
was reduced to $7.50 per share and the August 2022 Warrants were modified such that they are not exercisable unless and until the Company
obtains stockholder approval of the issuance of any shares of common stock upon exercise of the August 2022 Warrants. On September 16,
2022, the exercise price of the August 2022 Warrants was further adjusted to $6.00 per share. These warrants were valued using a Black-Scholes
Model and the resulting valuation was recorded as an implied dividend.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Note Financing Follow On:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2022, the Company entered into
a SPA with a certain accredited investor to purchase $555,555 in principal amount of August 2022 Notes, resulting in gross proceeds to
the Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and warrants (the
&#8220;August 2022 Follow On Warrants&#8221;) to purchase up to 74,074 shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2022 Follow On Warrants are exercisable for a period of
five (5) years from the period commencing on the commencement date (as defined in the August 2022 Follow On Warrant) and ending on 5:00
p.m. eastern standard time on the date that is five (5) years after the date of issuance, at an initial exercise price of $7.50, subject
to adjustments. These warrants were valued using a Black-Scholes Model and the resulting relative fair value was recorded as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2022, the exercise price of the
August 2022 Follow On Warrants was adjusted to $6.00 per share. These warrants were valued using a Black-Scholes Model and the resulting
valuation was recorded as an implied dividend.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the principal balance
of $2,388,888, a prepayment penalty of $238,889 and all accrued interest of $119,444 relating to the August 2022 Notes was paid off in
full.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921913312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesLineItems', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; LEASES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our lease agreements generally do not provide
an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement
date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on December 31, 2022 and
December 31, 2021 for all leases that commenced prior to that date. In determining this rate, which is used to determine the present value
of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease
and in a similar economic environment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters is located in Richmond,
Virginia, where we lease approximately 25,000 square feet. The lease expires in August 2026, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also lease approximately 5,810 square feet
of laboratory and office space in Mountain View, California. The lease expires in August 2024, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, we lease approximately 3,150 square
feet of office space in Melville, New York. The lease expires in December 2024, subject to extension.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December 31, 2022 the Company is
in arrears on certain lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Costs</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of total lease costs:</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expense</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,396,875</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">819,587</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease costs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,396,875</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">819,587</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Positions as of December 31, 2022 and
December 31, 2021</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ROU lease assets and lease liabilities for our
operating leases are recorded on the balance sheet as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Right of use asset &#8211; long term</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,160,457</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,097,117</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total right of use asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,160,457</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,097,117</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities &#8211; short term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,086,658</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,145,126</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,885,218</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,765,933</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,971,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,911,059</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Lease Terms and Discount Rate as of December
31, 2022</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years) &#8211; operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Maturities of leases are as follows:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Year Ended December 31, 2022</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,129,853</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004,982</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">710,546</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,269,311</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297,436</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,086,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total maturities, due beyond one year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,885,218</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI https://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595924691104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS &amp; CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; COMMITMENTS &amp; CONTIGENCIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License Agreement with Loma Linda University</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2018, as amended
on July 1, 2020, we entered into a LLU License Agreement directly with Loma Linda University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LLU License
Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical
information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled
by LLU and/or any of its affiliates (the &#8220;LLU Patent and Technology Rights&#8221;) and related to therapy for immune-mediated inflammatory
diseases (the ADI&#8482; technology). In consideration for the LLU License Agreement, we issued 500 shares of common stock to LLU.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the LLU License
Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July 2020 for outstanding milestone payments
and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically,
we are required to make the following milestone payments to LLU: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March
31, 2026; and $500,000 on March 31, 2027. In lieu of the $175,000 milestone payment due on March 31, 2022, the Company paid LLU an extension
fee of $100,000. Upon payment of this extension fee, an additional year will be added for the March 31, 2022 milestone. Additionally,
as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made the
following payments to LLU: $70,000 at the end of December 2018, and a final payment of $60,000 at the end of March 2019. We are required
to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe royalty payments
of (i) 1.5% of Net Product Sales (as such terms are defined under the LLU License Agreement) and Net Service Sales on any Licensed Products
(defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or
supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services (as such terms are defined
under the LLU License Agreement) not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond
the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development
and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and
Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The LLU License Agreement
shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application
licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU.
LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance
fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision
that requires us to meet certain deadlines for milestone events (each, a &#8220;Milestone Deadline&#8221;)) not cured within 90 days after
delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by
us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application
to initiate first-in-human clinical trials on or before March 31, 2022, which has been extended to March 31, 2023 due to payment of a
$100,000 extension fee paid in March 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-20</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Agreement with Leland Stanford Junior
University</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2020, we entered
into an exclusive license agreement (the &#8220;February 2020 License Agreement&#8221;) with Stanford regarding a patent concerning a
method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an exclusive
worldwide license to Stanford&#8217;s patent regarding use, import, offer, and sale of Licensed Products (as defined in the agreement).
The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement,
and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive
license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those
terms are defined in the February 2020 License Agreement&#8221;). However, Stanford agreed to not grant further licenses under the Licensed
Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the February 2020
License Agreement which extended our exclusive right to license the technology deployed in AditxtScore<sup>TM</sup>&#160;and securing
worldwide exclusivity in all fields of use of the licensed technology.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were obligated to pay and
paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 375 shares of the Company&#8217;s common stock to
Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement in the
amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of the patent. The
Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone fees of $50,000 on
the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in
vitro diagnostic product developed and a potential licensed product. The Company paid a milestone fee for a clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product of $25,000 in March of 2022. We are also required
to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which
has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and
operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation
studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which
has been completed), (iv) submit a 510(k) application to the FDA, Emergency Use Authorization (&#8220;EUA&#8221;), or a Laboratory Developed
Test (&#8220;LDT&#8221;) by March 31, 2021 (which has been completed), (vi) develop a prototype assay for human profiling by December
31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity, or
infectious disease purposes by March 31, 2022 (which has been completed) and (viii) provided further development and commercialization
milestones for specific fields of use in writing prior to December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated upon our election on at least 30 days advance
notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and commercializing
Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020 License Agreement;
or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30) day cure period
to remedy such violation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595923885456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2021, the Company increased the number
of authorized shares of the Company&#8217;s common stock, par value $0.001&#160;per share, from&#160;27,000,000&#160;to&#160;100,000,000&#160;(the
&#8220;Authorized Shares Increase&#8221;) by filing a Certificate of Amendment (the &#8220;Certificate of Amendment&#8221;) to its Amended
and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation
Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the
Company at the Company&#8217;s Annual Meeting of Stockholders on May 19, 2021.&#160;On September 13, 2022, the Company effectuated a 1
for 50 reverse stock split (the &#8220;Reverse Split&#8221;). The Company&#8217;s stock began trading at the Reverse Split price effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#8217;s common
stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued&#160;148,227&#160;shares of common stock and recognized expense of $507,558&#160;in stock-based compensation for consulting services,
consisting of capital markets and investor relations. The stock-based compensation for consulting services is calculated by the number
shares multiplied by the closing price on the effective date of the contract. The Company also granted&#160;11,644&#160;Restricted Stock
Units and,&#160;18,469&#160;Restricted Stock Units&#160;vested which resulted in the issuance of shares. As a result, the Company recognized
expense of $1,209,906&#160;in stock-based compensation. The stock-based compensation for shares issued or RSU&#8217;s granted during the
period were valued based on the fair market value on the date of grant. The Company issued 58,256 shares in relation to the issuance of
notes (See Note 8). The Company issued 1,224,333 shares of common stock as part of the September 2022 Offering (See Note 1). The Company
also issued 1,766,917 shares of common stock as a result of the exercise of prefunded warrants from the September 2022 Offering (See Note
1). The Company issued 179,419 shares of common stock from the exercise of warrant, modification of warrant, and the issuance of warrant.
The Company issued 9,237 shares of common stock for the settlement of accounts payable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company
issued 2,031 shares of common stock and recognized expense of $254,242 in stock-based compensation for consulting services. The Company
also issued 1,602 shares of common stock to Stanford University and two employees and recognized expense of $64,875 relating to the agreement
with Stanford University. The Company also issued 189,843 shares of common stock upon the exercise of warrants and received $3,727,285
in cash proceeds. The Company granted 9,300 Restricted Stock Awards, as a result the Company recognized expense of $1,443,700 in stock-based
compensation. The Company granted 500 Restricted Stock Awards of which 500 vested, as a result, the Company recognized expense of $17,000
in stock-based compensation for consulting services. The Company also granted 36,456 Restricted Stock Units, of which 16,519 vested and
resulted in the issuance of shares, as a result, the Company recognized expense of $1,843,902 in stock-based compensation. (See Note 7)
The Company issued 96,050 shares of common stock for the conversion of a convertible note. (See Note 9) The Company issued 91,667 shares
of common stock as part of the August 2021 Offering. The Company issued 56,667 shares of common stock as part of the October 2021 Offering.
The Company issued 164,929 shares of common stock as part of the December 2021 Offering. The stock-based compensation for shares issued
or RSU&#8217;s granted during the period, were valued based on the fair market value on the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue&#160;3,000,000&#160;shares
of preferred stock, par value $0.001&#160;per share. There were no shares of preferred stock outstanding as of December 31, 2022 and December
31, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuance of Series B Preferred Stock:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#8220;Purchaser&#8221;), pursuant to which the Company
agreed to issue and sell one (1) share of the Company&#8217;s Series B Preferred Stock (the &#8220;Preferred Stock&#8221;), par value
$0.001&#160;per share, to the Purchaser for $20,000&#160;in cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2022, the Company filed a certificate
of designation (the &#8220;Certificate of Designation&#8221;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;250,000,000&#160;votes and will vote together with the outstanding shares of the Company&#8217;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#8217;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#8217;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000&#160;in cash. On September 13, 2022, the
share was redeemed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redemption of Series B Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2022, the Company paid $20,000 in
consideration for the one share of Preferred Stock which was redeemed on September 13, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;).&#160;The 2017 Plan provides for the grant of equity
awards to directors, employees, and consultants.&#160;The Company is authorized to issue up to&#160;2,500,000&#160;shares of our common
stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after
adoption, unless terminated earlier by the Board of Directors.&#160;All shares of our common stock pursuant to awards under the 2017 Plan
have been awarded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 24, 2021, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for grants of nonqualified
stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based
awards (collectively, the &#8220;Awards&#8221;). Eligible recipients of Awards include employees, directors or independent contractors
of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the &#8220;Committee&#8221;) will
administer the 2021 Plan. A total of&#160;60,000&#160;shares of common stock, par value $0.001&#160;per share, of the Company may be issued
pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a
stock option will be no less than one hundred percent (100%) of the Fair Market Value (as defined in the 2021 Plan) of a share of Common
Stock on the date of grant. The 2021 Plan was submitted and approved by the Company&#8217;s stockholders at the 2021 annual meeting of
stockholders, held on May 19, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
granted no new options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021, the Company
granted 1,850 stock option grants, with a weighted average grant date fair value $8.39. The fair value of each option granted was estimated
using the assumption and/or factors in the Black-Scholes Model.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is an analysis of the stock option
grant activity under the Plan:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,710</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">170.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">44,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">170.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.74</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,038</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,025</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">96.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 there were 42,685 exercisable
options, these options had a weighted average exercise price $173.50.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to options granted and vesting expense of $791,187&#160;during the year ended December 31, 2022, of which $555,772&#160;is
included in general and administrative expenses and $235,415&#160;is included in research and development expenses in the accompanying
statements of operations. The remaining value to be expensed is $179,892&#160;with a weighted average vesting term of&#160;0.75&#160;years
as of December 31, 2022. The Company recognized stock-based compensation expense related to options issued and vesting of $826,795 during
the year ended December 31, 2021, of which $587,209 is included in general and administrative expenses and $239,586 is included in research
and development expenses in the accompanying statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes warrant forfeitures
as they occur as there is insufficient historical data to accurately determine future forfeitures rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Warrants</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued&#160;6,497,530&#160;warrants.&#160;During the year ended December 31, 2021, the Company issued&#160;678,242&#160;warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2022, the fair
value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$7.50-20.00</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.55%-3.47</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00-5.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">147%-165</span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the fair
value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%-0.42</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00-5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">154%-159</span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate assumption for warrants
granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term
of warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined the expected volatility
assumption for warrants granted using the historical volatility of comparable public companies&#8217; common stock. The Company will continue
to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that
the Company&#8217;s common stock has enough market history to use historical volatility.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The dividend yield assumption for warrants granted
is based on the Company&#8217;s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends
on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes warrant forfeitures as
they occur as there is insufficient historical data to accurately determine future forfeitures rates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant issuances are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">601,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.38</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,497,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,946,419</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expired or forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(62,512</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Rounding for Reverse Split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,090,024</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92,567</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,497,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,435,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to warrants granted and vesting expense of $609,748 during the year ended December 31, 2022, of which $105,049&#160;is
included in general and administrative and $504,699 is included in sales and marketing in the accompanying Statements of Operations. The
Company recognized stock-based compensation expense related to warrants granted and vesting expense of $189,899&#160;during the year ended
December 31, 2021, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to
be expensed is zero as of December 31, 2022. The weighted average vesting term is 0.22 years as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2022, the Company entered an agreement
with a holder of certain of the Series C Warrants (the &#8220;Holder&#8221;).&#160;Pursuant to the agreement, the Holder has agreed to
exercise in cash 179,419 of its Series C Warrants at a reduced exercise price of $7.50 per Share (reduced from $57.50 per share), for
gross proceeds to the Company of approximately $1.35 million. As an inducement to such exercise, the Company has agreed to reduce the
exercise price of the Holder&#8217;s remaining Series C Warrants to purchase up to 49,153 Shares from $57.50 to $12.395 per share, which
will be non-exercisable for a period of six months following the closing date. The modification of this exercise price resulted in an
increase of $344,158 to the fair value of the Series C Warrants. This modification was an inducement on the transaction and as such was
recorded to equity resulting in no net change to additional paid in capital. In addition, the Company issued to the Holder a new warrant
to purchase up to 407,991 shares of the Company&#8217;s common stock at an exercise price of $12.395 per share, which will be non-exercisable
for a period of six months following issuance date and have a term of five and one-half years.&#160;This inducement resulted in a total
increase of $3,759,044&#160;to the fair value of the warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2022, the Company and the Warrant
Agent entered into Amendment No. 2 to the Series C Warrant Agent Agreement, pursuant to which the exercise price of the Series C Warrants
was reduced from $57.50 per share to $12.395 per share. In addition, on December 21, 2022, the Company issued an Amended and Restated
Unit Purchase Option to the agent in the Offering reflecting a reduced exercise price of $12.395 per Unit. This modification of these
warrants resulted in a $29,058 increase to the fair value of the warrants (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of Restricted Stock Units (&#8220;RSUs&#8221;)
issuances are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested RSUs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,565</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,197</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized stock-based compensation
expense related to RSUs granted and vesting expense of $1,222,875&#160;and&#160;$1,843,902 during the years ended December 31, 2022 and
December 31, 2021, respectively, of which, $848,597&#160;is included in general and administrative, $356,105&#160;is included in research
and development, and $18,346 is included in sales and marketing in the accompanying Statements of Operations. The remaining value to be
expensed is $321,603&#160;with a weighted average vesting term of&#160;0.40&#160;years as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
granted a total of&#160;11,644&#160;RSUs. As of December 31, 2022,&#160;18,506 RSUs vested and the Company issued&#160;18,469&#160;shares
of common stock for the&#160;18,469 vested RSUs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595925424672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8211; INCOME TAXES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December&#160;31, 2022 and
2021, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by
the Company. The Company&#8217;s losses before income taxes consist solely of losses from domestic operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of income tax expense (benefit)
computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Income taxes at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Permanent Differences/Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13.1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred taxes are recognized for temporary differences
between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s
deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are comprised of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 13.7pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,499,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,896,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,943</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,511,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,541,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169,887</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Section 174 Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,547,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Loss on impairment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,288,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,140,318</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 13.7pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,933</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 27.35pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,114,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,934,427</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,217,401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,670,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">897,533</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,263,837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(722,127</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,169,887</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(175,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,950</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(897,533</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,263,837</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&#8217;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&#160;31, 2022 and 2021, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&#8217;s valuation allowance increased during 2022 by approximately $3.5&#160;million primarily
due to the generation of net operating loss and tax credit carryforwards and the capitalization of research and experimental expenditures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022 and 2021, the Company
had U.S. federal net operating loss carryforwards of $56.6&#160;million and $38.0&#160;million, respectively, which may be available to
offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#8221; TCJA&#8221;) will generally allow losses incurred after
2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss
carryover or&#160;80% of a corporation&#8217;s taxable income (subject to Section&#160;382 of the Internal Revenue Code of 1986, as amended).
Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent
of the lesser of a corporation&#8217;s net operating loss carryover or&#160;100% of a corporation&#8217;s taxable income and be available
for&#160;twenty years&#160;from the period the loss was generated. The Company has federal net operating losses generated following 2017
of $56.5&#160;million, which do not expire. The federal net operating losses generated prior to 2018 of $0.1&#160;million will expire
at various dates through 2037.&#160;The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019
and 2020 to the five prior tax years.&#160;In addition, net operating losses generated in these years could fully offset prior year taxable
income without the&#160;80% of the taxable income limitation under the TCJA which was enacted on December 22, 2017. The Company has been
generating losses since its inception, as such the net operating loss carryback provision under the CARES Act is not applicable to the
Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022 and 2021, the Company
also had U.S. state net operating loss carryforwards (post-apportioned) of $26.2&#160;million and $44.8&#160;million, respectively, which
may be available to offset future income tax liabilities and expire at various dates through 2042.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;31, 2022, the Company had
$0.1 million federal tax credit carryforwards available to reduce future tax liabilities which expire at various dates through 2042. As
of December&#160;31, 2021, the Company had no federal tax credit carryforwards. As of December&#160;31, 2022 and 2021, the Company had
state research and development tax credit carryforwards of approximately $0.4&#160;million and $0.2&#160;million, respectively, which
may be available to reduce future tax liabilities and can be carried over indefinitely.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the U.S. federal and state net
operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section&#160;382
and Section&#160;383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes
that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and
research and development credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively.
The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership
changes since its formation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research
and development tax credit carryforwards before utilization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not, as of yet, conducted a study
of research and development tax credit carryforwards. Such a study, once undertaken by the Company, may result in an adjustment to the
research and development tax credit carryforwards; however, a full valuation allowance has been provided against the Company&#8217;s research
and development tax credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance.
Thus, there would be no impact to the balance sheet or statement of operations if an adjustment is required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files tax returns in the United States,
California, Virginia, and New York. The Company is subject to U.S. federal and state tax examinations by tax authorities for the tax years
ended December 31, 2019 through present. As of December&#160;31, 2022 and 2021, the Company has recorded no liability for unrecognized
tax benefits, interest, or penalties related to federal and state income tax matters and there currently no pending tax examinations.
The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595926672432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13 &#8211; SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2022, the Company entered into
an At The Market Offering Agreement (the &#8220;ATM&#8221;) with H.C. Wainwright &amp; Co., LLC as agent (the &#8220;Agent&#8221;), pursuant
to which the Company may offer and sell, from time to time through the Agent, shares of the Company&#8217;s common stock having an aggregate
offering price of up to $50,000,000 (the &#8220;Shares&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The offer and sale of
the Shares was made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-257645) filed by the
Company with the SEC on July 2, 2021, amended on July 6, 2021 and declared effective by the SEC on July 13, 2021, under the Securities
Act of 1933, as amended.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No sales of Shares were
made during the year ended December 31, 2022 under the ATM.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the period beginning
January 1, 2023 through the date of this report, the Company sold 338,513 Shares at an average price of $1.55 per share under the ATM.
The sale of Shares generated net proceeds of approximately $507,000 after paying commissions and related fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Adimune,
Inc. a Delaware, wholly owned subsidiary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, the Company formed Pearsanta,
Inc. a Delaware, wholly owned subsidiary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2023, the Company entered into
an agreement for the purchase and sale of future receipts (the &#8220;Future Receipts Agreement&#8221;) with a commercial funding source
pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $2,160,000&#160;(the
&#8220;Future Receipts Purchased Amount&#8221; for gross proceeds to the Company of $1,500,000, less origination fees of $75,000. Pursuant
to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#8217;s present and future
accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be repaid by the Company
in 28 weekly installments of approximately $77,000 with the final payment due on September 5, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 17, 2023, the Company entered into a consulting
agreement (the "Independent Consulting Agreement") with an independent consultant for a term of thirty days. Pursuant to the
Independent Consulting Agreement, the independent consultant agreed to provide the Company with business advisory services, guidance on
growth strategies and networking with its clients on a non-exclusive basis for general business purposes (the "Independent Consulting
Services&#8221;). In consideration for the Independent Consulting Services, the Company issued to the independent consultant 187,000 shares
of the Company's common stock (the "Independent Consulting Shares"). The issuance of the Independent Consulting Shares will
not be registered under the Securities Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 4, 2023, the Company entered into a Business
Loan and Security Agreement (the "April Loan Agreement") with a commercial funding source (the "April Lender"), pursuant
to which the Company obtained a loan from the April Lender in the principal amount of $1,060,000, which includes origination fees of $60,000
(the "April Loan"). Pursuant to the April Loan Agreement, the Company granted the April Lender a continuing secondary security
interest in certain collateral (as defined in the April Loan Agreement). The total amount of interest and fees payable by the Company
to the April Lender under the April Loan (the "April Repayment Amount") will be (i) $1,000,000 if paid prior to April 6, 2023,
(ii) $1,219,000 if paid prior to April 10, 2023, or (iii) $1,590,000 if paid after April 10, 2023 and will be repaid in 20 weekly installments
of $79,500 commencing on April 10, 2023 and ending on August 21, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 13, 2023, the Company formed Adivir, Inc.
a Delaware, wholly owned subsidiary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595923176432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and
the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the
reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include
the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair
value of stock options and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements and Fair Value of
Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted Financial Accounting Standards
Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 58px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 -</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs are unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not identify any assets or liabilities
that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the short-term nature of all financial
assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash accounts at financial
institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally
insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all the Company&#8217;s accounts
receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk
is mitigated due to the Company&#8217;s number of customers. In addition, for receivables due from U.S government agencies, the Company
does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and
payment is primarily dependent upon submitting the appropriate documentation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include short-term,
liquid investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inventory</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of laboratory materials and
supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable
value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FixedAssetsPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets are stated at cost less accumulated
depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs
are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are
removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the
straight-line method over the estimated useful lives or lease life of the related assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Useful lives assigned to fixed assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three years to five years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab Equipment</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Furniture</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other fixed assets</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of estimated useful life or remaining lease term</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intangible Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets are stated at cost less accumulated
amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated
useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounts Receivable and Allowance for Doubtful
Accounts</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are stated at the amount management
expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company
determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management.
As of December 31, 2022 and 2021, there was an allowance for doubtful accounts of $18,634&#160;and&#160;zero, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offering costs incurred in connection with equity are recorded as a
reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 606 (Revenue From Contracts
with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects
the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle,
the Company applies the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the contract with a customer</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identify the performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Determine the transaction price</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Allocate the transaction price to performance obligations in the contract</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognize revenue when or as the Company satisfies a performance obligation</i></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues reported from services relating to the
AditxtScore&#8482; are recognized when the AditxtScore<sup>TM </sup>report is delivered to the customer. The services performed include
the analysis of specimens received in the Company&#8217;s CLIA laboratory and the generation of results which are then delivered upon
completion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in the following
manner for the following types of customers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client Payers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Client payers include physicians or other entities
for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for
client payers based on historical collection experience and the period of time the receivable has been outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Pay:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Customers are billed based on established patient
fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the
ability of the patients to pay.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insurance:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursements from healthcare insurers are based
on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between
amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of
the Company&#8217;s contractual arrangements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Topic 842 (Leases), operating lease expense
is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space,
and lab equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases with an initial term of twelve months or
less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right
of use (&#8220;ROU&#8221;) assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation
costs under the provisions of ASC 718, Compensation&#8212;Stock Compensation, which requires the measurement and recognition of compensation
expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense
recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant
date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled
during the periods reported. Stock-based compensation is recognized as expense over the employee&#8217;s requisite vesting period and
over the nonemployee&#8217;s period of providing goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PatentsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company incurs fees from patent licenses,
which is reflected in research and development expenses, and are expensed as incurred. During the years ended December 31, 2022 and 2021,
the Company incurred patent licensing fees for the patents of $263,273&#160;and $76,455, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incur research and development costs during
the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs
qualify for capitalization under applicable guidance. During the years ended December 31, 2022 and 2021, the Company incurred research
and development costs of $7,268,084 and $5,042,617, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Net Loss per Common Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per common share is computed by dividing the net loss by
the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the
net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect
of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock
equivalents because their inclusion would be anti-dilutive. As of December 31, 2022,&#160;44,710&#160;stock options,&#160;7,197&#160;unvested&#160;restricted
stock units, and&#160;5,090,024&#160;warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of
December 31, 2021,&#160;44,710&#160;stock options, 15,565 unvested restricted stock units and&#160;601,399&#160;warrants were excluded
from dilutive earnings per share as their effects were anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and 2021,
the Company recognized an implied dividend from the modification of warrants of $37,667 and $102,267, respectively. Theses implied dividends
resulted in an increase in the net loss attributable to common stockholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB issues ASUs to amend the authoritative
literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes
that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or
(iv) are not expected to have a significant impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FixedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Assets Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FixedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PatentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patents Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PatentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595924654560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of useful lives assigned to fixed assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers</span></td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three years to five years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab Equipment</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seven to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office Furniture</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other fixed assets</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five to ten years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of estimated useful life or remaining lease term</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921803520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">376,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(197,907</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178,522</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,572,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(579,015</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,993,705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,200</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,224</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,381</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold Improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">90,799</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,134,850</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(815,987</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,318,863</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">312,489</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(75,053</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">237,436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,240,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306,688</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,933,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office Furniture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,857</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Fixed Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,809</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(412</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Fixed Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,654,307</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(387,010</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,267,297</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of maturities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111,512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total Payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,512</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595924628928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">321,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(214,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">107,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">321,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(214,000</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">107,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Proprietary Technology</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">321,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(107,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">214,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Intangible Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">321,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(107,000</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">214,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595925344656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2022</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year<br/>
Ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Components of total lease costs:</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 78%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease expense</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,396,875</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">819,587</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease costs</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,396,875</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">819,587</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of maturities of leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Right of use asset &#8211; long term</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,160,457</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,097,117</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total right of use asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,160,457</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,097,117</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities &#8211; short term</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,086,658</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,145,126</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#8211; long term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,885,218</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,765,933</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,971,876</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,911,059</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of lease terms and discount rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years) &#8211; operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,129,853</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004,982</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">710,546</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423,930</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,269,311</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297,436</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,086,657</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total maturities, due beyond one year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,885,218</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921740992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock', window );">Schedule of analysis of the stock option grant activity under the plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,710</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">170.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">44,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">170.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.74</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Vested and Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">601,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.38</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,497,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,946,419</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expired or forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(62,512</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Rounding for Reverse Split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Outstanding December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,090,024</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested RSUs</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">15,565</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,506</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,197</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">46.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of warranty issuance</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,063</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,038</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,025</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">96.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested on December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">92,567</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,497,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,435,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(55,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Nonvested on December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$7.50-20.00</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.55%-3.47</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00-5.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">147%-165</span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Exercise price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%-0.42</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life in years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00-5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">154%-159</span></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595924666016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Income taxes at U.S. statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">State income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Permanent Differences/Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10.5</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13.1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 13.7pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,499,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,896,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Tax credits carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,943</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,511,849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,541,936</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169,887</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt">Section 174 Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,547,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Loss on impairment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,288,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,140,318</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 13.7pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,933</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 27.35pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,114,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,934,427</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,217,401</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,670,590</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">897,533</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,263,837</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 13.7pt">Right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(722,127</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,169,887</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(175,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(93,950</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(897,533</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,263,837</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt">Net deferred taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921354496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2022</div></th>
<th class="th"><div>Dec. 06, 2021</div></th>
<th class="th"><div>Oct. 20, 2021</div></th>
<th class="th"><div>Oct. 18, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Company issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Issued warrants to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DebtInstrumentTermDescription', window );">Debt instrument term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants have an exercise price of $126.50&#160;per
share and are exercisable for a&#160;five-year&#160;period commencing six months from the date of issuance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantsExercisePrice', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PurchaseOfCommonStock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShares', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Net of underwriting discounts (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 17,200<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PrefundedWarrantsShares', window );">Prefunded warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PurchaseOfEquityShares', window );">Purchase of equity shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price term (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShares', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,224,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PrefundedWarrantsShares', window );">Prefunded warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DebtInstrumentTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument term, description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DebtInstrumentTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExercisePricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExercisePricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OrganizationandNatureofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OrganizationandNatureofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PurchaseOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PurchaseOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 805<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505872&amp;loc=d3e30785-158569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921825696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern Analysis (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GoingConcernsDisclosureAbstract', window );"><strong>Going Concern Analysis [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetLossCashFlowFromOperatingActivities', window );">Net loss cash flow from operating activities</a></td>
<td class="nump">$ 27,649,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Operating activities</a></td>
<td class="nump">22,049,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">2,768,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerFunds', window );">Future funds</a></td>
<td class="nump">$ 51,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetLossCashFlowFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss cash flow from operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetLossCashFlowFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917905648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 18,634<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LicensingFeeForPatents', window );">Licensing fees</a></td>
<td class="nump">263,273<span></span>
</td>
<td class="nump">76,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 7,268,084<span></span>
</td>
<td class="nump">$ 5,042,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantsOfStockOptions', window );">Stock options issued (in Shares)</a></td>
<td class="nump">44,710<span></span>
</td>
<td class="nump">44,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Restricted stock units (in Shares)</a></td>
<td class="nump">7,197<span></span>
</td>
<td class="nump">15,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DilutiveEarningShares', window );">Dilutive earning shares (in Shares)</a></td>
<td class="nump">5,090,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantsExercisedShares', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockAwardForfeituresDividends', window );">Recognized an implied dividend</a></td>
<td class="nump">$ 37,667<span></span>
</td>
<td class="nump">$ 102,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DilutiveEarningShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive Earning Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DilutiveEarningShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LicensingFeeForPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LicensingFeeForPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Of Stock Options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockAwardForfeituresDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of dividends forfeited related to restricted stock awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockAwardForfeituresDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921869456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Useful lives assigned to fixed assets</a></td>
<td class="text">Three years to five years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Useful lives assigned to fixed assets</a></td>
<td class="text">Seven to ten years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sic_Z2520', window );">Office Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Useful lives assigned to fixed assets</a></td>
<td class="text">Five to ten years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember', window );">Other Fixed Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Useful lives assigned to fixed assets</a></td>
<td class="text">Five to ten years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Useful lives assigned to fixed assets</a></td>
<td class="text">Shorter of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sic_Z2520">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sic_Z2520</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917822720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2022</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Oct. 18, 2021</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Aug. 27, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLoansPayable', window );">Completion of a proposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommonStockYieldsPercentage', window );">Common stock yields percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DescriptionOfShareExchangeAgreement', window );">Share exchange agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 28, 2021, we entered into a Share
Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued and outstanding
equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of
$250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5%
of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and
a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CreditAgreementAmendmentDescription', window );">Credit agreement amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered
into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the &#8220;Credit Agreement Amendment&#8221;),
pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by
$8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment.
The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the
Company from the exercise of existing warrants or any other capital raises, including the October Offering.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_AdvancedCreditAgreement', window );">Advanced credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CreditAgreement', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableWithVariableRatesOfInterest1', window );">Note receivable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss', window );">Credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Aggregate amount</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DebtLoanAmount', window );">Debt loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableWithFixedRatesOfInterest1', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AdvancedCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advanced credit agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AdvancedCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonStockYieldsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock yields percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonStockYieldsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CreditAgreementAmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit agreement amendment description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CreditAgreementAmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DebtLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DebtLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DescriptionOfShareExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of share exchange agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DescriptionOfShareExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableWithFixedRatesOfInterest1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loan with fixed rate of interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableWithFixedRatesOfInterest1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableWithVariableRatesOfInterest1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loan with variable or adjustable rate of interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableWithVariableRatesOfInterest1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term loans payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the principal amount outstanding for securitized loans only (across all types of loans).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=d3e107314-111719<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on security purchased under agreement to resell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921235104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,977<span></span>
</td>
<td class="nump">$ 369,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,359,091<span></span>
</td>
<td class="nump">$ 1,690,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments', window );">Monthly payment</a></td>
<td class="nump">$ 37,171<span></span>
</td>
<td class="nump">$ 9,733<span></span>
</td>
<td class="nump">$ 19,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123416376&amp;loc=d3e50796-112755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917566144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Details) - Schedule of fixed assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">$ 3,134,850<span></span>
</td>
<td class="nump">$ 2,654,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(815,987)<span></span>
</td>
<td class="num">(387,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">2,318,863<span></span>
</td>
<td class="nump">2,267,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">376,429<span></span>
</td>
<td class="nump">312,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(197,907)<span></span>
</td>
<td class="num">(75,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">178,522<span></span>
</td>
<td class="nump">237,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">2,572,720<span></span>
</td>
<td class="nump">2,240,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(579,015)<span></span>
</td>
<td class="num">(306,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">1,993,705<span></span>
</td>
<td class="nump">1,933,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">56,656<span></span>
</td>
<td class="nump">90,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(8,200)<span></span>
</td>
<td class="num">(4,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">48,456<span></span>
</td>
<td class="nump">85,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember', window );">Other Fixed Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">8,605<span></span>
</td>
<td class="nump">10,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">7,381<span></span>
</td>
<td class="nump">$ 10,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost Basis</a></td>
<td class="nump">120,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(29,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net</a></td>
<td class="nump">$ 90,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adtx_OtherFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917717632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Details) - Schedule of maturities<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfMaturitiesAbstract', window );"><strong>Schedule Of Maturities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 111,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total Payments</a></td>
<td class="nump">$ 111,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595925081376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_AmortizationOfIntangibleAsset', window );">Amortization expense</a></td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_EstimatedUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AmortizationOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AmortizationOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_EstimatedUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_EstimatedUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921818160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - Schedule of intangible assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_ProprietaryTechnologyMember', window );">Proprietary Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost Basis</a></td>
<td class="nump">$ 321,000<span></span>
</td>
<td class="nump">$ 321,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(214,000)<span></span>
</td>
<td class="num">(107,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">107,000<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_TotalIntangibleAssetsMember', window );">Total Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost Basis</a></td>
<td class="nump">321,000<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(214,000)<span></span>
</td>
<td class="num">(107,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_ProprietaryTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_ProprietaryTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_TotalIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=adtx_TotalIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917730096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PreferredStockVotes', window );">Preferred stock votes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Cash received on consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Accrue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PromissoryNotes', window );">Promissory note amount</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PreferredStockVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock votes in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PreferredStockVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of promissory notes may also be referred to as an IOU, a loan agreement, or just a note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595916955344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
<th class="th"><div>May 27, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 07, 2022</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_AggregateAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GrossProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Origination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repaid purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,206,887)<span></span>
</td>
<td class="num">$ (315,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PrincipalAmountPercentage', window );">Principal amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,307,487<span></span>
</td>
<td class="nump">890,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_InvestorPurchaseAmount', window );">Purchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion Price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantExercisePrice', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PrincipalAmount', window );">Principal amount</a></td>
<td class="nump">$ 555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalancePrincipalAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaymentFeesOnAdvancesNet', window );">Prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adtx_August2022WarrantsMember', window );">August 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adtx_August2022FollowOnWarrantsMember', window );">August 2022 Follow On Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares (in Shares)</a></td>
<td class="nump">11,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant to purchase shares (in Shares)</a></td>
<td class="nump">74,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,074<span></span>
</td>
<td class="nump">74,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adtx_FutureReceiptsAgreementMember', window );">Future Receipts Agreement[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_AggregateAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantToPurchaseCommonShares', window );">Warrant to purchase common shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Sale of net issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Every stock option has an exercise price, also called the strike price, which is the price at which a share can be bought.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_InvestorPurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_InvestorPurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Precentage of principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantToPurchaseCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant To Purchase Common Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantToPurchaseCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For investments which are quantified by principal amount, the principle balance held at close of period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaymentFeesOnAdvancesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaymentFeesOnAdvancesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=adtx_August2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=adtx_August2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=adtx_August2022FollowOnWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=adtx_August2022FollowOnWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adtx_FutureReceiptsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adtx_FutureReceiptsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595923178704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>m&#178; </div>
<div>ft&#178;</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderlyingAssetClassAxis=stpr_VA', window );">Virginia [Membe]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetLeases', window );">Net lease</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesExpire', window );">Lease expires</a></td>
<td class="text">August 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderlyingAssetClassAxis=stpr_CA', window );">California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetLeases', window );">Net lease | ft&#178;</a></td>
<td class="nump">5,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesExpire', window );">Lease expires</a></td>
<td class="text">August 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnderlyingAssetClassAxis=stpr_NY', window );">New York [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetLeases', window );">Net lease</a></td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_LeasesExpire', window );">Lease expires</a></td>
<td class="text">December 2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LeasesExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration date means the last day of the lease term, subject to any other date on which the lease is terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LeasesExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnderlyingAssetClassAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnderlyingAssetClassAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921231408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease costs - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfLeaseCostsAbstract', window );"><strong>Schedule Of Lease Costs Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,396,875<span></span>
</td>
<td class="nump">$ 819,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,396,875<span></span>
</td>
<td class="nump">$ 819,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917686896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RightOfUseAssetShortTerm', window );">Right of use asset &#8211; long term</a></td>
<td class="nump">$ 3,160,457<span></span>
</td>
<td class="nump">$ 4,097,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_TotalRightOfUseAsset', window );">Total right of use asset</a></td>
<td class="nump">3,160,457<span></span>
</td>
<td class="nump">4,097,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OperatingLeaseLiabilitiesShortTerm', window );">Operating lease liabilities &#8211; short term</a></td>
<td class="nump">1,086,658<span></span>
</td>
<td class="nump">1,145,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OperatingLeaseLiabilitiesLongTerm', window );">Operating lease liabilities &#8211; long term</a></td>
<td class="nump">1,885,218<span></span>
</td>
<td class="nump">2,765,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_TotalLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 2,971,876<span></span>
</td>
<td class="nump">$ 3,911,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OperatingLeaseLiabilitiesLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities long term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OperatingLeaseLiabilitiesLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OperatingLeaseLiabilitiesShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liabilities short term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OperatingLeaseLiabilitiesShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssetShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use asset &#8211; short term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssetShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TotalLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TotalLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TotalRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TotalRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917916880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease terms and discount rate<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract', window );"><strong>Schedule Of Lease Terms And Discount Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years) &#8211; operating leases</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate &#8211; operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595918001200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of leases<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfMaturitiesOfLeasesAbstract', window );"><strong>Schedule Of Maturities Of Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,129,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,004,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">710,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">423,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,269,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(297,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OperatingLeasesLiabilityCurrent', window );">Less current portion</a></td>
<td class="num">(1,086,657)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total maturities, due beyond one year</a></td>
<td class="nump">$ 1,885,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OperatingLeasesLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OperatingLeasesLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfMaturitiesOfLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfMaturitiesOfLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595922742256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2027</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommitmentsContingenciesDetailsLineItems', window );"><strong>Commitments &amp; Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesAndLicenses', window );">License fee paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectTaxesAndLicensesCosts', window );">License milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts', window );">Extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationTechnologyAndDataProcessing', window );">Technology rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage', window );">Net Product percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFeePaidIndirectly', window );">Fee paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionOtherPaymentsRequired', window );">Required to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PaymentOfMilestoneFees', window );">Payment of milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClearanceFees', window );">Regulatory clearance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration', window );">Potential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount', window );">Financial revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual', window );">Loss Contingency Accrual, Product Liability, Net, Explanation of Material Change in Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription', window );">License maintenance fees description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommitmentsContingenciesDetailsLineItems', window );"><strong>Commitments &amp; Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommitmentsContingenciesDetailsLineItems', window );"><strong>Commitments &amp; Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommitmentsContingenciesDetailsLineItems', window );"><strong>Commitments &amp; Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage', window );">Net Product percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommitmentsContingenciesDetailsLineItems', window );"><strong>Commitments &amp; Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectTaxesAndLicensesCosts', window );">License milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommitmentsContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommitmentsContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PaymentOfMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone fees payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PaymentOfMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of extensions, discoveries and improved recovery of proved oil and gas reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section Item 18<br> -Subsection Instruction 2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 35A<br> -URI https://asc.fasb.org/extlink&amp;oid=126939881&amp;loc=SL6807758-109447<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=34713648&amp;loc=d3e63123-109448<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 35<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126939881&amp;loc=d3e62500-109447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472701&amp;loc=d3e49107-107924<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BroadcastersLicenseAgreementCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClearanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for clearance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClearanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectTaxesAndLicensesCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax incurred and cost of license directly related to good produced or service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectTaxesAndLicensesCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of premium revenue on financial guarantee insurance contracts recognized during the period that was accelerated for revenue recognition purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6933581&amp;loc=SL5749298-161291<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationTechnologyAndDataProcessing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses incurred in the period for information technology and data processing products and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationTechnologyAndDataProcessing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFeePaidIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6488101&amp;loc=d3e8702-115831<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFeePaidIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the nature or cause of a material change in the expected aggregate amount since the prior balance sheet date, other than a change resulting from pay-down of the obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149879-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionOtherPaymentsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other amounts the seller-lessee is required to pay under the terms of the transaction involving the sale of property to another party and lease of the property back to the seller, including reimbursements for such items, as utilities, taxes, insurance and common area maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123416376&amp;loc=d3e50796-112755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionOtherPaymentsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesAndLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesAndLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595907598176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>May 27, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Feb. 03, 2020</div></th>
<th class="th"><div>Dec. 20, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 24, 2021</div></th>
<th class="th"><div>Jul. 19, 2019</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>May 24, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Company issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,227<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RecognizedExpense', window );">Recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,843,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesIssued1', window );">Company issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,224,333<span></span>
</td>
<td class="nump">189,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,030<span></span>
</td>
<td class="nump">$ 254,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesOfCommonStock', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants and received (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,574<span></span>
</td>
<td class="nump">$ 3,727,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SettlementOfAccountsPayableShares', window );">Settlement of accounts payable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_sharesIssued1', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability', window );">Purchaser (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption preferred stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFeePaidIndirectly', window );">Company paid (in Dollars)</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Preferred stock share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FairMarketValue', window );">Fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CompanyGranted', window );">Company granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_weightedAverageGrant', window );">Weighted average grant (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Stock Option, Exercise Price, Decrease (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockOptionsShares', window );">Stock options shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 826,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,049<span></span>
</td>
<td class="nump">587,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">General and administrative expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 504,699<span></span>
</td>
<td class="nump">$ 239,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_warrantIssued', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,497,530<span></span>
</td>
<td class="nump">678,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantsIssuedAndVesting', window );">Warrants issued and vesting (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Remaining expensed (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Weighted average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercised (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Share purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,759,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_OfferingReflectingReducedExercisePricePerShare', window );">Offering Reflecting Reduced Exercise Price, Per Share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SharesIssued1', window );">Company issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,766,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedPaymentRemnainingExpenses', window );">Share based payment remaining expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RecognizedExpense', window );">Recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,443,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WarrantsIssuedAndVesting', window );">Warrants issued and vesting (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adtx_OneYearMember', window );">One Year [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=adtx_OneYearMember', window );">One Year [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ExercisePricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SettlementOfAccountsPayableShares', window );">Settlement of accounts payable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RecognizedExpense', window );">Recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare', window );">Preferred stock price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adtx_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Share purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Exercise price increase (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=adtx_StanfordUniversityMember', window );">Stanford University [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RecognizedExpense', window );">Recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,644<span></span>
</td>
<td class="nump">36,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RecognizedExpense', window );">Recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,209,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedPaymentRemnainingExpenses', window );">Share based payment remaining expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 848,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Weighted average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_VestingExpense', window );">Vesting expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,222,875<span></span>
</td>
<td class="nump">$ 1,843,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Sales and marketing (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GrantTotal', window );">Grant total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_CommonStockIssuedVested', window );">Common stock issued, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonStockIssuedVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued, vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonStockIssuedVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CompanyGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CompanyGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GrantTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GrantTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OfferingReflectingReducedExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share of offering reflecting reduced exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OfferingReflectingReducedExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RecognizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of recognized expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RecognizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SettlementOfAccountsPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of accounts payable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SettlementOfAccountsPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedPaymentRemnainingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment remnaining expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedPaymentRemnainingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_VestingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_VestingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsIssuedAndVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsIssuedAndVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_sharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_sharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_warrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_warrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_weightedAverageGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_weightedAverageGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be repaid to the counterparty to the repurchase agreement when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under the repurchase agreement exceeds 10 percent of total assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(m)(1)(ii)(A)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(m)(1)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value of the auction market preferred security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFeePaidIndirectly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6488101&amp;loc=d3e8702-115831<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFeePaidIndirectly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=adtx_OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=adtx_OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=adtx_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adtx_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adtx_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adtx_StanfordUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adtx_StanfordUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595922584784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">22.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price, Vested | $ / shares</a></td>
<td class="nump">70.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price, Forfeited | $ / shares</a></td>
<td class="nump">77.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 46.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedStockOptionsMember', window );">Vested and Nonvested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding beginning balance | shares</a></td>
<td class="nump">44,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life, Outstanding beginning balance</a></td>
<td class="text">6 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeGranted', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Number, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeExercised', window );">Weighted Average Remaining Life, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, Expired or forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeExpiredOrForfeited', window );">Weighted Average Remaining Life, Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding ending balance | shares</a></td>
<td class="nump">44,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance', window );">Weighted Average Remaining Life, Outstanding ending balance</a></td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedWarrantsMember', window );">Vested and Nonvested Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding beginning balance | shares</a></td>
<td class="nump">601,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 83.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life, Outstanding beginning balance</a></td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number, Granted | shares</a></td>
<td class="nump">6,497,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeGranted', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Number, Exercised | shares</a></td>
<td class="num">(1,946,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeExercised', window );">Weighted Average Remaining Life, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, Expired or forfeited | shares</a></td>
<td class="num">(62,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or forfeited | $ / shares</a></td>
<td class="nump">$ 45.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeExpiredOrForfeited', window );">Weighted Average Remaining Life, Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Number, Rounding for Reverse Split | shares</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceRoundingForReverseSplit', window );">Weighted Average Exercise Price, Rounding for Reverse Split | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeRoundingForReverseSplit', window );">Weighted Average Remaining Life, Rounding for Reverse Split</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding ending balance | shares</a></td>
<td class="nump">5,090,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 12.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance', window );">Weighted Average Remaining Life, Outstanding ending balance</a></td>
<td class="text">4 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedRSUsMember', window );">Nonvested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding beginning balance | shares</a></td>
<td class="nump">15,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number, Granted | shares</a></td>
<td class="nump">11,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number, Vested | shares</a></td>
<td class="num">(18,506)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number, Forfeited | shares</a></td>
<td class="num">(1,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Outstanding ending balance | shares</a></td>
<td class="nump">7,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodShareStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodShareStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceRoundingForReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share of weighted average exercise price rounding for reverse split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceRoundingForReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageRemainingLifeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life Exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageRemainingLifeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageRemainingLifeExpiredOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life, Expired or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageRemainingLifeExpiredOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageRemainingLifeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageRemainingLifeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageRemainingLifeRoundingForReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining Life, rounding for reverse split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageRemainingLifeRoundingForReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_VestedAndNonvestedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595917750816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of warranty issuance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedStockOptionsMember', window );">Nonvested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of warranty issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number, Nonvested at beginning balance | shares</a></td>
<td class="nump">9,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Nonvested at beginning balance | $ / shares</a></td>
<td class="nump">$ 108.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross', window );">Number, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceGranted', window );">Weighted- Average Exercise Price, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number, Vested | shares</a></td>
<td class="num">(7,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisesPriceVested', window );">Weighted- Average Exercise Price, Vested | $ / shares</a></td>
<td class="nump">$ 112.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceExpiredOrForfeited', window );">Weighted- Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Nonvested at ending balance | shares</a></td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Nonvested at ending balance | $ / shares</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedWarrantsMember', window );">Nonvested Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of warranty issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number, Nonvested at beginning balance | shares</a></td>
<td class="nump">92,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Nonvested at beginning balance | $ / shares</a></td>
<td class="nump">$ 75.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross', window );">Number, Granted | shares</a></td>
<td class="nump">6,497,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceGranted', window );">Weighted- Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 4.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number, Vested | shares</a></td>
<td class="num">(6,435,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisesPriceVested', window );">Weighted- Average Exercise Price, Vested | $ / shares</a></td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number, Forfeited | shares</a></td>
<td class="num">(55,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceExpiredOrForfeited', window );">Weighted- Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number, Nonvested at ending balance | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Nonvested at ending balance | $ / shares</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceExpiredOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price, Expired or forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceExpiredOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price, Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisesPriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisesPriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921896320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">147.00%<span></span>
</td>
<td class="nump">154.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems', window );"><strong>Stockholders&#8217; Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate</a></td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">0.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="nump">159.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921843072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.6<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetOperatingLossCarryover', window );">Percentage of net operating loss carryover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_incomeLossOfGenerated', window );">Income loss of generated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetOperatingLosse', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetOperatingLossesGeneratedPrior', window );">Net operating losses generated prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseDescription', window );">Net operating losses, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019
and 2020 to the five prior tax years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PercentageOfIncomeTaxable', window );">Income taxable</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestIncomeMember', window );">Interest Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetOperatingLossCarryover', window );">Percentage of net operating loss carryover</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetOperatingLossCarryover">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryover.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetOperatingLossCarryover</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetOperatingLosse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetOperatingLosse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetOperatingLossesGeneratedPrior">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating losses generated prior.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetOperatingLossesGeneratedPrior</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PercentageOfIncomeTaxable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PercentageOfIncomeTaxable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_incomeLossOfGenerated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss  of Generated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_incomeLossOfGenerated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595921816368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract', window );"><strong>Schedule Of AReconciliation Of Income Tax Expense Benefit Computed At The Statutory Federal Income Tax Rate To Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Income taxes at U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax Credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_PermanentDifferencesOthers', window );">Permanent Differences/Others</a></td>
<td class="num">(10.50%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ChangeInValuationAllowanceinDollars', window );">Change in valuation allowance</a></td>
<td class="num">(13.10%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_TotalProvisionForIncomeTaxesinDollars', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ChangeInValuationAllowanceinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ChangeInValuationAllowanceinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PermanentDifferencesOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent Differences/Others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PermanentDifferencesOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TotalProvisionForIncomeTaxesinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total provision for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TotalProvisionForIncomeTaxesinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595907386864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,499,811<span></span>
</td>
<td class="nump">$ 10,896,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Tax credits carryforwards</a></td>
<td class="nump">430,468<span></span>
</td>
<td class="nump">161,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">1,511,849<span></span>
</td>
<td class="nump">1,541,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Lease liability</a></td>
<td class="nump">722,126<span></span>
</td>
<td class="nump">1,169,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_Section174Capitalization', window );">Section 174 Capitalization</a></td>
<td class="nump">1,547,343<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Loss on impairment of debt</a></td>
<td class="nump">3,288,363<span></span>
</td>
<td class="nump">4,140,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">114,973<span></span>
</td>
<td class="nump">23,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">21,114,933<span></span>
</td>
<td class="nump">17,934,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_ValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20,217,401)<span></span>
</td>
<td class="num">(16,670,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetDeferredTaxAssets', window );">Net deferred tax assets</a></td>
<td class="nump">897,533<span></span>
</td>
<td class="nump">1,263,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_RightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(722,127)<span></span>
</td>
<td class="num">(1,169,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_FixedAssets', window );">Fixed assets</a></td>
<td class="num">(175,406)<span></span>
</td>
<td class="num">(93,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_TotalDeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(897,533)<span></span>
</td>
<td class="num">(1,263,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_NetDeferredTaxes', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetDeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetDeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_Section174Capitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Cuts and Jobs Act of 2017 (TCJA) made a significant change to Section 174 that went into effect for taxable years beginning after December 31, 2021. The change completely eliminated the ability to currently deduct R&amp;E expenses. Instead, taxpayers must now capitalize and amortize these costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_Section174Capitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TotalDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TotalDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140595922733696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2023</div></th>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Aug. 21, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
<th class="th"><div>Apr. 06, 2023</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Dec. 20, 2022</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_AggregateOfferingPriceaAmount', window );">Aggregate offering pricea amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap-sup_InvestmentCompanyIssuanceOfSharesPerShare', window );">Average price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Paying commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 507,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_GrossProceed', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties', window );">Origination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredLoanOriginationFeesNet', window );">Origination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Repayment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,500<span></span>
</td>
<td class="nump">$ 1,590,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Repayment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Final payment due</a></td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AggregateOfferingPriceaAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering pricea amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AggregateOfferingPriceaAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GrossProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GrossProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap-sup_InvestmentCompanyIssuanceOfSharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap-sup_InvestmentCompanyIssuanceOfSharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap-sup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredLoanOriginationFeesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126974470&amp;loc=d3e8622-111531<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredLoanOriginationFeesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of bad debt reserves for tax purposes of qualified lenders excluded in calculating deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109255323&amp;loc=d3e66323-112835<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28200-109314<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OriginationOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OriginationOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>f10k2022_aditxtinc_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adtx="http://www.aditxt.com./20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sic="http://xbrl.sec.gov/sic/2022"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:us-gaap-sup="http://fasb.org/us-gaap-sup/2022q3"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adtx-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2023-04-14</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-10-18</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-10-20</startDate>
            <endDate>2021-10-20</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-12-06</startDate>
            <endDate>2021-12-06</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-12-06</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-06</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-09-20</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sic:Z2520</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-08-27</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-04</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adtx:OtherFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:ProprietaryTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:TotalIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:ProprietaryTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">adtx:TotalIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-07-10</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adtx:FutureReceiptsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-05-27</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-05-27</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-12-07</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adtx:FutureReceiptsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-08-04</startDate>
            <endDate>2022-08-04</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:August2022WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:August2022FollowOnWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-09-02</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnderlyingAssetClassAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-03-01</startDate>
            <endDate>2027-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-24</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adtx:StanfordUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">adtx:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">adtx:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adtx:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-24</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">adtx:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adtx:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <instant>2022-12-20</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adtx:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:VestedAndNonvestedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-27</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-20</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-05</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-04-06</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-04-10</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-21</startDate>
            <endDate>2023-04-10</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-39336</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Aditxt, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">82-3204328</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">737 N. Fifth Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">23219</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">870-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">ADTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" unitRef="usd">7923275</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">4832714</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c0">3501</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0">dbbmckennon</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">2768640</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">7872061</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">527961</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" unitRef="usd">89844</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PublicUtilitiesInventory contextRef="c3" decimals="0" unitRef="usd">950093</us-gaap:PublicUtilitiesInventory>
    <us-gaap:PublicUtilitiesInventory contextRef="c4" decimals="0" unitRef="usd">494697</us-gaap:PublicUtilitiesInventory>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" unitRef="usd">496869</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" unitRef="usd">460102</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent contextRef="c4" decimals="0" unitRef="usd">500000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">4743563</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" unitRef="usd">9416704</us-gaap:AssetsCurrent>
    <adtx:FixedAsset contextRef="c3" decimals="0" unitRef="usd">2318863</adtx:FixedAsset>
    <adtx:FixedAsset contextRef="c4" decimals="0" unitRef="usd">2267297</adtx:FixedAsset>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">107000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c4" decimals="0" unitRef="usd">214000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c3" decimals="0" unitRef="usd">355366</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c4" decimals="0" unitRef="usd">379250</us-gaap:DepositsAssetsNoncurrent>
    <adtx:RightOfUseAssetLongTerm contextRef="c3" decimals="0" unitRef="usd">3160457</adtx:RightOfUseAssetLongTerm>
    <adtx:RightOfUseAssetLongTerm contextRef="c4" decimals="0" unitRef="usd">4097117</adtx:RightOfUseAssetLongTerm>
    <us-gaap:DeferredCosts contextRef="c3" decimals="0" unitRef="usd">50000</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="0" unitRef="usd">289539</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">10735249</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" unitRef="usd">16663907</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">1958502</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">1575543</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <adtx:FinancingOnFixedAssets contextRef="c3" decimals="0" unitRef="usd">409983</adtx:FinancingOnFixedAssets>
    <adtx:FinancingOnFixedAssets contextRef="c4" decimals="0" unitRef="usd">700433</adtx:FinancingOnFixedAssets>
    <us-gaap:DeferredRentCreditCurrent contextRef="c3" decimals="0" unitRef="usd">188581</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="c4" decimals="0" unitRef="usd">186058</us-gaap:DeferredRentCreditCurrent>
    <adtx:OperatingLeaseLiabilityShortTermCurrent contextRef="c3" decimals="0" unitRef="usd">1086658</adtx:OperatingLeaseLiabilityShortTermCurrent>
    <adtx:OperatingLeaseLiabilityShortTermCurrent contextRef="c4" decimals="0" unitRef="usd">1145126</adtx:OperatingLeaseLiabilityShortTermCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">3643724</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" unitRef="usd">3607160</us-gaap:LiabilitiesCurrent>
    <adtx:FinancingOfFixedAssetLongTerm contextRef="c4" decimals="0" unitRef="usd">110041</adtx:FinancingOfFixedAssetLongTerm>
    <adtx:OperatingLeaseLiabilityLongTermNoncurrent contextRef="c3" decimals="0" unitRef="usd">1885218</adtx:OperatingLeaseLiabilityLongTermNoncurrent>
    <adtx:OperatingLeaseLiabilityLongTermNoncurrent contextRef="c4" decimals="0" unitRef="usd">2765933</adtx:OperatingLeaseLiabilityLongTermNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">5528942</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" unitRef="usd">6483134</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">4307487</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">890614</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">4305470</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">888579</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">4307</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" unitRef="usd">899</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares contextRef="c3" decimals="0" unitRef="shares">2017</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="c4" decimals="0" unitRef="shares">2017</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="c3" decimals="0" unitRef="usd">201605</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c4" decimals="0" unitRef="usd">201605</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">100443967</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="0" unitRef="usd">77734288</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-95040362</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" unitRef="usd">-67352809</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">5206307</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">10180773</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">10735249</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" unitRef="usd">16663907</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">933715</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">105034</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" unitRef="usd">766779</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" unitRef="usd">77979</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">166936</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" unitRef="usd">27055</us-gaap:GrossProfit>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" unitRef="usd">1516805</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" unitRef="usd">3927551</us-gaap:ShareBasedCompensation>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">15985552</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">22084389</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensation contextRef="c8" decimals="0" unitRef="usd">591518</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c9" decimals="0" unitRef="usd">713130</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">7268084</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">5042617</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="0" unitRef="usd">1023045</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c11" decimals="0" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">1849460</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">334977</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c0" decimals="0" unitRef="usd">543938</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:RestructuringSettlementAndImpairmentProvisions contextRef="c5" decimals="0" unitRef="usd">14500000</us-gaap:RestructuringSettlementAndImpairmentProvisions>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">25647034</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">41961983</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-25480098</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-41934928</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="0" unitRef="usd">753038</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c5" decimals="0" unitRef="usd">93209</us-gaap:InterestExpenseOther>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" unitRef="usd">57348</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="0" unitRef="usd">3101</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" unitRef="usd">58960</us-gaap:OtherIncome>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-2500970</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" unitRef="usd">1533048</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c5" decimals="0" unitRef="usd">1845358</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OtherExpenses contextRef="c0" decimals="0" unitRef="usd">2169778</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c5" decimals="0" unitRef="usd">4436436</us-gaap:OtherExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-27649876</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-46371364</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-27649876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-46371364</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStock contextRef="c0" decimals="0" unitRef="usd">37667</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="c5" decimals="0" unitRef="usd">102267</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" unitRef="usd">-27612199</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c5" decimals="0" unitRef="usd">-46269097</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-14.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-121.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">1854724</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">381811</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="INF" unitRef="shares">888597</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">899</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">-201605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">77734288</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">-67352809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">10180773</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c21" decimals="0" unitRef="usd">1413904</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c0" decimals="0" unitRef="usd">1413904</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c20" decimals="INF" unitRef="shares">18469</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <adtx:IssuanceOfRestrictedStockUnitsForCompensation contextRef="c20" decimals="0" unitRef="usd">19</adtx:IssuanceOfRestrictedStockUnitsForCompensation>
    <adtx:IssuanceOfRestrictedStockUnitsForCompensation contextRef="c21" decimals="0" unitRef="usd">1209887</adtx:IssuanceOfRestrictedStockUnitsForCompensation>
    <adtx:IssuanceOfRestrictedStockUnitsForCompensation contextRef="c0" decimals="0" unitRef="usd">1209906</adtx:IssuanceOfRestrictedStockUnitsForCompensation>
    <adtx:IssuanceOfSharesForServicesinShares contextRef="c20" decimals="INF" unitRef="shares">148227</adtx:IssuanceOfSharesForServicesinShares>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c20" decimals="0" unitRef="usd">150</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c21" decimals="0" unitRef="usd">507408</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c0" decimals="0" unitRef="usd">507558</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <adtx:ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares contextRef="c20" decimals="INF" unitRef="shares">179419</adtx:ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c20" decimals="0" unitRef="usd">180</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c21" decimals="0" unitRef="usd">1203589</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="0" unitRef="usd">1203769</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <adtx:SaleOfSeriesBPreferredSharesToRelatedParty1 contextRef="c19" decimals="INF" unitRef="shares">1</adtx:SaleOfSeriesBPreferredSharesToRelatedParty1>
    <adtx:SaleOfSeriesBPreferredSharesToRelatedParty contextRef="c21" decimals="0" unitRef="usd">20000</adtx:SaleOfSeriesBPreferredSharesToRelatedParty>
    <adtx:SaleOfSeriesBPreferredSharesToRelatedParty contextRef="c0" decimals="0" unitRef="usd">20000</adtx:SaleOfSeriesBPreferredSharesToRelatedParty>
    <adtx:RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares contextRef="c19" decimals="INF" unitRef="shares">-1</adtx:RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c21" decimals="0" unitRef="usd">-20000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="0" unitRef="usd">-20000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares contextRef="c20" decimals="INF" unitRef="shares">47779</adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts contextRef="c20" decimals="0" unitRef="usd">48</adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts contextRef="c21" decimals="0" unitRef="usd">146474</adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts contextRef="c0" decimals="0" unitRef="usd">146522</adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCosts>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c21" decimals="0" unitRef="usd">878622</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c0" decimals="0" unitRef="usd">878622</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <adtx:ResetProvisionOnWarrantsAndModificationOfWarrants contextRef="c21" decimals="0" unitRef="usd">37677</adtx:ResetProvisionOnWarrantsAndModificationOfWarrants>
    <adtx:ResetProvisionOnWarrantsAndModificationOfWarrants contextRef="c23" decimals="0" unitRef="usd">-37677</adtx:ResetProvisionOnWarrantsAndModificationOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c20" decimals="INF" unitRef="shares">10477</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20" decimals="0" unitRef="usd">11</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c21" decimals="0" unitRef="usd">96019</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">96030</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20" decimals="INF" unitRef="shares">1766917</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <adtx:ExerciseOfWarrants contextRef="c20" decimals="0" unitRef="usd">1767</adtx:ExerciseOfWarrants>
    <adtx:ExerciseOfWarrants contextRef="c21" decimals="0" unitRef="usd">-1767</adtx:ExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c20" decimals="INF" unitRef="shares">1224333</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c20" decimals="0" unitRef="usd">1224</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c21" decimals="0" unitRef="usd">17232083</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="0" unitRef="usd">17233307</us-gaap:StockIssuedDuringPeriodValueOther>
    <adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants contextRef="c21" decimals="0" unitRef="usd">-94195</adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants>
    <adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants contextRef="c0" decimals="0" unitRef="usd">-94195</adtx:IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c20" decimals="INF" unitRef="shares">9237</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c20" decimals="0" unitRef="usd">9</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c21" decimals="0" unitRef="usd">79991</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="0" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <adtx:RoundingAdjustmentFromStockSplitShares contextRef="c20" decimals="INF" unitRef="shares">12015</adtx:RoundingAdjustmentFromStockSplitShares>
    <adtx:RoundingAdjustmentFromStockSplit contextRef="c21" decimals="0" unitRef="usd">-13</adtx:RoundingAdjustmentFromStockSplit>
    <adtx:RoundingAdjustmentFromStockSplit contextRef="c0" decimals="0" unitRef="usd">-13</adtx:RoundingAdjustmentFromStockSplit>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="0" unitRef="usd">-27649876</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-27649876</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c26" decimals="INF" unitRef="shares">4305470</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" unitRef="usd">4307</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" unitRef="usd">-201605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" unitRef="usd">100443967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" unitRef="usd">-95040362</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c31" decimals="INF" unitRef="shares">259474</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="0" unitRef="usd">262</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="0" unitRef="usd">-201605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="0" unitRef="usd">32092003</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="0" unitRef="usd">-20879178</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="0" unitRef="usd">11011482</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c38" decimals="0" unitRef="usd">1016962</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="c5" decimals="0" unitRef="usd">1016962</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c39" decimals="INF" unitRef="shares">189844</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <adtx:ExerciseOfWarrants contextRef="c39" decimals="0" unitRef="usd">191</adtx:ExerciseOfWarrants>
    <adtx:ExerciseOfWarrants contextRef="c38" decimals="0" unitRef="usd">3727094</adtx:ExerciseOfWarrants>
    <adtx:ExerciseOfWarrants contextRef="c5" decimals="0" unitRef="usd">3727285</adtx:ExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c38" decimals="0" unitRef="usd">1843902</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c5" decimals="0" unitRef="usd">1843902</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <adtx:IssuanceOfSharesForServicesinShares contextRef="c39" decimals="INF" unitRef="shares">4133</adtx:IssuanceOfSharesForServicesinShares>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c39" decimals="0" unitRef="usd">7</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c38" decimals="0" unitRef="usd">366110</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c5" decimals="0" unitRef="usd">336117</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c39" decimals="INF" unitRef="shares">9300</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c39" decimals="0" unitRef="usd">191</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c38" decimals="0" unitRef="usd">1443690</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="c5" decimals="0" unitRef="usd">1443700</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <adtx:IssuanceOfSharesForVestedRestrictedStockUnits contextRef="c39" decimals="INF" unitRef="shares">16533</adtx:IssuanceOfSharesForVestedRestrictedStockUnits>
    <adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits contextRef="c39" decimals="0" unitRef="usd">18</adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits>
    <adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits contextRef="c38" decimals="0" unitRef="usd">-18</adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c39" decimals="INF" unitRef="shares">96050</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <adtx:IssuanceOfSharesForTheSettlementOfDebt contextRef="c39" decimals="0" unitRef="usd">97</adtx:IssuanceOfSharesForTheSettlementOfDebt>
    <adtx:IssuanceOfSharesForTheSettlementOfDebt contextRef="c38" decimals="0" unitRef="usd">5749825</adtx:IssuanceOfSharesForTheSettlementOfDebt>
    <adtx:IssuanceOfSharesForTheSettlementOfDebt contextRef="c5" decimals="0" unitRef="usd">5749922</adtx:IssuanceOfSharesForTheSettlementOfDebt>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c38" decimals="0" unitRef="usd">1322840</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c5" decimals="0" unitRef="usd">1322840</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c39" decimals="INF" unitRef="shares">256596</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c39" decimals="0" unitRef="usd">257</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c38" decimals="0" unitRef="usd">26123354</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="0" unitRef="usd">26123611</us-gaap:StockIssuedDuringPeriodValueOther>
    <adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares contextRef="c39" decimals="INF" unitRef="shares">56667</adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares>
    <adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts contextRef="c39" decimals="0" unitRef="usd">57</adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts>
    <adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts contextRef="c38" decimals="0" unitRef="usd">3744943</adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts>
    <adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts contextRef="c5" decimals="0" unitRef="usd">3745000</adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c38" decimals="0" unitRef="usd">231316</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c5" decimals="0" unitRef="usd">231316</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c38" decimals="0" unitRef="usd">102267</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c40" decimals="0" unitRef="usd">-102267</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c40" decimals="0" unitRef="usd">-46371364</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-46371364</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="INF" unitRef="shares">888597</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="0" unitRef="usd">899</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" unitRef="usd">-201605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" unitRef="usd">77734288</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" unitRef="usd">-67352809</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" unitRef="usd">10180773</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-27649876</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">-46371364</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">3131368</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">4640681</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">428977</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">369236</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">107000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" unitRef="usd">107000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" unitRef="usd">1533048</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c5" decimals="0" unitRef="usd">1845358</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c5" decimals="0" unitRef="usd">-2500970</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c0" decimals="0" unitRef="usd">-543938</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c5" decimals="0" unitRef="usd">-14500000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <adtx:DisposalOfFixedAssets1 contextRef="c0" decimals="0" unitRef="usd">6976</adtx:DisposalOfFixedAssets1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">36767</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">312460</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" unitRef="usd">-23884</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c5" decimals="0" unitRef="usd">306954</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDepositsOutstanding contextRef="c0" decimals="0" unitRef="usd">438117</us-gaap:IncreaseDecreaseInDepositsOutstanding>
    <us-gaap:IncreaseDecreaseInDepositsOutstanding contextRef="c5" decimals="0" unitRef="usd">89844</us-gaap:IncreaseDecreaseInDepositsOutstanding>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">455396</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" unitRef="usd">494697</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" unitRef="usd">412959</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" unitRef="usd">1333930</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-22392006</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-22278144</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="c0" decimals="0" unitRef="usd">367079</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="c5" decimals="0" unitRef="usd">1015752</us-gaap:PaymentsForProceedsFromProductiveAssets>
    <adtx:TIAllowanceReceivable contextRef="c0" decimals="0" unitRef="usd">-125161</adtx:TIAllowanceReceivable>
    <adtx:TIAllowanceReceivable contextRef="c5" decimals="0" unitRef="usd">287018</adtx:TIAllowanceReceivable>
    <adtx:NoteReceivablesAndAccruedInterest contextRef="c5" decimals="0" unitRef="usd">15002521</adtx:NoteReceivablesAndAccruedInterest>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-241918</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-16305291</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromSecuredNotesPayable contextRef="c0" decimals="0" unitRef="usd">80000</us-gaap:ProceedsFromSecuredNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="0" unitRef="usd">80000</us-gaap:RepaymentsOfNotesPayable>
    <adtx:DiscountOnConvertibleNotePayableFromOfferingCosts contextRef="c0" decimals="0" unitRef="usd">2795000</adtx:DiscountOnConvertibleNotePayableFromOfferingCosts>
    <adtx:DiscountOnConvertibleNotePayableFromOfferingCosts contextRef="c5" decimals="0" unitRef="usd">4473540</adtx:DiscountOnConvertibleNotePayableFromOfferingCosts>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="c0" decimals="0" unitRef="usd">-3206887</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="c5" decimals="0" unitRef="usd">-315790</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <adtx:SaleOfPreferredSharesToRelatedParty contextRef="c0" decimals="0" unitRef="usd">20000</adtx:SaleOfPreferredSharesToRelatedParty>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c0" decimals="0" unitRef="usd">-20000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" unitRef="usd">17233307</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c5" decimals="0" unitRef="usd">29868611</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="0" unitRef="usd">1109574</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c5" decimals="0" unitRef="usd">3727285</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c0" decimals="0" unitRef="usd">400491</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c5" decimals="0" unitRef="usd">598976</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c5" decimals="0" unitRef="usd">1200000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="usd">17530503</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">35954670</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-5103421</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">-2628765</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">7872061</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="0" unitRef="usd">10500826</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">2768640</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">7872061</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestExpenseOtherLongTermDebt contextRef="c0" decimals="0" unitRef="usd">753038</us-gaap:InterestExpenseOtherLongTermDebt>
    <us-gaap:InterestExpenseOtherLongTermDebt contextRef="c5" decimals="0" unitRef="usd">15789</us-gaap:InterestExpenseOtherLongTermDebt>
    <adtx:OriginalOfferingDiscountOnConvertibleNotePayable contextRef="c5" decimals="0" unitRef="usd">5749922</adtx:OriginalOfferingDiscountOnConvertibleNotePayable>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="0" unitRef="usd">3131388</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c0" decimals="0" unitRef="usd">80000</us-gaap:StockIssued1>
    <adtx:OriginalIssuanceDiscountOnNotesPayable contextRef="c5" decimals="0" unitRef="usd">1000000</adtx:OriginalIssuanceDiscountOnNotesPayable>
    <adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable contextRef="c0" decimals="0" unitRef="usd">878622</adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable>
    <adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable contextRef="c5" decimals="0" unitRef="usd">1322840</adtx:DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable>
    <adtx:DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts contextRef="c5" decimals="0" unitRef="usd">231316</adtx:DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">146522</us-gaap:ConvertibleNotesPayableCurrent>
    <adtx:LiabilityRecognizedForFinancedAssets contextRef="c5" decimals="0" unitRef="usd">821862</adtx:LiabilityRecognizedForFinancedAssets>
    <adtx:ReductionInExercisePriceOfWarrants contextRef="c5" decimals="0" unitRef="usd">102267</adtx:ReductionInExercisePriceOfWarrants>
    <adtx:SharesIssuedForIntangibleAssets contextRef="c0" decimals="0" unitRef="usd">96030</adtx:SharesIssuedForIntangibleAssets>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="c0" decimals="0" unitRef="usd">37677</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:IncreaseDecreaseInDeferredCharges contextRef="c0" decimals="0" unitRef="usd">50000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2013; ORGANIZATION AND NATURE OF BUSINESS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Company Background&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Overview&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are a biotech innovation company with a mission
of prolonging life and enhancing its quality by improving the health of the immune system. We are an innovation company developing and
commercializing technologies with a focus on monitoring and modulating the immune system. Our immune reprogramming technologies are currently
at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection
of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technologies are designed to provide a personalized
comprehensive profile of the immune system and we plan to utilize them in our upcoming reprogramming clinical trials to monitor subjects&#x2019;
immune response before, during and after drug administration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 13, 2022, the Company effectuated
a 1 for 50 reverse stock split (the &#x201c;Reverse Split&#x201d;). The Company&#x2019;s stock began trading on a split-adjusted basis effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#x2019;s common
stock. All shares amounts referenced in this report are adjusted to reflect the Reverse Split.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Offerings&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2021, the Company completed a registered
direct offering (&#x201c;August 2021 Offering&#x201d;). In connection therewith, the Company issued&#160;91,667&#160;shares of common stock,
at a purchase price of $120.00&#160;per share, resulting in gross proceeds of approximately $11.0&#160;million. In a concurrent private
placement, the Company issued warrants to purchase up to&#160;91,667&#160;shares.&#160;The warrants have an exercise price of $126.50&#160;per
share and are exercisable for a&#160;five-year&#160;period commencing six months from the date of issuance.&#160;The warrants exercise
price was subsequently repriced to $75.00. In addition, the Company issued a warrant to the placement agent to purchase up to&#160;4,584&#160;shares
of common stock at an exercise price of $150.00&#160;per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 18, 2021, the Company entered into
an underwriting agreement with Revere Securities LLC, relating to the public offering (the &#x201c;October 2021 Offering&#x201d;) of&#160;56,667&#160;shares
of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) by the Company. The Shares were offered, issued, and sold at a price to
the public of $75.00&#160;per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective
shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13,
2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25&#160;million. The Company utilized a portion of
the proceeds, net of underwriting discounts of approximately $3.91&#160;million from the October 2021 Offering to fund certain obligations
under the Credit Agreement. (See Note 4)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 6, 2021, the Company completed a public
offering for net proceeds of $16.0&#160;million (the &#x201c;December 2021 Offering&#x201d;). As part of the December 2021 Offering, we
issued&#160;164,929&#160;units consisting of shares of the Company&#x2019;s common stock and warrant to purchase shares of the Company&#x2019;s
common stock and&#160;166,572&#160;prefunded warrants. The warrant issued as part of the units had an exercise price of $57.50&#160;and
the prefunded warrants had an exercise price of $0.001. On June 15, 2022, the Company entered an agreement with a holder of certain warrants
in the December 2021 Offering. (See Note 11)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 20, 2022, the Company completed a
public offering for net proceeds of $17.2&#160;million (the &#x201c;September 2022 Offering&#x201d;). As part of the September 2022 Offering,
we issued&#160;1,224,333 of shares of the Company&#x2019;s common stock, pre-funded warrants to purchase 2,109,000 shares of common stock,
and warrants to purchase 3,333,333 shares of the Company&#x2019;s common stock. The warrants had an exercise price of $6.00&#160;and the
pre-funded warrants had an exercise price of $0.001.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a limited operating history and
is in the very early stages of generating revenue from intended operations. The Company&#x2019;s business and operations are sensitive
to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions.
A host of factors beyond the Company&#x2019;s control could cause fluctuations in these conditions. Adverse conditions may include: changes
in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for
clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These
adverse conditions could affect the Company&#x2019;s financial condition and the results of its operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &#x201c;Public Health Emergency of
International Concern&#x201d; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the
spread of the coronavirus included restrictions on travel, and quarantines in certain areas, and forced closures for certain types of
public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had an adverse impact on the economies and
financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these
conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts
and additional development of our technologies may be negatively affected.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonUnitIssued contextRef="c41" decimals="0" unitRef="shares">91667</us-gaap:CommonUnitIssued>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare contextRef="c42" decimals="2" unitRef="usdPershares">120</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds contextRef="c42" decimals="-5" unitRef="usd">11000000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="c42" decimals="0" unitRef="shares">91667</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <adtx:DebtInstrumentTermDescription contextRef="c42">The warrants have an exercise price of $126.50&#160;per
share and are exercisable for a&#160;five-year&#160;period commencing six months from the date of issuance.</adtx:DebtInstrumentTermDescription>
    <adtx:WarrantsExercisePrice contextRef="c41" decimals="2" unitRef="usdPershares">75</adtx:WarrantsExercisePrice>
    <adtx:PurchaseOfCommonStock contextRef="c41" decimals="0" unitRef="shares">4584</adtx:PurchaseOfCommonStock>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c43" decimals="2" unitRef="usdPershares">150</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:CommonUnitIssued contextRef="c44" decimals="0" unitRef="shares">56667</us-gaap:CommonUnitIssued>
    <adtx:ExercisePricePerShares contextRef="c45" decimals="2" unitRef="usdPershares">75</adtx:ExercisePricePerShares>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds contextRef="c46" decimals="-4" unitRef="usd">4250000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:OtherUnderwritingExpense contextRef="c46" decimals="-4" unitRef="usd">3910000</us-gaap:OtherUnderwritingExpense>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c47" decimals="-5" unitRef="usd">16000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:CommonUnitIssued contextRef="c48" decimals="0" unitRef="shares">164929</us-gaap:CommonUnitIssued>
    <adtx:PrefundedWarrantsShares contextRef="c48" decimals="0" unitRef="shares">166572</adtx:PrefundedWarrantsShares>
    <adtx:ExercisePricePerShares contextRef="c47" decimals="2" unitRef="usdPershares">57.5</adtx:ExercisePricePerShares>
    <adtx:PrefundedWarrantsShares contextRef="c49" decimals="3" unitRef="shares">0.001</adtx:PrefundedWarrantsShares>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c50" decimals="-5" unitRef="usd">17200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <adtx:ExercisePricePerShares contextRef="c51" decimals="0" unitRef="usdPershares">1224333</adtx:ExercisePricePerShares>
    <adtx:PurchaseOfEquityShares contextRef="c52" decimals="0" unitRef="shares">2109000</adtx:PurchaseOfEquityShares>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="c53" decimals="0" unitRef="shares">3333333</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c53" decimals="2" unitRef="usdPershares">6</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c52" decimals="3" unitRef="usdPershares">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <adtx:GoingConcernsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; GOING CONCERN ANALYSIS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Management Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was incorporated on September 28,
2017 and has not generated significant revenues to date. During the year ended December 31, 2022, the Company had a net loss of $27,649,876&#160;and
negative cash flow from operating activities of $22,049,040. As of December 31, 2022, the Company&#x2019;s cash balance was $2,768,640.
As of December 31, 2022, the Company had $51.5&#160;million of&#160;remaining availability, subject to regulatory requirements, to raise
future funds pursuant to an effective shelf registration statement filed with the SEC on Form S-3 declared effective on July 13, 2021.
However, factors such as stock price, volatility, trading volume, market conditions, demand and regulatory requirements may adversely
affect the Company&#x2019;s ability to raise capital in an efficient manner.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition to the shelf registration, the Company
has the ability to raise capital from equity of debt through private placements or public offerings pursuant to a registration statement
on Form S-1. We may also secure loans from related parties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Because of these factors, the Company believes
that this creates substantial doubt with the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The financial statements included in this report
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the matters discussed herein. The Company&#x2019;s ability to continue as a going
concern is dependent upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to
control operating expenses. In addition, the Company is consistently focused on raising capital, strategic acquisitions and alliances,
and other initiatives to strengthen the Company.&lt;/p&gt;</adtx:GoingConcernsDisclosureTextBlock>
    <adtx:NetLossCashFlowFromOperatingActivities contextRef="c0" decimals="0" unitRef="usd">27649876</adtx:NetLossCashFlowFromOperatingActivities>
    <us-gaap:InterestPaid contextRef="c0" decimals="0" unitRef="usd">22049040</us-gaap:InterestPaid>
    <us-gaap:Cash contextRef="c3" decimals="0" unitRef="usd">2768640</us-gaap:Cash>
    <us-gaap:CustomerFunds contextRef="c3" decimals="-5" unitRef="usd">51500000</us-gaap:CustomerFunds>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and
the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the
reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include
the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair
value of stock options and warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements and Fair Value of
Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company adopted Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company did not identify any assets or liabilities
that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to the short-term nature of all financial
assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains its cash accounts at financial
institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally
insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Substantially all the Company&#x2019;s accounts
receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk
is mitigated due to the Company&#x2019;s number of customers. In addition, for receivables due from U.S government agencies, the Company
does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and
payment is primarily dependent upon submitting the appropriate documentation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include short-term,
liquid investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consists of laboratory materials and
supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable
value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fixed Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fixed assets are stated at cost less accumulated
depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs
are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are
removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the
straight-line method over the estimated useful lives or lease life of the related assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Useful lives assigned to fixed assets are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three years to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Seven to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other fixed assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are stated at cost less accumulated
amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated
useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful
Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are stated at the amount management
expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company
determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management.
As of December 31, 2022 and 2021, there was an allowance for doubtful accounts of $18,634&#160;and&#160;zero, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Offering costs incurred in connection with equity are recorded as a
reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 606 (Revenue From Contracts
with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects
the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle,
the Company applies the following five steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Identify the contract with a customer&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Identify the performance obligations in the contract&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Determine the transaction price&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Allocate the transaction price to performance obligations in the contract&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recognize revenue when or as the Company satisfies a performance obligation&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues reported from services relating to the
AditxtScore&#x2122; are recognized when the AditxtScore&lt;sup&gt;TM &lt;/sup&gt;report is delivered to the customer. The services performed include
the analysis of specimens received in the Company&#x2019;s CLIA laboratory and the generation of results which are then delivered upon
completion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue in the following
manner for the following types of customers:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Client Payers:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Client payers include physicians or other entities
for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for
client payers based on historical collection experience and the period of time the receivable has been outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash Pay:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Customers are billed based on established patient
fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the
ability of the patients to pay.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Insurance:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Reimbursements from healthcare insurers are based
on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between
amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of
the Company&#x2019;s contractual arrangements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under Topic 842 (Leases), operating lease expense
is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space,
and lab equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases with an initial term of twelve months or
less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right
of use (&#x201c;ROU&#x201d;) assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based compensation
costs under the provisions of ASC 718, Compensation&#x2014;Stock Compensation, which requires the measurement and recognition of compensation
expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense
recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant
date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled
during the periods reported. Stock-based compensation is recognized as expense over the employee&#x2019;s requisite vesting period and
over the nonemployee&#x2019;s period of providing goods or services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company incurs fees from patent licenses,
which is reflected in research and development expenses, and are expensed as incurred. During the years ended December 31, 2022 and 2021,
the Company incurred patent licensing fees for the patents of $263,273&#160;and $76,455, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We incur research and development costs during
the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs
qualify for capitalization under applicable guidance. During the years ended December 31, 2022 and 2021, the Company incurred research
and development costs of $7,268,084 and $5,042,617, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per common share is computed by dividing the net loss by
the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the
net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect
of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock
equivalents because their inclusion would be anti-dilutive. As of December 31, 2022,&#160;44,710&#160;stock options,&#160;7,197&#160;unvested&#160;restricted
stock units, and&#160;5,090,024&#160;warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of
December 31, 2021,&#160;44,710&#160;stock options, 15,565 unvested restricted stock units and&#160;601,399&#160;warrants were excluded
from dilutive earnings per share as their effects were anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2022 and 2021,
the Company recognized an implied dividend from the modification of warrants of $37,667 and $102,267, respectively. Theses implied dividends
resulted in an increase in the net loss attributable to common stockholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The FASB issues ASUs to amend the authoritative
literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes
that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or
(iv) are not expected to have a significant impact on our financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and
the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the
reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include
the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair
value of stock options and warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements and Fair Value of
Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company adopted Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, Fair Value Measurements. ASC Topic 820 clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 58px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 -&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company did not identify any assets or liabilities
that are required to be presented on the balance sheets at fair value in accordance with ASC Topic 820.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to the short-term nature of all financial
assets and liabilities, their carrying value approximates their fair value as of the balance sheet dates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains its cash accounts at financial
institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally
insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Substantially all the Company&#x2019;s accounts
receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk
is mitigated due to the Company&#x2019;s number of customers. In addition, for receivables due from U.S government agencies, the Company
does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and
payment is primarily dependent upon submitting the appropriate documentation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include short-term,
liquid investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consists of laboratory materials and
supplies used in laboratory analysis. We capitalize inventory when purchased. Inventory is valued at the lower of cost or net realizable
value on a first-in, first-out basis. We periodically perform obsolescence assessments and write off any inventory that is no longer usable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <adtx:FixedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fixed Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fixed assets are stated at cost less accumulated
depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and other assets. Maintenance and repairs
are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are
removed from the accounts and any resulting gain or loss is reflected in operations. The costs of fixed assets are depreciated using the
straight-line method over the estimated useful lives or lease life of the related assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Useful lives assigned to fixed assets are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three years to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Seven to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other fixed assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</adtx:FixedAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 50%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three years to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab Equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Seven to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office Furniture&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other fixed assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Five to ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="c54">Three years to five years</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="c55">Seven to ten years</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="c56">Five to ten years</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="c57">Five to ten years</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="c58">Shorter of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intangible assets are stated at cost less accumulated
amortization. For intangible assets that have finite lives, the assets are amortized using the straight-line method over the estimated
useful lives of the related assets. For intangible assets with indefinite lives, the assets are tested periodically for impairment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful
Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable are stated at the amount management
expects to collect from outstanding balances. The Company generally does not require collateral to support customer receivables. The Company
determines if receivables are past due based on days outstanding, and amounts are written off when determined to be uncollectible by management.
As of December 31, 2022 and 2021, there was an allowance for doubtful accounts of $18,634&#160;and&#160;zero, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="c3" decimals="0" unitRef="usd">18634</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables contextRef="c4" decimals="0" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <adtx:OfferingCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Offering costs incurred in connection with equity are recorded as a
reduction of equity and offering costs incurred in connection with debt are recorded as a reduction of debt as a debt discount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</adtx:OfferingCostsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 606 (Revenue From Contracts
with Customers), revenue is recognized when a customer obtains control of promised services. The amount of revenue recognized reflects
the consideration to which the Company expects to be entitled to receive in exchange for these services. To achieve this core principle,
the Company applies the following five steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Identify the contract with a customer&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Identify the performance obligations in the contract&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Determine the transaction price&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Allocate the transaction price to performance obligations in the contract&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recognize revenue when or as the Company satisfies a performance obligation&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues reported from services relating to the
AditxtScore&#x2122; are recognized when the AditxtScore&lt;sup&gt;TM &lt;/sup&gt;report is delivered to the customer. The services performed include
the analysis of specimens received in the Company&#x2019;s CLIA laboratory and the generation of results which are then delivered upon
completion.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes revenue in the following
manner for the following types of customers:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Client Payers:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Client payers include physicians or other entities
for which services are billed based on negotiated fee schedules. The Company principally estimates the allowance for credit losses for
client payers based on historical collection experience and the period of time the receivable has been outstanding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash Pay:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Customers are billed based on established patient
fee schedules or fees negotiated with physicians on behalf of their patients. Collection of billings is subject to credit risk and the
ability of the patients to pay.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Insurance:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Reimbursements from healthcare insurers are based
on fee for service schedules. Net revenues recognized consist of amounts billed net of contractual allowances for differences between
amounts billed and the estimated consideration the Company expects to receive from such payers, collection experience, and the terms of
the Company&#x2019;s contractual arrangements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under Topic 842 (Leases), operating lease expense
is generally recognized evenly over the term of the lease. The Company has operating leases consisting of office space, laboratory space,
and lab equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases with an initial term of twelve months or
less are not recorded on the balance sheet. We combine the lease and non-lease components in determining the lease liabilities and right
of use (&#x201c;ROU&#x201d;) assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for stock-based compensation
costs under the provisions of ASC 718, Compensation&#x2014;Stock Compensation, which requires the measurement and recognition of compensation
expense related to the fair value of stock-based compensation awards that are ultimately expected to vest. Stock-based compensation expense
recognized includes the compensation cost for all stock-based payments granted to employees, officers, and directors based on the grant
date fair value estimated in accordance with the provisions of ASC 718. ASC 718 is also applied to awards modified, repurchased, or cancelled
during the periods reported. Stock-based compensation is recognized as expense over the employee&#x2019;s requisite vesting period and
over the nonemployee&#x2019;s period of providing goods or services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <adtx:PatentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company incurs fees from patent licenses,
which is reflected in research and development expenses, and are expensed as incurred. During the years ended December 31, 2022 and 2021,
the Company incurred patent licensing fees for the patents of $263,273&#160;and $76,455, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</adtx:PatentsPolicyTextBlock>
    <adtx:LicensingFeeForPatents contextRef="c0" decimals="0" unitRef="usd">263273</adtx:LicensingFeeForPatents>
    <adtx:LicensingFeeForPatents contextRef="c5" decimals="0" unitRef="usd">76455</adtx:LicensingFeeForPatents>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We incur research and development costs during
the process of researching and developing our technologies and future offerings. We expense these costs as incurred unless such costs
qualify for capitalization under applicable guidance. During the years ended December 31, 2022 and 2021, the Company incurred research
and development costs of $7,268,084 and $5,042,617, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">7268084</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">5042617</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per common share is computed by dividing the net loss by
the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the
net loss attributable of common stockholders by the weighted average number of shares of common stock outstanding plus the dilutive effect
of shares issuable through the common stock equivalents. The weighted-average number of common shares outstanding excludes common stock
equivalents because their inclusion would be anti-dilutive. As of December 31, 2022,&#160;44,710&#160;stock options,&#160;7,197&#160;unvested&#160;restricted
stock units, and&#160;5,090,024&#160;warrants were excluded from dilutive earnings per share as their effects were anti-dilutive. As of
December 31, 2021,&#160;44,710&#160;stock options, 15,565 unvested restricted stock units and&#160;601,399&#160;warrants were excluded
from dilutive earnings per share as their effects were anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2022 and 2021,
the Company recognized an implied dividend from the modification of warrants of $37,667 and $102,267, respectively. Theses implied dividends
resulted in an increase in the net loss attributable to common stockholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <adtx:WarrantsOfStockOptions contextRef="c0" decimals="0" unitRef="shares">44710</adtx:WarrantsOfStockOptions>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock contextRef="c0" decimals="0" unitRef="shares">7197</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <adtx:DilutiveEarningShares contextRef="c0" decimals="0" unitRef="shares">5090024</adtx:DilutiveEarningShares>
    <adtx:WarrantsOfStockOptions contextRef="c5" decimals="0" unitRef="shares">44710</adtx:WarrantsOfStockOptions>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock contextRef="c5" decimals="0" unitRef="shares">15565</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <adtx:WarrantsExercisedShares contextRef="c5" decimals="0" unitRef="shares">601399</adtx:WarrantsExercisedShares>
    <us-gaap:RestrictedStockAwardForfeituresDividends contextRef="c0" decimals="0" unitRef="usd">37667</us-gaap:RestrictedStockAwardForfeituresDividends>
    <us-gaap:RestrictedStockAwardForfeituresDividends contextRef="c5" decimals="0" unitRef="usd">102267</us-gaap:RestrictedStockAwardForfeituresDividends>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The FASB issues ASUs to amend the authoritative
literature in ASC. There have been several ASUs to date, including those above, that amend the original text of ASC. Management believes
that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or
(iv) are not expected to have a significant impact on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; NOTE RECEIVABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cellvera Global Note Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 25, 2021, the Company entered into a
letter of intent (&#x201c;the LOI&#x201d;) to acquire AiPharma Global Holdings LLC, a Delaware limited liability company, which subsequently
changed its name to Cellvera Global Holdings LLC (&#x201c;Cellvera Global&#x201d;) which is commercializing COVID-19 antiviral oral therapy.
Key terms of the proposed transaction as stated in the Letter of Intent included: the completion of a proposed $6.5&#160;million secured
loan from the Company to Cellvera Global by August 31, 2021, as well as the issuance of such number of shares of the Company&#x2019;s common
stock that yields&#160;50% of the number of the Company&#x2019;s outstanding shares post-closing of the transaction. The acquisition is
subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive
agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed
to be issued in the transaction. The Company and Cellvera Global agreed to an exclusivity period until September 30, 2021 (the &#x201c;Exclusivity
Period&#x201d;), with a view to settling the definitive agreement. On September 30, 2021, the parties entered into a letter agreement pursuant
to which they agreed to extend the Exclusivity Period until October 4, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 28, 2021, we entered into a Share
Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued and outstanding
equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of
$250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5%
of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and
a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.&#160;Additionally,
we may elect to raise additional capital due to market conditions or strategic considerations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the contemplated acquisition
with Cellvera Global,&#160;the Company entered into a secured credit agreement dated August 27, 2021 (the &#x201c;Credit Agreement&#x201d;)
with Cellvera Global and certain affiliated entities (collectively, the &#x201c;Borrower&#x201d;), pursuant to which the Company made a
secured loan to Cellvera Global in the principal amount of $6.5&#160;million (the &#x201c;Loan&#x201d;). The Loan was funded on August 31,
2021, following the closing of the Company&#x2019;s August 2021 Offering. The Loan bears interest at a rate of&#160;8% per annum and matured
on November 30, 2021. The Loan is secured by certain accounts receivable and other assets of Cellvera Global and certain of its affiliates.
The Credit Agreement also contains certain covenants that prohibit Cellvera Global from incurring additional indebtedness, incurring liens
or making any dispositions of its property.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 18, 2021,&#160;the Company entered
into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the &#x201c;Credit Agreement Amendment&#x201d;),
pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by
$8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment.
The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the
Company from the exercise of existing warrants or any other capital raises, including the October Offering.&#160;As of December 31, 2021,
an additional $8.0&#160;million was advanced under the Credit Agreement for a total of $14.5&#160;million.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Credit Agreement was amended on multiple occasions,
for which the final amendment was signed on December 31, 2021, extending the Loan&#x2019;s maturity date to January 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined that Cellvera Global may
not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of $14.5&#160;million as of December
31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Forbearance Agreement:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 31, 2022, the Company&#x2019;s $14.5&#160;million
loan to Cellvera Global became fully due and payable under the Credit Agreement. On February 14, 2022, the Company entered into a Forbearance
Agreement and Seventh Amendment to Credit Agreement (the &#x201c;Forbearance Agreement&#x201d;) with Cellvera Global.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Forbearance Agreement, the Company
agreed to forbear from exercising its rights and remedies against Cellvera Global and certain affiliated guarantor parties until the earlier
of (i) June 30, 2022 or (ii) the date of occurrence of any event of default under the Forbearance Agreement (the &#x201c;Forbearance Period&#x201d;).
Given that the parties continue to conduct due diligence in connection with the Share Exchange Agreement, the Company and Cellvera Global
also agreed that should the initial closing occur under the Share Exchange Agreement, the existing event of default will be waived. Under
the Forbearance Agreement, the Company and Cellvera Global also agreed to certain amendments to the Credit Agreement, including, but not
limited to: (i) the delivery by the Borrower of certain financial statements and forecasts, and (ii) certain regularly scheduled payments
to be made by Cellvera Global to the Company during the Forbearance Period. As of the date of filing of this Quarterly Report, the regularly
scheduled payments under the Forbearance Agreement have not been made, and the note receivable remains fully impaired.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 4, 2022, the Company and Cellvera Global
entered into a Forbearance Agreement and Eighth Amendment to the Credit Agreement (the &#x201c;April Forbearance Agreement&#x201d;) pursuant
to which among other things (i) the Company agreed to extend the forbearance period until the earlier of March 31, 2023 or the date of
occurrence of any event of default under the April Forbearance Agreement, (ii) Cellvera Global shall be permitted to factor certain receivables,
and (iii) certain conforming changes were made relating to the Revenue Sharing Agreement (as defined below). In connection with the Forbearance
Agreement, the Company entered into a series of security agreements with Cellvera Global (the &#x201c;Security Agreements&#x201d;) and certain
affiliated entities pursuant to which Cellvera Global enhanced the Company&#x2019;s security interest in connection with the Credit Agreement.
In addition, and as a condition to entering into the April Forbearance Agreement, the Company required that Cellvera Global enter into
a Revenue Sharing Agreement (the &#x201c;Revenue Sharing Agreement&#x201d;), pursuant to which, among other things, Cellvera Global agreed
to pay the Company a certain portion of its revenues up to the aggregate amount of $30&#160;million. As of the date of filing of this
Annual Report, the Company has not received any payments from Cellvera Global pursuant to the Revenue Sharing Agreement. Upon termination
of the April Forbearance agreement, the amounts under the Secured Credit agreement (as amended) shall become immediately due and payable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrently with the execution of the April Forbearance
Agreement and the Revenue Sharing Agreement, the Company and AiPharma Group, Ltd. entered into an Amendment to the Share Exchange Agreement
(the &#x201c;Share Exchange Amendment&#x201d;) which amended the Share Exchange Agreement to, among other things: (i) modify the financial
statements required to be delivered by AiPharma Group, Ltd. at the initial closing to include the unaudited financial statements for the
three months ended March 31, 2022 and 2021, (ii) permit the Company to amend its Certificate of Incorporation without the consent of AiPharma
Group, Ltd. in order to effect a reverse stock split of the Company&#x2019;s common stock, if necessary, in order to maintain its listing
on the Nasdaq Capital Market, and (iii) make certain other conforming changes related to the March Forbearance Agreement and Revenue Sharing
Agreement.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Target Company Note Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 10, 2021, the Company entered into
a secured credit agreement dated December 10, 2021 (the &#x201c;Target Company Credit Agreement&#x201d;) and signed on December 10, 2021
with the Target Company, pursuant to which the Company made a secured loan to the Target Company in the principal amount of $500,000 (the
&#x201c;Target Company Loan&#x201d;) and agreed to make additional secured loans, as requested by the Target Company and approved by the
Company, in an amount not to exceed $4.5 million. The Target Company Loan bears interest at a rate of 8% per annum and mature on December
8, 2022, provided, that the Letter of Intent currently contemplates that the Target Company Loan will be forgivable upon the closing of
the acquisition contemplated by the letter of intent. The Target Company Credit Agreement also contains certain covenants that prohibit
the Target Company from incurring additional indebtedness, entering into any fundamental transactions, issuing any equity interests subject
to certain limited exceptions, or making any dispositions of its property. In connection with the Target Company Credit Agreement, the
Company entered into a Security Agreement with the Target Company, pursuant to which the Target Company granted the Company a security
interest in all of the Target Company&#x2019;s assets as security for the Target Company Loan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined that the Target Company
may not have the ability to repay the note receivable. Accordingly, the Company recognized a full impairment of the principal and accrued
interest of $0.5&#160;million as of December 31, 2022.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:OtherLoansPayable contextRef="c59" decimals="-5" unitRef="usd">6500000</us-gaap:OtherLoansPayable>
    <adtx:CommonStockYieldsPercentage contextRef="c60" decimals="2" unitRef="pure">0.50</adtx:CommonStockYieldsPercentage>
    <adtx:DescriptionOfShareExchangeAgreement contextRef="c61">On December 28, 2021, we entered into a Share
Exchange Agreement with Cellvera Global f/k/a AiPharma Global, pursuant to which we&#160;(i) will acquire 9.5% of the issued and outstanding
equity interests in Cellvera Global in exchange for the issuance of 96,324 shares of our common stock of Aditxt and a cash payment of
$250,000, at an initial closing upon the satisfaction or waiver of certain conditions to closing; and (ii) acquire the remaining 90.5%
of the issued and outstanding equity interests in Cellvera Global in exchange for the issuance of 798,560 shares of our common stock and
a cash payment of $250,000 at a secondary closing upon the satisfaction or waiver of certain conditions to closing.</adtx:DescriptionOfShareExchangeAgreement>
    <us-gaap:PrincipalAmountOutstandingOnLoansSecuritized contextRef="c62" decimals="-5" unitRef="usd">6500000</us-gaap:PrincipalAmountOutstandingOnLoansSecuritized>
    <us-gaap:InvestmentInterestRate contextRef="c63" decimals="2" unitRef="pure">0.08</us-gaap:InvestmentInterestRate>
    <adtx:CreditAgreementAmendmentDescription contextRef="c64">the Company entered
into the first amendment to the Credit Agreement with Cellvera Global and certain affiliated entities (the &#x201c;Credit Agreement Amendment&#x201d;),
pursuant to which the Company agreed to increase the amount which Cellvera Global was permitted to borrow under the Credit Agreement by
$8.5 million to an aggregate of $15.0 million, of which $6.5 million was outstanding prior to entering the Credit Agreement Amendment.
The Company agreed to fund such additional borrowings, as requested by Cellvera Global, by advancing 70% of any amounts received by the
Company from the exercise of existing warrants or any other capital raises, including the October Offering.</adtx:CreditAgreementAmendmentDescription>
    <adtx:AdvancedCreditAgreement contextRef="c5" decimals="-5" unitRef="usd">8000000</adtx:AdvancedCreditAgreement>
    <adtx:CreditAgreement contextRef="c5" decimals="-5" unitRef="usd">14500000</adtx:CreditAgreement>
    <us-gaap:LoansReceivableWithVariableRatesOfInterest1 contextRef="c4" decimals="-5" unitRef="usd">14500000</us-gaap:LoansReceivableWithVariableRatesOfInterest1>
    <us-gaap:SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss contextRef="c65" decimals="-5" unitRef="usd">14500000</us-gaap:SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c66" decimals="-6" unitRef="usd">30000000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c67" decimals="0" unitRef="usd">500000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <adtx:DebtLoanAmount contextRef="c68" decimals="-5" unitRef="usd">4500000</adtx:DebtLoanAmount>
    <us-gaap:LoansReceivableWithFixedRatesOfInterest1 contextRef="c67" decimals="0" unitRef="usd">8</us-gaap:LoansReceivableWithFixedRatesOfInterest1>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c3" decimals="-5" unitRef="usd">500000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; FIXED ASSETS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s fixed assets include the following
on December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;376,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(197,907&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;178,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,572,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(579,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,993,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold Improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;90,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,134,850&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(815,987&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,318,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s fixed assets include the following
on December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;312,489&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(75,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;237,436&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,240,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(306,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,933,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,857&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,809&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(412&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,654,307&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(387,010&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,267,297&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $428,977&#160;and $369,236,
for the years ended December 31, 2022 and 2021, respectively. None of the Company&#x2019;s fixed assets serve as collateral against any
loans as of December 31, 2022 and December 31, 2021, other than those subject to the financed asset liability. As of December 31, 2022
and 2021, the fixed assets that serve as collateral subject to the financed asset liability have a carrying value of $1,359,091 and $1,690,420,
respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Financed Assets:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2020, the Company purchased two pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $19,487, with an interest rate of 8%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January of 2021, the Company purchased one
piece of lab equipment and financed it for a period of twenty-four months with a monthly payment of $9,733, with an interest rate of 8%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March of 2021, the Company purchased five pieces
of lab equipment and financed them for a period of twenty-four months with a monthly payment of $37,171, with an interest rate of 8%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Maturities as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;111,512&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;376,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(197,907&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;178,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,572,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(579,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,993,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,200&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,224&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold Improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120,440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;90,799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,134,850&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(815,987&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,318,863&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;312,489&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(75,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;237,436&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,240,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(306,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,933,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,757&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,857&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,809&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(412&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,397&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,654,307&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(387,010&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,267,297&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="0" unitRef="usd">376429</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c75" decimals="0" unitRef="usd">197907</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c75" decimals="0" unitRef="usd">178522</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="0" unitRef="usd">2572720</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c76" decimals="0" unitRef="usd">579015</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c76" decimals="0" unitRef="usd">1993705</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c77" decimals="0" unitRef="usd">56656</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c77" decimals="0" unitRef="usd">8200</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c77" decimals="0" unitRef="usd">48456</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c78" decimals="0" unitRef="usd">8605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c78" decimals="0" unitRef="usd">1224</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c78" decimals="0" unitRef="usd">7381</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c79" decimals="0" unitRef="usd">120440</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c79" decimals="0" unitRef="usd">29641</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c79" decimals="0" unitRef="usd">90799</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">3134850</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">815987</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">2318863</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c80" decimals="0" unitRef="usd">312489</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c80" decimals="0" unitRef="usd">75053</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c80" decimals="0" unitRef="usd">237436</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c81" decimals="0" unitRef="usd">2240252</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c81" decimals="0" unitRef="usd">306688</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c81" decimals="0" unitRef="usd">1933564</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c82" decimals="0" unitRef="usd">90757</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c82" decimals="0" unitRef="usd">4857</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c82" decimals="0" unitRef="usd">85900</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c83" decimals="0" unitRef="usd">10809</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c83" decimals="0" unitRef="usd">412</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c83" decimals="0" unitRef="usd">10397</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" unitRef="usd">2654307</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="usd">387010</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" unitRef="usd">2267297</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">428977</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">369236</us-gaap:Depreciation>
    <us-gaap:TimeDepositsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">1359091</us-gaap:TimeDepositsAtCarryingValue>
    <us-gaap:TimeDepositsAtCarryingValue contextRef="c4" decimals="0" unitRef="usd">1690420</us-gaap:TimeDepositsAtCarryingValue>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments contextRef="c69" decimals="0" unitRef="usd">19487</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:InvestmentInterestRate contextRef="c70" decimals="2" unitRef="pure">0.08</us-gaap:InvestmentInterestRate>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments contextRef="c71" decimals="0" unitRef="usd">9733</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:InvestmentInterestRate contextRef="c72" decimals="2" unitRef="pure">0.08</us-gaap:InvestmentInterestRate>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments contextRef="c73" decimals="0" unitRef="usd">37171</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:InvestmentInterestRate contextRef="c74" decimals="2" unitRef="pure">0.08</us-gaap:InvestmentInterestRate>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;111,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total Payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;111,512&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="c3" decimals="0" unitRef="usd">111512</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" unitRef="usd">111512</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets include
the following on December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Proprietary Technology&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(214,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(214,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets include
the following on December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Proprietary Technology&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(107,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(107,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amortization expense was $107,000&#160;and $107,000&#160;for
the years ended December 31, 2022 and 2021, respectively. None of the Company&#x2019;s intangible assets serve as collateral against any
loans as of December 31, 2022 and 2021. The Company&#x2019;s proprietary technology is being amortized over its estimated useful life of
three years.&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Proprietary Technology&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(214,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(214,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Cost Basis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Proprietary Technology&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(107,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;321,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(107,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;214,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c84" decimals="0" unitRef="usd">321000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c84" decimals="0" unitRef="usd">214000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c84" decimals="0" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c85" decimals="0" unitRef="usd">321000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c85" decimals="0" unitRef="usd">214000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c85" decimals="0" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c86" decimals="0" unitRef="usd">321000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c86" decimals="0" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c86" decimals="0" unitRef="usd">214000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c87" decimals="0" unitRef="usd">321000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c87" decimals="0" unitRef="usd">107000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c87" decimals="0" unitRef="usd">214000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <adtx:AmortizationOfIntangibleAsset contextRef="c0" decimals="0" unitRef="usd">107000</adtx:AmortizationOfIntangibleAsset>
    <adtx:AmortizationOfIntangibleAsset contextRef="c5" decimals="0" unitRef="usd">107000</adtx:AmortizationOfIntangibleAsset>
    <adtx:EstimatedUsefulLife contextRef="c0">P3Y</adtx:EstimatedUsefulLife>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 28, 2022, the Company granted&#160;9,600&#160;restricted
stock units to an officer of the Company pursuant to the Company&#x2019;s 2021 Equity Incentive Plan. The Company recognized $146,613&#160;in
stock-based compensation for the issuance of these vested and unvested restricted stock units during the year ended December 31, 2022.
(Note 11)&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#x201c;Purchaser&#x201d;), pursuant to which the Company
agreed to issue and sell one (1) share of the Company&#x2019;s Series B Preferred Stock (the &#x201c;Preferred Stock&#x201d;), par value
$0.001&#160;per share, to the Purchaser for $20,000&#160;in cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 19, 2022, the Company filed a certificate
of designation (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;250,000,000&#160;votes and will vote together with the outstanding shares of the Company&#x2019;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#x2019;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#x2019;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000&#160;in cash. On September 13, 2022, the
share was redeemed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 21, 2022, the Chief Executive Officer
loaned $80,000 to the Company.&#160;The loan was evidenced by an unsecured promissory note (the &#x201c;Promissory Note&#x201d;). Pursuant
to the terms of the Promissory Note, it will accrue interest at a rate of four and three-quarters percent (4.75%) per annum, the Prime
rate on the date of signing, and is due on the earlier of January 22, 2023, or an event of default. On October 7, 2022, the Company fully
repaid the $80,000 Promissory Note and $812 of accrued interest to its Chief Executive Officer. The Chief Executive Officer and the Company
entered the Promissory Note on July 21, 2022.&#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c88" decimals="0" unitRef="shares">9600</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c89" decimals="0" unitRef="usd">146613</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SaleOfStockPricePerShare contextRef="c90" decimals="3" unitRef="usdPershares">0.001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c91" decimals="0" unitRef="usd">20000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <adtx:PreferredStockVotes contextRef="c91" decimals="0" unitRef="shares">250000000</adtx:PreferredStockVotes>
    <us-gaap:DividendsPreferredStockCash contextRef="c0" decimals="0" unitRef="usd">20000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent contextRef="c92" decimals="0" unitRef="usd">80000</us-gaap:DueToOfficersOrStockholdersCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c93" decimals="4" unitRef="pure">0.0475</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adtx:PromissoryNotes contextRef="c94" decimals="0" unitRef="usd">80000</adtx:PromissoryNotes>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c95" decimals="0" unitRef="usd">812</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 27, 2022, the Company entered into an agreement
for the purchase and sale of future receipts (the &#x201c;Future Receipts Agreement&#x201d;) with a commercial funding source pursuant to
which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $792,000&#160;(the &#x201c;Future
Receipts Purchased Amount&#x201d; for gross proceeds to the Company of $550,000, less origination fees of $16,500&#160;and professional
service fees of $13,500. Pursuant to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#x2019;s
present and future accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be
repaid by the Company in 28 weekly installments of approximately $28,000 with the final payment due on December 7, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2022, the principal balance and
accrued interest was paid off in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 31, 2022, the Company entered into an
Agreement for the Purchase and Sale of Future Receipts (the &#x201c;Agreement&#x201d;) with a commercial funding source pursuant to which
the Company agreed to sell to the funder certain future trade receipts in the aggregate amount $288,000 (the &#x201c;Purchased Amount&#x201d;)
for gross proceeds to the Company of $200,000, less origination fees of $20,000. Pursuant to the Agreement, the Company granted the funder
a security interest in all of the Company&#x2019;s present and future accounts receivable in an amount not to exceed the Purchased Amount.
The Purchased Amount shall be repaid by the Company in 20 weekly installments of approximately $14,400 with the final payment due on January
18, 2023. In connection with the Agreement, the Company also issued a warrant to purchase 26,667 shares of the Company&#x2019;s common
stock with an exercise price of $7.50 and an expiration of five years from the issuance date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 30, 2022, the principal balance and
accrued interest was paid off in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Note Financing:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 4, 2022, the Company entered into a
Securities Purchase Agreement (the &#x201c;SPA&#x201d;) with certain accredited investors to purchase $1,277,778&#160;in principal amount&#160;10%
Senior Secured Promissory Notes (the &#x201c;August 2022 Notes&#x201d;), resulting in gross proceeds to the Company of $1,150,000, exclusive
of placement agent commission and fees and other offering expenses. In connection therewith, the Company issued,&#160;25,556&#160;shares
of common stock as commitment fees and warrants (the &#x201c;August 2022 Warrants&#x201d;) to purchase up to&#160;108,517&#160;shares of
the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 11, 2022, the Company entered into a
SPA with certain accredited investors to purchase $555,556 in principal amount of August 2022 Notes, resulting in gross proceeds to the
Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and August 2022 Warrants
to purchase up to 47,182 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The August 2022 Notes have a maturity date of
twelve (12) months from the date of issuance and are convertible at the option of the Investor at any time prior to maturity in shares
of Common Stock (the &#x201c;Conversion Shares&#x201d;) at an initial conversion price of $11.78 per share, subject to adjustments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The August 2022 Warrants are exercisable for a period of five (5) years
from the period commencing on the commencement date (as defined in the August 2022 Warrant) and ending on 5:00 p.m. eastern standard time
on the date that is five (5) years after the date of issuance, at an initial exercise price of $11.78, subject to adjustment provided
therein (including cashless exercise). These warrants were valued using a Black-Scholes Model and the resulting relative fair value was
recorded as a debt discount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 25, 2022, the Company entered into a
First Amendment and Waiver with the holders of the August 2022 Warrants, pursuant to which the exercise price of the August 2022 Warrants
was reduced to $7.50 per share and the August 2022 Warrants were modified such that they are not exercisable unless and until the Company
obtains stockholder approval of the issuance of any shares of common stock upon exercise of the August 2022 Warrants. On September 16,
2022, the exercise price of the August 2022 Warrants was further adjusted to $6.00 per share. These warrants were valued using a Black-Scholes
Model and the resulting valuation was recorded as an implied dividend.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Note Financing Follow On:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 12, 2022, the Company entered into
a SPA with a certain accredited investor to purchase $555,555 in principal amount of August 2022 Notes, resulting in gross proceeds to
the Company of $500,000. In connection therewith, the Company issued 11,112 shares of common stock as commitment fees and warrants (the
&#x201c;August 2022 Follow On Warrants&#x201d;) to purchase up to 74,074 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The August 2022 Follow On Warrants are exercisable for a period of
five (5) years from the period commencing on the commencement date (as defined in the August 2022 Follow On Warrant) and ending on 5:00
p.m. eastern standard time on the date that is five (5) years after the date of issuance, at an initial exercise price of $7.50, subject
to adjustments. These warrants were valued using a Black-Scholes Model and the resulting relative fair value was recorded as a debt discount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 16, 2022, the exercise price of the
August 2022 Follow On Warrants was adjusted to $6.00 per share. These warrants were valued using a Black-Scholes Model and the resulting
valuation was recorded as an implied dividend.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the principal balance
of $2,388,888, a prepayment penalty of $238,889 and all accrued interest of $119,444 relating to the August 2022 Notes was paid off in
full.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <adtx:AggregateAmount contextRef="c96" decimals="0" unitRef="usd">792000</adtx:AggregateAmount>
    <adtx:GrossProceeds contextRef="c97" decimals="0" unitRef="usd">550000</adtx:GrossProceeds>
    <us-gaap:LegalFees contextRef="c97" decimals="0" unitRef="usd">16500</us-gaap:LegalFees>
    <us-gaap:ProfessionalFees contextRef="c97" decimals="0" unitRef="usd">13500</us-gaap:ProfessionalFees>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c98" decimals="0" unitRef="usd">28000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <adtx:AggregateAmount contextRef="c99" decimals="0" unitRef="usd">288000</adtx:AggregateAmount>
    <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="c99" decimals="0" unitRef="usd">200000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
    <us-gaap:LegalFees contextRef="c99" decimals="0" unitRef="usd">20000</us-gaap:LegalFees>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c100" decimals="0" unitRef="usd">14400</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <adtx:WarrantToPurchaseCommonShares contextRef="c101" decimals="0" unitRef="shares">26667</adtx:WarrantToPurchaseCommonShares>
    <adtx:ExercisePrice contextRef="c102" decimals="2" unitRef="usdPershares">7.5</adtx:ExercisePrice>
    <us-gaap:DeferredFinanceCostsNet contextRef="c103" decimals="0" unitRef="usd">1277778</us-gaap:DeferredFinanceCostsNet>
    <adtx:PrincipalAmountPercentage contextRef="c104" decimals="2" unitRef="pure">0.10</adtx:PrincipalAmountPercentage>
    <us-gaap:DeferredOfferingCosts contextRef="c105" decimals="0" unitRef="usd">1150000</us-gaap:DeferredOfferingCosts>
    <us-gaap:CommonStockSharesIssued contextRef="c106" decimals="0" unitRef="shares">25556</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c106" decimals="0" unitRef="shares">108517</us-gaap:ClassOfWarrantOrRightOutstanding>
    <adtx:InvestorPurchaseAmount contextRef="c107" decimals="0" unitRef="usd">555556</adtx:InvestorPurchaseAmount>
    <adtx:GrossProceeds contextRef="c107" decimals="0" unitRef="usd">500000</adtx:GrossProceeds>
    <us-gaap:CommonStockSharesIssued contextRef="c108" decimals="0" unitRef="shares">11112</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c108" decimals="0" unitRef="shares">47182</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c3" decimals="2" unitRef="usdPershares">11.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <adtx:WarrantExercisePrice contextRef="c59" decimals="2" unitRef="usdPershares">7.5</adtx:WarrantExercisePrice>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c109" decimals="2" unitRef="usdPershares">6</us-gaap:WarrantExercisePriceIncrease>
    <adtx:PrincipalAmount contextRef="c110" decimals="0" unitRef="usd">555555</adtx:PrincipalAmount>
    <adtx:GrossProceeds contextRef="c110" decimals="0" unitRef="usd">500000</adtx:GrossProceeds>
    <us-gaap:CommonStockSharesIssued contextRef="c111" decimals="0" unitRef="shares">11112</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c111" decimals="0" unitRef="shares">74074</us-gaap:ClassOfWarrantOrRightOutstanding>
    <adtx:ExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">7.5</adtx:ExercisePrice>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c112" decimals="2" unitRef="usdPershares">6</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:InvestmentOwnedBalancePrincipalAmount contextRef="c3" decimals="0" unitRef="usd">2388888</us-gaap:InvestmentOwnedBalancePrincipalAmount>
    <us-gaap:PrepaymentFeesOnAdvancesNet contextRef="c0" decimals="0" unitRef="usd">238889</us-gaap:PrepaymentFeesOnAdvancesNet>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c0" decimals="0" unitRef="usd">119444</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2013; LEASES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our lease agreements generally do not provide
an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement
date for purposes of determining the present value of lease payments. We used the incremental borrowing rate on December 31, 2022 and
December 31, 2021 for all leases that commenced prior to that date. In determining this rate, which is used to determine the present value
of future lease payments, we estimate the rate of interest we would pay on a collateralized basis, with similar payment terms as the lease
and in a similar economic environment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our corporate headquarters is located in Richmond,
Virginia, where we lease approximately 25,000 square feet. The lease expires in August 2026, subject to extension.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also lease approximately 5,810 square feet
of laboratory and office space in Mountain View, California. The lease expires in August 2024, subject to extension.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Additionally, we lease approximately 3,150 square
feet of office space in Melville, New York. The lease expires in December 2024, subject to extension.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Subsequent to December 31, 2022 the Company is
in arrears on certain lease payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Lease Costs&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year&lt;br/&gt;
Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year&lt;br/&gt;
Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Components of total lease costs:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,396,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;819,587&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,396,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;819,587&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Lease Positions as of December 31, 2022 and
December 31, 2021&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ROU lease assets and lease liabilities for our
operating leases are recorded on the balance sheet as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Right of use asset &#x2013; long term&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,160,457&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,097,117&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,160,457&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,097,117&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities &#x2013; short term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,086,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,145,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities &#x2013; long term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,885,218&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,765,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,971,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,911,059&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Lease Terms and Discount Rate as of December
31, 2022&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Weighted average remaining lease term (in years) &#x2013; operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Maturities of leases are as follows:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Year Ended December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,129,853&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,004,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;710,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,269,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,086,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total maturities, due beyond one year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,885,218&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <adtx:NetLeases contextRef="c113" decimals="0" unitRef="sqm">25000</adtx:NetLeases>
    <adtx:LeasesExpire contextRef="c113">August 2026</adtx:LeasesExpire>
    <adtx:NetLeases contextRef="c114" decimals="0" unitRef="sqft">5810</adtx:NetLeases>
    <adtx:LeasesExpire contextRef="c114">August 2024</adtx:LeasesExpire>
    <adtx:NetLeases contextRef="c115" decimals="0" unitRef="sqm">3150</adtx:NetLeases>
    <adtx:LeasesExpire contextRef="c115">December 2024</adtx:LeasesExpire>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year&lt;br/&gt;
Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year&lt;br/&gt;
Ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Components of total lease costs:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 78%; padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,396,875&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;819,587&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="padding-left: 9pt; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,396,875&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;819,587&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="0" unitRef="usd">1396875</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c5" decimals="0" unitRef="usd">819587</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" unitRef="usd">1396875</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c5" decimals="0" unitRef="usd">819587</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Right of use asset &#x2013; long term&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;3,160,457&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,097,117&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,160,457&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,097,117&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities &#x2013; short term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,086,658&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,145,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities &#x2013; long term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,885,218&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,765,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,971,876&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,911,059&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <adtx:RightOfUseAssetShortTerm contextRef="c3" decimals="0" unitRef="usd">3160457</adtx:RightOfUseAssetShortTerm>
    <adtx:RightOfUseAssetShortTerm contextRef="c4" decimals="0" unitRef="usd">4097117</adtx:RightOfUseAssetShortTerm>
    <adtx:TotalRightOfUseAsset contextRef="c0" decimals="0" unitRef="usd">3160457</adtx:TotalRightOfUseAsset>
    <adtx:TotalRightOfUseAsset contextRef="c5" decimals="0" unitRef="usd">4097117</adtx:TotalRightOfUseAsset>
    <adtx:OperatingLeaseLiabilitiesShortTerm contextRef="c3" decimals="0" unitRef="usd">1086658</adtx:OperatingLeaseLiabilitiesShortTerm>
    <adtx:OperatingLeaseLiabilitiesShortTerm contextRef="c4" decimals="0" unitRef="usd">1145126</adtx:OperatingLeaseLiabilitiesShortTerm>
    <adtx:OperatingLeaseLiabilitiesLongTerm contextRef="c3" decimals="0" unitRef="usd">1885218</adtx:OperatingLeaseLiabilitiesLongTerm>
    <adtx:OperatingLeaseLiabilitiesLongTerm contextRef="c4" decimals="0" unitRef="usd">2765933</adtx:OperatingLeaseLiabilitiesLongTerm>
    <adtx:TotalLeaseLiability contextRef="c3" decimals="0" unitRef="usd">2971876</adtx:TotalLeaseLiability>
    <adtx:TotalLeaseLiability contextRef="c4" decimals="0" unitRef="usd">3911059</adtx:TotalLeaseLiability>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Weighted average remaining lease term (in years) &#x2013; operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" unitRef="pure">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,129,853&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,004,982&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;710,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,930&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,269,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,086,657&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total maturities, due beyond one year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,885,218&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" unitRef="usd">1129853</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" unitRef="usd">1004982</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="0" unitRef="usd">710546</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="0" unitRef="usd">423930</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" unitRef="usd">3269311</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" unitRef="usd">297436</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <adtx:OperatingLeasesLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">1086657</adtx:OperatingLeasesLiabilityCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c3" decimals="0" unitRef="usd">1885218</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2013; COMMITMENTS &amp;amp; CONTIGENCIES
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License Agreement with Loma Linda University&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 15, 2018, as amended
on July 1, 2020, we entered into a LLU License Agreement directly with Loma Linda University.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the LLU License
Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property, including patents, technical
information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and specifications, owned or controlled
by LLU and/or any of its affiliates (the &#x201c;LLU Patent and Technology Rights&#x201d;) and related to therapy for immune-mediated inflammatory
diseases (the ADI&#x2122; technology). In consideration for the LLU License Agreement, we issued 500 shares of common stock to LLU.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the LLU License
Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July 2020 for outstanding milestone payments
and license fees. We are also required to pay to LLU milestone payments in connection with certain development milestones. Specifically,
we are required to make the following milestone payments to LLU: $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March
31, 2026; and $500,000 on March 31, 2027. In lieu of the $175,000 milestone payment due on March 31, 2022, the Company paid LLU an extension
fee of $100,000. Upon payment of this extension fee, an additional year will be added for the March 31, 2022 milestone. Additionally,
as consideration for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made the
following payments to LLU: $70,000 at the end of December 2018, and a final payment of $60,000 at the end of March 2019. We are required
to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe royalty payments
of (i) 1.5% of Net Product Sales (as such terms are defined under the LLU License Agreement) and Net Service Sales on any Licensed Products
(defined as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or
supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services (as such terms are defined
under the LLU License Agreement) not covered by a valid patent claim for technology rights and know-how for a three (3) year period beyond
the expiration of all valid patent claims. We also are required to produce a written progress report to LLU, discussing our development
and commercialization efforts, within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and
Technology Rights shall remain with LLU (other than improvements developed by or on our behalf).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The LLU License Agreement
shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day that the last patent application
licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement or by us upon 90 days written notice to LLU.
LLU may terminate the LLU License Agreement in the event of (i) non-payments or late payments of royalty, milestone and license maintenance
fees not cured within 90 days after delivery of written notice by LLU, (ii) a breach of any non-payment provision (including the provision
that requires us to meet certain deadlines for milestone events (each, a &#x201c;Milestone Deadline&#x201d;)) not cured within 90 days after
delivery of written notice by LLU and (iii) LLU delivers notice to us of three or more actual breaches of the LLU License Agreement by
us in any 12-month period. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND application
to initiate first-in-human clinical trials on or before March 31, 2022, which has been extended to March 31, 2023 due to payment of a
$100,000 extension fee paid in March 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;F-20&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;License Agreement with Leland Stanford Junior
University&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 3, 2020, we entered
into an exclusive license agreement (the &#x201c;February 2020 License Agreement&#x201d;) with Stanford regarding a patent concerning a
method for detection and measurement of specific cellular responses. Pursuant to the February 2020 License Agreement, we received an exclusive
worldwide license to Stanford&#x2019;s patent regarding use, import, offer, and sale of Licensed Products (as defined in the agreement).
The license to the patented technology is exclusive, including the right to sublicense, beginning on the effective date of the agreement,
and ending when the patent expires. Under the exclusivity agreement, we acknowledged that Stanford had already granted a non-exclusive
license in the Nonexclusive Field of Use, under the Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those
terms are defined in the February 2020 License Agreement&#x201d;). However, Stanford agreed to not grant further licenses under the Licensed
Patents in the Licensed Field of Use in the Licensed Territory. On December 29, 2021, we entered into an amendment to the February 2020
License Agreement which extended our exclusive right to license the technology deployed in AditxtScore&lt;sup&gt;TM&lt;/sup&gt;&#160;and securing
worldwide exclusivity in all fields of use of the licensed technology.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We were obligated to pay and
paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 375 shares of the Company&#x2019;s common stock to
Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License Agreement in the
amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of the patent. The
Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone fees of $50,000 on
the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory clearance of an in
vitro diagnostic product developed and a potential licensed product. The Company paid a milestone fee for a clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product of $25,000 in March of 2022. We are also required
to: (i) provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which
has been completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and
operations, and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation
studies by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which
has been completed), (iv) submit a 510(k) application to the FDA, Emergency Use Authorization (&#x201c;EUA&#x201d;), or a Laboratory Developed
Test (&#x201c;LDT&#x201d;) by March 31, 2021 (which has been completed), (vi) develop a prototype assay for human profiling by December
31, 2021 (which has been completed), (vii) execute at least one partnership for use of the technology for transplant, autoimmunity, or
infectious disease purposes by March 31, 2022 (which has been completed) and (viii) provided further development and commercialization
milestones for specific fields of use in writing prior to December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated upon our election on at least 30 days advance
notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment; (ii) are not diligently developing and commercializing
Licensed Product; (iii) miss certain performance milestones; (iv) are in breach of any provision of the February 2020 License Agreement;
or (v) provide any false report to Stanford. Should any events in the preceding sentence occur, we have a thirty (30) day cure period
to remedy such violation.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">500</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:TaxesAndLicenses contextRef="c116" decimals="0" unitRef="usd">455000</us-gaap:TaxesAndLicenses>
    <us-gaap:DirectTaxesAndLicensesCosts contextRef="c117" decimals="0" unitRef="usd">175000</us-gaap:DirectTaxesAndLicensesCosts>
    <us-gaap:DirectTaxesAndLicensesCosts contextRef="c118" decimals="0" unitRef="usd">100000</us-gaap:DirectTaxesAndLicensesCosts>
    <us-gaap:DirectTaxesAndLicensesCosts contextRef="c119" decimals="0" unitRef="usd">500000</us-gaap:DirectTaxesAndLicensesCosts>
    <us-gaap:DirectTaxesAndLicensesCosts contextRef="c120" decimals="0" unitRef="usd">500000</us-gaap:DirectTaxesAndLicensesCosts>
    <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="c117" decimals="0" unitRef="usd">175000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <srt:ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts contextRef="c117" decimals="0" unitRef="usd">100000</srt:ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts>
    <us-gaap:InformationTechnologyAndDataProcessing contextRef="c121" decimals="0" unitRef="usd">70000</us-gaap:InformationTechnologyAndDataProcessing>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c121" decimals="0" unitRef="usd">60000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage contextRef="c122" decimals="3" unitRef="pure">0.015</us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage>
    <us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage contextRef="c121" decimals="4" unitRef="pure">0.0075</us-gaap:ProductLiabilityContingencyThirdPartyRecoveryPercentage>
    <us-gaap:InvestmentCompanyFeePaidIndirectly contextRef="c117" decimals="0" unitRef="usd">100000</us-gaap:InvestmentCompanyFeePaidIndirectly>
    <us-gaap:InvestmentCompanyFeePaidIndirectly contextRef="c123" decimals="0" unitRef="usd">25000</us-gaap:InvestmentCompanyFeePaidIndirectly>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c0" decimals="0" unitRef="shares">375</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CostMaintenance contextRef="c124" decimals="0" unitRef="usd">40000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance contextRef="c125" decimals="0" unitRef="usd">60000</us-gaap:CostMaintenance>
    <us-gaap:SaleLeasebackTransactionOtherPaymentsRequired contextRef="c0" decimals="0" unitRef="usd">25000</us-gaap:SaleLeasebackTransactionOtherPaymentsRequired>
    <adtx:PaymentOfMilestoneFees contextRef="c0" decimals="0" unitRef="usd">50000</adtx:PaymentOfMilestoneFees>
    <us-gaap:ClearanceFees contextRef="c0" decimals="0" unitRef="usd">25000</us-gaap:ClearanceFees>
    <us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration contextRef="c126" decimals="0" unitRef="usd">25000</us-gaap:RegistrationPaymentArrangementMaximumPotentialConsideration>
    <us-gaap:FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount contextRef="c127" decimals="0" unitRef="usd">10000000</us-gaap:FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount>
    <us-gaap:BroadcastersLicenseAgreementCommitmentsDescription contextRef="c0">In addition to the annual
license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License
Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when
Net Sales are above $5 million annually.</us-gaap:BroadcastersLicenseAgreementCommitmentsDescription>
    <us-gaap:LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual contextRef="c0">$5</us-gaap:LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 24, 2021, the Company increased the number
of authorized shares of the Company&#x2019;s common stock, par value $0.001&#160;per share, from&#160;27,000,000&#160;to&#160;100,000,000&#160;(the
&#x201c;Authorized Shares Increase&#x201d;) by filing a Certificate of Amendment (the &#x201c;Certificate of Amendment&#x201d;) to its Amended
and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware. In accordance with the General Corporation
Law of the State of Delaware, the Authorized Shares Increase and the Certificate of Amendment were approved by the stockholders of the
Company at the Company&#x2019;s Annual Meeting of Stockholders on May 19, 2021.&#160;On September 13, 2022, the Company effectuated a 1
for 50 reverse stock split (the &#x201c;Reverse Split&#x201d;). The Company&#x2019;s stock began trading at the Reverse Split price effective
on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company&#x2019;s common
stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
issued&#160;148,227&#160;shares of common stock and recognized expense of $507,558&#160;in stock-based compensation for consulting services,
consisting of capital markets and investor relations. The stock-based compensation for consulting services is calculated by the number
shares multiplied by the closing price on the effective date of the contract. The Company also granted&#160;11,644&#160;Restricted Stock
Units and,&#160;18,469&#160;Restricted Stock Units&#160;vested which resulted in the issuance of shares. As a result, the Company recognized
expense of $1,209,906&#160;in stock-based compensation. The stock-based compensation for shares issued or RSU&#x2019;s granted during the
period were valued based on the fair market value on the date of grant. The Company issued 58,256 shares in relation to the issuance of
notes (See Note 8). The Company issued 1,224,333 shares of common stock as part of the September 2022 Offering (See Note 1). The Company
also issued 1,766,917 shares of common stock as a result of the exercise of prefunded warrants from the September 2022 Offering (See Note
1). The Company issued 179,419 shares of common stock from the exercise of warrant, modification of warrant, and the issuance of warrant.
The Company issued 9,237 shares of common stock for the settlement of accounts payable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the Company
issued 2,031 shares of common stock and recognized expense of $254,242 in stock-based compensation for consulting services. The Company
also issued 1,602 shares of common stock to Stanford University and two employees and recognized expense of $64,875 relating to the agreement
with Stanford University. The Company also issued 189,843 shares of common stock upon the exercise of warrants and received $3,727,285
in cash proceeds. The Company granted 9,300 Restricted Stock Awards, as a result the Company recognized expense of $1,443,700 in stock-based
compensation. The Company granted 500 Restricted Stock Awards of which 500 vested, as a result, the Company recognized expense of $17,000
in stock-based compensation for consulting services. The Company also granted 36,456 Restricted Stock Units, of which 16,519 vested and
resulted in the issuance of shares, as a result, the Company recognized expense of $1,843,902 in stock-based compensation. (See Note 7)
The Company issued 96,050 shares of common stock for the conversion of a convertible note. (See Note 9) The Company issued 91,667 shares
of common stock as part of the August 2021 Offering. The Company issued 56,667 shares of common stock as part of the October 2021 Offering.
The Company issued 164,929 shares of common stock as part of the December 2021 Offering. The stock-based compensation for shares issued
or RSU&#x2019;s granted during the period, were valued based on the fair market value on the date of grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is authorized to issue&#160;3,000,000&#160;shares
of preferred stock, par value $0.001&#160;per share. There were no shares of preferred stock outstanding as of December 31, 2022 and December
31, 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Issuance of Series B Preferred Stock:&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 19, 2022, the Company entered into a Subscription
and Investment Representation Agreement with its Chief Executive Officer (the &#x201c;Purchaser&#x201d;), pursuant to which the Company
agreed to issue and sell one (1) share of the Company&#x2019;s Series B Preferred Stock (the &#x201c;Preferred Stock&#x201d;), par value
$0.001&#160;per share, to the Purchaser for $20,000&#160;in cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 19, 2022, the Company filed a certificate
of designation (the &#x201c;Certificate of Designation&#x201d;) with the Secretary of State of Delaware, effective as of the time of filing,
designating the rights, preferences, privileges and restrictions of the share of Preferred Stock. The Certificate of Designation provides
that the share of Preferred Stock will have&#160;250,000,000&#160;votes and will vote together with the outstanding shares of the Company&#x2019;s
common stock as a single class exclusively with respect to any proposal to amend the Company&#x2019;s Restated Certificate of Incorporation
to effect a reverse stock split of the Company&#x2019;s common stock. The Preferred Stock will be voted, without action by the holder,
on any such proposal in the same proportion as shares of common stock are voted. The Preferred Stock otherwise has no voting rights except
as otherwise required by the General Corporation Law of the State of Delaware.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Preferred Stock is not convertible into, or
exchangeable for, shares of any other class or series of stock or other securities of the Company. The Preferred Stock has no rights with
respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale,
dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Preferred Stock will not be entitled
to receive dividends of any kind.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The outstanding share of Preferred Stock shall
be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion
or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split.
Upon such redemption, the holder of the Preferred Stock will receive consideration of $20,000&#160;in cash. On September 13, 2022, the
share was redeemed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Redemption of Series B Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 7, 2022, the Company paid $20,000 in
consideration for the one share of Preferred Stock which was redeemed on September 13, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2017, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;).&#160;The 2017 Plan provides for the grant of equity
awards to directors, employees, and consultants.&#160;The Company is authorized to issue up to&#160;2,500,000&#160;shares of our common
stock pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires ten years after
adoption, unless terminated earlier by the Board of Directors.&#160;All shares of our common stock pursuant to awards under the 2017 Plan
have been awarded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 24, 2021, our Board of Directors adopted
the Aditx Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for grants of nonqualified
stock options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units, and other stock-based
awards (collectively, the &#x201c;Awards&#x201d;). Eligible recipients of Awards include employees, directors or independent contractors
of the Company or any affiliate of the Company. The Compensation Committee of the Board of Directors (the &#x201c;Committee&#x201d;) will
administer the 2021 Plan. A total of&#160;60,000&#160;shares of common stock, par value $0.001&#160;per share, of the Company may be issued
pursuant to Awards granted under the 2021 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a
stock option will be no less than one hundred percent (100%) of the Fair Market Value (as defined in the 2021 Plan) of a share of Common
Stock on the date of grant. The 2021 Plan was submitted and approved by the Company&#x2019;s stockholders at the 2021 annual meeting of
stockholders, held on May 19, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
granted no new options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2021, the Company
granted 1,850 stock option grants, with a weighted average grant date fair value $8.39. The fair value of each option granted was estimated
using the assumption and/or factors in the Black-Scholes Model.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following is an analysis of the stock option
grant activity under the Plan:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Vested and Nonvested Stock Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;44,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;170.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.74&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested Stock Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested on December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,038&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested on December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,025&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;96.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 there were 42,685 exercisable
options, these options had a weighted average exercise price $173.50.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized stock-based compensation
expense related to options granted and vesting expense of $791,187&#160;during the year ended December 31, 2022, of which $555,772&#160;is
included in general and administrative expenses and $235,415&#160;is included in research and development expenses in the accompanying
statements of operations. The remaining value to be expensed is $179,892&#160;with a weighted average vesting term of&#160;0.75&#160;years
as of December 31, 2022. The Company recognized stock-based compensation expense related to options issued and vesting of $826,795 during
the year ended December 31, 2021, of which $587,209 is included in general and administrative expenses and $239,586 is included in research
and development expenses in the accompanying statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes warrant forfeitures
as they occur as there is insufficient historical data to accurately determine future forfeitures rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
issued&#160;6,497,530&#160;warrants.&#160;During the year ended December 31, 2021, the Company issued&#160;678,242&#160;warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2022, the fair
value of each warrant granted was estimated using the assumption and/or factors in the Black-Scholes Model as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$7.50-20.00&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.55%-3.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00-5.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;147%-165&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2021, the fair
value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%-0.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.00-5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;154%-159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The risk-free interest rate assumption for warrants
granted is based upon observed interest rates on the United States Government Bond Equivalent Yield appropriate for the expected term
of warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined the expected volatility
assumption for warrants granted using the historical volatility of comparable public companies&#x2019; common stock. The Company will continue
to monitor peer companies and other relevant factors used to measure expected volatility for future warrant grants, until such time that
the Company&#x2019;s common stock has enough market history to use historical volatility.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The dividend yield assumption for warrants granted
is based on the Company&#x2019;s history and expectation of dividend payouts. The Company has never declared nor paid any cash dividends
on its common stock, and the Company does not anticipate paying any cash dividends in the foreseeable future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes warrant forfeitures as
they occur as there is insufficient historical data to accurately determine future forfeitures rates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of warrant issuances are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Vested and Nonvested Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;601,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,497,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,946,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expired or forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(62,512&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Rounding for Reverse Split&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,090,024&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested on December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,567&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,497,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,435,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested on December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized stock-based compensation
expense related to warrants granted and vesting expense of $609,748 during the year ended December 31, 2022, of which $105,049&#160;is
included in general and administrative and $504,699 is included in sales and marketing in the accompanying Statements of Operations. The
Company recognized stock-based compensation expense related to warrants granted and vesting expense of $189,899&#160;during the year ended
December 31, 2021, which is included in general and administrative in the accompanying Statements of Operations. The remaining value to
be expensed is zero as of December 31, 2022. The weighted average vesting term is 0.22 years as of December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 15, 2022, the Company entered an agreement
with a holder of certain of the Series C Warrants (the &#x201c;Holder&#x201d;).&#160;Pursuant to the agreement, the Holder has agreed to
exercise in cash 179,419 of its Series C Warrants at a reduced exercise price of $7.50 per Share (reduced from $57.50 per share), for
gross proceeds to the Company of approximately $1.35 million. As an inducement to such exercise, the Company has agreed to reduce the
exercise price of the Holder&#x2019;s remaining Series C Warrants to purchase up to 49,153 Shares from $57.50 to $12.395 per share, which
will be non-exercisable for a period of six months following the closing date. The modification of this exercise price resulted in an
increase of $344,158 to the fair value of the Series C Warrants. This modification was an inducement on the transaction and as such was
recorded to equity resulting in no net change to additional paid in capital. In addition, the Company issued to the Holder a new warrant
to purchase up to 407,991 shares of the Company&#x2019;s common stock at an exercise price of $12.395 per share, which will be non-exercisable
for a period of six months following issuance date and have a term of five and one-half years.&#160;This inducement resulted in a total
increase of $3,759,044&#160;to the fair value of the warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2022, the Company and the Warrant
Agent entered into Amendment No. 2 to the Series C Warrant Agent Agreement, pursuant to which the exercise price of the Series C Warrants
was reduced from $57.50 per share to $12.395 per share. In addition, on December 21, 2022, the Company issued an Amended and Restated
Unit Purchase Option to the agent in the Offering reflecting a reduced exercise price of $12.395 per Unit. This modification of these
warrants resulted in a $29,058 increase to the fair value of the warrants (See Note 1).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of Restricted Stock Units (&#x201c;RSUs&#x201d;)
issuances are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested RSUs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,197&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized stock-based compensation
expense related to RSUs granted and vesting expense of $1,222,875&#160;and&#160;$1,843,902 during the years ended December 31, 2022 and
December 31, 2021, respectively, of which, $848,597&#160;is included in general and administrative, $356,105&#160;is included in research
and development, and $18,346 is included in sales and marketing in the accompanying Statements of Operations. The remaining value to be
expensed is $321,603&#160;with a weighted average vesting term of&#160;0.40&#160;years as of December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
granted a total of&#160;11,644&#160;RSUs. As of December 31, 2022,&#160;18,506 RSUs vested and the Company issued&#160;18,469&#160;shares
of common stock for the&#160;18,469 vested RSUs.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c128" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c129" decimals="0" unitRef="shares">27000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c130" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="c0" decimals="0" unitRef="shares">148227</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" unitRef="usd">507558</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c131" decimals="0" unitRef="shares">11644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c132" decimals="0" unitRef="shares">18469</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <adtx:RecognizedExpense contextRef="c131" decimals="0" unitRef="usd">1209906</adtx:RecognizedExpense>
    <adtx:SharesIssued1 contextRef="c3" decimals="0" unitRef="shares">58256</adtx:SharesIssued1>
    <us-gaap:ExcessStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">1224333</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c133" decimals="0" unitRef="shares">1766917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ExcessStockSharesIssued contextRef="c134" decimals="0" unitRef="shares">179419</us-gaap:ExcessStockSharesIssued>
    <adtx:SharesIssued1 contextRef="c26" decimals="0" unitRef="shares">9237</adtx:SharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="c5" decimals="0" unitRef="shares">2031</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">254242</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <adtx:SharesOfCommonStock contextRef="c5" decimals="0" unitRef="shares">1602</adtx:SharesOfCommonStock>
    <adtx:RecognizedExpense contextRef="c135" decimals="0" unitRef="usd">64875</adtx:RecognizedExpense>
    <us-gaap:ExcessStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">189843</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c5" decimals="0" unitRef="usd">3727285</us-gaap:ProceedsFromWarrantExercises>
    <adtx:SettlementOfAccountsPayableShares contextRef="c136" decimals="0" unitRef="shares">9300</adtx:SettlementOfAccountsPayableShares>
    <adtx:RecognizedExpense contextRef="c137" decimals="0" unitRef="usd">1443700</adtx:RecognizedExpense>
    <adtx:SettlementOfAccountsPayableShares contextRef="c5" decimals="0" unitRef="shares">500</adtx:SettlementOfAccountsPayableShares>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="c136" decimals="0" unitRef="shares">500</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <adtx:RecognizedExpense contextRef="c138" decimals="0" unitRef="usd">17000</adtx:RecognizedExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c139" decimals="0" unitRef="shares">36456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c139" decimals="0" unitRef="shares">16519</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <adtx:RecognizedExpense contextRef="c5" decimals="0" unitRef="usd">1843902</adtx:RecognizedExpense>
    <adtx:SharesOfCommonStock contextRef="c140" decimals="0" unitRef="shares">96050</adtx:SharesOfCommonStock>
    <adtx:sharesIssued1 contextRef="c141" decimals="0" unitRef="shares">91667</adtx:sharesIssued1>
    <adtx:SharesOfCommonStock contextRef="c142" decimals="0" unitRef="shares">56667</adtx:SharesOfCommonStock>
    <adtx:SharesOfCommonStock contextRef="c143" decimals="0" unitRef="shares">164929</adtx:SharesOfCommonStock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c24" decimals="0" unitRef="shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <adtx:SharesOfCommonStock contextRef="c144" decimals="0" unitRef="shares">1</adtx:SharesOfCommonStock>
    <us-gaap:AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare contextRef="c145" decimals="3" unitRef="usdPershares">0.001</us-gaap:AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare>
    <us-gaap:AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability contextRef="c146" decimals="0" unitRef="usd">20000</us-gaap:AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c146" decimals="0" unitRef="shares">250000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RedemptionPremium contextRef="c0" decimals="0" unitRef="usd">20000</us-gaap:RedemptionPremium>
    <us-gaap:InvestmentCompanyFeePaidIndirectly contextRef="c94" decimals="0" unitRef="usd">20000</us-gaap:InvestmentCompanyFeePaidIndirectly>
    <us-gaap:PreferredStockDividendsShares contextRef="c94" decimals="0" unitRef="shares">1</us-gaap:PreferredStockDividendsShares>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c147" decimals="0" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="c148" decimals="0" unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c149" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <adtx:FairMarketValue contextRef="c148" decimals="2" unitRef="pure">1</adtx:FairMarketValue>
    <adtx:CompanyGranted contextRef="c5" decimals="0" unitRef="shares">1850</adtx:CompanyGranted>
    <adtx:weightedAverageGrant contextRef="c5" decimals="2" unitRef="usd">8.39</adtx:weightedAverageGrant>
    <adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Vested and Nonvested Stock Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;170.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;44,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;170.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.74&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Vested and Nonvested Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;601,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,497,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,946,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expired or forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(62,512&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Rounding for Reverse Split&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,090,024&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested RSUs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,506&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,506&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,197&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c164" decimals="INF" unitRef="shares">44710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c164" decimals="2" unitRef="usdPershares">170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c165">P6Y8M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c166" decimals="INF" unitRef="shares">44710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c166" decimals="2" unitRef="usdPershares">170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance contextRef="c165">P5Y8M26D</adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested Stock Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested on December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,063&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,038&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested on December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,025&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;96.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Nonvested Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested on December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92,567&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,497,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,435,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(55,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Nonvested on December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber contextRef="c173" decimals="INF" unitRef="shares">9063</adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice contextRef="c173" decimals="2" unitRef="usdPershares">108.5</adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c174" decimals="INF" unitRef="shares">7038</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <adtx:WeightedAverageExercisesPriceVested contextRef="c174" decimals="2" unitRef="usdPershares">112.41</adtx:WeightedAverageExercisesPriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c173" decimals="INF" unitRef="shares">2025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c173" decimals="2" unitRef="usdPershares">96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c3" decimals="0" unitRef="shares">42685</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:StockOptionExercisePriceDecrease contextRef="c0" decimals="2" unitRef="usdPershares">173.5</us-gaap:StockOptionExercisePriceDecrease>
    <adtx:StockOptionsShares contextRef="c150" decimals="0" unitRef="shares">791187</adtx:StockOptionsShares>
    <adtx:ExercisePricePerShare contextRef="c151" decimals="0" unitRef="usdPershares">555772</adtx:ExercisePricePerShare>
    <adtx:ExercisePricePerShare contextRef="c152" decimals="0" unitRef="usdPershares">235415</adtx:ExercisePricePerShare>
    <adtx:ShareBasedPaymentRemnainingExpenses contextRef="c153" decimals="0" unitRef="usd">179892</adtx:ShareBasedPaymentRemnainingExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c153">P0Y9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:StockOptionPlanExpense contextRef="c0" decimals="0" unitRef="usd">826795</us-gaap:StockOptionPlanExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">587209</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">239586</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <adtx:warrantIssued contextRef="c3" decimals="0" unitRef="shares">6497530</adtx:warrantIssued>
    <adtx:warrantIssued contextRef="c4" decimals="0" unitRef="shares">678242</adtx:warrantIssued>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$7.50-20.00&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.55%-3.47&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.00-5.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;147%-165&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%-0.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.00-5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;154%-159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c177" decimals="2" unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c178" decimals="2" unitRef="usdPershares">20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c177" decimals="4" unitRef="pure">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c178" decimals="4" unitRef="pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c177">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c178">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c177" decimals="2" unitRef="pure">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c178" decimals="2" unitRef="pure">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="c5" decimals="2" unitRef="usdPershares">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c137" decimals="4" unitRef="pure">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c179" decimals="4" unitRef="pure">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c137">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c179">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c137" decimals="2" unitRef="pure">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c179" decimals="2" unitRef="pure">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c167" decimals="INF" unitRef="shares">601400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c167" decimals="2" unitRef="usdPershares">83.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c168">P4Y4M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c168" decimals="INF" unitRef="shares">6497530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c168" decimals="2" unitRef="usdPershares">4.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <adtx:WeightedAverageRemainingLifeGranted contextRef="c168">P4Y7M28D</adtx:WeightedAverageRemainingLifeGranted>
    <adtx:StockIssuedDuringPeriodShareStockOptionsExercised contextRef="c168" decimals="INF" unitRef="shares">-1946419</adtx:StockIssuedDuringPeriodShareStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c168" decimals="2" unitRef="usdPershares">0.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c168" decimals="INF" unitRef="shares">62512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c168" decimals="2" unitRef="usdPershares">45.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="c168" decimals="INF" unitRef="shares">25</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c169" decimals="INF" unitRef="shares">5090024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c169" decimals="2" unitRef="usdPershares">12.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance contextRef="c168">P4Y6M14D</adtx:WeightedsAverageRemainingLifeOutstandingEndingBalance>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber contextRef="c175" decimals="INF" unitRef="shares">92567</adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice contextRef="c175" decimals="2" unitRef="usdPershares">75.5</adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross contextRef="c176" decimals="INF" unitRef="shares">6497530</adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross>
    <adtx:WeightedAverageExercisePriceGranted contextRef="c176" decimals="2" unitRef="usdPershares">4.71</adtx:WeightedAverageExercisePriceGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c176" decimals="INF" unitRef="shares">6435097</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <adtx:WeightedAverageExercisesPriceVested contextRef="c176" decimals="2" unitRef="usdPershares">5.55</adtx:WeightedAverageExercisesPriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c176" decimals="INF" unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <adtx:WeightedAverageExercisePriceExpiredOrForfeited contextRef="c176" decimals="2" unitRef="usdPershares">20</adtx:WeightedAverageExercisePriceExpiredOrForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c175" decimals="INF" unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c175" decimals="2" unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <adtx:WarrantsIssuedAndVesting contextRef="c0" decimals="0" unitRef="usd">609748</adtx:WarrantsIssuedAndVesting>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">105049</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">504699</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <adtx:WarrantsIssuedAndVesting contextRef="c154" decimals="0" unitRef="usd">189899</adtx:WarrantsIssuedAndVesting>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0">P0Y2M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="0" unitRef="usd">179419</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c155" decimals="2" unitRef="usdPershares">7.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c156" decimals="2" unitRef="usdPershares">57.5</us-gaap:WarrantExercisePriceDecrease>
    <adtx:GrossProceeds contextRef="c156" decimals="-4" unitRef="usd">1350000</adtx:GrossProceeds>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="c155" decimals="0" unitRef="shares">49153</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <adtx:ExercisePricePerShare contextRef="c157" decimals="2" unitRef="usdPershares">57.5</adtx:ExercisePricePerShare>
    <adtx:ExercisePricePerShare contextRef="c158" decimals="3" unitRef="usdPershares">12.395</adtx:ExercisePricePerShare>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 contextRef="c155" decimals="0" unitRef="usd">344158</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:ExcessStockSharesIssued contextRef="c159" decimals="0" unitRef="shares">407991</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c156" decimals="3" unitRef="usd">12.395</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c156" decimals="0" unitRef="usd">3759044</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c160" decimals="2" unitRef="usdPershares">57.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c161" decimals="3" unitRef="usdPershares">12.395</us-gaap:WarrantExercisePriceDecrease>
    <adtx:OfferingReflectingReducedExercisePricePerShare contextRef="c162" decimals="3" unitRef="usdPershares">12.395</adtx:OfferingReflectingReducedExercisePricePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c163" decimals="0" unitRef="usd">29058</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c170" decimals="INF" unitRef="shares">15565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c171" decimals="INF" unitRef="shares">11644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">22.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c171" decimals="INF" unitRef="shares">18506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">70.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c171" decimals="INF" unitRef="shares">1506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">77.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c172" decimals="INF" unitRef="shares">7197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">46.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <adtx:VestingExpense contextRef="c131" decimals="0" unitRef="usd">1222875</adtx:VestingExpense>
    <adtx:VestingExpense contextRef="c139" decimals="0" unitRef="usd">1843902</adtx:VestingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c131" decimals="0" unitRef="usd">848597</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c131" decimals="0" unitRef="usd">356105</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c131" decimals="0" unitRef="usd">18346</us-gaap:OtherSellingAndMarketingExpense>
    <adtx:ShareBasedPaymentRemnainingExpenses contextRef="c131" decimals="0" unitRef="usd">321603</adtx:ShareBasedPaymentRemnainingExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c131">P0Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <adtx:GrantTotal contextRef="c132" decimals="0" unitRef="shares">11644</adtx:GrantTotal>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c0" decimals="0" unitRef="shares">18506</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ExcessStockSharesIssued contextRef="c132" decimals="0" unitRef="shares">18469</us-gaap:ExcessStockSharesIssued>
    <adtx:CommonStockIssuedVested contextRef="c132" decimals="0" unitRef="shares">18469</adtx:CommonStockIssuedVested>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 &#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December&#160;31, 2022 and
2021, the Company did not record a current or deferred income tax expense or benefit due to current and historical losses incurred by
the Company. The Company&#x2019;s losses before income taxes consist solely of losses from domestic operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of income tax expense (benefit)
computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Tax Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Permanent Differences/Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred taxes are recognized for temporary differences
between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s
deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are comprised of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 13.7pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,499,811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,896,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Tax credits carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,511,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,541,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,169,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Section 174 Capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,547,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Loss on impairment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,288,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,140,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 27.35pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,114,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,934,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,217,401&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,670,590&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897,533&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,263,837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(722,127&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,169,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(175,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(897,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,263,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&#x2019;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&#160;31, 2022 and 2021, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&#x2019;s valuation allowance increased during 2022 by approximately $3.5&#160;million primarily
due to the generation of net operating loss and tax credit carryforwards and the capitalization of research and experimental expenditures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December&#160;31, 2022 and 2021, the Company
had U.S. federal net operating loss carryforwards of $56.6&#160;million and $38.0&#160;million, respectively, which may be available to
offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#x201d; TCJA&#x201d;) will generally allow losses incurred after
2017 to be carried over indefinitely, but will generally limit the net operating loss deduction to the lesser of the net operating loss
carryover or&#160;80% of a corporation&#x2019;s taxable income (subject to Section&#160;382 of the Internal Revenue Code of 1986, as amended).
Also, there will be no carryback for losses incurred after 2017. Losses incurred prior to 2018 will generally be deductible to the extent
of the lesser of a corporation&#x2019;s net operating loss carryover or&#160;100% of a corporation&#x2019;s taxable income and be available
for&#160;twenty years&#160;from the period the loss was generated. The Company has federal net operating losses generated following 2017
of $56.5&#160;million, which do not expire. The federal net operating losses generated prior to 2018 of $0.1&#160;million will expire
at various dates through 2037.&#160;The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019
and 2020 to the five prior tax years.&#160;In addition, net operating losses generated in these years could fully offset prior year taxable
income without the&#160;80% of the taxable income limitation under the TCJA which was enacted on December 22, 2017. The Company has been
generating losses since its inception, as such the net operating loss carryback provision under the CARES Act is not applicable to the
Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December&#160;31, 2022 and 2021, the Company
also had U.S. state net operating loss carryforwards (post-apportioned) of $26.2&#160;million and $44.8&#160;million, respectively, which
may be available to offset future income tax liabilities and expire at various dates through 2042.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December&#160;31, 2022, the Company had
$0.1 million federal tax credit carryforwards available to reduce future tax liabilities which expire at various dates through 2042. As
of December&#160;31, 2021, the Company had no federal tax credit carryforwards. As of December&#160;31, 2022 and 2021, the Company had
state research and development tax credit carryforwards of approximately $0.4&#160;million and $0.2&#160;million, respectively, which
may be available to reduce future tax liabilities and can be carried over indefinitely.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Utilization of the U.S. federal and state net
operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section&#160;382
and Section&#160;383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, due to ownership changes
that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and
research and development credit carryforwards that can be utilized annually to offset future taxable income and tax liabilities, respectively.
The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership
changes since its formation. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research
and development tax credit carryforwards before utilization.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has not, as of yet, conducted a study
of research and development tax credit carryforwards. Such a study, once undertaken by the Company, may result in an adjustment to the
research and development tax credit carryforwards; however, a full valuation allowance has been provided against the Company&#x2019;s research
and development tax credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance.
Thus, there would be no impact to the balance sheet or statement of operations if an adjustment is required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company files tax returns in the United States,
California, Virginia, and New York. The Company is subject to U.S. federal and state tax examinations by tax authorities for the tax years
ended December 31, 2019 through present. As of December&#160;31, 2022 and 2021, the Company has recorded no liability for unrecognized
tax benefits, interest, or penalties related to federal and state income tax matters and there currently no pending tax examinations.
The Company will recognize interest and penalties related to uncertain tax positions in income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;State income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Tax Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Permanent Differences/Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10.5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c0" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c5" decimals="2" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" unitRef="pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="3" unitRef="pure">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="3" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c5" decimals="3" unitRef="pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <adtx:PermanentDifferencesOthers contextRef="c0" decimals="3" unitRef="pure">-0.105</adtx:PermanentDifferencesOthers>
    <adtx:PermanentDifferencesOthers contextRef="c5" decimals="3" unitRef="pure">-0.05</adtx:PermanentDifferencesOthers>
    <adtx:ChangeInValuationAllowanceinDollars contextRef="c0" decimals="3" unitRef="pure">-0.131</adtx:ChangeInValuationAllowanceinDollars>
    <adtx:ChangeInValuationAllowanceinDollars contextRef="c5" decimals="3" unitRef="pure">-0.23</adtx:ChangeInValuationAllowanceinDollars>
    <adtx:TotalProvisionForIncomeTaxesinDollars contextRef="c0" decimals="2" unitRef="pure">0</adtx:TotalProvisionForIncomeTaxesinDollars>
    <adtx:TotalProvisionForIncomeTaxesinDollars contextRef="c5" decimals="2" unitRef="pure">0</adtx:TotalProvisionForIncomeTaxesinDollars>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 13.7pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,499,811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,896,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Tax credits carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,511,849&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,541,936&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,169,887&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Section 174 Capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,547,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Loss on impairment of debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,288,363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,140,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 27.35pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,114,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,934,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,217,401&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,670,590&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;897,533&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,263,837&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 13.7pt"&gt;Right of use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(722,127&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,169,887&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(175,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(93,950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(897,533&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,263,837&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c0" decimals="0" unitRef="usd">13499811</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c5" decimals="0" unitRef="usd">10896410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c0" decimals="0" unitRef="usd">430468</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c5" decimals="0" unitRef="usd">161943</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="0" unitRef="usd">1511849</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="0" unitRef="usd">1541936</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="0" unitRef="usd">722126</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c4" decimals="0" unitRef="usd">1169887</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <adtx:Section174Capitalization contextRef="c0" decimals="0" unitRef="usd">1547343</adtx:Section174Capitalization>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="0" unitRef="usd">3288363</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c5" decimals="0" unitRef="usd">4140318</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="0" unitRef="usd">114973</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="0" unitRef="usd">23933</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" unitRef="usd">21114933</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" unitRef="usd">17934427</us-gaap:DeferredTaxAssetsGross>
    <adtx:ValuationAllowance contextRef="c0" decimals="0" unitRef="usd">-20217401</adtx:ValuationAllowance>
    <adtx:ValuationAllowance contextRef="c5" decimals="0" unitRef="usd">-16670590</adtx:ValuationAllowance>
    <adtx:NetDeferredTaxAssets contextRef="c0" decimals="0" unitRef="usd">897533</adtx:NetDeferredTaxAssets>
    <adtx:NetDeferredTaxAssets contextRef="c5" decimals="0" unitRef="usd">1263837</adtx:NetDeferredTaxAssets>
    <adtx:RightOfUseAssets contextRef="c0" decimals="0" unitRef="usd">-722127</adtx:RightOfUseAssets>
    <adtx:RightOfUseAssets contextRef="c5" decimals="0" unitRef="usd">-1169887</adtx:RightOfUseAssets>
    <adtx:FixedAssets contextRef="c0" decimals="0" unitRef="usd">-175406</adtx:FixedAssets>
    <adtx:FixedAssets contextRef="c5" decimals="0" unitRef="usd">-93950</adtx:FixedAssets>
    <adtx:TotalDeferredTaxLiabilities contextRef="c0" decimals="0" unitRef="usd">-897533</adtx:TotalDeferredTaxLiabilities>
    <adtx:TotalDeferredTaxLiabilities contextRef="c5" decimals="0" unitRef="usd">-1263837</adtx:TotalDeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-5" unitRef="usd">3500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c3" decimals="-5" unitRef="usd">56600000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c4" decimals="-5" unitRef="usd">38000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <adtx:NetOperatingLossCarryover contextRef="c180" decimals="2" unitRef="pure">0.80</adtx:NetOperatingLossCarryover>
    <adtx:NetOperatingLossCarryover contextRef="c0" decimals="2" unitRef="pure">1</adtx:NetOperatingLossCarryover>
    <adtx:incomeLossOfGenerated contextRef="c0">P20Y</adtx:incomeLossOfGenerated>
    <adtx:NetOperatingLosse contextRef="c5" decimals="-5" unitRef="usd">56500000</adtx:NetOperatingLosse>
    <adtx:NetOperatingLossesGeneratedPrior contextRef="c5" decimals="-5" unitRef="usd">100000</adtx:NetOperatingLossesGeneratedPrior>
    <us-gaap:LessorOperatingLeaseDescription contextRef="c5">The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019
and 2020 to the five prior tax years.</us-gaap:LessorOperatingLeaseDescription>
    <adtx:PercentageOfIncomeTaxable contextRef="c181" decimals="2" unitRef="pure">0.80</adtx:PercentageOfIncomeTaxable>
    <us-gaap:OperatingLossCarryforwards contextRef="c35" decimals="-5" unitRef="usd">26200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="-5" unitRef="usd">44800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c5" decimals="-5" unitRef="usd">100000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c35" decimals="-5" unitRef="usd">400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c4" decimals="-5" unitRef="usd">200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:ScheduleOfSubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2022, the Company entered into
an At The Market Offering Agreement (the &#x201c;ATM&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC as agent (the &#x201c;Agent&#x201d;), pursuant
to which the Company may offer and sell, from time to time through the Agent, shares of the Company&#x2019;s common stock having an aggregate
offering price of up to $50,000,000 (the &#x201c;Shares&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The offer and sale of
the Shares was made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-257645) filed by the
Company with the SEC on July 2, 2021, amended on July 6, 2021 and declared effective by the SEC on July 13, 2021, under the Securities
Act of 1933, as amended.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;No sales of Shares were
made during the year ended December 31, 2022 under the ATM.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the period beginning
January 1, 2023 through the date of this report, the Company sold 338,513 Shares at an average price of $1.55 per share under the ATM.
The sale of Shares generated net proceeds of approximately $507,000 after paying commissions and related fees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2023, the Company formed Adimune,
Inc. a Delaware, wholly owned subsidiary.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2023, the Company formed Pearsanta,
Inc. a Delaware, wholly owned subsidiary.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 21, 2023, the Company entered into
an agreement for the purchase and sale of future receipts (the &#x201c;Future Receipts Agreement&#x201d;) with a commercial funding source
pursuant to which the Company agreed to sell to the funder certain future trade receipts in the aggregate amount of $2,160,000&#160;(the
&#x201c;Future Receipts Purchased Amount&#x201d; for gross proceeds to the Company of $1,500,000, less origination fees of $75,000. Pursuant
to the Future Receipts Agreement, the Company granted the funder a security interest in all of the Company&#x2019;s present and future
accounts receivable in an amount not to exceed the Future Receipts Purchased Amount. The Purchased Amount shall be repaid by the Company
in 28 weekly installments of approximately $77,000 with the final payment due on September 5, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 17, 2023, the Company entered into a consulting
agreement (the "Independent Consulting Agreement") with an independent consultant for a term of thirty days. Pursuant to the
Independent Consulting Agreement, the independent consultant agreed to provide the Company with business advisory services, guidance on
growth strategies and networking with its clients on a non-exclusive basis for general business purposes (the "Independent Consulting
Services&#x201d;). In consideration for the Independent Consulting Services, the Company issued to the independent consultant 187,000 shares
of the Company's common stock (the "Independent Consulting Shares"). The issuance of the Independent Consulting Shares will
not be registered under the Securities Act.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 4, 2023, the Company entered into a Business
Loan and Security Agreement (the "April Loan Agreement") with a commercial funding source (the "April Lender"), pursuant
to which the Company obtained a loan from the April Lender in the principal amount of $1,060,000, which includes origination fees of $60,000
(the "April Loan"). Pursuant to the April Loan Agreement, the Company granted the April Lender a continuing secondary security
interest in certain collateral (as defined in the April Loan Agreement). The total amount of interest and fees payable by the Company
to the April Lender under the April Loan (the "April Repayment Amount") will be (i) $1,000,000 if paid prior to April 6, 2023,
(ii) $1,219,000 if paid prior to April 10, 2023, or (iii) $1,590,000 if paid after April 10, 2023 and will be repaid in 20 weekly installments
of $79,500 commencing on April 10, 2023 and ending on August 21, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 13, 2023, the Company formed Adivir, Inc.
a Delaware, wholly owned subsidiary.&lt;/p&gt;</us-gaap:ScheduleOfSubsequentEventsTextBlock>
    <adtx:AggregateOfferingPriceaAmount contextRef="c182" decimals="0" unitRef="usd">50000000</adtx:AggregateOfferingPriceaAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c183" decimals="0" unitRef="shares">338513</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap-sup:InvestmentCompanyIssuanceOfSharesPerShare contextRef="c183" decimals="2" unitRef="usdPershares">1.55</us-gaap-sup:InvestmentCompanyIssuanceOfSharesPerShare>
    <us-gaap:PaymentsForCommissions contextRef="c183" decimals="0" unitRef="usd">507000</us-gaap:PaymentsForCommissions>
    <us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement contextRef="c184" decimals="0" unitRef="usd">2160000</us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement>
    <adtx:GrossProceed contextRef="c185" decimals="0" unitRef="usd">1500000</adtx:GrossProceed>
    <us-gaap:OriginationOfNotesReceivableFromRelatedParties contextRef="c185" decimals="0" unitRef="usd">75000</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c186" decimals="0" unitRef="usd">77000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:SharesIssued contextRef="c187" decimals="0" unitRef="shares">187000</us-gaap:SharesIssued>
    <us-gaap:BadDebtReserveForTaxPurposesOfQualifiedLender contextRef="c188" decimals="0" unitRef="usd">1060000</us-gaap:BadDebtReserveForTaxPurposesOfQualifiedLender>
    <us-gaap:AmortizationOfDeferredLoanOriginationFeesNet contextRef="c189" decimals="0" unitRef="usd">60000</us-gaap:AmortizationOfDeferredLoanOriginationFeesNet>
    <us-gaap:PriorPeriodReclassificationAdjustment contextRef="c190" decimals="0" unitRef="usd">1000000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment contextRef="c191" decimals="0" unitRef="usd">1219000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment contextRef="c192" decimals="0" unitRef="usd">1590000</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment contextRef="c193" decimals="0" unitRef="usd">79500</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:FinancingOfFixedAssetLongTerm
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-10"
      unitRef="usdPershares">-121.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-14.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-12"
      unitRef="shares">1854724</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-13"
      unitRef="shares">381811</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c13"
      id="hidden-fact-16"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c19"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c18"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c19"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c22"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c23"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares
      contextRef="c18"
      id="hidden-fact-25"
      unitRef="shares"
      xsi:nil="true"/>
    <adtx:SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares
      contextRef="c19"
      id="hidden-fact-26"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c18"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c19"
      id="hidden-fact-28"
      unitRef="shares"
      xsi:nil="true"/>
    <adtx:ExerciseOfWarrants
      contextRef="c18"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c18"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c19"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c24"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c24"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c25"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c25"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c3"
      decimals="0"
      id="hidden-fact-36"
      unitRef="usd">5206307</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c30"
      id="hidden-fact-37"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c30"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c36"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c37"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:ExerciseOfWarrants
      contextRef="c36"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c36"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c36"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="c36"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits
      contextRef="c36"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:IssuanceOfSharesForTheSettlementOfDebt
      contextRef="c36"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c36"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c36"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:IssuanceOfSharesForOfferingsNetOfIssuanceCosts
      contextRef="c36"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c36"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c39"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c12"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:DisposalOfFixedAssets1
      contextRef="c5"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:NoteReceivablesAndAccruedInterest
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSecuredNotesPayable
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c5"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:SaleOfPreferredSharesToRelatedParty
      contextRef="c5"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c5"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:OriginalOfferingDiscountOnConvertibleNotePayable
      contextRef="c0"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c5"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:OriginalIssuanceDiscountOnNotesPayable
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts
      contextRef="c0"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="c4"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:LiabilityRecognizedForFinancedAssets
      contextRef="c0"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:ReductionInExercisePriceOfWarrants
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:SharesIssuedForIntangibleAssets
      contextRef="c5"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="c5"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="c3"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="c3"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="c3"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
      contextRef="c3"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="c3"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c3"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c3"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c165"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-82"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeGranted contextRef="c165" id="hidden-fact-83" xsi:nil="true"/>
    <adtx:StockIssuedDuringPeriodShareStockOptionsExercised
      contextRef="c165"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-85"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeExercised contextRef="c165" id="hidden-fact-86" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c165"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeExpiredOrForfeited contextRef="c165" id="hidden-fact-89" xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeExercised contextRef="c168" id="hidden-fact-90" xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeExpiredOrForfeited contextRef="c168" id="hidden-fact-91" xsi:nil="true"/>
    <adtx:WeightedAverageExercisePriceRoundingForReverseSplit
      contextRef="c168"
      id="hidden-fact-92"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <adtx:WeightedAverageRemainingLifeRoundingForReverseSplit contextRef="c168" id="hidden-fact-93" xsi:nil="true"/>
    <adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross
      contextRef="c174"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <adtx:WeightedAverageExercisePriceGranted
      contextRef="c174"
      id="hidden-fact-95"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c174"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <adtx:WeightedAverageExercisePriceExpiredOrForfeited
      contextRef="c174"
      id="hidden-fact-97"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <adtx:Section174Capitalization
      contextRef="c5"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:NetDeferredTaxes
      contextRef="c0"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <adtx:NetDeferredTaxes
      contextRef="c5"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001726711</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M$WBXJC6U8P0'3P<'#W;YNX&WNU#$:#HQ4H(5O#/'.+T#+FN-Z1C!H*^#0?_
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MF5RK/-+6LJI5NQ<EC!'.=\%9Y+P LR%P+7\A)V5,RXD*J"78Y'4D#3O'*GT
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M&)K28+MNO"VX[4H[<&#WP'&Z6$3%$VL1@^)9SD&4@E"L(RUB*V#+5&&8@9*
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MN@[VL9BQE\^T)$14O!6+>?X?O)2V5@>L]ERPI'26")(H+7Z#UW(@CAR@T^*
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MLZ43.R2%#:NY?A+[C] *"@U>(KBR_V3?VGH.26JE1=$Z(X,B+YLO>VTWHN=
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M"XT%EFUF6 .#- 8XOQ%"OW7, EU5O?H!4$L#!!0    ( /")D58PY8%%S@P
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M/MF#A&0VXNY2^D)^2V[](=TU9@^[X]=Q](NU(_-;Z86Q(D>9KPB>+,4TO)8
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M;,5_K@%\Y6@!?E]:,'%Z( 7=][K3_P%02P,$%     @ \(F15H8![?9X!0
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M'^P-R7>S9O<279/FNX6+F!;38X7QG+ULP'KI7-R\R ';@7_^#U!+ P04
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M_'2@+[4XPA)FXH@@F9W%FT$QO!D\((J0=WSUUHWCJ:>GL*MB='F*-+B**CQ
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M?[U$G&S]F!#\P0B$?IE?V"*A!Y"#W_YZDI],SKH7=B S Q_+$)K77J?2UMQ
M]&X@XQ6TUW?8?TB ;%^ \6,"C,_S\XOS0Q*(1 (6X.)DG)_^^NLC[&?_/^S_
MEX"?9M.:AK2<RCE@5)U<=:S3UY!@\$XF IS3R_SBXM*CS?AD OAY@#7?"%[=
M@P/HQIBN3$(10M4U.C[INA'!X6CE0>Z#:!WQ/'GOS5UK:GPN5/_"%KUSQ0$'
M?J:S6^Z4Y%J%UD>VS0K--]UV;E6&FIK:B99[1:I\6!*K_)">NVM'%]+TME<@
M1656'BH];QEZRPZ-QI9?8J.2LCL,!RUUS<W$?1.*++H&Z]YD#!?'X=403XI9
M+^-10FF>;3S13T.9HG@873$!D(XI*,<2K/$S>F3&,%^PUO>!CG\/"_A%H3Z+
MX:B66YLG>MLO2$MA5H<4+GF!D ;^Z.')75I[\*W!T:'W@8^3][C7RB[Y;75^
M>[%N_"O=W;?="_%3_QYXO]R_3?]1VB5-12NUP-:3T>7YD>^,XD-C-OQ6^-PT
MC5GSQY62<"5:@-\7QC3Q@0[H_C>!-_\$4$L#!!0    ( /")D59QBC"*S T
M %TK   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+U:6W/;-A9^YZ_
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ML\OI+"Z8T!-_>B<BZ>BTX""$J808;X,89X?5$IQP(#R%L(?TB0MYL:A/XD[
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M^ #>+PQPMPM6T/U$<_$G4$L#!!0    ( /")D58D?X/U@P@  *<;   9
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MTV)VTCD-C\X&).\$ODBQ,CMK1IY,E?I.#Q^SDTY A$0N4DL('']+<2[RG(!
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M%\Y"D,4A(4L_F$T1=K"8)(%+@N'>V=P/I@MVSL(PFL2A]XN+_''P$<ZEH@3
M+V>(^=5(X[#IFI!QY,\6B?%,6)9Z-B#",O15FM(-SX:4>L\OGH;S*1#63].<
MWOU8)]B.HVG(I)(YL[-1?M0K)![%YLX YLO0#Q=SMT=\W#G8&<5IDB3^?!Z!
M[GLZHI+77.M& 'DX':DPF[\59F/5+SJ-IHD?APG:COL\MD!Y#1O@H@SJH:+:
M43EEG]9FB5-)XA$@[E%#9VL"?;73!83.>6N!1S610.4A5*#1 #/$X!2'LXME
M-.J #/,PO<0M@LD\48FH-])C_F8YLB-RU$'1%2.*;Q'-_/DRT>+S'G;'CO@6
M<SRYL,_^;Q#?TD\6LS'Q>=\B/G9<? <\E&:>:=Q3B_,$CJ%?0&*6II!FJV^U
M4 C*%EOEF FR38Z'8["6QWC"*;_ )P #*.XSH0H(\.XM@G5W8+@&</K3#%-_
MY/C0S(^7<S^9!G8V^WU1U:C&;+Z@\7@'[1>=73V,&@9/KQ\\#8,'HR?[L>B)
MLE&Q4SZQL<<XP3FXP(L(HP>&(4$U@NDIL?L<4YN _>1]S"4>F1#4(!183Y!T
M6#1)DI\NII-X#HLL "AG<*&N'!, ?I%@#+$+;BN<SQ<8F<-X_M-%.$O83X_A
M8/@@![5\'L' &MN;\B_B(R#WW4P,)B'P()B .HTR<:J8&(PP,8F!B<D2F$@.
M&#:Z&-C((1YK :.[-E,$VU5^DGINU0V=,\[Z0*1)OW&*3DD&7?P54NNZ)-?S
MH@*JL6(& >'W?Q$#*/T&9E%.J04M#"GH!#SGW$3?$5DGD?6?ZAC@C5#6%4M6
M 1Q_Y#!056Q0IE&[>]?>%'FJKI2YL*?6#X<-!D4JBK!ZS<M68'\6UN5X*' G
M1-T!<BINB#KBEGRJ5KQ6JABT%5RB)QP@DVC3CK+G,23V8V"-ZEM2?Q9'3-Y#
M$Q-JMXNR:M<;,X96_+E'3%HYPBY%^YZ&/R "SRJ7UI]]O,S&NOT$M-OFJ=UI
MQ^^QJ]WG/8T,L),+BI(6O*;ZJ5:M3KQ/!VULGQQ'/-A\[A?HO#^[8EDEU&P$
M<(= MD.MA<VI;7P TO@,(!O"L9Z8D)2^): " [W_GX!Z9=Z/<8XJV2,NDJ97
MKJL;K)5L4/[.,FD6A'X<8.VRP"R<Q9/IPM887;".)W,HJ2:SF5,TG87^,I[1
MV;YS\)VSY5@)=3:+_"2,8%6<3&81+/M8M0HAU-#^R6DH1AXNN!(_6 90N,18
M%T63Q11P2]R2:XPM#U=;@.IL#F#GB5MM]3EA"R^X/$5<YD ;K$^<TNL,Z@1L
M19TS%=4?*,/TNPVX,8KA+ZB%#GSO6#$T"Y;^/%Y\3S$4!D!DO/R&8HB2Z"2(
M_=GR( G'V9YRS<H'4HMA(&V^[J7-[_MIL_>#I<>CV4;G$8&(0;9Y PF3XMGC
M"X]O)GV@X//V"KY_B[H:.QVD8!PO 0%$, %UU;.(,4!T/ 5\7Y@<.QR$O:/^
M@5#NS/;P\ I0TYV,IE';R\ZTW9[Q;_18UPK_X+11B8EF'X6)6DX1RYX#\FQ?
MPAP*-2>7 0.,5(<8<'5((FM3'+OT,U%J,Z I8]^7WK)A9V8IG7D^3>QM:J^>
M^^@-(0>LI+3G4>TTU73?5RJ!^TH)-<29TW R3=@6TAXZM7A%';F\Q'W,-)9R
M$8-=7Q(]!FA*:/1Y2$S'-ILI=.IVR!H M]-'F/1P+5[Z83(U+QRY+(";I^#%
MIU#1._UX,A>OZW*7%T[+B0('UP?[Z+1#_A5S/7PCL>M/(L[FQ0QLHBH-WS]3
MWD DWY>>>_"4EYYY[XVD.HUCH&1A1--OP0ZJ*NX+>_0VQL*H+RJ=CX'Y@WM*
M36U)QUM:->GUT*?AH WW5M-0C:EVE=2O;IS7A7B6T<$)\#"4AY%JT[LSZI4R
M?7NPM-;T:5OAU G7WM$;$&\P]Y?+\/A!I[WC.4UOQ-'9S8@RL!%E\!ZE#/;L
M,+73D;,TO^2VM[4R\:DJQ<6&%ROEY;3P'$'UE$/-GO8TQ)\G2PB,\;B.=!76
M^](]"#OD+TU2K-7)NUI39\D]8MF]G_>NFK#([+NOB4P]>M5YP^%#DL/F?Z#7
MGCY],.[4!FU[3_7<?"@:ZAUU;4#SNB5S7[>DMZ+L@4G=9^\</Q*L0ZE]::46
M*QJIZM,GHP[<P1PW&;)CQ1LI/)LX]-7C- )-H+?>M((\J!)[+_N,O.'5*QY&
MUIR9-QRO/]DQL3=>8'0I*CZPGSH[MP_39@CTR<R.$6S:K-]C@Y1@'MND.5SX
M23"#Q'@.14,O90[-#52B(_M%;.Z'2\S2X]ED'OT5V3)1_&#*YT>@FOAB"Z6Q
MW9L$>SF@',N=Z:6&@=30/8#=Y=<^.UW$P"R@]-%9(SPS368^).:/;5'[FIB%
M/XT/^MI_24H^/(CP>H.(:83O)$V_81 1!P]EH3\T^N7=H0+S-B:HR&1L0D8O
M9*+VDB)UK[ ,^3']ZN;(*QVF*:=7.18Y&?J)@4OG!R'HQ"3^[ 4&VK9LU&]#
MV*OVES6NU ]*=,O5SW*\Y?4Z+R4KQ H>Q5'/B3K/8KXTU8Y^7N*F:IIJ2Q\W
M@D-V@ O@_JH"IZ6_X ;V]T:>_P=02P,$%     @ \(F15A&7Q*O "P  HB
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE5IK<]NV$OW.7X%QTXXS
MP\HB*4MR'IYQG'1N.DV:B9/>V[ES/T D)*&F"!4$+:N__IY=D!0ETZ\/L?@
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MSJSX<JDDG$H#\'YNC&MN:('VOR6<_Q]02P,$%     @ \(F15O'N[O:H!P
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MUKQ:^D!3ZD#+8+H;]P9O?8>6,CE?+J90)ZW N6UG2=>8I. IDF'QPZBMPKX
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M3CZ13WV\+*@15Q$!(!U<>@Y#8(SKL4*DX0N$6KM"CJ'W?@!=?FZC EBJH4+
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M#V+%6Q:M=^#_I3&T4WR"?F^G_P!02P,$%     @ \(F15L<#X65Q P  O@<
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC57;;N,V$'WW5Q#:HG
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M:0VW18U6H#0Y8]@[81"3\TXA:Z5$4])@9Y@WP=FA+1+4Z'R\4$))W@)9P;/
MTL*#TFZP3>G0!D.[X1[=Q17(C7UQH&>SQ]VUW,_VCYK+[BY_4>]>1)^YW!2U
MPK37:.I-$SS#9/?*Z 0M&GNSKX3&=X(=;O%A!M(HX/I:"'T0C(/^J;?\!E!+
M P04    " #PB9%6C%Q[?I@$   -#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6R=5UU3VS@4?<^ON).6%F8<1Y:_$@J9@9;N[D-;!K;E86<?A'V3
M:+"M5)(3^/=[92<F+"%E.LR 95V=>\[]D"\G*Z7OS!S1PGU95.:T/[=V<3P<
MFFR.I3"^6F!%.U.E2V%IJ6=#L] H\N9060PY8\FP%++J3TZ:=Y=Z<J)J6\@*
M+S68NBR%?CC'0JU.^T%_\^)*SN;6O1A.3A9BAM=HOR\N-:V&'4HN2ZR,5!5H
MG)[VSX+C\\39-P8_)*[,UC,X);=*W;G%7_EIGSE"6&!F'8*@/TO\B$7A@(C&
MSS5FOW/I#FX_;] _-]I)RZTP^%$5-S*W\]/^J \Y3D5=V"NU^A/7>F*'EZG"
M-+]AM;9E?<AJ8U6Y/DP,2EFU?\7].@ZO.<#7!WC#NW74L/PDK)B<:+4"[:P)
MS3TT4IO31$Y6+BG75M.NI'-V<FU5=C=718[:O'LSXD'Z 2Y^UM(^P.'?XK9
M<W0RM.3(F0^S->AY"\I?  TX?%&5G1NXJ'+,GP(,B6%'DV]HGO.]B)\P\R$,
M/.",\SUX82<[;/#"5\A^OQ'\55F$?\YNC=54+/_NTMVB1KM170,=FX7(\+1/
M'6)0+[$_>?<F2-B'/9RCCG.T#WUR30V9UP6"FH*H1/%@I''/=HY@G!Y0BZ;2
M9UI4MJUW)ZNF'.C&:E&(:I>JO7YWJ_J!QF)./'(*6[5L5TU4X5O#PL#7NKPE
MQS=-8]#NYJ'WK;;&TDE9S8 2BXW9.KD!1)&7!@S>0I RGS%(_#3J_>$D$<;
M_?0N[E%GTFRM%U+32FF@:VJ*\M%TGR_^S%?L?.V4=B.TH_#;JA(6>!%SKD:A
M'S.(_'#4J4J\:)QZ<>A>IQ0!/TFV-!X&WC@BDV ,1\#\9/R2XL.$>S'UWA%$
ML9]P,KM2=4N(C. *EU3M"->+0EK@\2OB$WMLS#S&(Q<B[H]"XA9'O<>P7%U_
M?Q:2K>WG<0AB+TYB@ALG%/ N D'@)5$$G&\EX# 8>3%+2 XE)XE[GQ^%!IN-
ME&*YQQ^'U O&*;F+J(PX[.G"N.O"^-5=N&J+X@&D,;6H,MS57'OA=C?7*SMJ
ML*6<VOYYL,<>2T*7.C9R<=IJHB[&J<?"$44RH/1&P5:,G=%>> Z<*N,QE;_N
ME5_SI?I-7+;2>)OOT_;HJ-/KT!5H2O3)_DF!Q+1!W79$N$^Y[102,-:8DV/7
MFWNJ).FJ)'EUE4R%U+ 41=VL4&3S3>$T=4.D5L( T9,T9-"J-JX9W7TM:+ML
M[W0RGZ%QE]+0]3Q=[DH;D%5C=UZ([&Y /A5]K^G3FV.QJQ+W4MY=B9M;"!9:
M9@AO77P&;4SI"J+)BOCF])G)D6[+!XE%#@P.>E?2W,%4(Q)#BX1F20!]7#FE
MZ6 0^E%*1AU (:?.$!Y0D*:8P =-_CN#I2J$E87[F 51>C (Z 8YZ/V?&^7R
MMXDQ/R!<YD?\96)A2XR]0"R.B%@\AH.=]3/<&M%*U+-F$#60T05MVVFM>]O-
MNF?MB/=HW@[*7X2>2;H-"IS24>:G=,/H=OAL%U8MFH'O5ED:'YO'.<WKJ)T!
M[4\5#3KKA7/0_0<P^0]02P,$%     @ \(F15JF.96$L!   7PD  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&ULC59M;]LV$/ZN7T&H6Y$ K"52LB2G
MMH&\K%B =@OJM,,P[ ,MG6TBDNB2=)SLU^](R8Z#N5X_V"*INX?/W7-':KQ5
M^L&L "QY:NK63,*5M>N+*#+E"AIA!FH-+;Y9*-T(BU.]C,Q:@ZB\4U-'/(ZS
MJ!&R#:=COW:GIV.UL;5LX4X3LVD:H9^OH%;;2<C"W<)GN5Q9MQ!-QVNQA!G8
M+^L[C;-HCU+)!EHC54LT+";A);NX&CI[;_!5PM8<C(F+9*[4@YO<5I,P=H2@
MAM(Z!(&/1[B&NG9 2.-;CQGNMW2.A^,=^@<?.\8R%P:N5?V'K.QJ$A8AJ6 A
M-K7]K+:_0A^/)UBJVOA_LNUMXY"4&V-5TSLC@T:VW5,\]7GX$0?>.W#/N]O(
ML[P15DS'6FV)=M:(Y@8^5.^-Y&3K1)E9C6\E^MGI;5NJ!LB]> )#SN[%O 9S
M/HXL0CN#J.QAKCH8_AT8QLDGU=J5(;^T%52O 2+DM"?&=\2N^$G$&R@')&&4
M\)CS$WC)/M#$XR7_&RBYD::LE=EH(']=SHW56!I_'XNY0TR/([IVN3!K4<(D
MQ'XPH!\AG+Y]P[+X_0F^Z9YO>@I].L/VJS8U$+4@ LN_5&TI:RE\+>.:[.*Q
M& \\88L:(&=S:&$A[3G!5^N-A8H(2^P*B+'";JS2SV0!%6A1'[IK87&@#I;
M',O&2;['L^&T<P*RX/8 W+'Z,I@-#FAY#IR1G_U?,+-N?DB(L$%&LL$H< )>
M:ZBD=6LQB0<LN /LSQ9:B](N%J"A+<%$OV/D&HN:Q8,A.2=G0[0^#ZY7HETZ
M;/(HZDV73E'CV230"8V3 7/&//'6]\IBLM9:/4I_#.$I^)I6C)3=[X3BP[WB
MPQ]6',\5T!BE%T@8 QBM:"N"!3#'*K#RN$0G-S@NT9\@=-^U!'L.FCEHUW?!
MBW8W_R43_(;W!=X,J)MLEP2[R9!2:/V,"=H*71GR$V$)34<C6C#F)C$M1AE-
M6>P5+'L%7_ND24S3K" L8W24)E@&JGQXYP[=RI<T5GDG&*-#QFB1CMPH1>,D
M"SX"VNT3]$QRSBGC&5JP#%D4>3#K;P*6I^1:K"5**__9 Z8Y3=*$O L^NF!P
M339K(77CRLHK,K<DH;PH:)(E)*4LC6G"BL"7&6$LI:,\(3Q!,DE?-\=4Y,C'
MV28)\L!'2E.>!U^/U2*/*4>;-/85R3*:Y3$=CEQ=NO0?0R]&.1TZ:,JSA!9)
M_EJ\@_()_/WK(MM@VGKWLRYIN=]OES?<[H-\<H=);\3R(9+*G-$(PQV^-$KU
MG<W(V8Z8!^ZY'8D#7.&\?5-PQM\?C(YU5W1PZ36@E_YJQXI2F]9V]]]^=?_U
M<-E=FB_FW:?')Z&7LC6DA@6ZQH,<^TAWUWDWL6KMK]"YLG@A^^$*OX! .P-\
MOU#*[B9N@_TWU?1?4$L#!!0    ( /")D58X&_FS00<  ,]$   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;+V<6V_;-AB&[_<K"*\86J"-)<66XRXQ
MT$9'8-V*IETOAETH,AT+M427I)-VOW[4(3K8,FMU;U>@L23K>SY2?L73*^CR
M@?%/8DVI)%_232:N1FLIMR_'8Q&O:1J),[:EF?IFQ7@:2;7+[\9BRVFT+(+2
MS=@R#'N<1DDV6EP6Q][RQ27;R4V2T;><B%V:1OSK:[IA#U<C<_1XX%URMY;Y
M@?'B<AO=T1LJ/VS?<K4WKBG+)*692%A&.%U=C5Z9+T-KF@<49_R9T ?1VB9Y
M56X9^Y3OA,NKD9&7B&YH+'-$I#[NZ37=;'*2*L?G"CJJ<^:![>U'NE=47E7F
M-A+TFFT^)DNYOAI=C,B2KJ+=1KYC#P&M*E04,&8;4?PE#]6YQHC$.R%96@6K
M$J1)5GY&7ZH+T0HP)T<"K"K .C7@O HX/S5@4@5,3@V85@'3_8#ID0"["K!/
MS3"K F:G!EQ4 1=[ 4=_AWD5,"_D4/Y^Q8_O1#):7'+V0'A^MJ+E&X6"BFCU
MFR=9+O8;R=6WB8J3BS_X790E_T2E\K(E^3V2.TX)6Y'7.Z%.%H(\=:B,DHUX
M1EZ0#S<.>?KD&7E"QD2L(TX%23+R(4ND>*X.JNWW:[83BB0NQU(5,$\SCJO"
M>&5AK".%,<D;ELFU(&ZVI,MN_%A5K*Z=]5B[UY86>$.W9\0RGJO_EM53GFM]
MN$/C,V+81;C9$^[HP_^(99V]+]P](=R\.!KNG5#W\^-U]T\(-^VCX<%_"P_U
MX:]V=ZKP9E_=.T(XKV5^7O#.(3+_ZS=UA(22IN+OGK*_+G--^G/EW=-+L8UB
M>C52_8^@_)Z.%K_\;-K&KWT21,(<),Q%PCPDS$?" B0L!,$Z(I_4(I_HZ(MK
MEFZC["M)A-CM-Y^E<+7Q0X5;PJ8%+!]3W2],>S*WYI?C^[8DD3G=PYQ3V[9G
MW90>,J6/A 5(6'AX,>9F^V)T1#2M1335BNCMCL=K-7HD6Y[$ZB_E93]/GJJ^
MW6&;3<1%<_19G\JT"8:J# ESD# 7"?.0,!\)"Y"PL(39[3;#,OH%:]>"M;6"
M]3E3G?>6LYC2I6C+M%><6MA0<2)ACGUP;2;6U.@V;2XRHX>$^4A8@(2%AQ?6
M- WCB.QFM>QF6MF%12=+'B+.HTP*(AG9/C:=:E19SHWZ!*C%#A4@$N8@82X2
MYB%A/A(6(&'A;$B'?E$+]4(K5(?>2C4O%Y+O4II)(BE/GY,E%3%/MOE\J$^D
M6N10D2)A#A+F(F$>$N8C80$2%NK5]GY-FS9Q'=U3-=LF] OE<5*/*57S^,2T
M[+.I4691H\F?RC%F/C///ZN Z'9#R8IQ$I4GKI)[^N(KC7@=E[ EB5FJA!TG
MV1T1R1>2EDM(*\Y2(E5IEI$L4N:SHBB+Z9EFIC6O[ZFYMI8?'VNX5[/3Q\A:
M_M ;# ESD# 7"?.0,!\)"Y"P<'XP7)E-^[L TVA6>8W39G7J1LCO%Y81(5G\
MJ4^:>M10;4)I#I3F0FD>E.9#:0&4%E:T]D!E,KV8'!%IRXHP3VE5O[]1U?,'
M*Q=)<Z T%TKS*EJ[R;&[\T[_VZ<$WSXE1!6[*S"K$9BE%9C;%=;WK&WI,PR6
M6$F;M]<S9V?3O154:$ZWHAWI7RI!(#/Z4%H I84H6E>1C2UE:@V!Q>]4YEWR
M+EM2_L 3F0]BEXF(V2X?77YK+4L/'RQ&J!-5T=HR.Y^;^\M9T)P>E.9#:0&4
M%J)H7=DV1I.I=YIRV9Z\XEJQ.NMO,\O8D\)UWVFVL7^:HR_9X,802?.@-!]*
M"Z"T$$7KZJ_QJ,QOF%2<KO(VL[7^>GS!5<\:W$I.>VQ/>SJS]G4*]9J@- ]*
M\Z&T $H+4;2N3AMKRM1[4^UI-_V\2^17G4ZAUA24YD!I+I3F5;3V'6F9QOR@
MZ_"A:0,H+431ND)MS"Q3[V;50M7($VI<06D.E.9":9YYZ.J<E__VY0DUIJ"T
M$$7KRK.QL$R]J[ W<<\MK"%S=JB;!:4Y4)H+I7D5;=92KG%F&.:^;J%>%906
MHFA=W38VD:GWB:[+I?:;?*F=_/6&IK>4]SY1JN<,EBC4$(+27"C-@])\*"V
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MTB90F@NE35&T4YDXG$>W\P^D%SETDX^X>#71?"<Z6?.. _7:A=)Z4%H?2AM
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MF KZ^P7G:O?!.-B_AO#A'U!+ P04    " #PB9%6#!A@\U4#   ,#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RMEVMOVC 4AO^*E4U3)VWD2@(,
MD"@!UDG=JE;=/DS[8)(#1$UB9IO;OY_MA(Q+FH*4+Q [YWU\G/?$L;L;0E_8
M H"C;1*GK*<M.%]V=)T%"T@P:Y EI.+.C- $<]&D<YTM*>!0B9)8MPS#U1,<
MI5J_J_H>:+]+5CR.4GB@B*V2!-/=+<1DT]-,;=_Q&,T77';H_>X2S^$)^//R
M@8J67E#"*(&4121%%&8];6!V)IZ,5P$_(]BP@VLD9S(EY$4V[L*>9LB$((:
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M<'&04)<+<5P%*@/$_1DA?-^0 Q0'X/X_4$L#!!0    ( /")D58H^"R[L00
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MLSD718#^?I'GZOFD>&Q0/2::_0]02P,$%     @ \(F15C<N^"A< @  6@<
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M/JH%J!:B6M0_+6^?**-Q>X&O&!TU0;44U3)*:^9*7=_>%]>W&\6R*//'_;*
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MJIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E5::['CR51I)PU:X(]J*:IEE-9,FKK
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M $/Y*PWP_5Q*\S(H%VANHR;_ E!+ P04    " #PB9%6(SP75+,$  !3&P
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M25<%Y.\K2L7;C:J@.4>;_PM02P,$%     @ \(F15J+BWEE= P  %PH  !D
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M^HMF9FQN%-_78]>:*SW$U9<[/6=380ST[QO.U=.->4$WN2_^ 5!+ P04
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MJ#S5BZ2W1!0QJ>JUK?FO]4_-?R1FE=AX+__IF6F^RGYDBPX2<Y&8A\1\)!:
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M0U^<=83D,Z;TDR6]<6JZ0S4+JME0S8%J+E3SH)H/U0*4UAP3=0G7H#]LLF1
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M,B8<;0NW)^#O XXMY/.&>8[0^AU[SO-V3I3L6\DM:D7TZAH;#=)<;$HM<$U
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MP*IBWK [&$?B&$.@%NTU&H;([(3PL:\/=I<$01S;$<#L#H( 0^!NQ!', 7C
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MZ!J86_ZK";/UD[O0N?%,&$K\&7+BWXK("_122Q'&V <RWW0'&Q)C0B+(D$4
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M<]^\]>4ED^6E(>&C>W]$B[ =O&BD//)E%^J'9M7V3QS;/Z!\_0=02P,$%
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M<' N>&UL4$L! A0#%     @ \(F15NXH%7GO    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ \(F15IE<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #PB9%6]<4UBJ '   E,P  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ \(F15AS,4]98
M!@  L!H  !@              ("!Y \  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( /")D58R@8A&"@,  )H*   8              "
M@7(6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #PB9%6
M#7$R+S$&  !'%P  &               @(&R&0  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ \(F15N\M"E)X P  80L  !@
M     ("!&2   'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M /")D58PY8%%S@P  #>    8              " @<<C  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #PB9%69"?']-0)  ":+P  &
M            @('+,   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ \(F15NP>!#TO"P  NQL  !@              ("!U3H  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /")D5:& >WV> 4  /P+
M   8              " @3I&  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #PB9%6 +;3'P02   R,   &0              @('H2P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /")D59QBC"*
MS T  %TK   9              " @2->  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ \(F15HCS]\[V!   [ L  !D
M ("!)FP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #P
MB9%6'!V@7R #  "Y!P  &0              @(%3<0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( /")D5;3.ECJ2 <  *X1   9
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M970Q."YX;6Q02P$"% ,4    " #PB9%6$9?$J\ +  "B(   &0
M    @(%TK@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M /")D5;Q[N[VJ <  *\3   9              " @6NZ  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ \(F15I6RO6PD$P  +SH  !D
M             ("!2L(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #PB9%6=O_YNYL"  ##!0  &0              @(&EU0  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /")D5;' ^%E<0,
M +X'   9              " @7?8  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ \(F15I8?<=%= @  SP4  !D              ("!
M']P  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #PB9%6
M*_Q6B-8#  #V"0  &0              @(&SW@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( /")D5:,7'M^F 0   T,   9
M      " @<#B  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ \(F15JF.96$L!   7PD  !D              ("!C^<  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #PB9%6.!OYLT$'  #/1
M&0              @('RZP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( /")D58DT;)#> (  "(&   9              " @6KS  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ \(F15@M9:LB
M P  R0H  !D              ("!&?8  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #PB9%6,J=:D&8#  "/#@  &0
M@('0^0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /")
MD5:S"QG'"@D  ))0   9              " @6W]  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ \(F15@P88/-5 P  # \  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( /")D5:V74WYU00  .DA   9
M  " @7D7 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M\(F15KKC_Y8]"P  HYX  !D              ("!A1P! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #PB9%6>]AM!M0"  !N"@  &0
M            @('Y)P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( /")D5:>MWR#<0(  $\&   9              " @00K 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ \(F15MQ.D3(* P
MD D  !D              ("!K"T! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #PB9%6BEZ+,TD"   Q!0  &0              @('M
M, $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /")D58-
M]%J'Y (  *@(   9              " @6TS 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ \(F15K@JCX'!"0  A74  !D
M     ("!B#8! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /")D58C/!=4LP0  %,;   9              "
M@6]U 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ \(F1
M5J+BWEE= P  %PH  !D              ("!67H! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #PB9%6KP[N;S($  #%#P  &0
M        @('M?0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( /")D58?:-1I< 8  .)"   9              " @5:" 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ \(F15JU(1 I- P  K!4
M  T              ( !_8@! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #P
MB9%6EXJ[',     3 @  "P              @ %UC $ 7W)E;',O+G)E;'-0
M2P$"% ,4    " #PB9%6!MI+T$0$   $(P  #P              @ %>C0$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ \(F15GQ^Z1O4 0  QA\  !H
M             ( !SY$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ \(F15BIDTJ;* 0  FQ\  !,              ( !VY,! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #T /0"B$   UI4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>465</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/OrganizationandNatureofBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Going Concern Analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/GoingConcernAnalysis</Role>
      <ShortName>Going Concern Analysis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/NoteReceivable</Role>
      <ShortName>Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aditxt.com./role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Commitments &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/CommitmentsContingencies</Role>
      <ShortName>Commitments &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/FixedAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Organization and Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails</Role>
      <ShortName>Organization and Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/OrganizationandNatureofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Going Concern Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/GoingConcernAnalysisDetails</Role>
      <ShortName>Going Concern Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/GoingConcernAnalysis</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/NoteReceivableDetails</Role>
      <ShortName>Note Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/NoteReceivable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/FixedAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Fixed Assets (Details) - Schedule of fixed assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleoffixedassetsTable</Role>
      <ShortName>Fixed Assets (Details) - Schedule of fixed assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/FixedAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Fixed Assets (Details) - Schedule of maturities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofmaturitiesTable</Role>
      <ShortName>Fixed Assets (Details) - Schedule of maturities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/FixedAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofintangibleassetsTable</Role>
      <ShortName>Intangible Assets (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/RelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aditxt.com./role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/NotesPayable</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Leases (Details) - Schedule of lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/LeasesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Leases (Details) - Schedule of lease terms and discount rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable</Role>
      <ShortName>Leases (Details) - Schedule of lease terms and discount rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/LeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Leases (Details) - Schedule of maturities of leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/LeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Commitments &amp; Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/CommitmentsContingenciesDetails</Role>
      <ShortName>Commitments &amp; Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/CommitmentsContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Stockholders??? Equity (Details) - Schedule of analysis of the stock option grant activity under the plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of analysis of the stock option grant activity under the plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Stockholders??? Equity (Details) - Schedule of warranty issuance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of warranty issuance</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Stockholders??? Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable</Role>
      <ShortName>Stockholders??? Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2022_aditxtinc.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_aditxtinc.htm 6050</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 6 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_aditxtinc.htm 6296, 6715, 6761, 7041, 9809, 9826</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentDepreciationMethods in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_aditxtinc.htm 7636, 7639, 7642, 7645, 7648</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToOfficersOrStockholdersCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_aditxtinc.htm 8299</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:StockholdersEquity, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10k2022_aditxtinc.htm 9796, 9797, 9798, 9799, 9822</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_aditxtinc.htm">f10k2022_aditxtinc.htm</File>
    <File>adtx-20221231.xsd</File>
    <File>adtx-20221231_cal.xml</File>
    <File>adtx-20221231_def.xml</File>
    <File>adtx-20221231_lab.xml</File>
    <File>adtx-20221231_pre.xml</File>
    <File>f10k2022ex23-1_aditxtinc.htm</File>
    <File>f10k2022ex31-1_aditxtinc.htm</File>
    <File>f10k2022ex31-2_aditxtinc.htm</File>
    <File>f10k2022ex32-1_aditxtinc.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1">http://fasb.org/us-gaap-sup/2022q3</BaseTaxonomy>
    <BaseTaxonomy items="648">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_aditxtinc.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap-sup/2022q3": 1,
    "http://fasb.org/us-gaap/2022": 648,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "adtx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adtx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_aditxtinc.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adtx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adtx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adtx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 630,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 70,
    "http://www.aditxt.com./20221231": 31,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 104
   },
   "keyCustom": 126,
   "keyStandard": 339,
   "memberCustom": 18,
   "memberStandard": 29,
   "nsprefix": "adtx",
   "nsuri": "http://www.aditxt.com./20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.aditxt.com./role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note Receivable",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.aditxt.com./role/NoteReceivable",
     "shortName": "Note Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Fixed Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.aditxt.com./role/FixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.aditxt.com./role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.aditxt.com./role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Notes Payable",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.aditxt.com./role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.aditxt.com./role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Commitments & Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.aditxt.com./role/CommitmentsContingencies",
     "shortName": "Commitments & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.aditxt.com./role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.aditxt.com./role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.aditxt.com./role/ConsolidatedBalanceSheet",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.aditxt.com./role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.aditxt.com./role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Fixed Assets (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.aditxt.com./role/FixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.aditxt.com./role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.aditxt.com./role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.aditxt.com./role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.aditxt.com./role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c48",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonUnitIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Organization and Nature of Business (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
     "shortName": "Organization and Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c48",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonUnitIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:NetLossCashFlowFromOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Going Concern Analysis (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.aditxt.com./role/GoingConcernAnalysisDetails",
     "shortName": "Going Concern Analysis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:NetLossCashFlowFromOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c54",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDepreciationMethods",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of useful lives assigned to fixed assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c54",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDepreciationMethods",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c59",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLoansPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note Receivable (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.aditxt.com./role/NoteReceivableDetails",
     "shortName": "Note Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c59",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLoansPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Fixed Assets (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.aditxt.com./role/FixedAssetsDetails",
     "shortName": "Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TimeDepositsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Fixed Assets (Details) - Schedule of fixed assets",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
     "shortName": "Fixed Assets (Details) - Schedule of fixed assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Fixed Assets (Details) - Schedule of maturities",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.aditxt.com./role/ScheduleofmaturitiesTable",
     "shortName": "Fixed Assets (Details) - Schedule of maturities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AmortizationOfIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.aditxt.com./role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AmortizationOfIntangibleAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c84",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Intangible Assets (Details) - Schedule of intangible assets",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.aditxt.com./role/ScheduleofintangibleassetsTable",
     "shortName": "Intangible Assets (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c84",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c90",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.aditxt.com./role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c90",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c99",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AggregateAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Notes Payable (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.aditxt.com./role/NotesPayableDetails",
     "shortName": "Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c99",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AggregateAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.aditxt.com./role/ConsolidatedIncomeStatement",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c113",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:NetLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqm",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.aditxt.com./role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c113",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:NetLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqm",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Leases (Details) - Schedule of lease costs",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.aditxt.com./role/ScheduleofleasecostsTable",
     "shortName": "Leases (Details) - Schedule of lease costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:RightOfUseAssetShortTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable",
     "shortName": "Leases (Details) - Schedule of ROU lease assets and lease liabilities for our operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:RightOfUseAssetShortTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Leases (Details) - Schedule of lease terms and discount rate",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable",
     "shortName": "Leases (Details) - Schedule of lease terms and discount rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Leases (Details) - Schedule of maturities of leases",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable",
     "shortName": "Leases (Details) - Schedule of maturities of leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockOtherSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Commitments & Contingencies (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
     "shortName": "Commitments & Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockOtherSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c4",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Stockholders\u2019 Equity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.aditxt.com./role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c128",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of analysis of the stock option grant activity under the plan",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of analysis of the stock option grant activity under the plan",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c4",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c173",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of warranty issuance",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of warranty issuance",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c173",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Stockholders\u2019 Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
     "shortName": "Stockholders\u2019 Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Statements of Operations (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c6",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.aditxt.com./role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c182",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AggregateOfferingPriceaAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.aditxt.com./role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c182",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adtx:AggregateOfferingPriceaAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.aditxt.com./role/ShareholdersEquityType2or3",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.aditxt.com./role/ConsolidatedCashFlow",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Nature of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.aditxt.com./role/OrganizationandNatureofBusiness",
     "shortName": "Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adtx:GoingConcernsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Going Concern Analysis",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.aditxt.com./role/GoingConcernAnalysis",
     "shortName": "Going Concern Analysis",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_aditxtinc.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adtx:GoingConcernsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "adtx_AdvancedCreditAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced credit agreement.",
        "label": "Advanced Credit Agreement",
        "terseLabel": "Advanced credit agreement"
       }
      }
     },
     "localname": "AdvancedCreditAgreement",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_AggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Amount",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "AggregateAmount",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_AggregateOfferingPriceaAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering pricea amount.",
        "label": "Aggregate Offering Pricea Amount",
        "terseLabel": "Aggregate offering pricea amount"
       }
      }
     },
     "localname": "AggregateOfferingPriceaAmount",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_AmortizationOfIntangibleAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Asset",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAsset",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_August2022FollowOnWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2022 Follow On Warrants Member",
        "terseLabel": "August 2022 Follow On Warrants [Member]"
       }
      }
     },
     "localname": "August2022FollowOnWarrantsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_August2022WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2022 Warrants Member",
        "terseLabel": "August 2022 Warrants [Member]"
       }
      }
     },
     "localname": "August2022WarrantsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_ChangeInValuationAllowanceinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation allowance.",
        "label": "Change In Valuation Allowancein Dollars",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ChangeInValuationAllowanceinDollars",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_CommitmentsContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments &amp; Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsContingenciesDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_CommitmentsContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments &amp; Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsContingenciesDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_CommonStockIssuedVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued, vested.",
        "label": "Common Stock Issued Vested",
        "terseLabel": "Common stock issued, vested"
       }
      }
     },
     "localname": "CommonStockIssuedVested",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_CommonStockYieldsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock yields percentage.",
        "label": "Common Stock Yields Percentage",
        "terseLabel": "Common stock yields percentage"
       }
      }
     },
     "localname": "CommonStockYieldsPercentage",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_CompanyGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Granted",
        "terseLabel": "Company granted"
       }
      }
     },
     "localname": "CompanyGranted",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_CreditAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit agreement.",
        "label": "Credit Agreement",
        "terseLabel": "Credit agreement"
       }
      }
     },
     "localname": "CreditAgreement",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_CreditAgreementAmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit agreement amendment description",
        "label": "Credit Agreement Amendment Description",
        "terseLabel": "Credit agreement amendment, description"
       }
      }
     },
     "localname": "CreditAgreementAmendmentDescription",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Discount From Warrant Consideration For Convertible Debt Offering Costs",
        "terseLabel": "Debt discount from warrant consideration for convertible debt offering costs"
       }
      }
     },
     "localname": "DebtDiscountFromWarrantConsiderationForConvertibleDebtOfferingCosts",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Discount From Warrants Issued With Convertible Note Payable",
        "terseLabel": "Debt discount from warrants issued with convertible note payable"
       }
      }
     },
     "localname": "DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_DebtInstrumentTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument term, description",
        "label": "Debt Instrument Term Description",
        "terseLabel": "Debt instrument term, description"
       }
      }
     },
     "localname": "DebtInstrumentTermDescription",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_DebtLoanAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt loan amount.",
        "label": "Debt Loan Amount",
        "terseLabel": "Debt loan amount"
       }
      }
     },
     "localname": "DebtLoanAmount",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Abstract",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_DescriptionOfShareExchangeAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of share exchange agreement.",
        "label": "Description Of Share Exchange Agreement",
        "terseLabel": "Share exchange agreement, description"
       }
      }
     },
     "localname": "DescriptionOfShareExchangeAgreement",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_DilutiveEarningShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dilutive Earning Shares.",
        "label": "Dilutive Earning Shares",
        "terseLabel": "Dilutive earning shares (in Shares)"
       }
      }
     },
     "localname": "DilutiveEarningShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_DiscountOnConvertibleNotePayableFromOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of discount on convertible note payable from offering costs.",
        "label": "Discount On Convertible Note Payable From Offering Costs",
        "terseLabel": "Proceeds from notes and convertible notes payable, net of offering costs"
       }
      }
     },
     "localname": "DiscountOnConvertibleNotePayableFromOfferingCosts",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_DisposalOfFixedAssets1": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal of fixed assets.",
        "label": "Disposal Of Fixed Assets1",
        "terseLabel": "Disposal of fixed assets"
       }
      }
     },
     "localname": "DisposalOfFixedAssets1",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_EstimatedUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "EstimatedUsefulLife",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_ExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants",
        "label": "Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share exercise of warrants, modification of warrants, and issuance of warrants.",
        "label": "Exercise Of Warrants Modification Of Warrants And Issuance Of Warrantsin Shares",
        "terseLabel": "Exercise of warrants, modification of warrants, and issuance of warrants (in Shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrantsinShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Every stock option has an exercise price, also called the strike price, which is the price at which a share can be bought.",
        "label": "Exercise Price",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_ExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share.",
        "label": "Exercise Price Per Share",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePricePerShare",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_ExercisePricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per shares",
        "label": "Exercise Price Per Shares",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePricePerShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_FairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value.",
        "label": "Fair Market Value",
        "terseLabel": "Fair market value"
       }
      }
     },
     "localname": "FairMarketValue",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_FinancingOfFixedAssetLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing of fixed asset - long term.",
        "label": "Financing Of Fixed Asset Long Term",
        "terseLabel": "Financing on fixed assets - long term"
       }
      }
     },
     "localname": "FinancingOfFixedAssetLongTerm",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_FinancingOnFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing on fixed assets.",
        "label": "Financing On Fixed Assets",
        "terseLabel": "Financing on fixed assets \u2013 current"
       }
      }
     },
     "localname": "FinancingOnFixedAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_FixedAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Assets Value.",
        "label": "Fixed Asset",
        "terseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "FixedAsset",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_FixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Assets.",
        "label": "Fixed Assets",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "FixedAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_FixedAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Assets Policies.",
        "label": "Fixed Assets Policy Text Block",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "FixedAssetsPolicyTextBlock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adtx_FutureReceiptsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Receipts Agreement Member",
        "terseLabel": "Future Receipts Agreement [Member]",
        "verboseLabel": "Future Receipts Agreement[Member]"
       }
      }
     },
     "localname": "FutureReceiptsAgreementMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_GoingConcernsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern Analysis [Abstract]"
       }
      }
     },
     "localname": "GoingConcernsDisclosureAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_GoingConcernsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern disclosure text block.",
        "label": "Going Concerns Disclosure Text Block",
        "terseLabel": "GOING CONCERN ANALYSIS"
       }
      }
     },
     "localname": "GoingConcernsDisclosureTextBlock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/GoingConcernAnalysis"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adtx_GrantTotal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares grant.",
        "label": "Grant Total",
        "terseLabel": "Grant total"
       }
      }
     },
     "localname": "GrantTotal",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_GrossProceed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.",
        "label": "Gross Proceed",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceed",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The proceeds received before any deductions are made are known as gross proceeds, and they comprise all the expenses incurred in the transaction.",
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IncomeTaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_IncomeTaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_InvestorPurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Purchase Amount",
        "terseLabel": "Purchase amount"
       }
      }
     },
     "localname": "InvestorPurchaseAmount",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants.",
        "label": "Issuance Costs Related To Exercise Of Warrants Modification Of Warrants And Issuance Of Warrants",
        "terseLabel": "Issuance costs related to exercise of warrants, modification of warrants, and issuance of warrants"
       }
      }
     },
     "localname": "IssuanceCostsRelatedToExerciseOfWarrantsModificationOfWarrantsAndIssuanceOfWarrants",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IssuanceOfRestrictedStockUnitsForCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance of restricted stock units for compensation.",
        "label": "Issuance Of Restricted Stock Units For Compensation",
        "terseLabel": "Issuance of restricted stock units for compensation"
       }
      }
     },
     "localname": "IssuanceOfRestrictedStockUnitsForCompensation",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Shares For Offerings Net Of Issuance Costs",
        "terseLabel": "Issuance of shares for offerings, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfSharesForOfferingsNetOfIssuanceCosts",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares for offerings, net of issuance costs",
        "label": "Issuance Of Shares For Offerings Net Of Issuance Costs Shares",
        "terseLabel": "Issuance of shares for offerings, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfSharesForOfferingsNetOfIssuanceCostsShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_IssuanceOfSharesForServicesinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share issuance of shares for services.",
        "label": "Issuance Of Shares For Servicesin Shares",
        "terseLabel": "Issuance of shares for services (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfSharesForServicesinShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_IssuanceOfSharesForTheSettlementOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares for the settlement of debt",
        "label": "Issuance Of Shares For The Settlement Of Debt",
        "terseLabel": "Issuance of shares for the conversion of debt"
       }
      }
     },
     "localname": "IssuanceOfSharesForTheSettlementOfDebt",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_IssuanceOfSharesForVestedRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares for vested restricted stock units",
        "label": "Issuance Of Shares For Vested Restricted Stock Units",
        "terseLabel": "Issuance of shares for vested restricted stock units (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfSharesForVestedRestrictedStockUnits",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment Member",
        "terseLabel": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_LeasesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_LeasesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "localname": "LeasesDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_LeasesExpire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration date means the last day of the lease term, subject to any other date on which the lease is terminated.",
        "label": "Leases Expire",
        "terseLabel": "Lease expires"
       }
      }
     },
     "localname": "LeasesExpire",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/Leases"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_LiabilityRecognizedForFinancedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Recognized For Financed Assets",
        "terseLabel": "Liability recognized for financed assets"
       }
      }
     },
     "localname": "LiabilityRecognizedForFinancedAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_LicensingFeeForPatents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "Licensing Fee For Patents",
        "terseLabel": "Licensing fees"
       }
      }
     },
     "localname": "LicensingFeeForPatents",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NetDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net deferred tax assets.",
        "label": "Net Deferred Tax Assets",
        "terseLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NetDeferredTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net deferred taxes.",
        "label": "Net Deferred Taxes",
        "terseLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "NetDeferredTaxes",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NetLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Leases",
        "terseLabel": "Net lease"
       }
      }
     },
     "localname": "NetLeases",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "adtx_NetLossCashFlowFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss cash flow from operating activities.",
        "label": "Net Loss Cash Flow From Operating Activities",
        "terseLabel": "Net loss cash flow from operating activities"
       }
      }
     },
     "localname": "NetLossCashFlowFromOperatingActivities",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/GoingConcernAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NetOperatingLossCarryover": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryover.",
        "label": "Net Operating Loss Carryover",
        "terseLabel": "Percentage of net operating loss carryover"
       }
      }
     },
     "localname": "NetOperatingLossCarryover",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_NetOperatingLosse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating losses.",
        "label": "Net Operating Losse",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "NetOperatingLosse",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NetOperatingLossesGeneratedPrior": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating losses generated prior.",
        "label": "Net Operating Losses Generated Prior",
        "terseLabel": "Net operating losses generated prior"
       }
      }
     },
     "localname": "NetOperatingLossesGeneratedPrior",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NonvestedRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested RSUs Member",
        "terseLabel": "Nonvested RSUs [Member]"
       }
      }
     },
     "localname": "NonvestedRSUsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_NonvestedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Stock Options Member",
        "terseLabel": "Nonvested Stock Options [Member]"
       }
      }
     },
     "localname": "NonvestedStockOptionsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_NonvestedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Warrants Member",
        "terseLabel": "Nonvested Warrants [Member]"
       }
      }
     },
     "localname": "NonvestedWarrantsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_NoteReceivablesAndAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note receivable and accrued interest.",
        "label": "Note Receivables And Accrued Interest",
        "negatedLabel": "Notes receivable and accrued interest"
       }
      }
     },
     "localname": "NoteReceivablesAndAccruedInterest",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_NotesPayableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Line Items]"
       }
      }
     },
     "localname": "NotesPayableDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_NotesPayableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Table]"
       }
      }
     },
     "localname": "NotesPayableDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_OfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Policy Text Block.",
        "label": "Offering Costs Policy Text Block",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "OfferingCostsPolicyTextBlock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adtx_OfferingReflectingReducedExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share of offering reflecting reduced exercise price.",
        "label": "Offering Reflecting Reduced Exercise Price Per Share",
        "terseLabel": "Offering Reflecting Reduced Exercise Price, Per Share (in Dollars per share)"
       }
      }
     },
     "localname": "OfferingReflectingReducedExercisePricePerShare",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_OneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Year Member",
        "terseLabel": "One Year [Member]"
       }
      }
     },
     "localname": "OneYearMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_OperatingLeaseLiabilitiesLongTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities long term.",
        "label": "Operating Lease Liabilities Long Term",
        "terseLabel": "Operating lease liabilities \u2013 long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesLongTerm",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OperatingLeaseLiabilitiesShortTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liabilities short term.",
        "label": "Operating Lease Liabilities Short Term",
        "terseLabel": "Operating lease liabilities \u2013 short term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesShortTerm",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OperatingLeaseLiabilityLongTermNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Long Term Noncurrent.",
        "label": "Operating Lease Liability Long Term Noncurrent",
        "terseLabel": "Lease liability - long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityLongTermNoncurrent",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OperatingLeaseLiabilityShortTermCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Short Term Current.",
        "label": "Operating Lease Liability Short Term Current",
        "terseLabel": "Lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityShortTermCurrent",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OperatingLeasesLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Leases Liability Current",
        "negatedLabel": "Less current portion"
       }
      }
     },
     "localname": "OperatingLeasesLiabilityCurrent",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OrganizationandNatureofBusinessDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Business (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandNatureofBusinessDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_OrganizationandNatureofBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Business (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandNatureofBusinessDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_OriginalIssuanceDiscountOnNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original issuance discount on notes payable.",
        "label": "Original Issuance Discount On Notes Payable",
        "terseLabel": "Original offering discount on convertible note payable"
       }
      }
     },
     "localname": "OriginalIssuanceDiscountOnNotesPayable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OriginalOfferingDiscountOnConvertibleNotePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Original Offering Discount On Convertible Note Payable",
        "terseLabel": "Issuance of shares for the settlement of notes payable"
       }
      }
     },
     "localname": "OriginalOfferingDiscountOnConvertibleNotePayable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_OtherExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense Abstract",
        "terseLabel": "OTHER EXPENSE"
       }
      }
     },
     "localname": "OtherExpenseAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_OtherFixedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Fixed Assets Member",
        "terseLabel": "Other Fixed Assets [Member]"
       }
      }
     },
     "localname": "OtherFixedAssetsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_PatentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents Policy Text Block.",
        "label": "Patents Policy Text Block",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsPolicyTextBlock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adtx_PaymentOfMilestoneFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone fees payments.",
        "label": "Payment Of Milestone Fees",
        "terseLabel": "Payment of milestone fees"
       }
      }
     },
     "localname": "PaymentOfMilestoneFees",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_PercentageOfIncomeTaxable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Income Taxable",
        "terseLabel": "Income taxable"
       }
      }
     },
     "localname": "PercentageOfIncomeTaxable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_PermanentDifferencesOthers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent Differences/Others.",
        "label": "Permanent Differences Others",
        "terseLabel": "Permanent Differences/Others"
       }
      }
     },
     "localname": "PermanentDifferencesOthers",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_PreferredStockVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred stock votes in shares.",
        "label": "Preferred Stock Votes",
        "terseLabel": "Preferred stock votes (in Shares)"
       }
      }
     },
     "localname": "PreferredStockVotes",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_PrefundedWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants shares",
        "label": "Prefunded Warrants Shares",
        "terseLabel": "Prefunded warrants shares"
       }
      }
     },
     "localname": "PrefundedWarrantsShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_PrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "PrincipalAmount",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_PrincipalAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precentage of principal amount.",
        "label": "Principal Amount Percentage",
        "terseLabel": "Principal amount percentage"
       }
      }
     },
     "localname": "PrincipalAmountPercentage",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_PromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of promissory notes may also be referred to as an IOU, a loan agreement, or just a note.",
        "label": "Promissory Notes",
        "terseLabel": "Promissory note amount"
       }
      }
     },
     "localname": "PromissoryNotes",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_ProprietaryTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proprietary Technology Member",
        "terseLabel": "Proprietary Technology [Member]"
       }
      }
     },
     "localname": "ProprietaryTechnologyMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_PurchaseOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of common stock.",
        "label": "Purchase Of Common Stock",
        "terseLabel": "Purchase of common stock"
       }
      }
     },
     "localname": "PurchaseOfCommonStock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_PurchaseOfEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of equity shares.",
        "label": "Purchase Of Equity Shares",
        "terseLabel": "Purchase of equity shares"
       }
      }
     },
     "localname": "PurchaseOfEquityShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_RecognizedExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of recognized expense",
        "label": "Recognized Expense",
        "terseLabel": "Recognized expense (in Dollars)"
       }
      }
     },
     "localname": "RecognizedExpense",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares redemption of series B preferred shares to related party.",
        "label": "Redemption Of Series BPreferred Shares To Related Partyin Shares",
        "terseLabel": "Redemption of Series B Preferred shares to related party (in Shares)"
       }
      }
     },
     "localname": "RedemptionOfSeriesBPreferredSharesToRelatedPartyinShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ReductionInExercisePriceOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reduction in exercise price of warrants.",
        "label": "Reduction In Exercise Price Of Warrants",
        "terseLabel": "Reduction in exercise price of warrants"
       }
      }
     },
     "localname": "ReductionInExercisePriceOfWarrants",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_ResetProvisionOnWarrantsAndModificationOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reset provision on warrants and modification of warrants.",
        "label": "Reset Provision On Warrants And Modification Of Warrants",
        "terseLabel": "Reset provision on warrants and modification of warrants"
       }
      }
     },
     "localname": "ResetProvisionOnWarrantsAndModificationOfWarrants",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards Member",
        "terseLabel": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Member",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_RevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Abstract",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "RevenueAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_RightOfUseAssetLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset \u2013 long term.",
        "label": "Right Of Use Asset Long Term",
        "terseLabel": "Right of use asset - long term"
       }
      }
     },
     "localname": "RightOfUseAssetLongTerm",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RightOfUseAssetShortTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use asset \u2013 short term.",
        "label": "Right Of Use Asset Short Term",
        "terseLabel": "Right of use asset \u2013 long term"
       }
      }
     },
     "localname": "RightOfUseAssetShortTerm",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets.",
        "label": "Right Of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "RightOfUseAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RoundingAdjustmentFromStockSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rounding adjustment from stock split",
        "label": "Rounding Adjustment From Stock Split",
        "terseLabel": "Rounding from reverse stock split"
       }
      }
     },
     "localname": "RoundingAdjustmentFromStockSplit",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_RoundingAdjustmentFromStockSplitShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rounding adjustment from stock split",
        "label": "Rounding Adjustment From Stock Split Shares",
        "terseLabel": "Rounding from reverse stock split (in Shares)"
       }
      }
     },
     "localname": "RoundingAdjustmentFromStockSplitShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_SaleOfPreferredSharesToRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of preference shares are company stock with dividends that are paid to shareholders before common stock dividends are paid out.",
        "label": "Sale Of Preferred Shares To Related Party",
        "terseLabel": "Sale of Series B Preferred shares to related party"
       }
      }
     },
     "localname": "SaleOfPreferredSharesToRelatedParty",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SaleOfSeriesBPreferredSharesToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sale of series B preferred shares to related party.",
        "label": "Sale Of Series BPreferred Shares To Related Party",
        "terseLabel": "Sale of Series B Preferred shares to related party"
       }
      }
     },
     "localname": "SaleOfSeriesBPreferredSharesToRelatedParty",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SaleOfSeriesBPreferredSharesToRelatedParty1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares sale of series B preferred shares to related party.",
        "label": "Sale Of Series BPreferred Shares To Related Party1",
        "terseLabel": "Sale of Series B Preferred shares to related party (in Shares)"
       }
      }
     },
     "localname": "SaleOfSeriesBPreferredSharesToRelatedParty1",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of AReconciliation Of Income Tax Expense Benefit Computed At The Statutory Federal Income Tax Rate To Income Taxes Abstract"
       }
      }
     },
     "localname": "ScheduleOfAReconciliationOfIncomeTaxExpenseBenefitComputedAtTheStatutoryFederalIncomeTaxRateToIncomeTaxesAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Analysis Of The Stock Option Grant Activity Under The Plan Abstract"
       }
      }
     },
     "localname": "ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Analysis Of The Stock Option Grant Activity Under The Plan Table Text Block",
        "terseLabel": "Schedule of analysis of the stock option grant activity under the plan"
       }
      }
     },
     "localname": "ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Each Warrant Issued Was Estimated Using The Assumption Ranges And Or Factors In The Black Scholes Model Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfEachWarrantIssuedWasEstimatedUsingTheAssumptionRangesAndOrFactorsInTheBlackScholesModelAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfFixedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fixed Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfFixedAssetsAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Costs Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseCostsAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfLeaseTermsAndDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Terms And Discount Rate Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseTermsAndDiscountRateAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfMaturitiesOfLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeasesAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rou Lease Assets And Lease Liabilities For Our Operating Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfRouLeaseAssetsAndLeaseLiabilitiesForOurOperatingLeasesAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Useful Lives Assigned To Fixed Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesAssignedToFixedAssetsAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_ScheduleOfWarrantyIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warranty Issuance Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantyIssuanceAbstract",
     "nsuri": "http://www.aditxt.com./20221231",
     "xbrltype": "stringItemType"
    },
    "adtx_Section174Capitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Cuts and Jobs Act of 2017 (TCJA) made a significant change to Section 174 that went into effect for taxable years beginning after December 31, 2021. The change completely eliminated the ability to currently deduct R&amp;E expenses. Instead, taxpayers must now capitalize and amortize these costs.",
        "label": "Section174 Capitalization",
        "terseLabel": "Section 174 Capitalization"
       }
      }
     },
     "localname": "Section174Capitalization",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CWarrants Member",
        "terseLabel": "Series C Warrants [Member]"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_SettlementOfAccountsPayableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of accounts payable shares.",
        "label": "Settlement Of Accounts Payable Shares",
        "terseLabel": "Settlement of accounts payable shares"
       }
      }
     },
     "localname": "SettlementOfAccountsPayableShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Grants In Period Gross",
        "terseLabel": "Number, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantsInPeriodGross",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number",
        "terseLabel": "Number, Nonvested at beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Nonvested at beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_ShareBasedPaymentRemnainingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment remnaining expenses",
        "label": "Share Based Payment Remnaining Expenses",
        "terseLabel": "Share based payment remaining expenses (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedPaymentRemnainingExpenses",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SharesIssued1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued1",
        "terseLabel": "Company issued shares"
       }
      }
     },
     "localname": "SharesIssued1",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of shares issued as inducement on loans, net of issuance costs.",
        "label": "Shares Issued As Inducement On Loans Net Of Issuance Costs",
        "terseLabel": "Shares issued as inducement on loans, net of issuance costs"
       }
      }
     },
     "localname": "SharesIssuedAsInducementOnLoansNetOfIssuanceCosts",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares shares issued as inducement on loans, net of issuance costs.",
        "label": "Shares Issued As Inducement On Loans Net Of Issuance Costsin Shares",
        "terseLabel": "Shares issued as inducement on loans, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "SharesIssuedAsInducementOnLoansNetOfIssuanceCostsinShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_SharesIssuedForIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued for intangible assets.",
        "label": "Shares Issued For Intangible Assets",
        "terseLabel": "Shares issued for debt offering costs"
       }
      }
     },
     "localname": "SharesIssuedForIntangibleAssets",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_SharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock",
        "label": "Shares Of Common Stock",
        "terseLabel": "Shares of common stock"
       }
      }
     },
     "localname": "SharesOfCommonStock",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_StanfordUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stanford University Member",
        "terseLabel": "Stanford University [Member]"
       }
      }
     },
     "localname": "StanfordUniversityMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_StockIssuedDuringPeriodShareStockOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Share Stock Options Exercised",
        "terseLabel": "Number, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareStockOptionsExercised",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares for vested restricted stock units",
        "label": "Stock Issued During Period Value Issuance Of Shares For Vested Restricted Stock Units",
        "terseLabel": "Issuance of shares for vested restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForVestedRestrictedStockUnits",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_StockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option exercise price.",
        "label": "Stock Options Shares",
        "terseLabel": "Stock options shares"
       }
      }
     },
     "localname": "StockOptionsShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of analysis of the stock option grant activity under the plan [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of warranty issuance [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofwarrantyissuanceLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsScheduleofwarrantyissuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) - Schedule of warranty issuance [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsScheduleofwarrantyissuanceTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adtx_TIAllowanceReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TIAllowance Receivable",
        "negatedLabel": "Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "TIAllowanceReceivable",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_TotalDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total deferred tax liabilities.",
        "label": "Total Deferred Tax Liabilities",
        "terseLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "TotalDeferredTaxLiabilities",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_TotalIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Intangible Assets Member",
        "terseLabel": "Total Intangible Assets [Member]"
       }
      }
     },
     "localname": "TotalIntangibleAssetsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_TotalLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total lease liability.",
        "label": "Total Lease Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "TotalLeaseLiability",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_TotalProvisionForIncomeTaxesinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total provision for income taxes.",
        "label": "Total Provision For Income Taxesin Dollars",
        "terseLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "TotalProvisionForIncomeTaxesinDollars",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "adtx_TotalRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total right of use asset.",
        "label": "Total Right Of Use Asset",
        "terseLabel": "Total right of use asset"
       }
      }
     },
     "localname": "TotalRightOfUseAsset",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_TwoZeroOneSevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Zero One Seven Equity Incentive Plan Member",
        "terseLabel": "2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoZeroOneSevenEquityIncentivePlanMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_ValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance.",
        "label": "Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowance",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_VestedAndNonvestedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested And Nonvested Stock Options Member",
        "terseLabel": "Vested and Nonvested Stock Options [Member]"
       }
      }
     },
     "localname": "VestedAndNonvestedStockOptionsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_VestedAndNonvestedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested And Nonvested Warrants Member",
        "terseLabel": "Vested and Nonvested Warrants [Member]"
       }
      }
     },
     "localname": "VestedAndNonvestedWarrantsMember",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "domainItemType"
    },
    "adtx_VestingExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting expense.",
        "label": "Vesting Expense",
        "terseLabel": "Vesting expense (in Dollars)"
       }
      }
     },
     "localname": "VestingExpense",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_WarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise price.",
        "label": "Warrant Exercise Price",
        "terseLabel": "Warrant exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePrice",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WarrantToPurchaseCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant To Purchase Common Shares.",
        "label": "Warrant To Purchase Common Shares",
        "terseLabel": "Warrant to purchase common shares (in Shares)"
       }
      }
     },
     "localname": "WarrantToPurchaseCommonShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_WarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise price",
        "label": "Warrants Exercise Price",
        "terseLabel": "Warrants exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantsExercisePrice",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised Shares.",
        "label": "Warrants Exercised Shares",
        "terseLabel": "Warrants issued (in Shares)"
       }
      }
     },
     "localname": "WarrantsExercisedShares",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_WarrantsIssuedAndVesting": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued And Vesting",
        "terseLabel": "Warrants issued and vesting (in Dollars)"
       }
      }
     },
     "localname": "WarrantsIssuedAndVesting",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adtx_WarrantsOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Of Stock Options.",
        "label": "Warrants Of Stock Options",
        "terseLabel": "Stock options issued (in Shares)"
       }
      }
     },
     "localname": "WarrantsOfStockOptions",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_WeightedAverageExercisePriceExpiredOrForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Exercise Price, Expired or forfeited",
        "label": "Weighted Average Exercise Price Expired Or Forfeited",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExpiredOrForfeited",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WeightedAverageExercisePriceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Exercise Price, Granted",
        "label": "Weighted Average Exercise Price Granted",
        "terseLabel": "Weighted- Average Exercise Price, Granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceGranted",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WeightedAverageExercisePriceRoundingForReverseSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share of weighted average exercise price rounding for reverse split.",
        "label": "Weighted Average Exercise Price Rounding For Reverse Split",
        "terseLabel": "Weighted Average Exercise Price, Rounding for Reverse Split"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceRoundingForReverseSplit",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WeightedAverageExercisesPriceVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Exercise Price, Vested",
        "label": "Weighted Average Exercises Price Vested",
        "terseLabel": "Weighted- Average Exercise Price, Vested"
       }
      }
     },
     "localname": "WeightedAverageExercisesPriceVested",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "adtx_WeightedAverageRemainingLifeExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Life Exercised.",
        "label": "Weighted Average Remaining Life Exercised",
        "terseLabel": "Weighted Average Remaining Life, Exercised"
       }
      }
     },
     "localname": "WeightedAverageRemainingLifeExercised",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_WeightedAverageRemainingLifeExpiredOrForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Life, Expired or forfeited.",
        "label": "Weighted Average Remaining Life Expired Or Forfeited",
        "terseLabel": "Weighted Average Remaining Life, Expired or forfeited"
       }
      }
     },
     "localname": "WeightedAverageRemainingLifeExpiredOrForfeited",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_WeightedAverageRemainingLifeGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life Granted",
        "terseLabel": "Weighted Average Remaining Life, Granted"
       }
      }
     },
     "localname": "WeightedAverageRemainingLifeGranted",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_WeightedAverageRemainingLifeRoundingForReverseSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining Life, rounding for reverse split.",
        "label": "Weighted Average Remaining Life Rounding For Reverse Split",
        "terseLabel": "Weighted Average Remaining Life, Rounding for Reverse Split"
       }
      }
     },
     "localname": "WeightedAverageRemainingLifeRoundingForReverseSplit",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_WeightedsAverageRemainingLifeOutstandingEndingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighteds Average Remaining Life Outstanding Ending Balance",
        "terseLabel": "Weighted Average Remaining Life, Outstanding ending balance"
       }
      }
     },
     "localname": "WeightedsAverageRemainingLifeOutstandingEndingBalance",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_incomeLossOfGenerated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss  of Generated.",
        "label": "income Loss Of Generated",
        "terseLabel": "Income loss of generated"
       }
      }
     },
     "localname": "incomeLossOfGenerated",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adtx_sharesIssued1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued.",
        "label": "shares Issued1",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "sharesIssued1",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_warrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share warrant issued.",
        "label": "warrant Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "warrantIssued",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adtx_weightedAverageGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "weighted Average Grant",
        "terseLabel": "Weighted average grant (in Dollars)"
       }
      }
     },
     "localname": "weightedAverageGrant",
     "nsuri": "http://www.aditxt.com./20221231",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aditxt.com./role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sic_Z2520": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2520 Office Furniture [Member]",
        "terseLabel": "Office Furniture [Member]"
       }
      }
     },
     "localname": "Z2520",
     "nsuri": "http://xbrl.sec.gov/sic/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer.",
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief financial officer.",
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer [Member]"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts": {
     "auth_ref": [
      "r445",
      "r448",
      "r477",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of extensions, discoveries and improved recovery of proved oil and gas reserves.",
        "label": "Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs",
        "terseLabel": "Extension fee"
       }
      }
     },
     "localname": "ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r339",
      "r429",
      "r457",
      "r475",
      "r476",
      "r491",
      "r492",
      "r499",
      "r553",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r339",
      "r429",
      "r457",
      "r475",
      "r476",
      "r491",
      "r492",
      "r499",
      "r553",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r337",
      "r339",
      "r363",
      "r364",
      "r365",
      "r428",
      "r429",
      "r457",
      "r475",
      "r476",
      "r491",
      "r492",
      "r499",
      "r548",
      "r553",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r337",
      "r339",
      "r363",
      "r364",
      "r365",
      "r428",
      "r429",
      "r457",
      "r475",
      "r476",
      "r491",
      "r492",
      "r499",
      "r548",
      "r553",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r223",
      "r224",
      "r239",
      "r398",
      "r399",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r176",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r239",
      "r272",
      "r273",
      "r379",
      "r397",
      "r398",
      "r399",
      "r400",
      "r411",
      "r419",
      "r420",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r176",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r239",
      "r272",
      "r273",
      "r379",
      "r397",
      "r398",
      "r399",
      "r400",
      "r411",
      "r419",
      "r420",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r340",
      "r536",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r228",
      "r340",
      "r511",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r228",
      "r340",
      "r511",
      "r512",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r540",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California [Member]"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "New York [Member]"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Virginia [Membe]"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Initial Price Paid Per Share",
        "terseLabel": "Purchase price per share (in Dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r75",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r497"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r528",
      "r529",
      "r530",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise",
        "terseLabel": "Stock option and warrant compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r81",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant consideration for convertible debt offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation (in Dollars)"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.",
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r36",
      "r49",
      "r119",
      "r314"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "negatedLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredLoanOriginationFeesNet": {
     "auth_ref": [
      "r67",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments.",
        "label": "Amortization of Deferred Loan Origination Fees, Net",
        "terseLabel": "Origination fees"
       }
      }
     },
     "localname": "AmortizationOfDeferredLoanOriginationFeesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r28",
      "r314",
      "r409",
      "r522"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r49",
      "r68",
      "r72"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r140",
      "r186",
      "r208",
      "r253",
      "r256",
      "r260",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r390",
      "r394",
      "r401",
      "r497",
      "r551",
      "r552",
      "r597"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r178",
      "r192",
      "r208",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r390",
      "r394",
      "r401",
      "r497",
      "r551",
      "r552",
      "r597"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be repaid to the counterparty to the repurchase agreement when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under the repurchase agreement exceeds 10 percent of total assets.",
        "label": "Assets Sold under Agreements to Repurchase, Repurchase Liability",
        "terseLabel": "Purchaser (in Dollars)"
       }
      }
     },
     "localname": "AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value of the auction market preferred security.",
        "label": "Auction Market Preferred Securities, Stock Series, Par Value Per Share",
        "terseLabel": "Preferred stock price per share (in Dollars per share)"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BadDebtReserveForTaxPurposesOfQualifiedLender": {
     "auth_ref": [
      "r136",
      "r137",
      "r153",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of bad debt reserves for tax purposes of qualified lenders excluded in calculating deferred taxes.",
        "label": "Bad Debt Reserve, Tax Purpose of Qualified Lender",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "BadDebtReserveForTaxPurposesOfQualifiedLender",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BroadcastersLicenseAgreementCommitmentsDescription": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.",
        "label": "Broadcasters License Agreement Commitments, Description",
        "terseLabel": "License maintenance fees description"
       }
      }
     },
     "localname": "BroadcastersLicenseAgreementCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r468",
      "r469",
      "r497",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/GoingConcernAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r181",
      "r479"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r52",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r44",
      "r51",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AT END OF YEAR",
        "periodStartLabel": "CASH AT BEGINNING OF YEAR"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r44",
      "r118"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r208",
      "r232",
      "r233",
      "r236",
      "r238",
      "r242",
      "r243",
      "r270",
      "r294",
      "r296",
      "r297",
      "r298",
      "r301",
      "r302",
      "r320",
      "r321",
      "r323",
      "r327",
      "r333",
      "r401",
      "r478",
      "r510",
      "r524",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrant to purchase shares (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClearanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense in the period for clearance fees.",
        "label": "Clearance Fees",
        "terseLabel": "Regulatory clearance"
       }
      }
     },
     "localname": "ClearanceFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r288",
      "r289",
      "r471",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS &amp; CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Issuance of shares"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r528",
      "r529",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Shares of common stock (in Shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock shares (in Shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r497"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized, 4,307,487 and 890,614 shares issued and 4,305,470 and 888,579 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssued": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units issued of limited liability company (LLC).",
        "label": "Common Unit, Issued",
        "terseLabel": "Company issued"
       }
      }
     },
     "localname": "CommonUnitIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r138",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Debt discount from shares issued as inducement for convertible note payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r30",
      "r434"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r527",
      "r584",
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal tax credit carryforwards"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerFunds": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts received from and refundable to customers unless used by them to obtain goods and services from the entity.",
        "label": "Customer Funds",
        "terseLabel": "Future funds"
       }
      }
     },
     "localname": "CustomerFunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/GoingConcernAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "terseLabel": "Issued warrants to purchase of shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r206",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "NOTES PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r82",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion Price (in Dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails",
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r20",
      "r120",
      "r318",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Accrue interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repaid purchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r127",
      "r139",
      "r514"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r121",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Sale of net issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Tax credits carryforwards"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r169",
      "r515",
      "r592"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r111",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "auth_ref": [
      "r110",
      "r111",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r111",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r111",
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.",
        "label": "Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds",
        "terseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r49",
      "r73"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow",
      "http://www.aditxt.com./role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DirectTaxesAndLicensesCosts": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax incurred and cost of license directly related to good produced or service rendered.",
        "label": "Cost, Direct Tax and License",
        "terseLabel": "License milestone payment due"
       }
      }
     },
     "localname": "DirectTaxesAndLicensesCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r89",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Implied Dividends"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r89",
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "terseLabel": "Cash received on consideration"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOfficersOrStockholdersCurrentAndNoncurrent": {
     "auth_ref": [
      "r122",
      "r131",
      "r145",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.",
        "label": "Due to Officers or Stockholders",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "DueToOfficersOrStockholdersCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r201",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r229",
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r399",
      "r400",
      "r452",
      "r455",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r201",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r232",
      "r236",
      "r237",
      "r238",
      "r239",
      "r399",
      "r400",
      "r452",
      "r455",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r582",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Income taxes at U.S. statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r582",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r582",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofareconciliationofincometaxexpensebenefitcomputedatthestatutoryfederalincometaxratetoincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r87",
      "r175",
      "r197",
      "r198",
      "r199",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r227",
      "r241",
      "r271",
      "r336",
      "r368",
      "r369",
      "r370",
      "r378",
      "r379",
      "r398",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r420",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Issue of common stock"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r49",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrant (in Dollars)"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of premium revenue on financial guarantee insurance contracts recognized during the period that was accelerated for revenue recognition purposes.",
        "label": "Financial Guarantee Insurance Contracts, Accelerated Premium Revenue, Amount",
        "terseLabel": "Financial revenue"
       }
      }
     },
     "localname": "FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r184",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of maturities"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r71",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r71",
      "r435"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net",
        "totalLabel": "Total Payments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable",
      "http://www.aditxt.com./role/ScheduleofmaturitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r49",
      "r83",
      "r84"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow",
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses, includes $1,516,805 and $3,927,551 in stock-based compensation, respectively"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r29",
      "r208",
      "r253",
      "r255",
      "r259",
      "r261",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r401",
      "r488",
      "r551"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r125",
      "r132",
      "r148",
      "r253",
      "r255",
      "r259",
      "r261",
      "r453",
      "r488"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r146",
      "r177",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r373",
      "r374",
      "r377",
      "r380",
      "r382",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r210",
      "r226",
      "r227",
      "r252",
      "r372",
      "r381",
      "r383",
      "r456"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r45",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "negatedLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "terseLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositsOutstanding": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.",
        "label": "Increase (Decrease) in Deposits Outstanding",
        "negatedLabel": "Deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Impairment on notes receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationTechnologyAndDataProcessing": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses incurred in the period for information technology and data processing products and services.",
        "label": "Information Technology and Data Processing",
        "terseLabel": "Technology rights"
       }
      }
     },
     "localname": "InformationTechnologyAndDataProcessing",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r70",
      "r431",
      "r432",
      "r433",
      "r435",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r36",
      "r313",
      "r319",
      "r489",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Remaining expensed (in Dollars)"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOtherLongTermDebt": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on long-term debt classified as other, including, but not limited to, interest on long-term notes and amortization of issuance costs.",
        "label": "Interest Expense, Other Long-Term Debt",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestExpenseOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which reported facts about interest income have been included.",
        "label": "Interest Income [Member]",
        "terseLabel": "Interest Income [Member]"
       }
      }
     },
     "localname": "InterestIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/GoingConcernAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r180",
      "r190",
      "r240",
      "r277",
      "r278",
      "r279",
      "r430",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentCompanyFeePaidIndirectly": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction.",
        "label": "Investment Company, Fee Paid Indirectly",
        "terseLabel": "Fee paid",
        "verboseLabel": "Company paid (in Dollars)"
       }
      }
     },
     "localname": "InvestmentCompanyFeePaidIndirectly",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyIssuanceOfSharesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InvestmentCompanyIssuanceOfSharesPerShare",
        "terseLabel": "Average price per share (in Dollars per share)"
       }
      }
     },
     "localname": "InvestmentCompanyIssuanceOfSharesPerShare",
     "nsuri": "http://fasb.org/us-gaap-sup/2022q3",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r35",
      "r251"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Interest rate per annum",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssetsDetails",
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentOwnedBalancePrincipalAmount": {
     "auth_ref": [
      "r156",
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.",
        "label": "Investment Owned, Balance, Principal Amount",
        "terseLabel": "Principal balance"
       }
      }
     },
     "localname": "InvestmentOwnedBalancePrincipalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Exercise of warrants, modification of warrants, and issuance of warrants"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r416",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Origination fee"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseDescription": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessor's operating lease.",
        "label": "Lessor, Operating Lease, Description",
        "terseLabel": "Net operating losses, description"
       }
      }
     },
     "localname": "LessorOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r208",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r391",
      "r394",
      "r395",
      "r401",
      "r487",
      "r551",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofROUleaseassetsandleaseliabilitiesforouroperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r130",
      "r143",
      "r497",
      "r526",
      "r545",
      "r588"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r179",
      "r208",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r391",
      "r394",
      "r395",
      "r401",
      "r497",
      "r551",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "NOTE RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansReceivableWithFixedRatesOfInterest1": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan with fixed rate of interest.",
        "label": "Loans Receivable with Fixed Rates of Interest",
        "terseLabel": "Loan interest rate"
       }
      }
     },
     "localname": "LoansReceivableWithFixedRatesOfInterest1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansReceivableWithVariableRatesOfInterest1": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan with variable or adjustable rate of interest.",
        "label": "Loans Receivable with Variable Rates of Interest",
        "terseLabel": "Note receivable amount"
       }
      }
     },
     "localname": "LoansReceivableWithVariableRatesOfInterest1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature or cause of a material change in the expected aggregate amount since the prior balance sheet date, other than a change resulting from pay-down of the obligation.",
        "label": "Loss Contingency Accrual, Product Liability, Net, Explanation of Material Change in Accrual",
        "terseLabel": "Loss Contingency Accrual, Product Liability, Net, Explanation of Material Change in Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualProductLiabilityNetExplanationOfMaterialChangeInAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r44",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r50",
      "r133",
      "r147",
      "r177",
      "r195",
      "r196",
      "r199",
      "r208",
      "r216",
      "r218",
      "r219",
      "r221",
      "r222",
      "r226",
      "r227",
      "r234",
      "r253",
      "r255",
      "r259",
      "r261",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r400",
      "r401",
      "r488",
      "r551"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r218",
      "r219",
      "r221",
      "r222",
      "r229",
      "r230",
      "r235",
      "r238",
      "r253",
      "r255",
      "r259",
      "r261",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Warrant modification"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r451"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Note receivable, net"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r253",
      "r255",
      "r259",
      "r261",
      "r488"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "NET LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r415",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate \u2013 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r414",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years) \u2013 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofleasetermsanddiscountrateTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total maturities, due beyond one year"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofmaturitiesofleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r167",
      "r168",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of lease terms and discount rate"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND NATURE OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OriginationOfNotesReceivableFromRelatedParties": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Origination of Notes Receivable from Related Parties",
        "terseLabel": "Origination fees"
       }
      }
     },
     "localname": "OriginationOfNotesReceivableFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Loss on impairment of debt"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r33",
      "r150"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedTotalLabel": "Total other expense"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLoansPayable": {
     "auth_ref": [
      "r7",
      "r129",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term loans payable classified as other.",
        "label": "Other Loans Payable",
        "terseLabel": "Completion of a proposed"
       }
      }
     },
     "localname": "OtherLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payment due"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development (in Dollars)"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling and marketing expense classified as other.",
        "label": "Other Selling and Marketing Expense",
        "terseLabel": "Sales and marketing (in Dollars)"
       }
      }
     },
     "localname": "OtherSellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expense classified as other.",
        "label": "Other Selling, General and Administrative Expense",
        "terseLabel": "General and administrative expenses (in Dollars)"
       }
      }
     },
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r150",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Net of underwriting discounts (in Dollars)"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Paying commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromProductiveAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.",
        "label": "Payments for (Proceeds from) Productive Assets",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsForProceedsFromProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedLabel": "Cash paid on extinguishment of note payable"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments on financing on fixed asset"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r38",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Final payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Final payment due"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable preferred class B stock or outstanding preferred class B stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Preferred Class B [Member]",
        "terseLabel": "Preferred"
       }
      }
     },
     "localname": "PreferredClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Preferred Stock Dividends, Shares",
        "terseLabel": "Preferred stock share"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "netLabel": "Preferred Stock [Member]",
        "terseLabel": "Preferred Shares",
        "verboseLabel": "B Shares"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r8",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r8",
      "r497"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 3,000,000 shares authorized, zero shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r191",
      "r280",
      "r281",
      "r480"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaymentFeesOnAdvancesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity.",
        "label": "Prepayment Fees on Advances, Net",
        "terseLabel": "Prepayment"
       }
      }
     },
     "localname": "PrepaymentFeesOnAdvancesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans).",
        "label": "Principal Amount Outstanding on Loans Securitized or Asset-Backed Financing Arrangement",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "PrincipalAmountOutstandingOnLoansSecuritized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts.",
        "label": "Prior Period Reclassification Adjustment",
        "terseLabel": "Repayment Amount"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Common stock and warrants issued for cash, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Redemption of Series B Preferred shares to related party"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.",
        "label": "Proceeds from (Repayments of) Notes Payable",
        "terseLabel": "Repayments of notes and convertible notes payable",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow",
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSecuredNotesPayable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from Secured Notes Payable",
        "terseLabel": "Proceeds from note payable - related party"
       }
      }
     },
     "localname": "ProceedsFromSecuredNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercised (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants, net of offering costs",
        "verboseLabel": "Exercise of warrants and received (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.",
        "label": "Product Liability Contingency, Third-Party Recovery, Percentage",
        "terseLabel": "Net Product percentage"
       }
      }
     },
     "localname": "ProductLiabilityContingencyThirdPartyRecoveryPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r177",
      "r195",
      "r196",
      "r203",
      "r208",
      "r216",
      "r226",
      "r227",
      "r253",
      "r255",
      "r259",
      "r261",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r389",
      "r392",
      "r393",
      "r400",
      "r401",
      "r453",
      "r488",
      "r494",
      "r495",
      "r519",
      "r551"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable",
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Useful lives assigned to fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "FIXED ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r74",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r77",
      "r144",
      "r454",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilitiesInventory": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period end amount for a type of inventory held by the utility in a schedule of inventories.",
        "label": "Public Utilities, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "PublicUtilitiesInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Public Utility, Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilityPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Public Utility, Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "PublicUtilityPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofusefullivesassignedtofixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedemptionPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.",
        "label": "Redemption Premium",
        "terseLabel": "Redemption preferred stock (in Dollars)"
       }
      }
     },
     "localname": "RedemptionPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement.",
        "label": "Registration Payment Arrangement, Maximum Potential Consideration",
        "terseLabel": "Potential"
       }
      }
     },
     "localname": "RegistrationPaymentArrangementMaximumPotentialConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r338",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r166",
      "r423",
      "r424",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r338",
      "r423",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r449",
      "r450",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r421",
      "r422",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayments of note payable - related party"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r104",
      "r161",
      "r606"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, includes $591,518 and $713,130 in stock-based compensation, respectively",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement",
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockAwardForfeituresDividends": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of dividends forfeited related to restricted stock awards forfeited.",
        "label": "Restricted Stock Award, Forfeitures, Dividends",
        "terseLabel": "Recognized an implied dividend"
       }
      }
     },
     "localname": "RestrictedStockAwardForfeituresDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Shares vested"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringSettlementAndImpairmentProvisions": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.",
        "label": "Restructuring, Settlement and Impairment Provisions",
        "terseLabel": "Impairment on notes receivable"
       }
      }
     },
     "localname": "RestructuringSettlementAndImpairmentProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r89",
      "r142",
      "r462",
      "r467",
      "r497"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r175",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r227",
      "r271",
      "r368",
      "r369",
      "r370",
      "r378",
      "r379",
      "r398",
      "r458",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r200",
      "r208",
      "r249",
      "r250",
      "r254",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r270",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r401",
      "r453",
      "r551"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r413",
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease liability recognized from right of use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleLeasebackTransactionMonthlyRentalPayments": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.",
        "label": "Sale Leaseback Transaction, Monthly Rental Payments",
        "terseLabel": "Monthly payment"
       }
      }
     },
     "localname": "SaleLeasebackTransactionMonthlyRentalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleLeasebackTransactionOtherPaymentsRequired": {
     "auth_ref": [
      "r167",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other amounts the seller-lessee is required to pay under the terms of the transaction involving the sale of property to another party and lease of the property back to the seller, including reimbursements for such items, as utilities, taxes, insurance and common area maintenance.",
        "label": "Sale Leaseback Transaction, Other Payments Required",
        "terseLabel": "Required to pay"
       }
      }
     },
     "localname": "SaleLeasebackTransactionOtherPaymentsRequired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of a reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, classified as other.",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of maturities of leases"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffixedassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.",
        "label": "Public Utility Property, Plant, and Equipment [Table Text Block]",
        "terseLabel": "Schedule of useful lives assigned to fixed assets"
       }
      }
     },
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r95",
      "r98",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of warranty issuance"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of each warrant issued was estimated using the assumption ranges and/or factors in the Black-Scholes Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsequentEventsTextBlock": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.",
        "label": "Schedule of Subsequent Events [Table Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "ScheduleOfSubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss": {
     "auth_ref": [
      "r274",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on security purchased under agreement to resell.",
        "label": "Securities Purchased under Agreements to Resell, Allowance for Credit Loss",
        "terseLabel": "Credit agreement"
       }
      }
     },
     "localname": "SecuritiesPurchasedUnderAgreementsToResellAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NoteReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Sales and marketing, includes $1,023,045, and $0 in stock-based compensation, respectively"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r516",
      "r517",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow",
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Weighted average vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Weighted average vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Life, Outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number, Vested",
        "terseLabel": "Number of shares, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price term (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number, Expired or forfeited",
        "negatedTerseLabel": "Number, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number, Granted",
        "verboseLabel": "Number of shares, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number, Outstanding ending balance",
        "periodStartLabel": "Number, Outstanding beginning balance",
        "terseLabel": "Number, Nonvested at ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning balance",
        "terseLabel": "Weighted- Average Exercise Price, Nonvested at ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Price, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleoffairvalueofeachwarrantissuedwasestimatedusingtheassumptionrangesandorfactorsintheBlackScholesModelTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Number, Vested",
        "terseLabel": "Vested, share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Issued shares (in Shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r208",
      "r232",
      "r233",
      "r236",
      "r238",
      "r242",
      "r243",
      "r270",
      "r294",
      "r296",
      "r297",
      "r298",
      "r301",
      "r302",
      "r320",
      "r321",
      "r323",
      "r327",
      "r333",
      "r401",
      "r478",
      "r510",
      "r524",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r24",
      "r87",
      "r175",
      "r197",
      "r198",
      "r199",
      "r213",
      "r214",
      "r215",
      "r217",
      "r224",
      "r227",
      "r241",
      "r271",
      "r336",
      "r368",
      "r369",
      "r370",
      "r378",
      "r379",
      "r398",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r420",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r241",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Warrants issued with loans"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares for the settlement of accounts payable"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r23",
      "r87",
      "r88",
      "r89",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of shares for debt issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares for the conversion of debt (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of shares for settlement of AP (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of shares and warrants for offering, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Purchase shares",
        "verboseLabel": "Share purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of restricted stock units for compensation (in Shares)",
        "verboseLabel": "Restricted stock of shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Number, Rounding for Reverse Split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of shares for employee compensation (in Shares)",
        "verboseLabel": "Recognized expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Company issued shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Fair value of warrants issued with convertible note payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r24",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Redemption of Series B Preferred shares to related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance of shares for employee compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of shares for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of shares for settlement of AP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of shares and warrants for offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r8",
      "r9",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock unit compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r89",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of shares for debt issuance costs",
        "verboseLabel": "Stock based compensation (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Reduction in exercise price of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Decrease",
        "terseLabel": "Stock Option, Exercise Price, Decrease (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Compensation expense (in Dollars)"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r66",
      "r497",
      "r526",
      "r545",
      "r588"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet",
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r207",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r336",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r408",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r408",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r408",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable",
      "http://www.aditxt.com./role/ScheduleofwarrantyissuanceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesAndLicenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense, excluding income, excise, production and property taxes, and licenses and fees not related to production.",
        "label": "Taxes and Licenses",
        "terseLabel": "License fee paid amount"
       }
      }
     },
     "localname": "TaxesAndLicenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/CommitmentsContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.",
        "label": "Temporary Equity, Aggregate Amount of Redemption Requirement",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TimeDepositsAtCarryingValue": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Time Deposits, at Carrying Value",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "TimeDepositsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r22",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r22",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r22",
      "r91",
      "r92"
     ],
     "calculation": {
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, 2,017 and 2,017 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnderlyingAssetClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by underlying asset class.",
        "label": "Underlying Asset Class [Axis]"
       }
      }
     },
     "localname": "UnderlyingAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r244",
      "r245",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "auth_ref": [
      "r333",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.",
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Exercise price increase (in Dollars)"
       }
      }
     },
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Warrant exercise price, per share (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Warrant exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/NotesPayableDetails",
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails",
      "http://www.aditxt.com./role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r231",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares outstanding during the year - basic and diluted (in Shares) (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r229",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding during the year - basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.",
        "label": "Weighted Average Number of Shares, Restricted Stock",
        "terseLabel": "Restricted stock units (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=6472701&loc=d3e49107-107924",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=109255323&loc=d3e66323-112835",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6933581&loc=SL5749298-161291",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "805",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505872&loc=d3e30785-158569",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=6488101&loc=d3e8702-115831",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123416376&loc=d3e50796-112755",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "https://asc.fasb.org/topic&trid=2208923",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(i))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL109261905-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62500-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Form 20-F",
   "Publisher": "SEC",
   "Section": "Item 18",
   "Subsection": "Instruction 2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "235",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=34713648&loc=d3e63123-109448",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r503": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r504": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r505": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r506": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126974470&loc=d3e8622-111531",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q1)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001213900-23-030316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-030316-xbrl.zip
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M7C1$"OI#F9Z@5EJ]\V7D?7^*$:U85NDCO5#:K?9V4JL;Y1IG?K$@D7"SF6O
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M98!5BXP0-I7_4?/_2EF94#H]KU3F\_E+C=U#-(@!03;6 .$7E'*9$5R3;&#
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M+3]13LS^YU%V:)64K;*S+(W2R?!3J#UF.20LB-Y6..LAH\ZCW[]02P,$%
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MZ#(]#1[B(DB@W5H"*G.2B1 I]9W01C W--\B1=%Y@%-BW.6+,"RW)4NC.B-
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M;E9;3PT>=,7O/>7Z(DT;O6PIQ;K/.JRP^HE,(C%:;N$+T'%4'K_KX#B+D[(
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M+EO8)'"I/\'?34-"?_*RM8"4RQ:FLU]+@3#]4#^3W66#8D6,E#$DW2D;J^[
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M$R7E0HR_?.U'D(ZEB%9!F11CBY&"Z<KQ0!T@98'PGNS'EG4'F+721\6O*\!
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MSO+&C':L6D&0="^YGU!Q_OR0!"E;M^2 (8QBNIPW=*%?IO5GT*_,H+S-<NT
MBT>CVI'5*CK!61#14!R$\^[+>O,Y'N4ACA\<G#H6#,S3TK9!6JLFTT@Y;LUF
MXN?D/E#LFMEMQF:_<+@C$*57 (UAK"J!"<?53V13#.%N%?=GL>D#OK^6J$
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M.1R?G;DKG;66.H80P$%R2:XVS_]$.PBUTAG1BTO(4I%TP8#.BVZ0JDZ3&_1
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M\[VQ//E;'0^7%62X\6)TAOT,G0B]>*Z=I-N'S1S4I$*/1P@KSB1M#M+V '<
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M;[P O2Z\8#,+C@K"6$BD8G0UK%VG4\'4U6:-01B =4EQ"\BM>/8'L+*;3D:
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M-Z)IYTLIZEAN=]D86(R+BE&R=)1[/ Y8AQ'KK#(-*B4.%W"3WR_5Z"8\:)H
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M)Y>JT2?Y@8#>3&,G?B+5J5SH7AT>T$<_#68[(JL%FQ$Z%Y^)LCB?4O,UHT"
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M X[B&&HO^=TRF85+G4\1ZQ@L=2+VG:(;<$@_NQ* &$LK)U/[+BA+"I6A;[S
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M)):" >-MYWBI)L'+!AE$+)HH3ZL>J@*[H*7LQ3O%''#OK.> >S?\''#O!'+
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MW&-?V^E8Q#E;%=_%]D'UR%M WT\S:WURHB\07[!]HJUU.@LY6%I(XE3H27/
M;_-N-MT71/E82<$BLG+E"CQEIYM>L$2=PL)11:.#;2'.HA+2\"N[Q1S8'*H6
M"& L3W?8IU#M!CHMM)H-5_\!>WS:AV4Z4=GA,SZ:2>&<?Z3-_VF[U%VW/3]3
M?T\60XY])XZO^CWU*G.8KVQ)H:+MT+-NY^.QAPJ-QNK4_:I*I95ZP45S?/.B
M5(,&?KFMVOEL"15,QE0S?M!6IOFK$[@ J730;K]\B^D'\ZO:YE/EQTTEY*V7
MKXXV@_%DIQ0BVD(;25.[]S2'.<RPQ<9)K!::YKHDFMOQL<9P&HR=G9<X?B\
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MK9P<WE1D5<;:5._WZF.G-+K<32\PC-DSH)T@P<>K?^Q:B $Q'L.R'"#.N.)
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MZLX_H$R&Z4 !54)9IWP)S_A#>/C]XO>E+Z&B!+  \Z[H*$.\T\ZIQ\6)3+M
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M[2]KD3EM/+0%Z&();WG;YMEKY?DGP=7J:U!T"Y1K;Y0SB(V"8$\RC*:JHRS
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MU)V#;GR#-J!LXLCUW+H],-OGLR'?MU+%] U.^P&,'W0Z9ZV']-X49G"M))?
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M\2$$5A%TO61(P!+D:*6DE, VJ$.LH35$/XS)ME6 3,Q.?:N2>5,;U^K)4,>
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MX-B>R%%%]AFP#B-P'>X?D_7>!WESJQ90*=Y7W.J$-THEH4H>QC$.8[6[CSN
M\2QT/&K:DBF3/D-(A\SC12/Y,7.EJC+S'"(!:P\1PL(-.OUP'=)>A>?V^6S<
M@ZU4,0U!I!\H=;1Z[ ASLWSDB"U>^1K$^1H@)&D:^$>.EI0=K)G,7WD<:AAH
M2MO:?9P)<*N>C(.W2%7-5:F(5>;!V'YE:5"'BLUJ_)TO2!@K&!"'S+TAE;]
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M54HK#DQ)SA1TQ=VC_90X<80',UVU590P!I#.3\_>@[03*'H!W,VN5*O$P>*
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MJ2[!WFH%+K$=4=5\WN\??6_UD'@^NDK8D_7PK)29V;!D*4$:*UT:&0%D0YR
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M)C#:[Q)X%4FR^7[[F^_/S][_(8]<^5TV\[?@#2A+ _G\^&<T R D@)0&0(@
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M77$)"6^-FD*]97@YZ41X,(,*=5&:NL-K"$]@67:*PDR+5GWQY$3P"LE4+D[
M"X.8F!I'$7$4(E-?'8YMT-N<5)/ NCOR/SA]XRAP<6*=WC+;]$*BT;#X'A;
M507C'@.YE/O$5R7ROJ\][I 4BF$5^W_=?5MSY+B1[E]!Q$9LS$14CRUIQEZ'
MGZIUF=79[BX=23T37L>&@RJB5/10I$RRU-+^^H/$C2 )@&!5"<DY#_:H)0!$
M9N*2R,N7[^Z\P@6!\,YDJHMT)JLX2)(N)]?1,"#4X!>TREX2* L)UP* 2[\;
MMK+W4Y&]H[ZY.-95VX6H/K- %PF1H+F<1DG?'XCV/6]NQ#LWZ+;D-6/G@P\W
M?LL=YW[RAYD?(=<M)O1JP$P.R9R8;3K6Q!2IO>'5_,-.>XL&#(,/!33V^@Q;
M-G:C^HR27=S/SD#.[.E*$P7D[I/7/>QCKKXQG6J..?CK__'F?O]:])4Q(@B]
M''P$[^5J&PXX[13Q]8_G=//,8N):<!P5^.O!?42,$7]()<!NO=MW>]FXOQ,9
M,MXUC]!JQBYC#XZY9TQZGM+&EB?-9#20MN+MT7RXPS%CI<D,OCRQ<C%Z-HQ3
M')8*Q0=GM/16TW3MPCM 5# -ST0"3X6Y*1LAPFD5T#'Z]T->L(\Z\04S-DA$
M=(*1J>RS4F:BBH2*:FS%^)22HP@G+=<[.+RXL\$FI&7Z C!7Z7E%TZQ9/E:4
M'W8PGS_:W#>R.5GS]B11'7Y W;T.*@9B\%)[])TQSOQ'-H-'=K^L-AMV(1:/
M[')<TV3Y5.X\(E"=V&TJ>I%GWHTDO-\/B#%R7H*&TA@G'V5+/)55(S.N(=6U
M \7NDLH]@(]HR=!7\/!1LMXFU2/;+<DC4QWJAM"D*AB=-6E*DN3\+J <CV1=
MLK\R[2AK@>T3 6S_75$6S]NWFB.KR=\594-V-1LW*YCLRW3'?3??PS\34K_5
M[$1ALU_S%/E*9([GY"DI"D!W+07 *U? :C[3-7BVV.\?:$$W;%.#0$F]6V_E
M]WX@RYH-S":R3NJM(F[!QLG8 +D >F,_)FG*!GI(UK_!: 5EOQ0ORF];6A V
M__4.$H79@N7CL)F_9+S'&V$JH2((*N&(=&(#UR4KTJQB$R5/M-F6Z0]X\3C>
MU3%<XN-K"6.)GV_!ZWQ=_)+D.^&'9HOQ&QR-67%1YGE2U:Z%+KJ"H%Y49[Z4
M>>\?\&)8QBD:AJ^$<N'8[ZEQ^91/3V7![9S7'#3G%_8.H:E+)E]V@& (Y\>:
M=Y0@SP)O9T%>>&?$/>,@QQI/Y"0[_O5L3.=O&<W3FKU:U]#AD3IWA\G_-]X)
MCEK9ZP=,G=5#C4\0=LJ/'.,Y+HHP]?3<HY5&Y_>(+NK403$9NV3_EW)K!ZW7
M5<8AN4*9S?1/V9FD;6_4)3].W)A8W R)+JH+^M!<,RVRXLWN:?44("3H1#+=
MBS2LV\(AG]CB\1(T$$P ^1BJ%$SK4YD4_D<;?Q[P%G!+IR"4G'4:/-DP1-#.
MWLKS/G$X3-:27FUXE.3EZYIK;Z-7@M$56%]#9_:$$;UM-T5\$8S29I%+(#_B
M'U)9OH,PL$OQTN5S<[XE5&,B6Q/1'%$6MMD/N>^F\?BNN0".UVO8G:OBO"Q>
M*'MNLO<E)*K+//4K1IXRL)R7=>.41N^,DL,2MF_6[<!@>Z#D6>;R<TN!-D.!
M$0-5>!,981'L7JQ$.1&S^KFLDQQ*5K[25)0)/'%O--&:@^M">V79P;S]K138
M9.(D-/8KY/*5/8.RFJXVOPI$6^=>4BV-VAHUIB8\G/F T2[BXK^[AS/Y7*;9
M)EM+,YKZ[;)(KV69CO:76>&_<UI;B5(%AI):D"?C@]V_@$U5%TDQ_H+ZMC\*
MQP)6Q-YRP#@BU?2Y5\&Y4=DQ_]8MBK9- #6\71C<N\($G]<E&+%S,);S0FI5
M]IO^Z[=MMMZ"$9P;U^%W)&GD;Q.YU-9LU =*'LK=XQ91X>SPQ2ET@VMX)P"?
MQ VM^%(:/6L%VY_9[N;\1C1X6N?O9W672@0]TCJ;\0NNQ_0:4:.P4Q#&]AI'
MH[A*LNIS4OU&&W!".)<X-"-/O)VHBX!ZV_0F/6"PE:CH+]&KK& W$M/43<WQ
M4UD\@NG(R6C5J:<IDP\D+\$7R?HBGBM>FH9R&.< QKW<3JLP5/H B13.MPNB
M($P:/!(8DAK]J-$3<+,:N"OF2'X9'#,(3%8SMC"V2PS"Z1*P<EMVSH61MB4Z
M7)?Q3P0]AYLRS]9O]_2U^9@SG3QHJ?(^&<4^$5PT^%AN)1=! C^7W*3%2*R*
M&LQ@>0DE'$?EP/N1M>C(;8:B([LH7QOR %U1I3)&UT V88R(?7;_#$_J^[))
M\D"S1BU*>^/R7D]ZR.4>/=&/[Y^KLJYOJG)-W5$U]_PESYO4I*)KFKU L!K=
ME&Q])\4;2:F,O*L)/.^?DI3R'WXKRF\%TU*8#-A7]!C"=M1LZ1N$Z;!W$WL]
M)7G.+08RI@[JDZUW524BX> /38O-@&FL-?EED6:?F?'W1SL#?HV=_,[DB2K0
MH5)@X6=\(Y"R*7)/B\0KN2\/,DJ&N;ZT>9<[M-A2$=@O3?D>QN+H693'Y^I@
M^;R;Y/ 6X6H#J6!5!K'2/"[N:Y$U]559F6A.$Y<7^[G2@TH;] Z&)>Q(XF>*
M&G@&ZR6( <Z5,(%]T76!=H["$LAFI9R\]1?:K#:=Y>PWBUX;LI6*&,A2N<C9
MD0!A\8,S!O%FWX=ZCYBGLC"VIF"9Z1VM7K(UG>PYS.RRKN5PJ-=[ )DA0K2S
M9@X[E!VI=[1I1/+):@.!:A/W)/?AZ2%46-[,A&8A,T1N3NY@7J!Z=B*JWW8A
M3!2A2&QP7*+S.E/=-(?(<XQCT7>D0+F_?'W.W'Y9W@9>0IG(YR(I9+L]4?8
MXILO3^J&_>X-A,K_S=N+ .5Z]_!/2/>"/#GV,BLYHC?OS\817O6V"WC=6:^L
M2'#37$RF#*0ZY%CLJ^\3.\D+R*B[HI2MJ1O&+<^3B-_4[?,57C)PZ8DTO/S-
M?!4]TH*G[!6/).??H.RO+[38T1^(_BA)#*A3&#??I71!'G8-'Q=2&O/L*1-#
M+DB5/6X;GB>Y@V<U>>:S73!UZ?F-_VW!9+[>%F5>/KXM(+EQ!_7"=S(?EKU<
M:Z9LU>6F^0;#PWE?L?<\^% Q5XA5!,.UXI%4[%7#U+<+RE0YM@CNDU>_QX.U
M99>H:$R:Y-7FJ8O.<QL! XZ[J8Q^M':GXE%'>\S&C)ONSWF$OXC1TE_  U[7
MYTF]O<K+;SRB]UF>7LMUD[UD3>;G>0XV0)[ O&$#R!!H-01)]!BH^G\8F38Q
M!7,GOBH)+TDU&S'-JGHK7VCE$U<K&BDXV0?]4+*38A.)CVB,XZDS'Z?Z-V0^
M_I[HSGR4UTB*VF :]<]"PZ(I1\^:PG&EG+$[XAGZSFO9]RD;EXB5%=$%5#;T
MECN0("L$#-;+];K:T?2Z8 \1]DIS2@B29RK=4VC5HBM ?_"^B+?X&%E#\80Q
M(OY5T<G2"8PI47V(>/J(7@2ZD8^]0(;8DO&1,Q#*..UX\KBEFYR]'_E/Z6Y-
MTTF1WC<JRAA,!CKMK-)CLA_YH+W8?4S'^33"G;*<PC<$K;H]H\'*\2E+'K*<
MJXIC\;:K]KKBIIR\[3J+@-M1PH82"V,%PA9T3>QN6U;-OD*JH7-?2C.2DR8N
M7% ]?F"$2-OG]J:6T)=2F.7<6>^MR(055@]!8 P"@Y!VE!F*SD)KH 2=7)K-
MN?BF5]CYOE+D(P@QGEMD.!<A]@D-%:&=0?@[L=8S')'<#9L,>!5YL@YH*TP[
MKBG]]^2YK/]:Z^1ZIJJ4#WGV*/PCX-(2)^RS*/]5]ZU+_*\+LH:BX;R*+$2E
M638QKO@'7!H1NX.K&/NURAZS(LF5"ZX%!("73BUA )S;5?9N(P-,$ 4 3J@5
M<@*JL(*(',IL F_B:S?21Q+XU).MO6^\^(*QTS 0A(_4V)806:=PM?F<L1.N
M*0MZ1=WF\VX<W)/J0C94[ Q^YN'9/^S$6/COICDZ_]D=F10 3Y;!2Y$R FM>
M/-HI ]V#&%W^(/H@LMY)QY#](R0C7!OLMA>^+1Z7\0L<A^-!9,^JDPQ:>>'W
M0U;( !?$1Z^%G*$47"1C*&DPF5V1TE1%"_L#^71S'8\]S%U'8;J%!BOCG;0B
MW+M55JRSYR07$''C"*DW8/[F+<0FD-V'X.7Q!>"@Q"("+\W177(WC BF<I;5
MVQ??T;/4-^^S[B"UTJ?D3>";/(![0L44E$0@H5ROOBY((@$+%;[< F)J_KFK
M&XX,WB!"/_?(MXC+PI[X0F(C;A/(?C# =9V;1#;N0SIC;@_;_(>\=E.)<2_K
MV8@R@2/7@L%T*NHE#JYB3+Z;-'@8/R0UME)Z2]?E8Y']+W@I>!I<V'N@TMU4
M^ARJ26M Q8#G#CKCLSNE3PH+E%89K3^VVAE?!O>E6>Y[8IX#),"I#_!?\D^0
MCZ8"*]JQ"T-%A3[#A_"NA'U98A'Q(;Q%./)N50[K==%Q$4[-@:S4./ BZ;I3
M9X-Z-TZK39Y![,%XQ=S2FC8W4!0%:N6M"B,?TIXH&2I)P"]Z5N/R 'KU[('X
M$U?V*N;NG<@(BYCW8B6*U"&8?;7Y6M,@@"K>',3$P^(Y-!6O\7SR5YN_/+KD
M[,0,Y>,C.OXCMC>=48>X1PAV?SBR'-Q.<#_E,]@/SD-N* -,DUE_UF.,1E00
MV+V00CAW"H]W: I1WOR==O><9TZ/INI'$MU1%@KCULL:^J(J R-T#242Q(CH
MROS(K/RJ^U0AS4Y*+C5\ E?B7Q]W2<X42.^[P"4PZ-HZ \"7H1Y3'#"X?'J&
M]$<AO6]9LR5I!C7SBA12*!.1.O><9-Q8QSMNRSRE5:U@;3KUP-J^NENY0XT;
M".#<8"T$<SNZB4_,+.29&*:YUW)Q[//BQI)E"/4.D88S+O:A'#X_9P6&@5'E
M(.'.5[;# @Z3F8=P@%-N$SCY\X_GR7/6)+FLV.G;IO?)*SG?R3?T_RD?:K)<
M\UU[^L>3/Y/O[L__S_)["2%&ZNRQX(].MJ]EX2$F7/E5PCXK#O-O<%UG!>!,
M;3:0_<YA*I)7GBKR1A-^K#]F!2^5DVS8(X-<T#7E"^OL9,&^?'KR X')R8_
M_9'3AN9OA$)R=2$RMN&0D7&$[%LR?"Q7^&?D]M^3I^>_7FH,LQ\(E-VB2;J
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M>@QV67VC8)BHZ$M6[FJFD1IW'$<*DO64.%[0-[*EN8&K2Y-Z5R'ZG#N<M*^
M+I^1E!4YB65]74 F*=>I"BCR:D%J#+13"*FV:R'3(X.W$>+&7,"7N$^#J>SP
M2G4"0U$>$U.G.CE,Y%C+8/[KP!DN<B"346YJ.=VKLKIF38M'J'GJ=[W==03-
ME3S=<P:%14>H\@K-R04$3YV85U"\Z)V^EDV#/[)67?M#19WDH9R.\'FQ!"XX
MAN -K;)26"GYWX3>72OUVEDTH@\2K%[KWY4*NH*#DWZO8ZI2D@K00M!BI"T.
MRNFQKV,^BZ;R8RC>_3@Z(^'S"ECX\+4S$?UT;H0NB7WYC* _&^MVQ )KFCB<
M:#0HHNW,WRXC"XGQF<W+ QF@D09"A_-9 EVZ"*0&5@GJ6\-#S4 &HY3'UA/Y
MA+H(#7X1='%B,#V7EJG;^6TC#^,RXI/1H:M<'V4Z'>6HJ5EQ4>9YXD[N%=QO
M8WV%;@[]L1%B@\BR2R:,&2A[HA?5YQ=+-8A81!9';_9V[EM)C&ZF!!U!F,CS
MO/P&BH*+U[HEU.(235$/_N',!WQV$1?_S@65J[5).UDL6BES/-XJ[DYWR%<+
M-1A'NDPR"/.]B;8>!,/H7+9-?\!K-XW1SPHYE?M2Y41*"X-785=\OR^)S@,5
M_<@=?A*HER27+'P,0-P&]91]4/<V JJ=V$J B_LV,A&,B/W9I$';H":ZO6WY
MHW,^]:]\.[7QKU,UG=7&?%:/\GZU(<)^L!H$[."QODN#D_,V4F.KYKZ0"%&
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MV"!$C4+X,.#WGD42\ 1Z;6?Y9'9%A8%^H<6.CKG 9;-9E,KJ37FP2ZPD13N
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M7Z>&><=6ZS-RX).'-%-805R(:VF%,X+2[AFAR[ZJH("+'1VY-\4PEO-3C[6
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M']Z'["/Q4&1WE(RR(*) 9$6T*YJR99'?)Z]R(A_9.MED3D5+=B.R'_<L*C3
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ME,*D$(!(715$CX=I,IM*NUU-F<Z]F9ZE<.9=L2\?]0R% 6<;-&DA_I"CL\O
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MRM]$<H?[<2*G(AJ9('SG<Y(5#86X2'?F.6NV($9#[#)_G5G;MHZ5L+A/NX.
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M\\7+^Y-V /*-C2"M/'P,;G&6HV#:FD,)M;ZM)C$I;BJI)WV]%T_)$_NX5^^
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MMOL59K/38N;D,SB.[E'(K0"SILQ(<1?,\_F24^5,^CF@\+A:Q'?>7E.3#I]
M;@TWB/E3JN#DOPQI\C<;G/#M+V96AZ]<YF>K&P'IYX#">DB(_[FR]:E:J-,/
MP:Q1YCLLO&=EJ,I?P,GO(7V,T6\I$\#ECDM!V7C7/H/CZ'0/.-N+GU3%UC(
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M:9^3TQG_EJ. E=NE)!H'A_SM5[#!$>9,)7B'<C:AEU<'-9<AQ$YMKBS"+M@
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M0>]#I9%=N'ZJLJD@X-29_^#A*.9['HKGT>4SWP=3'*^S6[<+] @>Q.RDY^K
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M0C?:@S:$)OCW_ ;BFF$?K7A>[BR.$?ASF YBCOT+%YK0!;^K4L[-_%WAR&-
M1*N&'!Y@Y:B1<GWN=J\;=>RA>[7KZ<4'#T<QGRF*Y]'E,Y]4BN.UK-98;^7H
MIO<E:HB"% PJ1O^0J4F$5CSDTMN$L#GSUE/H F7_9;/D>8H,%H1WO#L)>$VB
M;H).HZXN-$5%" :5I"6JHJ,F%SC>DM@+N85[YJ^-^<:G5O%$\NF7XT_*L'-<
M;;I!V8KYY$EQEB(4&H1'<NFL&&W001309801_LSW21KQ/*C"V%@7>P-)E\$E
M_071+OPF1 U"!?*-'D;P=Q1M/1Q</O.(AGVAU\BY7>'0(J]C:1 TL.[772"V
M&^'$8F<P-9HO2_*-J!H8>>OBOXYV#!I"X=_.M]-RZLQ#2[L"HL$97R9EV*W\
MSMOS76<6!>QO:,H(8>\1AS;J)A@R\:*40@UVUXUCU>]GG:4C3'IKT,&W1U<H
MPMCHG^;8Q"FW;;'+!)4V!EY&@DHKQ$X[@S/;)8(B5X0RIGV$@IBGZ+*?@Y3S
M:N?&296JT^W"?+E4$EM4 08]*6KIPN)Z%C+%Y@^;9,$ 2:BO^4N79_I^0I,@
M 7JJTY',+4E*C,1'#^,Z8FN?S4A)2MVCN+ZEZ2<U!93@#F9V-UYG&ZXC%TQ9
MP<TVV5ZI.A6/"U#LARMC5_Y6&P,OP]]JA1CL0&:8$'SP 421/13P-5"<(>&S
MA%NIC7"G5E@=M;SA=CP!DXF-!'Z/MKD'.%]:E+24S!A=:$T9RR%T%VZ_P+$(
M_LRC4M5,SES.&]?'HOJ,>FDE_5$G+%X#"%WGW96MS4 +6XGDR[+CG>L=HHJU
M05,@J"Y."NV;IBI.):"@'+"^*_A8S>6D"G[V%XC]H_@;BVM:@XD)V_J^\/<(
MG .DU39S?4XV&Q(-IQ]E>B,-V(!H0P57L)RYOG+/"SX5Q:(LO.>4DWIYTCY%
M,Q=T_UHZ?6Y!++^ED))Y"99="F$N69U*/,!),4?>>/9]-2/?KIQE]%[(BN[&
M-1>^3F$?V/Q']9DZ"[XZ3G]07AUF@5>X&+RA!G ^^?_S(CD[=CX1&;I%67W^
M#\SAK/Y%Z3>S$G"G&2)^F/*4O\MG?^U%*W3/5/5RN43@(?R!F7=\^#12Q:'E
MV^-A<%6=!U?F,>FFTYC5\'K6)W:9U7EZ2#R:.+6%X(6\>BO0%V6J2M7"# *@
M#=7=#$N0I-MM*.YHO;"XH[V.EH1N,O@M%>U2I#J.PGV*M]?*4$*%OPS3S<D&
M+;QG'H?'T*7GZZ.[SC_04^Y:?G@5)W<)?4>6LB2:_'F2>%M\0Z+5 M&-A6H
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MM;11FI0@E:"#JKDS65]*]\!B;I6LN=(7B#'B9X&FCRA9DV PG[J)M-OMQNP
MJM;#L0GGB68C'H,U#7$9L[!,_PB,+-C2\QG3D'$69;(6[("UL(I:),5A($4Q
M9J*N$S !DZ\1$[ ;4LW5["1< OWXBWU\038>CH:2=XFBZPB9F:NKA&5IQS:N
M$_LUQ@4>XP)Y7?4UQM4CQ@41:3%Z&)G2""?\)C4*V$[.?[)SM&\AY/0(:[:@
MVF"#"]9\C9W!Q<X *AM_C9V-+G;6NQS.R_*JH6-EH#[U!TKBP8Y/&;&Q>M)F
M,; <0+<-5&:^GVY24>^O')-C/X=(0!L%Y5?]TLD *P(86R,UE:T: R<3@_/
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M6;V:&CM6;&(S#9>'=B5=KF3D-\-4-7XF^+,A-_RY"#,"5HS?Z?B.6WCJ(M\
MD+D9W"'Z2$X-X?C-B/9IQ#P+HZ=!R>3U*<)YA5$K^EP:WH49,3P;GJIU&2;
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MRXJ\)*-/0%XR7 "3J$>_(:C[."!]N^"+_S4]E!(](* C?F9,.%D&NHZK<A7
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MS-7OE*4?Z_K##0.=Z*(N)S>U"V-W-\;M"B'*W$NE ''I")DX<;8O_XOJE3%
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M4'#FA?PHWBH'P J<;33'[6UHXE<(>=B0QC%:7(2(^=7./,I[<UD(2;51FH9
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MB\##,8B5O;,%BN;E@TW$QIV"4(AD\$C#99[1YA/*W\UQMD7!K'/^7([NSTD
MD8_5/OXD[)X24(48!W]D>N1PX3U?!VQ.A^Q?L'4F&WDJ!K$#GT)V$-$),]'-
M@H"A%^?_X?-X!R"VIE$GM.(:02ED!1&K !/6>RO">C]M8;T_"@OBY6<_89VS
M'^=T09[:BJ)HBJHTYI2"%@V(%')R%KG(>1+;ZIS>4;+#[?V\-$55'WB"\CK!
MIA :0 RCE]#N"#NIA__ 6R"/L7'82;GWS< 4\AH\A,%7^HPBK[=\*@--(8A>
MG7F1G]P_4J$K@1O"+\36)((X^IX,-I&U<0I"(1"@;JGJ\GA ?DJ9;KQ[_[C
M2<\'=B>#340>IR 4\A@\%%&P<OGLK[UHA7J_!6L<<!+>=#,4A60<1A=$OV->
M!F^'+KS$RS,Z02)$C0-/R46385.(S<%3BOPBY0K3S76_:\#J2-,02VWVA1P
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MO#AJMO=E&I_?/S(=F[)QO-(!?")^%7%>BZ,$.OH.KKA,Z0W/X@(&=I2Z,<(
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M N^[8VIW(1%L;Q_YI*[]7>,U-2^MEAS3,!?HA/>=4=,ML*V^M7GY7=C@W]0
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M&.4F'^R\G6R.?$].9?"-GD-MGC:F;(K2(#^X2'%-J7>24O>_/:5Z4+!69DV
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M#Q"48:)(HTB,B[6I[.FAF?PHRH:BI@;]3UAO.>L_![NN<@$J88YL CXM64:
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M$),:3'NH#@,#C6;*U5MDY'![P1_V=LU AY*V$NF<F#1)"L?"I76L+Q!FI/;
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M19=4M.22ZCKB *'OJZ>5.[%TJQ%F?UP'DI8#2?OK0-)MU5L'AZ^T%NB(6)!
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MPEWY@J&X@0U-?W%#$I26$X+'P4IS77H:3]V>-"^_]]E)Z,"(2%E.'.,\=FV
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M/='K- ?RT[\23"F)6QY[>;#Q/;)I*S]6H-E22DA\4^-&'8].T-SC0@3GD?,
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M0F\-ZEB5#J,NP*'QUV\B6-7K"8)UZE" X%RC".\M(_:*AN(5#4.I?CZZ'-4
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M^3B-4L2HN.X3TBLV9RB';HF<2]0]"3!/ZNA3XA_N6:3_(@2Y9;P=VG6[?61
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MX-9AG?,:O6Y<-'.6D-)$\:D&'XD-T%>@MV!Y-_3R]/2N)!O'OQ!*V),Q6(<
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M72#?9TI#]))53PZN[B_U1\IV![+#BCD3YQ#I?FB&;C P2EG\K9!^2X>S&[-
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MWC5\,E6'(_$R/CEX#TK1L<:XN8F3'PPK8@&LZ6QPK-M=(=\ >WE+-R=F?:!
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M]W=/$TF/M)P6:X;D:K\3"DYI[$H?2Z-4_[R#$ ^EEQ?T$F.18A\V1ZGHKFK
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MFBT&M5*_,1,N)#O8<&$R(T3@,Z$-BY!%,D[)/Z5L#99OUCNJ9I#\0NAHA:
MWLO''=0/PIZX0A-'3%%I5\IY]DU-#SQ(9G-#!28?Y[4'NI!PV:SW+HF^>@@W
M5,K0:!8@$*Q%AHGXJ>Q( 7P_:4OB T\[DG)J=.X&H>F._M=X5O-(6;68WG#R
MT#$SP_6D>Z]N*,U,VP] J_'*(_EPRG7HH<)?C3D0Q<8+R2E2$9$S9=P%.]/S
MOZB]?X ,Q8<K3CPL5O+0"G)H*(Y?1$L6:[G96GP(HW<\52/A2YW^+=_4Z.1
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M2MI.1UOU//O>$*R%Z/76 3J1>H(TDJ(O2&<@+*>:G0]$!VRE4>A$LY2K%'J
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MM!^"'DE9%# /U<W?#MU1.^X,463N]E6[)]TXN(-Z)TH GR0@=[B 0Q,VK;J
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MPD/NG=MML6I%=$>FEN9)?B0/2*KQ9#G1 3*E/>7F](%W"<OY:'QK]]8#JF+
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M7(XHS*:SQF\Z^22%^=FAJ<GRY8#LLA&#D;TG[-M!PERS\WQ\OZ7\[,4EK=,
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M%7Y_79P+'U=)1UBTOPG"/6!.(]T*!WU<\PE%RPBJNZ$FBI0A# 10):"X&'$
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M'HX/# A$:!-V;8-HV'*OFM_XBH,H$..JAJ6NTU=<>>.L[:&!R*63[!E][A6
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M/ENX[!R$*+*.]1_\'LS\1BTB)@P2<RI,<ZN38A?!HS=2G018#3SQF*KF&+J
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M7^#E80U,'\OYWZ/^0&Q<Y?UD?NR4+E],F)B*\$H.S>CSIG]WY[51;G:CG_C
MKX8OFZ$^HSL^\>=:3\OX6MT3CO8$W\FC^\VIIZDXL@X\7X<*23<*M<30M=O1
MM4<$*'$#88\J2', $1,BVXA4?90G]U^EPSTZ)F.K0?6I.+6 LG%N.OLS.OO3
M(_4#UW1%ZB?M9;VJ!VB$R>F+O@-13BFL(BM5=(K81X#V7V9YJ<J$K('UB:(
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MG9]98U0],9DC0>A^IW(%+N^J'_V,6'&:B^A'@X!SJ@[2ATC+.6I..12I*F_
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MY5>)(* 1A:J,TR"P0 &20-IY]4.W9=]A^?@$EH:?RA;TBMA(R+X_((PR]L#
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MR=^A/R/J!C(B*EOR^FRKX"6;=6U3:[6,E\% #V"14$L?T'&HI0_E9V$.>40
M6N?D7B+8(8>W8Y+K-#*?A%*S"72;5U%$UJLZU:IJ=&"5@6@=%*DI8>DR+KNA
MI#)^VP.G& -W<EJ[Q&HC:X_,%%2+2K$!:U5$R[,F@/&HBS9K*GW*O1[('#9^
M'4S'($&M3BA^_(G;5%3!5YI,BEQI0%PJAI>9FW (K((0E !=@<0B*)6&RC-'
M[TH4F E"7B02Y&Z"&7?>^ID\@YB4*TEOG@O8(]; -0JC<K#&T:,7I(]PT7MD
MO!0=KGZHD-B\@'U_02"XAY+J#V\Z^SAA%Y,RT"5+$5 #>(5*.?KD[(T%_@J'
MP$PYQ#Y1YS]SYCKV]S!Z.+R+'@BRR\.*@Q@L:H\\H1X&DF7R#;H2*.5/-G3"
M;G1T_&58.6!8=)FT_($R!AZ5X,E0['*G%7]\R?G'^(J;S,=\13/5-PLSJ@DU
MAJFL[.LEQ?]0'F<\(H/ &P[9!M+F +W5C$7J5VD46*R.D<=81<B-S;;SFRU%
M6%-+I@*2)TP3\U_WYV?>\\.%( RP;\L>:.C'9+QQ'9T00I'6/@:SGAZEYG(X
M\D^-9I.N"U_A!"-$*H,,I3KV,D0W;(H^?06C:/$MJ%^1Y%T'D]/B"92,4U:1
MH&!(S=9P^DG,!% '"Q,NK!)"#!&O)0\84O)FGM,O]D]NFTD03384^A6^JU9+
MOVO =TW]G97[KL6JC?%]_MDV':# %V-U\^DI%*9I]\>B.+%\1Q.UF1;=P:G@
M]GFX[W@%RQ54[#]&D8;!M%47A-SO*?_+\"A@D861:(%WK3KH^?ED\ZY8^708
MKF&9D!0C:F&KT42Q0".6B/G()>S^14<0NGF'"$_E29'?QQJ3OCX7LT0A<0;I
MNA/0,87];_,VR0H;'-]$NI7J!N782#3'C(8_M<J>9>+ @QWJE3C)GL]8A-E>
MP(03+I6SDZE(#X(W+WH0EKQ4L]5+8&6WTJ1\J&\BQ1@_NI5DS[P#3P8A\+V)
MS%X=T'V=:;RE\^#;!T>\YK8YJ@M?2#TLY>_[ZGWP*C4PZ9&/2&8_P42Z\C1/
MA0"CJR/FHB1P$%ZLAE#!&CCE9<1J  YA/KYW,E!IQ$N90I_R-2)[%Q>(O]6?
M7JM>0HK"U@LHC*%+H]&$Q]X_59O4"SQ_R&<UHP/K,C07I<+(A%HL&A;60?T]
MGWC9QZ(K'J-0*6=:84?W9!"4O$[> !1$F[R8B X8S$$$6H+ZQ7023 %B3#QY
M%AV-K(?QB'%<: YJ1MEY.F#'PO,ROQFVN-$$K>PQ,<Z[<2X)81R7B#?A%,51
MD8D%CB4OKIF<!?H,Y4ZAI-(VMWU@@ _+I#(^>7)1O'%XT7(@H"M@F,'RHR?L
MY]L(5>=F&G];3%+5XU6HMNF@9:>XOQSD\Q3_48TBL]HX4;<(7&[,I)0HA_I^
MC[O8RAM,#Z,'EJ,9SG)5,J:&QH*<+HR'Q>%LRI9.7\5C]?QIJX=C8K3,/4/1
M:AR6P-<[5>9<=41"K$9#U<TBU8W4)YRRILE4Z:"B'K*<G@4]9J)FPC_F>E3S
M-I WA&/H((:.9]$U+$**5Z"^QQ*(TF/DT5,+4$CC6!7%F X32^(-<EC">C:Z
M=;$$=D"RWYBG ?E^H*TY2\+F:2QXRF*6U6:,.#[$?MZ9$NGU T3*Y%P?O38B
M#LA@?#=6\TD#ZZO^P:E\4)E4[PLKMIZY8G6MP*KQ+_G[)-MI6Y7,QD)H%'39
M')BI))(2#2 S"R0_D>QZM-W:(5A7F/M:R%2VB^O4H?A?B%\88I7HJC)0*<A5
M%OFCK;/.OYWF8F]FP<%$*82.H,F:")FZ09[]@JK+E[W&CR"-E3.9\C^MHZXL
M>T$K_<S+-/B\9DPZLQ]J50U?1/R(ZY;]4>1U-S'W@Y'.KWU?6 C0GT:TE)G@
MR TO#JN*.<ZG#J+M"<DX]^^Q](5*9N2QI B@V@69;O'Y]+@PC?8F1O+FB:,=
M[>-HQ3A:?1]'6W7OJ6D!-!'@T;Q./=0O"+T?+=L2$ ;U$W6;+"O8MP%:G=G]
MNEYTR>O06>;Q+4:N3)]GUDH;75.%G9@(IJFMR/I):C6Q%V&B*4$C>=90I'>1
M2F]+36@IX25C>>EA]9=T-F6)63H+JV)/^NJ>F"J10;=N@2MS5E8QAG@,IN$<
M/5Y(MK9Q(A!>BG'%J9>$]#U[G!]<8FM[B;8R64^T--EEV,>8 2E;]-(\N@%Y
MCN3<\WFU@@TH2N6AAF(X%&). 2\1Z:4JGP4@90B(4Q4S4K':3J,J(!NU?C)'
MD?Y_:#-9S89*2/)>TAY:NX'HWZJ:1,TCU#@K0/#Y1V5#6%Q]5N1-J5-_ Y5)
M?T<B#<G\!R[1L-DUU3GRH![6GYL/%KZ\$7'LDS/^@- -,%.YZ"&03\UY. PP
M,KUZ(I/L9Y-JG!>"N%*KEL%-:X&+HF!>YESCIEQN2<PNY)B;4CZ149]8K-04
MM8*(5K415E)LJ=F;?&J:I?N"&OH098W,K]^2\>CCS=??/N!_6;IRQEIO/!&=
M,EF0:ZM =022D,IN8(QE-J5^^<X'/?Z4K:5EG%T'#BC,0+JZIQW:-7:5&_)1
M6: M:8]A7X^)&RAS3LE 5+W=- )1ACM="ULS.&49;P,[:B+(PEV9<O8Q2DB8
MOR>SL;G2/JMWA<=)1?#87)SC) -+L80<8J,N[N['A@U>87B&5"XTV1T<@9#>
MZ23U8M7T$+YLPJE._<!D1B52V151=/EEPK=BW=R9S=1+(E"<$$"[IC9+A0VR
M?N*4;LPFNHS/\N5SHML#!.1I-TQV<CM0WSM:EI6C:.8:I,N/RXVRLR9=QTP6
M.2GI^S&N)G9!Y!)O.69J6+V]0'@,/L-FKX_@5&D<J<).+!E5;\M<?1P_R'+L
M)R>67[SD^-S2I:]VYN2LB<G9BYF<>>RTS0R?H=E<'O>#\\)NA"R//\@Z.E)U
MA6[3 P+!&]JTN 3+Y\>!T/P"RE(\]C7$&!:&&0^.HL3GG)Q)D[DJ\9<L[3;0
M/4_?2T,_FYGN^T:)M@P'QCT&_L6X"A,48]5"YA)K=8L<3*+G)>B-SJ4ODQ#+
M^MZP:I.UJ=&/R6,);(GY]2FZ+I#DBNP$EC0F<4(Y6?5J;JGVM*7"6F7"L%62
M(MS%QM^C5'9UG&_(^_<V-K9 GHG%(2$^<&DO>M[H4E3)7-(9D7N#-=\;-$Q(
MTZT>?'\_Z5J2HSOVV9"J:'J/I'<<CT%ABE5T0%E?9W]H#!&'.>V+U\4F\GAF
M3O4YN,$*,@V;=WJC38M)]G)G3_\>2"YYA6@4I1%5AW/"._(VNY*XP D)UGVT
M)EMK/OD.>(GX04'2C&4X<JP3XNE=ANIAJ#N,H*K2O0T,&4QZLJ@D4!>^R:00
M3#2#(R>*QZTV8Z[LO+KWC3/7UWKFDP$>*PO\<_6*,L?RJA4&7F0O2PXN X=,
M$K2V\UJ64:2DCA#K,1H:K^#EC\9IP*'9;G0OLI@RWLR9K4VA T)4##DF6HP@
MHZHPC^UB&4%.(_BM&3B+@6?> D_%^Y)?[,;/;"YFT\#+J2NP%A&3#OX]Y@*/
MG[(VJ4R#@()Q+7[<RC].BR][A*_MIU2W8CB(U"RR3P*%?!=FI[C.>JQ%97(]
M800(%,D=&3S26^ /8&OXRF4K$78-_8(I#1P^JD KX;R2>_Q7&7^)N0ZV#X((
MZUL1H<(H]P-39[*T>=*G\*N\9/ 2R'0ZH[PE.\*_LFCWN"E:/O"3Q73*%.)B
M]N:ON):#>^,BQ\P!T$*$$53.=/9K;C:'/Y*A']7A$QTRC*R%!BCI3EACF-7U
M8(#<Q]#P0;WZWL*X(94HR3 Y 0X.1?^1>?W>CX)]\4RQ-QKP^@WH>?OJ I+%
M,^;VIV ,6L1(&78#P:W;/1)[F#(5RU;DE/.A$1V3GL\U[/IFS%^GQOL4&!Q5
MU&L<W5Y$J1#H*:&W^'@2+ ZO8F:Z?.D@DDC 9%..1QB10JU"MG4CG!M*<3)%
MB%&^-Q6[33U'0)GPPXF@F&/)C%]#_:=^O%BKRI'J$;D;LXFL*)-B<]ALUOG[
M/4*BGK '?'\(YSB$#]RZLQ>!SLM0@7 U989,C>LSVM+?<<^W* +"\8_-O@[2
M<N-VZ/!MQ3[--!M*N6*'94%CI1Q&\E)3H_<@8KRJGVIMI]7H.$?MENSLD-SQ
MYTZ[=01?55$E,I,8M0I<]+%(DSTW82,'M.>-_!0T1*S])1-6^W;#B'"A2OJG
MDWT[+BMAEH\B,!,AR5?L8ZRHE0 M\N*G<B0T*G1AB[*QL9IE,*9T/0JCC"B@
MH0-%_,V5^J;@!>>TV>/Q+0)!TANN!07LKB70"YP/:BR&7CML>UI\@-]A%=]A
MJ[ZT!HOP&D@JZ2[M9@0(]U1W%$<U"$/Y/U3SB)]JKC;_#4V84I72!Q'<"XO2
M.Y(<N(5.:>)\- )11Z&/W'M'70%PTV4CC&2, &*^=+'3EA$X=-:C5SEB0C@]
MMENS^8V\(:CN]*C=2&*!M8[9XN0^ZD?C;BK!.7 X ]9!ES!3(?4M"249EE/Y
MAFC"4H[>!DJH>5(6.ON4A6+*0F.?LK#^8/TL_2#K@RX[G^]UA+D5=3OPASXI
M""PW$:S,3SC8>8,=P!F+(^5FX(G^.?^([L?RIN7D)6#'&B(?\4VH83G84@8!
M:QG&=L5&2PO+)[C/L,(\5D48['T)*!8JK]M<$W"'NX,[NCK#T> U?F_,3IY!
M3.<7705PBC$<17D=W<=,]Y87O0^:C1=C*RD&^\GU?^>IEO=X+]=>'()JG:X,
MX45HX<09PH?J2DQ=!A_352?4,$Q?;0KN1[8/0QC)[+(BL\.H0H$QO%#%EU58
MPUC7#295Z#B=5%APOK)L #U,#KIL."*O?&I>[XZN<'(+IQH0,S:V:)TNS,TY
MIK,$F11?2/@+O24K%6;;2KG??$4\*W=.M0[(9V.*J4*,C6&+WS[X'_>7QQR7
M1V8KJL@>2K-.O>ZTW28'JMUJTZG6&\_< 4?AF(&1@2[JDRCA5#9=H:3'LIX:
MBVK_?VJW6DZ[W>%)M=M.I]V9>,EF4GF3.8!= -:3V\K5TZI$TN-[CWQQQA&5
M ?K&$9B+G2,)$(@1%[Z]F-485LQ$_)+./KP/+:H5;3J=HZ;3;.JT>UD3 #S@
M.DVWY1Q5FX2RC4DQLND1]7L($UE,G_7CHG+-++R'X[>=6NO(J1XUBL,W._B"
M(VOFX(FNO,L\BMF%C@MPCD 5:+2J9?.OUNI.M3%S_C0V8HCZ,7>6I!(.9;)S
M^1 FH-0;3J=^Q-Z4;%4<I9^R?C\A)2)@+0FT+-&7/ANWT73J1S59"HT2V%P7
M>SY_JCOU=M-I-]L2;SN;<C08)"+E*D PG@^Q=1'L,G*E2IZ;.BGE84D*+JE\
MB3%%BGWNBFD1\\DGR8"7,1\_Q, *YL@ @P\35L% -PRY/T*NBT-*W>[H=WO9
M\5K9,45TN'.+CH8+[ PL77NYZ !!A>>Z?M0I'KTZC-P&J>*^0G3 1=BH.2VW
M71R^[=8=MUY]I>BH(P'@;IL0 ?84$> VG*:JK"<IH"=H/2$%\L>_W7(:S28;
M92J7$"/O#DJL#@@RM].B%@ME.4@@/*KUCM.LUR>E@I0:';BX&_PMEZ-.G9BD
MQ?K;@6WID42;SVR_H7FK/Y^K/]>CY:F#35J9/*"45FFRJS7)KO/-P-U$A^OZ
MK*$O_K_'?E]UI#B141 PD,#J[XF]>VQN]YB^?\P00>8IDVZ1Q&<@5.II'FDW
MB_3DF)X8]NJ8T:K"8,K$0;];(JCJVY)>&+X 'NV0 -FZ ML :(=+("@>5>YZ
M4I&XD""HAV/&5L*4II[/5U0'KX"J4V_5N(- 'XL#"-=6!=%81:UV.LY1O3,]
M1B=5L9F104+QD=H;JH>MME,%"PU[_O@_"$HC$3*G&A%ZC,\XLID]FZ,OYD./
M_:!/L9O!1#2H@AV_S A572'<#(SQS'=Q5G_@=3'QRE>W5JM&^=OT'8J]<4I]
MZ1DTAP;D8@#T.6+3^3CT<?/VBN*SYW8QCJU2#VO6YG@4"[YW8,?&0[XHL'&;
M=$K.B-CM]^/%0A%#K:(8;"7#2@6$=:]M5<R'1TC>1WW1E:VZ"8.2BJH8OLLH
MN-0YN/2>\\L+1H7S4/>T)F+-G4J6W @RQ(Q,PZGGB#(9EC)H *,Y1@/:OHX[
M)T+&FQ\HWVZ>(+-5(J^EUWS/8L\_\J&5I2"XU5)^\&2^["$B@N43%!2XGT)D
MHZ@5YHN9*'Z-(Y+2F"R>4"KJ9QX.N/ /_HR*X31>!U418H(VR'D%61^-5!XR
M55Q0/ 9;AJ2RA0P"O(19WL0DIBBF7TZ\UI%Y)++2":B3))J+K6)^1:?24CR_
M+7PV1P)"L[I/0"@F(#3W"0CK3T!XKAS[FQ=R GAS:I6P<0D:Z6)Y!&RJ@X,I
MI&,9!P8%'D;P&?P4N]UB)KF!.' N/U1Y8_J"4C>Q!SJLSLU*.(=,-0OK&3ED
M9(F;(T\FF.7QEB>_E:E_LNC!JC5D^I7#K5<EVC1YE+,'&1BK3%I2N2L'H!'0
M66)*LYA5*-VJ0).0V'2EJ4Y$JU@@:V4^G"P6<_.>XHGM0:Q#+Z$1^<58]CJY
M0:102)H[N(T:5$$F/QC?8XF1)4O7_0PXFVR^ P_QI"@;4F$ 25 <[<>.\H/1
MXBHUK?K07IW@ )<\0)8Z>-!]3P#</L7L_1"[J.H<"MX JEY@TAO^]ZRP@8MA
M5(*>YFYTZ-!V,^I95^3VDPC9 79K3D/.M0Z0BFBQW?KWY-<D; 6U6&-NLI!$
M)R!.4$=KG)H^NIB*$=.0)6%W<=$1V+/461:4"]=5M=3OV>]XT$-:W4<!,! N
MD=*SL8UHR/ 5JI?MQ/LE,8LXXOBI 7VN#[K;,J#.L[U TE@,*IRO[<Z=Q1S]
M)_#/J4+(K;4J3>/HS' .4(F2 9@+,P>3:\09J]DF&%(!C[:LE*-OV!"?N<_;
MHJ1LT-S@$BE(JPE-.!:WJGTPX\'_FBF=F;TTJ3NZU8H[U6#:3%IL^#Y=]-*(
MLZ;+-\JP!;BM43YW^J=ZY4AK\WA0,_'L)_K1'!1YRVFUVGGA8<T"@=COZTOV
M54O+ULOVU6U5JL_;6+>%H<P.FZ><^4@Y>BB+YX?\D/I*\=)YYA!NJ^4TVS7T
ML['7QY*#)ODF&TH?,Q<HY!JDX[FDP4:SC5>4JCW0[U"C3G_4^@GUPA4&?=X2
M3YLU'H8_WKQ6)NL^RGF[7:GQ4G,*J&[-DJLDN9!#9>UNCO.\,N7WQM'@=[E.
MK=9PZO6Z_:P#X1#:PR1_I9&E3T;-<:N=$HWLJ3/"TS*&S Y;'>=)<YUG2%;Z
M<N=JUN$!R5+5D$[J !56./WY_0EZL1><8W"L])*&]43]V604L*Q626WB))XJ
M=[.(=0I%#Y5T-&82@N?'J6 #2NX^&01%II=-HJ1%$>>4^0E/O&RUI<Q?]C-@
M$UE.YJ8F+YR)@1G[\AJ+^X?4Q\L:R.):<B? C"()D@&OD%$<Z:#->LT^Y!?
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MYDA6 V<OM/0+;?P@4%7"^E,NFZ6)/%#)+][WA!T@>P*OKA'PVZMT_?-.A-;
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M]ER??2QDBE-3&-,JTK\AX\Y/;*(Y=BF@EIF>,F22H1<$U,92&:*3)C8V1A3
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ML@0!Q6T7O31B_#[@M[U"MS1&W+D4T3)&G)45D&/$=4@[1>\RKK.V2.3MHS[
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MCDO@$,<7<6L$FO&7OXM0Q/#9"6Q^(E[8XG#797)SUX)VY4Q;AF[4%5X\@<S
M23OW\,_GR>L)K$,9YJM--1"!Z440 !>5*M?&M]G':;]B?)X3Z=MW,-8FPO=1
M0#P-)5' <3S)\G,9DZ")[Z(MN0F"??>BAL#,;L;*GF3F0MP0)P&S.]$Q;49Z
M>B7^SG1^^W!L(/!0.TF9-S&-X[8HC[BY>[&]<BXK1/>> A1C0:EAL9O+R9!X
M-N]MJ[3;O<A;K2WY\-_5>JTV%:-SBA9+X+$O46+S=^92\\P(1K;U=I3+W8NN
ME?!H0;<L 1E16F+1S,E01J3+X&VQYB9(TMT+IY5P:8G2^#27GHI[$40C^I)0
MN=\VLZY-CNY>P*R$0PL*YSP<.FE=OW$.W01QNGLQKQ)F+62$D=XIHTU7(DF)
MI^;AX$*L:DO8=P.0Q]I[Y+$B\EAMCSRVK<ACI0.M$HZL]=R [QN%(RL5^84D
MRBN,FXT%!G;CTL[#,G7!D.>SPV!<8U]Z,6SN/;! 17M._E\TT^]>P+CNNJT.
M8OJWW&K'S7G:\K[>C*7A.B!>TAUQ9 MM07'@<3J.D<]ZPA^ER1*;+HY#8=?7
MH%:OB35W+WI;KW5J+6;-5JU:PIJ9@_=;5 '%C]R\3\2_9&@"F4=%"Y;,HTL(
M2FR6T-R]8&P)9]9RG'D>]L<R,G8Q %Y"/CK[(>*>#^)2\^A)- 2UP+Y.([ M
MM#25G+MLT;F66-F:.'3W KDE'%HOO=9Q8LOO_[X3<G#WPK0E7-8HY;*5=Q[;
M.1&W>_'71K7!_8];M4YG2A_/ZW$WZ<5@B"A0C_,0ADZ'DGUBD<"_O'*TY[^-
MP21V.\O7$>$UM>H;EXV[%WAMN.TVR\9ZO5TKL5[^"!.9DW(91T,_2:+X$0R9
M5)C\5WN5:V=^_EM'?&I-K+A[$=9&J]XX(E9LN(WV#!_/>ML=NV]=".Y>N+2$
M\VKEWD79*@Q%'<G +62V395X[=VKW2OANW+SU^2[5;5#?NMRKKU[4902?BLW
MA!7GD,EQA7G*R7;?L!LK]'8O7E+"A,U9:M[C=G/>9LF\W0N"-!O-%K,;_*LQ
MM4:#.&X2SA)=,;)3O!@,1(_:7>2:QKXNIV$>SKP6H]1$8ML)J;A[D9 2-BVB
MK4X  6\ESVV6/-R]8$BS597!D&;["!EMNCA<@I\EIUA>8\XQC:6X\/K0+>/"
M'8J0M'<O0C+)D8UBXN)")-_&\-YFB<#=BWD4&:Z W#@E(JQYZ6TPXL8*P=T+
M?A1YLHC&J'@R%H>?QU2[\S;8<+/DX>Z%/XYJ+9=LCW:U72V+ ><S6&MS9; N
MS3C)@(UV)ZWZ:/=B(R5,.24F5U;'^$?HIYG1<L&9-5O)DJ\5CL@][A+9IJR$
MSJXR6\Q3J#;!+R]CEWH5-HL+1-K-9NUH1O+ 210FXR#-ES\]AS/^O_EX@FN>
M9&),73+$:(,$%#)&;0<8XZC>J!%CP'=EY1F*,3Z-$S\426)_B;Q0]8:=#$!P
MSA/#.#&"9'T)O,/CMQ?+.INC9=7JE:V,O4K ,;B,:O6BUPP%"^G/ [O?[?[F
M?QSVOHLPC,+?/O@?'=N'2VJ$-Q7\)":&$)A4-QIW []G>[T>[!5)I8$?#]^X
M1E-W5\$ Q6VKES@[3W#Y R  J0AD7L%W_L@+2EJ<@T:1C#V&ZKH:!R+A2;EU
M[]!M''CO^4^0'9;;[)L?H;G&Y8B&4_7L1P];H0K[N$=LXW;J(%.\Q#[N1R,4
M)N;KK@7A?/)P(-;P 1K/B[L>R*W#BQ^!>%1#U4#V,1.]$9D!++."4'DIRQ3@
MLF:P3-:/F8 QLE,]R4'64QQDKX*#K*5ST&;*G]J:Y$]M#OE#-<M%&>1DO.5,
M,)<EF2NQF4GD1MN=:FO'I(1;=2OGWZ[+]K9L_Q;XYO,P .W1_ONGJR_V>0A6
M*.I_IU%OC&ICY0W?Y4CRZY._KIGD-]Z/*(R&CW!>4A$FY-'LW8FAM^@]V"Q>
M/SG^LGF$/_&"WCA@>?;%#[]WO430+';E.)R>?=Z\73D5 S_TE[XIFW4^OAQ_
MVKR=^.)U1: W86=.Q>75V>;MQ:596[DKYZ(TNV[)^W 2818E@:6=XXH\3J8\
M]5(/%-M V >#*!YZJ02-XFVC>=#6H<+;@S$]^+1O^R%LX9W?]3%CUWU?OD4*
M[>\%^'<YCV4)<-L\4']'>ZB_(M1?_2U#_2V.OXRY@!7I]__RSOMGM=9"M$GO
MXX)>.T7,=#]>G__^[?CFCZLS,*.Z'V>@8"[DQ07S>B6ODQ_ZY(Z%'U::?OCN
MH^DL0:,Y!O[T8W+\)Y8RI)]RON0=_O8="+,^UB[WO'$BL*^?G\# Y/N'UW2%
MG<#$V.WOIPE\<.<% PPCX$!DS\L?P-^Q (,_LF@\;YS>13%(6'H4AY6>I/9O
MR7CT,;T#H0C_Y0_[WB.%2BFN@$&%2D;H]6SK\D$OM<2$&SCP1@D(#/6O.? P
MW\V\&'$DO'+^\JZ^T$A#]Z.)O<CG[[G:QS-F;GR_B+$72(E/C[^4.NCT[&N:
M.2;NQ6[)O;BP:7U(/M!4CH=Q9!\'72\,O=?LD/J19-M6=38HJ?Q98ZY?-1<*
M4DI7N7KI=,^I?'?=7>C+%T7N4J9=+B/?^&D@2GEYD<HUM><LA*MFJL5KE/U+
M4UTN+_X\N[(O/MO'-S<75]_._K%K&LQ_?[OXTS[^\L7^] _[YJ]GUV<V6-W7
M9]]NKATKO?-26WB].WL$.@7H# ]W4<+JAT=@J-YH)+P859 @>D!K"UZ4CE/!
M/0K@V\A'O#_S,-(W-W>PA,3^6\7^[,6!>.3P!+V)E:8AA:10\8EBZPZC6/&8
MX5@#[V$P#FPP^Z(X%(\)K <.08\K[SS,* 2:T$@/?GI'*A'\/K!'T0,, Z,G
MXR[/$NQWAR!?[_RAC?^1'6K!5.07TR<A2#'''F%2MV-%*#2$U\?8O*VZ('HP
M>L]#%01U/ =U-*10[GM/I4,FK"GZB<SFX)7#9YC)0;--Z(4T><$6:\**'/P(
M?QOA'U9?^AH2G D0/I0!'/HE/NQDZS<44&HBI9101&GTDX3H<(NJ)T8=45V$
M.?C])TB,$>O\AAEDIA^RMID^XNKZ/'=@([39>7]HRT'X I7DV$ 7F 'IT(F?
M\G[#PD228+<UUGW[42B8^O"*;C1.*2 Y IW;3Y#ZP#8X$?HY4AX8D,A$KQ_'
M(V#@A'A+X XG\)\A%JOC'[UH'/1QJC \,[R#+" P0<?#$X2SDVX%3+F@/^$5
M>$RL.4A&K*892_,A3T3_!3\<@N[-? [K@/G@W- 6,$D D[KWXQ1.!4XQ&E1V
M26@]T^R:L+9\Y ;JO1>7]!E%\ZN+W2ND$<6R35I7 S 'H@?<>&:0!)^5!IA\
M;ZPM.4M*$_PT$Q!\B/E3S W#$]S'8*[HKW\/-]K&8GU]JBI<[_Q<<'D55/ME
MNTK1&Z*NQTEC;,J\W9_+)_6TOKXI*R:-=>FKK54W8[6G<%1?:V<O-&UD0WY?
MLI,&69Z,8_"6/KW#"S;.IQKFSXZ[S$.O:2)MI8;=2E:V@K"4;(TKDYY?9>4O
MW_'PTI.V2-GE?SR8D:KZ'K..EY7C-ELX[&7F=LG,2?O]S<C-+!EW+S=7*S?G
M8:F5RL>G\K+WXG(O+N<4EY]B'T;[%'O]U4M*XHG%+>?4CT4OC?9R<55R<4[>
MV=Y3NQ=FVR7,OGG#>R^V_]OW?+&79GMI]MR<@+F89WO/[5Z<;9<X^YL8#&+Q
M:/]9L:_&X:UP[*^5T\I>L.T%V[,F]7PVVMZSO!=QVR7BKN^\NSCZ?H?_Z'J8
M^['MXHV==>=A&-US'8ZJE4=7S<[+OE7OQF;PU_,'6=I^E\F'7!+EJK,[YJD^
MZNRKCXK51XVW5'VTN/*CW[IZ(LO/EC6R=8]/SV_^?N/8Y]].*BM^]>?S;\??
M3LZ/O]C7-\<W9U\Q0W;54[BXPA1=^Q]GQU?7]MFWT[/3%<_@].SD[.NGLZNL
MB<7QMU/\A[L1:=-KSEZCN[<D<:E3_?GIRZDT56KJ+YY.@YJF?*HY34G#6FBF
M%,J?TDPITXHH%C[_U\G)V=GGS^\^/GE9+P&Q[;\&_ZQ6W7<?%=@>JID9#-M5
M!L-VR3!L1F#PLQ\/[8/+D^.+3_;YZ7_)K?-__!)&X;?Q$-[<HXID6,D5OJH'
MS(CIY7]YUQ?^+\?CO@]:*PYR#G=CO5F%0Y5[^&,!(W0R*#J/];'<7?]\6"O=
M[:?W<F(9BUC6I!ZVZ6Q7>_?QDQ<0#M#UG1!IL@W[7;1"]OL]YW[7P792(.K4
M(NIB)!A<?2MVOK'?^9?N?&-RYZ_3J/?]+@JP>%L"2=MG_Q[[Z>,V<$)SSPDO
MY83F)"><>,F=_3F('K9"!K3W.__2G6^]^X@-H:DB,$LVRYAA&[;_J&3[WVZY
ML.%06Z0SI3#]&6XZ6*[L39#\@F^0P)UOW'?W^? EWCOW+3GO5N6[,Q"$I"6\
M"@2AJ[/+BZL;K,,__W9Z=HF^K6\W]M79[^?7-V=79Z?VY1^?OIR?V,<G)Q=_
M?+LY__:[]?G\ZNM&>)V6]+H;+FW]%'EQ'_4"%=;B E)37X1O5S:K/-C,VZ0\
M\./%R \)7)GK=,NOY[?*>^4UUW\*^\[#9L;HIV)P*>I!,(3['ROCK:YT723D
MNB#P*(-9[ -\ $V;6O77$WZ*_G)_?2\;).N>.-J[C)R.WF5'5E8'U# CR>G+
MD;:9'?BF8$59@JPHQEGHH6X]0-V:D1]PU$="L."&0+-FP  %V2Q"TMT.T/W+
M;9X#V<<#G8,(/D"P#6K% \5!5C9[M?P*$,B.QC$LA;B.5ZN?,-<[8O!)>^#Y
M<?#(,!1! 'L*@M2G@O9D!+-))H<818EOHH7+#;">)GRV;.R!0S]'1(J,ZHR9
M 1]EQ)V@+?PK9 ([$JT"02 0&8(@*K)&%M:(JR\"(.RM".$-"(  WPM"II>E
M]-BH2?3Y)":RG5,,RN];ED>_1^A@/HG@?,7A<B3/BJ-Z,V7-S81LL<N.#XLC
M@FJ 8S'R8L(!3<:$RV$P.7 9(K1$R&)C:L;NV;=$SQ[3LV(?)W;?3WKC)&$V
M0[N,F]9-.XF.9;Q!=_X*16H'44) )*&X]:B\4I\+>Q!'PYR\8A 3/Y H*<CI
M"1ZDD9_B8?9\1-M!9! $9X%/^M&XFS+L"1TY^2QVAIBYOJ]>"-KDT&Q'.@)A
M3> Q,<PS[LNUPOL(416U#,3W"9+([HND%_M=DS(5^V8*7:Q^A)(1?MH+QGW!
M(#A]W&R)?H.00HRXPA*%B8+$A$7!C@L643YV)H#)(WQK^OB6C_8G+_%98DJE
M8]<4BQMBNU)F0AZ4E\\(#HPOCTK^$M,L/=1<7K$OX#J=>,HG3XOX@7<HWEKJ
MNE5*WN1PI3('P9X)O@7O:U*%DHH-JA&=EBFMF<SF31J4288/E8PRZPOO"< 3
M3@CK_@=\X5E\X;VW#Z1*08'&3(5"41)K*)R^Q HR>TC1NZ6&H&2;>C\J$C"%
MN$\JG)[E'Y7KBCT0?;R*[40CZEB!]Y!HU< ;C6 I%'N/L3\-?0%KEHC^B5U$
MY)F"0Z6'I+6]T5,_5;T&<=T?]U"WR9@+-L8JVQB\$OK '9JX3#&LS$[,;R4[
ML-Q]$"3V<U!<M('X*N2(J(OR%A[RDBBD#<4+-<976WSK/-R)]$YV%2K54)$'
M![$@,:[54MQ>]1-'C]$?$Z(5:,P@_.#_!C%,A*\6S98)W28&4UMXZ\/M"K]_
M@!.%:Q+A+9Q[XGBY*KQ9Y:JDOHHP8''HL1X01X%-X.+9"A@)"HX?*0.@3-"3
MV3XX^"+S?%D9N>!=C+J+5,<3C.^<]WUV%ZB*:U0ZLP0IPT&DK&+8L4EQ)08#
MMCNP Z$U120^9]G$9?!/M"N0JE)0AA&H((CSQJ_?J4-Y89Y#4FCTP6%S)>J)
M_CAF'[Z'>A\;?;&??$^FG@!U9$OURMFGPS'/+L&0Z2DP6B/?>5*=0S:BJ53L
M:]Q"8[YZ.>*'!P/!4 XRE@=D2%*\Y7R$4;SW^^0R91U1Z=7>$*\J%N*H-H/&
M*\?$KZVR9?&%+$E)6F4V@7LO&'NI'CR[" UKD("P\7T(RD:]KX",,%-_2$;@
MT.L3(EZF 3AHVCX(A%Y,)E^!9P"MYI'9R6'&GM %WQ6!+^ZE(#7D,] 4J024
M,Z1F5^ETEF'6O]&3PS4&STUS0E_]NX_%KI>3*4\K7LJ*7Z=\:HF([[F+19D0
M]YAD%EP$<!9K5??HS;+2<]GH2\1=\-Y]O(8;\M07MY&#W:1\.'NA[TURT^K<
MY!-U&NO:K7DBBNX^>%@2/*SM@X?SA^_64@QP>7QU8Y_;L&B=FG_^[?/%U=?C
MF_.+;V_7BT*+/P?=!,[4YD:F)N+(M=7$D==8(/+I^ MPX9E]_=>SL]64AJRK
M'F)J"42N5.*E:+YRJH>!&) AYM; %)LPSP[S'\](!,O&I>RE!X&.-7QYT"^O
M]2MI%U)XLORU*HK&H]9=YWDSV*:I/ET+OO;=_=56K]*W*VH@<U/R*25&IL,]
M36N,IT[.MG1J)2-NY6K=Q:QV53Q6,HWCZVL2X;R,>6GX-+/.^'.! Z^1<"=_
M7%UAXA83\)>W3L&7-5-]'I7EC=INP86*J>&3AZN\5G#RG5/ UW$*[S[^-&7,
MR1K!&+=:V^B?J2%G%.:-]/H[NR]Z_M +$E(NN$7G7][Y/])?PO'PL!^EA_('
MRIP?)X>WGC?Z!5=W'/;Q/UCY<.\%J,P>IR=>'&,2 !FIL*6P#8+&'H<^OW6<
M ._5G';KR&DUJLKH5Q/\.)5D9<0H%[@;1N7&VJC<=H[:-:?:<A='Y=><MBD]
M<E^N9?#T9#06PV<] 30"-1H3.M*9<J=$ULQBJ16>++6<*[V:;R(]&<<Q$&+Z
M5C=K;:<SQT8_M>!U$.L5!^1EQ#KJ.$>-QBMIM3GW#G;!OH=/HOAQ2WF>\RO^
M2#'WPQ>)7L[T+>PTJTZU4]\U?G\^H1J=AM/JM-?([$L2^Y>81NAC3'0DPD0D
MV\KZO(PS7L63HJO1:3E'K<[.\?TSJ=2J.FZU]F8D?)'_I_H0*.=SBB8TT\:?
MJ2P_[7*8EVF>-Y)B*R-6<YB(WJ'_X_#.[P.1?K'YO]3 [[#Z[N.A=*?.Y]:8
M=];;1[$E'40J@@63Y$ODA<]54:MP95>?MOA>M%5KOZ"><+GQC&\N;HZ_V'G'
MRY;>6\=)(M+D:4GLM!MUI]G:.4UM3OITG(;;<MK5MV2-K&3?GO[A"IGH)9-9
MN\0J3N^S_X/+<D2:;*,+Q>NG/WZA1=#IF^5^K+M'H$?OC%1Z!F5JK;936ZO!
MN&S=&?TEJ1?>^C)G?DNY7=TT%YB!G*V(+YYOLS;9K;;GTL3>"/._G% UM[$
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MS@)JW,M4[+%/$GLOD5<D/65^\3XVK("I@*F J8"I@*F J8"I@*F J8"I@*F
MJ8"I@*F J8!9\C3@ G=.[DG-G9+/$UO[O1J>9SB!ALVWF.,; 4T>4UB^PQ>O
MRKE2W&K_<$S-K>L6DUNGX*SH5<&Q 'KM*7H]%C@K.!X''-/HM5Y5]'HL<%9P
M5'!,3:&IU_+GT/1-[+Y,?9X?W:C% #86N'%$1P$J-A@:/C,O8I9KWS&O?C!O
M9/EL,"9;=T"FKI^2A*,W:PV]5TWJMZ[0] C05+&;XX!C4:,;%+?9C1=4)?D=
M/0F6R%^O@*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8"I@'G*27XWOC^C
MEI_N6/.8'WC6",< ^^BAI$6C3])''ZE*^U-Q!P5'!4<%1P5'!4<%Q]+$<^O5
MK3I1HJ:#6A S+V<>Z&1WL 37Y TJ[T.-B"[KOQJ>^:OG^LE16]FNLM;5F^W,
MS8,4+AXM+F9++C#,X,<GJ8</Q@LX]QOJW]>N%T\F2,D94&AWI&BG1-EQP''G
MF9 [91]ZO=K3N]W,K985]AT6]BDN<AQPW'6"X^Z92*_:+B<347F+BK(.(P2A
M@*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8"I@%GRO,6"LA1YE)TR$GWF
MO5@CYBML5D&"(X5C:I.DFGB9@O/!PUG!\3C@F$JO=46OQP+GPH*W^;(9%^*W
M/'OQVO4>A(9D.?RK]+S%)JA]=97[H= NQQS#Y13:?QKVC%U-IK;[QAA=<S?S
M1L^&S^YL(RU_H%55*%A>%$R5< TEX8X%SL6QFBW:/>Z8U;2J';U9S3R,6J%A
MR=A-4[&;8X%S8>RF/(H-<IM6JZ3<1J5%*A([C B' J8"I@*F J8"I@*F J8"
MI@*F J8"I@*F J8"I@*F F;)TR(+;><H9\Q@HJ08UPP73US3&L->T=M(2Y_[
M%4<[6[$$2_F+(@:5I:7@J."HX*C@J."HX/B>0=PMLB*CL7N_"\7F>TP=BK[M
M.V:40"F_S)8WV>GI3=5Y3R'FAND%L7Q=ZB[JF!+M8IF[ ^_"-JQ)VIS(KLJ7
M/%+44[+M..!86#[DKEB(7J\V]%97R; C14#%2(X#CD5E.NZ4CW3*VOQ<Y3@J
MXCJ,<(4"I@*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8"YBGG.#X8-N4I
MXL]PWU?MSF-CYGG,I"6+_I"!JWG,-G"8]=3P@C>%]BJ@H."HX'BD<$P-#-5Z
MN;.GD-D.QIS5?@T9+4^*>G3O.8>]0P9;2\^1*F=$2"&>8B *C@J."HX*C@J.
M"HX'D/JWH5JV.EFG7M6K594Z?*1XI_C'<<"QD$G/Q\X^5**?HJG#\-DK8"I@
M*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8)YRHM\],]ED2EY/E>ZGH@D*
MC@J."H[\Q3\7E>\7\=QL\:&D!FD^;/G_?#@K:1;@1X6*BJ4H."HX*C@J."HX
M*CB^JZI6U##D"]=Y89Y/>MQOH(:M4=#*E=&C5#3%2A0<-V4E!0TZ/B).HM("
M%7D=AH=? 5,!4P%3 5,!4P%3 5,!4P%3 5,!4P%3 5,!4P%3 ?.4TP)YP@F-
M+&:F9L!?CCD;L0FL@ \W=C3;-1QX@,,"S!P,AQN/7%^--4[ _S.?C<ZL'V?/
ME@EP_*3Q?V$IH^"LWA(O4[&'@X>S@N-QP#&57MN*7H\%S@J."HY%C47F6A2/
M^?;]FU"%&CC?4'FZ9<%@+*?"7:#>E&D4<K.C=SHEG?ZF<'&/N+A),Z)-,7%U
M3Z)F5Z'><:*>$F?' <>"VB'NCH74FFV]V6DJ/G*<^*?XR'' L9BVB+ME(ZUZ
MO9QL1.5!*MHZC)"& J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F N8I
MYT'^;GB>X01A)N2K%3SSS$>%VBIFH."HX*C@J."HX*C@J."HX*C@J."HX'A0
M<"RV<6#?,:4%N:+S5]3X>>'ZU6DOW4Y7;Y<U[45AI.(L"HY%9,^=.&-1^72*
MV@[#-:Z J8"I@*F J8"I@*F J8"I@*F J8"I@*F J8"I@*F ><KY=/?,9X$V
M]=P7RZ>9PX[V*OR2_%#B_S4</GYXXIK6&(Y"3BF6=RAJ4($'!4<%1P5'!4<%
M1P5'!4<%1P5'!4<%QX."8S'MZLC2O).&YL"1Z2]]Q_P>LR<'X_5Y,8V.WNYT
MRID6H]!OVQ>OF1W=> _\6S'RM32(J(9''Z,H4REV"DD/PUNN@*F J8"I@*F
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MVOI!Z!=J,6HQ:C''IZU_^((B@<I^W+'&7;\H532?>2_6B*F PH)BWBB;8EY
M0(%<=Q(O!F,>0+AVO0>!$Y;#OUK30;?66)\[7_Y#VYV6=369VNX;8W3-W<P;
M/1L^N[,-9[66E=0!L!0'6!JZ?0_S)P<@&^VV7JLE=9,NQ3$>!#@+,G[R0+.!
MT-R6.)7I<Q#*FEJ,6HQ:S/&9/DF!BA7&$!,B0H4L4BRCY@E81ME2K?"_7Q<S
MM5.-I9[>J)96.7Q78^DK<]C8"M+U,96)56Y#*1L0J>M]NU=:.C@(4!9L)&T
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MICZ@C_SKL_9JF<$S;J7ZTV<MZ[8^9/)D+7NI5C/Y1=%'J/[*4&SCXVPS69^
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M$</FGO.Q[;YJEL/I![!5U>R5(0TRG_Q>#FEBHICEC-P)TP+CQ_HX2&EE0=;
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MYD<E^L-<BVK1LK]7J.R_9"/N<FZO<P=QZ5$)A39R&:2D#7A,9PM+7[(*;.2
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M=NN?PSA-W/&).!J[]._^;/KE\3L@'?[!7X7^4I-A#ICH#TW21#@TN"<T7(5
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M>'A0<()?M3N/C9F'6R4JG%_3_&^QE0'&4[_.2CKKZ,VI]XV-^Y8,QO3B.R!
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MXE^"A&&@/($EYMKBU2C+'?&&I=>_/G-Q_P*7@^'H62"<X0[+B7W!3X +-?F
M1+F(0 +9B)Z> )1+E,(>MRG@-%"9<LP0+G_ FLHH1W9/:.TM"*W .-ECDFZ7
MI-W"#[9=&:+:8*)# 7T1@#<N()H&Z$U0AV_ % \ &2D*P[7YGZV/FC7FZ@_>
M.YGR8"$2HLEB^L=7U_"H4^DE:"6CP/4P\$,."\!BQ!T?[0G4ZP U?[;@L<8,
MF+Q!J2R L$0Y^*#0L'"8'Y(:Z9+D!Y&.RA3-4;,F4YN\)A3P25(>SRN_X?L6
MMJ7'-+]4(I$4,8J;WNL[KVXS*T?2WKP)<0'V^9;6O08FY@.HE]S76&O$[,P*
MQR<,O$J\.01RSTVI!8XQD'9\O39GQR?[\B@ NM:5WMMBEN[EC#VZXFW^P"-<
MXGCO7\P NZ@-Z:WKC/B'E/&ZR2BV$$\XYY!%=H5;(XQBA- CSD'@NYE#XAL^
M@T4U0>'GO2%?8@M>Q/ W](5+O\4Y.M[(OUD1;P:%>.)'1#QWEXY=SHF0C='(
MF[&HW;!!QJ9@*M1LV2 ;UF/L[,\9X!(<$'9E1HU;2\]%ZLTUKVIN.'AJ&-PX
MH'O,%AL37TGN>,<7 7IM6J_BYGFGM=RN^"-N 78&J]#%^0!"5_B^.1<VQ1F@
M+P5].70.%H8JPDN8X=D69Y1AM*U.V-U K0YA"HR7=Z0VV=B8V0$Q&SDRHI/H
MT9J!,  U;&I8W'>PA@9R5#<+3XS$B-N57IA4!%] J0SSFWI;32*;1PB0I8;/
M^H2]IL2/E$TD-#0C)8X_(,)_# "LCC$(?]N* (0Q[^VIR*A' @$B"LVQP_/L
MK+_$F0\(I2VR'%;<7GQ&0S?,:,"/#]I=_U_]K]^N#C")81T$9,+">D@5J0E\
M-P#S$]G??*003$D9_PMG"<J) CQ$!^1.DFJ& 6ZNEDZ!?N,2\YK_=B]_"T.*
M\SY_@QR6(%0LPX;G"7L")."(Q6.'E:78H1;%#BEB*$?UP2/0: <]W0!54ZPP
M\ PSMD[A1S6>X!%/*'&,B3O+,L.@ER/CG^?.R5?UZ4VK66:G5T]1GI</N!(>
M\%TX\X&_0YPS!02?,,,#%9P1')F_H"5EV':.E%G:-F66W(G7KMYTJY4L[73-
M)F/,LP"]1>(#XUZ6W2]8LL-O "?[FJ7F;;3U5FH")IST&%8.7QIVY?]O[UV;
MVT:61,'O^!58[_1=.P92$WS3W>L(68\^ZK$MC21W3Y\;-S8@LBCAF 1X %"/
M_O6;F56%-T@ !$A"THVY?2P21%5E9N7[@6F'(*FVL/7+T+)K3M!)/4&@STH:
MR;S&J9E-X2MH2+_8<R#GX>(9&-U/#P*)% 0^EH2O"YH"TK(K3%^#^^^(1?$K
MBQX$C-@\C9E8/K[C^+T03KG8I]Q5H=XRJ00*_X(\("S:'JJ/C/V8X1^N!T]3
M US29Q: \"?*MH1OU^!W@\RNJ#IVQ?PQ+V?&>"UG:0_3-4H_6H>38&;^/!>A
M<?O90$)N-,$0+R:;.SEE<[UI/($KI-,*2^B%8UIC<P&(N35FE.D%MT-)*-!H
MV1+9VM.I2G)O-GMYJ.KF1%6]B1%'RSOXRT^/6ZE)*4$FE=2D+L.:U+70I.),
M*RSH-].<>-:54K/FM(;GE<B^+*8VM8<9W"TM/2VF(7U0JE"1-D@PE0K2&5BK
MP-1%9_6+*;D(+HUGE'JKO*U5*T\;'"6'\I3A'4ZJ'KE5#:6PJJ%6HVHD5 ME
MI6JA9JL6K2I4"[VUB:=_$]U"[VK=XKJ%<-\I.D^6[QRJYW0BB_'#^;_.H 0X
MI4@<Q62T1\-Q!/7XQNH:<)7-I_J3+W5C2U0?4](-S[!?G5G5U_K]Y!S6U=E1
M(J='I-?+677L"7F_2RK".,?0>;U58F8DKR02*U$*:X[4U<%A+X46\*K1MA=F
M$+BB\82\]FL*W"^:TX[.X)>GQ/1R*C$U)DJ\Z9OY4-7/B:H:0^V\'N(XE+Y"
MCFP^F!PTON:.)%\'U$%.X-<;/17*?G>]KJ]<!VE OHX?J/]A1?3Z\BBJRTNE
M&^\9FY@>O12+,S"?(2S0UK'X#2;7G(@ OYAYC[W)UC1NU-J#@388) >3^I'^
M@)L80N->F^2LMTI,516Q-;$8UU;R12KUI*3Z"3!IF6 27(O <"R*%+/..(%0
MB3!]&U28 *=<SB@9!$"QH7VAMS8*XW'47DSA?V$_A-M5B-4S';)^)C8F_"]F
MH!OR2<)W^%_44TSR/W+%FHD<<9XF9XO5966]&]?W\"F&]R%ZS;B&I^6BG0TZ
M\@@=#G4LKLCQDK\UB?):K]?/H'_^D)+(R>;ZG,D+KWP8"?4UF[B$TNG35X0O
M+!?P9^T0PDS(BZG8R(5SA1F,%T$>V$I0Z:VAUM.3JF\85EC\OC:W?@\%W5XD
MD/??$LC3$L@';PGD]2:0K]//ACGUN,$V]#@]A]-6 ?6L8K6L;/ST7*PF]<EU
M?IA>+UT@J2FZ&.H<">4EC]*B%%!:Z@X<9_@^"VD6Z[Q$&P3LRN@40*)Z6MY4
M5HE7NCJ1ICDH"8VASJ-OHBQT!YH^7 F#)JH)F_'144X^.JPW[S_!,JAZ537@
M!1YWP8L<3L6CZ>SJ>[W]006\>/<A'Y_,\_1]?>0==%BD4$?4SMH+Z2W$OR1+
MC)0+ &_#Z)H=; *85Z!_\VN8TAR ^U7(8.'WTU>NZ>TJMGO#\-HX>"ZGM[53
MW(A-]\2'7#_!;LD3J^=PQ>KZ88I]KH8:"+C+VW_)TJ,)8II"#R_O^NBMG/=G
MM+W[(QDS4;[PY\MB-+A1"^HSX[O)W_<^<%>YXE\C\00%@LD=*).DQ2?<.*?+
M]AX$Q81-38L7X7CI6_E %Y'Q8#*\J_>QU5(7A_-#E1DN*$G(7>$)K+G!BZ>$
MT[:IV-UT8YM5:>1WZJ778K<L):)!])M!I++,?J*0>(=#O0\JXK#&A.*?\J4?
M*.^'^OD)H#\RK(Y&DPD[L/&:'3)R#J['6*+DJE_M"9OY"<:!9N1@D0>><FJ8
MHHD(>L05;$?D8 \=JF"? *%1 1*%!E_>A=+S)K6VMJ'9MWLY-/LSTX%'C_RJ
M+D3MGX;Y$&Y:(.I1I+Q)NZ]9;6V2!)SU!D44-RW'/!%C3<?&44F7J%BNF@">
M+S3\&Y'*R^A:S>V).36QW]228,-%^3,Q.HRCAYG=TJ*+RCM6>>8LDLUOWZ(%
MYG*E3I3(44P<;IT$<+@)%C5-2->4J=3/1]$*Y,1KT_J:$E!6?AQ3D&RZ=,CY
MR=E6'F3KK1+8EKI#&L)EV48.Q/</TZ+X/N*+LU EBX7BCSC7X3<AQ#AY(242
MCZS\?8',,W=%0(TE >MBB^H9C6&"V_!RHXQZWO1/?5OYGWI[G2!3#-5W41FK
MG%1%?%1ZV2[&L;#;.N=4LBZP,N=4),EQO7.J](GWR#FE;]#+;7?.J4BL2TF)
M=?F,)T?4JTX(;>+#&G2UUJ#[YL.*,-&\&=QZS>,(5Q/;.GM<B9FX-=CCB4VE
M6>9*MF6NUFV95^W]JB[3T'<7*#&?5NT. /5U.0#R9C+JVTIE!$M-76.I*6MN
M/F*Q@*VFE\BIW5=;+8O:E1=GJ^6CVCH'C:3/F,A(P56*\=MB.D[0!/KB$631
M9[YD;J6^K76&0VTX3 89-)28CBQG <*TC)F70R_?H(;ATE\.2U NK*/) QYF
MS6R>#NY_E)&P[C=K"24_U]IP:;..&[H^TKK=%*V32RQLB&LG= T>QHNE="M!
M2G=S.V-\0>"!!O^%N2YC&_3(6/NB^KMEC/QN&5].CZY/FSCK(S\ZI'NL" +K
MTS&6CCIC5+(IT[E=]8XWOIT]JQ.;7-HB&J5(F3@V/4RA<_@<<VQR] LW]3&3
M3./:->KMU-<7KCF^%GE^Y"?4^XAA4RDR%/@D")1@%N<IE&K[8)@S0P3,^3[#
MYH9"RCU:,& W+VR7VY[RI;)'MBR(X[HL/,!?)(L1#]4_&8XIXJK!BOW:R7GM
M-#I)24QQYT85\%=:R>5&BMSX) CIT^=4"H1^D^B^ 3JXJB9B,/ GWZ,= "UY
M.B7H7!(])+R&^5.9N XD[2*_[@44*GLYF^!O5.JY&<R2HC$DMSC-FS=W5EUS
M#HAQ_+(WWAO,<.G5M#2-84#?G?\L*%>6/0?&QJP'T[$M_.$^JE1[D?(Z>$MY
M34MY';ZEO-:;\II?*G4*R[$ZPPP@QV2_4J;>,V/B]Q8$S@F[,'CP0+T"9CJW
MK8FF_&'B:TV#NOUB3T[),Z-UR6N,Y!+F";F#0&_G@$MWM/Y[3A48J77_+AZ-
M>NZ(AB]\VU1]RJB/P2I%DK8<V@C?Q2G]&*PW7W?NQU6C2*H*O(Y9F*ZUCPR\
M*@KO%J;P&EV[H*1047@)&BW;T7$=C>*\UIXV3*DS"],HZB2@P^'-Q#(S*IJB
M_H:JNS#&U(C@*QKB&.C[PV2/FGH,9X<]PMTL1=_=7/3=?:/O7F'ZKM';>329
M4+-VM#NTDLRX[/C7',RX@X6#672N()VC,IT@;#9[,&?8$AQA\Y?M_"A%T;T5
M%.T;'V\T;8?JVHO<@MI@@6/I2$4E^">-QVA,7$%KR7$H?H40$,D/,6OU!>-N
M4!AW-1;(_VI^HGVH5%',DX1>+.2'A2$_>+?.7;G6YXB O4'G3MC32*/>@?9G
M,S$PGG@Q_HU,5?Y=& >/YL2[QT=;/_FF,+DW%B[8@?)?[VC<O.?(]U/R& @$
MB2YN$;X3]ITW"4^K7_49+@#;MRB,)BW1J#U^&[?'TVQK@ ^^)GS\@ZDQ-V?/
M']<!@)YUS;\9AQ?Y7O\"5O/KK?/S)^44QZ/R?THNQ8\!K(I_C/R*NV5Q!Y_6
M'OGE@D'/ P;XCU.4F*H[%,H4VY)]MCP;G9G2>PK,[&->)*8A+(P.FO/S+B_Z
MZULA-[3A[@-]W3E@;TSP_MO.1_7_/CX^/3T["Q A7R%XQF (+$,PHX,9FP+'
M&:&7B+9I L4@#SH8$3%5AL&+!8U L>X"51'[2J0A+K9=_:=4<.6_;Z'W5'>>
M_UBU\]Q[0DRD4$>%W*"FT*>/3A)\IQR9J[J4=$9];9@R:&)S G@CDYK)9(-F
M-@7)9*B/M-XPV7>D.)%LQ$ ?[TV/)=GGMEGF35S,Y99RJ^BK2_0UL9?8J'2G
ME![>24/9H*_V5\7Z<JL9;RC>$@O+@>(B;"N52?U,1N(NLD,R;/,Z3?-18=.\
MQBX)OE/DTN:C-5TQJSQG8L0+=Z/XA?A%T%L;,*XNODLG.A^RBJ$7_L',-&[-
M&6_HB+DJ]M)1[*C)P2L%_(Q8D7,O.Z>Z]^CQQB)0RC-&D_+E8E4OGK'5VL@]
M=CV^9Y/EC%U,+S"MZHC0=V1-Z*\O >ZVY3W+=)A%'&N;>,]"DI%$U2-#@8>_
MF4T"Z]O/R$ YF6Z_K'<Q)3)?A'2,+IGF=0JS,W('J=PK%MU_ZF93UGC7V/-'
M?6*"L5<!A!).,WXWY/)E7$SR=%%LK/BSPA=O8G8Y=[?OVZVNADG>[5[OPSH+
MK'6HMWNFY5_903]F)N-CF;1&]8$HZ9=2GO@YNS,;$Q:9,X\3@6]K%J+@W%0;
M>GW\&*1\1S>3^WVC#.]!Q44*%,KE59?3[RXC.KZ^MQWO!B"9K3QW-("8UNVE
MJ<_%H)\&M72.]'KP6#93IC@>NUIK--#TE*ZQ5>-Q$Q[S9[IK9SW7Z 8>&2?!
M.=8)BVX9DNIF6,Y%R"CK'7E(IVS%/0$I1C]57/\4H.:_\2\"(V6S@8IA)/]%
M+H&1>O2#/+I-QDW/(IC5,;L"+]RCS53(.#^%C+8]/.E>;68G.G%R2_$(;-AE
M(C5?%^5\1/4M!L<$#]R6WAD--(6(,X?FHFNM85_K]Y)EL?42W<; *JO<;08L
MO=O3]':R;_7.>%'!FY"I\^>Y()FF81UV1%X^5>Q-.[F&7P!NZPAK..QI;7W]
M+=S0^'M9F*J<!ZS'5%L;]'O:J-.I!U/UBLM"EEZ4#SR_2*.B[%4G"$6(YWD5
MR8P&<,$'ZZ7&FY57]D870DA'&^F@]_22K30J-/+V+JQ=;U2M1!^$.AN&RLCV
M#:]DMR;JB6AOI5[1-.A(G%N1<>Z7'M$N7N5+W43+QSZCDG9-7Y(&Q#O+R5V9
MR1A/9>3<XT^*H&&?*E@3:\H=-C=XXP@N@U'EQI;QO!O>!U\?C\?X,WW-^5)(
M"X<05OOD4\FE$V'I!RX;?YPL'3S7:LJ1,#KB(+J2$*(O\9(#,VD?#EI)9ICI
M?M^YGST%\[(''^_GL0[/-;EY\FM,W0WR86,8E>P9N;,8B+EJ&N8PK:?<>B/\
MIU<MHXM7P-?9W?37VT]?^1 <DW?Z"24J15*1ZNT>!=N0>!(+[00WQ:NWZVQ6
M*>JH5"JA2J8#-J3!>E& ]C:L@L0%TET+SX+2GYN8XU6'S@-4U*E!74D8J-O-
M LE%"I>B]OMDR;[!8C<T?.RKC6/'5GJ>VR-MV%OO=MHO#8>W,=@3=:4>)"*C
MO'FT5X98X*:,4L8$[E,H+15WO=> NWN'K2C+&N@MK=?=PXA/*L+ZKP!A9_;2
M69'!T>YHHTX9XV#'=VU0-^I"C?/0\#XPGP[NS<F$P2/\?P^F *N#P>C=IP.A
M4>T;C6>&+V^PZ1N-"6A^Q"LGGH:M3#PU(/04C3+)?CC-2;PHRKA612/:_9'6
MT?4FB!@\+G8-7GJA/N,U,Z[W.\'==TLZX]CD]&D,CZ[M,#\::-U.&4WAPWX$
M?P5K)!R/EXY#W?!M!P_1>*Y:.1&E)!*X/O$<<^BM3[LJGF>:R<LK(*(J$L3G
MOD]/4R=+IMZR9QN;1%J,PA<O,FJ] 0^*4= 9M?O^:EKF?#G/)3[*IPZ5"&87
M=&-OS66[?QV_AV\=O],Z?H_>.GY71.5%IHL<^Z,-L>[XF+Z[P[EOS-U@U$BQ
MM]8_=T1O^1'3XXNO7\]OOIY^N[E6_Y<Q7^ GWV[.?SO]=GQ^>JWL)J94Q6"2
MDIB4V3FE":'FT;Y?S#$V1U*/Y-@2/I?B"[Q5_6):$T/];N'P<Y<2$>N?\%MG
M4+ D#CJ;H;#>H<!?#6=\K^HTV5X?:C1Q#6?7LXD"Y_]].7M6>>BPQ4>71(;=
MJU^^?%>3%# Q'3;VX)?9I%!C^]Q8>ZO68<^T:LK?*HG1[F8$46-D_W+IX'1.
M3X[P"N%7\?%+A&#?8E-D,:R'/8UG2Q>'53KV,XY@ SEO.)CV\F@[L\FC.<%T
M9$XFV%S9HODY.)@''1&S&5#+$@R0A8/Y,MZSAM-_9DL:0[HP/#XWQV/C>PN-
M(24TF @^=@QXN<O&#L.G\!6.R3S#>>;ZO_PEF$EW\.(?EOUX<&\_:CCNQ]!(
MWU_.#+1X' -'#+D:;<]=@-(_A>6HN8ZFVCBX3K4=(@#'ABU/E-MG@@\\_C..
M&>(#H4WL[S*=@BUIX,0SG#ZLBNG#^/ E'8>6N/&WI5*18S!_&+^E86I\SA V
M&S$6S]0@QIS/EQ8[F+.)*29I3&?&?$XM_96)Z?)$#%KUZ.0<WM@=MG\)0>"#
MG SM DX<3M/XWABRU2BR\\R)WL"2"DV)ILXJ?%1TWB'(O=39'.G#H@&:<,I7
MS7QZFS&?&E-7\C,?WA'IWTO3X3<$)V49R%<L9".2TTP9DPA7CV:N33^E\8/X
MYG535_OEZ?G&>&((5+'Y%<D!W5[&;!E3R%X4O*(SE'\;U+DY8T#/5N!]IR%?
MH7/S86J4CX6S2N*PXE!)>0^N.P[&QI/\EOWO)^R!S>P%27C_E[#0M625.#!"
M2<'.W/C!1YWQQ+#T$X@]?5R+E\$&@R])+XECA_K*K_#2##)09$OE2>96_;)V
M[\-M[[W5RK?W[OJ]C[:\]]ZZO<O4__XO)##7[+^]R<#46O8O83\@D3PSV5+,
MCZ[S"I!\E=[)&_MH3-?T,PYKQI!*F7N0N,OD/$[<#BTR9<-GP\"VF9R'@N-;
MUD^^+75^U_$^GLIU2,#98(F K)/C;A"SYW,<L,DF5XR^?<9PRA77PTI>M$/U
M^P+V+P%#^#7=X,3(JVE.I^%/W2%?.W!>4(YO&7X.3%1J:%&(!I '^1:>VJ.
M$9=4\?BT2]' '#D]!8HFJE!C430X-BC22QQVB4GZQ/7Q:DW8E(F)W>MT6)*Q
M<U3)<1!ZP/"+LOFVOLFX:=\^"/8'Z#T!C?_2L3$@F*53\KRAC(MK>-S8H<%9
M06JML)MQDK,Z-1&#(737>,P5M_@W0.0*:NWG.B G-CC=R%<FI%17:/II;J(
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M4)#D(LE!$PE0/GF84R ;KH9Q#R]0%$9./9F-*U(8,4>?JXV_B!PB>!I]MQ,
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MI6=OT,PA':VA\/'GY^ 1&5P&?7!R0;YM]S?<IGMN\3N1@^YUK=_M9I #JL$
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M%[L(_N47/*\([ZU2%42<X#4(-;_W7QFVNB/F.#5G5'DR#@IH4*V;,!?>(OJ
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MF["7Z\;J"[>B]QW?E5_ETE8X12@D4MRX>8QNR!#R3NF_GXT93;W[U,MA*I?
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M/MR3C?<2&\]-Q-M+LUU!U _V#. Q WNI:12]3\KY*E+YPX?P.N5"3V&)Q>1
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M;&U%7F;G_ZYB#ZW#=L^T0+ND./S"L1],%Y&"\<\T>^WEY?V7<+@0Q1'$+B7
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M"#J5*I@J0([(3B?LB*R1A%>@;.>TW2U!VYT=T/8WFPB:^*^D9A ["I&S*#U
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M!.S21]OY@3NBM]$(WIG);S1P%V LU@%PE=G2)5^FX9H\*"QJ>8/E06]8V%A
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M!Q^_7Y_(E\BO^/;DI_BNQ'O=>\-A;L:KQ7'ID<2[5[\7]GO)G-#;0Z^?F ]
M43& XR^_+>?,,3Q;5HT4/6L$_;$7)A8[898]-RWQ;<:"*R&0NF3LM6%T^^=>
M [L%O/W=ITQ\X->IIU^-Z'_/W_E;CKUWZ3D?X?N"*';_/?52M\E?-_62FXR]
M\&?SZ2, UEXZ8^;R/^^9,:&J(7@4X/5)_O?6GCQ_@L_NO?GLT_\/4$L#!!0
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M9##+T1R>@.ELU)=QG]F"/F;M1\*(LA.:0":M$CR1>0_1PO4Q03L0L7>0^AW
M-9U@FL %%J4[GE^&+:Y71-;AZ\2U8*G,@1P"X0PI$4 -<UPV<]=EGB+*<2?1
MC\QC523H$VB<@T4$)$NCQFP ,!$/B!]*S8!>8LP^&!I<0LQ$QQ%9% H&0+<&
M!/UPUOL3<]MGJ=(C.X&^$3UIG>$8B-/)X#>\C.80;"?.//)V"^(58?1NHR#N
MW+OCOQC[I= GMH1I*>$HF.DTE3C<L;L>#FW&C?#  Y!D5PD""!- >U=)VZ<6
M9)8AEE,\I^-$VEAI6Z =17FC54#@P.A8)#AMV0X EP@@.*"J=1?W>=X3K(D
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M]J$YR""2)LI3F&7H#D_ =#;JRZC/;$Z_9OU'PHAB$%I *JT2/)99#]'"];%
M.Q"1=Y#&'< U'6.9P 4VI3N>WX8MKE=$UM'KQ+5@B<R ' +A#"EE@!KFN&WF
M[LLL093C3F(<F44JCS$FT#@'BS*0+(T:LP' 1#P@?B@U WJ!,?MH:G ),1,#
ME\DB5S  NC4@Z*>SWI^(VSY+E![9"?2-Z$GK#,=$G!J#W_"R/(=@.W'FB;=;
M$*\(HW<;!7'GP1-_:^SG7)_8 J:%A*-@II-$XG+'[GHXM!DWP@,/0))=)0@@
M3 #M725MGWJ068I83O&<KF-I(Z5MCGX4Y8U6 8$#HR,1H]FR'0 N%D!P0%7K
M/NKSK"=8$P'T-E>PJ![QO>KQC@A>5(_C<!4N)>GL+""?QF<49><($0!*OBP]
M4?)@H@03T3H?TP06I&=JBZ%?\6JTL0;Q^[_1N2\1_?OJY!V^NTEZG@N+H8%2
M+SN^3*$R*:*(YW;Y+B1-N@)T*&8*8D?G!@,@V ^E]2D$5B+SXU!!-TL^\PG,
M",4]OPJU,^,(%%:06CY39F206Y(_/M!8KY5\'M%68!Z'O$6+&7!"5*XXI3]X
MZ\>>R2CT"*)L7DOBOZX@0V0H]!?Q:\U(FTYA*[NR1E9U7Q&KEDX;3\BU?,)9
MFF/@Y5#&1!UN=<8ILW(+VE$A0GSB)IZ0 &R3O"N5=&/2;HNF):9[OG@J!)(^
M,)TK9'P"OR\6-,C- %2T7FM&$5* =\"7-#V104(J,!)WQ( D()F@7 NL@XR5
M ^30+>]>'^^BC?*N->0JYTX$4(HD0=4BAX"375!]3+7H$BDL7"XN2#S-T!&U
ME0UE3U?G[GD/EDFR?&HMJ*9+OES;L^ZD6O210X2=@#\G-/B6*:^.*?%F,U0
MX5,PT\%84:SX.PL9LT)>(BVGHR@W!-DYA;5@U%1;AW9ZG8&Q+!XI^YQ#H&'H
MG6>Z). >,L8CZ\+Q"(SP9WK9PZ/?W>!5G]NIRJ1<X[DJ8I^$_7X4"7+,E+P3
MJCC@>V1?_NHM>H&?V\)N@X79\8]Y;.+?>\03=I=G:8&RU#S#9AF".+*"1GU2
M>TV]XWDLG39V*@M] X9,4^F<$"_DX*Z&\*3[L81_?I =\! ISU)*Q5^J B?!
M0WS.)=SW@2+/(G_:N+L]'=F>CJQY^J9"!8/!)4A&!W%TI!=) 4H4FG!Z2C$2
M_(Y$7JAHO,SSM9A_@30Y$5^):,7)0S@&79"*>(R.5DPST;.D+"HX= &S@*9R
M4)H6Z[9Y"H1CP7XQA0)8^.Y@JR)?IXK<[#E'$V(Q,8CR9:!5^-P$O/O7E 4Q
MRD%KR6RHU5"0X,IXKWC;:HIT)M*!TF.!NZ.^#@F,/Z =:+(6-;J_S1#+9XA?
M#MZLM>  (&JL.3!2L>JO979X<'CT(G2+976U<SJML:[BT1VK[A]C=ZQ6,I[N
MPKOU.EIO-RJV\N1[HWJEW?BZ^+<P3JQ5,C[V^#5[>]:7(F$74Y)>!R%;/R4_
M=V["(1_:9Q:4HIJS<\"BP^X7.#W/ZL#5/2RT1A]Z%9<3A$W9^Y##]"4C?<$8
M/FFD+Q__!5!+ P04    " #PB9%62Z%S_Q0$  "A%   '    &8Q,&LR,#(R
M97@S,BTQ7V%D:71X=&EN8RYH=&WM6&UOXD80_AZ)_S!"NHA(YL5PN?:"#\F
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M=E7M>I[ZN_1W$_!.459!%@ '!P<P^_< _JX"I &HR,@HR$BH*"@H:&BHZ)A
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MHUR,])$>;#BJ32..S6 EW)0'5]3I-W1H1-.ZH40_<>07^00<&T"8$&KM5<$
MD[G_(DH*$G#%)87)<&T'\(E9I&J&^T?Z3R4W7GS.W!R$*-?55<I2_*0?4JHA
M?H-"/]/?U8>_7:EV2I[J99)WK1A7];'IRZV1WR9[NMU#W529!"T3 I@1AM?
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MK1\<2VP?SJ\#N[R"T!=\/])?T;EIY:+5]+MLXGZ6/OR??_[?"(0UYAQ6W10
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MP<B7>5[)U\OFG8"IVD17LQW$>PZ=+(Z^0(.S>.\[V!?<K*^UD"VJLWSRE-4
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MVNY:.FOOISRK!;3/SZ:6N!-5#0X5^CBK$;1;P =:$5*WC#R^MNO";9'\I-$
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M:<DVCE9I)UK;5AX!]:->&%(_R:3VK%T G%/2\=-CN.J')<*@_*MW9$A# 7\
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M NQFZQ0UQOMUI[C\]7T1FG^]%#YIX<IB67MRXD%G?3&.R?B,MT,K)QT&N3=
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M]L0$ZZKBY:YR *29F+WH5OGDMEYE0%I=;Z3^:"72TADV\)MMZO*J<,?-*79
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MXKJ1.5.H*&BQO>YJRR(/D*MK5J#4D'ENO>Z_UB#QK<LI5)?<&F+FP;\N4EG
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MN)8BT.A7C-Z'G'"N352:#%8-P612Y,T[XKZT<YJQ]IOAL8[D\J0V=NX<Z7P
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MA-PWD@9!)HF3?O55=5AYY(&L9J2,CYLG:2=>ISOL8A(T,O(J)=BJ<UA@JUV
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M?+5.=4GI4045]PRRJ*XD+8[^6K?;R7&"O5=7E+IRJV@ZZISAF@/#F[GDHR7
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M6OZDO\+G2O9&J<0PPXX++0<-?2E\@KABG_D?LD/.GE0;B<^SQ*)]C*O141^
MMGP(;2THG+?C[7CRQ1_8D6]I%@X0'!.\&>?1R:$&M&"^Q..!9+W(N#!0 %;
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M+FR=6F:5("/#-R 4\H*HZ7FA5&02$&,:?'@AJ$%+O65K,C.B$=6A(:"YQLZ
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M!M2V*7;Y5EV!;LBE/9$U#4(8G85E'5?&FNH9 &F:GXX&WPB";[64GW#STH+
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M6+@XN!1X>!3\C#2,_/^ORY\>@ @3-(3R' QB E"(0& BT)]^@!X 0&B@?RK
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MO#6V?,DTCFJ.>: U4%;KY^S%/ $M7'X5)GH]9&)T&1>@T"7_*X8^98Y>->8
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MKNH.%CEITX^/#JM6#7DLA+'3LAJVM$7F >$11"N"G6YO6+H;*1DB@S,X*)_
M2=VXGRR$=C "+^6)PL,72I(,FD-6WB2#DL?YVH.TT!P%5\+]6%9=$F!9@>S'
M'.R"-;':6ZFBI:F&ZR-Y$*G67"15QL>L]B96"A[L\RE58Q]JAYR,U6,#;*7U
MG3#V%<=KW[/E8226*J/RVA)5ZMFHH]M6*G=\ZL#V6VMD^?U\RU*]4<*D+O43
M+^6K-_5+PUXYID[UZUXG,I!=)'-[HNC:(I;[]F:CD'"!-4MW>.E+S-%"C9&Y
MN[DORYE1[C QL(1?*'Z(@!I=A=/HD_,PZ=/O7^1E*%,=KCTG<?AYS[NG!/-]
M;W4G$[@0^FO/Y4&7;$P-;U31XSR%5PFE/1;W9.:.XM>U[%#S,#A[I=-!::'V
M@5<3@HU5WK+$U9XJ]Y=DO&J2C4,0&662V@0^C%WIO(5N\3<MX]4I'2RQ8,Y>
MI@*6RVY#IL^O\<D]-L-@8-9=I<[V?/5WO(ZO7BI)ADF #";?<*X\4S #2QS+
M$6C6J7>VE$11CWJDM%L_OX1L5)F\6C4K' 9[;C:H C8+B^14P7S2 QF4\"%U
M[$COSYEKUJLYY*RZ%U5N/H((61I5&TL&9;KT):'7CD<&(?6%'8IR8LQ:X!:C
MAHI8Z#L;?;O?>VP8[H65+,V=]R-WM.^;M8\I.+LJWC_Q,7W&;B; 9R6CB-JJ
M;*W1,A<YF;OX6LY3AB9%AD09==9Q<'W#0(3];;KT?,'OG, Q[)P9R>Q<!N53
M^Z*:3;T6?HKK1@NY5LA7$ETS,V6WHJU)36Q@Y+$J,$#EM7+2_H;4^DQ=49?+
MN(N*$7E,K1YIJ[*3G3I)'W$H>UG7%11S;/F(<A74B[&(K!0N\L*;4_/ ?I71
M6EUT,]11B!YJ9Q9J.P#6^.#_)3#K7B_4;G5*M..UE8J- 8<XP!&BK.,L5G=4
M$C/"=12Y&:[Y</2I6^%ZS?KREB9^+L18,97461/@'9_H4#D:L),O-8^KL4\>
M5. G"Q 8BU@AM7'VB%/,U&,R,+"DBO\*1N1+_+YJG14FG_R.!VB9$\NU-:HQ
M"?)OR0!WA><1JIUZ4V[#T[TDKOIH 6P8=<^BM5OS$I+"9!E2>H=,W*]:<HPI
MWV1HV63J\$M5HN07E9NM:3SBZX13*')Y;-,?&)_@MB[&V\0,S[S2IA=-HQUR
M6DW3;TU04CL3(6K+H"O/O\VHM7$+C@=_I'FP;<J%6_585ES"[&5-"2\?L_-X
M@SG;'WZ5NOE\>_H?F[G'HX0\C9\@ET11[Y"L%4[G7+*31AD&T&TK"; ,Z?%%
M6_L"=_U\3RPZR[.36WV'"_@FX@87L>X=-E"P\;2]3NSD6VO.@KV^OI9FBS1.
M97U<-1EN^S"TH ZP?^9(X,><U($)"U=N?\BYS2;! 5H]]U8=6*L$ND_2S.)9
MQI@?W<4JN+?3T.3/N[9(V"HE-^$2EJG<O O$U4*C]*Y"NSACYAVC.>EN^@,0
M;*P7OU;N3)7#8<3A3;&U\D.C_X3F-!0"63@;(3=JZJ!^25 F2]< :HLM,R 6
M/[:5?5,R-XWF<'&0W7 __1H*9'I1BF8M)0[6F_<)'>=#*A/-HK #??:>A!C,
MV-BLC\N@;L"_7I1/5:_(LF6<#P^\?!/!0#*;"X0?\K F7C0J!(6U@W]Z:(5:
MJZ:-HO(.I[YK3$F"TLT'.V5^LHI,G#V+'AK5+!1LJ%R)(=9/=GVNFDH@6HC3
M V"TB+^S7F1PCF7T25$/\MQ^\=3IEQ=TC-G)<V3QM! [MY2<9("P[9X<;5&4
M2XJ3?Q'>U99L5AM<NJ,8\\$?2AOB7)AJ]$WNC%>?%EYM:/+^32T[8SJO[W*X
MINZ>#*1P]GBCW?1=-1*+-M[B2HJ= >GV2H+Y\SES1,1TXW =W/WHJS^Q'Q;S
M$.;[<XW6.88.%OVWO0BT*9V'@(W?7/AXA^6<2+OD%4?"9]2(V=,*C8K5]='9
M;C7J8 1AWH5D[H)I.YTU]FBY[+S7!.>J/$ED@+[9%6L88UM;JI3<CB?Z"# H
M52/JN,B(EZQ/1/GKB\CCOKS- Q./]0'FM'K?FR>$F7L%3L^[7[&O?\]+!DEY
MR) >'E6T-K?K@'Q];2@OJQ\OS<K2=C>J3HD?X]*V]_G4?>3#/ED7II.W1S1(
M_2(RS0E?+PR3N\L%QA"#5Z9J0>Q61/+4ME]\U:R::[G&A;^J5YL)$"7VS-"5
MN<UTU_K"0G+<=LJ"5ARLB+N_-[8IL=4!*@P)3PR$=/?1;)XYMI$3KQ>#MB>K
M>V./)0QRUWON/#ALHV38<FV6$VJ%S\P$Q[8'I:T(5(%1<PYC:SNR;^3F76K"
MWY9VZ55;IY^:K9I,<&D/;8^U5XJ)#JCA-[A"9>)7F O2=0*8ZEC&=;J81*TJ
M4,'(, 'NYH.8!JN,ET?$PT-+5(F<U%UBF1M0XM_;G_/#\O$<5IVT3'(D9R,3
M_"1\Z>8.3+_7URV818X> _D1"V%\47&>4.CV!FBH:M)#8Z[NV$AHM3$FSD41
M_*;]GBG(H+:SI5NGV89O6695W,O@UQ*BGE+UXQKE@0Q-_V=_!;*QN):LK72;
M:(P&H18_6Z:5Y3A;7-=5860@<J#*!![$W6SI1=3W40;/S#E&5Z),.]Z>K0RP
MDG[M/7P53CZ6ZL&>GA]1+]U2Y&7/U?G*"X9F0!:?=F+P8AZ(&;4UCZBQ+U-8
MSBB>PF7U?B0"$UB$@/*7]:?27*G")-MSJ/-W\CMM/PWXEO+8ZF,KMSA0?R<6
M"K QZB-&US33S3U;X_M@@T%)<W59B-L_ZZ:XJD/8;JQ6,)J\Y\>)RTG7<\#Y
M05,V=\&Y4D=1.8?T=2%;G<'];'0P0C\L42-^/2J,'STM^%QIFU='V, N^)AM
MVI>T=N$=+?WA$IW=N/Y7_I"0O:5"W,>''>,B,'TO: G!ITP-X>V&^!Z>*3$S
MKR6#==C0@VQ--;+3$@I#*H=?I$\=KC2L#E9V,69\\9"2K5O51@"?[D=SZK@+
M1<T1O8DA3H\.[ZHV(UG:XIF)TI>'8@G*O(T**P5!DZQ9_I8>H_W8&9$K'L.'
M!&4LVRU(C=UFF>8VF!S^<XPZ[VR(*T8+X-6T/$7ZBYQ5<H3Y9DD,T/OAF,7Y
M(HN'?"<E)^NQGU!34][I/:3((\D)V+68V7Z5;;)F@\/HG?$E,42YCL.QS<H0
MBTH9"U7RR6?E6_S!3NX29+P6AA1=3D!C.KO*N_;8 @\S/_1TQT67.+O18I;L
ML=W I-/ZL/AX[68M=$F3X#W:;([" 4Z!$#SI3<W4H)J%8:(I@DR"Y\Z&$ LM
M# G\M$>I1(>;W#1!H)3SE*,].<>L<E8,S\':VA0)-TE?#&0GEQ8:8)D@?:Q6
M(E%=Z?CJM=<PQ8 \:Y:G5;2WZ?V4 *_6$M=?B9306(7Q%LW:M692QQ3JVZY2
M<:_)GA289.));W@KMX1\<.:3]*;9:>53@H%)[H0W#Z\=4*)2%6W%+FJH,EK&
M&U=BHK;E[_HQ4'_C.7ZUB]="-TBQ];!UY1]I%A@V1_=$,\R=/-O?)W,@PX(F
M"SRIRTM271N"6.=-H]MD$H=4?UY0MH'C")_GV2.K\(3WBDSYPZWAZOEN@>?(
M3MP'?>YNS-8?]?$7-ZD1R6'=14OJIU1,<M46W_A]>A&JNC@$>5CZ'^!=A;.:
M$9;^$HT8;1,RJNE#_M!A JY#8W6DRZXOI]??,>Z"(U3W\'ZZP D*)?.?.$G/
MG*).5+M3;&*UC;$KXZ,^#6)H)UXB72&@AQF_:'29AEEH<BA!@\,_*-&.T#6O
M2+&J\$ 3OAIB,:9-/!HD:*OS-GIX*M\EK;1S[+:WOJV/=L07]#I9E]-]W7$9
MS.'"$,6G ZA!6NBD Y&S[\<MP<K,8QRM(1*Z[A=5QVYL6:!P;Q_U35\)N[;3
M24?A"!E*7P,-TO<CA%R:CQ374OU/]!G?OF^6JZ(:M8L;L\YS$9JV>A KC;C>
MJ;P7A:VTC6KUT)Q/[;?@N)Q<HY'EL1A^I<UX&^P##_6S++%ED< 4&0HR$]T!
M+D>6M][&ZOF6+WA#WCNI7-2\"MIB4><27B%0/W/VAIW\ ?;+EF%@=&?[<+?@
M'Q_4&^MIO*+!B=(M?LHOC6J)ZCUVA_E_UJ&$Q1.EY)VKHL/ CXP3EB7L,9'*
M-$6EVJL&'LVIQB:VK?V:WHF(L6G\BN5.,QVK, $AV!\ 6;M+1$DF(M8SR2\^
MC]J4PPUEQV$NWWLM^IT@\/MIN"P&!#1N9/Q.$UNUC<Y%1X D'I1_<\QAKDI)
M=K/U4F3])[6Y'W-^WX,!TSQ8P([!X*D/5@.E9F9JU9GX2[X14BXR3ZE?!%P8
M#JER?MZ]-(;R"#X9BEC:\4!(]=OC+(]/(NKV+?:EY(^8CVATLD>'SODWF>F<
MJQFF02<R-'.^9[(>-+,]9S+,'DV4!]/?JKOY:QO[QQ*&#V>^TE9J6@0M6B)>
M!HGR8/+WURO+KVJAXW7;J1P?<ULX@B)UH P'B%AN^U2U8D;/J$6']7:T\VGL
MO<UXI7 M-.UI$.*%:"$N^]&RV"&+\%V&%=];G&'F%QED.9!3)Z)BA2/LB,R,
MYR-'^9?3X?MB94QAO&Y,/$*FGJ^WD]'U!STE=&VCC,Q?CUBQ-!%M*)\&+7R/
MQ_@2WAY/=H)X 0-GW9'V+M7A$*I;W%KXU)BH>TH=#O\!!,GB#5COKP*$.OL8
M(N+IV)-[DEF'DYDN>QZ6<5CF,Z?:U^9=?1#^LL>G\M@B=_^;(]G:KXI4?GXI
MSK(A2+3HPS"<../4?3@J2V&BQ0#PM5Z*W4;&C=LM<[A4/C"\+25EH>W[D FP
M0XS%G</<T1I ^LU&'RSQ)(1]X39X9">VB.N+W3*!&<T/-._V$EJI2G!Z]\O3
M3?]<<F(7\]>&8K>Y^2IE:FIOORNDJKP66#V=\,XN%[3,)M-2^:X!\%."B;,9
MRD'#!P.:<(3)?]KKH___0OPT2)&%&X!H*_Y_"SI>N5C?PD@$AU)TJ;/Q/4;*
M'U(^5YP)SD@%2N;\C*_YHJ=KDUW57.+!4VAOFG[%5Z M^=WJI*?[2?!FBV=7
M>?;2RZ"C>J@AVQ]'WXMH$AG'J97K?8RQB/@#</.M&GKC!WK).=:44%W8*Y6\
M6JA,1<C*E%MQ_T=OP_QO@XX66-/$^L-,6IA$VK1NWF;NF7OL4W&'MN^=-DO)
M\9K\!5V'4ONVG- *G,A\UN(*,/3;X\05G5P-MB?9<7H2=BF:7Z0S=EQN)$&S
M*+$4:2.W=P4F3H//RCS@YU*:,[S^*I9%(Z157D_FW+SO?M8?V?!-4:.4TB,_
MQ/YX%E?7K5F.!<+Q(1\3-.]MR.W0-;G%[P@H<M+^L@R/)0P;U<3_D%$FGE<_
M1&:?.42BT?Y+Y;;P,1@!NJQ]C.>/6.S/U?/+/!JA\);2NZ5:O:I_?R6-_CQ#
M3!3N%#VC""'^+S>KOXC*1 #]I_KC"R\HYW@80E*9F6L"#<<\G\S2\V5W$<.]
MYF-/GFGZSX4.T%:'+J(W9&[HS,#H,B;,]Y/J-N;JV.92(!TUJD7DB<W#TTRW
M^3L%9G4%'JH9&>M;.D,I[7J4-]6[3PE47SJTYB$<TPS>M"@'_,B\]>^VXD;*
M,64R/97\H7+R3.:1ZLWLQN-?2:=_9R@>,CDN_3U[KK['@O"E58081"?^EPOI
M+^C2M65HKA,>;VG,/SZ(".6X25R62JZ24FFHD'3\ S!%5?P!S#2"I^AO,VX-
MN4.F6C?\*R@_\BT5IR,-V:]!:O$(U:=SV(O*QC_J^0L(+2_.J#[$-.3?D_\!
MAD\)?GLZW4*\Z_<?8]U$A=*969,A8'5)J/_UY^$_8_?7/Q"<H+\MNS6<E1;\
M Z0\UOT#U+-^L$OZK;/( RVZIN'^,3474%HFF#$:\E9;$0):^L7S,&R'Z ^@
MGOLADI9SMR'RRYF4_,.#3/Y6/R1]>F'=3W\2;P(K;I$._J_F^3_R??&O?!O*
M@_]-2[V9LORQJ.E&0>4Y7-61,_W.HA@! S?^-/T#0.<>7P[4?-=^)A7,_4!^
MG_[VV_P%K/[V0;?1A*$?^!R*$7,__OD>RG\]\$,'"\[8]D,O^Q?'9_X U2:W
M]O^F8;O?6WHS\@/E;9)@>GEJAV;KW]O2$O21'_]%CZ3GBY^^W- 5/=@"]S,Y
MQ$G)CX)L#XR[S;]&K/E?KLS_N5+);S/^,Y6J"@,Y%(<_^*YT*L"$G?WO6]<"
M#[6<$D&@64=;!D>1!?+PPR[^;AIE!EX0^#<\2PTC0Z@**/:8_#]=5/]?P@0$
M>-A_?P&:^CE[K_!;\[X]]R;WT27G,_7_L6[6GAB]^KRM[['V3NK?H^JJ5Q&B
MA6']H^U>N3+T(,YPNOA#X#]*P/SB!<DY/L,?(-AJ1I&TZNM_]]-X;.@U:D$T
MZEIVRO?[N+FN<[4V1DP;7VI"O77-E"WMF6-*'CR"%/QVP2LC8["-H'7L#R"=
M2J0C'P!99>?X ZRYX7D^]]\H[U+1R)P>)Y?H-#3FPO*B>.S3F-S78JOZKNI'
M[I.\(C<;X\DG$D@^BJUP_3H[WT>X!0=04;:[OH6: WP#3!6KB@GM ;>UC/%:
MAUUD?-)HH^+O35X.7<?T@=GW8N['YINQJF[KHQ,'B D]SO0E+C1*>F2CH4XG
M%O7(VV@#@$!;C;7B^=M/HR2/B+PN(;^+R=F;4@:HHV6<R324=BAZDZ$"_;3
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M'DX2V87->5?P189_2FB=ZU5#?9F!$'2"9&<7 \,.MO>0-O3G_0$>HG7-N3_
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MBP(>?3O]_/^@NYYJD6@D>OU%,O%DYJ)?#C154<6>%XMA.5!+.#U1O  $#ET
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M,7@:T"G=Y01_BP!PY-410+KC^.4A&]VBUT78SY:MZ;-Q4H-JU7XU!!"2F8L
M\^#6U1E)VFZE.P(X0Y^!S#UL_ H5"5K+A7P9'$8 ZQ0>", /6_W$4!1RB>+4
MLO/1Q%I6TJQN(W@Q-!6'[N=T,62*I.6?1QM_X_3UNN"@D;H*3# ]'LCZO9(@
MN!+IJK;6*DYJTF_=K$'=6/ZFRLY-!\UO9!+\+]6'@WFN^NK7+C_*_S%7#3A7
M"6]& A].:LH_#F>56K#;0 "'>/4(H#G$YSV)&W?=QC^J5%G)16VP-54P(6,M
MKM;=W]3=1;I,.G(AA@!B.[G.Y@]9;ZT5E\Q"BD1A+7Y7E9L#=N#= V^3+$"B
MJ;/#95;V2MEE1:-4,X0QSA=  _0S"EHA]F[D<6RO)Q4X>LT"1)<]<ZMFR@MX
M4GFI%Y2JO?Q87Z="P[<)'#G6.@*F%6=YTM2+[AJWTF.7YZPRHC&CQHXC@V2D
M(>_CR%;.N&Y@W*DG+!:F(6&GW&O 28N:*AC/$Z\QPX+L>Y^/_TXIGQQV\5(\
M-;YIMMQX=3Z[)L72G!!AWK/X)7XD"RC4X771@'A?F3(:ZC%S>@[.M%;C909/
M&;1ZM1-SZYK/]DRFU+'[2+^I$G/N3H?-P,\T.;:S",7+?[3GA3=%+7PY&T;N
M("7Z(;W$QF^[@M^&W[!UF#&[BI/W+7Z?_35YOO5&[%@ ;\F%9N8&68G]"Z\5
M->YI3^+6@KG=E!/GJR"Z4]QQC#W\*WDLR!94CT-C4D@BX8JXY19XDC((@!XF
MM2"VNW.)*K5/44*9D?LAI-\: ;S::8,<$B" ;IOH$[4+(03P /\BU*$S+Q-L
MMC2E\7Z&DB+3<G' O_//K2G_[>#_U)SRQ]PNMSQ0QJ]\8%X7S/Y4H/.$7<D(
M+&EK?O^R5HX OG@MM)QA0I;YM R\6V1&N"PJJYL.F-\M$)M3E) 4]:.#TR[D
M0)HAL=>+/4N'I\.E#/$-1\KR!UMF^3>?NCL?1XJ"@1C*BGL?IT&_Q'$*JY6G
M##7 [Y:LNBQ@:[(>;QCY.7Y9#.U) XJY?7CZ))K9JCW-R*>&EF^?EX)/L4<R
M G@2VBB?5Q:&N@QQ#GD=4GQGA2Q0#@?((IM!6X]V%EXC +AN!PEV!Y:[@TCQ
MO931XV^8+P71,3ND7XJ8QZ^Z"&[+'@A')U\T)T/'0.2(::8<#O*Q4AI\WY:I
M&+-VWK?IDR%U2__17OV'0-U;GR518H>]BME,H.866(X<JU#O6:9IX<O5P:!1
M37<Q;DDW_BB=V"S;TT3NUOYY-B40CL.E2T,IS*<9Y._Z6#^I"/GN(D7Y1IPG
M)VN#Q\!@/$[9;VG+B/\Q#@760I.$,8\!U?*4C*!;)Y+DO$X#C22-!*,^3(]7
M<-7>R)69G"[;."-Q2+QFT?EW/"(V&2XZ45?=P]M4]QT.>R/(%3]!OF4PMUO$
M3[<S"YEKO2*])73WV[XOVYC4@J&=Z<'0P=45_F[F%6E.R.5Y__F)U)?<]R$?
ME@_UP&19-=#2XH, (!@GFF "''Z( %(3THYW(2'4A>P^$J2;2PO-0<K(Q\ET
MI^M27Z)/=&%D%X>-"* E^()EQ=SR*TN)'AB,[-,10+_RS<P)X"K!"$""2VIG
M'IQ01%__MQY2?]>C^/_K,=K5YHA:@7><#!E^< 7&1]"4TXT_]?KZI>OMH$G)
M/ZO'=<&FBG'E:W)M+LGST@KQU/J2,,B^< <",&8L;OAG+9HR3_B4!N"$?G;C
MZ-8/ Q1.R?E90J(";S+[Z/D./%<WY,YO>-3!,U*_&@K"#'^G_<'* @LU<()0
M;SU=GLMCP>9%#^UH>B@R7V60<IK<D<3&UD*^I*W]'44JM(>LTX0SM2%'Q?%0
MB[+N:)PGB[KVVS!Y#_,8:53;9-\#78X+$0_G/"-CGUTZCN.&;;'7/<+(]4]9
M;W6)"87.*G]Z<[$^NNPX6"UIMS\I?/PYCV%W=%E]598IW1V;8%OXI6W"\6H]
MC(4T2K.166S:Y]XB+?<7Z5NKYM'O$$!%AVKNR5,'MBV?B!A>QDZ;9T3SL9'@
M>7C6&[+01&SU2:R4>S_VLCUXU&TC @3'2+Y_[[KPP:F]O)_]KKWELYBL5S9F
MBG0!Q3"0U#G%N>C+8 R,6&P^1MB<Z,1E1P+8)W*NS/VN6.&6 0V**V$R/_$\
M?FBJL#]_LV!_T6/<1\Y>!]A2+*TPG#?JSD9;WDNQ&.A9<;(W5'G$_2GU2R6+
M!"M:])V3, 3 \*H%WL$67Z*Z)Q]4A??").YL:G56^.M]Q[<BW860$UW#EHLK
M@ZNJ)+7E9!W2*3"ZE(\B@+7]?CCH+?'@T4O%0XK8N,LZ-)^47+!QF%Y!V$$V
MDUHP>(H #DYMSP9M&* 9#0]V>W5%$(!JY5+48<MNH8?_.#CJMN5_&'5;N("M
M"G1@ZT^@ Z^D;<E?L-$8-6VG;<DF1MV';LNW<>A'A$]+UN[(_WT\^^=%AQ>M
M+?O"]BT[:2M&=+N%59#3BXI+!_D'N[=RLQW&O(:?&/%KE+'G)Z>R9G7Z$F[Z
M5])6>J7#BY0H4Z@NE]1R<N40@/=P'BJ8,NG_XSN7/CN+'P W0A]443*Q98MN
M-W> $1P%,FU& /DUS!YVG/>#6 EB:T;,-9ZB<YWU2&'[\4#&%$&J??,'-I)H
MH.CM2(VEJ)HV7A,M\@/P%^Y_7P3Z+6(#*%J?P!LRLCGW#X.0WH !' 393$B3
M>@[C;Q-";P!V(_9R&,Y_9G;S*T81"6WEYS\"/>S&\'0%$!1DKG7_MX)'$C86
M0'ECZ3#93LN"^LT8=)+'-A'!TG@W^OOQ7-_;P_8@*$O6C4*9EU9I(:(PJ6N3
M\W^;K(7TZ3AM2RWGAE-B8O[J"^(IA&PL145]\6QXG0 <@W:]IYP\HD+G(V<6
MH"7YDSF8ABR+$4/76X3TA[56$/=+5<G$FU3&(F&7#L]!T<J$-(+[MCZW0WFS
M<8_)-16ZL-73^]P$4]EY XX%(Q@@<.=;"AC,*Q:NP=+%[H>Z?-YQ@P_N447F
MOGZM#F_</H40JY@2&^:_L8G2\<'A^LH7A+4T7H7D]AS:*LE2A5ELD63)2N]Y
M,8F*GTX]<@S[J0NQ<2.))ME+H/)YM@SP_%)%<C.!MB6UEW:MG.H>2!JS9T5@
M^B[3^=^7W\/+32SKHMY7Z"Y'TUDSI^B?9\%)(M$3?VEDM1!2K\Z?9)"I8]J,
M\5@"Z' P-,D>N?WMR6.#12+,@^^8Z9Q&&76#BWHPAT2.]#<K40OFX6Z[\\FW
M)1,%GO?JQNT;-9AC,\V47W0;L34PMV0CN1E"US+V1+,+G\].O[,G\R9(SJ/X
MC)JZ/%*T&,Y16I[5]5VKU,RE38KU0A:T+.90(! #NDUA08;%SLOKY"+WD(@7
MZ:+@*BF?YM$/FUD%\03LV^J-#RCZD#)YX0B L"]C+HO'*"MPZ8<RM45YRX)8
M P)($V[9R=0\6;N2$033?]?9.)\I:V27!>OX.WH.PD-R%1J*P8BL*ELP9V'-
MS%V<MH&H3BGUQT@6R$ZF<39IUV7VFRO+S$T2J7>;+0NB#?T7/AW7O>JRO>O7
M-$?I*QWT!ZT8;^-U%S-7/3VQ3",RN%3?+]H]#;WK84G&F>-1JLV@]EA9.UKE
M^O6HJ9[#!?J?9//GT_8_^%@6X(<4OMW-U9*_OJ<>/']X30;43,#_X"89@;?Y
M\?5M_J, 1DK3WHO66"'IV9D]C<*,7,'Q4M[<_9Q2+D@FB$@MBS8,BNHP:# W
M;>@_[NKYBN$9PVBTM(0;5'NLD$*[:HB!Y(#[!38PD%$159.;_WA<B?0=[]L+
M XDP0Z,4D^]#D/N+SES'%JKM+@^$@1<#9/PLA9,>O9A.]('%#WR0GI70ZU'T
M2"F]ARN3_V"8Z22O'N";HUC;3>=\DE&^LG?K RH^VTPFZGP!7&IMK'+DET;;
M1XK5@-O0;MH[U=YM,GCMWVSL'MZ-B$-_+E&FA6>"]6RM+M#JO1F%N^:!O\D(
M6A\E&R>';\='1:9WTQ5YKB3!JU.^M*SCE+-ICE05/_*GZ9)"4..:9RN1LA\4
MGE2%8R" A"P,V\0'2R@4%Y<%#E0G E2>J9/A<M0Y"IT*Z=A"S7>'*WN[JNN\
MB';G[B^;C=#M?K";.Q@R/9\?YUC<BR;H ;%@K'1KM4RDZ*F'->K[V%\:O1O?
M86^=M0:E%G@&6]:R6HY;LT$D[@)C<RJ(MW/HC9O0M:O)DDDJB/7@KWY9L*WW
MNBWNNBWZ1*72^72#ZW+7X7M>YKE-BQ7=I/N+BH'Q3E'N[@/KK;1:>\@?TZ8=
MMY:(K4(ATP+G=ZYZ,V=2PT'?BXH$V80)?'WAT>TFKL\=C%WKF:*9:G>]'L;1
M$]J?<#\QK>J1[<B.3#XY*N=O/'U/BAU:J=>C$< 36+VFJ6)HWN;CB)4&\?L#
M&DG0=5ZI>O^<-)7H7VGYN>.*<3?)('CLIHH AJ[.%%6UR*N]7(V;:/U:[@'&
M1_("8KLCMTD9F^XOLUSUI-U2T45VFM(1E;M7:536=\V0T+3KZ#%%3N6=9.EW
M?\&<Q ]PG'N<J)>8Q:^J/LDB63)Z.ZMB:LO?6_UN^DTLRO?@1'L[4[]10VX@
MI12O[*(K, :2^.E0XS:?T8/AJ7GE%6ZQWACJA221'IJS$>6%(A%>71&4VQA>
M,+? "Y'#HR)?%AP*CH4F@1H+,M6N$T8&)]_ =3Q3Z!B+N8(FJ2:Q1>J"KZ6
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MJ=,O-$):GBVZBW^H_0NS_SUB0?]7S/Z=V/_#"PK @(?[.WGP. !QP-T#8T$
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M1G>F9$@\DZ#\&)P3'E?*<T-U?7!DH)*Y74TZL(XRR]#6G;'%KD;7(;!&.W(
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M??!>G.%3RP21>J#2CN#FTUY^ Q03IO;OK*+0X%&(3!:*9^OEO8EB_ LF;$4
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M5E6VB>#B5?L[?F]U3?ZOLLW_?P,"]S1Y$S;/%"XM8GJ\A"@H<[;3H@#D%74
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MWM$Y,#@T/#(Z-OYM?F%Q"0)=_KZR#=O9_;$'WS\X/#N_N+RZOKG]=?>77D@
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MG"O57K-88\OBQ;B)\I28;JL.MC@;KH\KEV>8%?H==D-<B$(J&R0[9@P&KMA
MP)(]@C..9-NX+HR)"D7J.]W2B/FC 8@VL QX;C[RDS8I%<OV5(XB$%5O\.P)
M,,3%^C+T^\ZW]74YW=$C*X_ --D/#;MQK$PPBS$5C^4'0:NK>G\Z/'.#.*/P
M:W-IS>?G=##^FX7V8>E@E)(DS"(\(=3O?9.3^+1YXFO:D#"Q3:*$)P!U,!GY
MWJKKT$X;+;#TML_+PPD!U<O%*N109*43#)>Q,?;F0S%W,FNX!JTO9D''R5-0
M4T,GQ$;EI!^.-(9[:2*&"VG;YT[L.$B&U7R.(W(!9VYD9NO[5*'AK"T087KP
M(6^3I:26UM:JUX?5&M 15U<1]KU#]QSW27WE0E\SWM=8F-XO]XXQM@I?B=/!
M"1[?U4&$6@ G'I52J@"YC#W_U_O/DX4X8-EGU"/H?D[##<DNU[N$\3H8V4Z^
MY#*LMVXP E++P[MXOT>[+PR)GI\_2/!R7K5,33<@+KZ:!;<1"$&A<^#A/.ZY
MB&F@K*XFEK<VT8K3O+/OY,GR@B7V:78A]A.@^=AR,[R;Y'K%.KKA"L.N8^'8
M%)7:_U?'#"3LQ4ZB&WFPQ1(X;DKA<%5[WF7(]_IZ/OM<E9Y_U&SW,L^Z,5CT
M-@6X%U JWLA\!>\)W*O= @+["$/=3#;4;$(8 _0[<7_5[@-EM6ZM;:K\@99S
M93TY:48N\]\&630!KL$R3X 4E)=PV?U:2U;_>GI-A'U#I:FYJ=EMX5MP&Y*N
M5,K"@O#W@00:S"]J/>FO.W:$D(1)=.70_C= CU5<GD6ZG<NM#0H%5IE.!/@)
M#*+:\A[/8H\L!+\M=6Y<'T=;^6RF E>?2HD\ZCJ0HR53NZX8K\-C&Z$2 <^S
M5*Q$)TC-Y,57W<2TL.;LX)$;+>(E5"R+XN(H5R6]P*\(<40I*4U^ALX^=E6,
M5AK+#OA;E#-0F;$CB22I__G]=1+_)KSXB@2L@TR*^GKN@X82@.*?:R!_6 DO
MCJ=+_W/GM1XLEAVY]KN9FFCN=2,XXG;R==%TW9;>G!P6.%#W0_[\GY,P]OZ*
M_X[$EH81Q;)/J6($2NH.LU=VA?V99_HY0*M)H_,%JLJ.*-&W(-+)7D WF;.9
M+O/++;O7+Z9#FBPL[N)O5MYW58)Z0(?#5<R5L#GLU/8?TOT-3HYSB[7LG/X,
M\;$-P$I34Z:*%K!N[0/BLXP;". _-3A8M^94I=CF\.S6UV3O?+$>PG5><U-K
MA@LQ7H%^ -5M>_BYV#\&&'Y-HO?GOX/6KQY<^TI._1%!23#5Y)&K$2+S;=J)
MI16<*,XB[FOXE35,?!,'N-): P*N^-:@E;M5O:I.>*>V42<@6'A;WT@7&'I5
M&X8@G806\IWEWY"EFJFZEM"]BB0#//^Z P4%8I( P+I* )+_-52U6P \)+,;
M/7?ZU8#_V']_#P5W=I3I;MTS]5&%I>@BU/?!*333H5W'5_5=BI#C8/FRP>KO
MQ%_D;PAT0O#<W_,B0J.%+;V._<@G@!Y/ )Y9&M>;^M5!2*YK6HD2?N'1M<F(
M8A+L1OB[\>'C-\ZBX477 M5Z)QX<,\W+FSD++!BAE$ V0A(&'E6?6F!KRGD;
MQ+I&IS#ID90+CE'?"?IH]E='QT]0N$<MBN^77[Q*PR.)\-#Y]C[T!)JW*;\-
MI!71B"LBLEK3FH\D9OZ5S"\&('@UBU$U9\B]+9*ITW\A-2*,_=;K0K2CEG(4
M@VDV%^#E78U0H]B7"-0?14E,1Y9PN"C&9QN0/9>YA3[V,CP!YGS6C FVZ7_1
M!P.? -;/0O<[3_X[6_UGU#W8&K;.>7<E*)_%KO9'Y7\HY%)H%H9^T22Z:F'
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M>7DERG*V^3!L,ZU%<,L?O^8(^UL?BC34^)W4>)#E)_5^CSSY/2"W%9AZ&Q7
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M!G3'7/[D53,NRF<C?N<*H=Y!NA7^HB_GA0F.<<Q?MV%C#TW-I%=];B@NQB5
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MM:EU3T4"F/J:%D]^_Y_A@"^0_9_A=.I_AK(E)":O_S<!4$L! A0#%     @
M\(F15O_(>,8$&@  TSL! !$              ( !     &%D='@M,C R,C$R
M,S$N>'-D4$L! A0#%     @ \(F15L%CM=/S#   6IH  !4
M ( !,QH  &%D='@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( /")D59#
MPP\SNE(  '4!!0 5              "  5DG  !A9'1X+3(P,C(Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " #PB9%6G\247WSE  "[(@L %0
M@ %&>@  861T>"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ \(F15NJA
MM.1,4P  !$8% !4              ( !]5\! &%D='@M,C R,C$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( /")D59<78T65S0" )_2%  6              "
M 72S 0!F,3!K,C R,E]A9&ET>'1I;F,N:'1M4$L! A0#%     @ \(F15J&:
MMUY; @  " <  !P              ( !_^<# &8Q,&LR,#(R97@R,RTQ7V%D
M:71X=&EN8RYH=&U02P$"% ,4    " #PB9%6#$SVV:<&  !I*0  '
M        @ &4Z@, 9C$P:S(P,C)E>#,Q+3%?861I='AT:6YC+FAT;5!+ 0(4
M Q0    ( /")D59A9X[FM@8    I   <              "  77Q P!F,3!K
M,C R,F5X,S$M,E]A9&ET>'1I;F,N:'1M4$L! A0#%     @ \(F15DNA<_\4
M!   H10  !P              ( !9?@# &8Q,&LR,#(R97@S,BTQ7V%D:71X
M=&EN8RYH=&U02P$"% ,4    " #PB9%6H])-[=%W  #B>@  #0
M    @ &S_ , :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( /")D59<>?F1:V@
M $9L   -              "  :]T! !I;6%G95\P,#(N:G!G4$L! A0#%
M  @ \(F15@!0\4.44P  Y5X   T              ( !1=T$ &EM86=E7S P
M,RYJ<&=02P$"% ,4    " #PB9%6YP N=;,F  #?*P  #0
M@ $$,04 :6UA9V5?,# T+FIP9U!+ 0(4 Q0    ( /")D5:/6_XT3$4   ])
M   -              "  >)7!0!I;6%G95\P,#4N:G!G4$L! A0#%     @
M\(F15@3,8M$_0@  =$<   T              ( !69T% &EM86=E7S P-BYJ
8<&=02P4&     !  $  9!   P]\%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
